PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CUADRADO, A; CARNERO, A; DOLFI, F; JIMENEZ, B; LACAL, JC				CUADRADO, A; CARNERO, A; DOLFI, F; JIMENEZ, B; LACAL, JC			PHOSPHORYLCHOLINE - A NOVEL 2ND MESSENGER ESSENTIAL FOR MITOGENIC ACTIVITY OF GROWTH-FACTORS	ONCOGENE			English	Article							CHOLINE KINASE-ACTIVITY; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHOLIPASE-D; TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDE; PDGF RECEPTOR; RAS ONCOGENE; 3T3 CELLS; ACTIVATION; PROTEIN	Growth factor stimulation of quiescent cells induces a series of intracellular early and late events that ultimately lead to DNA synthesis and cell division. We describe here that production of phosphorylcholine is an essential component of the late events involved in the induction of DNA synthesis by platelet-derived growth factor (PDGF-BB), a prototype mitogen for fibroblasts. Moreover, phosphorylcholine itself is mitogenic when added exogenously to NIH3T3 cells, further indicating its role as a crucial intracellular messenger for DNA synthesis. Choline kinase, the first step in the route of phosphatidylcholine synthesis appears to be the critical regulatory enzyme in phosphorylcholine production, indicating that regulation of choline kinase represents a key step during mitogenic stimulation. We also describe that several growth factors (PDGF-AA, basic FGF, EGF and phorbol esters) rely on their ability to generate phosphorylcholine for their proliferating activity. In contrast, DNA synthesis induced by serum did not require phosphorylcholine. Moreover, the requirement for phosphorylcholine production in PDGF-stimulated cells can be over-ruled by addition of insulin. Thus, cell proliferation in NIH3T3 cells can be triggered off by alternative pathways and one of them involves generation of phosphorylcholine.	INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN; UNIV AUTONOMA MADRID,FAC MED,DEPT BIOQUIM,E-28029 MADRID,SPAIN	Autonomous University of Madrid			Cuenca, Benilde Jimenez/K-9959-2014; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979; Cuadrado, Antonio/0000-0002-4039-7140; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Cuadrado, Antonio/0000-0002-3444-9012				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; CANNON JG, 1988, PHARMACEUT RES, V5, P359, DOI 10.1023/A:1015955527100; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO CK, 1988, BIOCHEM J, V254, P33, DOI 10.1042/bj2540033; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; CUADRADO A, 1993, UNPUB; DALY PF, 1987, J BIOL CHEM, V262, P14875; DOOPLER W, 1987, GENE, V54, P147; EXTON JH, 1990, J BIOL CHEM, V265, P1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1990, J CELL SCI, V96, P193; JIMENEZ B, 1992, INT J CANCER, V49, P417; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1988, ONCOGENE HDB, P255; LEACH KL, 1991, J BIOL CHEM, V266, P3215; MACARA IG, 1985, AM J PHYSIOL, V248, pC3, DOI 10.1152/ajpcell.1985.248.1.C3; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; OHTSUKA T, 1990, BIOCHEM BIOPH RES CO, V170, P328, DOI 10.1016/0006-291X(90)91278-Z; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PORTER TJ, 1990, J BIOL CHEM, V265, P414; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TAMARU M, 1989, NEUROCHEM RES, V14, P607, DOI 10.1007/BF00964868; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSHOPP J, 1989, NATURE, V337, P272; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WARDEN CH, 1985, J BIOL CHEM, V260, P6006	45	169	173	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2959	2968						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414498				2022-12-25	WOS:A1993MC09300009
J	BEERS, EP; CALLIS, J				BEERS, EP; CALLIS, J			UTILITY OF POLYHISTIDINE-TAGGED UBIQUITIN IN THE PURIFICATION OF UBIQUITIN-PROTEIN CONJUGATES AND AS AN AFFINITY LIGAND FOR THE PURIFICATION OF UBIQUITIN-SPECIFIC HYDROLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME; HIGHER-PLANT; DEGRADATION; EXPRESSION; YEAST; CLONING; PATHWAY; INVIVO; CELLS; ACTS	The purification and biochemical characterization of protein substrates of the ubiquitin-dependent pathway of proteolysis is made difficult in part by the low steady state levels of ubiquitin-protein conjugates. We report here on the use of a polyhistidine-tagged ubiquitin molecule (HisUb) for the purification of ubiquitin-protein conjugates by metal chelate chromatography. When Escherichia coli extracts containing expressed HisUb were passed through a nitrilotriacetic acid-agarose column containing immobilized Ni2+ ions (Ni-NTA column), HisUb was retained. After washing to remove unbound and nonspecifically bound proteins, a pH 4.5 wash was used to elute highly purified HisUb. Purified HisUb and wild-type ubiquitin were tested for their ability to form Ni2+-binding ubiquitin-protein conjugates in a wheat germ in vitro conjugation reaction. In some experiments, wheat germ extracts were preincubated with iodoacetamide to inhibit ubiquitin activating and conjugating enzymes. Only those conjugation assays containing HisUb and an ATP-regenerating system not pretreated with iodoacetamide produced significant levels of multiple Ni2+-binding ubiquitin-protein conjugates. We also examined the potential of HisUb as an affinity ligand for the purification of higher plant ubiquitin-specific hydrolases. As a test, a crude lysate of E. coli expressing a yeast ubiquitin-specific hydrolase (Yuh1) was passed through a Ni-NTA column containing bound HisUb. Yuh1 was retained on the column and was specifically eluted when the column was equilibrated with buffer containing wild-type ubiquitin.	UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis				Callis, Judy/0000-0002-0622-078X				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BEERS EP, 1992, J BIOL CHEM, V267, P15432; BUTT TR, 1988, J BIOL CHEM, V263, P16364; Callis J., 1989, OXFORD SURV PLANT MO, V6, P1; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DUERKSENHUGHES PJ, 1989, BIOCHEMISTRY-US, V28, P8530, DOI 10.1021/bi00447a039; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; EYTAN E, 1993, J BIOL CHEM, V268, P4668; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HADARI T, 1992, J BIOL CHEM, V267, P719; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JONNALAGADDA S, 1989, J BIOL CHEM, V264, P10637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI M, 1991, J BIOL CHEM, V266, P21018; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MORI S, 1993, J BIOL CHEM, V268, P577; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; PICKART CM, 1985, J BIOL CHEM, V260, P7903; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SULLIVAN ML, 1990, PLANT PHYSIOL, V94, P710, DOI 10.1104/pp.94.2.710; VIERSTRA RD, 1987, PLANT PHYSIOL, V84, P332, DOI 10.1104/pp.84.2.332; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; VIERSTRA RD, 1988, BIOCHEMISTRY-US, V27, P3290, DOI 10.1021/bi00409a025	33	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21645	21649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408016				2022-12-25	WOS:A1993MC80900035
J	CASCIO, M; SCHOPPA, NE; GRODZICKI, RL; SIGWORTH, FJ; FOX, RO				CASCIO, M; SCHOPPA, NE; GRODZICKI, RL; SIGWORTH, FJ; FOX, RO			FUNCTIONAL EXPRESSION AND PURIFICATION OF A HOMOMERIC HUMAN-ALPHA-1 GLYCINE RECEPTOR IN BACULOVIRUS-INFECTED INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRYCHNINE-BINDING-SITE; GATED ION CHANNELS; RAT SPINAL-CORD; MEMBRANE-PROTEINS; SUBUNIT; SOLUBILIZATION; LOCALIZATION; BIOLOGY; NEURONS; SYSTEM	The human alpha1 glycine receptor (GlyR) was expressed in Sf9 insect cells infected with a recombinant Autographa californica nuclear polyhedrosis baculovirus. Previous studies had indicated that transient expression of this subunit in Xenopus oocytes or human kidney cell lines is sufficient to form active agonist-gated chloride channels. Expression of the alpha1 GlyR protein resulted in functional channels present on the cell surface of infected Sf9 cells as evidenced by whole-cell patch-clamping and single-channel recordings. These channels were gated by glycine, but not in the presence of strychnine. An immunoreactive 48-kDa protein could be easily visualized on Coomassie-stained sodium dodecyl sulfate-polyacrylamide gels of whole-cell lysates with maximal expression 3 days postinfection. The alpha1 GlyR protein was solubilized from a membrane fraction of infected Sf9 cells in 1% digitonin and 0.1% deoxycholate and purified by affinity chromatography using aminostrychnine agarose, yielding 0.33 mg/liter of cells. Given the low natural abundance of the native channel, the development of this expression system now provides sufficient purified channel protein for future biochemical and biophysical characterization. Since the glycine receptor shares sequence and structural homology with other members of a ligand-gated channel superfamily, further characterization may establish general rules governing the structure and mechanism of these membrane protein channels.	YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06511 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06511 USA; YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University					NINDS NIH HHS [NS21501] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021501] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ H, 1987, TRENDS NEUROSCI, V10, P113, DOI 10.1016/0166-2236(87)90055-5; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BETZ H, 1988, NEUROCHEM INT, V13, P137, DOI 10.1016/0197-0186(88)90048-4; BETZ H, 1992, Q REV BIOPHYS, V25, P381, DOI 10.1017/S0033583500004340; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; BHATTACHARYYA A, 1981, INT J BIOCH BIOPHYS, V18, P421; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; DIESENHOFFER J, 1985, NATURE, V318, P618; GOSWAMI BB, 1991, BIOTECHNIQUES, V10, P626; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HAGA K, 1985, NATURE, V316, P731, DOI 10.1038/316731a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; HJELMELAND LM, 1990, METHOD ENZYMOL, V182, P253; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; KUHSE J, 1991, ANN NY ACAD SCI, V625, P129, DOI 10.1111/j.1749-6632.1991.tb33836.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; PARKER EM, 1991, J BIOL CHEM, V266, P519; PFEIFFER F, 1981, BRAIN RES, V226, P273, DOI 10.1016/0006-8993(81)91099-4; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; ROSENMUND P, 1961, CHEM BER-RECL, V94, P3342, DOI 10.1002/cber.19610941223; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; Sakmann B, 1983, SINGLE CHANNEL RECOR, P37; Sambrook J, 1989, MOL CLONING LABORATO; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TWYMAN RE, 1991, J PHYSIOL-LONDON, V435, P303, DOI 10.1113/jphysiol.1991.sp018512; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VASUDEVAN S, 1991, FEBS LETT, V283, P52, DOI 10.1016/0014-5793(91)80551-D; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832; [No title captured]	43	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22135	22142						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408073				2022-12-25	WOS:A1993MC80900103
J	FRANKLIN, AE; HOFFMAN, NE				FRANKLIN, AE; HOFFMAN, NE			CHARACTERIZATION OF A CHLOROPLAST HOMOLOG OF THE 54-KDA SUBUNIT OF THE SIGNAL RECOGNITION PARTICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI 4.5S RNA; METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SRP-RNA; SEQUENCE RECOGNITION; NASCENT PREPROLACTIN; NUCLEOTIDE-SEQUENCE; BINDING-PROTEINS; TRANSPORT	Proteins and RNAs homologous to components of the eukaryotic signal recognition particle (SRP) have been identified in a number of prokaryotic organisms. Here we report the isolation of an Arabidopsis thaliana cDNA, FFC (fifty-four chloroplast homologue), that encodes a chloroplast protein (54CP) homologous to the 54-kDa subunit of the signal recognition particle. 54CP shares 27% identity with mammalian SRP54 and 44% identity with the Escherichia coli ffh gene product suggesting a prokaryotic origin for this gene. FFC is a nuclear gene encoding a 62-kDa cytoplasmically synthesized precursor that is capable of being imported into isolated chloroplasts and processed to a 53-kDa stromal polypeptide. Antibodies generated against a portion of 54CP recognize an endogenous 53-kDa chloroplast protein that sediments at 4 S and 70 S, the latter form may be associated with ribosomes. The FFC transcript is most abundant in green shoot tissue whereas etiolated buds and roots have transcript levels about 30 and 10%, respectively, relative to light grown green shoots. By analogy with the eukaryotic signal recognition particle which targets secretory proteins to the endoplasmic reticulum, it is speculated that 54CP may target chloroplast proteins to either the thylakoid or envelope membranes.	CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Carnegie Institution for Science; Stanford University					NIGMS NIH HHS [GM42609-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CHUA NH, 1976, J CELL BIOL, V71, P497, DOI 10.1083/jcb.71.2.497; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FRITSCH A, 1973, ANAL BIOCHEM, V55, P57, DOI 10.1016/0003-2697(73)90290-X; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; JAGENDORF AT, 1990, PLANT SCI, V70, P137; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIM JM, 1991, J BIOL CHEM, V266, P14931; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; LUTKE H, 1993, J CELL BIOL, V121, P977; MEADOWS JW, 1991, PLANT MOL BIOL, V17, P1241, DOI 10.1007/BF00028739; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SAEMBROOK J, 1989, MOL CLONING LABORATO; SAGHAIMAROOF MA, 1984, P NATL ACAD SCI-BIOL, V81, P8014, DOI 10.1073/pnas.81.24.8014; SAMUELSSON T, 1992, NUCLEIC ACIDS RES, V20, P5763, DOI 10.1093/nar/20.21.5763; SAMUELSSON T, 1990, NUCLEIC ACIDS RES, V18, P4938, DOI 10.1093/nar/18.16.4938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI Y, 1993, FEBS LETT, V316, P93, DOI 10.1016/0014-5793(93)81743-J; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; STRUB K, 1990, MOL CELL BIOL, V10, P777, DOI 10.1128/MCB.10.2.777; STRUB K, 1989, P NATL ACAD SCI USA, V86, P9794; Timko MP, 1985, MOL BIOL PHOTOSYNTHE, P381; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1982, NATURE, V299, P69; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	47	129	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22175	22180						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408079				2022-12-25	WOS:A1993MC80900109
J	ROBINSON, R; ROBINSON, LJ; JAMES, DE; LAWRENCE, JC				ROBINSON, R; ROBINSON, LJ; JAMES, DE; LAWRENCE, JC			GLUCOSE-TRANSPORT IN L6 MYOBLASTS OVEREXPRESSING GLUT1 AND GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; MUSCLE-CELLS; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; OKADAIC ACID; PROTEIN-PHOSPHORYLATION; INSULIN REGULATION; SKELETAL-MUSCLE; ISOFORMS; STIMULATION	The roles of the glucose transporter isoforms, GLUT1 and GLUT4, in mediating insulin-stimulated glucose transport were investigated by stably overexpressing the transporters in L6 myoblasts. Levels of GLUT1 and GLUT4 in myoblasts from the cell lines having the highest content of these transporters were approximately 16- and 30-fold higher, respectively, than levels in nontransfected cells. The basal rate of 2-deoxy[H-3]glucose uptake was severalfold higher in cells overexpressing GLUT1 than in the parent L6 myoblasts or in control cell lines that were generated by transfecting cells with expression vectors lacking transporter insert. The basal rate was not elevated in any of the lines expressing GLUT4. The net increase in 2-deoxy[H-3]glucose uptake produced by insulin was larger in both the GLUT1 and GLUT4 cells than in the control cells. Insulin increased uptake in GLUT4 cells by as much as 6-fold; whereas, the fold increase over basal uptake produced by insulin in GLUT1 cells was comparable to that (2-fold) observed in the control myocytes. Thus, both GLUT1 and GLUT4 can mediate insulin-stimulated glucose transport in L6 myoblasts, although GLUT4 is needed to observe large percentage increases comparable to those observed in skeletal muscle fibers in vivo. In contrast to insulin, the protein phosphatase inhibitors, okadaic acid and calyculin A, inhibited glucose transport in cells expressing either GLUT1 or GLUT4. Calyculin A, which produced a half-maximum effect at 10 nM, was approximately 100 times more potent than okadaic acid in decreasing both basal and insulin-stimulated 2-deoxyglucose uptake. Inhibition of uptake by calyculin A was associated with a decrease in the cell surface concentration of both GLUT1 and GLUT4. These results indicate that increased protein phosphorylation can lead to inhibition of transport mediated by both GLUT1 and GLUT4.	WASHINGTON UNIV, SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				James, David/0000-0001-5946-5257	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312, DK42503] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK042503] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; BILAN PJ, 1992, BIOCHEM BIOPH RES CO, V186, P1129, DOI 10.1016/0006-291X(92)90864-H; BILAN PJ, 1991, ADV EXP MED BIOL, V293, P273; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BOYLE WA, 1991, AM J PHYSIOL, V260, pH1236, DOI 10.1152/ajpheart.1991.260.4.H1236; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BURANT CF, 1987, BIOCHEM BIOPH RES CO, V147, P100, DOI 10.1016/S0006-291X(87)80092-X; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHARTIER L, 1991, CELL MOTIL CYTOSKEL, V18, P26, DOI 10.1002/cm.970180104; CZECH MP, 1982, CELL, V31, P8, DOI 10.1016/0092-8674(82)90399-3; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LAWRENCE JC, 1981, J BIOL CHEM, V256, P6213; LAWRENCE JC, 1992, P NATL ACAD SCI USA, V89, P3493, DOI 10.1073/pnas.89.8.3493; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SHINOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1984, J BIOL CHEM, V259, P2201; TANTI JF, 1991, J BIOL CHEM, V266, P2099; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; ZAPF J, 1981, CURR TOP CELL REGUL, V19, P257; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	45	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22119	22126						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408071				2022-12-25	WOS:A1993MC80900101
J	SHAPIRO, RA; PALMER, D; CISLO, T				SHAPIRO, RA; PALMER, D; CISLO, T			A DELETION MUTATION IN THE 3RD CYTOPLASMIC LOOP OF THE MOUSE M1 MUSCARINIC ACETYLCHOLINE-RECEPTOR UNMASKS CRYPTIC G-PROTEIN BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; FUNCTIONAL EXPRESSION; AGONIST BINDING; ALPHA-SUBUNIT; ACTIVATION; REGION; HYDROLYSIS; GENE; TRANSFORMATION	Mutations were introduced in the highly conserved carboxyl-terminal region of the third cytoplasmic loop of the mouse m1 muscarinic acetylcholine receptor (mAChR) gene by site-directed mutagenesis. The effects of these mutations on ligand binding and on mAChR coupling to phosphoinositide turnover have been examined following expression in mouse Y1 adrenal carcinoma cells, Chinese hamster ovary (CHO) cells, and Rat-2 fibroblasts. Point mutations in the region proximal to the sixth transmembrane domain had no effect on antagonist binding but did result in decreased agonist affinity. A deletion of four amino acids in the same region effectively uncoupled the receptor from phosphoinositol turnover in Y1 adrenal carcinoma cells but had no effect in either CHO cells or Rat-2 fibroblasts. Differential sensitivity to pertussis toxin indicates that the m1 mAChR can interact with multiple G-proteins in CHO cells and Rat-2 cells via distinct recognition sites on the receptor. These data demonstrate multiple G-proteins can interact with an individual receptor, that the same receptor may couple to different second messenger pathways, and that these responses can vary in a cell type-specific manner.			SHAPIRO, RA (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DICKINSON KEJ, 1992, EUR J PHARM-MOLEC PH, V225, P291, DOI 10.1016/0922-4106(92)90102-2; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEE CH, 1992, J BIOL CHEM, V267, P16044; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; STRADER CD, 1987, J BIOL CHEM, V262, P16439; VANDERHEYDEN P, 1987, BIOCHEM PHARMACOL, V36, P4119, DOI 10.1016/0006-2952(87)90569-7; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WONG SKF, 1990, J BIOL CHEM, V265, P6219	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21734	21738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408028				2022-12-25	WOS:A1993MC80900049
J	TYTLER, EM; SEGREST, JP; EPAND, RM; NIE, SQ; EPAND, RF; MISHRA, VK; VENKATACHALAPATHI, YV; ANANTHARAMAIAH, GM				TYTLER, EM; SEGREST, JP; EPAND, RM; NIE, SQ; EPAND, RF; MISHRA, VK; VENKATACHALAPATHI, YV; ANANTHARAMAIAH, GM			RECIPROCAL EFFECTS OF APOLIPOPROTEIN AND LYTIC PEPTIDE ANALOGS ON MEMBRANES - CROSS-SECTIONAL MOLECULAR SHAPES OF AMPHIPATHIC-ALPHA HELIXES CONTROL MEMBRANE STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; A-I; WASP VENOM; SECONDARY STRUCTURE; INVERTED PHASES; MASTOPARAN; PROTEINS; PHOSPHATIDYLCHOLINE; MELITTIN; CELLS	Apolipoprotein (class A) amphipathic helixes are postulated to act as detergents by virtue of their cross-section being wedge-shaped. Using computer analysis of naturally occurring class A and lytic (class L) amphipathic helixes, we designed two archetypical model peptides. Analogs of these two peptides, incorporating substitutions or modifications of interfacial or basic residues, had the following effects. Class A peptides stabilized bilayer structure, reduced leakage from large unilamellar vesicles and erythrocytes, and inhibited lysis induced by class L peptides. Class L peptides destabilized bilayer structure in model membranes and increased binding of class A peptides to erythrocytes. The ability of class L analogs to lyse membranes and induce inverted lipid phases was reduced by either decreasing the bulk of an interfacial residue, increasing the angle subtended by the polar face, or increasing the bulk of the basic residues. The ability of the class A analog to stabilize bilayer structure and inhibit erythrocyte lysis by class L peptides was enhanced by methylating the Lys residues. These results can be explained by a model that we term the reciprocal wedge hypothesis. By analogy to the reciprocal effects of phospholipid shapes on membrane structure, we propose that the wedge shape of class A helixes stabilizes membrane bilayers, whereas the inverted wedge shape of class L helixes destabilizes membrane bilayers, and, thus, one class will neutralize the effect of the other class on membranes.	UNIV ALABAMA,MED CTR,DEPT MED,ATHEROSCLEROSIS RES UNIT,D630,DREB 3,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,DEPT BIOCHEM,BIRMINGHAM,AL 35294; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; McMaster University			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558; Mishra, Vinod/0000-0002-4527-1512; Tytler, Ewan/0000-0002-4552-8170	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067632, P01HL034343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028928] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL67632, P01 HL34343] Funding Source: Medline; NIAID NIH HHS [R01 AI28928] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLOF E, 1991, BIOCHEMISTRY-US, V30, P8986; Anantharamaiah G. M., 1990, ADV EXP MED BIOL, V285, P131; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; ANANTHARAMAIAH GM, 1988, J LIPID RES, V29, P309; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BECHINGER B, 1992, BIOPHYS J, V62, P12, DOI 10.1016/S0006-3495(92)81763-0; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLACKBURN WD, 1991, J LIPID RES, V32, P1911; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; DEWAAL A, 1991, FEBS LETT, V293, P219, DOI 10.1016/0014-5793(91)81191-A; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; EPAND RM, 1977, BIOCHIM BIOPHYS ACTA, V491, P296, DOI 10.1016/0005-2795(77)90065-4; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; JOHN E, 1991, BIOPHYS J, V60, P319, DOI 10.1016/S0006-3495(91)82056-2; JONES MK, 1992, J LIPID RES, V33, P287; JORGENSEN EV, 1989, J BIOL CHEM, V264, P9215; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KANELLIS P, 1980, J BIOL CHEM, V255, P1464; LIU DX, 1990, BIOCHEMISTRY-US, V29, P3637, DOI 10.1021/bi00467a008; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OWENS RJ, 1990, J CLIN INVEST, V86, P1142, DOI 10.1172/JCI114819; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PERIANIN A, 1989, J IMMUNOL, V143, P1669; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; ROSENFELD SI, 1983, J CLIN INVEST, V71, P795, DOI 10.1172/JCI110833; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1991, MOL CONFORMATION BIO, P597; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; SILVIUS JR, 1985, BIOCHEMISTRY-US, V24, P5388, DOI 10.1021/bi00341a017; SMALL DM, 1992, PLASMA LIPOPROTEINS, P57; TALL AR, 1977, J BIOL CHEM, V252, P4701; TOSTESON MT, 1985, J MEMBRANE BIOL, V87, P35, DOI 10.1007/BF01870697; VANGORKOM LCM, 1992, BIOCHEMISTRY-US, V31, P671, DOI 10.1021/bi00118a006; VENKATACHALAPAT.YV, 1990, PEPTIDES CHEM BIOL, P672; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4; YUI Y, 1988, J CLIN INVEST, V82, P803, DOI 10.1172/JCI113682	48	99	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22112	22118						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408070				2022-12-25	WOS:A1993MC80900100
J	DHONDT, K; BOSCH, D; VANDAMME, J; GOETHALS, M; VANDEKERCKHOVE, J; KREBBERS, E				DHONDT, K; BOSCH, D; VANDAMME, J; GOETHALS, M; VANDEKERCKHOVE, J; KREBBERS, E			AN ASPARTIC PROTEINASE PRESENT IN SEEDS CLEAVES ARABIDOPSIS-2-S ALBUMIN PRECURSORS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE PROTEIN; PROCESSING ENZYME; GENE FAMILY; CATHEPSIN-D; EXPRESSION; SEQUENCE; BODIES; RNA; BIOSYNTHESIS; COTYLEDONS	The Arabidopsis thaliana 2 S albumins are examples of vacuolar proteins which undergo intensive posttranslational processing. An in vitro processing assay to screen for processing enzymes present in seeds was developed using an in vitro synthesized 2 S albumin precursor as the substrate. A protease was characterized which cleaved the substrate into two fragments with molecular weights (as determined from their migration distance on SDS-polyacrylamide gel) corresponding to those of the small and large subunits of Arabidopsis 2 S albumin. The pH optimum of this protease activity, its inhibition by pepstatin A, and partial sequence data led to the conclusion that the protease under study was an aspartic proteinase. Synthetic peptides representing two 2 S albumin propeptides allowed the determination of the in vitro cleavage sites, and suggested that the protease activity is capable, in vitro, of cleaving the amino-terminal propeptide as well as the internal propeptide linking the two subunits. Alterations of the amino acids in and around the cleavage sites, made to study the specificity of the protease activity, suggest that both structural and sequence determinants are important in cleavage site recognition.	STATE UNIV GHENT, FYSIOL SCHEIKUNDE LAB, LEDEGANCKSTR 35, B-9000 GHENT, BELGIUM; PLANT GENET SYST NV, B-9000 GHENT, BELGIUM	Ghent University; Bayer AG; Bayer CropScience								BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; CHRISPEELS MJ, 1982, J CELL BIOL, V93, P306, DOI 10.1083/jcb.93.2.306; CROUCH M L, 1983, Journal of Molecular and Applied Genetics, V2, P273; DANNTHINNE X, 1992, THESIS U GENT, P36; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DHONDT K, 1993, PLANT PHYSIOL, V102, P425, DOI 10.1104/pp.102.2.425; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257, DOI 10.1093/nar/15.8.3257; GAYLER KR, 1989, PLANT PHYSIOL, V91, P1425, DOI 10.1104/pp.91.4.1425; GIELEN J, 1984, EMBO J, V3, P835, DOI 10.1002/j.1460-2075.1984.tb01894.x; GRAVES MC, 1991, ADV EXP MED BIOL, V306, P395; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; HARANISHIMURA I, 1987, PLANT PHYSIOL, V85, P440, DOI 10.1104/pp.85.2.440; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; HIGGINS TJV, 1984, ANNU REV PLANT PHYS, V35, P191, DOI 10.1146/annurev.pp.35.060184.001203; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; HOLWERDA BC, 1992, PLANT CELL, V4, P307, DOI 10.1105/tpc.4.3.307; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUOKA K, 1990, J BIOL CHEM, V265, P19750; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; Sambrook J, 1989, MOL CLONING LABORATO; SARKKINEN P, 1992, PLANTA, V186, P317, DOI 10.1007/BF00195311; SCARBOROUGH PE, 1991, ADV EXP MED BIOL, V306, P343; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCOTT MP, 1992, P NATL ACAD SCI USA, V89, P658, DOI 10.1073/pnas.89.2.658; SHUTOV AD, 1987, PHYTOCHEMISTRY, V26, P1557, DOI 10.1016/S0031-9422(00)82245-1; STINISSEN HM, 1985, PLANT PHYSIOL, V77, P495, DOI 10.1104/pp.77.2.495; SUN SSM, 1987, EUR J BIOCHEM, V162, P477, DOI 10.1111/j.1432-1033.1987.tb10665.x; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VANDERKLEI H, 1993, PLANT PHYSIOL, V101, P1415, DOI 10.1104/pp.101.4.1415; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YOULE RJ, 1981, AM J BOT, V68, P44, DOI 10.2307/2442990	39	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20884	20891						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407921				2022-12-25	WOS:A1993MA28800041
J	KATZ, D; LAZAR, MA				KATZ, D; LAZAR, MA			DOMINANT-NEGATIVE ACTIVITY OF AN ENDOGENOUS THYROID-HORMONE RECEPTOR VARIANT (ALPHA-2) IS DUE TO COMPETITION FOR BINDING-SITES ON TARGET GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROMOTER TRANSCRIPTION FACTOR; DNA-BINDING; RESPONSE ELEMENTS; MESSENGER-RNA; RXR-BETA; NUCLEAR RECEPTORS; TRANS-ACTIVATION; ACID RECEPTORS; RAT-BRAIN	Regulation of development and metabolism by thyroid hormone (T3) may be influenced by a non-T3 binding T3 receptor (TR) isoform, TRalpha2, which can inhibit transcriptional activation by legitimate TRs. Numerous mechanisms have been postulated to explain the dominant negative actions of TRalpha2, including competition for target genes, formation of inactive heterodimers, and squelching. We have found that excess TRalpha2 was required to inhibit TRalpha1-mediated transactivation from multiple T3 response elements (TREs). Inhibition of T3 action by TRalpha2 was specific for TRE-containing genes, because a GAL4/TRalpha1 chimera, which heterodimerized with the 9-cis-retinoic acid receptor (RXR) and activated transcription from the GALA binding site in the presence of T3, was not inhibited by TRalpha2. In contrast, TRalpha2 inhibited transactivation by TRalpha/VP16, a chimeric protein containing the N-terminal DNA binding domain (DBD) of TRalpha1 fused to the transcriptional activation domain of VP16. Indeed, TRalpha2 inhibited the binding of TRalpha1 monomers, homodimers, and RXR-heterodimers to DNA in vitro, whereas the TRalpha2 C terminus alone did not. Although TRalpha2 bound to TREs with less affinity than TRalpha1, it bound directly to target genes in the cell nucleus. Furthermore, a TRalpha2 mutant which binds more avidly to TREs was a more effective inhibitor of T3 action than wild type TRalpha2. Together these data indicate that TRalpha2 inhibits T3 action by competing for binding to TREs.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINE,611 CRB,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043806, R01DK043806] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43806] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Braverman L.E., 1991, THYROID FUNDAMENTAL; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P996; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; MACCHIA E, 1990, ENDOCRINOLOGY, V126, P3232, DOI 10.1210/endo-126-6-3232; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKAI A, 1990, MOL CELL ENDOCRINOL, V72, P143, DOI 10.1016/0303-7207(90)90138-X; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; PUYMIRAT J, 1992, PROG NEUROBIOL, V39, P281, DOI 10.1016/0301-0082(92)90019-B; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1991, TRENDS ENDOCRIN MET, V2, P140, DOI 10.1016/1043-2760(91)90004-7; WEISS RE, 1992, ANNU REV MED, V43, P363, DOI 10.1146/annurev.med.43.1.363; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILLS KN, 1991, MOL ENDOCRINOL, V5, P1109, DOI 10.1210/mend-5-8-1109; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	66	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20904	20910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407924				2022-12-25	WOS:A1993MA28800044
J	LEE, CW; PARK, DJ; LEE, KH; KIM, CG; RHEE, SG				LEE, CW; PARK, DJ; LEE, KH; KIM, CG; RHEE, SG			PURIFICATION, MOLECULAR-CLONING, AND SEQUENCING OF PHOSPHOLIPASE-C-BETA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; INOSITOL-TRISPHOSPHATE; BOVINE BRAIN; BETA-GAMMA; COMPLETE CDNA; C ISOZYMES; G-PROTEINS; DROSOPHILA; SUBUNITS	We have characterized inositol phospholipid-specific phospholipase C (PLC) isozymes in bovine retina. Chromatography of a retinal homogenate on a heparin column partially resolved six peaks of PLC activity, which differed in their relative selectivities for the substrates phosphatidyl 4,5-bisphosphate (PIP2) and phosphatidylinositol (PI). Five of the peaks were shown to correspond to the known PLC isozymes PLC-beta1, PLC-beta3, PLC-gamma1, PLC-delta1, and PLC-delta2. PLC-beta1, PLC-beta3, PLC-gamma1, and PLC-delta1 in the retinal fractions were identified by immunoblotting with isozyme-specific antibodies, and PLC-delta2 was identified by direct sequencing of tryptic peptides. PLC-gamma2 and PLC-beta2 were not detectable by immunoblot analysis. In addition to five of the seven mammalian PLC isozymes identified to date, bovine retina contained a previously unidentified PLC, which exhibited the highest selectivity for PIP2 over PI. The new PLC was purified from a retinal particulate fraction to yield a preparation that contained a major protein band with an apparent molecular mass of 130 kDa on SDS-polyacrylamide gels. Sequence analysis of 12 tryptic peptides derived from the 130-kDa protein suggested that the primary structure of the new PLC is similar to those members of beta-type PLC isozymes, especially to that of PLC-norpA, which was originally identified in Drosophila eye. The new enzyme was thus named PLC-beta4. A search of a rat brain cDNA library with the polymerase chain reaction and oligonucleotide primers based on common PLC amino acid sequences resulted in the cloning of a rat brain cDNA corresponding to a previously uncharacterized PLC. The cDNA encoded a putative polypeptide of 1176 amino acids, with a calculated molecular mass of 134,532 daltons, that contained the sequences of all 12 tryptic peptides of PLC-beta4. Furthermore, the deduced amino acid sequence of the encoded protein was more related to PLC-norpA than to any of the three mammalian PLC-beta isozymes. These results suggest that the brain cDNA encodes PLC-beta4, which is likely a mammalian homolog of PLC-norpA.	NHLBI,BIOCHEM LAB,9000 ROCKVILLE PIKE,BLDG 3,RM 122,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Park, Do-Joon/J-2736-2012					Anderson R.E., 1988, Progress in Retinal Research, V8, P211, DOI 10.1016/0278-4327(88)90026-0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1987, BIOCHEM BIOPH RES CO, V146, P1392, DOI 10.1016/0006-291X(87)90804-7; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI AJ, 1993, EUR J BIOCHEM, V210, P521; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; EMARI Y, 1989, J BIOL CHEM, V264, P21885; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INOUE H, 1985, BIOCHEM BIOPH RES CO, V132, P513, DOI 10.1016/0006-291X(85)91163-5; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MATHEWS HR, 1988, NATURE, V334, P67; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZHU LQ, 1993, J BIOL CHEM, V268, P15994	45	113	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21318	21327						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407970				2022-12-25	WOS:A1993MA28800098
J	BOHME, B; HOLTRICH, U; WOLF, G; LUZIUS, H; GRZESCHIK, KH; STREBHARDT, K; RUBSAMENWAIGMANN, H				BOHME, B; HOLTRICH, U; WOLF, G; LUZIUS, H; GRZESCHIK, KH; STREBHARDT, K; RUBSAMENWAIGMANN, H			PCR MEDIATED DETECTION OF A NEW HUMAN RECEPTOR-TYROSINE-KINASE, HEK-2	ONCOGENE			English	Note								We have previously amplified cDNA subfragments of protein-tyrosine-kinases (PTKs) by using the polymerase chain reaction (PCR) and specific sets of oligonucleotide primers derived from nucleotide sequences of their kinase domain. In this study we have used a more directed approach to identify new members of the EPH/elk-family by PCR of human embryonic cDNA: we utilized oligonucleotide primers specifically designed to a highly conserved N-terminal motif and the kinase region of EPH/elk-PTKs in RNA-PCRs. The 5' and 3' elongation of the primary PCR product was achieved by the RACE (rapid amplification of cDNA ends)-technique. Sequence analysis of 3.8 kb of overlapping PCR products allowed to identify a novel receptor-PTK, HEK 2 (human embryo kinase 2), as an additional member of this family, without the need to screen a cDNA library. This approach should be useful for the rapid isolation of other PTK-genes as well. Analysis of genomic DNA placed HEK 2 on chromosome 3. Northern blot analysis demonstrated the expression of a 4.6 kb HEK 2-mRNA in lung, brain, pancreas, liver, placenta, kidney, skeletal muscle, heart and several human cells. In a protein kinase assay with HEK 2-specific immunoprecipitates from the human epidermoid carcinoma cell line A431, a protein of 130 kDa was found phosphorylated.	CHEMOTHERAPEUT FORSCHUNGSINST, GEORG SPEYER HAUS, PAUL EHRLICH STR 42-44, W-6000 FRANKFURT 70, GERMANY	Octapharma			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SHERR CJ, 1990, BLOOD, V75, P1; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275	26	67	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2857	2862						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397371				2022-12-25	WOS:A1993LX34300030
J	TENDIJKE, P; ICHIJO, H; FRANZEN, P; SCHULZ, P; SARAS, J; TOYOSHIMA, H; HELDIN, CH; MIYAZONO, K				TENDIJKE, P; ICHIJO, H; FRANZEN, P; SCHULZ, P; SARAS, J; TOYOSHIMA, H; HELDIN, CH; MIYAZONO, K			ACTIVIN RECEPTOR-LIKE KINASES - A NOVEL SUBCLASS OF CELL-SURFACE RECEPTORS WITH PREDICTED SERINE THREONINE KINASE-ACTIVITY	ONCOGENE			English	Note								Human cDNA clones encoding four novel putative transmembrane protein serine/threonine kinases, denoted activin receptor-like kinase (ALK) -1, -2, -3 and -4, were obtained using a polymerase chain reaction (PCR)-based strategy. The PCR primers were designed based upon the sequence similarity between the activin receptor type II and Daf-1. The cDNA clones for ALK-1, -2 and -3 encode complete proteins of 503, 509 and 532 amino acids respectively. The ALK-4 cDNA is incomplete and the predicted protein of 383 amino acids has a truncated extracellular domain. The ALKs share similar domain structures, comprising predicted signal sequences at the N-terminals, followed by hydrophilic cysteine-rich ligand-binding domains, single hydrophobic transmembrane regions and C-terminal intracellular portions that consist almost entirety of putative serine/threonine kinase domains. The ALKs have approximately 40% sequence identity to activin receptors type II and IIB, transforming growth factor-beta (TGF-beta) type II receptor and Daf-1 in the kinase domains. However, the sequence identities are higher (60-79%) between ALK-1, -2, -3 and -4, suggesting that they form a subfamily among the putative receptor serine/threonine kinases. The extracellular domains of ALKs show only tittle sequence identity to other putative receptor serine/threonine kinases, but the cysteine residues are conserved. Their structural properties suggest that ALK-1 to -4 are receptors that may bind ligands that are members of the TGF-beta super-family. The expression of mRNA in human tissues varied for the different ALKs; ALK-2 and ALK-4 showed ubiquitous tissue expression patterns, whereas the distribution of ALK-1 and ALK-3 varied strongly between different tissues with more restricted expression patterns. These results suggest that each ALK may have different in vivo functions.	UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	University of Tokyo	TENDIJKE, P (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1988, J BIOL CHEM, V263, P17225; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DONALDSON CJ, 1992, BIOCHEM BIOPH RES CO, V184, P310, DOI 10.1016/0006-291X(92)91194-U; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HINO M, 1989, J BIOL CHEM, V264, P10309; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEGERSKI R, 1992, BIOCHEM BIOPH RES CO, V183, P672, DOI 10.1016/0006-291X(92)90535-S; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PONCZ M, 1987, BLOOD, V69, P219; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SING GK, 1988, BLOOD, V72, P1504; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4863; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	60	314	347	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2879	2887						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397373				2022-12-25	WOS:A1993LX34300034
J	MACHIDA, S; SAITO, M				MACHIDA, S; SAITO, M			PURIFICATION AND CHARACTERIZATION OF MEMBRANE-BOUND CHITIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SYNTHETASE PARTICLES; CANDIDA-ALBICANS; PLASMA-MEMBRANE; CONCANAVALIN-A; S-CEREVISIAE; MUCOR-ROUXII; GENE; PROTEINS; CHITOSOMES	The membrane-bound chitin synthase, a key enzyme of chitin biosynthesis, was purified, for the first time to homogeneity as a zymogen form. Digitonin could solubilize the enzyme from microsomal fraction of the filamentous fungus Absidia glauca, with 60-70% of the enzyme activity. The solubilized form of the enzyme was effectively purified by a sequence of chelating Sepharose, concanavalin A-Sepharose, and Mono Q column. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the purified enzyme gave a single band with a molecular weight of 30,000. IgG prepared against this 30-kDa species on SDS-polyacrylamide gel electrophoresis immunoprecipitated chitin synthase. The purified enzyme existed as a zymogen, was converted into active form by treatment with trypsin, and the limited digestion with trypsin produced a little smaller polypeptide (28.5 kDa) of which the amino-terminal sequence was identical to the zymogen. The purified enzyme was the glycoprotein and showed a requirement for Mg2+. N-Acetylglucosamine stimulated the enzyme activity approximately 5-fold and polyoxin D, an analogue of substrate, and UDP, a by-product of enzyme reaction, strongly inhibited the enzyme activity.			MACHIDA, S (corresponding author), NATL FOOD RES INST, 2-1-2 KANNONDAI, TSUKUBA, IBARAKI 305, JAPAN.							ADAMS DJ, 1980, BIOTECHNOL LETT, V2, P75; AINOUZ IL, 1987, PHYTOCHEMISTRY, V26, P1435, DOI 10.1016/S0031-9422(00)81829-4; AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; Bartnicki-Garcia S, 1973, MICROBIAL DIFFERENTI, P245; BOWEN AR, 1992, P NATL ACAD SCI USA, V89, P519, DOI 10.1073/pnas.89.2.519; BRACKER CE, 1976, P NATL ACAD SCI USA, V73, P4570, DOI 10.1073/pnas.73.12.4570; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, 1988, MICROBIOL SCI, V5, P370; CABIB E, 1981, BIOL CARBOHYDRATES, V1, P51; Cabib E.., 1981, ENCY PLANT PHYSL N B, V13, P395; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CREAN EV, 1977, BIOCHEM BIOPH RES CO, V75, P488, DOI 10.1016/0006-291X(77)91068-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DICKINSON K, 1991, BIOCHIM BIOPHYS ACTA, V1073, P177, DOI 10.1016/0304-4165(91)90199-Q; DURAN A, 1975, P NATL ACAD SCI USA, V72, P3952, DOI 10.1073/pnas.72.10.3952; FRITSCH A, 1973, ANAL BIOCHEM, V55, P57, DOI 10.1016/0003-2697(73)90290-X; HUMPHREYS AM, 1984, J GEN MICROBIOL, V130, P1359; KANG MS, 1984, J BIOL CHEM, V259, P4966; KIKUCHI H, 1981, ANAL BIOCHEM, V115, P109, DOI 10.1016/0003-2697(81)90532-7; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; KOBAYASHI T, 1988, NIPPON NOGEIK KAISHI, V62, P1463; KOGA D, 1983, INSECT BIOCHEM, V13, P295, DOI 10.1016/0020-1790(83)90052-5; KONDO M, 1991, ELECTROPHORESIS, V12, P685, DOI 10.1002/elps.1150120918; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEALMORALES CA, 1988, P NATL ACAD SCI USA, V85, P8516, DOI 10.1073/pnas.85.22.8516; LENDING CR, 1991, EXP MYCOL, V15, P11, DOI 10.1016/0147-5975(91)90003-V; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASSON JM, 1987, EUR J MED CHEM, V22, P377, DOI 10.1016/0223-5234(87)90024-9; MONTGOMERY GWG, 1984, J GEN MICROBIOL, V130, P291; PITT JI, 1985, FUNGI FOOD SPOILAGE, P147; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RUIZHERRERA J, 1987, ARCH MICROBIOL, V149, P156, DOI 10.1007/BF00425082; RUIZHERRERA J, 1976, J GEN MICROBIOL, V97, P241, DOI 10.1099/00221287-97-2-241; SBURLATI A, 1986, J BIOL CHEM, V261, P5147; SILVERMAN SJ, 1989, YEAST, V5, P459, DOI 10.1002/yea.320050605; SMITH TL, 1989, P NATL ACAD SCI USA, V86, P7063, DOI 10.1073/pnas.86.18.7063; TEEPE H, 1988, FEBS LETT, V234, P100, DOI 10.1016/0014-5793(88)81312-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO M, 1991, J BIOL CHEM, V266, P3146; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101; WANG YC, 1992, J BIOL CHEM, V267, P2728; YAMAUCHI D, 1990, FEBS LETT, V260, P127, DOI 10.1016/0014-5793(90)80083-U; YARDEN O, 1991, GENE DEV, V5, P2420, DOI 10.1101/gad.5.12b.2420	47	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1702	1707						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420947				2022-12-25	WOS:A1993KH62000032
J	CHUANG, TH; XU, XM; KNAUS, UG; HART, MJ; BOKOCH, GM				CHUANG, TH; XU, XM; KNAUS, UG; HART, MJ; BOKOCH, GM			GDP DISSOCIATION INHIBITOR PREVENTS INTRINSIC AND GTPASE ACTIVATING PROTEIN-STIMULATED GTP HYDROLYSIS BY THE RAC GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXIDASE	The majority of the GTP-binding proteins of the Ras superfamily hydrolyze GTP to GDP very slowly. A notable exception to this are the Rac proteins, which have intrinsic GTPase rates at least 50-fold those of Ras or Rho. A protein (or proteins) capable of inhibiting this GTPase activity exists in human neutrophil cytosol. Since Rac appears to exist normally in neutrophils as a cytosolic protein complexed to (Rho)GDI, we examined the ability of (Rho)GDI to inhibit GTP hydrolysis by Rac. (Rho)GDI produced a concentration-dependent inhibition of GTP hydrolysis by Rac1 that paralleled its ability to inhibit GDP dissociation from the Rac protein. Maximal inhibition occurred at or near equimolar concentrations of the GDI and the Rac substrate. The ability of two molecules exhibiting GTPase activating protein (GAP) activity toward Rac to stimulate GTP hydrolysis was also inhibited by the presence of (Rho)GDI. The inhibitory effect of the GDI could be overcome by increasing the GAP concentration to levels equal to that of the GDI. (Rho)GDI weakly, but consistently, inhibited GTPgammaS (guanosine 5'-3-O-(thio) triphosphate) dissociation from Rac1, confirming an interaction of (Rho)GDI with the GTP-bound form of the protein. These data describe an additional activity of (Rho)GDI and suggest a mechanism by which Rac might be maintained in an active form in vivo in the presence of regulatory GAPs.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; CORNELL UNIV, DEPT BIOCHEM, ITHACA, NY 14853 USA; CORNELL UNIV, DEPT CELL & MOLEC BIOL, ITHACA, NY 14853 USA; CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA	Scripps Research Institute; Scripps Research Institute; Cornell University; Cornell University; Cornell University			Chuang, Tsung-Hsien/F-9679-2010	xu, xuemin/0000-0002-7426-272X; Hart, Matthew/0000-0002-2683-480X	NHLBI NIH HHS [HL48008] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, J BIOL CHEM, V266, P20846; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HORI Y, 1991, ONCOGENE, V6, P515; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1990, J BIOL CHEM, V265, P9373; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	27	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					775	778						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419353				2022-12-25	WOS:A1993KG07700006
J	GUELIN, E; CHEVALLIER, J; RIGOULET, M; GUERIN, B; VELOURS, J				GUELIN, E; CHEVALLIER, J; RIGOULET, M; GUERIN, B; VELOURS, J			ATP SYNTHASE OF YEAST MITOCHONDRIA - ISOLATION AND DISRUPTION OF THE ATP-EPSILON-GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; BOVINE MITOCHONDRIA; RAPID METHOD; RAT-LIVER; SUBUNIT; PROTEIN; DICYCLOHEXYLCARBODIIMIDE; COMPLEX	The nuclear gene encoding the subunit epsilon of the catalytic sector F1 of the yeast Saccharomyces cerevisiae ATP synthase was cloned and sequenced. Degenerated oligonucleotide primers were constructed from primary structure data. A part of the ATPepsilon gene was amplified by polymerase chain reaction from yeast genomic DNA. From the amplified DNA sequence a nondegenerated oligonucleotide probe was constructed and used for isolating a 2040-base pair EcoRI fragment bearing the whole gene. A 186-base pair open reading frame encoding a 62-amino acid polypeptide is described. The deduced amino acid sequence was one amino acid longer than the mature protein. A null mutant was constructed. The mutant strain was unable to grow on glycerol medium. The mutant mitochondria had no detectable oligomycin-sensitive ATPase activity. The catalytic sector appeared unstable during purification but F0-subunits were still bound to F1. The mutation promoted a highly oligomycin-sensitive uncoupling of the mitochondrial respiration rate.	UNIV BORDEAUX 2,CNRS,INST BIOCHIM CELLULAIRE,1 RUE CAMILLE ST SAENS,F-33077 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; AGGELER R, 1990, J BIOL CHEM, V265, P16389; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BAIRD BA, 1977, J BIOL CHEM, V252, P4743; BEECHEY RB, 1975, BIOCHEM J, V148, P533, DOI 10.1042/bj1480533; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; CAIN K, 1977, BIOCHEM J, V162, P575, DOI 10.1042/bj1620575; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; DUPUIS A, 1991, BIOCHEMISTRY-US, V30, P2954, DOI 10.1021/bi00225a032; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GAROFF H, 1981, ANAL BIOCHEM, V115, P450, DOI 10.1016/0003-2697(81)90031-2; GLASER E, 1982, EUR J BIOCHEM, V121, P525, DOI 10.1111/j.1432-1033.1982.tb05818.x; Guerin B, 1979, Methods Enzymol, V55, P149; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HEALY AM, 1990, CURR GENET, V18, P105, DOI 10.1007/BF00312597; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON JR, 1988, YEAST PRACTICAL APPR, P107; KIMURA T, 1989, J BIOL CHEM, V264, P3183; KOPECKY J, 1983, EUR J BIOCHEM, V131, P17, DOI 10.1111/j.1432-1033.1983.tb07226.x; LARDY HA, 1953, J BIOL CHEM, V210, P357; LEE CP, 1966, REGULATION METABOLIC, P218; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAZAT JP, 1986, BIOCHIM BIOPHYS ACTA, V849, P7, DOI 10.1016/0005-2728(86)90090-3; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; NORAIS N, 1991, J BIOL CHEM, V266, P16541; PAUL MF, 1992, EUR J BIOCHEM, V205, P163, DOI 10.1111/j.1432-1033.1992.tb16764.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENIN F, 1990, BIOCHEMISTRY-US, V29, P9358, DOI 10.1021/bi00492a008; RIGOULET M, 1987, EUR J BIOCHEM, V168, P275, DOI 10.1111/j.1432-1033.1987.tb13417.x; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKESHIGE K, 1976, H-S Z PHYSIOL CHEM, V357, P1605, DOI 10.1515/bchm2.1976.357.2.1605; VELOURS J, 1987, EUR J BIOCHEM, V164, P579, DOI 10.1111/j.1432-1033.1987.tb11166.x; VINAS O, 1990, BIOCHEM J, V265, P312; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183	48	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					161	167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416924				2022-12-25	WOS:A1993KE60300025
J	CHEN, JH; JEHA, S; OKA, T				CHEN, JH; JEHA, S; OKA, T			NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ETS1 GENE PROMOTER	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; DNA-BINDING; LOCALIZATION; EXPRESSION; PROTEIN; CELLS; IDENTIFICATION; THYMOCYTES; SEQUENCE	The human ETS1 gene promoter contains binding sites for transcription factors AP1, AP2 and ETS. These factors have been previously shown to be positive regulators for the expression of the ETS1 gene. In our previous report it was inferred that the ETS1 gene promoter also contains negative regulatory elements that might balance and prevent the overexpression of the ETS1 gene product. The studies reported here show that the ETS1 gene promoter also contains binding site motifs for transcription factors PEA3 and OCT. By subjecting deletion constructs of the ETS1 gene promoter to functional analysis, two negative regulatory elements (NREs) were located: NRE1 was mapped to 230 nt at the 5' end of the promoter, and NRE2 was mapped to 350 nt located between the second OCT motif and a 120-base sequence downstream from the SacI site. These NREs can also reduce the activity of a heterogeneous promoter. Gel mobility-shift assays showed that nuclear extracts from B-lymphoid (Daudi), T-lymphoid (HPB) and erthyromyeloid (K562) cells each form one major and several minor complexes with NRE1 and NRE2. The nuclear extract from promyelocytic (HL60) cells does not form complexes with either NRE1 or NRE2. The identification of NREs in the ETS1 gene promoter suggests that these elements play an important role in regulating the ETS1 gene expression in hematopoietic cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; ASAHIKAWA MED COLL,DEPT PEDIAT,ASAHIKAWA 07811,JAPAN	University of Texas System; UTMD Anderson Cancer Center; Asahikawa Medical College	CHEN, JH (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPTL PHYS,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHER RJ, 1991, ONCOGENE, V6, P2249; FUJIWARA S, 1988, ONCOGENE, V2, P99; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SACCHI N, 1988, LEUKEMIA, V2, P12; STRONG RC, 1985, BLOOD, V65, P21; SVAREN J, 1987, NUCLEIC ACIDS RES, V21, P8739; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1989, J BIOL CHEM, V264, P14840; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	27	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					133	139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423991				2022-12-25	WOS:A1993KN00500016
J	SLEEMAN, JP; LASKEY, RA				SLEEMAN, JP; LASKEY, RA			XENOPUS C-SKI CONTAINS A NOVEL COILED-COIL PROTEIN DOMAIN, AND IS MATERNALLY EXPRESSED DURING DEVELOPMENT	ONCOGENE			English	Article							MESSENGER-RNA; ONCOGENE PRODUCT; SKELETAL-MUSCLE; TGF-BETA; SEQUENCE; CLONING; CELLS; GENE; DIFFERENTIATION; IDENTIFICATION	v-ski is a virally transduced nuclear oncogene. The biology of its cellular progenitors is only poorly understood. The early development of Xenopus laevis provides an excellent model system for studying the role of genes in proliferation, differentiation and development. We have therefore characterized Xenopus c-ski. We report that Xenopus c-ski transcripts are maternally regulated during early development, and are widely expressed in adult tissues. Structural predictions indicate the presence of a previously unreported extensive C-terminal helical domain in Xenopus c-ski and ski-related proteins from other species. This domain shows homologies with proteins which contain heptad repeats characteristic of elongated coiled-coil formation, like myosin and the intermediate filament proteins, and itself has a heptad repeat structure. The ski C-terminal domain also contains two other previously unreported elements, a novel strictly alternating hydrophobic-basic motif that repeats along the helical domain, and an underlying 25-mer repeated sequence. The significance of these findings is discussed with reference to c-ski function and to the oncogenic activation of v-ski, which is a truncated version of c-ski and thus does not have the C-terminal helical domain.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND				Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; Berger S.L., 1987, METHODS ENZYMOLOGY, V152; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNAHASHI S, 1988, J GEN VIROL, V69, P35, DOI 10.1099/0022-1317-69-1-35; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; KAVINSKY CJ, 1984, J BIOL CHEM, V259, P2775; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KLYMKOWSKY MW, 1989, DEV BIOL, V134, P479, DOI 10.1016/0012-1606(89)90121-8; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANJULA BN, 1984, J BIOL CHEM, V259, P3686; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PARRY DAD, 1981, J MOL BIOL, V153, P459, DOI 10.1016/0022-2836(81)90290-4; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P431; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; [No title captured]	50	36	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					67	77						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423997				2022-12-25	WOS:A1993KN00500008
J	HAUPT, Y; BATH, ML; HARRIS, AW; ADAMS, JM				HAUPT, Y; BATH, ML; HARRIS, AW; ADAMS, JM			BMI-1 TRANSGENE INDUCES LYMPHOMAS AND COLLABORATES WITH MYC IN TUMORIGENESIS	ONCOGENE			English	Note							V-ETS; MICE; ONCOGENE; COOPERATION; EXPRESSION; LEUKEMIA; MODELS; VIRUS	The bmi-1 gene was discovered as a frequent target of Moloney virus insertion in virally accelerated B-lymphoid tumors of Emu-myc transgenic mice and hence is thought to collaborate with the myc gene in lymphomagenesis, but its oncogenic potential has not previously been tested directly. To determine whether bmi-1 overexpression can contribute to hematopoietic neoplasia in vivo, strains of transgenic mice were generated in which bmi-1 expression was directed to the lymphoid compartment by a coupled immunoglobulin heavy chain enhancer (Emu). Although the Emu-bmi-1 transgene was expressed in both B and T cells, lymphoid development was not perturbed. Nevertheless, 14% of the mice in the strain with highest expression have developed lymphoma. Unexpectedly, most tumors were of the T-cell lineage, although one case of B lymphoma was observed. Furthermore, cross breeding Emu-bmi-1 and Emu-myc mice established that the bmi-1 transgene markedly accelerated the onset of pre-B and B lymphomas. These results demonstrate directly that bmi-1 can contribute to lymphomagenesis in the T and B cell lineages and collaborate with the myc gene in tumor development.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAUPT Y, 1992, THESIS U MELBOURNE; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEVY LS, 1992, J VIROL, V66, P2885, DOI 10.1128/JVI.66.5.2885-2892.1992; LEVY LS, 1993, IN PRESS ONCOGENE; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1992, ONCOGENE, V7, P597; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WEINBERG RA, 1989, CANCER RES, V49, P3713	21	156	167	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3161	3164						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414519				2022-12-25	WOS:A1993MC09300034
J	CAO, YJ; SKURAT, AV; DEPAOLIROACH, AA; ROACH, PJ				CAO, YJ; SKURAT, AV; DEPAOLIROACH, AA; ROACH, PJ			INITIATION OF GLYCOGEN-SYNTHESIS - CONTROL OF GLYCOGENIN BY GLYCOGEN-PHOSPHORYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SYNTHASE; KINASE; BIOSYNTHESIS; BIOGENESIS; GLUCOSE; PROTEIN; LIVER	Glycogen biosynthesis involves a specific initiation event, mediated by a specialized protein, glycogenin. Glycogenin undergoes self-glucosylation to generate an oligosaccharide primer, which, when long enough, supports the action of glycogen synthase to elongate the polysaccharide chain, leading ultimately to the formation of glycogen. We report that primed glycogenin is also a substrate for glycogen phosphorylase. Phosphorylase removed glucose from the oligosaccharide attached to glycogenin in a phosphorolysis reaction that required phosphate and produced glucose 1-phosphate. The phosphorylated form, phosphorylase a, was much more effective than the dephosphorylated phosphorylase b. However, in the presence of the allosteric effector AMP, phosphorylase b also catalyzed the phosphorolysis reaction. Glucose, an allosteric inhibitor of phosphorylase, inhibited the reaction. Glycogen, but not a short oligosaccharide (maltopentaose), also inhibited the reaction. Treatment of fully primed glycogenin with phosphorylase converted the glycogenin to a form with slightly lower apparent molecular weight, which was less effective as a substrate for glycogen synthase. These results suggest a novel role for phosphorylase in the control of glycogen biosynthesis. We propose that the glucosylation level of glycogenin would be determined by the balance between the self-glucosylation reaction and the opposing action of phosphorylase. The level of glucosylation would in turn determine whether or not glycogenin was an effective primer for glycogen synthase. In this way, several known controls of phosphorylase activity, such as epinephrine, glucagon, and insulin, could influence not only the elongation/degradation stage of glycogen metabolism but also its initiation.			CAO, YJ (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202, USA.				NIDDK NIH HHS [DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1986, ARCH BIOCHEM BIOPHYS, V250, P329, DOI 10.1016/0003-9861(86)90734-4; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CARTER J, 1978, CARBOHYD RES, V61, P395, DOI 10.1016/S0008-6215(00)84499-7; COHEN P, 1907, EUR J BIOCHEM, V34, P1; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; EXTON JH, 1986, ADV CYCLIC NUCL PROT, V20, P211; HEMS DA, 1980, PHYSIOL REV, V60, P1; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; REBERS PA, 1986, CARBOHYD RES, V153, P132, DOI 10.1016/S0008-6215(00)90202-7; REINER JM, 1959, BEHAVIOR ENZYME SYST, P54; ROACH PJ, 1978, J CYCLIC NUCL PROT, V4, P245; ROBYT JF, 1987, BIOCH TECHNIQUES, P218; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; STALMANS W, 1983, HDB EXPT PHARM, V66, P291; THOMA JA, 1971, ENZYMES, V5, P115; Wang J. H, 1972, ENZYMES, V7, P435; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	28	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21717	21721						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408025				2022-12-25	WOS:A1993MC80900046
J	EADARA, JK; LUTTER, LC				EADARA, JK; LUTTER, LC			RNA-POLYMERASE LOCATIONS IN THE SIMIAN VIRUS-40 TRANSCRIPTION COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE TERMINATION; SV40 MINICHROMOSOMES; T-ANTIGEN; C-MYC; DNA; CELLS; ELONGATION; INVITRO; GENE; MECHANISM	Transcription complexes of simian virus 40 can be isolated from cells late in infection in a form that retains the ability to continue transcription in vitro. These complexes have been investigated previously to gain information about the nucleoprotein structure of a transcribing gene. However, several studies have reported that the RNA polymerase molecules in such complexes are located almost entirely at the 5' end of the transcription unit. This would indicate that these complexes cannot be those which were in the process of transcribing mRNA in the cell, because the transcribing complexes would be expected to contain polymerases that were distributed throughout the transcription unit at the time of extraction. Since this issue is important to the interpretation of studies which characterize the extracted complexes, we have determined the polymerase locations using two new approaches. The first employs a new application of a procedure in which the transcription complex DNA is radioactively tagged by transcription in vitro. The second is a new method, which analyzes run-off transcripts generated in vitro. Both methods demonstrate that the polymerases are distributed throughout the genome in the transcription complexes. This result indicates that these complexes were in the process of transcribing mRNA at the time of cell lysis.	HENRY FORD HOSP,MOLEC BIOL RES PROGRAM,2799 W GRAND BLVD,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								ACHESON NH, 1981, MOL BIOL TUMOR VIR 2, P61; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BONILLA PJ, 1991, NUCLEIC ACIDS RES, V19, P3965, DOI 10.1093/nar/19.14.3965; CHIKARAISHI DM, 1981, J VIROL, V37, P511, DOI 10.1128/JVI.37.1.511-517.1981; CHODER M, 1988, NUCLEIC ACIDS RES, V16, P895, DOI 10.1093/nar/16.3.895; CHODER M, 1984, EMBO J, V3, P2929, DOI 10.1002/j.1460-2075.1984.tb02234.x; CHODER M, 1988, J BIOL CHEM, V263, P12994; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; EDENBERG HJ, 1980, NUCLEIC ACIDS RES, V8, P573, DOI 10.1093/nar/8.3.573; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; GARIGLIO P, 1979, J MOL BIOL, V131, P75, DOI 10.1016/0022-2836(79)90302-4; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; HADLOCK KG, 1990, J MOL BIOL, V215, P53, DOI 10.1016/S0022-2836(05)80094-4; HADLOCK KG, 1987, J BIOL CHEM, V262, P15527; HADLOCK KG, 1988, DNA PROTEIN ENG TECH, V1, P9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; LAUB O, 1976, VIROLOGY, V75, P346, DOI 10.1016/0042-6822(76)90033-7; LAUB O, 1980, P NATL ACAD SCI-BIOL, V77, P3297, DOI 10.1073/pnas.77.6.3297; LAUB O, 1979, VIROLOGY, V92, P310, DOI 10.1016/0042-6822(79)90136-3; LLOPIS R, 1981, J VIROL, V38, P82, DOI 10.1128/JVI.38.1.82-90.1981; LLOPIS R, 1982, J VIROL, V44, P864, DOI 10.1128/JVI.44.3.864-870.1982; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; LUTTER LC, 1989, P NATL ACAD SCI USA, V86, P8712, DOI 10.1073/pnas.86.22.8712; MANIATIS T, 1982, MOL CLONING LABORATO, P380; PETRYNIAK B, 1987, CELL, V48, P289, DOI 10.1016/0092-8674(87)90432-6; PFEIFFER P, 1983, EMBO J, V2, P185, DOI 10.1002/j.1460-2075.1983.tb01403.x; SALZMAN NP, 1986, PAPOVAVIRIDAE, P27; SHANI M, 1977, J VIROL, V23, P20, DOI 10.1128/JVI.23.1.20-28.1977; SKOLNIKDAVID H, 1982, P NATL ACAD SCI-BIOL, V79, P2743, DOI 10.1073/pnas.79.9.2743; SPENCER CA, 1990, ONCOGENE, V5, P777; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; UCKER DS, 1984, J BIOL CHEM, V259, P7416; van Holde K. E., 1989, SPRINGER SERIES MOL, P355	33	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22020	22027						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408059				2022-12-25	WOS:A1993MC80900087
J	MILNER, RE; BUSAAN, JL; HOLMES, CFB; WANG, JH; MICHALAK, M				MILNER, RE; BUSAAN, JL; HOLMES, CFB; WANG, JH; MICHALAK, M			PHOSPHORYLATION OF DYSTROPHIN - THE CARBOXYL-TERMINAL REGION OF DYSTROPHIN IS A SUBSTRATE FOR IN-VITRO PHOSPHORYLATION BY P34(CDC2) PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; CARDIAC SARCOLEMMAL VESICLES; CYSTEINE-RICH DOMAIN; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; NONMUSCLE TISSUES; CELL-CYCLE; GENE; BINDING; ASSOCIATION	In this paper, we report that p34cdc2 protein kinase phosphorylates recombinant fragments of skeletal muscle dystrophin with a maximal incorporation of 1.8 mol of P(i)/mol of protein. Phosphorylation of both serine and threonine residues occurs within the carboxyl-terminal 201 amino acids of dystrophin, with phosphothreonine localized to within 25 residues of the carboxyl terminus. Supporting these in vitro studies, we also show that native dystrophin is phosphorylated by p34cdc2 kinase in isolated sarcolemmal vesicles. Sequence analysis indicates two consensus sites for p34cdc2 protein kinase within the carboxyl-terminal 201 amino acids of dystrophin. Importantly, neither of these sites is conserved in dystrophin-related protein, and only one site is conserved in the 71-kDa alternative product of the Duchenne muscular dystrophy gene, despite an otherwise extremely high degree of sequence conservation between these proteins. Importantly, in this study we also show that dystrophin is phosphorylated in vivo in rat skeletal muscle primary cultures, and we suggest that further investigation of both in vivo and in vitro phosphorylation of this protein will comprise an important part in determination of its function(s).	UNIV ALBERTA, DEPT BIOCHEM, CARDIOVASC DIS RES GRP, 424 HERITAGE MED RES CTR, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT GRP, EDMONTON T6G 2S2, AB, CANADA; UNIV CALGARY, FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP, CALGARY T2N 4N1, AB, CANADA	University of Alberta; University of Alberta; University of Calgary								AHMAD Z, 1982, J BIOL CHEM, V257, P8348; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BAR S, 1990, BIOCHEM J, V272, P557, DOI 10.1042/bj2720557; BIES RD, 1992, J CLIN INVEST, V90, P666, DOI 10.1172/JCI115909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHEN XY, 1991, BIOCHEM J, V279, P467, DOI 10.1042/bj2790467; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; CHOU YH, 1991, J BIOL CHEM, V266, P7325; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; HOFFMAN EP, 1991, ANN NEUROL, V30, P605, DOI 10.1002/ana.410300414; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KLAMUT HJ, 1989, BRIT MED BULL, V45, P681, DOI 10.1093/oxfordjournals.bmb.a072352; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LEW J, 1992, J BIOL CHEM, V267, P13383; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MAK AS, 1991, J BIOL CHEM, V266, P6678; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHALAK M, 1980, J BIOL CHEM, V255, P1327; MICHALAK M, 1990, J BIOL CHEM, V265, P5869; MILNER RE, 1992, BIOCHEM J, V288, P1037, DOI 10.1042/bj2881037; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WOLF M, 1985, J BIOL CHEM, V260, P5718; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	43	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21901	21905						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408045				2022-12-25	WOS:A1993MC80900071
J	NEUENSCHWANDER, PF; FIORE, MM; MORRISSEY, JH				NEUENSCHWANDER, PF; FIORE, MM; MORRISSEY, JH			FACTOR-VII AUTOACTIVATION PROCEEDS VIA INTERACTION OF DISTINCT PROTEASE-COFACTOR AND ZYMOGEN-COFACTOR COMPLEXES - IMPLICATIONS OF A 2-DIMENSIONAL ENZYME-KINETIC MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COAGULATION FACTOR-VII; FACTOR-DEPENDENT AUTOACTIVATION; BOVINE FACTOR-VII; TISSUE FACTOR; BLOOD-COAGULATION; FACTOR-X; HAGEMAN-FACTOR; FACTOR-XII; ACTIVATION; PROTHROMBINASE	Tissue factor (TF), an integral membrane protein, enhances the feedback activation of factor VII by factor VIIa (factor VII autoactivation). We found that, in contrast to the other known membrane-dependent coagulation activation reactions, TF-dependent factor VII autoactivation occurred preferentially on neutral phospholipid vesicles relative to negatively charged vesicles containing phosphatidylserine. This reaction was best described by a novel mechanism in which the enzyme and substrate are each bound to separate cofactor (TF) molecules. This unusual mechanism of substrate presentation to a membrane-bound protease predicts that the reaction rate will be directly dependent on the surface density, and hence lateral diffusion, of factor VII.TF and factor VIIa.TF complexes, obeying obligatorily two-dimensional enzyme kinetics. This prediction was confirmed, yielding a two-dimensional second-order rate constant (k2D) of 4.9 (+/- 0.8) x 10(6) m2 mol-1 s-1. Since intact cells normally sequester acidic phospholipids away from the outer leaflet of the plasma membrane, this reaction mechanism should permit factor VII autoactivation to predominate on unactivated/undamaged cell surfaces when other clotting reactions are dormant.	OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008710, R01HL047014] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-47014, F32 HL-08710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; FIORE MM, 1992, BLOOD, V80, P3127; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRIEP MA, 1986, BIOCHEMISTRY-US, V25, P6688, DOI 10.1021/bi00369a054; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MASYS DR, 1982, BLOOD, V60, P1143; MILLER BC, 1985, BLOOD, V65, P845; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORRISSEY JH, 1993, BLOOD, V81, P734; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1988, BLOOD, V71, P1; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; ROSING J, 1980, J BIOL CHEM, V255, P274; SMALL DM, 1967, J LIPID RES, V8, P551; TANS G, 1983, J BIOL CHEM, V258, P8215; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089	33	110	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21489	21492						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407997				2022-12-25	WOS:A1993MC80900010
J	LEHMAN, JJ; BROWN, KA; RAMANADHAM, S; TURK, J; GROSS, RW				LEHMAN, JJ; BROWN, KA; RAMANADHAM, S; TURK, J; GROSS, RW			ARACHIDONIC-ACID RELEASE FROM AORTIC SMOOTH-MUSCLE CELLS INDUCED BY [ARG(8)]VASOPRESSIN IS LARGELY MEDIATED BY CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOSOLIC PHOSPHOLIPASE-A2; VASOPRESSIN RECEPTORS; CANINE MYOCARDIUM; IDENTIFICATION; PURIFICATION; PHOSPHATIDYLINOSITOL; ACTIVATION; LINE; GLYCEROPHOSPHOLIPIDS; PHOSPHATIDYLCHOLINE	To identify the phospholipase mediating the majority of [Arg8]vasopressin (AVP)-induced release of arachidonic acid in A-10 smooth muscle cells, we exploited the specificity inherent in the mechanism-based inhibitor, (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)2H-pyran-2-one (HELSS), which possesses a 1,000-fold selectivity for inhibition of calcium-independent versus calcium-dependent phospholipases A2. Utilizing [H-3]arachidonic acid-labeled A-10 smooth muscle cells, one-half of AVP-inducible [H-3]arachidonic acid release was inhibited by pretreatment with only 1 muM HELSS and two-thirds of AVP-stimulated [H-3]arachidonic acid release was inhibited by 5 muM HELSS. The inhibition of [H-3]arachidonic acid release by HELSS was saturable (i.e. no additional inhibition of [H-3]arachidonic acid release was present at 10 muM HELSS), specific (i.e. the activities of six intracellular enzymes, as well as the rate of glucose oxidation, were not altered by HELSS treatment), and nontoxic (i.e. HELSS-treated cells excluded trypan blue dye and did not leak intracellular enzymes into the medium). Collectively, these results demonstrate that HELSS blocks AVP-induced arachidonic acid release by specific and irreversible inhibition of calcium-independent phospholipase A2 and underscore the importance of calcium-independent phospholipase A2 in agonist-induced arachidonic acid release in at least some cell types.	WASHINGTON UNIV, SCH MED,DEPT MED, DIV BIOORGAN CHEM & MOLEC PHARMACOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT LAB MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					PHS HHS [34839] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGWU DE, 1989, J BIOL CHEM, V264, P1405; BERGMEYER HU, 1978, CLIN CHEM, V24, P58; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; GARCIAGIL M, 1986, J IMMUNOL, V136, P3825; GAY RJ, 1968, CLIN CHEM, V14, P740; GONG MC, 1992, J BIOL CHEM, V267, P21492; GOSS RW, 1993, BIOCHEMISTRY-US, V32, P327; GRILLONE LR, 1988, J BIOL CHEM, V263, P2658; HAZEN SL, 1991, METHOD ENZYMOL, V197, P400; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LOEB LA, 1986, J BIOL CHEM, V261, P467; MCDANIEL ML, 1974, DIABETOLOGIA, V10, P303; MEADE CJ, 1986, BIOCHEM J, V238, P425, DOI 10.1042/bj2380425; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STASSEN FL, 1987, MOL PHARMACOL, V31, P259; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; THIBONNIER M, 1991, ENDOCRINOLOGY, V129, P2845, DOI 10.1210/endo-129-6-2845; THOMAS JMF, 1984, THROMB RES, V34, P117, DOI 10.1016/0049-3848(84)90068-9; WACKER WEC, 1956, NEW ENGL J MED, V255, P449, DOI 10.1056/NEJM195609062551001; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1991, FEBS LETT, V284, P27, DOI 10.1016/0014-5793(91)80753-P	35	109	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20713	20716						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407892				2022-12-25	WOS:A1993MA28800009
J	HELL, JW; YOKOYAMA, CT; WONG, ST; WARNER, C; SNUTCH, TP; CATTERALL, WA				HELL, JW; YOKOYAMA, CT; WONG, ST; WARNER, C; SNUTCH, TP; CATTERALL, WA			DIFFERENTIAL PHOSPHORYLATION OF 2 SIZE FORMS OF THE NEURONAL CLASS-C L-TYPE CALCIUM-CHANNEL ALPHA-1 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SKELETAL-MUSCLE; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CA2+ CHANNELS; DIHYDROPYRIDINE RECEPTOR; CATALYTIC SUBUNIT; ACTION-POTENTIALS; VERTEBRATE CELLS	L-type calcium channels mediate long-lasting calcium currents which are modulated by protein phosphorylation. Using site-directed anti-peptide antibodies, we show that the alpha1 subunit of the neuronal class C L-type calcium channel from rat brain exists in two size forms. The longer form, L(C2), with an apparent molecular mass of 210-235 kDa was phosphorylated in vitro by cAMP-dependent protein kinase (cA-PK), but the shorter form, L(C1), with an apparent molecular mass of 190-195 kDa was not a substrate for cA-PK. In contrast, L(C1) and L(C2) are both substrates for protein kinase C (PKC), calcium- and calmodulin-dependent protein kinase II, and cGMP-dependent protein kinase (cG-PK). The site-directed anti-peptide antibody CNC2 was produced against the COOH-terminal end of the class C L-type alpha1 subunit as predicted by molecular cloning and sequencing of cDNA. CNC2 recognized L(C2) but not L(C1) by immunoblotting and immunoprecipitated only L(C2) Phosphorylated by either cA-PK or PKC. These results indicate that L(C1) is truncated at its COOH-terminal end with respect to L(C2) and that cA-PK preferentially phosphorylates sites in the COOH-terminal region of the alpha1 subunit that are present in L(C2) but not L(C1). The selectivity of cA-PK for phosphorylation of the COOH-terminal region of L(C2) suggests that the channel activities of the two alpha1 subunit size forms may be differentially regulated by neurotransmitters and hormones which act through cAMP-dependent mechanisms, while both alpha1 subunit isoforms may be modulated by PKC, cG-PK, and calcium- and calmodulin-dependent protein kinase II.	UNIV WASHINGTON, GRAD PROGRAM NEUROBIOL, SEATTLE, WA 98195 USA; UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT ZOOL, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT NEUROSCI, VANCOUVER V6T 1W5, BC, CANADA	University of Washington; University of Washington Seattle; University of British Columbia; University of British Columbia; University of British Columbia	HELL, JW (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.		Snutch, Terrance P/L-3464-2019; Hell, Johannes W./P-5085-2019	Snutch, Terrance P/0000-0001-5182-1296; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020482, R01NS022625] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS22625, P01-NS 20482] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BLOCK LH, 1991, P NATL ACAD SCI USA, V88, P9041, DOI 10.1073/pnas.88.20.9041; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHANG FC, 1988, J BIOL CHEM, V263, P18929; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DOERNER D, 1990, J NEUROSCI, V10, P1699; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; DOROSHENKO PA, 1984, NEUROSCIENCE, V11, P263, DOI 10.1016/0306-4522(84)90229-X; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLOCKERZI V, 1986, EUR J BIOCHEM, V161, P217, DOI 10.1111/j.1432-1033.1986.tb10145.x; GERSCHENFELD HM, 1991, J PHYSIOL-LONDON, V434, P85, DOI 10.1113/jphysiol.1991.sp018460; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; GROSS RA, 1990, J PHYSIOL-LONDON, V429, P483, DOI 10.1113/jphysiol.1990.sp018268; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAI Y, 1990, J BIOL CHEM, V265, P20839; LIPSCOMBE D, 1992, SOC NEUR ABSTR, V14, P153; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MUNDINAWEILENMANN C, 1991, J BIOL CHEM, V266, P4067; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NASTAINCZYK W, 1987, EUR J BIOCHEM, V169, P137, DOI 10.1111/j.1432-1033.1987.tb13590.x; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; RANE SG, 1986, P NATL ACAD SCI USA, V83, P184, DOI 10.1073/pnas.83.1.184; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TAKAHASHI M, 1987, SCIENCE, V236, P88, DOI 10.1126/science.2436296; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WERZ MA, 1987, J NEUROSCI, V7, P1639; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; YOSHIDA A, 1990, J BIOCHEM, V107, P608, DOI 10.1093/oxfordjournals.jbchem.a123094; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	70	155	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19451	19457						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396138				2022-12-25	WOS:A1993LW81900048
J	OHMORI, Y; TANABE, J; TAKADA, S; LEE, WMF; OBINATA, M				OHMORI, Y; TANABE, J; TAKADA, S; LEE, WMF; OBINATA, M			FUNCTIONAL DOMAINS OF C-MYC INVOLVED IN THE COMMITMENT AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	ONCOGENE			English	Article							DNA-BINDING; LEUCINE ZIPPER; ERYTHROID DIFFERENTIATION; NUCLEAR-LOCALIZATION; PROTEIN; GENE; SEQUENCE; TRANSLOCATION; EXPRESSION; TRANSFORMATION	In the early event of the induction of mouse erythroleukemia (MEL) cell differentiation, c-myc mRNA levels show a drastic change. The elevated expression of a transfected c-myc gene inhibits the commitment and differentiation of MEL cell transformants. In the present work, we have introduced human c-myc mutants into MEL cells under the inducible promoter to define the functional domains of c-Myc involved in erythroid differentiation. The c-Myc domains necessary for commitment and differentiation are not co-localized; almost entire regions are required for inhibition of commitment, whereas domains II and IV that are essential for co-tranforming activity with ras are required for inhibition of differentiation. Interestingly, mutants that delete domains for c-Myc dimerization motifs enhanced differentiation. These results suggest that c-Myc may regulate commitment and differentiation by interacting with proteins through different domains.	TOHOKU UNIV,TUBERCULOSIS & CANC RES INST,DEPT CELL BIOL,SEIRYOMACHI 4-1,SENDAI,MIYAGI 980,JAPAN; UNIV PENN,DEPT MED,ONCOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104	Tohoku University; University of Pennsylvania; University of Pennsylvania				Takada, Shinji/0000-0003-4125-6056				ALONSO MC, 1988, EMBO J, V7, P2583; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; COPPOLA JA, 1986, NATURE, V320, P761; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; KLAEMBT C, 1989, EMBO J, V8, P203; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RUSTGI AK, 1991, NATURE, V352, P540; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKADA S, 1992, JPN J CANCER RES, V83, P61, DOI 10.1111/j.1349-7006.1992.tb02352.x; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMAMOTO T, 1989, CELL DIFFER DEV, V28, P129, DOI 10.1016/0922-3371(89)90049-X	34	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426744				2022-12-25	WOS:A1993KN00600017
J	CHENCLELAND, TA; SMITH, MM; LE, SY; STERNGLANZ, R; ALLFREY, VG				CHENCLELAND, TA; SMITH, MM; LE, SY; STERNGLANZ, R; ALLFREY, VG			NUCLEOSOME STRUCTURAL-CHANGES DURING DEREPRESSION OF SILENT MATING-TYPE LOCI IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGEN BROMIDE PEPTIDES; ACTIVE DNA-SEQUENCES; AMINO-ACID SEQUENCE; THYMUS HISTONE-III; SACCHAROMYCES-CEREVISIAE; AFFINITY-CHROMATOGRAPHY; REVERSIBLE CHANGES; GENETIC-EVIDENCE; CORE PARTICLE; C-FOS	Mutant a and alpha yeast cells were created with histone H3 containing cysteine in place of alanine 110. Because transcriptionally active nucleosomes ''unfold'' to reveal the histone H3-thiol groups at the center of the core, the active nucleosomes of the mutant strain can be isolated by mercury-affinity chromatography. We compared the unbound and mercury-bound nucleosomes of haploid H3-mutant strains expressing either the MATalpha or the MATa mating-type locus. In a MATalpha strain, the Hg-bound nucleosomes are enriched in MATalpha DNA but lack the DNA of the transcriptionally silent HMRa mating-type locus. Conversely, in a MATa strain, the Hg-bound nucleosomes are enriched in MATa DNA sequences but deficient in HMLalpha DNA. When the SIR3 gene, known to be required for silencing of the repressed mating-type loci, is mutated in the MATalpha strain, transcription of the HMRa ensues, and its nucleosomes, as well as those of the MATalpha locus, are retained by the organomercurial column. It follows that derepression of the silent mating-type locus, caused by the sir3 null mutation, is accompanied by an unfolding of its nucleosomes to reveal the histone H3 SH groups at their centers. Nucleosomes of the pheromone-encoding gene MFA2, a gene that is expressed in MATa cells but not in MATalpha cells, are bound to the organomercurial column when isolated from MATa cells but not from MATalpha cells. Thus, there is a good correlation between nucleosome unfolding and the renewed transcriptional activity at mating-type loci, and at MFA2, which had been silenced for prolonged periods. A close temporal correlation between nucleosome refolding and the cessation of transcription is not always observed in yeast, however, in contrast to observations in mammalian cells. For example, nucleosomes of the GAL1 gene are maintained in a ''poised'' or ''primed'' thiol-reactive state even when the gene is not being transcribed (Chen, T. A., Smith, M. M., Le, S., Sternglanz, R., and Allfrey, V. G. (1991) J. Biol. Chem. 266, 6489-6498). It follows that the unfolding of the nucleosome cores of the yeast H3 mutant is regulated by factors that are not temporally linked to the recruitment or traverse of the RNA polymerase complex, but which may determine the rate at which different domains of chromatin adapt to the need for transcription of the associated DNA sequences.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	Rockefeller University; University of Virginia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA014908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM028220, R01GM028220] Funding Source: NIH RePORTER; NCI NIH HHS [CA14908] Funding Source: Medline; NIGMS NIH HHS [GM17383, GM28220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALFREY VG, 1991, METHOD CELL BIOL, V35, P315; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRANDT WF, 1981, EUR J BIOCHEM, V121, P501; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAN S, 1988, J BIOL CHEM, V2633, P15643; CHEN TA, 1991, J BIOL CHEM, V266, P6489; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; DELANGE RJ, 1973, J BIOL CHEM, V248, P3261; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; HABER JE, 1979, GENETICS, V93, P13; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JOHNSON EM, 1978, ARCH BIOCHEM BIOPHYS, V191, P537, DOI 10.1016/0003-9861(78)90392-2; JOHNSON EM, 1987, J BIOL CHEM, V262, P6943; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KLAR AJS, 1981, CELL, V25, P517, DOI 10.1016/0092-8674(81)90070-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHLEAR L, 1990, NUCLEIC ACIDS RES, V18, P7015; LOHR D, 1979, P NATL ACAD SCI USA, V76, P4285, DOI 10.1073/pnas.76.9.4285; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MARDIAN JKW, 1978, BIOCHEMISTRY-US, V17, P3825, DOI 10.1021/bi00611a023; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RINE J, 1987, GENETICS, V116, P9; RINE J, 1979, GENETICS, V93, P837; ROSE AB, 1992, IN PRESS GENES DEV; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ LD, 1978, BIOCHEMISTRY-US, V17, P750, DOI 10.1021/bi00597a031; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1978, CELL, V13, P691, DOI 10.1016/0092-8674(78)90219-2; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SMITH MM, 1988, J CELL BIOL, V106, P557, DOI 10.1083/jcb.106.3.557; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STRATHERN JN, 1979, CELL, V18, P309, DOI 10.1016/0092-8674(79)90050-3; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; van Holde K.E., 1988, CHROMATIN; WALKER J, 1990, J BIOL CHEM, V265, P5736; YAU P, 1982, EUR J BIOCHEM, V129, P281, DOI 10.1111/j.1432-1033.1982.tb07050.x	55	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1118	1124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419318				2022-12-25	WOS:A1993KG07700055
J	HEEMSKERK, JWM; VIS, P; FEIJGE, MAH; HOYLAND, J; MASON, WT; SAGE, SO				HEEMSKERK, JWM; VIS, P; FEIJGE, MAH; HOYLAND, J; MASON, WT; SAGE, SO			ROLES OF PHOSPHOLIPASE-C AND CA2+-ATPASE IN CALCIUM RESPONSES OF SINGLE, FIBRINOGEN-BOUND PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; FURA-2-LOADED HUMAN-PLATELETS; INTRACELLULAR CALCIUM; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; TUMOR PROMOTER; RAT PLATELETS; CA2+ RELEASE; OSCILLATIONS; THAPSIGARGIN	Fura-2-loaded platelets were immobilized on fibrinogen, and cytosolic free calcium concentration ([Ca2+]i) was measured by video imaging of the fluorescence signal. In the immobilized, single platelets, ADP and low doses of thrombin evoked repetitive spikes of [Ca2+]i, whereas higher thrombin concentrations gave elevated plateaus in [Ca2+]i. Stimulation of the cells with thrombin after the addition of ADP changed the frequency of spiking, but not the maximal levels of [Ca2+]i reached. In suspensions of platelets, ADP and low doses of thrombin evoked transient elevation of myo-inositol phosphates, suggesting that the initiation of spiking was due to stimulation of phospholipase C. In platelet suspensions, the Ca2+-ATPase inhibitor thapsigargin (TGC) evoked a gradual rise in [Ca2+]i, which was potentiated by preactivation of the platelets and inhibited by prostaglandin E1 and nitroprusside. In single platelets, TG induced a sudden increase in [Ca2+]i after a long but variable delay, followed by a phase of slow oscillations. The effects of preactivation with ADP were 2-fold: the delay time before the response to TG was shortened and the maximal level of [Ca2+]i reached with TG was higher than the level of the preceding Ca2+ spikes. Apparently, Ca2+ responses induced by the inhibition of Ca2+-ATPases are potentiated by prior elevation of [Ca2+]i and reduced by substances that inhibit agonist-evoked increases in [Ca2+]i. The data point to a mechanism of Ca2+-induced Ca2+ release and the presence of TG-sensitive and TG-insensitive Ca2+ stores in platelets. Rapid spiking may involve both pools, whereas the latter alone may account for the slow TG-evoked oscillations.	UNIV LIMBURG,DEPT HUMAN BIOL,6200 MD MAASTRICHT,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT PHYSIOL,NIJMEGEN,NETHERLANDS; INST ANIM PHYSIOL & GENET RES,DEPT NEUROENDOCRINOL,CAMBRIDGE CB2 4AT,ENGLAND; UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	Hasselt University; Maastricht University; Radboud University Nijmegen; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	HEEMSKERK, JWM (corresponding author), UNIV LIMBURG,CTR BIOMED,DEPT BIOCHEM,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Heemskerk, Johan/AAM-8323-2021	Heemskerk, Johan/0000-0002-2848-5121; Sage, Stewart/0000-0001-8578-3558				ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; AVDONIN PV, 1991, EUR J BIOCHEM, V198, P267, DOI 10.1111/j.1432-1033.1991.tb16011.x; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRUNE B, 1991, J BIOL CHEM, V266, P19232; DANIEL JL, 1986, FEBS LETT, V206, P299, DOI 10.1016/0014-5793(86)81000-6; DRUMMOND AH, 1987, PLATELETS BIOL PATHO, V3, P373; ELY JA, 1991, J BIOL CHEM, V266, P18635; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FISHER GJ, 1985, BIOCHEM BIOPH RES CO, V129, P958, DOI 10.1016/0006-291X(85)91984-9; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; HEEMSKERK JWM, 1991, FEBS LETT, V284, P223, DOI 10.1016/0014-5793(91)80690-5; HEEMSKERK JWM, 1992, BIOCHEM J, V283, P379, DOI 10.1042/bj2830379; HEEMSKERK JWM, 1991, BIOCHEM J, V278, P399, DOI 10.1042/bj2780399; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KROLL MH, 1989, BLOOD, V74, P1181; LAPETINA EG, 1987, METHOD ENZYMOL, V141, P176; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; MAHOUTSMITH MP, 1992, J BIOL CHEM, V267, P3060; MASON WT, 1990, METHODS NEUROSCIENCE, V3, P109; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MUALLEM S, 1991, BIOCHEM J, V279, P367, DOI 10.1042/bj2790367; NELSON CB, 1990, AM J PHYSIOL, V259, pC675; NISHIO H, 1991, CELL CALCIUM, V12, P177, DOI 10.1016/0143-4160(91)90019-B; PAPP B, 1991, J BIOL CHEM, V266, P14593; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAGE SO, 1985, FEBS LETT, V188, P135, DOI 10.1016/0014-5793(85)80890-5; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SARGEANT P, 1992, CELL CALCIUM, V13, P553, DOI 10.1016/0143-4160(92)90035-Q; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VICKERS JD, 1990, EUR J BIOCHEM, V193, P521, DOI 10.1111/j.1432-1033.1990.tb19367.x; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9	43	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					356	363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416943				2022-12-25	WOS:A1993KE60300055
J	MUMMANENI, P; BISHOP, PL; TURKER, MS				MUMMANENI, P; BISHOP, PL; TURKER, MS			A CIS-ACTING ELEMENT ACCOUNTS FOR A CONSERVED METHYLATION PATTERN UPSTREAM OF THE MOUSE ADENINE PHOSPHORIBOSYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO DNA METHYLATION; EMBRYONIC-DEVELOPMENT; CELL-LINE; CPG; EXPRESSION; GENOMES; ISLANDS; TISSUES	A 2.1-kilobase pair region located just upstream of the mouse aprt (adenine phosphoribosyltransferase) gene has a methylation pattern that is conserved in mouse tissues and culture cell lines. This upstream region includes four HpaII/MspI sites. Two of these sites are fully methylated, one is partially methylated, and one is unmethylated. Transfection experiments have demonstrated that the conserved methylation pattern can be reproduced in a mouse embryonal carcinoma stem cell line via de novo methylation (Turker, M. S., Mummaneni, P., and Bishop, P. L. (1991) Somat. Cell Mol. Genet. 17, 151-157). To examine the molecular basis of the conserved methylation pattern, a plasmid-based deletion analysis was conducted by removing and rearranging specific portions of the upstream region. Unmethylated versions of these plasmid constructs were then transfected into the mouse stem cell line and the methylation status of the remaining HpaII/MspI sites determined with a Southern blot analysis. By using this approach, a cis-acting sequence within the upstream region of approximately 0.8 kilobase pairs was identified which appears responsible for the conserved methylation pattern. We use the term ''de novo methylation center'' to denote this sequence. Based on the results obtained, a model is offered to explain the formation of the conserved methylation pattern in the upstream region.	UNIV KENTUCKY, COLL MED,MARKEY CANC CTR,DEPT PATHOL,800 ROSE ST, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, COLL MED, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky					NIA NIH HHS [AG08199] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG008199] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOLDEN AH, 1986, MOL CELL BIOL, V54, P915; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; COOPER GE, 1992, SOMAT CELL MOLEC GEN, V18, P215, DOI 10.1007/BF01233858; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DOERFLER W, 1990, UCLA SYM BI, V128, P329; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3370; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MONK M, 1987, DEVELOPMENT, V99, P371; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Perbal B., 1988, PRACTICAL GUIDE MOL; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SHEMER R, 1991, J BIOL CHEM, V266, P23676; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1989, P NATL ACAD SCI USA, V86, P6853, DOI 10.1073/pnas.86.18.6853; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; TURKER MS, 1991, SOMAT CELL MOLEC GEN, V17, P151, DOI 10.1007/BF01232972; TURKER MS, 1989, SOMAT CELL MOLEC GEN, V15, P159, DOI 10.1007/BF01535077; TURKER MS, 1989, J BIOL CHEM, V264, P11632; WARD C, 1987, J BIOL CHEM, V262, P11057	36	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					552	558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416960				2022-12-25	WOS:A1993KE60300084
J	HOGG, PJ; OWENSBY, DA; CHESTERMAN, CN				HOGG, PJ; OWENSBY, DA; CHESTERMAN, CN			THROMBOSPONDIN-1 IS A TIGHT-BINDING COMPETITIVE INHIBITOR OF NEUTROPHIL CATHEPSIN-G - DETERMINATION OF THE KINETIC MECHANISM OF INHIBITION AND LOCALIZATION OF CATHEPSIN-G BINDING TO THE THROMBOSPONDIN-1 TYPE-3 REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBOSPONDIN; ADHESIVE GLYCOPROTEIN; LEUKOCYTE ELASTASE; PROTEINASES; DEGRADATION; FIBRONECTIN; GENE; ACTIVATION; COLLAGEN; MOUSE	Thrombospondin 1 was recently shown to bind to and inhibit the activity of neutrophil elastase (Hogg, P. J., Owensby, D. A., Mosher, D. F., Misenheimer, T. M., and Chesterman, C. N. (1993) J. Biol. Chem. 268, 7139-7146). This finding led us to question whether thrombospondin 1 also binds and inhibits the other major serine proteinase of neutrophils, cathepsin G. In a competitive binding assay, cathepsin G bound to thrombospondin 1 reversibly and saturably with a dissociation constant in the low nanomolar range. The kinetic mechanism of inhibition of cathepsin G activity by thrombospondin 1 was determined using the synthetic cathepsin G substrate, Suc-Ala-Ala-Pro-Phe-p-nitroanilide, and is consistent with hyperbolic tight-binding inhibition in which thrombospondin 1 binds cathepsin G and the Michaelis cathepsin G-substrate complex and weakens, but does not abolish, the efficiency of hydrolysis of Suc-Ala-Ala-Pro-Phe-p-nitroanilide. In the presence of 2 mM calcium ions, 2.9 +/-0.4 mol of cathepsin G interacted with 1 mol of thrombospondin 1 trimer with a site-binding constant of 7.0 +/- 3.5 nM, which reduced the efficiency of hydrolysis of Suc-Ala-Ala-Pro-Phe-p-nitroanilide 8.5 +/- 1.4-fold. A lower limit for the on rate constant of 5 x 10(6) M-1 s-1 was established. The affinity of binding and stoichiometry for the interaction between cathepsin G and thrombospondin 1 was enhanced in the absence of calcium ions. In the presence of EDTA, 5.3 +/- 0.5 mol of cathepsin G interacted with 1 mol of thrombospondin 1 with a site-binding constant of 2.1 +/- 1.6 nM, implying the existence of two binding sites for cathepsin G on each subunit of thrombospondin 1, one or both of which is variably exposed and sensitive to calcium ions. Thrombospondin 1 protected fibronectin from cleavage by cathepsin G and blocked cathepsin G-mediated platelet aggregation. In summary, the binding of cathepsin G to thrombospondin 1 is tight, reversible, and close enough to the active site of cathepsin G to perturb the interactions of a small synthetic substrate and exclude a macromolecular protein substrate and platelets. Using defined proteolytic fragments and different conformers of thrombospondin 1, the binding sites for cathepsin G have been localized to the thrombospondin 1 type 3 repeats.			HOGG, PJ (corresponding author), UNIV NEW S WALES, PRINCE WALES HOSP, CTR THROMBOSIS & VASC RES, DEPT HAEMATOL, HIGH ST, SYDNEY, NSW 2031, AUSTRALIA.			Hogg, Philip/0000-0001-6486-2863				BAICI A, 1987, BIOCHEM J, V244, P793, DOI 10.1042/bj2440793; BALE MD, 1985, J BIOL CHEM, V260, P7502; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Bieth JG, 1986, REGULATION MATRIX AC, P217; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; CAPODICI C, 1989, INFLAMMATION, V13, P245, DOI 10.1007/BF00914392; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; HECK LW, 1990, AM J PATHOL, V136, P1267; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; IDELL S, 1989, CHEST, V96, P1125, DOI 10.1378/chest.96.5.1125; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; KREIS C, 1989, J IMMUNOL, V143, P1961; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1986, BLOOD, V67, P1197; LAWLER J, 1986, ANN NY ACAD SCI, V485, P271; LOTTENBURG R, 1983, BIOCHIM BIOPHYS ACTA, V142, P558; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1990, ANNU REV MED, V41, P85; MOSHER DF, 1992, ADV MOL CELL BIOL, V7, P1; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; OKADA Y, 1989, FEBS LETT, V249, P253; PETERSON MW, 1989, J LAB CLIN MED, V113, P297; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REILLY CF, 1980, BIOCHIM BIOPHYS ACTA, V621, P147, DOI 10.1016/0005-2795(80)90070-7; ROCHAT T, 1988, AM J PHYSIOL, V255, pC603, DOI 10.1152/ajpcell.1988.255.5.C603; SAKLATVALA J, 1980, BIOCHIM BIOPHYS ACTA, V615, P167, DOI 10.1016/0005-2744(80)90020-0; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SEEMULLER U, 1986, PROTEINASE INHIBITOR, P337; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; STARKEY PM, 1977, BIOCHIM BIOPHYS ACTA, V483, P386, DOI 10.1016/0005-2744(77)90066-3; SUCHARD SJ, 1991, J IMMUNOL, V146, P3945; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; VAGAS JR, 1982, PROSTAGLANDINS, V23, P292; VARTIO T, 1981, J BIOL CHEM, V256, P471; VOS HL, 1992, J BIOL CHEM, V267, P12192; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704	51	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21811	21818						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408036				2022-12-25	WOS:A1993MC80900059
J	LIN, BF; HUANG, RFS; SHANE, B				LIN, BF; HUANG, RFS; SHANE, B			REGULATION OF FOLATE AND ONE-CARBON METABOLISM IN MAMMALIAN-CELLS .3. ROLE OF MITOCHONDRIAL FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CHINESE-HAMSTER CELLS; SUBCELLULAR-LOCALIZATION; DEPENDENT ENZYMES; OVARY CELLS; GLYCINE; SERINE; IDENTIFICATION; DEHYDROGENASE; ORGANELLES	Wild-type Chinese hamster ovary (CHO) cells and CHO cell transfectants expressing human folylpoly-gamma-glutamate synthetase (FPGS) activity contain mitochondrial FPGS activity of higher specific activity than the cytosolic isozyme. Expression of mitochondrial FPGS activity is required for folate accumulation by mitochondria. The mitochondrial folate pool in CHO cells is not in equilibrium with the cytosolic pool and contains folylpolyglutamates of longer glutamate chain length than cytosolic folates. The inability of AUX-coli, a CHO cell expressing high levels of Escherichia coli FPGS activity and containing pteroyltriglutamate, to support glycine synthesis is due to a lack of mitochondrial FPGS activity. AUX-coli cells lack mitochondrial folate despite containing high levels of cytosolic folate.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				LIN, BI-FONG/0000-0003-2260-6081	NCI NIH HHS [CA-41991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BARLOWE C K, 1988, Biofactors, V1, P171; BERGMEYER HU, 1965, METHOD ENZYMAT AN, P752; BRODY T, 1975, FED PROC, V34, P905; CHACE SC, 1987, THESIS J HOPKINS U B; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; CONTRACTOR SF, 1972, BIOCHEM J, V128, P11, DOI 10.1042/bj1280011; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; HOFFBRAN.AV, 1969, BIOCHIM BIOPHYS ACTA, V192, P479, DOI 10.1016/0304-4165(69)90397-3; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; KIM JS, 1993, J BIOL CHEM, V268, P21680; LEWIS KF, 1978, ARCH BIOCHEM BIOPHYS, V185, P443, DOI 10.1016/0003-9861(78)90187-X; LOWE KE, 1993, J BIOL CHEM, V268, P21665; LOWRY OH, 1957, METHOD ENZYMOL, V4, P366, DOI 10.1016/0076-6879(57)04065-3; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MCGUIRE JJ, 1979, DEV BIOCHEM, V4, P471; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SHANE B, 1989, VITAM HORM, V45, P263; SHIN YS, 1976, BIOCHIM BIOPHYS ACTA, V444, P794; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUSSMAN DJ, 1986, ANAL BIOCHEM, V158, P371, DOI 10.1016/0003-2697(86)90563-4; TAYLOR RT, 1985, MUTAT RES, V151, P293, DOI 10.1016/0027-5107(85)90082-X; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; WANG FK, 1967, BIOCHEM Z, V346, P458; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109; ZHONG XH, 1990, MOL CELL BIOL, V10, P770, DOI 10.1128/MCB.10.2.770	36	87	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21674	21679						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408020				2022-12-25	WOS:A1993MC80900039
J	MAIER, R; GANU, V; LOTZ, M				MAIER, R; GANU, V; LOTZ, M			INTERLEUKIN-11, AN INDUCIBLE CYTOKINE IN HUMAN ARTICULAR CHONDROCYTES AND SYNOVIOCYTES, STIMULATES THE PRODUCTION OF THE TISSUE INHIBITOR OF METALLOPROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEMATOPOIETIC PROGENITORS; PLATE CHONDROCYTES; MOLECULAR-CLONING; CARTILAGE; EXPRESSION; CULTURE; BIOSYNTHESIS; MODULATION; IDENTITY	This study on the regulation of interleukin (IL)-11 expression in human connective tissue cells shows that IL-11 expression is not restricted to cells of hematopoietic orgin but can also be induced in articular chondrocytes and synoviocytes. IL-11 mRNA was induced in chondrocytes in response to transforming growth factor (TGF)-beta1 and IL-1beta. Stimulation with IL-6 or growth factors, such as basic fibroblast growth factor, leukemia inhibitory factor, and platelet-derived growth factor-AA, had only weak or no detectable effects. Activation of protein kinase C by phorbol esters and inhibition of protein synthesis by cyclohexamide increased IL-11 transcripts, whereas calcium ionophore A23817 or dibutyryl cyclic AMP had no effect. Immunoprecipitations revealed the synthesis of IL-11 protein in response to TGF-beta1, IL-1beta, as well as phorbol 12-myristate 13-acetate, and a synergistic action of TGF-beta1 and IL-1beta was observed. Similar findings on IL-11 expression were made in synoviocytes. Analysis of effects on cell function showed that IL-11 stimulated the production of the tissue inhibitor of metalloproteinases in chondrocytes and synoviocytes but did not affect chondrocyte proliferation or increase stromelysin activity. These results suggest that IL-11 does not contribute to connective tissue degradation but conversely induces protective effects in joint tissue.	UNIV CALIF SAN DIEGO,DEPT MED,SAM & ROSE STEIN INST RES AGING,LA JOLLA,CA 92093; CIBA GEIGY CORP,SUMMIT,NJ 07901	University of California System; University of California San Diego; Novartis					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39799] Funding Source: Medline; NIA NIH HHS [AG07996] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BRUNO E, 1991, EXP HEMATOL, V19, P378; CHANDRASEKHAR S, 1988, BIOCHEM BIOPH RES CO, V157, P1352, DOI 10.1016/S0006-291X(88)81024-6; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GUERNE PA, 1990, J IMMUNOL, V144, P499; GUERNE PA, 1989, ANN NY ACAD SCI, V557, P558; HARVEY AK, 1991, EXP CELL RES, V195, P376, DOI 10.1016/0014-4827(91)90387-A; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; LOTZ M, 1992, J IMMUNOL, V148, P466; LOTZ M, 1992, J CLIN INVEST, V90, P888, DOI 10.1172/JCI115964; LOTZ M, 1991, J BIOL CHEM, V266, P2017; LOTZ M, 1992, BIOL REGULATION CHON, P237; Maniatis T., 1982, MOL CLONING; MURPHY G, 1985, J BIOL CHEM, V260, P3079; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; MUSASHI M, 1991, BLOOD, V78, P1448; OKEEFE RJ, 1988, CALCIFIED TISSUE INT, V43, P352, DOI 10.1007/BF02553278; OKEEFE RJ, 1988, ENDOCRINOLOGY, V122, P2953, DOI 10.1210/endo-122-6-2953; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; REDINI F, 1988, FEBS LETT, V234, P172, DOI 10.1016/0014-5793(88)81327-9; SCHIBLER KR, 1992, BLOOD, V80, P900; SKANTZE KA, 1985, CANCER RES, V45, P4416; VILLIGER PM, 1992, J CLIN INVEST, V90, P488, DOI 10.1172/JCI115885; VIVIEN D, 1990, J CELL PHYSIOL, V143, P534, DOI 10.1002/jcp.1041430319	25	135	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21527	21532						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408003				2022-12-25	WOS:A1993MC80900018
J	NIGAM, M; SEONG, CM; QIAN, YM; HAMILTON, AD; SEBTI, SM				NIGAM, M; SEONG, CM; QIAN, YM; HAMILTON, AD; SEBTI, SM			POTENT INHIBITION OF HUMAN TUMOR P21(RAS) FARNESYLTRANSFERASE BY A1A2-LACKING P21(RAS)CA1A2X PEPTIDOMIMETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN FARNESYLTRANSFERASE; TETRAPEPTIDE INHIBITORS; RAS; FARNESYL; P21RAS; DIFFERENTIATION; TRANSFORMATION; ISOPRENYLATION; REQUIREMENT; TRANSFERASE	The ras oncogene product p21ras requires farnesylation and subsequent plasma membrane association for its transforming activity. This key post-translational modification is catalyzed by p21ras farnesyltransferase, which transfers farnesyl from farnesylpyrophosphate to the cysteine of the CA1A2X carboxyl-terminal tetrapeptide of p21ras. In the present report, we describe potent inhibition of p21ras farnesyltransferase by CA1A2X peptidomimetics containing no peptidic amide bonds. We synthesized a series of CA1A2X analogues where the 2 aliphatic amino acids A1 and A2 were replaced by a hydrophobic spacer, 3-aminomethylbenzoic acid (AMBA). The peptidomimetic Cys-AMBA-Met, inhibits p21ras farnesyltransferase from human colon carcinoma (COLO-205) and Burkitt's lymphoma (Daudi) with IC50 values of 60 and 120 nM, respectively. Cys-AMBA-Met is 3-, 8-, and 9-fold (COLO-205) and 2-, 5-, and 7-fold (Daudi) more potent than the corresponding tetrapeptides of p21K(B-ras) (CVIM), p21N-ras (CVVM), and p21K(A-ras) (CIIM), respectively. Replacing methionine at the X position with negatively charged glutamate reduces its ability to inhibit the enzyme, whereas positively charged lysine at this position abolishes the inhibitory character of the peptidomimetic. A hydrophobic moiety at the X position, as in Cys-AMBA-Phe, retains potent inhibitory activity. Leucine in the X position of CA1A2X is a post-translational signal for protein geranylgeranylation rather than farnesylation, and, as expected, Cys-AMBA-Leu does not inhibit the enzyme. Furthermore, CVIM, CVVM, and CIIM are farnesylated by human p21ras farnesyltransferases and inhibit these enzymes by serving as alternative substrates. In contrast, the peptidomimetics described here are true p21ras farnesyltransferase inhibitors since none is farnesylated by this enzyme.	UNIV PITTSBURGH,FAC ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BROWN MJ, 1991, J AM CHEM SOC, V113, P3176, DOI 10.1021/ja00008a058; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; STEWART FHC, 1983, AUST J CHEM, V36, P2511, DOI 10.1071/CH9832511; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YANG CC, 1991, J AM CHEM SOC, V113, P3177, DOI 10.1021/ja00008a059	28	119	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20695	20698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407887				2022-12-25	WOS:A1993MA28800004
J	PABORSKY, LR; MCCURDY, SN; GRIFFIN, LC; TOOLE, JJ; LEUNG, LLK				PABORSKY, LR; MCCURDY, SN; GRIFFIN, LC; TOOLE, JJ; LEUNG, LLK			THE SINGLE-STRANDED-DNA APTAMER-BINDING SITE OF HUMAN THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; LABELED PEPTIDE; LYSYL RESIDUES; IDENTIFICATION; EXOSITE; HIRUDIN; COMPLEX; INHIBITION	A new class of thrombin inhibitors based on sequence-specific single-stranded DNA oligonucleotides (thrombin aptamer) has recently been identified. The aptamer-binding site on thrombin was examined by a solid-phase plate binding assay and by chemical modification. Binding assay results demonstrated that the thrombin aptamer bound specifically to alpha-thrombin but not to gamma-thrombin and that hirudin competed with aptamer binding, suggesting that thrombin's anion-binding exosite was important for aptamer-thrombin interactions. To identify lysine residues of thrombin that participated in the binding of the thrombin aptamer, thrombin was modified with fluorescein 5'-isothiocyanate in the presence or absence of the thrombin aptamer, reduced, carboxymethylated, and digested with endoproteinase Arg-C. The digestion products were analyzed by reversed-phase high performance liquid chromatography and the peptide maps compared. Four peptides with significantly decreased modification in the presence of the aptamer were identified and subjected to N-terminal sequence analysis. Results indicated that B chain Lys-21 and Lys-65, both located within the anion-binding exosite, are situated within or in close proximity to the aptamer-binding site of human alpha-thrombin. The thrombin aptamer binds to the anion-binding exosite and inhibits thrombin's function by competing with exosite binding substrates fibrinogen and the platelet thrombin receptor.			PABORSKY, LR (corresponding author), GILEAD SCI INC, 353 LAKESIDE DR, FOSTER CITY, CA 94404 USA.				NHLBI NIH HHS [1-R43 HL48431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL048431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHANG TL, 1979, BIOCHEMISTRY-US, V18, P113, DOI 10.1021/bi00568a018; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRIFFIN LC, 1993, BLOOD, V81, P3271, DOI 10.1182/blood.V81.12.3271.3271; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MANN KG, 1990, BLOOD, V76, P1; MESSMORE HL, 1979, FED PROC, V38, P758; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; PHILLIPS NFB, 1988, BIOCHEMISTRY-US, V27, P3314, DOI 10.1021/bi00409a029; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SHEEHAN JP, 1991, BLOOD S, V78, pA277; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1992, J BIOL CHEM, V267, P24408	28	167	177	4	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20808	20811						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407909				2022-12-25	WOS:A1993MA28800028
J	SHIMOZAWA, O; SAKAGUCHI, M; OGAWA, H; HARADA, N; MIHARA, K; OMURA, T				SHIMOZAWA, O; SAKAGUCHI, M; OGAWA, H; HARADA, N; MIHARA, K; OMURA, T			CORE GLYCOSYLATION OF CYTOCHROME-P-450 (AROM) - EVIDENCE FOR LOCALIZATION OF N-TERMINUS OF MICROSOMAL CYTOCHROME-P-450 IN THE LUMEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HUMAN PLACENTAL AROMATASE; ENCODING HUMAN AROMATASE; ENDOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY; SIGNAL; PURIFICATION; PROTEINS; SYSTEM; IDENTIFICATION	It was found that cytochrome P-450(arom) purified from human placenta microsomes is glycosylated, and the sugar chain was cleaved with endoglycosidase H (Endo H). The core glycosylation of P-450(arom) was examined with two heterologous expression systems, cultured insect cells and in vitro translation system. The P-450(arom) protein expressed in the insect cells was glycosylated, and the sugar chain was sensitive to Endo H. It was also glycosylated when translated with the wheat germ cell-free system in the presence of rough microsomal membrane, and the sugar chain could be removed by Endo H treatment. Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system. The core glycosylation did not occur when the Asn-12 residue was mutated, whereas the mutant protein with modified Asn-180 residue was glycosylated. These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation. We conclude that the N terminus of P-450(arom) is translocated across the endoplasmic reticulum membrane to be glycosylated at the luminal side.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 812,JAPAN; FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Kyushu University; Fujita Health University								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BERNHARDT R, 1988, BIOCHEM INT, V17, P1143; BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; BURAND JP, 1980, VIROLOGY, V101, P286, DOI 10.1016/0042-6822(80)90505-X; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; HARADA N, 1988, BIOCHEM BIOPH RES CO, V156, P725, DOI 10.1016/S0006-291X(88)80903-3; HARADA N, 1988, J BIOCHEM-TOKYO, V103, P106, DOI 10.1093/oxfordjournals.jbchem.a122213; HARADA N, 1992, J BIOL CHEM, V267, P4781; HIWATASHI A, 1980, BIOCHEM BIOPH RES CO, V97, P1443, DOI 10.1016/S0006-291X(80)80027-1; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAJIN S, 1981, J BIOL CHEM, V256, P3871; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Omura T., 1993, CYTOCHROME P 450; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAGUCHI M, 1993, FRONTIERS BIOTRANSFO, V8, P59; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SETHUMADHAVAN K, 1991, MOL CELL ENDOCRINOL, V78, P25, DOI 10.1016/0303-7207(91)90182-R; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; TAN L, 1986, EUR J BIOCHEM, V156, P243, DOI 10.1111/j.1432-1033.1986.tb09574.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERGERES G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P235, DOI 10.1016/0005-2736(91)90376-J; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YAMAMOTO A, 1985, J CELL BIOL, V101, P1733, DOI 10.1083/jcb.101.5.1733	41	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21399	21402						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407981				2022-12-25	WOS:A1993MA28800109
J	GLEMBOTSKI, CC; IRONS, CE; KROWN, KA; MURRAY, SF; SPRENKLE, AB; SEI, CA				GLEMBOTSKI, CC; IRONS, CE; KROWN, KA; MURRAY, SF; SPRENKLE, AB; SEI, CA			MYOCARDIAL ALPHA-THROMBIN RECEPTOR ACTIVATION INDUCES HYPERTROPHY AND INCREASES ATRIAL-NATRIURETIC-FACTOR GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MYOSIN LIGHT CHAIN-2; FIBROBLAST GROWTH-FACTOR; DORSAL-VENTRAL PATTERN; SERUM RESPONSE ELEMENT; CARDIAC MYOCYTES; ALPHA-1-ADRENERGIC RECEPTOR; ADRENERGIC STIMULATION; INDUCIBLE EXPRESSION; VENTRICULAR MYOCYTES	The protease, alpha-thrombin (alphaTh), affects myocardial cell contractility, a feature common among agents that induce hypertrophy. However, it is not known whether cardiac myocytes possess alphaTh receptors (alphaTh-R), or if long term treatment with alphaTh can enhance growth and gene expression. In the present study primary neonatal rat ventricular myocytes expressed a 3.6-kilobase mRNA species that hybridized with a rat alphaTh-R-specific probe. After 48 h, alphaTh induced hypertrophy, sarcomeric organization, and enhanced atrial natriuretic factor (ANF) expression, all of which were blocked by the alphaTh-selective protease inhibitor, D-Phe-Pro-Arg-chloromethyl ketone. The alphaTh-R agonist peptide, SFLLRNPND, was a potent activator of ANF expression, however, the non-agonist, FLLRNPND, was inactive. Transfection experiments showed the enhancement of ANF expression by alphaTh to be transcriptional. The abilities of alphaTh to induce myocyte hypertrophy and to augment ANF transcription and peptide production were inhibited by the protein kinase C inhibitor, chelerythrine, and by the tyrosine kinase inhibitor, tyrphostin. Thus, myocardial cell alphaTh-Rs are stimulated by the specific proteolytic actions of alphaTh, and pathways involving both protein kinase C and protein tyrosine kinases are required for subsequent hypertrophy and ANF expression. Further, these findings suggest a new role for extracellular proteases as regulators of myocardial cell gene expression and growth.	SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA	California State University System; San Diego State University	GLEMBOTSKI, CC (corresponding author), SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; GLEMBOTSKI CC, 1988, J BIOL CHEM, V263, P16073; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HUANG RS, 1991, J BIOL CHEM, V266, P18435; IRONS CE, 1992, J BIOL CHEM, V267, P5211; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; PARKER TG, 1992, J BIOL CHEM, V267, P3343; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Sambrook J, 1989, MOL CLONING LABORATO; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEINBERG SF, 1991, CIRC RES, V68, P1216, DOI 10.1161/01.RES.68.5.1216; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	45	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20646	20652						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397212				2022-12-25	WOS:A1993LY01900103
J	PAN, ZQ; AMIN, A; HURWITZ, J				PAN, ZQ; AMIN, A; HURWITZ, J			CHARACTERIZATION OF THE IN-VITRO RECONSTITUTED CYCLIN-A OR B1-DEPENDENT CDK2 AND CDC2 KINASE-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; DNA-REPLICATION; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MESSENGER-RNA; P34CDC2; P107; YEAST	Human cyclins A and B1 were assembled with the cdk2 or cdc2 protein to reconstitute their respective kinase activities in vitro. Both cyclins complemented either cdk2 or cdc2, yielding kinase activities that supported the phosphorylation of histone H1. Activation of cdk2-catalyzed H1 kinase activity by cyclin A required a 10-min preincubation of the two components, whereas cdc2 kinase supported phosphate incorporation without a detectable time lag upon the addition of cyclin B1, suggesting a slower association rate of cdk2 with cyclin A compared with cdc2 and cyclin B1. Both cdk2 and cyclin A, as well as cdc2 and cyclin B1, formed stable complexes in the absence of ATP and substrate that could be isolated after glycerol gradient centrifugation. Incubation of the isolated complexes with ATP and histone H1 supported the phosphorylation of the substrate. Cyclin A-activated cdk2 or cdc2 phosphorylated p107, a pRB-related cellular protein, 10 times more effectively than the cyclin B1-complexed kinases. This was most likely due to a direct association of cyclin A with p107 (Ewen, M. E., Faha, B., Harlow, E., and Livingston, D. (1992) Science 255, 85-87; Faha, B., Ewen, M. E., Tsai, L.-H., Livingston, D., and Harlow, E. (1992) Science 255, 87-90). The reconstituted cdc2-cyclin B1 complex incorporated 4-5-fold more phosphate into the p34 subunit of the three-subunit (p70, p34, and p14) human single-stranded DNA-binding protein (also called RP-A), a DNA replication and DNA, repair factor, than cdc2-cyclin A. No detectable phosphorylation of the p34 protein was observed with cdk2 complexed with either cyclin B1 or A. These data indicate that both cyclins as well as the catalytic subunits are important factors in controlling the rate of phosphorylation of a given substrate. The cyclin-activated cdc2 family kinases may target their cellular substrates through cyclin-mediated protein-protein interactions.			PAN, ZQ (corresponding author), MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.				NIGMS NIH HHS [5RO GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNY M, 1992, J BIOL CHEM, V265, P7693; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAN ZQ, 1993, J BIOL CHEM, V268, P20433; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20443	20451						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397207				2022-12-25	WOS:A1993LY01900077
J	GOKE, R; FEHMANN, HC; LINN, T; SCHMIDT, H; KRAUSE, M; ENG, J; GOKE, B				GOKE, R; FEHMANN, HC; LINN, T; SCHMIDT, H; KRAUSE, M; ENG, J; GOKE, B			EXENDIN-4 IS A HIGH POTENCY AGONIST AND TRUNCATED EXENDIN-(9-39)-AMIDE AN ANTAGONIST AT THE GLUCAGON-LIKE PEPTIDE 1-(7-36)-AMIDE RECEPTOR OF INSULIN-SECRETING BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG PANCREAS; HELODERMA-HORRIDUM VENOM; COVALENT CROSS-LINKING; RAT LUNG MEMBRANES; DISPERSED ACINI; INCRETIN HORMONE; PLASMA-MEMBRANES; RELEASE; PEPTIDE-1(7-36)AMIDE; PURIFICATION	Exendin-4 purified from Heloderma suspectum venom shows structural relationship to the important incretin hormone glucagon-like peptide 1-(7-36)-amide (GLP-1). We demonstrate that exendin-4 and truncated exendin-(9-39)-amide specifically interact with the GLP-1 receptor on insulinoma-derived cells and on lung membranes. Exendin-4 displaced I-125-GLP-1, and unlabeled GLP-1 displaced I-125-exendin-4 from the binding site at rat insulinoma-derived RINm5F cells. Exendin-4 had, like GLP-1, a pronounced effect on intracellular cAMP generation, which was reduced by exendin-(9-39)-amide. When combined, GLP-1 and exendin-4 showed additive action on cAMP. They each competed with the radiolabeled version of the other peptide in cross-linking experiments. The apparent molecular mass of the respective ligand-binding protein complex was 63,000 Da. Exendin-(9-39)-amide abolished the cross-linking of both peptides. Exendin-4, like GLP-1, stimulated dose dependently the glucose-induced insulin secretion in isolated rat islets, and, in mouse insulinoma betaTC-1 cells, both peptides stimulated the proinsulin gene expression at the level of transcription. Exendin-(9-39)-amide reduced these effects. In conclusion, exendin-4 is an agonist and exendin-(9-39)-amide is a specific GLP-1 receptor antagonist.	UNIV MARBURG,DEPT INTERNAL MED,DIV GASTROENTEROL & METAB,BALDINGER STR,W-3550 MARBURG,GERMANY; UNIV GIESSEN,DEPT INTERNAL MED,W-6300 GIESSEN,GERMANY; INST MOLEC BIOL & CANC RES,MICROCHEM UNIT,W-3550 MARBURG,GERMANY; VET AFFAIRS MED CTR,SOLOMON A BERSON RES LAB,BRONX,NY 10468	Philipps University Marburg; Justus Liebig University Giessen; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; EISSELE R, 1992, EUR J CLIN INVEST, V22, P283, DOI 10.1111/j.1365-2362.1992.tb01464.x; ENG J, 1992, REGUL PEPTIDES, V40, P142, DOI 10.1016/0167-0115(92)90201-5; ENG J, 1990, J BIOL CHEM, V265, P20259; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1991, INT J PANCREATOL, V8, P289; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FEHMANN HC, 1992, TRENDS ENDOCRIN MET, V3, P158, DOI 10.1016/1043-2760(92)90165-W; FEHMANN HC, 1992, MOL CELL ENDOCRINOL, V85, pC39, DOI 10.1016/0303-7207(92)90118-P; GOKE R, 1992, FEBS LETT, V300, P232, DOI 10.1016/0014-5793(92)80852-8; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; GOKE R, 1993, AM J PHYSIOL, V264, pL146, DOI 10.1152/ajplung.1993.264.2.L146; GOKE R, 1991, EUR J CLIN INVEST, V21, P135, DOI 10.1111/j.1365-2362.1991.tb01802.x; GOKE R, 1989, J MOL ENDOCRINOL, V2, P93, DOI 10.1677/jme.0.0020093; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; PARKER DS, 1984, J BIOL CHEM, V259, P1751; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; RAUFMAN JP, 1992, J BIOL CHEM, V267, P21432; RICHTER G, 1990, FEBS LETT, V267, P78, DOI 10.1016/0014-5793(90)80292-Q; RICHTER G, 1991, FEBS LETT, V280, P247, DOI 10.1016/0014-5793(91)80303-K; RICHTER G, 1993, IN PRESS AM J PHYSL; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VANDERMEERS A, 1984, FEBS LETT, V166, P273, DOI 10.1016/0014-5793(84)80094-0; WOLLHEIM CB, 1984, J BIOL CHEM, V259, P2262; Zunz E., 1929, ARCH INT PHYSL BIOCH, V31, P20	31	685	839	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19650	19655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396143				2022-12-25	WOS:A1993LW81900077
J	LEMAIGRE, FP; DURVIAUX, SM; ROUSSEAU, GG				LEMAIGRE, FP; DURVIAUX, SM; ROUSSEAU, GG			LIVER-SPECIFIC FACTOR-BINDING TO THE LIVER PROMOTER OF A 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; C/EBP-RELATED PROTEINS; RAT SKELETAL-MUSCLE; NUCLEAR FACTOR; FORK-HEAD; EXPRESSION; DNA; ENHANCER; SEQUENCES; REGION	The liver-type and muscle-type isozymes of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase are encoded by the same gene from different promoters. We have found earlier that the liver-type promoter is controlled by ubiquitous and liver-enriched transcription factors and that two cis-acting sequences, called sites III and IV, account for about half of the activity of this promoter (Lemaigre, F. P., Durviaux, S. M., and Rousseau, G. G. (1991) Mol. Cell. Biol. 11, 1099-1106). Site III contains the TGTTTGC sequence, i.e. the hepatocyte nuclear factor 5 motif, hepatocyte nuclear factor 5-TGTTTGC sequence motif, which is known to be functionally important in several liver-specific genes. We now show that site III actually binds the ubiquitous octamer factor 1 and the liver-enriched hepatocyte nuclear factor 3 (HNF-3) in a mutually exclusive way. We also show that site IV binds CCAAT/enhancer-binding protein (C/EBP)-related factors as well as another factor that is liver-specific. This factor is more abundant or has a higher affinity for site IV than the C/EBP-related proteins. Although it can bind to a high affinity HNF-3 site, this factor differs from known members of the HNF-3 family and from other liver-specific transcription factors.	UNIV CATHOLIQUE LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Lemaigre, Frederic/0000-0002-3609-434X				CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; FLEMING RE, 1992, J BIOL CHEM, V267, P479; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	40	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19896	19905						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396149				2022-12-25	WOS:A1993LW81900109
J	GANNON, PM; KUMAMOTO, CA				GANNON, PM; KUMAMOTO, CA			MUTATIONS OF THE MOLECULAR CHAPERONE PROTEIN SECB WHICH ALTER THE INTERACTION BETWEEN SECB AND MALTOSE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPORTED PROTEIN; LEADER PEPTIDE; GENE; TRANSLOCATION; MEMBRANE; CONFORMATION; RETARDATION; SUFFICIENT; PREPROTEIN	SecB is a 16-kDa cytosolic chaperone protein that is required for efficient export of particular proteins in Escherichia coli. To identify regions of SecB that contribute to efficient protein export, we isolated secB point mutants that are defective for protein export in vivo. We obtained missense mutations at residues Leu75 (SecBL75Q), Cys76 (SecBC76Y), and Glu77 (SecBE77K) in the center of the secB gene. In vivo, mutant SecBL75Q and SecBE77K proteins are capable of binding to precursor maltose-binding protein (MBP) and preventing the formation of export-incompetent precursor MBP; however, export of MBP is still defective. In vitro, purified SecBL75Q and SecBE77K proteins bound to unfolded MBP and blocked its refolding. SecBL75Q and SecBE77K were more effective than wild-type SecB at blocking the refolding of unfolded MBP, suggesting that SecBL75Q and SecBE77K have a higher affinity for unfolded MBP.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, 136 HARRISON AVE, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36415] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1992, J BIOL CHEM, V267, P11637; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; FAUST JR, 1991, J BIOL CHEM, V266, P9961; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1990, J BIOENERG BIOMEMBR, V22, P337, DOI 10.1007/BF00763171; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE C, 1989, J BACTERIOL, V171, P4609, DOI 10.1128/jb.171.9.4609-4616.1989; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Silhavy T.J., 1984, EXPT GENE FUSIONS; STRUHL K, 1983, GENE, V26, P231, DOI 10.1016/0378-1119(83)90193-2; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TRUN NJ, 1988, J BACTERIOL, V170, P5928, DOI 10.1128/jb.170.12.5928-5930.1988; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2248, DOI 10.1073/pnas.86.7.2248; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1590	1595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420934				2022-12-25	WOS:A1993KH62000017
J	SAGITOV, V; NIKIFOROV, V; GOLDFARB, A				SAGITOV, V; NIKIFOROV, V; GOLDFARB, A			DOMINANT LETHAL MUTATIONS NEAR THE 5' SUBSTRATE BINDING-SITE AFFECT RNA-POLYMERASE PROPAGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; ESCHERICHIA-COLI; BETA-SUBUNIT; NUCLEOTIDE-SEQUENCE; TERNARY COMPLEXES; GENE ORGANIZATION; CORE SUBUNITS; RPOB GENE; TRANSCRIPTION; INITIATION	The segment Asp1064-Lys1073 in the beta subunit of Escherichia coli RNA polymerase is evolutionarily conserved and is located near the ''5' face'' of the nucleotide binding pocket as was shown by affinity labeling with priming substrates (Grachev, M. A., Lukhtamov, E. A., Mustaev, A. A., Zaychikov, E. F., Abdukayumov, M. N., Rabinov, I. V., Richter, V. I., Skoblov, Y. S., and Chistyakov, P. G. (1989) Eur. J. Biochem. 180, 577-585). We engineered single Xaa --> Ala or Ala --> Ser substitutions of eight evolutionarily conserved amino acids in this segment as well as a multiple alanine (KRNK) substitution of four of these residues. The KRNK mutation as well as four of the single substitutions were dominant lethal, two of the single mutations were recessive lethal, and two were viable. RNA polymerase bearing the dominant mutations was prepared for biochemical study by in vitro reconstitution from subunits. All of the mutant enzymes formed stable, specific promoter complexes, capable of initiating RNA synthesis. However, the KRNK polymerase was totally blocked in initiation-to-elongation transition, whereas the four point mutants displayed allele-specific changes in promoter clearance rate. Each of the four mutations changed, in a specific way, both the pattern of short oligomers generated in abortive initiation and the pattern of RNA polymerase pausing during elongation. Thus, the mutations appear to distort but not destroy the active center and to alter, in allele-specific manner, the coupling between the catalytic reaction and RNA polymerase propagation along the template.	RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW 123182, RUSSIA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Russian Academy of Sciences; Columbia University					NIGMS NIH HHS [GM30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Burgess R.R., 1987, RNA POLYM REGULATION, P3; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAN PT, 1990, J BIOL CHEM, V265, P4091; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; HEUMANN H, 1986, EUR J BIOCHEM, V158, P575, DOI 10.1111/j.1432-1033.1986.tb09793.x; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JIN DJ, 1989, J BACTERIOL, V171, P5229, DOI 10.1128/jb.171.9.5229-5231.1989; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1989, J BACTERIOL, V171, P3002, DOI 10.1128/jb.171.6.3002-3007.1989; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MALIK S, 1985, J MOL BIOL, V185, P83, DOI 10.1016/0022-2836(85)90184-6; MALIK S, 1984, J BIOL CHEM, V259, P3292; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; OESCHGER MP, 1980, MOL GEN GENET, V178, P293, DOI 10.1007/BF00270475; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; SCHULTZ W, 1981, NUCLEIC ACIDS RES, V24, P6889; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STUDIER FW, 1979, J MOL BIOL, V135, P917, DOI 10.1016/0022-2836(79)90520-5; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZILLIG W, 1976, RNA POLYMERASE, P101	45	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2195	2202						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420987				2022-12-25	WOS:A1993KH62000104
J	PAYNE, JM; DAHMUS, ME				PAYNE, JM; DAHMUS, ME			PARTIAL-PURIFICATION AND CHARACTERIZATION OF 2 DISTINCT PROTEIN-KINASES THAT DIFFERENTIALLY PHOSPHORYLATE THE CARBOXYL-TERMINAL DOMAIN OF RNA-POLYMERASE SUBUNIT-IIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REPEAT DOMAIN; CALF THYMUS; CELL-CYCLE; WHEAT-GERM; TRANSCRIPTION; INITIATION; PROMOTER; ELONGATION; COMPLEXES	RNA polymerase II is a multisubunit enzyme composed of two large subunits of molecular weight in excess of 100,000 and a collection of 8-10 smaller subunits. The largest subunit, designated IIa, contains at its carboxyl terminus a highly repetitive domain consisting of tandem repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. Extensive phosphorylation within this COOH-terminal domain (CTD) gives rise to subunit IIo which has a markedly reduced mobility in SDS-polyacrylamide gel electrophoresis (PAGE) relative to subunit IIa. Recent evidence suggests that RNA polymerase IIA, containing an unphosphorylated CTD, is involved in preinitiation complex assembly, whereas RNA polymerase IIO is involved in elongation. Consequently, CTD phosphorylation is thought to occur after RNA polymerase II has bound to the promoter by a protein kinase that stably associates with the preinitiation complex. We present here the partial purification and characterization of two distinct CTD kinases from a HeLa cell transcription extract. These CTD kinases, designated CTDK1 and CTDK2, are fractionated by chromatography on Mono Q. CTDK1 catalyzes the incorporation of approximately 33 pmol of phosphate/pmol of calf thymus RNA polymerase subunit IIa, almost exclusively on serine. CTDK2 catalyzes the incorporation of approximately 50 pmol of phosphate/pmol of calf thymus subunit IIa, predominantly on serine; appreciable phosphate transfer onto threonine is also observed. Phosphorylation by CTDK2, but not CTDK1, results in a complete mobility shift in SDS-PAGE of subunit IIa to the position of IIo. CTDK1 can utilize ATP, dATP, or GTP as phosphate donor, whereas CTDK2 can utilize only ATP or dATP. The apparent K(m) for ATP is 30 muM for CTDK1 and 60 muM for CTDK2. CTDK1 and CTDK2 also differ in their protein substrate specificity. CTDK1 phosphorylates casein whereas CTDK2 does not. Neither kinase phosphorylates phosvitin or histone H1 to an appreciable extent. CTDK1 and CTDK2 do not appear to be related to cdc2 kinases as determined by their inability to phosphorylate H1 and their failure to react with antibodies directed against the cdc2 kinase. These results establish that a partially fractionated HeLa transcription extract contains two distinct CTD kinases that differ in their nucleotide requirements and in their patterns of CTD phosphorylation.	UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GUILFOYLE TJ, 1989, PLANT CELL, V1, P827, DOI 10.1105/tpc.1.8.827; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SPENCER CA, 1990, ONCOGENE, V5, P777; STONE N, 1992, J BIOL CHEM, V267, P6353; TEISSERE M, 1977, FEBS LETT, V82, P77, DOI 10.1016/0014-5793(77)80889-2; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	44	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					80	87						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416977				2022-12-25	WOS:A1993KE60300014
J	DAVIS, LJ; HALAZONETIS, TD				DAVIS, LJ; HALAZONETIS, TD			BOTH THE HELIX-LOOP-HELIX AND THE LEUCINE ZIPPER MOTIFS OF C-MYC CONTRIBUTE TO ITS DIMERIZATION SPECIFICITY WITH MAX	ONCOGENE			English	Article							DNA-BINDING; PROTEIN; SEQUENCE; GENE; TRANSCRIPTION; ONCOGENE; DIMER; TRANSFORMATION; FIBROBLASTS; COMPLEXES	The oncoprotein c-Myc contains two dimerization motifs - the helix-loop-helix (HLH) and the leucine zipper (LZ) - through which c-Myc specifically dimerizes with Max. We substituted regions of the c-Myc HLH and LZ motifs with the corresponding regions of structurally related proteins that do not interact with Max. Specific association of c-Myc with Max was dictated by helices 1 and 2 of the HLH motif and by the LZ. Within helix 2, residues 6 and 7 were important determinants of dimerization specificity. c-Myc and Max proteins with three amino acids inserted between their HLH and LZ motifs interacted efficiently, suggesting that the spacing between the motifs can be varied. Furthermore, alignment of the motifs at the primary sequence level was not obligatory, since Max with the three amino acid insertion could interact with wild-type c-Myc. These findings are consistent with our recently proposed model for the architecture of HLH/LZ domains.	MERCK SHARP & DOHME LTD,DEPT CANC RES,WP 16-3,W POINT,PA 19486	Merck & Company			Halazonetis, Thanos/D-7923-2011					ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	38	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					125	132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423990				2022-12-25	WOS:A1993KN00500015
J	OSHIMA, J; STEINMANN, KE; CAMPISI, J; SCHLEGEL, R				OSHIMA, J; STEINMANN, KE; CAMPISI, J; SCHLEGEL, R			MODULATION OF CELL-GROWTH, P34(CDC2) AND CYCLIN-A LEVELS BY SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article							DNA-REPLICATION; PROTEIN-KINASE; FISSION YEAST; INDEPENDENT GROWTH; HUMAN-FIBROBLASTS; SENESCENT HUMAN; C-FOS; CDC2; GENE; TEMPERATURE	Immortalization of rat lung epithelial cells by either wild-type SV-40 T antigen, a mutant form of T antigen that cannot bind pRb, or a temperature-sensitive T antigen increased by five- to 20-fold the steady state levels of p34cdc2 and cyclin A, positive regulators of progression through the cell cycle. Increased abundance of p34cdc2 was not accompanied by equivalent increases in cdc2 mRNA, indicating that increased expression of p34cdc2 is due, at least partially, to post-transcriptional mechanisms. Levels of p34cdc2 and cyclin A protein in cells immortalized with a temperature-sensitive T antigen remained elevated at the restrictive temperature unless T antigen was reduced to levels significantly below those where proliferation ceased, indicating that these two functions can be dissociated. These results show that SV-40 T antigen can dramatically enhance the expression of certain cell cycle regulatory proteins by mechanisms that are independent of pRb binding and cell growth status.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,DIV BIOL SCI,665 HUNTINGTON AVE,BOSTON,MA 02115; LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720	Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL CANCER INSTITUTE [R01CA049749, F32CA009235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010004] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA09235, NCI CA49749] Funding Source: Medline; NIA NIH HHS [AG10004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DRAETTA G, 1988, ONCOGENE, V2, P553; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KIT S, 1964, VIROLOGY, V1, P69; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1992, THESIS BOSTON U MED; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHTER KH, 1991, CANCER RES, V51, P6010; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SESHADRI T, 1993, IN PRESS J BIOL CHEM; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STUDIER FW, 1990, ANNU REV BIOCHEM, V185, P60; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253	41	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2987	2993						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414501				2022-12-25	WOS:A1993MC09300012
J	BIRD, GS; PUTNEY, JW				BIRD, GS; PUTNEY, JW			INHIBITION OF THAPSIGARGIN-INDUCED CALCIUM-ENTRY BY MICROINJECTED GUANINE-NUCLEOTIDE ANALOGS - EVIDENCE FOR THE INVOLVEMENT OF A SMALL G-PROTEIN IN CAPACITATIVE CALCIUM-ENTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LACRIMAL ACINAR-CELLS; RAT-LIVER MICROSOMES; CA-2+ RELEASE; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; GTP; POOLS; STIMULATION	Injection of mouse lacrimal acinar cells with the non-hydrolyzable analogue of GTP, GTPgammaS (guanosine 5'-3-O-(thio)triphosphate), caused a rapid release of intracellular calcium but failed to activate calcium entry. Injection of GTPgammaS together with the inositol 1,4,5-trisphosphate receptor inhibitor, heparin, did not induce calcium release but blocked the activation of capacitative calcium entry by thapsigargin. Injection of GDPbetaS (guanosine 5'-O-(thio)diphosphate) produced similar effects. The inhibitory effects of GDPbetaS were prevented if an equal concentration of GTP was included in the injection pipette. These findings suggest that one of the steps linking the depletion of intracellular calcium pools to calcium entry across the plasma membrane requires the hydrolysis of GTP and may involve a small G-protein.			BIRD, GS (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709, USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GILL DL, 1990, G PROTEINS CALCIUM M, P95; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; OZAWA T, 1991, BIOCHEM BIOPH RES CO, V180, P755, DOI 10.1016/S0006-291X(05)81130-1; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; THOMAS AP, 1988, J BIOL CHEM, V263, P2704	23	187	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21486	21488						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407996				2022-12-25	WOS:A1993MC80900009
J	HABUCHI, O; MATSUI, Y; KOTOYA, Y; AOYAMA, Y; YASUDA, Y; NODA, M				HABUCHI, O; MATSUI, Y; KOTOYA, Y; AOYAMA, Y; YASUDA, Y; NODA, M			PURIFICATION OF CHONDROITIN 6-SULFOTRANSFERASE SECRETED FROM CULTURED CHICK-EMBRYO CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN SULFOTRANSFERASE ACTIVITIES; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; FIBROBLAST GROWTH-FACTOR; HUMAN-SERUM; GOLGI RETENTION; TRANSMEMBRANE DOMAIN; HEPARAN-SULFATE; FUCOSYL-TRANSFERASE; SQUID CARTILAGE; ANIMAL SERA	Chondroitin 6-sulfotransferase, which transfers sulfate from 3'-phosphoadenylyl sulfate to position 6 of N-acetylgalactosamine in chondroitin, was purified 1,430-fold to apparent homogeneity with a 22% yield from the serum-free culture medium of chick embryo chondrocytes by affinity chromatography on heparin-Sepharose CL-6B, wheat germ agglutinin-agarose, and 3',5'-ADP-agarose. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified enzyme showed a single broad protein band with an apparent molecular weight of 75,000. Since the purified enzyme has an apparent molecular weight of 160,000 as judged by gel chromatography on Superose 12, the active form of chondroitin 6-sulfotransferase may be a dimer. The purified enzyme transferred sulfate to chondroitin, chondroitin sulfate, and corneal keratan sulfate. Chondroitin sulfate E from squid cartilage, dermatan sulfate, and heparan sulfate hardly served as acceptors of the sulfotransferase. The sulfated product derived from keratan sulfate was degraded by keratanase but not by chondroitinase ABC.			HABUCHI, O (corresponding author), AICHI UNIV EDUC,DEPT LIFE SCI,KARIYA 448,JAPAN.			Habuchi, Osami/0000-0001-9591-5374				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; FUJITAYAMAGUCHI Y, 1981, J BIOL CHEM, V256, P2701; GOHLER D, 1984, EUR J BIOCHEM, V138, P301, DOI 10.1111/j.1432-1033.1984.tb07915.x; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HABUCHI O, 1982, BIOCHIM BIOPHYS ACTA, V717, P414, DOI 10.1016/0304-4165(82)90282-3; HABUCHI O, 1985, J BIOL CHEM, V260, P3102; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KELLEN L, 1991, ANNU REV BIOCHEM, V60, P443; KIM JJ, 1980, J BIOL CHEM, V255, P1586; KIM JJ, 1977, J BIOL CHEM, V252, P8292; KIM JJ, 1976, J BIOL CHEM, V251, P6210; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MOMBURG M, 1972, H-S Z PHYSIOL CHEM, V353, P1351, DOI 10.1515/bchm2.1972.353.2.1351; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RUTER ER, 1984, J BIOL CHEM, V259, P1771; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SUGAHARA K, 1989, J BIOCHEM-TOKYO, V106, P910, DOI 10.1093/oxfordjournals.jbchem.a122951; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	45	76	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21968	21974						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408053				2022-12-25	WOS:A1993MC80900080
J	KISTER, L; DOMENJOUD, L; GALLINARO, H; MONIQUE, J				KISTER, L; DOMENJOUD, L; GALLINARO, H; MONIQUE, J			A CIS-ACTING SELECTOR OF A 5' SPLICE-SITE - COOPERATION BETWEEN THE SEQUENCE OF THE SITE AND AN UPSTREAM EXONIC ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; OSTEOGENESIS IMPERFECTA; MAMMALIAN SPLICEOSOME; ASSEMBLY PATHWAY; GENE; MUTATION; INVITRO; BINDING; MECHANISM; INTRON	To investigate the mechanism by which a 5' splice site (D1) is selected, while a nearby potentially functional site (Dcr1) is silenced, we have studied the importance of the 9- nucleotide sequence of these 5' splice sites for their respective usage. Our model system uses a transcript derived from the early transcription unit 3 of adenovirus-2. Transcripts, harboring an exonic element previously shown to be required for the selection of Dl in the presence of Dcr1, were mutated in the Dl and Dcr1 sequences and assayed for splicing in vitro. We first show that an increased ability of Dl to pair with U1 small nuclear (sn) RNA correlates with an increased accumulation of splicing intermediates, independently of the presence of Dcr1. This variation of efficiency of the first splicing reaction does not significantly affect the overall splicing efficiency except when the potential D1-U1 snRNA hybrid is less than 6 base pairs. Equally, the selector activity of the upstream exon element requires a Dl sequence that is able to form hybrids of 6 base pairs or more with U1 snRNA. This indicates that the cis-acting selector of DI includes the exonic element (a potential stem-loop structure) and a D1 sequence of sufficient strength.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AKLI S, 1990, J BIOL CHEM, V265, P7324; BELAGULI NS, 1992, J VIROL, V66, P2724, DOI 10.1128/JVI.66.5.2724-2730.1992; BOELENS W, 1992, NUCLEIC ACIDS RES, V12, P3165; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CAFFARELLI E, 1992, BIOCHEM BIOPH RES CO, V183, P680, DOI 10.1016/0006-291X(92)90536-T; CLADARAS C, 1985, VIROLOGY, V140, P28, DOI 10.1016/0042-6822(85)90443-X; DALESSIO M, 1991, AM J HUM GENET, V49, P400; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; Domenjoud Lionel, 1993, Gene Expression, V3, P83; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GANGULY A, 1991, J BIOL CHEM, V266, P12035; GRANT CE, 1990, NUCLEIC ACIDS RES, V18, P5457, DOI 10.1093/nar/18.18.5457; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; HAYNES SR, 1992, NEW BIOL, V4, P421; HODGES D, 1992, MECH DEVELOP, V37, P127, DOI 10.1016/0925-4773(92)90075-U; HODGES PE, 1989, P NATL ACAD SCI USA, V86, P4142, DOI 10.1073/pnas.86.11.4142; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LATCHMAN D S, 1990, New Biologist, V2, P297; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEE B, 1991, J BIOL CHEM, V266, P5256; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKeown M, 1990, Genet Eng (N Y), V12, P139; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; Rio Donald C., 1992, Gene Expression, V2, P1; SAWA H, 1991, NUCLEIC ACIDS RES, V19, P3953, DOI 10.1093/nar/19.14.3953; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPIKES D, 1992, NUCLEIC ACIDS RES, V20, P5719, DOI 10.1093/nar/20.21.5719; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; UTANS U, 1990, EMBO J, V9, P4119, DOI 10.1002/j.1460-2075.1990.tb07634.x; VIDAUD M, 1989, P NATL ACAD SCI USA, V86, P1041, DOI 10.1073/pnas.86.3.1041; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	44	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21955	21961						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408052				2022-12-25	WOS:A1993MC80900078
J	BEAUDETTE, KN; LEW, J; WANG, JH				BEAUDETTE, KN; LEW, J; WANG, JH			SUBSTRATE-SPECIFICITY CHARACTERIZATION OF A CDC2-LIKE PROTEIN-KINASE PURIFIED FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; CDC2 KINASE; XENOPUS OOCYTES; G1 PHASE; HOMOLOG; YEAST; P34CDC2; CDNA; COMPLEMENTATION	A serine/threonine kinase from bovine brain has been purified (Lew, J., Beaudette, K. N., Litwin, C. M. E., and Wang, J. H. (1992) J. Biol. Chem. 267, 13383-13390) and found to consist of a 33-kDa catalytic subunit having high sequence homology to p34cdc2 and cdk2 (Lew, J., Winkfein, R. J., Paudel, H., and Wang, J. H. (1992) J. Biol. Chem. 267, 25922-25926). Substrate specificity determinants for this cdc2-like kinase were examined using synthetic peptide substrates derived from the in vitro p34cdc2 phosphorylation sites of histone H1. The peptide P-K-T-P-K-K-A-K-K-L was found to be an excellent substrate for the bovine cdc2-like kinase, having a K(m) value in the micromolar range. Important determinants for efficient substrate phosphorylation of this peptide were found both within the proposed substrate consensus motif (S/T-P-X-K/R) of p34cdc2 kinase and outside of this sequence. In addition to the absolute requirement for a proline residue immediately COOH-terminal to the phosphorylatable residue (+1) and a basic residue at the +3 position, a basic amino acid at the +2 position was greatly preferred over an acidic amino acid. A proline residue at the -2 position and a cluster of basic amino acids further COOH-terminal to the consensus motif were also found to be important for substrate binding. HeLa cell p34cdc2 kinase displays similar specificity to that of the bovine cdc2-like kinase, as the additional determinants outside of the consensus motif that contribute to the efficient phosphorylation of the histone peptide by this novel enzyme also appear to be important for p34cdc2-catalyzed phosphorylation.	UNIV CALGARY, FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP, 3330 HOSP DR NW, CALGARY T2N 4N1, AB, CANADA	University of Calgary								BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HADWIGER JA, 1988, MOL CELL BIOL, V8, P2976, DOI 10.1128/MCB.8.7.2976; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HATSUSHIME H, 1992, CELL, V71, P323; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HIRT H, 1991, P NATL ACAD SCI USA, V88, P1636, DOI 10.1073/pnas.88.5.1636; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KUSUUTA, 1992, J BIOL CHEM, V267, P20937; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEREA KM, 1992, BIOCHEMISTRY-US, V31, P6553, DOI 10.1021/bi00143a027; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; MAK AS, 1991, J BIOL CHEM, V266, P6678; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	57	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20825	20830						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407912				2022-12-25	WOS:A1993MA28800031
J	YANAGITA, K; MATSUMOTO, K; SEKIGUCHI, K; ISHIBASHI, H; NIHO, Y; NAKAMURA, T				YANAGITA, K; MATSUMOTO, K; SEKIGUCHI, K; ISHIBASHI, H; NIHO, Y; NAKAMURA, T			HEPATOCYTE GROWTH-FACTOR MAY ACT AS A PULMOTROPHIC FACTOR ON LUNG REGENERATION AFTER ACUTE LUNG INJURY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET PROTOONCOGENE; SCATTER FACTOR; MESSENGER-RNA; CELL-GROWTH; UNILATERAL NEPHRECTOMY; LIVER-REGENERATION; EPITHELIAL-CELLS; FACTOR RECEPTOR; RAT PLATELETS; DNA-SYNTHESIS	Hepatocyte growth factor (HGF) has been shown to have hepatotrophic and renotropic functions for regeneration of the liver and kidney through its mitogenic, motogenic, and morphogenic properties. To examine the involvement of HGF in lung regeneration after acute injury, we analyzed changes of HGF mRNA, HGF activity, and HGF receptors in the rat lung after lung insult and measured HGF concentration in sera of patients with various lung diseases. Following the onset of acute lung injury induced by intratracheal hydrochloride injection, a compensatory DNA synthesis occurred in the bronchial epithelium with a peak at 24 h and in the alveolar epithelium with a peak at 48 h. Expression of HGF mRNA in the rat lung remarkably increased only 3 h after the treatment and HGF activity in the lung also increased to about 3-fold at 6 h later. HGF receptors in the lung but not in the other noninjured organs were down-regulated 12 h later. These marked increases in HGF mRNA and HGF activity and the concomitant down-regulation of HGF receptor occurred before the marked compensatory DNA synthesis in bronchial and alveolar epithelial cells. HGF concentration in sera of patients with various lung diseases, as measured by radioimmunoassay, was much higher than that in healthy donors. These results suggest that HGF is newly produced in the lung after acute lung injury and may have a role in regeneration of the lung.	OSAKA UNIV,CTR BIOMED RES,SCH MED,DEPT BIOCHEM,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN; DINABOT CO LTD,CTR RES & DEV,MINORIDAI,CHIBA 271,JAPAN; KYUSHU UNIV,FAC MED,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN	Osaka University; Kyushu University								AOKI J, 1991, JPN J CLIN HEMATOL, V32, P11; ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FREYCHET P, 1972, J BIOL CHEM, V247, P3953; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOLDIN GV, 1980, J EMBRYOL EXP MORPH, V60, P235; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IGAWA T, 1993, IN PRESS AM J PHYSL; ISHIBASHI K, 1992, BIOCHEM BIOPH RES CO, V187, P1454, DOI 10.1016/0006-291X(92)90465-W; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; JETTEN AM, 1991, AM J PHYSIOL, V260, pL361, DOI 10.1152/ajplung.1991.260.6.L361; JETTEN AM, 1986, EXP CELL RES, V147, P530; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; LECHNER JF, 1981, CANCER RES, V41, P2294; MASON R M, 1992, American Review of Respiratory Disease, V145, pA122; MASON RJ, 1990, AM J RESP CELL MOL, V3, P571, DOI 10.1165/ajrcmb/3.6.571; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1983, J BIOL CHEM, V258, P9283; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; STAHLMAN MT, 1988, LAB INVEST, V59, P25; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TAJIMA H, 1992, J BIOCHEM-TOKYO, V111, P401, DOI 10.1093/oxfordjournals.jbchem.a123769; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; VOELKER DR, 1990, LUNG CELL BIOL, P487; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WYNNE JW, 1982, CLIN CHEST MED, V3, P25; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZARNEGAR R, 1989, CANCER RES, V49, P3314	48	233	236	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21212	21217						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407957				2022-12-25	WOS:A1993MA28800084
J	GARRIDO, C; PLAZA, S; GOSPODAROWICZ, D; SAULE, S				GARRIDO, C; PLAZA, S; GOSPODAROWICZ, D; SAULE, S			FOS EXPRESSION INDUCES GROWTH ARREST IN TUMORIGENIC NEURORETINA CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE; C-MYC; V-FOS; GENE; JUN; TRANSFORMATION; PROTEINS; P135GAG-MYB-ETS; STIMULATION; INDUCTION	E26-infected chicken neuroretina (CNR) cells expressing P135gag-myb-ets are non-transformed and growth can be stimulated by basic fibroblast growth factor (bFGF). In contrast, MHE226-infected CNR cells, which express p61/63myc in addition to the P135gag-myb-ets of E26, are transformed, tumorigenic cells and are growth inhibited by bFGF. We looked for differences in both cells types which could help to understand the molecular basis of the bFGF response. We found marked differences in c-fos expression. In MHE226-CNR cells c-fos mRNA was induced by 12-0-tetradecanoyl phorbol 13-acetate (TPA) and bFGF, both inhibitors of MHE226-infected cell growth. In contrast, serum, a strong growth inducer, did not stimulate c-fos expression. In E26-infected cells all of these factors induced cell growth and c-fos expression. MHE226-CNR cells superinfected with v-fos(FBJ)-expressing retrovirus were inhibited in their growth and unresponsive to bFGF. Introduction of V-fos(FBJ) in E26 CNR cells transformed them but they remained sensitive to bFGF. These results suggest that fos is involved in the induced growth arrest of MHE226-CNR cells.	UNIV CALIF SAN FRANCISCO,MED CTR,CANC RES INST,M-1282,SAN FRANCISCO,CA 94143; INST PASTEUR,CNRS,EP 56,F-59019 LILLE,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			plaza, serge/F-5290-2015; Garrido, Carolina/GWM-5557-2022					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRICK KK, 1990, MOL CELL BIOL, V10, P184, DOI 10.1128/MCB.10.1.184; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IBA H, 1988, ONCOGENE RES, V2, P121; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; OKUNO H, 1991, ONCOGENE, V6, P1491; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9	28	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2713	2719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397368				2022-12-25	WOS:A1993LX34300012
J	LIU, XB; DAVIS, D; SEGALOFF, DL				LIU, XB; DAVIS, D; SEGALOFF, DL			DISRUPTION OF POTENTIAL SITES FOR N-LINKED GLYCOSYLATION DOES NOT IMPAIR HORMONE BINDING TO THE LUTROPIN CHORIOGONADOTROPIN RECEPTOR IF ASN-173 IS LEFT INTACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; CHORIONIC-GONADOTROPIN; DIRECTED MUTAGENESIS; OVERLAP EXTENSION; STRUCTURAL BASIS; CG RECEPTOR; OLIGOSACCHARIDES; CELLS; EXPRESSION; SEQUENCE	The rat lutropin/choriogonadotropin receptor (rLHR) is a G protein-coupled receptor, the large extracellular domain of which binds human choriogonadotropin (hCG) with high affinity. Within the extracellular domain are six potential sites for N-linked glycosylation. Although several studies have attempted to determine if N-linked carbohydrates are necessary for hormone binding, the results have been in apparent disagreement. In this study we have used site-directed mutagenesis to singly and collectively alter the consensus sequences for N-linked glycosylation in the rLHR. In particular, we examined the binding activity in both intact cells as well as detergent-solubilized extracts so that the effects on trafficking to the plasma membrane could be determined. In addition, we independently examined the effects of substituting a particular Asn versus Thr or Ser residue within a given glycosylation consensus sequence. Our data suggest that substitution of Asn-173 with Gln results in both a decreased ability of the receptor to be expressed on the plasma membrane as well as a vastly decreased binding affinity of the receptor for hCG. However, if the consensus sequence for N-linked glycosylation at Asn-173 is altered by substitution of Thr-175 with Ala (instead of Asn-173 to Gln), the resulting receptor binds hCG with high affinity although it is still impaired in its ability to be expressed at the plasma membrane. Furthermore, if all consensus sequences for N-linked glycosylation are mutated collectively while maintaining Asn-173 (by substituting Thr-175 with Ala instead of Asn-173 to Gln), the resulting deglycosylated receptor, although not expressed on the plasma membrane, binds hCG with high affinity. These results resolve the apparent discrepancies in the literature on the role of N-linked carbohydrates of the rLHR on the binding of hormone by showing that they are not required for high affinity binding but that Asn-173 is involved, either directly or indirectly in the high affinity binding of hormone.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NICHD NIH HHS [HD-22196, HD-00968] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000968, R01HD022196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; ASCOLI M, 1983, ENDOCRINOLOGY, V113, P2129, DOI 10.1210/endo-113-6-2129; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTIN G, 1980, J BIOL CHEM, V255, P8007; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JI IH, 1990, ENDOCRINOLOGY, V127, P494, DOI 10.1210/endo-127-1-494; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISHI T, 1989, P NATL ACAD SCI USA, V86, P1470, DOI 10.1073/pnas.86.5.1470; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PETAJAREPO UE, 1991, ENDOCRINOLOGY, V128, P1209, DOI 10.1210/endo-128-3-1209; ROCHE PC, 1985, ENDOCRINOLOGY, V117, P790, DOI 10.1210/endo-117-2-790; ROSEMBLIT N, 1988, ENDOCRINOLOGY, V123, P2284, DOI 10.1210/endo-123-5-2284; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; SEGALOFF DL, 1993, IN PRESS ENDOCRINE R; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WONG SKF, 1988, J BIOL CHEM, V263, P7925; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHANG R, 1991, BIOCHEM BIOPH RES CO, V181, P804, DOI 10.1016/0006-291X(91)91261-A	30	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1513	1516						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420926				2022-12-25	WOS:A1993KH62000004
J	ERICSSON, J; RUNQUIST, M; THELIN, A; ANDERSSON, M; CHOJNACKI, T; DALLNER, G				ERICSSON, J; RUNQUIST, M; THELIN, A; ANDERSSON, M; CHOJNACKI, T; DALLNER, G			DISTRIBUTION OF PRENYLTRANSFERASES IN RAT-TISSUES - EVIDENCE FOR A CYTOSOLIC ALL-TRANS-GERANYLGERANYL DIPHOSPHATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; COENZYME-A REDUCTASE; HMG-COA REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; POSTTRANSLATIONAL MODIFICATION; PYROPHOSPHATE SYNTHETASE; DOLICHOL SYNTHESIS; MEVALONIC ACID; METHYL-ESTER; LAMIN-B	The present study describes the presence of two different geranylgeranyl diphosphate (GGPP) synthase activities, one cytosolic and one membrane-associated, in a number of rat tissues. Both enzymes utilize farnesyl diphosphate (FPP) and isopentenyl diphosphate (IPP) as substrates, but they give rise to different products. The membrane-associated activity produces trans,trans,cis-(E,E,Z)-GGPP, involved in the biosynthesis of long-chain polyprenols. The cytosolic activity produces only the all-trans-(E,E,E) isomer of GGPP, which is utilized as substrate in cytosolic protein prenylation reactions. All-trans-GGPP synthase activity was recovered in the cytosolic fraction from all tissues investigated, but the specific activities varied. The highest specific activities were found in brain, spleen, and testis, followed by kidney and liver. The enzyme activity in rat brain cytosol was further characterized and found to exhibit a narrow pH optimum around 5.0-6.0 and to be highly stimulated by Zn2+. Maximal stimulation was attained with 1 mM Zn2+, whereas Mg2+ had no effect on the enzyme activity. The all-trans-GGPP synthase activity exhibited high affinities for its substrates, i.e. the apparent K(m) values for FPP and IPP were found to be 0.6 and 3.5 muM, respectively. When rats were fed mevinolin (lovastatin), FPP and all-trans-GGPP synthase activities were affected differently in certain tissues. Mevinolin treatment resulted in an increase in FPP but a decrease in all-trans-GGPP synthase activity in rat liver and kidney. In spleen mevinolin treatment caused a greater than 70% decrease in all-trans-GGPP synthase activity, while FPP synthase was almost unaffected. The presence of two different GGPP synthase activities in the cell, together with the fact that FPP and all-trans-GGPP synthesis in the cytosol are regulated independently, may be of significance in the regulation of isoprenoid biosynthesis, as well as of protein isoprenylation.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	ERICSSON, J (corresponding author), UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		Runquist, Marten/AAF-7613-2019; Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574				ASHBY MN, 1989, J BIOL CHEM, V264, P635; BABA T, 1987, ARCH BIOCHEM BIOPHYS, V252, P440, DOI 10.1016/0003-9861(87)90050-6; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BROWN MS, 1980, J LIPID RES, V21, P505; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN Z, 1988, ARCH BIOCHEM BIOPHYS, V266, P98, DOI 10.1016/0003-9861(88)90240-8; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1984, ACTA BIOCHIM POL, V31, P115; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; ELMBERGER PG, 1987, EUR J BIOCHEM, V168, P1, DOI 10.1111/j.1432-1033.1987.tb13379.x; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; ERCISSON J, 1992, J BIOL CHEM, V267, P19730; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; ERICSSON J, 1991, EUR J BIOCHEM, V209, P789; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST JR, 1979, ARCH BIOCHEM BIOPHYS, V192, P86, DOI 10.1016/0003-9861(79)90074-2; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEMMING FW, 1981, BIOCH ISOPRENOID COM, V2, P305; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; JAMES MJ, 1980, J BIOL CHEM, V255, P8618; JAMES MJ, 1980, J BIOL CHEM, V255, P16; JOLY A, 1991, J BIOL CHEM, V266, P13495; JOLY A, 1991, CURR OPIN LIPIDOL, V2, P283; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LUTZ RJ, 1992, J BIOL CHEM, V267, P7983; LWORY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MITROPOULOS KA, 1978, EUR J BIOCHEM, V82, P419, DOI 10.1111/j.1432-1033.1978.tb12036.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; POTTER JER, 1981, J BIOL CHEM, V256, P2371; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RUNQUIST M, 1992, BIOCHEM BIOPH RES CO, V186, P157, DOI 10.1016/S0006-291X(05)80788-0; SAGAMI H, 1991, J BIOL CHEM, V266, P3458; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SCHABERMD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WONG TK, 1982, J BIOL CHEM, V257, P6619; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	59	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					832	838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419360				2022-12-25	WOS:A1993KG07700015
J	CAPPEL, RE; GILBERT, HF				CAPPEL, RE; GILBERT, HF			OXIDATIVE INACTIVATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE AND SUBUNIT CROSS-LINKING INVOLVE DIFFERENT DITHIOL DISULFIDE CENTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; RAT-LIVER; GLUTATHIONE; EXCHANGE; ENZYME	Rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR) is extremely sensitive to oxidative inactivation by low concentrations (micromolar) of glutathione disulfide (GSSG) even in the presence of millimolar concentrations of glutathione (GSH). Inactivation involves the formation of an intramolecular protein-SS-protein disulfide in thiol/disulfide redox equilibrium with the reduced, active enzyme (Cappel, R. E., and Gilbert, H. F. (1988) J. Biol. Chem. 263, 12204-12212). In the absence of dithiothreitol, HMGR oxidation has been previously shown to cross-link the microsomal enzyme into a covalent dimer (Ness, G. C., McCreery, M. J., Sample, C. E., Smith, M., and Pendelton, L. C. (1985) J. Biol. Chem. 260, 12391-12393). Examination of the extent of HMGR cross-linking and residual HMGR activity in microsomes equilibrated with glutathione redox buffers establishes that inactivation and cross-linking result from oxidation of different dithiol pairs. The thiol/disulfide oxidation potential (K(ox)) for the oxidative inactivation of HMGR, E(SH)2,active + GSSG reversible E(S-S)inactive + 2 GSH, is 0.67 +/- 0.07 M. However, the equilibrium constant for HMGR cross-linking, E(SH)2,monomer + GSSG reversible E(S-S)dimer + 2 GSH, is 0.19 +/- 0.02 M, significantly lower than that for inactivation (p < 0.001). Because of the significantly different oxidation potentials and the lack of a linear relationship between cross-linking and inactivation, the two processes must involve two different sets of vicinal dithiols. HMGR becomes 5-10-fold more difficult to oxidize in the presence of saturating levels of the substrate, HMG-CoA. Both inactivation and cross-linking exhibit significantly lower oxidation potentials in the presence of this substrate, 0.072 +/- 0.01 and 0.047 +/- 0.007 M, respectively. The decrease in oxidation potential caused by substrate binding is observed for both inactivation and cross-linking, showing that both processes are affected by the binding of substrate to the enzyme. The dithiols involved in HMGR subunit cross-linking are 2-3-fold more difficult to oxidize than the dithiols that affect the enzyme activity. Thus, the observation of partial cross-linking of HMGR in vivo would imply that conditions are sufficiently oxidizing to result in significant enzyme inactivation. The extreme thermodynamic sensitivity of HMGR to oxidative inactivation and cross-linking in glutathione redox buffers that span the physiological redox state implies that thiol/disulfide redox state changes could provide a mechanism for regulating the activity and/or stability of this enzyme.			CAPPEL, RE (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA.				NHLBI NIH HHS [HL-28521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT AJ, 1985, ANAL BIOCHEM, V144, P553, DOI 10.1016/0003-2697(85)90153-8; Bevington PR, 1969, DATA REDUCTION ERROR; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V57, P209; CAPPEL RE, 1990, J BIOL CHEM, V265, P15464; CAPPEL RE, 1989, J BIOL CHEM, V264, P9180; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; DOTAN I, 1987, J BIOL CHEM, V262, P17058; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GILBERT HF, 1981, J BIOL CHEM, V256, P1782; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUZMANBARRON ES, 1951, ADV ENZYMOL, V11, P201; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NESS GC, 1985, J BIOL CHEM, V260, P2391; NESS GC, 1986, BIOCHEM J, V233, P167, DOI 10.1042/bj2330167; NESS GC, 1985, J BIOL CHEM, V260, P6395; PARKER RA, 1989, J BIOL CHEM, V264, P4877; SIES H, 1983, FUNCTIONS GLUTATHION, P231; SIES H, 1983, ADV ENZYME REGUL, V26, P175; TATEISHI N, 1974, J BIOCHEM, V75, P93, DOI 10.1093/oxfordjournals.jbchem.a130387; VERMILION JL, 1990, J BIOL CHEM, V265, P9984; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; ZAR JH, 1984, BIOSTAT ANAL, P126; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	30	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					342	348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416941				2022-12-25	WOS:A1993KE60300053
J	CHOU, DKH; JUNGALWALA, FB				CHOU, DKH; JUNGALWALA, FB			CHARACTERIZATION AND DEVELOPMENTAL EXPRESSION OF A NOVEL SULFOTRANSFERASE FOR THE BIOSYNTHESIS OF SULFOGLUCURONYL GLYCOLIPIDS IN THE NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLUCURONIC-ACID; RAT-BRAIN; HNK-1 ANTIBODY; CEREBROSIDE SULFOTRANSFERASE; HNK-1-REACTIVE ANTIGENS; NEUROPATHY; IGM; GLUCURONYLTRANSFERASE; LOCALIZATION; ENZYME	Sulfoglucuronly glycolipids (SGGLs) are temporally and spatially regulated molecules in the developing nervous system. A novel sulfotransferase (ST) from rat brain which catalyzes the terminal step in the biosynthesis in vitro of SGGLs is described. The enzyme catalyzes a transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to a hydroxyl group on carbon 3 of the terminal glucuronyl residue in IV3beta-glucuronyl neolactotetraosylceramide (GlcAnLcOse4Cer) and VI3beta-glucuronyl neolactohexaosylceramide (GlcAnLcOse6Cer) to form 3-sulfated glucuronyl glycolipids. The enzyme is highly specific for glucuronylglycolipids (GGLs) and requires the free-COOH group of the terminal glucuronic acid for reactivity. GGL:ST present in the microsomal membranes requires Mn2+ ions and a nonionic detergent, Triton X-100 for activity. The optimal pH is 7.2 with Tris-HCl buffer and K(m) values were 7 muM for 3'-phosphoadenosine 5'-phosphosulfate and 29 muM for GlcAnLcOse4Cer. GGL:ST was shown to be different from previously well studied galactocerebroside:sulfotransferase for the synthesis of myelin membrane-specific lipid sulfatide. This conclusion was based upon several criteria, i.e. including different requirements of incubation conditions for maximal activity, substrate competition experiments, different effects of heat, dithiothreitol, NaCl, and pyridoxal phosphate, as well as different profiles of expression of activity during development of the nervous tissues. The two enzymes were also partially resolved on a pyridoxal phosphate-ligated agarose column. Studies on the developmental expression of the GGL:ST in the rat cerebral cortex and cerebellum showed that it is not a regulatory enzyme controlling the expression of SGGLs in these neural tissues.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02214	Harvard University; Harvard Medical School	CHOU, DKH (corresponding author), EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,DEPT BIOCHEM,WALTHAM,MA 02254, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS24405] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABO T, 1982, J IMMUNOL, V129, P1752; ANDO S, 1977, J BIOL CHEM, V252, P6247; ARIGA T, 1987, J BIOL CHEM, V262, P848; BENJAMINS JA, 1982, J NEUROCHEM, V38, P233, DOI 10.1111/j.1471-4159.1982.tb10875.x; BONNERFRASER M, 1987, DEV BIOL, V123, P321; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CHOU DKH, 1990, T AM SOC NEUROCHEM, V21, P120; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CHURCHICH JE, 1984, EUR J BIOCHEM, V138, P327, DOI 10.1111/j.1432-1033.1984.tb07918.x; DAS KK, 1991, J BIOL CHEM, V266, P5238; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FIGLEWICZ DA, 1985, J LIPID RES, V26, P140; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; JUNGALWALA FB, 1992, J NEUROCHEM, V53, P1045; KOHRIYAMA T, 1988, J NEUROCHEM, V51, P869, DOI 10.1111/j.1471-4159.1988.tb01823.x; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; NAIR SM, 1992, T AM SOC NEUROCHEM, V23, P137; PESHEVA P, 1988, J NEUROSCI RES, V20, P420, DOI 10.1002/jnr.490200404; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SHASHOUA VE, 1986, BIOCHEM BIOPH RES CO, V138, P902, DOI 10.1016/S0006-291X(86)80581-2; SIEGRIST HP, 1977, BIOCHIM BIOPHYS ACTA, V489, P58, DOI 10.1016/0005-2760(77)90231-4; SUNDARAM KS, 1990, BIOCHEM BIOPH RES CO, V169, P927, DOI 10.1016/0006-291X(90)91982-X; TENNEKOON G, 1978, J NEUROCHEM, V31, P329, DOI 10.1111/j.1471-4159.1978.tb12466.x; TENNEKOON G, 1983, J CELL BIOL, V97, P1107, DOI 10.1083/jcb.97.4.1107; VANDERPAL RHM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P91, DOI 10.1016/0005-2760(90)90114-D	32	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					330	336						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416940				2022-12-25	WOS:A1993KE60300051
J	SHORE, SK; NABISSA, PM; REDDY, EP				SHORE, SK; NABISSA, PM; REDDY, EP			RIBOZYME-MEDIATED CLEAVAGE OF THE BCRABL ONCOGENE TRANSCRIPT - IN-VITRO CLEAVAGE OF RNA AND IN-VIVO LOSS OF P210 PROTEIN-KINASE ACTIVITY	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CELL-LINE; PHILADELPHIA-CHROMOSOME; ANTISENSE TRANSCRIPTS; EXPRESSION; POINT; GENE; K562	The t(9,22) chromosomal translocation generating the Philadelphia chromosome and the BCRABL oncogene has been shown both cytogenetically and molecularly to be the etiologic event in chronic myelogenous leukemia (CML). We have designed a ribozyme to cleave the BCRABL mRNA by targeting a GUU triplet adjacent to the junction of the c-BCR and c-ABL fused genes. This ribozyme efficiently cleaved BCRABL RNA transcripts as demonstrted by in vitro cleavage reactions. To determine the effect of constitutive expression of the ribozyme on the elimination of the BCRABL gene product, the ribozyme cDNA sequence was inserted into different retroviral expression vectors. Introduction of the recombinant retroviruses into the CML blast crisis cell-line K562, resulted in the elimination of the P210 protein-kinase activity in several single cell clones infected with the ribozyme expression cassette. Therefore BCR-ABL specific ribozymes may provide a potential genetic therapy for CML.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	SHORE, SK (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST MOLEC BIOL & CANC RES,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 47937-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047937] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kuzrock R, 1988, NEW ENGL J MED, V319, P990; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NOWELL PC, 1960, SCIENCE, V132, P1497; PERRIMAN R, 1992, GENE, V113, P157, DOI 10.1016/0378-1119(92)90391-2; ROWERY JD, 1973, NATURE, V243, P290; SCHTIVELMAN E, 1985, NATURE, V315, P550; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1990, US PATENT TRADEMARK; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	28	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3183	3188						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414522				2022-12-25	WOS:A1993MC09300037
J	TRAVERSE, S; COHEN, P; PATERSON, H; MARSHALL, C; RAPP, U; GRAND, RJA				TRAVERSE, S; COHEN, P; PATERSON, H; MARSHALL, C; RAPP, U; GRAND, RJA			SPECIFIC ASSOCIATION OF ACTIVATED MAP KINASE KINASE KINASE (RAF) WITH THE PLASMA-MEMBRANES OF RAS-TRANSFORMED RETINAL CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; MURINE SARCOMA-VIRUS; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION; LOCALIZATION; ONCOGENE; CASCADE; P21RAS; GENE	Plasma membrane-enriched fractions were prepared from human embryonic retinal cells transformed with either adenovirus El A and oncogenic ras DNA, or E1A and E1B DNA. Ras comprised 5-10 % of the membrane protein from the E1A/ras transformed cells, whereas the membranes from EIA/E1B transformed cells did not overexpress Ras. The membranes from E1a/ras cells contained MAP kinase kinase kinase (MAPKKK) activity, even after washing in 0.5 M NaCl, whereas the membranes from E1A/EIB cells did not. Neither membrane fraction contained MAP kinase kinase or MAP kinase activity after washing with 0.5M NaCl. Immunoblotting experiments revealed about 10-fold more c-Raf in the membranes from EIA/ras cells than from E1A/E1B cells, and 50-60% of the MAPKKK activity in Triton X100-solubilised membranes from E1A/ras cells was immunoprecipitated with anti-Raf antibodies. A striking enrichment of c-Raf in the plasma membranes of E1A/ras cells was also demonstrated by immunocytochemistry, where it was co-localized with Ras. The MAPKKK activity in E1A/ras membranes was unaffected by incubation with protein phosphatases or by inclusion of protein phosphatase inhibitors during isolation, nor was it activated by GTP-Ras or inhibited by GDP-Ras. The results support the view that Ras and c-Raf interact with one another, but that neither c-Raf phosphorylation nor its interaction with GTP-Ras are alone sufficient for activation. The identification of MAPKKK activity in the membranes of ras-transformed cells may prove useful in elucidating the mechanism by which Raf is activated by Ras.	UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	TRAVERSE, S (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND.							AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V214, P555; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORCE T, 1993, IN PRESS P NATL ACAD; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; GOMEZ N, 1992, FEBS LETT, V314, P461, DOI 10.1016/0014-5793(92)81527-S; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAND RJA, 1987, ONCOGENE, V1, P305; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JWOOD KW, 1992, CELL, V68, P1041; KAVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROZAKISADCOCK M, 1993, NATURE, V363, P831; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	41	108	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3175	3181						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414521				2022-12-25	WOS:A1993MC09300036
J	BEAN, DW; KALLAM, WE; MATSON, SW				BEAN, DW; KALLAM, WE; MATSON, SW			PURIFICATION AND CHARACTERIZATION OF A DNA HELICASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALF THYMUS; UNWINDING REACTION; BINDING PROTEIN; GENE-PRODUCT; I CATALYZES; HELA-CELLS; REPLICATION; SEQUENCE; SNF2	A novel DNA helicase, scHelI, has been purified from whole cell extracts of Saccharomyces cerevisiae using biochemical assays to monitor the fractionation. The enzyme unwinds partial duplex DNA substrates, as long as 343 base pairs in length, in a reaction that is dependent on either ATP or dATP hydrolysis. scHelI also catalyzes a single-stranded DNA-dependent ATP hydrolysis reaction; the apparent K(m) for ATP is 325 muM. The unwinding reaction on circular partial duplex substrates is biphasic, with a fast component occurring within 5 min of the initiation of the reaction and a slow component continuing to 60 min. This is in contrast to the ATP hydrolysis reaction, which exhibits linear kinetics for 60 min. The direction of the unwinding reaction is 5' to 3' with respect to the strand of DNA on which the enzyme is bound. The unwinding reaction is strongly stimulated by the addition of Escherichia coli single-stranded DNA-binding protein when long partial duplex substrates are used. The enzymatic activity of scHelI copurifies with a polypeptide of 135 kDa as determined by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. The polypeptide sediments as a monomer in a glycerol gradient in the presence of 0.2 M NaCl.	UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	BEAN, DW (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; GOETZ GS, 1988, J BIOL CHEM, V263, P383; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAWRENCE CW, 1979, J BACTERIOL, V139, P866, DOI 10.1128/JB.139.3.866-876.1979; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LI XY, 1992, BIOCHEMISTRY-US, V31, P3507, DOI 10.1021/bi00128a027; LI XY, 1992, J BIOL CHEM, V267, P25321; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4017; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; RONG L, 1993, J BIOL CHEM, V268, P1252; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; YANCEYWRONA JE, 1992, EUR J BIOCHEM, V207, P479, DOI 10.1111/j.1432-1033.1992.tb17074.x; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	36	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21783	21790						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408033				2022-12-25	WOS:A1993MC80900056
J	BOUDKER, O; FUTERMAN, AH				BOUDKER, O; FUTERMAN, AH			DETECTION AND CHARACTERIZATION OF CERAMIDE-1-PHOSPHATE PHOSPHATASE-ACTIVITY IN RAT-LIVER PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; SPHINGOMYELIN TURNOVER; CULTURED FIBROBLASTS; CERAMIDE KINASE; GOLGI-APPARATUS; PHOSPHOLIPASE-D; ANIMAL-CELLS; SPHINGOSINE	A calcium-dependent ceramide (Cer) kinase was recently detected in human leukemia (HL-60) cells (Kolesnick, R. N., and Hemer, M. R. (1990) J. Biol. Chem. 265, 18803-18808) where it may function in terminating the regulatory effects of Cer, and in synaptic vesicles (Bajjalieh, S. M., Martin, T. F. J., and Floor, E. (1989) J. Biol. Chem. 264,14354-14360). We now demonstrate that the addition of both Cer-1-phosphate (Cer-1-P) and a short-acyl chain analog of Cer-1-P, N-hexanoylsphingosine-1-phosphate (C6-Cer-1-P) to cultured cells and a variety of subcellular fractions results in rapid degradation to Cer and C6-Cer, respectively. The Cer-1-P phosphatase activity is enriched in a rat liver plasma membrane fraction and appears to be distinct from the phosphatase that hydrolyzes phosphatidic acid (PA), PA phosphohydrolase, as shown by the difference in sensitivity of Cer-1-P and PA hydrolysis to propranolol, detergent, and heat treatment. Moreover, the K(m) of Cer-1-P hydrolysis is 10-fold lower than the K(m) of PA hydrolysis in plasma membrane. PA is a noncompetitive inhibitor of Cer-1-P hydrolysis, with an inhibition constant 1-1.5-fold higher than the K(m) of Cer-1-P hydrolysis. In contrast, Cer-1-P does not inhibit PA hydrolysis. Finally, we describe the synthesis of a novel analog of Cer-1-P which is not hydrolyzed in vitro and in vivo and is internalized in cultured cells by endocytosis. These results are discussed in relation to the possible roles of Cer-1-P in regulating intracellular levels of Cer.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Futerman, Anthony/0000-0003-0013-0115				BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BARKER R, 1971, ORGANIC CHEM BIOL CO, P214; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUTERMAN AH, 1992, METHOD ENZYMOL, V209, P437; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; IWAMORI M, 1975, BIOCHIM BIOPHYS ACTA, V380, P308; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KANOH H, 1992, J BIOL CHEM, V267, P25309; KIM MY, 1991, J BIOL CHEM, V266, P484; KISHIMOTO Y, 1974, ARCH BIOCHEM BIOPHYS, V161, P426, DOI 10.1016/0003-9861(74)90324-5; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; YOUNES A, 1992, J BIOL CHEM, V267, P842	43	67	74	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22150	22155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408075				2022-12-25	WOS:A1993MC80900105
J	RAMSDEN, R; SOMMER, KM; OMIECINSKI, CJ				RAMSDEN, R; SOMMER, KM; OMIECINSKI, CJ			PHENOBARBITAL INDUCTION AND TISSUE-SPECIFIC EXPRESSION OF THE RAT CYP2B2 GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE CYTOCHROME-P-450; BACILLUS-MEGATERIUM; TRANSCRIPTIONAL REGULATION; MESSENGER-RNAS; LIVER; SEQUENCE; PROTEIN; BINDING	To investigate molecular events regulating the transcription of genes inducible by phenobarbital, transgenic mouse strains were developed incorporating rat cytochrome P450 2B2 (CYP2B2) genes. Expression in mouse tissues was analyzed for two series of rat CYP2B2 gene constructs, of 19 and-39 kilobase pairs total length, each containing the entire coding region, introns, and 3'-flanking sequences of CYP2B2, but differing in the respective lengths of 5'-flanking sequence. One group of mice, whose transgene included the complete 2B2 gene but only 800 base pairs of 5'-proximal sequence, were not phenobarbital-inducible in mouse liver or in any extrahepatic tissue; rather, these genes were expressed at very high levels constitutively and selectively in only kidney and liver. A second group of mice with an identical transgene, except for the presence of an additional 19 kilobase pairs of 5'-flanking sequence, expressed 2B2 only in the liver and at high levels only after phenobarbital treatment, analogous to the expression pattern observed for the endogenous CYP2B2 gene in the rat. These results demonstrate that, in vivo, phenobarbital induction and tissue-specific control requires interaction of regulatory elements far upstream of the core CYP2B2 promoter region and upstream of motifs indicated previously as determinants of phenobarbital responsiveness.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT ENVIRONM HLTH,SC-34,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM32281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; BURGER HJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P204, DOI 10.1016/0003-9861(90)90433-Y; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; GIACHELLI CM, 1989, J BIOL CHEM, V264, P7046; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HAYASHI Y, 1992, J BIOL CHEM, V267, P14580; HE JS, 1991, J BIOL CHEM, V266, P7864; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMIECINSKI CJ, 1992, MOL PHARMACOL, V42, P249; OMIECINSKI CJ, 1986, NUCLEIC ACIDS RES, V14, P1525, DOI 10.1093/nar/14.3.1525; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; SUWA Y, 1985, J BIOL CHEM, V260, P7980; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WEN LP, 1989, J BIOL CHEM, V264, P10996; WEN LP, 1987, J BIOL CHEM, V262, P6676	24	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21722	21726						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408026				2022-12-25	WOS:A1993MC80900047
J	SCHMIDT, JV; CARVER, LA; BRADFIELD, CA				SCHMIDT, JV; CARVER, LA; BRADFIELD, CA			MOLECULAR CHARACTERIZATION OF THE MURINE AHR GENE - ORGANIZATION, PROMOTER ANALYSIS, AND CHROMOSOMAL ASSIGNMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; SINGLE-MINDED GENE; ALPHA-SUBUNIT GENE; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; MESSENGER-RNA; DNA-BINDING; EXPRESSION; RECEPTOR; DROSOPHILA	The AH receptor is a ligand-activated transcription factor that mediates the biological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin. The AH receptor has primary sequence homology to its dimerization partner the AH receptor nuclear translocator, and to the Drosophila proteins Sim and Per. Characterization of the gene encoding the murine AH receptor (Ahr gene) reveals that its structural organization is also conserved with respect to the sim gene, since 6 of 11 Ahr exons are spliced at homologous sites. Interestingly, little splicing homology was observed between the Ahr and per genes. The promoter of the Ahr gene is GC-rich and contains no TATA or CCAAT boxes; however, sequence analysis has shown several binding sites for the transcription factor Sp1 (GC boxes). Additionally we have identified a potential cAMP response element, AP-1 and E box sites, and two elements demonstrated in other genes to confer placenta-specific expression. Using a restriction fragment length polymorphism in exon 7 and recombinant inbred mouse lines, the Ahr gene was found to be concordant with the phenotypically defined Ahr locus, supporting the identity of these two genetic elements.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005703, R37ES005703, R29ES005703] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09560] Funding Source: Medline; NIEHS NIH HHS [ES-05703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COBB RR, 1987, BIOCHEM GENET, V25, P401, DOI 10.1007/BF00554549; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DOLWICK KM, 1993, IN PRESS P NATL ACAD; EISEN HJ, 1983, BIOCHEM ACTION HORM, V10, P227; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EPPIG JT, 1993, MOUSE GENOME, V91, P8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOD Y, 1992, BIOTECHNIQUES, V13, P852; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEGRAVEREND C, 1984, GENETICS, V107, P447; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; NEBERT DW, 1969, ARCH BIOCHEM BIOPHYS, V134, P76, DOI 10.1016/0003-9861(69)90253-7; POLAND A, 1975, MOL PHARMACOL, V11, P389; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1987, MOL PHARMACOL, V32, P471; POLAND AP, 1974, J BIOL CHEM, V249, P5599; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIDA MM, 1992, P NATL ACAD SCI USA, V89, P3864, DOI 10.1073/pnas.89.9.3864; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAYLOR BA, 1976, GENETICS, V83, P373; WOOD AW, 1979, J BIOL CHEM, V254, P5647; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	46	122	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22203	22209						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408082				2022-12-25	WOS:A1993MC80900113
J	SHELLY, LL; LEI, KJ; PAN, CJ; SAKATA, SF; RUPPERT, S; SCHUTZ, G; CHOU, JY				SHELLY, LL; LEI, KJ; PAN, CJ; SAKATA, SF; RUPPERT, S; SCHUTZ, G; CHOU, JY			ISOLATION OF THE GENE FOR MURINE GLUCOSE-6-PHOSPHATASE, THE ENZYME-DEFICIENT IN GLYCOGEN-STORAGE-DISEASE TYPE-1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEPATIC-MICROSOMAL GLUCOSE-6-PHOSPHATASE; MULTIFUNCTIONAL GLUCOSE-6-PHOSPHATASE; SYSTEM; LIVER; IDENTIFICATION; PROTEINS	Glycogen storage disease (GSD) type 1a (von Gierke disease) is caused by a deficiency in glucose-6-phosphatase, the key enzyme in glucose homeostasis catalyzing the terminal step in gluconeogenesis and glycogenolysis. Despite its clinical importance, this membrane-bound enzyme has eluded molecular characterization. Here we report the cloning and characterization of a murine glucose-6-phosphatase cDNA by screening a mouse liver cDNA library differentially with mRNA populations representing the normal and the albino deletion mouse known to express markedly reduced glucose-6-phosphatase activity. Additionally, we identified the gene that consists of 5 exons. Biochemical analyses indicate that the in vitro expressed enzyme is indistinguishable from mouse liver microsomal glucose-6-phosphatase exhibiting essentially identical kinetic constants, latency, thermal lability, and vanadate sensitivity. The characterization of the murine glucose-6-phosphatase gene opens the way for studying the molecular basis of GSD type 1a in humans and its etiology in an animal model.	NICHHD, HUMAN GENET BRANCH, BLDG 10, RM 95242, BETHESDA, MD 20892 USA; GERMAN CANC RES CTR, INST CELL & TUMOR BIOL, W-6900 HEIDELBERG, GERMANY	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Helmholtz Association; German Cancer Research Center (DKFZ)								ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1972, J BIOL CHEM, V247, P2558; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BEAUDET AL, 1991, HARRISONS PRINCIPLES, P1854; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HERS H. G., 1964, ADVAN METAB DISORDERS, V1, P1; Hers HG, 1989, METABOLIC BASIS INHE, P425; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JORGENSON RA, 1980, J BIOL CHEM, V255, P5907; KRAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; NORDLIE RC, 1983, J BIOL CHEM, V258, P9739; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; SPETH M, 1992, EUR J BIOCHEM, V208, P643, DOI 10.1111/j.1432-1033.1992.tb17230.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	29	137	142	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21482	21485						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407995				2022-12-25	WOS:A1993MC80900008
J	BREITTMAYER, JP; PELASSY, C; COUSIN, JL; BERNARD, A; AUSSEL, C				BREITTMAYER, JP; PELASSY, C; COUSIN, JL; BERNARD, A; AUSSEL, C			THE INHIBITION BY FATTY-ACIDS OF RECEPTOR-MEDIATED CALCIUM MOVEMENTS IN JURKAT T-CELLS IS DUE TO INCREASED CALCIUM EXTRUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CA-2+; THAPSIGARGIN; LYMPHOCYTES; POOL	Numerous studies on the molecular basis of the mechanism of action of fatty acids have demonstrated their action in cell signaling and particularly on the regulation of cytosolic Ca2+ concentration. Stimulation of Jurkat T cells with CD3 monoclonal antibody results in an increase of intracellular calcium concentration, [Ca2+]i due both to a release of Ca2+ from intracellular stores and a Ca2+ influx. [Ca2+]i increase represents a dynamic balance between Ca2+ influx and efflux. Fatty acids, either saturated (C14:0), monounsaturated (C16:1), or polyunsaturated, belonging to the C18 and the C20 series induce a marked decrease of CD3-induced [Ca2+]i rise. This property of fatty acid is independent of the position of the carbon-carbon double bond but specific of the cis stereoisomeric form. Fatty acids does not block CD3-induced signals but greatly stimulates the Ca2+ extrusion process probably by activating the plasma membrane Ca2+-ATPase. This was documented by the observation that fatty acids, reduced to the same extent as [Ca2+]i, elicited either with CD3 monoclonal antibody the calcium ionophore ionomycin or the Ca2+-ATPase inhibitor thapsigargin.	FAC MED NICE,INSERM,U343,F-06107 NICE,FRANCE; FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur								BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITTMAYER JP, 1993, IN PRESS CELL IMMUNO; BROWN RE, 1983, J IMMUNOL, V131, P1011; CHOW SC, 1990, BIOCHEM J, V267, P727, DOI 10.1042/bj2670727; CHOW SC, 1990, J BIOL CHEM, V265, P902; CHOW SC, 1989, LIPIDS, V24, P700, DOI 10.1007/BF02535207; CZARNY M, 1992, BIOCHEM BIOPH RES CO, V186, P1582, DOI 10.1016/S0006-291X(05)81588-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; MASON MJ, 1991, J BIOL CHEM, V266, P20856; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; NORDSTROM T, 1991, CELL CALCIUM, V12, P449, DOI 10.1016/0143-4160(91)90027-C; PELASSY C, 1992, BIOCHEM J, V288, P785, DOI 10.1042/bj2880785; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; SPECTOR A A, 1978, P229; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; YANG MCW, 1989, IMMUNOLOGY, V68, P181	17	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20812	20817						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407910				2022-12-25	WOS:A1993MA28800029
J	CLOSS, EI; LYONS, CR; KELLY, C; CUNNINGHAM, JM				CLOSS, EI; LYONS, CR; KELLY, C; CUNNINGHAM, JM			CHARACTERIZATION OF THE 3RD MEMBER OF THE MCAT FAMILY OF CATIONIC AMINO-ACID TRANSPORTERS - IDENTIFICATION OF A DOMAIN THAT DETERMINES THE TRANSPORT-PROPERTIES OF THE MCAT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; GLUCOSE TRANSPORTER; CELLS; MEMBRANE; GENE	We have identified the third member of a family of cationic amino acid transporters in lipopolysaccharide-stimulated murine macrophages. The deduced amino acid sequence of this transporter is the same as MCAT-2 (mouse cationic amino acid transporter-2), the low affinity transporter expressed in hepatocytes, except for a stretch of 41 amino acids that connects the eighth and ninth membrane-spanning domains. These transporters apparently result from differential splicing of transcripts from a single gene and therefore have been named MCAT-2A (hepatocyte) and MCAT-2B (macrophage). Despite their similarity, MCAT-2B is saturated at one-fifth the arginine concentration, has a lower apparent V(max), and is more sensitive to trans-stimulation than MCAT-2A. Introduction of the unique regions of MCAT-2A and MCAT-2B into the equivalent portion of the related protein, MCAT-1, created chimeric transporters with properties most like the donor of this region. Our findings suggest these 41 amino acids contain a domain that binds the amino acid substrate during its translocation across the membrane.	BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST,RM 925,THORN BLDG, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289	NATIONAL CANCER INSTITUTE [R29CA047075] Funding Source: NIH RePORTER; NCI NIH HHS [CA47075] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1982, J BIOL CHEM, V257, P69	12	150	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20796	20800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407907				2022-12-25	WOS:A1993MA28800026
J	GORBEA, CM; MARCHAND, P; JIANG, WP; COPELAND, NG; GILBERT, DJ; JENKINS, NA; BOND, JS				GORBEA, CM; MARCHAND, P; JIANG, WP; COPELAND, NG; GILBERT, DJ; JENKINS, NA; BOND, JS			CLONING, EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF THE MOUSE MEPRIN BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-LINKAGE MAP; KIDNEY; SEQUENCES; DNA; METALLOENDOPEPTIDASES; ASTACIN; REVEALS; PROTEIN; ENZYME; ALPHA	Meprins are plasma membrane homo- or hetero-oligomeric metalloendopeptidases that contain glycosylated alpha and/or beta subunits. This paper reports the cloning and sequencing of the mouse kidney beta subunit. The primary translation product is composed of 704 amino acids which includes a transient signal sequence of 20 amino acids at the NH2 terminus. The protease domain (Asn-63 to Leu-260) contains the putative zinc-binding motif characteristic of metalloendopeptidases of the ''astacin family.'' The COOH terminus contains an epidermal growth factor-like domain, a potential membrane-spanning domain, and an additional 26 amino acids. The beta subunit has an overall 42% identity to the alpha subunit, however, a 56-amino acid segment near the COOH terminus of alpha is missing in beta, and the putative transmembrane and cytoplasmic domains of the subunits share no significant sequence similarity. NH2-terminal analyses of detergent-solubilized mature forms revealed that, unlike alpha, the prosequence (Leu-21 to Lys-62) is not removed from the beta subunit. Northern blot analysis revealed a 2.5-kilobase message for the beta subunit in the kidney and intestine of C57BL/6 and C3H/He mice. The gene for the beta subunit was localized to mouse chromosome 18. These studies indicate that alpha and beta probably derived from a common ancestral gene, but have evolved so that their genes are on two different chromosomes, and their tissue-specific expression and post-translational processing differ.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT BIOL CHEM,HERSHEY,PA 17033; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ADV BIOSCI LABS INC,BASIC RES PROGRAM,FREDERICK,MD 21702	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Gorbea, Carlos/L-4406-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019691, R37DK019691, R56DK019691] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1990, PROSITE DICT PROTEIN; BEYNON RJ, 1983, SCIENCE, V219, P1351, DOI 10.1126/science.6338590; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUDRY Y, 1991, BIOCHEM J, V280, P57, DOI 10.1042/bj2800057; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; Green EL, 1981, GENETICS PROBABILITY, P77; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JIANG W, 1992, FEBS LETT, V321, P110; JIANG WP, 1993, J BIOL CHEM, V268, P10380; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENNY AJ, 1987, BIOCHEM J, V245, P525; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MAUXION F, 1989, IMMUNOGENETICS, V29, P397, DOI 10.1007/BF00375868; MIYATANI S, 1992, P NATL ACAD SCI USA, V89, P8443, DOI 10.1073/pnas.89.18.8443; RECKELHOFF JF, 1985, IMMUNOGENETICS, V22, P617, DOI 10.1007/BF00430310; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOLZ RL, 1991, BIOCHEMISTRY-US, V30, P8488, DOI 10.1021/bi00098a029; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3	34	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21035	21043						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407940				2022-12-25	WOS:A1993MA28800062
J	LEWENDON, A; SHAW, WV				LEWENDON, A; SHAW, WV			TRANSITION-STATE STABILIZATION BY CHLORAMPHENICOL ACETYLTRANSFERASE - ROLE OF A WATER MOLECULE BOUND TO THREONINE-174	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; X-RAY; MUTAGENESIS; RESOLUTION; MECHANISM; BINDING	The structure of the type III variant of chloramphenicol acetyltransferase reveals that Thr-174, a conserved residue, is hydrogen-bonded to a bound water molecule (water 252). Modeling studies (P. C. E. Moody and A. G. W. Leslie, unpublished data) suggested that water 252 could play a part in transition state stabilization via a hydrogen bond to the oxyanion of the putative tetrahedral intermediate. In addition, water 252 is one of three bound water molecules hydrogen-bonded to the 1-hydroxyl group of chloramphenicol in the chloramphenicol acetyltransferase-chloramphenicol binary complex. A combination of site-directed mutagenesis and the use of an alternative substrate has allowed the quantitation of the energetic contribution of each of the interactions made by water 252 to catalysis. Thr-174 was replaced by alanine, valine, and isoleucine, each substitution removing the hydroxyl group hydrogen-bonded to water 252. Steady-state kinetic analysis of the mutant enzymes was carried out using both chloramphenicol and 1-deoxy-chloramphenicol as acetyl acceptors. The substitutions at Thr-174 result in a fall in k(cat) and in decreased affinities for each acetyl acceptor in the binary complexes and also in the ternary complexes with acetyl-CoA. From the calculated free energies in the transition state, the hydrogen bond between water 252 and the oxyanion of the tetrahedral intermediate can be estimated to contribute 0.9 kcal mol-1 toward transition state stabilization, whereas the free energy of the hydrogen bonds between the 1-hydroxyl of chloramphenicol and three bound water molecules provides 1.6 kcal mol-1.	UNIV LEICESTER,DEPT BIOCHEM,UNIV RD,LEICESTER LE1 7RH,ENGLAND	University of Leicester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; ELLIS J, 1991, BIOCHEMISTRY-US, V30, P10806, DOI 10.1021/bi00108a029; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; HARDING SE, 1987, BIOCHEM SOC T, V15, P513; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KLEANTHOUS C, 1984, BIOCHEM J, V223, P211, DOI 10.1042/bj2230211; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LESLIE AGW, 1986, J MOL BIOL, V188, P283, DOI 10.1016/0022-2836(86)90310-4; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1988, BIOCHEMISTRY-US, V27, P7385, DOI 10.1021/bi00419a032; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURRAY IA, 1991, BIOCHEMISTRY-US, V30, P3763, DOI 10.1021/bi00229a025; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; QUICHO FA, 1989, NATURE, V340, P404; Shaw W V, 1975, Methods Enzymol, V43, P737; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522	21	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20997	21001						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407936				2022-12-25	WOS:A1993MA28800056
J	MIRZA, AM; SHEEHAN, JP; HARDY, LW; GLICKMAN, RL; IORIO, RM				MIRZA, AM; SHEEHAN, JP; HARDY, LW; GLICKMAN, RL; IORIO, RM			STRUCTURE AND FUNCTION OF A MEMBRANE ANCHOR-LESS FORM OF THE HEMAGGLUTININ-NEURAMINIDASE GLYCOPROTEIN OF NEWCASTLE-DISEASE VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; HN GLYCOPROTEIN; ANTIGENIC SITES; SENDAI VIRUS; PROTEIN; IDENTIFICATION; PARAMYXOVIRUS; SEQUENCE; FUSION; ENVELOPE	The hemagglutinin-neuraminidase (HN) glycoprotein of paramyxoviruses is anchored in the virion membrane near its amino terminus, protruding from the virion surface to mediate attachment to cellular receptors. Solubilization of HN spikes can be achieved by treatment of virions with detergent and high salt concentrations. When the solubilized HN protein from the Australia-Victoria (AV) isolate of the virus is incubated at 37-degrees-C, a chymotrypsin-sensitive site between residues 112 and 113 is exposed. A chymotrypsin-cleaved soluble form of the protein, named CT-HN, has been prepared using this approach. It is membrane anchor-less, due to removal of a 14-kDa fragment from the NH2 terminus of HN. It retains all potential glycosylation sites and cysteines present in the ectodomain of the native protein. It migrates in nonreducing gels and sediments in sucrose gradients at the rate expected for homodimeric HN. The latter is also consistent with our demonstration by site-directed mutagenesis that cysteine residues at positions 6 and 123, respectively, mediate disulfide-linked homotetramer and homodimer formation. CT-HN retains almost total antigenicity, suggesting that it is conformationally very similar to the intact molecule, as well as receptor recognition function and, at low pH, neuraminidase activity. It should prove to be a useful tool for further studies of the structure and function of this important viral glycoprotein.	UNIV MASSACHUSETTS,SCH MED,DEPT MOLEC GENET & MICROBIOL,55 LAKE AVE N,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024770, R01AI124770, R01AI012467, R01AI024770, R21AI024770] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12467, AI-24770] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMINOF D, 1961, BIOCHEM J, V81, P3384; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; GOTOH B, 1988, VIROLOGY, V163, P174, DOI 10.1016/0042-6822(88)90244-9; IORIO RM, 1989, VIRUS RES, V13, P245, DOI 10.1016/0168-1702(89)90019-1; IORIO RM, 1989, VIROLOGY, V173, P196, DOI 10.1016/0042-6822(89)90235-3; IORIO RM, 1984, J IMMUNOL, V133, P2215; IORIO RM, 1991, J VIROL, V65, P4999, DOI 10.1128/JVI.65.9.4999-5006.1991; IORIO RM, 1992, J GEN VIROL, V73, P1167, DOI 10.1099/0022-1317-73-5-1167; IORIO RM, 1986, J GEN VIROL, V67, P1393, DOI 10.1099/0022-1317-67-7-1393; IORIO RM, 1992, J VIROL, V66, P6626, DOI 10.1128/JVI.66.11.6626-6633.1992; IORIO RM, 1983, J VIROL, V48, P440, DOI 10.1128/JVI.48.2.440-450.1983; KINGSBURY DW, 1978, INTERVIROLOGY, V10, P137, DOI 10.1159/000148979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1980, J VIROL, V33, P152, DOI 10.1128/JVI.33.1.152-166.1980; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGINNES LW, 1987, VIRUS RES, V7, P187, DOI 10.1016/0168-1702(87)90027-X; MOORE NF, 1974, J GEN VIROL, V25, P275, DOI 10.1099/0022-1317-25-2-275; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; SAKAGUCHI T, 1989, VIROLOGY, V169, P260, DOI 10.1016/0042-6822(89)90151-7; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SCHEID A, 1973, J VIROL, V11, P263, DOI 10.1128/JVI.11.2.263-271.1973; Scheid A., 1978, NEGATIVE STRAND VIRU, P181; SCHUY W, 1984, VIRUS RES, V1, P415, DOI 10.1016/0168-1702(84)90027-3; SHEEHAN JP, 1992, VIROLOGY, V189, P778, DOI 10.1016/0042-6822(92)90605-O; SHEEHAN JP, 1987, VIROLOGY, V161, P603, DOI 10.1016/0042-6822(87)90158-9; SMITH GW, 1981, J VIROL, V37, P256, DOI 10.1128/JVI.37.1.256-267.1981; TAKIMOTO T, 1992, J VIROL, V66, P7597, DOI 10.1128/JVI.66.12.7597-7600.1992; THOMPSON SD, 1988, J VIROL, V62, P4653, DOI 10.1128/JVI.62.12.4653-4660.1988; YUSOFF K, 1988, VIRUS RES, V11, P319, DOI 10.1016/0168-1702(88)90005-6	31	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21425	21431						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407985				2022-12-25	WOS:A1993MA28800113
J	NEDDERMANN, P; JIRICNY, J				NEDDERMANN, P; JIRICNY, J			THE PURIFICATION OF A MISMATCH-SPECIFIC THYMINE-DNA GLYCOSYLASE FROM HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXTRACTS; G.T MISPAIRS; REPAIR; PROTEIN; 5-METHYLCYTOSINE; DIFFERENTIATION; POLYMERASE; RESIDUES; ENZYMES; LINES	G/T mispairs that arise in the DNA of higher eukaryotes as a result of spontaneous hydrolytic deamination of 5-methylcytosine to thymine must be corrected to G/C pairs. We describe here the purification to apparent homogeneity of the enzyme that initiates this repair process by excising the mispaired thymine from the heteroduplex to generate an apyrimidinic site. The enzymatic activity could be attributed to a 55-kDa polypeptide, which was purified from extracts of HeLa cells by a combination of conventional and DNA-affinity chromatography. The enzyme is a mismatch-specific thymine-DNA N-glycosylase, capable of hydrolyzing the carbon-nitrogen bond between the sugar-phosphate backbone of the DNA and a mispaired thymine. In addition to the G/T, the enzyme can remove thymine also from C/T and T/T mispairs in the order G/T >> C/T > T/T. It has no detectable endonucleolytic activity on apyrimidinic sites and does not catalyze the removal of thymine from A/T pairs or from single-stranded DNA.	IST RICH BIOL MOLEC P ANGELETTI,DEPT BIOCHEM,VIA PONTINA KM 30600,I-00040 POMEZIA,ITALY									AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BIRD AP, 1979, CELL, V17, P889, DOI 10.1016/0092-8674(79)90329-5; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P6579, DOI 10.1093/nar/14.16.6579; JIRICNY J, 1991, NUCLEIC ACIDS MOL BI, P72; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JOST JP, 1993, DNA METHYLATION MOL; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Ullah Sibghat, 1993, Nucleic Acids Research, V21, P1281; WEISS B, 1987, ADV ENZYMOL, P1; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; YEH YC, 1991, J BIOL CHEM, V266, P6480	31	185	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21218	21224						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407958				2022-12-25	WOS:A1993MA28800085
J	RICHARDSON, JM; PESSIN, JE				RICHARDSON, JM; PESSIN, JE			IDENTIFICATION OF A SKELETAL MUSCLE-SPECIFIC REGULATORY DOMAIN IN THE RAT GLUT4 MUSCLE-FAT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; THYROID-HORMONE; MESSENGER-RNA; CARDIAC ACTIN; DIFFERENTIAL EXPRESSION; BINDING-PROTEIN; INSULIN; ELEMENTS; SEQUENCE; ENHANCER	To identify sequences responsible for the muscle-specific expression of the rat GLUT4/muscle-fat gene, we examined the transcriptional regulation of this gene in the differentiating murine C2C12 skeletal muscle cell line. Differentiated myofibers displayed a 4-5-fold increase in GLUT4 mRNA compared with undifferentiated myoblasts which paralleled the conversion from non-muscle beta-actin mRNA to muscle-specific alpha-actin mRNA expression. Transient transfection of progressive 5' and 3' deletions of the GLUT4 5'-flanking DNA identified a 281-base pair region located between -517 and -237 relative to the transcription start site which conferred myotube-specific expression. This region increased reporter activity in the context of the GLUT4 minimal promoter in an orientation-independent manner and, in addition, onto the heterologous thymidine kinase promoter. Myotube-specific expression of both GLUT4 reporter constructs and the endogenous mouse GLUT4 mRNA was also observed to be thyroid hormone-dependent. Further, cotransfection of reporter constructs containing the 281-base pair GLUT4 differentiation-specific enhancer with the thyroid hormone receptor specifically increased luciferase activity in myotubes approximately 12-fold. Thus, these data demonstrate the presence of a proximal skeletal muscle-specific activation domain that is necessary for both myotube-specific GLUT4 expression and thyroid hormone responsiveness.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NIDDK NIH HHS [DK01822, DK25925, DK42452] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001822, R01DK042452] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRODIE C, 1990, J NEUROCHEM, V55, P186, DOI 10.1111/j.1471-4159.1990.tb08837.x; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DEVLIN RB, 1979, DEV BIOL, V69, P202, DOI 10.1016/0012-1606(79)90286-0; DIMITRIADIS G, 1985, AM J PHYSIOL, V248, pE593, DOI 10.1152/ajpendo.1985.248.5.E593; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAHAM F, 1973, VIROLOGY, V52, P452; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; HALL CV, 1983, J MOL APPL GENET, V2, P401; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MULLER MJ, 1988, AM J PHYSIOL, V255, pE146, DOI 10.1152/ajpendo.1988.255.2.E146; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINSTEIN SP, 1991, ENDOCRINOLOGY, V129, P455, DOI 10.1210/endo-129-1-455; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	52	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21021	21027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407939				2022-12-25	WOS:A1993MA28800060
J	LIANG, XH; VOLKMANN, M; KLEIN, R; HERMAN, B; LOCKETT, SJ				LIANG, XH; VOLKMANN, M; KLEIN, R; HERMAN, B; LOCKETT, SJ			COLOCALIZATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 AND HUMAN PAPILLOMAVIRUS-E6 PROTEIN IN HUMAN CERVICAL-CARCINOMA CELL-LINES	ONCOGENE			English	Article								The loss of the tumor-suppressor activity of p53, either by mutation or by interaction with the human papillomavirus (HPV) E6 protein, is considered to be an important mechanism in the carcinogenesis of cervical cancer. We have studied the cytological distribution of these proteins in human cervical carcinoma cell lines using polyclonal anti-p53 and monoclonal anti-E6 antibodies. The antibody specificity was confirmed by immunoblot and immunocompetition analyses. The intracellular localization of p53 and E6 was detected using the techniques of conventional and three-dimensional confocal microscopy. In the HPV-18 or -16 integrated cell lines, HeLa, CaSki and SiHa, viral oncoprotein E6 and endogenous tumor-suppressor protein, p53, were observed by immunofluorescence in the cytoplasm; p53 also had a weak punctate staining in the nuclei of HeLa and CaSki cells. In the HPV-negative cervical carcinoma cell lines, C-33A and HT-3, which have mutated p53, p53 was localized predominantly to the nucleus, with C-33A cells having elevated levels of p53 compared with the other cell lines. High spatial resolution imaging, using confocal microscopy, was performed on the cells after double fluorescence staining for p53 (fluorescein) and E6 (rhodamine). The images showed that both p53 and E6 had similar cytoplasmic distributions, which implied that these two proteins may exist as a cytoplasmic complex. To substantiate this implication, fluorescence resonance energy transfer microscopy was performed, which provided direct evidence of a close association between p53 and E6 within individual HeLa cells. The results from this study support the theory that p53 protein binds HPV-16/18 E6 protein in the cell cytoplasm, thus preventing p53 from exerting its tumor-suppressor function in the nucleus. Hence, inactivation of wild-type p53 by p53-E6 complex formation in cervical cancer may be a critical step in malignant transformation.	GERMAN CANC RES CTR, W-6900 HEIDELBERG, GERMANY; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC RES CTR, CHAPEL HILL, NC 27599 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of North Carolina; University of North Carolina Chapel Hill	LIANG, XH (corresponding author), UNIV N CAROLINA, DEPT CELL BIOL & ANAT, CELL BIOL LABS, 22 TAYLOR HALL, CB 7090, CHAPEL HILL, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R37CA051323, R01CA051323] Funding Source: NIH RePORTER; NCI NIH HHS [CA51323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN TM, 1992, ONCOGENE, V7, P1541; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; DEVILLIERS EM, 1992, GENITOURIN MED, V68, P50; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GUIOT MCP, 1989, CANCER CEL, V7, P193; HAUSEN HZ, 1982, LANCET, V2, P1370; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOCKETT SJ, 1991, ANAL QUANT CYTOL, V13, P27; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIOU G, 1990, LANCET, V335, P1171; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	41	73	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2645	2652						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397367				2022-12-25	WOS:A1993LX34300005
J	HANISSIAN, SH; FRANGAKIS, M; BLAND, MM; JAWAHAR, S; CHATILA, TA				HANISSIAN, SH; FRANGAKIS, M; BLAND, MM; JAWAHAR, S; CHATILA, TA			EXPRESSION OF A CA(2+) CALMODULIN-DEPENDENT PROTEIN-KINASE, CAM KINASE-GR, IN HUMAN T-LYMPHOCYTES - REGULATION OF KINASE-ACTIVITY BY T-CELL RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ CALMODULIN; DIFFERENTIAL EXPRESSION; BINDING PROTEIN; AUTOPHOSPHORYLATION; PHOSPHORYLATION; ACTIVATION; CALCINEURIN; CALCIUM; IDENTIFICATION; GENE	Ca2+/calmodulin-dependent protein kinase type Gr (CaM kinase-Gr) is a Ca2+/calmodulin-dependent protein kinase which is enriched in the brain and thymus. In this study, we examined the expression of CaM kinase-Gr in human lymphocytes and the regulation of its catalytic activity by antigen receptor signaling. CaM kinase-Gr was found selectively expressed in T lymphocytes in a developmentally regulated manner. It was present at severalfold higher levels in immature thymocytes (CD3low, CD4+CD8+) relative to mature thymocytes (CD3high, CD4+CD8-/CD8+CD4-) or to circulating T lymphocytes. The kinase was preferentially expressed in CD4+ T lymphocytes, but was not detected in B lymphocytes or in monocytes. The impact of T cell antigen receptor-CD3 complex (TCR.CD3) signaling on kinase activity was examined using Jurkat human leukemic T lymphocytes as a model. Treatment of Jurkat cells with anti TCR-CD3 monoclonal antibody induced rapid autophosphorylation of the kinase on serine residues and a dramatic, autophosphorylation-dependent enhancement of both Ca2+/calmodulin-dependent and autonomous kinase activity. Enzyme autophosphorylation and activation were dependent on the influx of extracellular Ca2+ following receptor signaling but could not be induced by an influx of extracellular Ca2+ triggered by ionophores, indicating that additional signals delivered via TCR.CD3 contribute to the activation of CaM kinase-Gr. These findings suggest a role for CaM kinase-Gr in T lymphocyte development and activation and indicate the presence of stringent regulatory mechanisms governing the activity of this kinase in situ.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; WELLCOME RES LABS,RES TRIANGLE PK,NC 27709	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Wellcome Research Laboratories				Chatila, Talal/0000-0001-7439-2762				ALRAYES H, 1992, J ALLERGY CLIN IMMUN, V90, P630, DOI 10.1016/0091-6749(92)90136-P; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FISHER CL, 1991, J IMMUNOL, V146, P1743; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; JACOBS S, 1986, J BIOL CHEM, V261, P934; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P4050, DOI 10.1073/pnas.88.9.4050; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOURAD W, 1989, J EXP MED, V170, P2011, DOI 10.1084/jem.170.6.2011; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OHTA Y, 1988, J BIOL CHEM, V263, P11540; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ONO T, 1989, J BIOL CHEM, V264, P2081; PATTON BL, 1990, J BIOL CHEM, V265, P11204; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SANCHO J, 1992, J IMMUNOL, V148, P1315; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SPERTINI F, 1992, J IMMUNOL, V148, P2045	35	89	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20055	20063						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397199				2022-12-25	WOS:A1993LY01900023
J	TOUHARA, K; PRESTWICH, GD				TOUHARA, K; PRESTWICH, GD			JUVENILE-HORMONE EPOXIDE HYDROLASE - PHOTOAFFINITY-LABELING, PURIFICATION, AND CHARACTERIZATION FROM TOBACCO HORNWORM EGGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BINDING-PROTEINS; PARTITION ASSAY; MANDUCA-SEXTA; JH-I; ESTERASE; HYDRASE; DROSOPHILA; METABOLISM; HEMOLYMPH	Juvenile hormone epoxide hydrolase (JHEH), which may play a pivotal role in regulating insect juvenile hormone (JH) titer along with JH esterase, was identified in tobacco hornworm (Manduca sexta) eggs by using photoaffinity analogs of JHs. The UV light-induced covalent labeling with [H-3]epoxyhomofarnesyl diazoacetate, a JHII analog, revealed a membrane-associated 50-kDa protein that was selectively and specifically labeled. This 50-kDa protein was copurified 171-fold with the JHEH activity to homogeneity through DEAE-Sephacel, Mono Q, and hydroxylapatite columns, which led us to conclude that the labeled 50-kDa protein was a JHEH. The steady-state kinetics of the purified microsomal JHEH showed that it followed Michaelis-Menten kinetics with K(m) values of 0.61, 0.55, and 0.28 muM for JHI, II, and III, respectively, and that JHIII showed a significantly higher V(max) than JHI or JHII. JH acid was also converted to the corresponding diol at a rate 4-fold slower than the corresponding JH. Thus, the differences in the binding of substrate and the rate of turnover by JHEH were affected by the epoxyfarnesoate ester moiety of JH and the difference between the cis-11-methyl group of JHIII versus the cis-11-ethyl group of JHI and II. Purified JHEH showed optimal enzyme activity at pH 7.5-8.5. Interestingly, the presence of recombinant M. sexta JH binding protein (JHBP) dramatically decreased the degradation of JH by JHEH in vitro. Since the cytosolic JHBP in eggs closely resembles the hemolymph JHBP, we suggest that cytosolic JHBP may play a role in protecting JHs from JHEH in vivo. Furthermore, JHEH may play a significant role in the secondary metabolism of JH acid generated by JH esterase.			TOUHARA, K (corresponding author), SUNY, DEPT CHEM, STONY BROOK, NY 11794 USA.							ABDELAAL YAI, 1988, INSECT BIOCHEM, V18, P743, DOI 10.1016/0020-1790(88)90084-4; Bergot B. J., 1981, JUVENILE HORMONE BIO, P33; BROOKS GT, 1977, GEN PHARMACOL, V8, P221, DOI 10.1016/0306-3623(77)90016-7; CASAS J, 1991, INSECT BIOCHEM, V21, P17, DOI 10.1016/0020-1790(91)90060-R; DUBOIS GC, 1978, J BIOL CHEM, V253, P2932; Goodman W., 1976, The juvenile hormones., P75; GOODMAN WG, 1985, COMPREHENSIVE INSECT, V7, P491; GUENGERICH FP, 1982, REV BIOCHEM TOXICOL, V4, P5; Hammock B.D., 1980, MOL BASIS ENV TOXICI, P229; HAMMOCK BD, 1990, NATURE, V344, P458, DOI 10.1038/344458a0; HAMMOCK BD, 1985, METHOD ENZYMOL, V111, P487; HAMMOCK BD, 1985, COMPREHENSIVE INSECT, V7, P431; HARSHMAN LG, 1991, INSECT BIOCHEM, V21, P887, DOI 10.1016/0020-1790(91)90095-V; HEINEMANN FS, 1984, J BIOL CHEM, V259, P797; ILENCHUK TT, 1987, INSECT BIOCHEM, V17, P1085, DOI 10.1016/0020-1790(87)90125-9; IVIE GW, 1980, MUTAT RES, V79, P73; JESUDASON P, 1992, ARCH INSECT BIOCHEM, V20, P87, DOI 10.1002/arch.940200202; Koeppe J.K., 1985, P165; KRAMER KJ, 1974, P NATL ACAD SCI USA, V71, P493, DOI 10.1073/pnas.71.2.493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU AYH, 1980, ANNU REV PHARMACOL, V20, P513, DOI 10.1146/annurev.pa.20.040180.002501; LU AYH, 1977, J BIOL CHEM, V252, P3715; MOHAMED MA, 1989, ANAL BIOCHEM, V177, P287, DOI 10.1016/0003-2697(89)90053-5; MULLIN CA, 1980, INSECT BIOCHEM, V10, P681, DOI 10.1016/0020-1790(80)90058-X; MUMBY SM, 1979, ANAL BIOCHEM, V92, P16, DOI 10.1016/0003-2697(79)90619-5; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; PALLI SR, 1990, P NATL ACAD SCI USA, V87, P796, DOI 10.1073/pnas.87.2.796; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; PRESTWICH GD, 1985, P NATL ACAD SCI USA, V82, P1663, DOI 10.1073/pnas.82.6.1663; PRESTWICH GD, 1987, INSECT BIOCHEM, V17, P551, DOI 10.1016/0020-1790(87)90054-0; PRESTWICH GD, 1985, P NATL ACAD SCI USA, V82, P5290, DOI 10.1073/pnas.82.16.5290; PRESTWICH GD, 1987, SCIENCE, V237, P999, DOI 10.1126/science.3616631; PRESTWICH GD, 1991, INSECT BIOCHEM, V21, P27, DOI 10.1016/0020-1790(91)90061-I; PRESTWICH GD, 1992, INSECT JUVENILE HORM, V5, P247; RIDDIFORD LM, 1986, ARCH INSECT BIOCHEM, P75, DOI 10.1002/arch.940030709; ROE RM, 1990, MORPHOGENETIC HORMON, V1, P126; SANBURG LL, 1975, NATURE, V253, P266, DOI 10.1038/253266a0; Schooley D.A., 1984, P373; SHARE MR, 1988, ARCH INSECT BIOCHEM, V8, P173, DOI 10.1002/arch.940080304; SHARE MR, 1988, ANAL BIOCHEM, V169, P81, DOI 10.1016/0003-2697(88)90257-6; TOUHARA K, 1993, BIOCHEMISTRY-US, V32, P2068, DOI 10.1021/bi00059a026; TOUHARAK, 1992, BIOCHEM BIOPH RES CO, V182, P466; UJVARY I, 1990, J LABELLED COMPD RAD, V28, P65, DOI 10.1002/jlcr.2580280108; WISNIEWSKI JR, 1986, INSECT BIOCHEM, V16, P843, DOI 10.1016/0020-1790(86)90122-8; YAMAMOTO K, 1988, SCIENCE, V239, P916, DOI 10.1126/science.3124270	45	69	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19604	19609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396141				2022-12-25	WOS:A1993LW81900071
J	BOUHSS, A; KRIN, E; MUNIER, H; GILLES, AM; DANCHIN, A; GLASER, P; BARZU, O				BOUHSS, A; KRIN, E; MUNIER, H; GILLES, AM; DANCHIN, A; GLASER, P; BARZU, O			COOPERATIVE PHENOMENA IN BINDING AND ACTIVATION OF BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE BY CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SKELETAL-MUSCLE; ESCHERICHIA-COLI; CONFORMATIONAL CHANGE; PHOSPHORYLASE-KINASE; DOMAIN; IDENTIFICATION; PROTEINS; SEQUENCE; CONTAINS	The catalytic domain of Bordetella pertussis adenylate cyclase located within the first 400 amino acids of the protein can be cleaved by trypsin in two subdomains (T25 and T18) corresponding to ATP-(T25) and calmodulin (CaM)-(T18) binding sites. Reassociation of subdomains by CaM is a cooperative process, which is a unique case among CaM-activated enzymes. To understand better the molecular basis of this phenomenon, we used several approaches such as partial deletions of the adenylate cyclase gene, isolation of peptides of various size, and site-directed mutagenesis experiments. We found that a stretch of 72 amino acid residues overlapping the carboxyl terminus of T25 and the amino terminus of T18 accounts for 90% of the binding energy of adenylate cyclase-CaM complex. The hydrophobic ''side'' of the helical region situated around Trp242 plays a major role in the interaction of adenylate cyclase with CaM, whereas basic residues that alternate with acidic residues in bacterial enzyme play a much less important role. The amino-terminal half of the catalytic domain of adenylate cyclase contributes only 10% to the binding energy of CaM, whereas the last 130 amino acid residues are not at all involved in binding. However, these segments of adenylate cyclase might affect protein/protein interaction and catalysis by propagating conformational changes to the CaM-binding sequence which is located in the middle of the catalytic domain of bacterial enzyme.	INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE REGULAT EXPRESS GENET, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Munier-Lehmann, Helene/N-9889-2017; Munier-Lehmann, Hélène/Q-1867-2019; Glaser, Philippe/O-2641-2015	Munier-Lehmann, Helene/0000-0001-7579-8561; Munier-Lehmann, Hélène/0000-0001-7579-8561; Glaser, Philippe/0000-0003-4156-2782; Danchin, Antoine/0000-0002-6350-5001				BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; Gibson TJ, 1984, THESIS CAMBRIDGE U; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; GROSS MK, 1992, P NATL ACAD SCI USA, V89, P4898, DOI 10.1073/pnas.89.11.4898; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KEMP BE, 1987, J BIOL CHEM, V262, P2542; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1988, J BIOL CHEM, V263, P2612; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MUNIER H, 1993, J BIOL CHEM, V268, P1695; MUNIER H, 1991, EUR J BIOCHEM, V196, P469, DOI 10.1111/j.1432-1033.1991.tb15838.x; MUNIER H, 1992, J BIOL CHEM, V267, P9816; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; PRECHEUR B, 1992, BIOCHEMISTRY-US, V31, P229, DOI 10.1021/bi00116a032; PRECHEUR B, 1991, EUR J BIOCHEM, V196, P67; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; White A A, 1974, Methods Enzymol, V38, P41; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	37	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1690	1694						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420945				2022-12-25	WOS:A1993KH62000030
J	CSERMELY, P; KAJTAR, J; HOLLOSI, M; JALSOVSZKY, G; HOLLY, S; KAHN, CR; GERGELY, P; SOTI, C; MIHALY, K; SOMOGYI, J				CSERMELY, P; KAJTAR, J; HOLLOSI, M; JALSOVSZKY, G; HOLLY, S; KAHN, CR; GERGELY, P; SOTI, C; MIHALY, K; SOMOGYI, J			ATP INDUCES A CONFORMATIONAL CHANGE OF THE 90-KDA HEAT-SHOCK PROTEIN (HSP90)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COMPLEXES; AMINO-ACID SEQUENCE; ROUS-SARCOMA VIRUS; SECONDARY STRUCTURE; DNA-REPLICATION; GLUCOCORTICOID RECEPTOR; AUTOPHOSPHORYLATING ACTIVITY; NUCLEOPROTEIN STRUCTURES; TRANSFORMING PROTEINS; DEPENDENT ACTIVATION	The 90-kDa heat shock protein (hsp90) is a well conserved, abundant cytosolic protein believed to be a ''chaperone'' of most steroid receptors. We have recently demonstrated that hsp90 has an ATP-binding site and autophosphorylating activity (Csermely, P., and Kahn, C. R. (1991) J. Biol. Chem. 266, 4943-4950). Circular dichroism analysis of highly purified hsp90 from rat liver shows that ATP induces an increase of beta-pleated sheet content of hsp90. Vanadate, molybdate, and heat treatment at 56-degrees-C induce a similar change in the circular dichroism spectrum. Fourier transformed infrared spectroscopy reveals an ATP-induced increase in the interchain interactions of the 90-kDa heat shock protein due to an increase in its beta-pleated sheet content. In further studies we found that ATP: 1) decreases the tryptophan fluorescence of hsp90 by 11.6 +/- 1.9%; 2) increases the hydrophobic character of the protein as determined by its distribution between an aqueous phase and phenyl-Sepharose; and 3) renders hsp90 less susceptible to tryptic digestion. Our results suggest that hsp90 undergoes an ''open --> closed'' conformational change after the addition of ATP, analogous in many respects to the similar changes of the DnaK protein, the immunoglobulin heavy chain binding protein (BiP/GRP78), and hsp70. The ATP-induced conformational change of hsp90 may be important in regulating its association with steroid receptors and other cellular proteins.	EOTVOS LORAND UNIV, DEPT ORGAN CHEM, H-1518 BUDAPEST, HUNGARY; HUNGARIAN ACAD SCI, CENT RES INST CHEM, H-1525 BUDAPEST, HUNGARY; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Eotvos Lorand University; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	CSERMELY, P (corresponding author), SEMMELWEIS UNIV MED, INST BIOCHEM 1, H-1444 BUDAPEST, HUNGARY.		Sőti, Csaba/O-6070-2017; Kahn, Ronald/AAY-2435-2021; Csermely, Peter/J-2067-2017	Sőti, Csaba/0000-0002-4057-7678; Kahn, Ronald/0000-0002-7583-9228; Csermely, Peter/0000-0001-9234-0659	NIDDK NIH HHS [DK 36836, DK 33201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BINART N, 1989, BIOCHEM BIOPH RES CO, V159, P140, DOI 10.1016/0006-291X(89)92415-7; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CSERMELY P, 1985, BIOCHEM J, V230, P807, DOI 10.1042/bj2300807; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; MOORE SK, 1989, J BIOL CHEM, V264, P5343; MOUDGIL VK, 1980, BIOCHEM J, V190, P799, DOI 10.1042/bj1900799; NECHAY BR, 1986, FASEB J, V45, P123; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANDO JJ, 1979, J BIOL CHEM, V254, P4772; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANETTEN RL, 1974, J AM CHEM SOC, V96, P6782, DOI 10.1021/ja00828a053; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; Woody R. W., 1985, PEPTIDES, V7; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	67	135	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1901	1907						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420964				2022-12-25	WOS:A1993KH62000062
J	KAWALLECK, P; KELLER, H; HAHLBROCK, K; SCHEEL, D; SOMSSICH, IE				KAWALLECK, P; KELLER, H; HAHLBROCK, K; SCHEEL, D; SOMSSICH, IE			A PATHOGEN-RESPONSIVE GENE OF PARSLEY ENCODES TYROSINE DECARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION-CULTURES; GLUTATHIONE-S-TRANSFERASE; NICOTIANA-TABACUM; ESCHERICHIA-COLI; TRYPTOPHAN DECARBOXYLASE; ORNITHINE DECARBOXYLASE; 4-COUMARATE-COA LIGASE; CATHARANTHUS-ROSEUS; DOPA DECARBOXYLASE; ENZYME-ACTIVITIES	A group of recently isolated parsley (Petroselinum crispum) cDNAs representing genes that are transcriptionally activated upon fungal infection or elicitor treatment have been demonstrated to encode tyrosine decarboxylase (TyrDC). The deduced TyrDC protein sequence shares extensive similarity with two functionally related enzymes, tryptophan decarboxylase from periwinkle and dopa decarboxylase from Drosophila melanogaster. Expression of TyrDC cDNA in Escherichia coli yielded catalytically active protein with high substrate specificity for tyrosine. All four identified parsley TyrDC genes have been cloned and encode at least three TyrDC isozymes. Treatment of cultured parsley cells with fungal elicitor caused very rapid and transient increases in TyrDC mRNA and enzyme activity levels.	MAX PLANCK INST ZUCHTUNGSFORSCH,BIOCHEM ABT,W-5000 COLOGNE 30,GERMANY	Max Planck Society			Somssich, Imre/GLT-3738-2022	Somssich, Imre/0000-0003-3066-5794				AYERS AR, 1976, PLANT PHYSIOL, V57, P751, DOI 10.1104/pp.57.5.751; CHAPPLE CCS, 1984, THESIS U GUELPH GUEL; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COHEN E, 1982, PLANT PHYSIOL, V70, P540, DOI 10.1104/pp.70.2.540; DELUCA V, 1989, P NATL ACAD SCI USA, V86, P2582; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGLAS C, 1987, EMBO J, V6, P1189, DOI 10.1002/j.1460-2075.1987.tb02353.x; EVELETH DD, 1986, EMBO J, V5, P2663, DOI 10.1002/j.1460-2075.1986.tb04549.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUGLER K, 1988, EUR J BIOCHEM, V170, P661, DOI 10.1111/j.1432-1033.1988.tb13748.x; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HAHLBROCK K, 1987, INNOVATIVE APPROACHE, P229; JACKSON FR, 1990, J MOL EVOL, V31, P325, DOI 10.1007/BF02101126; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; KELLER H, 1990, THESIS U COLOGNE COL; KNOBLOCH KH, 1981, Z NATURFORSCH C, V36, P40; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; MANECKJEE R, 1983, BIOCHEMISTRY-US, V22, P6058, DOI 10.1021/bi00295a003; Maniatis T., 1982, MOL CLONING; MARQUES IA, 1988, PLANT PHYSIOL, V88, P46, DOI 10.1104/pp.88.1.46; MORGAN BA, 1986, EMBO J, V5; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P6323; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEGREL J, 1987, PHYTOCHEMISTRY, V26, P2185, DOI 10.1016/S0031-9422(00)84681-6; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P2747, DOI 10.1016/0031-9422(84)83008-3; NOE W, 1984, PLANT MOL BIOL, V3, P281, DOI 10.1007/BF00017782; PALAVAN N, 1982, PHYSIOL PLANTARUM, V55, P438, DOI 10.1111/j.1399-3054.1982.tb04524.x; PERDRIZET E, 1981, PHYTOCHEMISTRY, V20, P2131, DOI 10.1016/0031-9422(81)80099-4; RAGG H, 1981, J BIOL CHEM, V256, P61; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMSSICH IE, 1989, PLANT MOL BIOL, V12, P227, DOI 10.1007/BF00020507; TOCHER RD, 1972, PHYTOCHEMISTRY, V11, P1161; ZIMMERMANN A, 1975, ARCH BIOCHEM BIOPHYS, V166, P54, DOI 10.1016/0003-9861(75)90364-1	37	90	97	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2189	2194						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420986				2022-12-25	WOS:A1993KH62000103
J	NAKAMOTO, RK; MAEDA, M; FUTAI, M				NAKAMOTO, RK; MAEDA, M; FUTAI, M			THE GAMMA-SUBUNIT OF THE ESCHERICHIA-COLI ATP SYNTHASE - MUTATIONS IN THE CARBOXYL-TERMINAL REGION RESTORE ENERGY COUPLING TO THE AMINO-TERMINAL MUTANT GAMMA-MET-23-]LYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; FACTOR-I; ADENOSINE-TRIPHOSPHATASE; SPINACH-CHLOROPLASTS; PHOTOPHOSPHORYLATION; ACTIVATION; F1; RECONSTITUTION; MICROSCOPY; SEQUENCE	The gamma subunit mutations, gammaMet-23-->Lys or Arg, in the Escherichia coli ATP synthase were previously reported to cause dramatically inefficient energy coupling between ATPase catalysis and H+ translocation (Shin, K., Nakamoto, R. K., Maeda, M., and Futai, M. (1992) J. Biol. Chem. 267, 20835-20839). In this paper, we report that second-site mutations in the gamma subunit can suppress the effects of gammaMet-23-->Lys. By screening randomly mutagenized uncG (gammaMet-23-->Lys), eight mutations in the carboxyl-terminal region were identified; strains carrying gammaArg-242-->Cys, gammaGln-269-->Arg, gammaAla-270-->Val, gammaIle-272-->Thr, gammaThr-273-->Ser, gammaGlu-278-->Gly, gammaIle-279-->Thr, or gammaVal-280-->Ala in combination with gammaMet-23-->Lys were able to grow by oxidative phosphorylation. H+ pumping assayed in membranes prepared from double mutation strains demonstrated that efficient ATP-dependent H+ transport was restored. Interestingly, the single mutations, gammaGln-269-->Arg or gammaThr-273-->Ser, caused reduced growth by oxidative phosphorylation; however, when these mutations were in combination with gammaMet-23-->Lys, growth was substantially increased. Furthermore, strains carrying gammaMet-23-->Lys, gammaGln-269-->Arg, or gammaThr-273-->Ser as single mutations were temperature sensitive, whereas, strains with the double mutations, gammaMet-23-->Lys/gammaGln-269-->Arg or gammaMet-23-->Lys/gammaThr-273-->Ser, were thermally stable. Taken together, these results strongly suggest that gammaMet-23, gammaArg-242, and the region between gammaGln-269 to gammaVal-280 are close to each other and interact to mediate efficient energy coupling.			NAKAMOTO, RK (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN.							BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BOYER PD, 1975, FEBS LETT, V58, P1, DOI 10.1016/0014-5793(75)80212-2; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P212; DUNN SD, 1980, J BIOL CHEM, V255, P113; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V103, P604; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HUMBERT R, 1989, J BACTERIOL, V171, P1435, DOI 10.1128/jb.171.3.1435-1444.1989; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KANAZAWA H, 1985, ARCH BIOCHEM BIOPHYS, V241, P364, DOI 10.1016/0003-9861(85)90558-2; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI J, 1986, ARCH BIOCHEM BIOPHYS, V251, P458, DOI 10.1016/0003-9861(86)90352-8; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; NALIN CM, 1984, J BIOL CHEM, V259, P7275; PAPA S, 1990, FEBS LETT, V272, P117, DOI 10.1016/0014-5793(90)80462-R; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1989, MOL CLONIN GLABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHIN K, 1992, J BIOL CHEM, V267, P20835; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WEISS MA, 1977, J BIOL CHEM, V252, P8007; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936	35	69	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					867	872						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419364				2022-12-25	WOS:A1993KG07700020
J	SCHROCK, RD; LLOYD, RS				SCHROCK, RD; LLOYD, RS			SITE-DIRECTED MUTAGENESIS OF THE NH2 TERMINUS OF T4-ENDONUCLEASE-V - THE POSITION OF THE ALPHA-NH2 MOIETY AFFECTS CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 ENDONUCLEASE-V; DIMER-DNA GLYCOSYLASE; ESCHERICHIA-COLI; DENV GENE; BACTERIOPHAGE-T4; SEQUENCE; REPAIR; BINDING; MECHANISMS; INHIBITION	Reductive methylation of the alphaNH2 moiety of the DNA repair enzyme T4 endonuclease V has been shown previously to eradicate both the N-glycosylase and apyrimidinic/apurinic lyase activities of the enzyme (Schrock, R. D., III, and Lloyd, R. S. (1991) J. Biol. Chem. 266, 17631-17639). The present study uses the technique of site-directed mutagenesis to investigate the important parameters involved in the cleavage mechanism. The prediction was that the addition of an amino acid in the immediate NH2-terminal region of the protein would alter the proximity of the alphaNH2 moiety of Thr2 to its target, thereby severely compromising the enzyme's catalytic activity. However, substitutions in this region generally should be tolerated. To test this hypothesis, three substitutions of the NH2-terminal amino acid were produced: Ser2 (T2S), Val2 (T2V), and Pro2 (T2P). An addition mutant was also produced by adding a glycine between the first and second amino acids of the protein (Thr2-Gly-Arg3) (+Gly). The T2P and +Gly mutants had negligible pyrimidine dimer-specific N-glycosylase activity as well as negligible pyrimidine dimer-specific nicking activity in vitro. Conversely, the T2S enzyme exhibited wild type levels of activity and the T2V exhibited intermediate levels of activity in vitro. Results from ultraviolet (UV) survival studies of the mutant enzymes indicated that the in vivo activities of these enzymes were directly correlated to the enzymes' ability to cleave at pyrimidine dimers in vitro. These results indicate that a critical parameter for the functionality of endonuclease V is the relative distance between the primary alphaNH2 group in the active site of the enzyme and those elements responsible for DNA binding and pyrimidine dimer recognition.	VANDERBILT UNIV,CTR MOLEC TOXICOL,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES07028, ES04091, ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028, R01ES004091] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONURA T, 1982, BIOCHIMIE, V64, P643, DOI 10.1016/S0300-9084(82)80104-1; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12728; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HIGGINS KM, 1987, MUTAT RES, V183, P117, DOI 10.1016/0167-8817(87)90053-8; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE CW, 1990, MOL GEN GENET, V222, P166, DOI 10.1007/BF00283040; LIUZZI M, 1987, BIOCHEMISTRY-US, V26, P3315, DOI 10.1021/bi00386a011; LLOYD RS, 1978, CANCER RES, V38, P3191; LLOYD RS, 1986, MUTAT RES, V165, P86; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NICKELL C, 1991, J BIOL CHEM, V266, P5634; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RADANY EH, 1984, J VIROL, V52, P846, DOI 10.1128/JVI.52.3.846-856.1984; RECINOS A, 1986, BIOCHEM BIOPH RES CO, V138, P945, DOI 10.1016/S0006-291X(86)80587-3; RECINOS A, 1986, J BACTERIOL, V168, P1014, DOI 10.1128/jb.168.2.1014-1018.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; VALERIE K, 1984, NUCLEIC ACIDS RES, V12, P8085, DOI 10.1093/nar/12.21.8085; VALERIE K, 1985, P NATL ACAD SCI USA, V82, P4763, DOI 10.1073/pnas.82.14.4763; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	35	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					880	886						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419366				2022-12-25	WOS:A1993KG07700022
J	SEO, HC; ETTINGER, MJ				SEO, HC; ETTINGER, MJ			IDENTIFICATION AND PURIFICATION OF A SELF-ASSOCIATING COPPER-BINDING PROTEIN FROM MOUSE HEPATIC CYTOSOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLISM; CU-67; RAT	The proteins which bind copper when it first enters cells and deliver that copper to the cellular sites where copper is incorporated into copper enzymes are unknown. When radiolabeled (Cu-64(II)) cytosol proteins were fractionated on Superose columns, two large copper-binding protein fractions were detected which together bound 63% of the total Cu-64 recovered from the column. A self-associating, 50-kDa copper-binding protein was identified whose tetramer and dimer appeared to elute in one of the major copper-binding fractions and the monomer eluted in the other. This protein was purified to homogeneity by successive Mono Q, chelating Superose, and phenyl-Superose columns. The concentrated, purified protein showed high amounts of tetramer and monomer plus some dimer, each of which bound copper. Rechromatography of the tetramer-dimer fraction on Superose gave rise to approximately equal amounts of tetramer, dimer, and monomer. Similarly, rechromatography of the monomer fraction gave rise to dimer and tetramer. Thus, the results with the purified protein confirmed that the 50-kDa protein exists as a tetramer-dimer-monomer equilibrium. The 50-kDa protein apparently makes a major contribution to the total copper-binding activity of the mouse hepatic cytosol and may play a significant role in intracellular copper metabolism.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019708] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19708] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; FREEDMAN JH, 1989, BIOCHEM BIOPH RES CO, V164, P134, DOI 10.1016/0006-291X(89)91693-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCEAU N, 1973, BIOCHIM BIOPHYS ACTA, V328, P351, DOI 10.1016/0005-2795(73)90268-7; MARCEAU N, 1973, BIOCHIM BIOPHYS ACTA, V328, P338, DOI 10.1016/0005-2795(73)90267-5; PALIDA FA, 1990, BIOCHEM J, V268, P359, DOI 10.1042/bj2680359; PALIDA FA, 1991, J BIOL CHEM, V266, P4586; SEO HC, 1993, J BIOL CHEM, V268, P1160; SEO HC, 1991, THESIS STATE U NEW Y; TERAO T, 1973, AM J PHYSIOL, V224, P682, DOI 10.1152/ajplegacy.1973.224.3.682; TERAO T, 1976, TOHOKU J EXP MED, V120, P209, DOI 10.1620/tjem.120.209; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	12	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1151	1159						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419319				2022-12-25	WOS:A1993KG07700059
J	WANG, WC; ZINN, K; BJORKMAN, PJ				WANG, WC; ZINN, K; BJORKMAN, PJ			EXPRESSION AND STRUCTURAL STUDIES OF FASCICLIN-I, AN INSECT CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; DROSOPHILA-MELANOGASTER CELLS; HUMAN CD4; PROTEINS; SUPERFAMILY; GRASSHOPPER; SEQUENCE; RECEPTOR; GLYCOPROTEINS; EFFICIENT	Fasciclin I is a lipid-linked cell-surface glycoprotein that can act as a homophilic adhesion molecule in tissue culture cells. It is thought to be involved in growth cone guidance in the embryonic insect nervous system. To facilitate structure-function studies, we have generated Chinese hamster ovary (CHO) cell lines expressing high levels of cell surface grasshopper and Drosophila fasciclin I. Grasshopper fasciclin I released by phospholipase C cleavage was purified on an immunoaffinity column and single crystals were obtained that diffracted to approximately 5-angstrom resolution. We also generated CHO and Drosophila S2 cell lines that produce a secreted form of fasciclin I. Fasciclin I expressed in S2 cells contains significantly less carbohydrate than the protein expressed in CHO cells, and may therefore be more suitable for crystallization. Biochemical characterization of purified fasciclin I indicates that the extracellular portion exists as a monomer in solution. Circular dichroism studies suggest that fasciclin I is primarily alpha-helical. Its structure is therefore different from other known cell adhesion molecules, which are predicted to be elongated beta-sheet structures. This suggests that fasciclin I may define a new structural motif used to mediate adhesive interactions between cell surfaces.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute				Wang, Wen-Ching/0000-0002-7422-3667	NINDS NIH HHS [NS28182] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028182] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V1, pCH9; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CARR SA, 1989, J BIOL CHEM, V264, P21286; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCALLISTER L, 1992, J NEUROSCI, V12, P895; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SNOW PM, 1988, P NATL ACAD SCI USA, V85, P5291, DOI 10.1073/pnas.85.14.5291; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WANG WC, 1992, THESIS CALTECH; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	47	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1448	1455						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419345				2022-12-25	WOS:A1993KG07700102
J	CONCONI, A; RYAN, CA				CONCONI, A; RYAN, CA			DNASE-I AND MICROCOCCAL NUCLEASE ANALYSIS OF THE TOMATO PROTEINASE INHIBITOR-I GENE IN CHROMATIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; RIBOSOMAL-RNA GENE; NUCLEOTIDE-SEQUENCE; PLANT-LEAVES; EXPRESSION; FRUIT; SENSITIVITY; MECHANISM; DEFENSE; INSECTS	The chromatin structure of the wound- inducible proteinase inhibitor I gene was investigated in nuclei from leaves of wounded and unwounded tomato plants. DNase I digestion of intact nuclei revealed that the inhibitor I chromatin structure was highly sensitive to the enzyme compared to the inactive ribosomal chromatin. This sensitivity was independent of wounding. Digestion of tomato nuclei with micrococcal nuclease, which produces a nucleosomal ladder from bulk chromatin in agarose gels, supported these observations. Micrococcal nuclease produced only a faint nucleosomal repeat superimposed on a smear for the coding region of the inhibitor I gene, whereas digestion of inactive ribosomal chromatin produced a well defined nucleosomal ladder. Two DNase I-hypersensitive sites were found in the promoter region of the inhibitor I gene. Both were present before and after wound induction. These two constitutive DNase I-hypersensitive sites may correspond to DNA regulatory regions of the gene. The combined results indicate the existence of an open chromatin conformation in the inhibitor I gene DNA region, present before gene induction by wounding.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA	Washington State University								BELLARD M, 1989, METHOD ENZYMOL, V170, P317; BISHOP PD, 1984, J BIOL CHEM, V259, P3172; BISHOP PD, 1981, P NATL ACAD SCI-BIOL, V78, P3536, DOI 10.1073/pnas.78.6.3536; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CONCONI A, 1992, P NATL ACAD SCI USA, V89, P5256, DOI 10.1073/pnas.89.12.5256; DOHERTY HM, 1988, PHYSIOL MOL PLANT P, V33, P377, DOI 10.1016/0885-5765(88)90004-5; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FLAVELL RB, 1985, MOL FORM FUNCTION PL, P1; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; KAHL G, 1987, DEV GENET, V8, P405, DOI 10.1002/dvg.1020080510; KERNAN A, 1989, PLANT PHYSIOL, V91, P73, DOI 10.1104/pp.91.1.73; KISS T, 1989, NUCLEIC ACIDS RES, V17, P796, DOI 10.1093/nar/17.2.796; KISS T, 1988, NUCLEIC ACIDS RES, V16, P7179, DOI 10.1093/nar/16.14.7179; KISS T, 1989, NUCLEIC ACIDS RES, V17, P2127, DOI 10.1093/nar/17.5.2127; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LUTHE DS, 1980, PLANT PHYSIOL, V65, P305, DOI 10.1104/pp.65.2.305; Maniatis T, 1989, MOL CLONING; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; MURRAY MG, 1984, BIOCHEMISTRY-US, V23, P4225, DOI 10.1021/bi00313a032; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, 1988, PLANTA, V175, P527, DOI 10.1007/BF00393075; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PENACORTES H, 1989, P NATL ACAD SCI USA, V86, P9851, DOI 10.1073/pnas.86.24.9851; REEVES R, 1988, CHROMOSOMES CHROMATI, V1, P109; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SPIKER S, 1983, P NATL ACAD SCI-BIOL, V80, P815, DOI 10.1073/pnas.80.3.815; STEINMULLER K, 1986, EUR J BIOCHEM, V158, P519, DOI 10.1111/j.1432-1033.1986.tb09785.x; THOMAS GH, 1984, NATO ASI SER, V101, P77; van Holde K.E., 1988, CHROMATIN; WALKERSIMMONS M, 1983, BIOCHEM BIOPH RES CO, V110, P194, DOI 10.1016/0006-291X(83)91279-2; WIDMER RM, 1984, EMBO J, V3, P1635, DOI 10.1002/j.1460-2075.1984.tb02022.x; WINGATE VPM, 1989, J BIOL CHEM, V264, P17734; WINGATE VPM, 1991, PLANT PHYSIOL, V97, P496, DOI 10.1104/pp.97.2.496; WOOD WI, 1982, J BIOL CHEM, V257, P7730	39	14	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					430	435						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416948				2022-12-25	WOS:A1993KE60300066
J	FANJUL, AN; FARIAS, RN				FANJUL, AN; FARIAS, RN			COLD-SENSITIVE CYTOSOLIC 3,5,3'-TRIIODO-L-THYRONINE-BINDING PROTEIN AND PYRUVATE-KINASE FROM HUMAN ERYTHROCYTES SHARE SIMILAR REGULATORY PROPERTIES OF HORMONE BINDING BY GLYCOLYTIC-INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; ISOZYMES; FRUCTOSE-1,6-BISPHOSPHATE; MONOMER; RAT; PURIFICATION; GENE; CELL	Similar cold-sensitive properties, values of dissociation constants (K(d) = 1 x 10(-10) M), and regulatory effectors were found for the cold-sensitive cytosolic 3,5,3'-triiodo-L-thyronine (L-T3)-binding protein (CTBP) and pyruvate kinase from human erythrocyte. Various metabolites of the blood cell were assayed for their effects on CTBP activity after heat and cold preincubation treatments. Among these compounds, five- and six-carbon phosphorylated sugars were effective in protecting the CTBP activity against cold inactivation, whereas only ATP and dATP blocked activation by heat treatments. The effects of fructose 1,6-bisphosphate, fructose 2,6-bisphosphate, and ATP were obtained at physiological concentrations. Three-carbon phosphorylated intermediates of glycolysis, ADP, AMP, cAMP, and GTP had no effect on cold and heat treatments. The monomer-tetramer interconversion of the enzyme was also regulated by fructose 1,6-bisphosphate and ATP. The association is under the control of fructose 1,6-bisphosphate, whereas the dissociation is under ATP control. This regulation may have physiological relevance since the hormone binds to the tetrameric form of the enzyme at a site other than the active site.	UNIV NACL TUCUMAN,CONICET,INSIBIO,DEPT BIOQUIM NUTR,CHACABUCO 461,RA-4000 TUCUMAN,ARGENTINA; INST QUIM BIOL DR BERNABE BLOJ,RA-4000 TUCUMAN,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional de Tucuman								ASHIZAWA K, 1991, BIOCHEMISTRY-US, V30, P7105, DOI 10.1021/bi00243a010; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; ATAULLAKHANOV FI, 1981, EUR J BIOCHEM, V115, P359, DOI 10.1111/j.1432-1033.1981.tb05246.x; BARTLETT GR, 1958, J BIOL CHEM, V234, P449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIN MC, 1972, HEMOGLOBIN RED CELL, V28, P145; FANJUL AN, 1991, J BIOL CHEM, V266, P16415; HARADA K, 1978, BIOCHIM BIOPHYS ACTA, V524, P327, DOI 10.1016/0005-2744(78)90169-9; HERS HG, 1982, BIOCHEM J, V206, P13; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; KATO H, 1989, P NATL ACAD SCI USA, V86, P7861, DOI 10.1073/pnas.86.20.7861; KITAGAWA S, 1987, J BIOL CHEM, V262, P3903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIE J, 1980, EUR J BIOCHEM, V108, P251, DOI 10.1111/j.1432-1033.1980.tb04718.x; MINAKAMI S, 1964, BIOCHEM BIOPH RES CO, V17, P748, DOI 10.1016/0006-291X(64)90425-5; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; PARKISON C, 1991, BIOCHEM BIOPH RES CO, V179, P668, DOI 10.1016/0006-291X(91)91424-B; RAPAPORT S, 1974, HUMAN RED CELL IN VI; RAPAPORT TA, 1976, BIOCHEM J, V54, P449; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TANI K, 1988, GENE, V73, P509; VANSCHAFTINGEN E, 1981, EUR J BIOCHEM, V117, P319, DOI 10.1111/j.1432-1033.1981.tb06339.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	24	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					175	179						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416925				2022-12-25	WOS:A1993KE60300027
J	MATHEW, S; MURTY, VVVS; DALLAFAVERA, R; CHAGANTI, RSK				MATHEW, S; MURTY, VVVS; DALLAFAVERA, R; CHAGANTI, RSK			CHROMOSOMAL LOCALIZATION OF GENES ENCODING THE TRANSCRIPTION FACTORS, C-REL, NF-KAPPA-BP50, NF-KAPPA-BP65, AND LYT-10 BY FLUORESCENCE INSITU HYBRIDIZATION	ONCOGENE			English	Note							NF-KAPPA-B; INT-2 GENES; CARCINOMAS; AMPLIFICATION; ONCOGENE; COAMPLIFICATION; LYMPHOMA; CLONING; SUBUNIT; CANCERS	We have used fluorescence in situ hybridization (FISH) to perform precise chromosomal mapping of the genes encoding the transcription factors c-rel, NF-kappaBp50, NF-kappaBp65, and lyt-10. The previously published assignments of c-rel and NF-kappaBp50 have been refined to specific bands. The map position of lyt-10, inferred from its isolation from a t(10;14)(q24;q32) translocation, has been confirmed. NF-kappaBp65 has now been mapped to 11q13, a site of frequent involvement in aberration in multiple tumor types.	MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,1275 YORK AVE,NEW YORK,NY 10021; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Memorial Sloan Kettering Cancer Center; Columbia University					NCI NIH HHS [CA-34775, CA-20194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775, P01CA020194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1989, ONCOGENE, V4, P935; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LU D, 1991, ONCOGENE, V6, P1235; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MANIATIS T, 1982, MOL CLONING LABORATO, P109; MATHEW S, 1992, IN PRESS GENOMICS; NARAYANAN R, 1992, SCIENCE, V256, P357; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SOMERS KD, 1990, ONCOGENE, V5, P915; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA T, 1989, CANCER RES, V49, P5505; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VANDENBERGHE H, 1979, CANCER, V44, P179; ZHOU DJ, 1988, ONCOGENE, V2, P279	23	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					191	193						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423996				2022-12-25	WOS:A1993KN00500023
J	OELRICHS, RB; REID, HH; BERNARD, O; ZIEMIECKI, A; WILKS, AF				OELRICHS, RB; REID, HH; BERNARD, O; ZIEMIECKI, A; WILKS, AF			NYK/FLK-1 - A PUTATIVE RECEPTOR PROTEIN TYROSINE KINASE ISOLATED FROM E10 EMBRYONIC NEUROEPITHELIUM IS EXPRESSED IN ENDOTHELIAL-CELLS OF THE DEVELOPING EMBRYO	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; DEVELOPING MOUSE-BRAIN; ONCOGENE C-KIT; W-LOCUS; CONSERVED FEATURES; CDNA; SEQUENCE; FAMILY; GENE; DNA	A protein tyrosine kinase (NYK/FLK-1), bearing all the hallmarks of a growth factor receptor, has been isolated from a cDNA library generated from enriched populations of mouse day 10 embryonic neuroepithelium and from day 18 embryonic colon. Sequence analysis of cDNAs covering the entire coding region of this 5.7 kb mRNA predicted the presence of seven immunoglobulin-like domains in the extracellular region of this molecule. This feature, coupled with the detection of an insert domain bisecting the kinase domain of the predicted protein sequence, places NYK/FLK-1 firmly in the Platelet-derived Growth Factor Receptor-related class of molecules. NYK/FLK-1 is expressed at high levels in adult heart, lung, kidney, brain and skeletal muscle, but is also expressed at lower levels in most other adult tissues. In situ hybridization of day 12.5 embryo sections demonstrated NYK/FLK-1 mRNA expression in endothelial cells lining the dorsal aorta and intervertebral veins. In addition, expression was found in cells lining the capillary plexus which surrounds the developing neuroepithelium, and in the endothelial cells which are found within the embryonic lung, spleen, liver and metanephros.	ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Bern			Bernard, Olivier/J-1133-2014; Wilks, Andrew F/R-5542-2019	Bernard, Olivier/0000-0003-2539-9014; Wilks, Andrew F/0000-0002-8554-2399				BAER T, 1980, ADV ANAT EMBRYOL CEL, V264, P8222; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DRAGO J, 1991, J NEUROSCI METH, V37, P251, DOI 10.1016/0165-0270(91)90031-T; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOVENS CM, 1992, IN PRESS P NATL ACAD; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REID HH, 1990, THESIS U MELBOURNE; ROSNET O, 1991, ONCOGENE, V6, P1641; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; STEVENSON DA, 1991, P NATL ACAD SCI USA, V88, P6; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	42	80	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					11	18						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423988				2022-12-25	WOS:A1993KN00500002
J	REUVEN, NB; DEUTSCHER, MP				REUVEN, NB; DEUTSCHER, MP			MULTIPLE EXORIBONUCLEASES ARE REQUIRED FOR THE 3' PROCESSING OF ESCHERICHIA-COLI TRANSFER-RNA PRECURSORS INVIVO	FASEB JOURNAL			English	Article						TRANSFER RNA MATURATION; SUPPRESSION	POLYNUCLEOTIDE PHOSPHORYLASE; TURNOVER; INVITRO; BN	Our knowledge of the 3' processing of tRNA precursors is severely limited. Although six exoribonucleases able to act on Escherichia coli tRNA precursors in vitro have been identified, their involvement in tRNA maturation in vivo has not been demonstrated. Here we show, using a wide range of multiple RNase-deficient strains and a quantitative suppression assay, that at least five of these enzymes-RNase II, RNase D, RNase BN, RNase T, and RNase PH - can participate in the synthesis of functional tRNA(Tyr)su+3 in vivo. Moreover, any one of the five RNases is sufficient to allow tRNA processing to proceed although with varying effectiveness. Examination of the level of aminoacylation of tRNA isolated from RNase-deficient strains suggested that tRNA precursors accumulate in the most defective cells. These data indicate that exoribonucleases are required for tRNA maturation in vivo and that there is a high degree of functional overlap among the enzymes. These studies contribute to the identification of all the enzymes necessary for defining the complete processing pathway for E. coli tRNA precursors.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut			Reuven, Nina/AAM-8711-2020	Reuven, Nina/0000-0003-1569-3818	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BIKOFF EK, 1975, J BIOL CHEM, V250, P6240; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CRAVEN MG, 1992, J BACTERIOL, V174, P41727; CUDNY H, 1988, J BIOL CHEM, V263, P1518; CUDNY H, 1980, P NATL ACAD SCI USA, V77, P834; DEUTSCHER MP, 1977, J MOL BIOL, V109, P593, DOI 10.1016/S0022-2836(77)80093-4; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DEUTSCHER MP, 1974, J BACTERIOL, V118, P628; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KELLY KO, 1992, IN PRESS J BACTERIOL; KING TC, 1987, ESCHERICHIA COLI SAL, P703; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; MCCLAIN WH, 1977, ACCOUNTS CHEM RES, V10, P418, DOI 10.1021/ar50119a006; MICHELSEN U, 1989, J BACTERIOL, V171, P5987, DOI 10.1128/jb.171.11.5987-5994.1989; Miller JH., 1972, EXPT MOL GENETICS; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; REILLY RM, 1986, J BIOL CHEM, V261, P2928; SAKANO H, 1978, J MOL BIOL, V123, P287, DOI 10.1016/0022-2836(78)90082-7; SCHEDL P, 1976, CELL, V8, P581, DOI 10.1016/0092-8674(76)90226-9; SEKIYA T, 1979, J BIOL CHEM, V254, P5802; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651	28	62	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					143	148		10.1096/fasebj.7.1.8422961	http://dx.doi.org/10.1096/fasebj.7.1.8422961			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422961				2022-12-25	WOS:A1993KH88000021
J	SIRINIAN, MI; MARCHETTI, A; DIROCCO, G; STARACE, G; JUCKER, R; NASI, S				SIRINIAN, MI; MARCHETTI, A; DIROCCO, G; STARACE, G; JUCKER, R; NASI, S			RAS ONCOGENE TRANSFORMATION OF HUMAN B-LYMPHOBLASTS IS ASSOCIATED WITH LYMPHOCYTE-ACTIVATION AND WITH A BLOCK OF DIFFERENTIATION	ONCOGENE			English	Article							MOLECULAR-CLONING; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; CELL ACTIVATION; PC12 CELLS; H-RAS; TRANSCRIPTION; GENE; ADHESION	The p21ras small GTP binding proteins participate in signal transduction from cell surface receptors and affect neoplastic transformation and development in many different cell types. In the present study, we examined the relationship between ras transformation and differentiation of human B lymphocytes. We show that the constitutive expression of the T24 Ha-ras oncogene in EBV-immortalized B lymphoblasts was associated with the induction of the interleukin 2 receptor alpha subunit, with an impaired immunoglobulin gene expression, altered adhesion properties and increased survival in serum-free medium. Since induction of the IL-2 receptor alpha subunit is a hallmark of lymphocyte activation, we suggest that p21ras naturally triggers B cell activation. The ras-transformed lymphocytes displayed a fully functional IL-2r, as assessed by c-fos induction following treatment with IL-2; nevertheless, they were not growth stimulated by this lymphokine. The decreased expression of immunoglobulin genes indicates that the ras oncogene blocks terminal differentiation to plasma cells, possibly by inhibiting the activity of lymphocyte-specific transcription factors. Somewhat unexpectedly, the constitutive p21ras activity did not cause an increased DNA binding of transcription factors PEA1 (AP1), PEA3, Oct-2 or NF-kB.	UNIV ROME LA SAPIENZA,DIPARTIMENTO GENET & BIOL MOLEC,CNR,CTR ACIDI NUCL,I-00185 ROME,ITALY; CNR,IST MED SPERIMENTALE,ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)			Di Rocco, Giuliana/G-5682-2012; Di Rocco, Giuliana/P-1413-2019; Di Rocco, Giuliana/J-4776-2018; Marchetti, Alessandra/AAD-5498-2019	Di Rocco, Giuliana/0000-0003-1210-6008; Di Rocco, Giuliana/0000-0003-1210-6008; MARCHETTI, ALESSANDRA/0000-0001-9706-848X				ARIMA N, 1987, J IMMUNOL, V138, P3069; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BICHTHUY LT, 1990, CELL IMMUNOL, V128, P22, DOI 10.1016/0008-8749(90)90003-A; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CARUSO M, 1990, EMBO J, V9, P947, DOI 10.1002/j.1460-2075.1990.tb08193.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DANG LH, 1991, J IMMUNOL, V146, P3273; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ENDO K, 1991, ONCOGENE, V6, P1391; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NASI S, 1990, ONCOGENE, V5, P117; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YAGURA H, 1990, BLUT, V60, P181, DOI 10.1007/BF01720273	45	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					157	163						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423993				2022-12-25	WOS:A1993KN00500019
J	CHATRENET, B; CHANG, JY				CHATRENET, B; CHANG, JY			THE DISULFIDE FOLDING PATHWAY OF HIRUDIN ELUCIDATED BY STOP GO FOLDING EXPERIMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; RIBONUCLEASE-A; PROTEIN; BPTI; MECHANISM; NMR	The folding pathway of hirudin was analyzed by structural characterization and stop/go folding experiments of acid-trapped intermediates. The results show that the folding is initiated by a near-random packing, followed by the reorganization and fine adjustment of partially compact intermediates to attain the active molecule. The process of packing is observed as the unfolded hirudin flows sequentially via three groups of equilibrated intermediates, namely one-disulfide, two-disulfide, and three-disulfide (scrambled species) isomers. Nearly all possible disulfide species were found to exist along the pathway. Specific tertiary interactions then take effect at the final stage, refining and consolidating the loosely packed intermediates, in the presence of free thiols, to form the active hirudin. The rate of packing and reorganization can be selectively regulated by a number of external factors, and conditions can be chosen to allow the completion of folding process within 10 min or 10 h.	CIBA GEIGY AG,PHARMACEUT RES LAB,K-121,104,CH-4002 BASEL,SWITZERLAND	Novartis								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BOERNSEN KO, 1990, CHIMIA, V44, P412; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHANG JY, 1990, J BIOL CHEM, V265, P22159; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5802; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOBSON C M, 1992, Current Biology, V2, P343, DOI 10.1016/0960-9822(92)90047-E; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; HABER E, 1962, J BIOL CHEM, V237, P1839; HARRISON SC, 1985, P NATL ACAD SCI USA, V82, P4028, DOI 10.1073/pnas.82.12.4028; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KARAS M, 1990, TRAC-TREND ANAL CHEM, V9, P321, DOI 10.1016/0165-9936(90)85065-F; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KONISHI Y, 1981, BIOCHEMISTRY-US, V20, P3945, DOI 10.1021/bi00517a001; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RICHARDS FM, 1991, SCI AM, P34; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; SCHERAGA HA, 1987, P NATL ACAD SCI USA, V84, P5740, DOI 10.1073/pnas.84.16.5740; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SUN XJ, 1989, J BIOL CHEM, V264, P11288; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	38	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20988	20996						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407935				2022-12-25	WOS:A1993MA28800055
J	EBERHARDT, TL; BERNARDS, MA; HE, LF; DAVIN, LB; WOOTEN, JB; LEWIS, NG				EBERHARDT, TL; BERNARDS, MA; HE, LF; DAVIN, LB; WOOTEN, JB; LEWIS, NG			LIGNIFICATION IN CELL-SUSPENSION CULTURES OF PINUS-TAEDA - IN-SITU CHARACTERIZATION OF A GYMNOSPERM LIGNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CINNAMYL-ALCOHOL-DEHYDROGENASE; ELICITOR-MEDIATED RESPONSES; PHENYLPROPANOID METABOLISM; FORSYTHIA-INTERMEDIA; FREE-EXTRACTS; FAGUS-GRANDIFOLIA; SPRUCE LIGNIN; WHEAT STRAW; SOLID-STATE; BIOSYNTHESIS	Pinus taeda suspension cultures grown in medium containing 2,4-dichlorophenoxyacetic acid showed only primary cell wall formation and essentially no lignification, as determined by histochemical, ultrastructural, chemical, and NMR spectroscopic analyses. However, these cultures maintained a functional phenylpropanoid pathway as demonstrated by formation of the lignans (-)-matairesinol and (-)-pinoresinol. Administration of [1-C-13]Phe to these cultures, followed by solid-state carbon-13 NMR spectral analysis of their cell walls, demonstrated that the phenylalanine incorporated into the cell wall matrix was primarily as protein, rather than lignin. Successive transfer of the 2,4-dichlorophenoxyacetic acid-grown cultures to alpha-naphthaleneacetic acid-containing medium induced cell wall thickening concomitant with lignification. The presence of lignin was confirmed by histochemical, ultrastructural, chemical, biochemical, and NMR spectroscopic analyses. Specific labeling of the lignin polymer in situ with [1-C-13]-, [2-C-13]-, and [3-C-13]Phe and analysis of the cell wall preparations by solid-state carbon-13 NMR spectroscopy permitted the first direct determination of the in situ bonding patterns in a gymnosperm lignin. Several dominant interunit linkages were observed, including beta-O-aryl, furanofuran, phenylcoumarin, and phenolic-linked monolignols, consistent with those predicted but hitherto not proven. Finally, milled wood lignin derivatives prepared from these C-13-specifically enriched lignin tissues gave a relatively high fidelity copy of the native lignin.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; PHILIP MORRIS USA RES CTR, RICHMOND, VA 23261 USA	Washington State University; Philip Morris International Inc				Davin, Laurence/0000-0002-3248-6485; Eberhardt, Thomas/0000-0002-8818-4822; Lewis, Norman/0000-0001-5742-032X				BAO WL, 1992, P NATL ACAD SCI USA, V89, P6604, DOI 10.1073/pnas.89.14.6604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CL, 1968, FOREST SCI, V14, P62; BRUNOW G, 1990, PHYTOCHEMISTRY, V29, P2535, DOI 10.1016/0031-9422(90)85183-G; CAMPBELL MM, 1992, PLANTA, V186, P409, DOI 10.1007/BF00195322; CAMPBELL MM, 1992, PHYTOCHEMISTRY, V31, P737, DOI 10.1016/0031-9422(92)80004-X; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; FUKUDA T, 1988, MOKUZAI GAKKAISHI, V34, P149; FUNK C, 1990, PHYTOCHEMISTRY, V29, P845, DOI 10.1016/0031-9422(90)80030-K; GAGNAIRE D, 1977, MAKROMOL CHEM, V178, P1477; GROSS GG, 1979, RECENT ADV PHYTOCHEM, V12, P177; HARTLEY RD, 1990, PHYTOCHEMISTRY, V29, P3699, DOI 10.1016/0031-9422(90)85316-8; Hayashi M., 1986, Bulletin of the Faculty of Agriculture, Kagoshima University, P1; HIGUCHI T, 1967, PHYTOCHEMISTRY, V6, P875, DOI 10.1016/S0031-9422(00)86035-5; HIGUCHI T, 1967, PHYTOCHEMISTRY, V6, P1551, DOI 10.1016/S0031-9422(00)82949-0; HIGUCHI T, 1980, LIGNIN BIODEGRADATIO, V1, P1; Hosel W., 1982, Plant Cell, Tissue and Organ Culture, V1, P137; Johnson D. B., 1961, TAPPI, V44, P793; KATAYAMA T, 1992, PHYTOCHEMISTRY, V31, P3875, DOI 10.1016/S0031-9422(00)97545-9; KNOGGE W, 1986, PLANTA, V167, P196, DOI 10.1007/BF00391415; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P47, DOI 10.1515/hfsg.1986.40.1.47; LAPIERRE C, 1988, HOLZFORSCHUNG, V42, P1, DOI 10.1515/hfsg.1988.42.1.1; LAPIERRE C, 1988, HOLZFORSCHUNG, V42, P409, DOI 10.1515/hfsg.1988.42.6.409; LEWIS NG, 1987, SCIENCE, V237, P1344, DOI 10.1126/science.237.4820.1344; LEWIS NG, 1987, MACROMOLECULES, V20, P1752, DOI 10.1021/ma00174a006; LEWIS NG, 1988, J CHEM SOC CHEM COMM, P1626, DOI 10.1039/c39880001626; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; LEWIS NG, 1989, ACS SYM SER, V399, P169; MARCINOWSKI S, 1978, EUR J BIOCHEM, V87, P37, DOI 10.1111/j.1432-1033.1978.tb12349.x; MILLER AR, 1986, CAN J BOT, V64, P2716, DOI 10.1139/b86-358; MORELLI E, 1986, PHYTOCHEMISTRY, V25, P1701, DOI 10.1016/S0031-9422(00)81239-X; MORRISON IM, 1972, J SCI FOOD AGR, V23, P455, DOI 10.1002/jsfa.2740230405; NIMZ H, 1975, Zeitschrift fuer Naturforschung Teil C Biochemie Biophysik Biologie Virologie, V30, P442; NIMZ H, 1974, MAKROMOL CHEM, V175, P2563; OZEKI Y, 1990, PHYSIOL PLANTARUM, V78, P400, DOI 10.1111/j.1399-3054.1990.tb09055.x; RAHMAN MMA, 1990, PHYTOCHEMISTRY, V29, P1841, DOI 10.1016/0031-9422(90)85025-B; RAMSDEN L, 1987, J CELL SCI, V88, P467; ROBERT D, 1989, PLANT PHYSIOL BIOCH, V27, P297; Rowell, 1986, CELLULOSE STRUCTURE, P77; SARNI F, 1984, EUR J BIOCHEM, V139, P259, DOI 10.1111/j.1432-1033.1984.tb08002.x; SCALBERT A, 1985, PHYTOCHEMISTRY, V24, P1359, DOI 10.1016/S0031-9422(00)81133-4; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Sjostrom E., 1981, WOOD CHEM FUNDAMENTA, P1; SUN HH, 1987, CARBOHYD POLYM, V7, P143, DOI 10.1016/0144-8617(87)90056-7; TALMADGE KW, 1973, PLANT PHYSIOL, V51, P158, DOI 10.1104/pp.51.1.158; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; UMEZAWA T, 1991, J BIOL CHEM, V266, P10210; WUTHRICH K, 1976, NMR BIOL RES PEPTIDE, P1; WYRAMBIK D, 1975, EUR J BIOCHEM, V59, P9, DOI 10.1111/j.1432-1033.1975.tb02418.x; YAMAMOTO E, 1989, ACS SYM SER, V399, P68; YAMAMOTO E, 1985, J PLANT PHYSIOL, V117, P441, DOI 10.1016/S0176-1617(85)80051-1; YAMAMOTO E, 1990, PLANT PHYSIOL, V94, P209, DOI 10.1104/pp.94.1.209; ZENK MH, 1975, PLANTA MED, P79, DOI 10.1055/s-0028-1104768; ZUCKER M, 1965, PLANT PHYSIOL, V40, P779, DOI 10.1104/pp.40.5.779	54	72	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21088	21096						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407945				2022-12-25	WOS:A1993MA28800069
J	MIYASHITA, K; MURAKAMI, M; YAMADA, M; IRIUCHIJIMA, T; MORI, M				MIYASHITA, K; MURAKAMI, M; YAMADA, M; IRIUCHIJIMA, T; MORI, M			HISTIDYL-PROLINE DIKETOPIPERAZINE - NOVEL FORMATION THAT DOES NOT ORIGINATE FROM THYROTROPIN-RELEASING-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIS-PRO; PRECURSOR; SECRETION; ENZYME; TRH; AMINOPEPTIDASE; GLYCINE; BRAIN	We asked whether cyclo(His-Pro) may arise from a substance other than the initially found progenitor thyrotropin-releasing hormone (TRH). Incubation of TRH-Gly (pGlu-His-Pro-Gly), a TRH precursor, with brain hypothalamic cytosols caused significant formation of His-Pro-Gly followed by the generation of histidyl-proline diketopiperazine (cyclo(His-Pro)), whereas TRH was not formed. The addition of purified pyroglutamyl aminopeptidase resulted in the transformation of TRH-Gly to His-Pro-Gly and cyclo(His-Pro) but not to TRH. Neither TRH nor cyclo(His-Pro) was produced from TRH-Gly in the presence of alpha-amidating enzyme under the present conditions. Nonenzymatic conversion of His-Pro-Gly to cyclo(His-Pro) occurred. The present results provide evidence that cyclo(His-Pro) can emanate from a direct predecessor form of TRH by pyroglutamyl aminopeptidase action, not through TRH formation.	GUNMA UNIV, SCH MED, DEPT INTERNAL MED 1, MAEBASHI, GUNMA 371, JAPAN	Gunma University								BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BROWNE P, 1983, EUR J BIOCHEM, V137, P75, DOI 10.1111/j.1432-1033.1983.tb07797.x; FUSE Y, 1990, ENDOCRINOLOGY, V127, P2501, DOI 10.1210/endo-127-5-2501; MORI M, 1990, J CLIN ENDOCR METAB, V71, P252, DOI 10.1210/jcem-71-1-252; MORI M, 1991, LIFE SCI, V49, P1031, DOI 10.1016/0024-3205(91)90304-T; PRASAD C, 1988, NEUROSCI BIOBEHAV R, V12, P19, DOI 10.1016/S0149-7634(88)80069-1; PRASAD C, 1983, NEUROCHEM RES, V8, P389, DOI 10.1007/BF00965728; PRASAD C, 1989, ANN NY ACAD SCI, V553, P232; STEPHENS RL, 1989, REGUL PEPTIDES, V25, P51, DOI 10.1016/0167-0115(89)90247-4; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; YAMADA M, 1990, P SOC EXP BIOL MED, V194, P346	12	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20863	20865						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407917				2022-12-25	WOS:A1993MA28800037
J	YAMAGATA, K; DAIHO, T; KANAZAWA, T				YAMAGATA, K; DAIHO, T; KANAZAWA, T			LABELING OF LYSINE-492 WITH PYRIDOXAL 5'-PHOSPHATE IN THE SARCOPLASMIC-RETICULUM CA(2+)-ATPASE - LYSINE-492 RESIDUE IS LOCATED OUTSIDE THE FLUORESCEIN 5-ISOTHIOCYANATE-BINDING REGION IN OR NEAR THE ATP BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; ACTIVE-SITE; CA-2+-TRANSPORTING ATPASE; LYSYL RESIDUE; ISOTHIOCYANATE; CALCIUM; MUSCLE; TRIPHOSPHOPYRIDOXAL; PHOSPHORYLATION; IDENTIFICATION	Sarcoplasmic reticulum vesicles were treated with 2 mM pyridoxal 5'-phosphate (PLP) at 25-degrees-C and pH 7.0 for 6 min and reduced by NaBH4. Both the activity of the Ca2+-ATPase and the capacity for high affinity Mg-ATP binding were greatly reduced. Acetyl phosphate hydrolysis or phosphoenzyme formation from P(i) was not inhibited. The enzyme was protected by high affinity Mg-ATP binding against the PLP-induced inhibition. A similar protective effect was obtained by Mg-AMP as well as by Mg-ADP. Acetyl phosphate or P(i) gave no protection. The PLP-treated vesicles were solubilized in SDS, and the Ca2+-ATPase was purified by size exclusion high performance liquid chromatography (HPLC). Mapping the fluorescently labeled peptides in the tryptic digest by reversed phase HPLC revealed a single fluorescent peak, which was protected by Mg-ATP against labeling. Sequencing showed that Lys-492 is the residue labeled with PLP. These results demonstrate that Lys-492 is located in or near the ATP binding site but not in the phosphorylation site or the P(i) binding site. When Lys-515 was entirely prelabeled with fluorescein 5-isothiocyanate (FITC), the subsequent labeling of Lys-492 with PLP was not prevented. This finding demonstrates that Lys-492 is located outside the FITC-binding region. It has been widely accepted that FITC occupies the adenosine-binding region within the ATP binding site. In contrast to FITC, Mg-AMP strongly inhibited the labeling of Lys-492 with PLP. These findings lead to the conclusion that Lys-492 is located outside the adenosine-binding region, most probably in or near the region occupied by the alpha-phosphoryl group of Mg-ATP bound to the ATP binding site.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,JAPAN; ASAHIKAWA MED COLL,DEPT INTERNAL MED 3,ASAHIKAWA 078,JAPAN	Asahikawa Medical College; Asahikawa Medical College								ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; ARAV R, 1983, J BIOL CHEM, V258, P433; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; DEGANI C, 1973, J BIOL CHEM, V248, P8222; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FISCHER EH, 1963, CHEMICAL BIOLOGICAL, P543; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; HASSELBACH W, 1961, BIOCHEM Z, V333, P519; HINZ HR, 1990, J BIOL CHEM, V265, P10260; KANAZAWA T, 1971, J BIOCHEM-TOKYO, V70, P95, DOI 10.1093/oxfordjournals.jbchem.a129631; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MAROUX S, 1966, BIOCHIM BIOPHYS ACTA, V122, P147, DOI 10.1016/0926-6593(66)90098-1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MURPHY AJ, 1977, ARCH BIOCHEM BIOPHYS, V180, P114, DOI 10.1016/0003-9861(77)90014-5; NEIL GL, 1966, NATURE, V210, P903, DOI 10.1038/210903a0; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; PUCELL A, 1971, J BIOL CHEM, V246, P3389; SILLEN LG, 1971, STABILITY CONSTANT S, V1, P644; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; TAMURA S, 1989, J BIOL CHEM, V264, P8580; TERUEL JA, 1988, BIOCHEMISTRY-US, V27, P5885, DOI 10.1021/bi00416a010; WANG K, 1992, J BIOL CHEM, V267, P3577; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	41	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20930	20936						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407928				2022-12-25	WOS:A1993MA28800048
J	WANG, NP; TO, H; LEE, WH; LEE, EYHP				WANG, NP; TO, H; LEE, WH; LEE, EYHP			TUMOR SUPPRESSOR ACTIVITY OF RB AND P53 GENES IN HUMAN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; WILD-TYPE P53; HUMAN PROSTATE CARCINOMA; MEDIATED FOCUS FORMATION; RECESSIVE MUTATION; PROTO-ONCOGENE; OSTEO-SARCOMA; ALLELE LOSS; SHORT ARM; EXPRESSION	Breast cancer is the most common cancer of women in Western countries. Various genetic alterations have been implicated in its development. Two tumor suppressor genes, the retinsoblastoma susceptibility gene (RB) and the gene encoding the p53 protein, are frequently found to be deleted or mutated in breast cancer cell lines and primary tumor samples. Breast carcinoma cell lines MDA-MB468 and BT549 both harbor partial RB gene deletions as well as point mutations of their p53 genes, thus providing an excellent model system for testing the roles played by these two genes in the oncogenesis of breast cancer. Single copies of wild-type RB or p53 were delivered to these cells by retrovirus-mediated gene transfer. Restoration of RB expression in cells reduced their ability to grow in soft agar and their tumorigenicity in nude mice, although no significant alteration of growth rate in culture could be detected. Introduction of wild-type p53 into these cells exerted a similar effect on the neoplastic phenotypes. This effect occurred even in the presence of their endogenous mutated p53 alleles, which argues for the phenotypical dominance of the wild-type p53 over mutated p53 during human oncogenesis. The ability of RB and p53 genes to suppress the tumorigenicity of breast carcinoma cells provides functional evidence that deletion or mutational inactivation of tumor suppressor genes represents an important step in the genesis of breast cancer.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN YM, 1991, ONCOGENE, V6, P1799; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Crawford L V, 1984, Mol Biol Med, V2, P261; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HENSEL CH, 1990, CANCER RES, V50, P3067; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MUNCASTER MM, 1992, CANCER RES, V52, P654; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	72	116	118	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					279	288						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426737				2022-12-25	WOS:A1993KN00600006
J	ZHU, X; GUDERMANN, T; BIRNBAUMER, M; BIRNBAUMER, L				ZHU, X; GUDERMANN, T; BIRNBAUMER, M; BIRNBAUMER, L			A LUTEINIZING-HORMONE RECEPTOR WITH A SEVERELY TRUNCATED CYTOPLASMIC TAIL (LHR-CT628) DESENSITIZES TO THE SAME DEGREE AS THE FULL-LENGTH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; ADENYLYL CYCLASE; BOVINE RHODOPSIN; ALPHA-SUBUNIT; CARBOXYL TAIL; LUTEAL CELLS; G-PROTEIN; RAT; GENE	The wild type murine luteinizing hormone (mLH) receptor, which in its mature form is predicted to be a protein of 674 amino acids (mLHR), and an artificially mutated form lacking the last 46 amino acids (mLHR-ct628) were stably expressed in murine L cells. Both forms stimulated adenylyl cyclase and underwent rapid desensitization. The mutation removed 1 tyrosine, 2 threonines, and 6 serines from the receptor. The results indicate that none of these potential phosphorylation sites participates in either adenylyl cyclase stimulation or receptor desensitization. Our results with the mLHR-ct628 (carboxyl-terminal amino acid sequence CCKHRAEL) differ from those reported recently for the essentially identically mutated rat LHR that lacks the last 43 amino acids (rLHR-ct631 with carboxyl-terminal amino acid composition CCKRRAELYRR). This 43-amino acid truncation was described to have the effect of preventing hormone-induced desensitization. While the reasons for the discrepant results are not known, our results do not support the proposal for a participatory role of the extreme carboxyl terminus of the receptor in its desensitization.	BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	ZHU, X (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041244] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45198] Funding Source: Medline; NICHD NIH HHS [HD-09581] Funding Source: Medline; NIDDK NIH HHS [DK-41244] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONELLI M, 1991, COMP BIOCHEM PHYS B, V99, P827, DOI 10.1016/0305-0491(91)90149-8; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; DAVIS JS, 1984, J BIOL CHEM, V259, P5028; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUDERMANN T, 1992, MOL ENDOCRINOL, V6, P272, DOI 10.1210/me.6.2.272; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUDERMANN T, 1992, BIOL REPROD S1, V46, P332; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P211, DOI 10.1210/endo-99-1-211; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KIRCHICK HJ, 1983, ENDOCRINOLOGY, V113, P1638, DOI 10.1210/endo-113-5-1638; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAMPRECHT SA, 1973, J ENDOCRINOL, V57, P217, DOI 10.1677/joe.0.0570217; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Maniatis T., 1982, MOL CLONING; MARSH JM, 1970, J BIOL CHEM, V245, P1596; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; RODRIGUEZ MC, 1990, ENDOCRINOLOGY, V127, P674, DOI 10.1210/endo-127-2-674; RODRIGUEZ MC, 1991, ENDOCRINOLOGY, V128, P999; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THEMMEN APN, 1993, IN PRESS J REC RES; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530	34	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1723	1728						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420950				2022-12-25	WOS:A1993KH62000035
J	KREBS, JF; FIERKE, CA				KREBS, JF; FIERKE, CA			DETERMINANTS OF CATALYTIC ACTIVITY AND STABILITY OF CARBONIC ANHYDRASE-II AS REVEALED BY RANDOM MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC POCKET; MIXED OLIGODEOXYNUCLEOTIDES; EFFICIENT PROCEDURE; REFINED STRUCTURE; RNA-POLYMERASE; BINDING; SITE; EXPRESSION; MUTATIONS; CO2	The functional importance of a conserved hydrophobic face in human carbonic anhydrase II (CAII), including amino acid residues 190-210, was investigated by random mutagenesis. The catalytic activity, inhibitor binding, and level of CAII expression in Escherichia coli of 57 single amino acid variants were measured revealing that the function of amino acids correlates with their secondary structure placement. Side chains of amino acids in beta-sheet structure are required for the formation of folded, stable protein while those in the turn region determine catalytic efficiency and inhibitor specificity. The CAII active site is extremely plastic, accommodating amino acid substitutions of varied size, charge, and hydrophobicity with little effect on catalysis; only substitutions at Leu198 and Thr199 decrease the rates of CO2 hydration and ester hydrolysis more than 5-fold. These results pinpoint the hydrogen bond network, including the zinc-solvent molecule and Thr199, as crucial for high catalytic efficiency and also suggest that Leu198 forms a portion of a CO2 association site. Increased activity is observed for substitutions at Thr200 (esterase) and Leu203 (hydrase). In addition, the pK(a) of the zinc-bound water molecule varies upon substitution of amino acids which alter the overall charge of the active site. Three residues interact with sulfonamide inhibitors; substitutions at Thr199 decrease binding (up to 10(3)-fold) while mutations at Thr200) and Cys206 increase binding of dansylamide (up to 80-fold). Mutations in the beta-sheet structure (Asp190-Ser197 and Val207-Ile-210) decrease the protein expression of CAII in E. coli, causing the formation of insoluble protein aggregates in many cases. This may suggest an important role for these residues in the folding process. In addition, mutations in Trp192, cis-Pro202, and Trp209 increase thermal lability (up to 5000-fold).	DUKE UNIV,MED CTR,DEPT BIOCHEM,BOX 3711,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040602, R29GM040602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40602] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; BEHRAVAN G, 1991, EUR J BIOCHEM, V195, P393, DOI 10.1111/j.1432-1033.1991.tb15718.x; BEHRAVAN G, 1990, EUR J BIOCHEM, V190, P351, DOI 10.1111/j.1432-1033.1990.tb15582.x; BRION LP, 1988, ANAL BIOCHEM, V175, P289, DOI 10.1016/0003-2697(88)90391-0; CARLSSON U, 1973, BIOCHIM BIOPHYS ACTA, V310, P376, DOI 10.1016/0005-2795(73)90119-0; CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287; CHEN RF, 1967, J BIOL CHEM, V242, P5813; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; Coleman JE., 1986, ZINC ENZYMES, P49; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DERBYSHIRE KM, 1986, GENE, V46, P145, DOI 10.1016/0378-1119(86)90398-7; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; FIERKE CA, 1991, CARBONIC ANHYDRASE, P22; GUILBAULT GG, 1964, ANAL CHEM, V36, P409, DOI 10.1021/ac60208a052; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSCH C, 1985, MOL PHARMACOL, V27, P493; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; Hewett-Emmett D., 1991, CARBONIC ANHYDRASES, P15; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; JONSSON B, 1978, J AM CHEM SOC, V100, P1658, DOI 10.1021/ja00474a003; KANAMORI K, 1983, BIOCHEMISTRY-US, V22, P2658, DOI 10.1021/bi00280a011; KANNAN KK, 1977, FEBS LETT, V73, P115, DOI 10.1016/0014-5793(77)80028-8; KING RW, 1976, PROC R SOC SER B-BIO, V193, P107, DOI 10.1098/rspb.1976.0034; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KREBS JF, 1991, BIOCHEMISTRY-US, V30, P9153, DOI 10.1021/bi00102a005; KREBS JF, 1982, INVESTIGATION ROLES, V2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JY, 1990, P NATL ACAD SCI USA, V87, P3675, DOI 10.1073/pnas.87.10.3675; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; LINDSKOG S, 1966, BIOCHEMISTRY-US, V5, P2641, DOI 10.1021/bi00872a023; MAREN TH, 1988, ANNU REV PHYSIOL, V50, P695; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; MERZ KM, 1991, J AM CHEM SOC, V113, P406, DOI 10.1021/ja00002a004; MURAKAMI H, 1987, Genomics, V1, P159, DOI 10.1016/0888-7543(87)90008-5; NAIR SK, 1991, J BIOL CHEM, V266, P17320; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; POCKER Y, 1972, BIOCHEMISTRY-US, V11, P698, DOI 10.1021/bi00755a005; Pocker Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P149; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; RIEPE ME, 1968, J BIOL CHEM, V243, P2779; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTON JR, 1979, NEW ENGL J MED, V301, P1329, DOI 10.1056/NEJM197912133012406; TAYLOR PW, 1971, BIOCHEMISTRY-US, V10, P3859, DOI 10.1021/bi00797a010; TAYLOR PW, 1970, BIOCHEMISTRY-US, V9, P3894, DOI 10.1021/bi00822a007; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0; TU CK, 1982, BIOCHEMISTRY-US, V21, P6353, DOI 10.1021/bi00268a006; VEDANI A, 1984, J PHARM SCI, V73, P352, DOI 10.1002/jps.2600730316; VIDGREN J, 1990, INT J BIOL MACROMOL, V12, P342, DOI 10.1016/0141-8130(90)90040-H; WOOLLEY P, 1975, NATURE, V258, P677, DOI 10.1038/258677a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	61	61	69	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					948	954						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419374				2022-12-25	WOS:A1993KG07700031
J	KARLSSON, GB; BUTTERS, TD; DWEK, RA; PLATT, FM				KARLSSON, GB; BUTTERS, TD; DWEK, RA; PLATT, FM			EFFECTS OF THE IMINO SUGAR N-BUTYLDEOXYNOJIRIMYCIN ON THE N-GLYCOSYLATION OF RECOMBINANT GP120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HUMAN-IMMUNODEFICIENCY-VIRUS; HAMSTER OVARY CELLS; ALPHA-D-MANNOSIDASE; ENVELOPE GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; RAT-LIVER; PROCESSING GLUCOSIDASES; SECRETORY GLYCOPROTEINS; INHIBITOR	The imino sugar N-butyldeoxynojirimycin (NB-DNJ) exhibits anti-HIV activity in vitro and inhibits the purified glycoprocessing enzyme alpha1,2-glucosidase I. It has been speculated that the anti-viral activity of this compound may result from inhibition of HIV envelope glycoprotein processing. However, structural evidence that glucosidase inhibition takes place in intact cells at the anti-viral concentration (0.5 mM) is lacking. In this study, N-linked glycosylation of recombinant gp120 expressed in Chinese hamster ovary cells cultured in the presence or absence of NB-DNJ has been characterized. Immunoprecipitation, in conjunction with endoglycosidase H (endo H) digestion and SDS-polyacrylamide gel electrophoresis analysis, revealed that the glycosylation of gp120 was profoundly altered in the presence of NB-DNJ. The majority of the gp120 oligosaccharides from untreated cells were resistant to endo H. However, nearly complete endo H sensitivity was observed following treatment with 0.5 mM NB-DNJ indicating that gp120 expressed in treated cells carries immature, high mannose type oligosaccharides. In addition, using metabolic labeling with [H-3]mannose, gel filtration chromatography, and digestion with highly purified glucosidases I and II, we provide the first definitive evidence that glucosidase I inhibition occurs at the anti-viral concentration of NB-DNJ. These data indicate that glucosidase inhibition is a candidate mechanism for the anti-viral activity of this compound.	UNIV OXFORD,INST GLYCOBIOL,DEPT BIOCHEM,SEARLE RES GRP,S PARKS RD,OXFORD OX1 3QU,ENGLAND	University of Oxford			Platt, Frances/G-1004-2010; Hedestam, Gunilla Karlsson/AAN-9616-2021	Platt, Frances/0000-0001-7614-0403				ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; DATEMA R, 1982, P NATL ACAD SCI-BIOL, V79, P6787, DOI 10.1073/pnas.79.22.6787; DATEMA R, 1987, PHARMACOL THERAPEUT, V33, P221, DOI 10.1016/0163-7258(87)90066-0; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DEDERA D, 1990, AIDS RES HUM RETROV, V6, P785, DOI 10.1089/aid.1990.6.785; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17; FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6; FODDY L, 1988, EUR J BIOCHEM, V175, P291, DOI 10.1111/j.1432-1033.1988.tb14196.x; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GEYER H, 1988, J BIOL CHEM, V263, P11760; GRINNA LS, 1979, J BIOL CHEM, V254, P8814; GROSS V, 1983, J BIOL CHEM, V258, P2203; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUGHES RC, 1987, BIOCHEM J, V247, P537, DOI 10.1042/bj2470537; JACOB GS, 1992, IN PRESS NATURAL PRO; KARLSSON GB, 1991, ANAL BIOCHEM, V199, P219, DOI 10.1016/0003-2697(91)90093-9; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229; KOBATA A, 1987, METHOD ENZYMOL, V138, P779; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LEE WR, 1992, J VIROL, V66, P1799, DOI 10.1128/JVI.66.3.1799-1803.1992; LEMANSKY P, 1984, J BIOL CHEM, V259, P129; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599; Mizuochi T, 1988, Biomed Chromatogr, V2, P260; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; PLATT FM, 1992, EUR J BIOCHEM, V208, P187, DOI 10.1111/j.1432-1033.1992.tb17173.x; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RATNER L, 1991, VIROLOGY, V181, P180, DOI 10.1016/0042-6822(91)90483-R; REARICK JI, 1981, J BIOL CHEM, V256, P6255; ROMERO PA, 1986, J BIOL CHEM, V261, P5936; ROMERO PA, 1983, VIROLOGY, V130, P238, DOI 10.1016/0042-6822(83)90133-2; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; TAN A, 1991, J BIOL CHEM, V266, P14504; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; WILLEY RL, 1986, P NATL ACAD SCI USA, V83, P5033; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199	46	170	175	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					570	576						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416962				2022-12-25	WOS:A1993KE60300086
J	PORTER, DJT				PORTER, DJT			S-ADENOSYLHOMOCYSTEINE HYDROLASE - STEREOCHEMISTRY AND KINETICS OF HYDROGEN TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INHIBITORS; L-HOMOCYSTEINE HYDROLASE; NEPLANOCIN-A; NUCLEOSIDE ANALOGS; RAT-LIVER; INACTIVATION; 2'-DEOXYADENOSINE; CELLS; ENZYME; POTENT	The stereochemistry and kinetics for hydrogen transfer to the catalytically essential NAD+ of S-adenosylhomocysteine hydrolase (SAHase) have been determined for selected adenosine analogues. Reduced SAHase (E(NADH)), which was made by reconstituting apoSAHase with NADH, stereospecifically transferred the pro-R hydrogen of NADH to 3'-ketoadenosine, a proposed reaction intermediate. Reduction of SAHase by 5'-deoxyadenosine, alpha-L-lyxofuranosyladenine, or adenosine-5'-carboxylate quenched the intrinsic protein fluorescence and increased the absorbance of the enzyme at 330 nm. The kinetics for reduction were consistent with a two-step mechanism [GRAPHICS] where E.L was an initial complex between ligand (L) and enzyme (E), and E'.L' was a complex between reduced enzyme and oxidized ligand. Initial complex formation between SAHase and alpha-L-lyxofuranosyladenine (k-1/k1 = 22.6 muM) was too rapid to be followed by stopped-flow spectrofluorometry at 25-degrees-C. The first-order rate constants for reduction (k2) and oxidation (k-2) of the enzyme were 7.7 and 0.22 s-1, respectively. The dissociation constant for initial complex formation between 5'-deoxyadenosine and SAHase was 24 muM; k2 and k-2 were 8.4 x 10(-3) and 4.2 x 10(-3) s-1, respectively. The association rate constant for binding of adenosine-5'-carboxylate to SAHase (k1) was 2.1 x 10(5) M-1 s-1, and the dissociation rate constant (k-1) was 0.15 s-1; k2 and k-2 were 0.1 and 0.15 s-1, respectively. The association rate constant for adenine was 5.5 x 10(6) M-1 s-1, and the dissociation rate constant was 6.4 s-1.			PORTER, DJT (corresponding author), BURROUGHS WELLCOME CO,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							ABELES RH, 1980, BIOCHEM BIOPH RES CO, V95, P612, DOI 10.1016/0006-291X(80)90829-3; ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; Bevington P. R., 1969, DATA REDUCTION ERROR; BORCHARDT RT, 1984, J BIOL CHEM, V259, P4353; BORCHERDING DR, 1988, J MED CHEM, V31, P1729, DOI 10.1021/jm00117a011; CHIANG PK, 1981, ARCH BIOCHEM BIOPHYS, V207, P175, DOI 10.1016/0003-9861(81)90023-0; CREWS RP, 1983, NUCLEOS NUCLEOT, V2, P275, DOI 10.1080/07328318308078861; DECLERCQ E, 1989, BIOCHEM PHARMACOL, V38, P1771, DOI 10.1016/0006-2952(89)90411-5; DELAHABA G, 1986, BIOCHEMISTRY-US, V25, P8337, DOI 10.1021/bi00373a031; GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; KIM IY, 1985, BIOCHIM BIOPHYS ACTA, V829, P150, DOI 10.1016/0167-4838(85)90183-9; MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021; MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265; MCCARTHY JR, 1989, J AM CHEM SOC, V111, P1127, DOI 10.1021/ja00185a052; MERTA A, 1983, COLLECT CZECH CHEM C, V48, P2701, DOI 10.1135/cccc19832701; NARAYANAN SR, 1988, J MED CHEM, V31, P500, DOI 10.1021/jm00398a002; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PARRY RJ, 1985, J AM CHEM SOC, V107, P1417, DOI 10.1021/ja00291a055; PARRY RJ, 1991, BIOCHEMISTRY-US, V30, P9988, DOI 10.1021/bi00105a025; PORTER DJT, 1992, J BIOL CHEM, V267, P3205; PORTER DJT, 1991, J BIOL CHEM, V266, P21616; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P5100, DOI 10.1021/bi00642a024; STIPANUK MH, 1986, ANNU REV NUTR, V6, P179, DOI 10.1146/annurev.nu.06.070186.001143; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TSENG CKH, 1989, J MED CHEM, V32, P1442, DOI 10.1021/jm00127a007; WANG SF, 1970, J BIOL CHEM, V245, P8; WOLFSON G, 1986, J BIOL CHEM, V261, P4492; YOU KS, 1982, METHOD ENZYMOL, V87, P101; 1961, OR18 PABST LAB CIRC, P2	35	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					66	73						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416969				2022-12-25	WOS:A1993KE60300012
J	TAUSSIG, R; QUARMBY, LM; GILMAN, AG				TAUSSIG, R; QUARMBY, LM; GILMAN, AG			REGULATION OF PURIFIED TYPE-I AND TYPE-II ADENYLYLCYCLASES BY G-PROTEIN BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION VECTORS; ADENYLATE-CYCLASE; BOVINE BRAIN; PURIFICATION; AFFINITY; CHANNEL; CLONING	Type I and type II adenylylcyclases have been purified after expression in Sf9 cells, each by application of a two-step purification protocol. The specific activities of the essentially homogeneous enzymes are approximately 7 and 2 mumol.min-1.mg-1, respectively. Each purified enzyme preparation is activated by G(salpha), but they are regulated in an opposite fashion by G protein betagamma subunits. Purified betagamma inhibits G(salpha)-stimulated type I adenylylcyclase directly, while betagamma activates type II adenylylcyclase and potentiates the G(salpha)-mediated stimulation of the enzyme. This is the first demonstration of the activation of a purified effector molecule by G protein betagamma subunits.			TAUSSIG, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Quarmby, Lynne/0000-0001-6661-680X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOCHST H, 1988, J VAC SCI TECHNOL B, V6, P1320, DOI 10.1116/1.584257; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PFEUFFER T, 1982, FEBS LETT, V146, P369, DOI 10.1016/0014-5793(82)80955-1; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	25	208	213	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					9	12						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416978				2022-12-25	WOS:A1993KE60300003
J	PRICE, MG; GOMER, RH				PRICE, MG; GOMER, RH			SKELEMIN, A CYTOSKELETAL M-DISC PERIPHERY PROTEIN, CONTAINS MOTIFS OF ADHESION RECOGNITION AND INTERMEDIATE FILAMENT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL CELL-ADHESION; AMINO-ACID-SEQUENCE; LIGHT CHAIN KINASE; MOLECULE N-CAM; IMMUNOGLOBULIN-LIKE DOMAINS; SECONDARY-STRUCTURE; MESSENGER-RNA; SUPERFAMILY; MUSCLE; FIBRONECTIN	In striated muscle, myofibrils are anchored to an interconnecting cytoskeleton of desmin intermediate filaments. Skelemin (195 kDa) may be a link between myofibrils and the intermediate filament cytoskeleton. Skelemin partitions with desmin to the insoluble cytoskeleton, and increases the thickness of reconstituted intermediate filaments. Concentrated at the M-disc periphery, skelemin may also contact myosin filaments. We used immunoscreening to isolate a mouse muscle cDNA which encodes a protein with a calculated molecular mass of 185 kDa. Anti-skelemin antibodies bound to the protein products of each of three nonoverlapping regions of the open reading frame. Antibodies directed against the protein products of each one-third of the cDNA react with a 195-kDa muscle protein and stain the M-disc indistinguishably from the original anti-skelemin antibodies, suggesting that the cDNA encodes skelemin. A single skelemin mRNA is detected in muscle but not non-muscle tissues, consistent with immunostaining results. Skelemin is a member of a family of myosin-associated proteins containing fibronectin type III and immunoglobulin superfamily C2 motifs. Skelemin is unique in this family in having intermediate filament core-like motifs, one near each terminus. We hypothesize that skelemin could interact with myosin or myosin-associated proteins through its fibronectin and/or immunoglobulin motifs, and with intermediate filaments through intermediate filament-like motifs.	RICE UNIV, HOWARD HUGHES MED INST, HOUSTON, TX 77251 USA	Howard Hughes Medical Institute; Rice University	PRICE, MG (corresponding author), RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA.			Gomer, Richard/0000-0003-2361-4307				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BAIROCH A, 1989, PROSITE DICT PROTEIN; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; CUNNINGHAM BA, 1988, ADV CELL BIOL, V2, P25; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FISCHMAN DA, 1991, INT CONGR SER, P211; Fraser R.D.B., 1990, CELLULAR MOL BIOL IN, P205; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FRITZ JD, 1991, NUCLEIC ACIDS RES, V19, P3747, DOI 10.1093/nar/19.13.3747; FRYBERG CC, 1992, P ROY SOC LOND B BIO, V249, P33; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GOUDIE RB, 1966, LANCET, V2, P1224; GRANZIER HLM, 1993, J GEN PHYSIOL, V101, P235, DOI 10.1085/jgp.101.2.235; GRODBERG J, 1988, NUCLEIC ACIDS RES, V16, P1209, DOI 10.1093/nar/16.3.1209; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; HALL AK, 1990, J CELL BIOL, V110, P817, DOI 10.1083/jcb.110.3.817; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P3037, DOI 10.1073/pnas.83.9.3037; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; Hynes RO, 1990, FIBRONECTINS; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY A, 1990, EMBO J, V9, P3459, DOI 10.1002/j.1460-2075.1990.tb07554.x; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LAZARIDES E, 1986, MOL BIOL MUSCLE DEV, P749; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; MCCORMICK MB, 1991, J CELL BIOL, V113, P1111, DOI 10.1083/jcb.113.5.1111; MCGRAW RA, 1990, BIOTECHNIQUES, V8, P674; MONROY AF, 1988, FOCUS, V10, P14; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; ODERMATT E, 1989, FIBRONECTIN, P25; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIEROBONBORMIOLI S, 1981, J MUSCLE RES CELL M, V2, P401, DOI 10.1007/BF00711967; Price M.G., 1983, Cell and Muscle Motility, V3, P1; PRICE MG, 1989, CELL MOTIL CYTOSKEL, V13, P274, DOI 10.1002/cm.970130406; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1984, AM J PHYSIOL, V246, pH566, DOI 10.1152/ajpheart.1984.246.4.H566; PRICE MG, 1991, ADV STRUCTURAL BIOL, V1, P175; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; Rutishauser U, 1989, CURR OPIN CELL BIOL, V1, P898, DOI 10.1016/0955-0674(89)90056-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEVEN AC, 1990, CELLULAR MOL BIOL IN, P233; STREET SF, 1983, J CELL PHYSIOL, V114, P346, DOI 10.1002/jcp.1041140314; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; THORNELL LE, 1990, DEVELOPMENTAL CARDIOLOGY, P115; THORNELL LE, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P369; TRINICK J, 1992, FEBS LETT, V307, P44, DOI 10.1016/0014-5793(92)80899-R; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; Wang K, 1985, Cell Muscle Motil, V6, P315; WANG K, 1983, J CELL BIOL, V96, P562, DOI 10.1083/jcb.96.2.562; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YUEN SW, 1989, BIOTECHNIQUES, V7, P74; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	109	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21800	21810						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408035				2022-12-25	WOS:A1993MC80900058
J	FRANKLIN, AA; KUBIK, MF; UITTENBOGAARD, MN; BRAUWEILER, A; UTAISINCHAROEN, P; MATTHEWS, MAH; DYNAN, WS; HOEFFLER, JP; NYBORG, JK				FRANKLIN, AA; KUBIK, MF; UITTENBOGAARD, MN; BRAUWEILER, A; UTAISINCHAROEN, P; MATTHEWS, MAH; DYNAN, WS; HOEFFLER, JP; NYBORG, JK			TRANSACTIVATION BY THE HUMAN T-CELL LEUKEMIA-VIRUS TAX PROTEIN IS MEDIATED THROUGH ENHANCED BINDING OF ACTIVATING TRANSCRIPTION FACTOR-II (ATF-2) ATF-2 RESPONSE AND CAMP ELEMENT-BINDING PROTEIN (CREB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; LEUCINE ZIPPER STRUCTURE; HTLV-I; CYCLIC-AMP; 21-BASE-PAIR REPEATS; RNA-POLYMERASE; NUCLEAR FACTOR; KINASE-A; GENE; IDENTIFICATION	The human T-cell leukemia virus type I (HTLV-I)-encoded transcriptional activator protein Tax is strongly implicated in HTLV-I pathogenesis. Tax regulates HTLV-I gene expression through three 21-base pair (bp) repeat enhancer elements located in the transcriptional control region of the virus. Tax does not bind these elements directly, but mediates transactivation through the cellular transcription factors that recognize a cAMP response element (CRE)-like sequence centered within each of the 21-bp repeats. In this report, we identify activating transcription factor-2 (ATF-2) and CRE-binding protein (CREB) as the principal T-cell proteins that bind the three 21-bp repeats in vitro. Purified Tax protein augments the level of RNA synthesis induced by ATF-2 and CREB in a cell-free transcription assay, providing evidence that Tax cooperates with these cellular proteins to activate HTLV-I transcription. Furthermore, Tax dramatically increases the binding of both the T-cell-derived and recombinant forms of ATF-2 and CREB to each of the 21-bp repeats. The target sequences for this enhancement reside within the DNA binding/dimerization domains of these proteins. These data suggest that Tax transactivates HTLV-I gene expression by increasing the number of bound ATF-2 and CREB molecules at the viral promoter.	COLORADO STATE UNIV, DEPT BIOCHEM, FT COLLINS, CO 80523 USA; COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; UNIV COLORADO, HLTH SCI CTR, DIV MED ONCOL, DENVER, CO 80262 USA	Colorado State University; Colorado State University; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Dynan, William/0000-0002-4045-5662	NATIONAL CANCER INSTITUTE [R55CA055035] Funding Source: NIH RePORTER; NCI NIH HHS [1 R55 CA55035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BEIMLING P, 1992, ONCOGENE, V7, P257; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HJELLE B, 1991, ARCH PATHOL LAB MED, V115, P440; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JEANG KT, 1987, J VIROL, V61, P708, DOI 10.1128/JVI.61.3.708-713.1987; KADISON P, 1990, J VIROL, V64, P2141, DOI 10.1128/JVI.64.5.2141-2148.1990; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; NIKI M, 1992, J VIROL, V66, P4348, DOI 10.1128/JVI.66.7.4348-4357.1992; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	37	160	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21225	21231						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407959				2022-12-25	WOS:A1993MA28800086
J	HOWE, LR; MARSHALL, CJ				HOWE, LR; MARSHALL, CJ			LYSOPHOSPHATIDIC ACID STIMULATES MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION VIA A G-PROTEIN-COUPLED PATHWAY REQUIRING P21(RAS) AND P74(RAF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHEROMONE RESPONSE PATHWAY; THREONINE TYROSINE KINASE; MAP KINASE; C-MYC; CELL-PROLIFERATION; SKELETAL-MUSCLE; GROWTH-FACTORS; S6 KINASE; PHOSPHORYLATION; RAS	Activation of tyrosine kinase receptors causes mitogen-activated protein (MAP) kinase stimulation via a pathway involving p21ras, p74raf-1 (acting as a MAP kinase kinase kinase), and MAP kinase kinases; however, the pathway by which heterotrimeric G-protein-coupled receptors activate MAP kinases is undefined. Since there are several MAP kinase kinase kinases it has been suggested that p74raf-1 may only couple tyrosine kinase receptors to MAP kinase activation. We therefore investigated the requirement for p21ras and p74raf-1 in G-protein receptor-mediated MAP kinase activation. Lysophosphatidic acid stimulates MAP kinase via a pertussis toxin-sensitive pathway, which is blocked by dominant negative Ras. Lysophosphatidic acid-stimulated MAP kinase activation is potentiated by overexpression of p74raf-1 and blocked by expression of a dominant negative Raf protein comprising the N-terminal 259 amino acids. We conclude that lysophosphatidic acid activates MAP kinases by a G-protein-coupled pathway that requires both p21ras and p74raf-1.	INST CANC RES, CHESTER BEATTY LABS, 237 FULHUM RD, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Howe, Louise/0000-0002-1468-7136				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI CCH, 1993, ONCOGENE, V8, P1685; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SETH A, 1991, J BIOL CHEM, V266, P23521; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	52	240	242	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20717	20720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407893				2022-12-25	WOS:A1993MA28800010
J	JANSEN, MAK; DEPKA, B; TREBST, A; EDELMAN, M				JANSEN, MAK; DEPKA, B; TREBST, A; EDELMAN, M			ENGAGEMENT OF SPECIFIC SITES IN THE PLASTOQUINONE NICHE REGULATES DEGRADATION OF THE D1 PROTEIN IN PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIZED 32-KILODALTON PROTEIN; PHOTOSYNTHETIC REACTION CENTER; REACTION CENTER POLYPEPTIDES; CHLOROPLAST MEMBRANE; THYLAKOID MEMBRANE; D1-PROTEIN DEGRADATION; INVIVO DEGRADATION; HERBICIDE BINDING; QB SITE; PHOTOINHIBITION	Rapid degradation of the photosystem-II reaction center protein, D1, is driven by visible and ultraviolet irradiance at low photon-flux in the intact plant. We find that all inhibitors of electron flow that replace bound plastoquinone (Q(B)) from its niche on D1 inhibit UV-B-driven D1 degradation, but only some inhibit visible light-driven degradation. Stabilization of the D1 protein by nitrophenol type inhibitors in visible light depends on the dimensions of the side chain at position 6 of the phenyl ring. Likewise, resistance to trypsinization of D1 at Arg-238 and to electron flow inhibitors in D1 mutant V219I (but not A251V, F255Y, S264A, or L275F) are functions of position 6 side chain dimensions in isolated thylakoids. We conclude that the configuration of the Q(B) niche controls D1 protein degradation in intact plants under physiological photon flux. This is true irrespective of the spectral quality of radiation driving degradation. We show that UV-B-driven D1 protein degradation, but not that driven by visible light, requires plastoquinone in the Q(B) niche to proceed. D1 degradation in visible light occurs as long as specific regions at the end of helix D and in the D-de loop of the protein are not engaged. These regions, through substrate (i.e. Q(B))-mediated stabilization, are proposed to regulate rapid degradation of the D1 protein.	RUHR UNIV BOCHUM,DEPT BIOL,W-4630 BOCHUM 1,GERMANY	Ruhr University Bochum	JANSEN, MAK (corresponding author), WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL.			Jansen, Marcel/0000-0003-2014-5859				ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; BARBATO R, 1991, FEBS LETT, V290, P162, DOI 10.1016/0014-5793(91)81250-C; CRAMER WA, 1985, TRENDS BIOCHEM SCI, V10, P125, DOI 10.1016/0968-0004(85)90273-7; Crosby D G, 1976, HERBICIDES CHEM DEGR, V2, P835; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DOSTATNI R, 1988, FEBS LETT, V239, P207, DOI 10.1016/0014-5793(88)80918-9; GALLOWAY RE, 1984, PLANT PHYSIOL, V74, P469, DOI 10.1104/pp.74.3.469; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GIARDI MT, 1988, BIOCHIM BIOPHYS ACTA, V934, P64, DOI 10.1016/0005-2728(88)90120-X; GONG H, 1991, J BIOL CHEM, V266, P21293; GOUNARIS K, 1987, FEBS LETT, V211, P94, DOI 10.1016/0014-5793(87)81281-4; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; GRESSEL J, 1985, WEED PHYSL, V2, P159; HOFFMANFALK H, 1982, J BIOL CHEM, V257, P4583; JANSEN MAK, 1990, Z NATURFORSCH C, V45, P408; JANSEN MAK, 1990, Z NATURFORSCH C, V45, P97; JANSEN MAK, 1992, REGULATION CHLOROPLA, P295; KLESS H, 1992, BIOCHEMISTRY-US, V31, P11065, DOI 10.1021/bi00160a016; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MARDER JB, 1987, PLANT MOL BIOL, V9, P325, DOI 10.1007/BF00014907; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OHAD N, 1990, Z NATURFORSCH C, V45, P402; ROCHAIX JD, 1988, TRENDS BIOCHEM SCI, V13, P56, DOI 10.1016/0968-0004(88)90029-1; ROCHAIX JD, 1984, PLANT MOL BIOL, V3, P363, DOI 10.1007/BF00033383; SOPORY SK, 1990, Z NATURFORSCH C, V45, P412; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; TREBST A, 1991, Z NATURFORSCH C, V46, P557; TREBST A, 1986, Z NATURFORSCH C, V41, P240; TREBST A, 1986, PHOTOSYNTH RES, V10, P381, DOI 10.1007/BF00118304; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; TREBST A, 1979, ADV PESTIC SCI, V2, P223; TREBST A, 1993, IN PRESS PHYTOCHEMIS; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VIRGIN I, 1991, FEBS LETT, V287, P125, DOI 10.1016/0014-5793(91)80031-W; WETTERN M, 1984, ISRAEL J BOT, V33, P253; WILDNER GF, 1990, Z NATURFORSCH C, V45, P1142	44	70	70	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21246	21252						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407962				2022-12-25	WOS:A1993MA28800089
J	KAPRONBRAS, C; FITZGIBBON, L; JEEVARATNAM, P; WILKINS, J; DEDHAR, S				KAPRONBRAS, C; FITZGIBBON, L; JEEVARATNAM, P; WILKINS, J; DEDHAR, S			STIMULATION OF TYROSINE PHOSPHORYLATION AND ACCUMULATION OF GTP-BOUND P21(RAS) UPON ANTIBODY-MEDIATED ALPHA-2-BETA-1 INTEGRIN ACTIVATION IN T-LYMPHOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; BETA-1 INTEGRINS; ANTIGEN RECEPTOR; FIBRONECTIN; ADHESION; PROTEIN; EXPRESSION; KINASE	Integrins are a family of heterodimeric integral plasma membrane proteins that behave as receptors for components of the extracellular matrix and also mediate cell to cell adhesion. Occupation of integrins can result in the transduction of intracellular signals, leading to cytoskeletal reorganization, tyrosine phosphorylation, and induction of gene expression. We report here that the ligation of alpha2beta1 integrin by collagen-adhesion stimulatory anti-alpha2 and anti-beta1 antibodies resulted in the accumulation of p21ras in the active GTP-bound state in Jurkat T-lymphoblastoid cells. The activation was accompanied by the tyrosine phosphorylation of proteins of 47-52 kDa. This stimulation of tyrosine phosphorylation and p21ras activation was specific for the activating antibodies and occurred within 2 min of the addition of these antibodies. Although treatment of the cells with the protein kinase C activator, phorbol 12-myristate 13-acetate also resulted in an induction of both cell attachment to collagen and of p21ras activation, tyrosine phosphorylation was not observed. These results demonstrate that alpha2beta1 integrin activation can result in the specific stimulation of tyrosine phosphorylation of 47-52-kDa proteins, as well as activation of a signaling pathway involving p21ras.	SUNNYBROOK HLTH SCI CTR, DEPT CANC RES,REICHMANN RES BLDG,S-218, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA; RDU RES LAB, DEPT MED, WINNIPEG R3A 1M4, MB, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Dedhar, Shoukat/0000-0003-4355-1657				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DEDHAR S, 1990, BIOESSAYS, V12, P583, DOI 10.1002/bies.950121205; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; Dedhar Shoukat, 1993, Molecular and Cellular Differentiation, V1, P1; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P390; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OLIVIER J, 1993, CELL, P179; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; YAMADA A, 1991, J IMMUNOL, V146, P53; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	42	125	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20701	20704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407889				2022-12-25	WOS:A1993MA28800006
J	MATSUSHITA, N; SOGAWA, K; EMA, M; YOSHIDA, A; FUJIIKURIYAMA, Y				MATSUSHITA, N; SOGAWA, K; EMA, M; YOSHIDA, A; FUJIIKURIYAMA, Y			A FACTOR-BINDING TO THE XENOBIOTIC RESPONSIVE ELEMENT (XRE) OF P-4501A1 GENE CONSISTS OF AT LEAST 2 HELIX-LOOP-HELIX PROTEINS, AH RECEPTOR AND ARNT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PLANAR AROMATIC-COMPOUNDS; DIOXIN RECEPTOR; REGULATORY ELEMENTS; INDUCIBLE EXPRESSION; LEVEL EXPRESSION; DNA INTERACTIONS; RNA-POLYMERASE; CLONING; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN	Xenobiotic responsive element (XRE) is an inducible enhancer element that drives inducible expression of P-4501A1 gene in response to xenobiotic inducers. The XRE-binding factor appears in the nuclei of Hepa-1 cells treated with 3-methylcholanthrene (3-MC). Association of the Ah receptor and Arnt (Ah receptor nuclear translocator) in an XRE-binding complex was examined by anti-Ah receptor and Arnt antibodies. Both antibodies inhibited the sequence-specific XRE-binding activity of nuclear extracts from 3-MC-treated Hepa-1 cells and of the cytosolic fraction which was prepared from the nontreated cells and treated in vitro with 3-MC. These results indicate that Ah receptor and Arnt proteins are components of the XRE-binding factor and suggest that Arnt as well as the Ah receptor are localized in the cytosol of nontreated cells. The Ah receptor present in C4 cells, a mutant of Hepa-1 cells defective in the Arnt function, showed an inducer-dependent association with Arnt synthesized in an in vitro translation system. Co-transfection of the expression plasmids of the Ah receptor and Arnt exhibited synergistically more activated transcription from a reporter gene pMC6.3k consisting of the P-4501A1 gene promoter and enhancer than transfection with either of the two plasmids alone. These findings indicate that the Ah receptor and Arnt proteins form a complex that activates transcription in an inducer-dependent manner.	TOHOKU UNIV,FAC SCI,DEPT CHEM,SENDAI,MIYAGI 980,JAPAN; NAGOYA UNIV,DEPT AGR CHEM,NAGOYA,AICHI 464,JAPAN	Tohoku University; Nagoya University				Ema, Masatsugu/0000-0003-0645-6183				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	31	146	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21002	21006						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407937				2022-12-25	WOS:A1993MA28800057
J	WANG, JP; NEEDLEMAN, DH; HAMILTON, SL				WANG, JP; NEEDLEMAN, DH; HAMILTON, SL			RELATIONSHIP OF LOW-AFFINITY [H-3] RYANODINE BINDING-SITES TO HIGH-AFFINITY SITES ON THE SKELETAL-MUSCLE CA(2+) RELEASE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED RYANODINE RECEPTOR; SARCOPLASMIC-RETICULUM; CA-2+ RELEASE; H-3 RYANODINE; FUNCTIONAL-STATE; PURIFICATION; PROBE	Both high and low affinity binding sites for [H-3]ryanodine exist in sarcoplasmic reticulum membranes derived from rabbit skeletal muscle. Negatively cooperative binding of [H-3]ryanodine at one of four initially identical sites cannot account for some of the kinetic features of the binding to high and low affinity sites. The presence of excess unlabeled ryanodine greatly slows the rate at which [H-3]ryanodine bound at the high affinity site dissociates. An examination of the rate of dissociation of [H-3]ryanodine bound at increasing [H-3]ryanodine concentrations reveals the existence of a second site, occupied only at high ligand concentrations. The occupation of this site correlates well with the conversion of the high affinity site from a site with a dissociation rate constant of approximately 0.0025 min-1 to one with a dissociation rate constant of less than 0.00025 min-1. The low affinity site itself has a dissociation rate constant of 0.013 min-1 and dissociation from this site is unaffected by the presence of 100 muM unlabeled ryanodine. These data suggest that the two binding sites are different but are either allosterically or sterically coupled. Association experiments support this interpretation. Low affinity binding sites for [H-3]ryanodine exist in transverse tubule (t-tubule) as well as sarcoplasmic reticulum membranes. High concentrations of both ryanodine and ruthenium red inhibit the binding of [H-3]PN200-110 to the dihydropyridine-binding protein in t-tubule membranes. Whether the low affinity site in t-tubule membranes is related to that found in sarcoplasmic reticulum membranes is not yet known.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044, R01HL037028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR041729, R01AR041729] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-37028, HL-37044] Funding Source: Medline; NIAMS NIH HHS [AR-41729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUCK E, 1982, J BIOL CHEM, V267, P23560; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CHU A, 1990, MOL PHARMACOL, V37, P735; EMMICK JT, 1993, BIOPHYS J A; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SUKHAREVA M, 1993, BIOPHYS J A; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	22	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20974	20982						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407933				2022-12-25	WOS:A1993MA28800053
J	IACOVELLI, L; FALASCA, M; VALITUTTI, S; DARCANGELO, D; CORDA, D				IACOVELLI, L; FALASCA, M; VALITUTTI, S; DARCANGELO, D; CORDA, D			GLYCEROPHOSPHOINOSITOL 4-PHOSPHATE, A PUTATIVE ENDOGENOUS INHIBITOR OF ADENYLYLCYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRTL-5 THYROID-CELLS; GTP-BINDING-PROTEINS; MURINE SARCOMA-VIRUS; ADENYLATE-CYCLASE ACTIVITY; EPITHELIAL-CELLS; PERTUSSIS TOXIN; IODIDE EFFLUX; ALPHA-1-ADRENERGIC RECEPTORS; ADRENERGIC-RECEPTOR; SIGNAL TRANSDUCTION	In a continuous line of rat thyroid cells transformed by the k-ras oncogene (KiKi), the expression of ras-p21 correlates with an increased activity of a phosphoinositide-specific phospholipase A2, which leads to elevated levels of glycerophosphoinositols. In this study we have characterized the biological activities of these compounds. Growth and differentiation in thyroid cells are mainly regulated by the activation of adenylylcyclase. Therefore, we have studied the effects of glycerophosphoinositols on the activity of this enzyme using a normal thyroid cell line (FRTL5). Micromolar concentrations of glycerophosphoinositol 4-phosphate (GroPIns-4-P) caused a approximately 50% inhibition of the adenylylcyclase activity in FRTL5 membranes stimulated by the GTP-binding protein activator fluoroaluminate. Similar concentrations of GroPIns-4-P were detected in KiKi cells but not in the normal FRTL5 line. Micromolar GroPIns-4-P was found to be taken up by intact FRTL5 cells and to induce nearly 50% inhibition of the thyrotropin- and cholera toxin-induced increase in cAMP levels. Similar results were also observed in other cell lines (smooth muscle, pituitary cells, and pneumocytes). GroPIns-4-P inhibited cAMP-dependent cellular functions such as iodide uptake and thymidine incorporation in FRTL5 cells when stimulated by thyrotropin and cholera toxin but not when induced by forskolin. These results are consistent with GroPIns-4-P exerting an inhibitory effect on the GTP-binding protein that stimulates adenylylcyclase. We propose that GroPIns-4-P might mediate a mechanism of cross-talk between adenylylcyclase and phospholipase A2 in thyroid as well as in other cell systems.			IACOVELLI, L (corresponding author), CONSORZIO MARIO NEGRI SUD,IST RIC FARMACOL MARIO NEGRI,CELLULAR & MOLEC ENDOCRINOL LAB,VIA NAZL,I-66030 SANTA MARIA IMBAR,ITALY.		Corda, Daniela/K-6385-2016; Valitutti, Salvatore/M-2999-2014; D'Arcangelo, Daniela/K-6533-2016; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Valitutti, Salvatore/0000-0002-6432-4421; D'Arcangelo, Daniela/0000-0002-7862-3289; Falasca, Marco/0000-0002-9801-7235				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL5 TODAY; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CORDA D, 1987, EUR J BIOCHEM, V166, P475, DOI 10.1111/j.1432-1033.1987.tb13540.x; CORDA D, 1985, J BIOL CHEM, V260, P9230; CORDA D, 1989, ADV EXP MED BIOL, V261, P245; CORDA D, 1985, P NATL ACAD SCI USA, V82, P8677, DOI 10.1073/pnas.82.24.8677; CORDA D, 1986, BIOCHEM BIOPH RES CO, V141, P1000, DOI 10.1016/S0006-291X(86)80143-7; CORDA D, 1992, HDB EXPT PHARM GTPAS; DIGIROLAMO M, 1992, J BIOL CHEM, V267, P17397; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; DIMARZO V, 1991, LIFE SCI, V49, P247, DOI 10.1016/0024-3205(91)90011-Y; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCOCCI C, 1988, ENDOCRINOLOGY, V123, P1705, DOI 10.1210/endo-123-4-1705; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MORGAN RO, 1988, PROG HPLC, V3, P27; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; TAHARA K, 1991, J BIOL CHEM, V266, P440; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VITTI P, 1982, P NATL ACAD SCI-BIOL, V79, P1525, DOI 10.1073/pnas.79.5.1525; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090	43	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20402	20407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397204				2022-12-25	WOS:A1993LY01900072
J	VOISIN, T; BENS, M; CLUZEAUD, F; VANDEWALLE, A; LABURTHE, M				VOISIN, T; BENS, M; CLUZEAUD, F; VANDEWALLE, A; LABURTHE, M			PEPTIDE YY RECEPTORS IN THE PROXIMAL TUBULE PKSV-PCT CELL-LINE DERIVED FROM TRANSGENIC MICE - RELATION WITH CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-Y; ADENYLATE-CYCLASE; SMALL-INTESTINE; RABBIT KIDNEY; CROSS-LINKING; GI-PROTEIN; INHIBITION; MEMBRANES; BINDING; RELEASE	Receptors for peptide YY (PYY) were identified in the PKSV-PCT renal proximal tubule cell line, derived from transgenic mice (SV40 large T antigen under the control of the rat L-type pyruvate kinase 5'-regulatory sequence). Binding of [I-125-Tyr36]monoiodo-PYY ([I-125] PYY to cell was specific, saturable, and reversible. The order of potency for peptides for inhibiting [I-125]PYY binding was: PYY > neuropeptide Y (NPY) = PYY(13-36) >> pancreatic polypeptide. A single class of receptors was observed with a K(d) of 0.37 +/- 0.05 nm and a B(max) of 103 +/- 10 fmol/mg protein. After cross-linking, electrophoresis of covalent [I-125]pyy-receptor complexes revealed a single band of M(r) 50,000. PYY receptors were exclusively present at the basolateral membrane surface of polarized cells and were coupled negatively to adenylylcyclase by a pertussis toxin-sensitive G protein. PKSV-PCT cell growth and T antigen expression could be modulated by D-glucose in the medium. PYY receptors were exclusively expressed in proliferative cells cultured in the presence of D-glucose. PYY receptors disappeared in the absence of D-glucose and were expressed again when proliferation was activated by reintroduction of D-glucose. PYY stimulated cell growth (17-26% increase) and promoted [methyl-H-3]thymidine incorporation into DNA (64% increase; ED50 = 5 nM PYY) of cells grown in D-glucose-enriched medium. This latter effect of PYY was largely reversed by pretreatment of cells with pertussis toxin. These findings suggest that PYY receptors play a role in epithelial cell growth.	INSERM, U246, UNITE PHYSIOL & PATHOL CELLULAIRE NEPHRON, F-75018 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	VOISIN, T (corresponding author), UNIV PARIS 07, UNITE BIOL & PHYSIOL CELLULES DIGEST, INSERM, U239, F-75018 PARIS, FRANCE.		LABURTHE, Marc/C-1875-2012; voisin, thierry/R-1241-2017	voisin, thierry/0000-0002-4320-5183				ADRIAN TE, 1987, SURGERY, V101, P715; ALLEN LG, 1985, LIFE SCI, V37, P617, DOI 10.1016/0024-3205(85)90428-X; AMIRANOFF B, 1989, J BIOL CHEM, V264, P20714; BALASUBRAMANIAM A, 1990, J BIOL CHEM, V265, P14724; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTIER N, 1993, J CELL SCI, V104, P695; CARTIER N, 1992, ONCOGENE, V7, P1413; CASTAN I, 1992, ENDOCRINOLOGY, V131, P1970, DOI 10.1210/en.131.4.1970; COUVINEAU A, 1992, AM J PHYSIOL, V262, pC1478, DOI 10.1152/ajpcell.1992.262.6.C1478; DILLINGHAM MA, 1989, AM J PHYSIOL, V256, pF408, DOI 10.1152/ajprenal.1989.256.3.F408; GOODLAD RA, 1989, EXPERIENTIA, V45, P168, DOI 10.1007/BF01954862; GOODLAD RA, 1987, GUT, V28, P221, DOI 10.1136/gut.28.Suppl.221; HACKENTHAL E, 1987, AM J PHYSIOL, V252, pF543, DOI 10.1152/ajprenal.1987.252.3.F543; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; JONES DR, 1988, FASEB J, V2, pA793; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1990, TRENDS ENDOCRIN MET, V1, P168, DOI 10.1016/1043-2760(90)90031-W; LACAVE R, 1993, J CELL SCI, V104, P705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNYPOURMIR I, 1989, ENDOCRINOLOGY, V124, P2635, DOI 10.1210/endo-124-5-2635; MARTIN MC, 1991, TRENDS PHARMACOL SCI, V10, P389; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; SCHUTZBANK T, 1982, CELL, V30, P481, DOI 10.1016/0092-8674(82)90245-8; SERVIN AL, 1989, ENDOCRINOLOGY, V124, P692, DOI 10.1210/endo-124-2-692; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; SHEIKH SP, 1989, REGUL PEPTIDES, V26, P253, DOI 10.1016/0167-0115(89)90193-6; SHEIKH SP, 1991, J BIOL CHEM, V266, P23959; SHEIKH SP, 1989, AM J PHYSIOL, V257, pF978, DOI 10.1152/ajprenal.1989.257.6.F978; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128; VOISIN T, 1991, J BIOL CHEM, V266, P10762; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; VOISIN T, 1990, ANN NY ACAD SCI, V611, P343; ZUKOWSKAGROJEC Z, 1993, PEPTIDES, V14, P263, DOI 10.1016/0196-9781(93)90040-N; ZWEIBAUM A, 1991, HDB PHYSL, V4, P2223	42	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20547	20554						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397209				2022-12-25	WOS:A1993LY01900090
J	WURGLER, SM; RICHARDSON, CC				WURGLER, SM; RICHARDSON, CC			DNA-BINDING PROPERTIES OF THE DEOXYGUANOSINE TRIPHOSPHATE TRIPHOSPHOHYDROLASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENE 1.2 PROTEIN; BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; DGTP TRIPHOSPHOHYDROLASE; NUCLEIC-ACIDS; MOLECULAR-CLONING; RECA PROTEIN; 32 PROTEIN; REPLICATION; IDENTIFICATION	The dgt gene of Escherichia coli encodes a deoxyguanosine triphosphate triphosphohydrolase (dGTPase) that hydrolyzes dGTP to deoxyguanosine and tripoly-phosphate. The enzyme is highly specific for dGTP which is hydrolyzed with a K(m) of 2-5 muM. Nitrocellulose filter binding assays demonstrate that, under physiological salt conditions, dGTPase binds with apparent cooperativity to single-stranded DNA with an association constant of 7.7 x 10(6) M-1. In the presence of NaCl, dGTPase binds weakly to double-stranded DNA. In the absence of NaCl, dGTPase binds both single- and double-stranded DNA with an association constant of 1 x 10(7) M-1. The dGTPase-double-stranded DNA complex, however, is readily dissociated with NaCl. Divalent cations such as Mg2+ or Mn2+ enhance, but are not required for DNA binding. The presence of dGTP or GTP does not effect the ability of dGTPase to bind DNA. dGTPase binds to oligonucleotides of length 17-35, but with lower affinities. The homopolymers poly(dT) and poly(rU) act as effective competitors of single-stranded DNA for binding to dGTPase. The bacteriophage T7 gene 1.2 protein, which specifically inhibits the enzymatic activity of dGTPase, also prevents dGTPase from binding to single-stranded DNA. dGTPase inhibits the activity of T7 DNA polymerase on a poly(dA)-oligo(dT) template. This inhibition is reversed by prior incubation of dGTPase with the T7 gene 1.2 protein.			WURGLER, SM (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; GAUSS P, 1987, MOL GEN GENET, V206, P24, DOI 10.1007/BF00326532; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600; HUBER HE, 1988, J BIOL CHEM, V263, P13549; JOSSE J, 1966, J BIOL CHEM, V241, P1938; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; Kornberg A, 1992, DNA REPLICATION, P53; KORNBERG SR, 1958, J BIOL CHEM, V233, P159; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MANIATIS T, 1982, MOL CLONING LABORATO, P88; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Moore D.D., 1987, CURRENT PROTOCOLS MO; MYERS JA, 1987, J BIOL CHEM, V262, P5288; NAKAI H, 1990, J BIOL CHEM, V265, P4411; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PRASAD BVV, 1987, J MOL BIOL, V193, P579; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; QUIRK S, 1989, MOL MICROBIOL, V3, P1391, DOI 10.1111/j.1365-2958.1989.tb00121.x; QUIRK S, 1990, GENE, V89, P13, DOI 10.1016/0378-1119(90)90200-B; QUIRK S, 1991, J BACTERIOL, V173, P6665, DOI 10.1128/jb.173.21.6665-6669.1991; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; SAITO H, 1981, J VIROL, V37, P343, DOI 10.1128/JVI.37.1.343-351.1981; SETO D, 1988, J BIOL CHEM, V263, P1494; SMOLARSKY M, 1970, BIOCHIM BIOPHYS ACTA, V199, P447, DOI 10.1016/0005-2787(70)90087-0; SRIVENUGOPAL KS, 1986, BIOCHEM BIOPH RES CO, V137, P795, DOI 10.1016/0006-291X(86)91149-6; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, 1979, J MOL BIOL, V135, P917, DOI 10.1016/0022-2836(79)90520-5; TABOR S, 1990, CURRENT PROTOCOLS MO; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740	51	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20046	20054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397198				2022-12-25	WOS:A1993LY01900022
J	LAMORTE, VJ; KENNEDY, ED; COLLINS, LR; GOLDSTEIN, D; HAROOTUNIAN, AT; BROWN, JH; FERAMISCO, JR				LAMORTE, VJ; KENNEDY, ED; COLLINS, LR; GOLDSTEIN, D; HAROOTUNIAN, AT; BROWN, JH; FERAMISCO, JR			A REQUIREMENT FOR RAS PROTEIN FUNCTION IN THROMBIN-STIMULATED MITOGENESIS IN ASTROCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVATING PROTEIN; RECEPTOR ACTIVATION; TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; GROWTH-FACTORS; DNA-SYNTHESIS; PC12 CELLS; PHOSPHORYLATION	Thrombin stimulation of 1321N1 astrocytoma cells results in polyphosphoinositide hydrolysis, Ca2+ mobilization, AP-1-mediated transcriptional activation, and DNA replication. Thrombin stimulation also activates Ras as assessed by an increase in the proportion of Ras in a GTP bound state. We examined the functional requirement for endogenous Ras protein in mediating thrombin-induced responses. Microinjection of a dominant interfering mutant of H-Ras into 1321N1 cells inhibited DNA synthesis in response to thrombin as did microinjection of an inhibitory antibody to Ras. Stimulation of AP-1-mediated transcriptional activity was also reduced by the expression of interfering Ras mutants. However, neither the stimulation of polyphosphoinositide hydrolysis nor the mobilization of intracellular Ca2+ was dependent on endogenous Ras function. These observations indicate that thrombin stimulation of mitogenesis requires Ras protein function. Our data suggest that the G-protein-coupled thrombin receptor stimulates pathways, which in part are convergent with those stimulated by tyrosine kinase growth factor receptors.	UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego					NCI NIH HHS [CA39811] Funding Source: Medline; NHLBI NIH HHS [HL46345] Funding Source: Medline; NIGMS NIH HHS [GM36927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039811] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JONES LG, 1989, MOL PHARMACOL, V36, P142; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P25423; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P157; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEISS RH, 1993, J BIOL CHEM, V268, P5724; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	50	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19411	19415						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396137				2022-12-25	WOS:A1993LW81900042
J	AHERN, SM; MIYATA, T; SADLER, JE				AHERN, SM; MIYATA, T; SADLER, JE			REGULATION OF HUMAN TISSUE FACTOR EXPRESSION BY MESSENGER-RNA TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; HUMAN VASCULAR ENDOTHELIUM; TUMOR NECROSIS FACTOR; C-FOS; GENE-EXPRESSION; 3T3 CELLS; PROCOAGULANT ACTIVITY; AUTO-REGULATION; PROTO-ONCOGENE; DEGRADATION	Tissue factor serves as the cellular receptor for circulating blood coagulation factor VII and s the principal physiological initiator of blood coagulation. Tissue factor is not normally expressed in cells that contact blood, such as endothelial cells and monocytes, but can be induced in these cells by tumor necrosis factor or tumor-promoting phorbol esters. Following induction, the human tissue factor mRNA is degraded with a half-life of approximately 0.75-1.5 h. The cellular mechanisms responsible for this rapid mRNA turnover were investigated with chimeric tissue factor.beta-globin constructs expressed in stably transfected mouse NIH/3T3 cells. These constructs were expressed with the transiently inducible c-fos promoter which eliminated the need to use transcriptional inhibitors to determine mRNA half-lives. Sequences capable of conferring rapid turnover to the normally stable beta-globin transcript were localized to the last 600 nucleotides of the tissue factor mRNA. The 3' end of this fragment is similar to previously described AU-rich mRNA destabilizing elements. Activity of the tissue factor element was dependent on its specific sequence and not simply a high AU nucleotide content. The degradation of unstable chimeric tissue factor.beta-globin mRNAs was prevented by inhibition of transcription with actinomycin D. Chimeric tissue factor.beta-globin mRNAs were superinduced by the protein synthesis inhibitor cycloheximide, and this superinduction may be due in part to stabilization of the mRNA.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,HOWARD HUGHES MED INST LABS,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NHLBI NIH HHS [HLBI 14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BROCK ML, 1983, J BIOL CHEM, V258, P5449; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARNEIRO M, 1984, J MOL BIOL, V178, P869, DOI 10.1016/0022-2836(84)90316-4; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MOON AM, 1991, BLOOD, V77, P2272; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NAWORTH PP, 1986, J EXP MED, V163, P740; NAWORTH PP, 1986, P NATL ACAD SCI USA, V83, P3460; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WELSH M, 1985, J BIOL CHEM, V260, P3590; WHITTEMORE LA, 1990, MOL CELL BIOL, V64, P1329; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	45	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2154	2159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420984				2022-12-25	WOS:A1993KH62000098
J	FREEZE, HH; SAMPATH, D; VARKI, A				FREEZE, HH; SAMPATH, D; VARKI, A			ALPHA-XYLOSIDE AND BETA-XYLOSIDE ALTER GLYCOLIPID SYNTHESIS IN HUMAN-MELANOMA AND CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBIT GLUCOSYLCERAMIDE SYNTHASE; CHONDROITIN SULFATE PROTEOGLYCAN; EMBRYONIC-CHICKEN CARTILAGE; BREFELDIN-A; PROTEOCHONDROITIN SULFATE; GANGLIOSIDE BIOSYNTHESIS; SUBSTRATE-SPECIFICITY; GOLGI-APPARATUS; D-GALACTOSIDES; UDP-GALACTOSE	Beta-D-xylosides are often used to competitively inhibit proteoglycan synthesis by serving as primers for free glycosaminoglycan (GAG) chain assembly. Quite unexpectedty, we found that when human melanoma cells and Chinese hamster ovary cells are labeled with [H-3] galactose in the presence of 4-methyl umbelliferyl beta-D-xyloside (Xylbeta4MU), a large portion of the labeled acceptor does not consist of the expected GAG chains, but of the novel G(M3) ganglioside-like structure: Sia-alpha2,3-[H-3]Galbeta1,4Xylbeta4MU. Moreover, formation of this derivative is associated with an inhibition of glycosphingolipid synthesis by up to 78% without affecting synthesis of other [H-3]Gal-labeled glycoconjugates. Inhibition occurs rapidly and equally for all glycolipid species and is partially abrogated by brefeldin A. Inhibition requires the addition of a single galactose residue to the xyloside within the lumen of the Golgi apparatus. This addition appears to be carried out by galactosyl transferase I that normally synthesizes the core region of GAG chains. Although alpha-xyloside does not inhibit proteoglycan synthesis, it is galactosylated, but not sialylated, and is nearly as effective as a beta-xyloside at inhibiting glycolipid biosynthesis. Similar results were obtained for human macrophage U937, and differentiated or undifferentiated PC12 cells. However, in neuroblastoma cell tine MR23, no low molecular weight xyloside products were made and glycolipid synthesis was not inhibited. These results suggest that some of the previously documented effects of beta-xylosides might result, in part, from their inhibition of glycolipid synthesis. The mechanism of inhibition is not a direct competition for glycolipid synthesizing enzymes; rather, it is an unexplained result of formation of Galbeta1,4Xyl-1(alpha or beta)4MU.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	FREEZE, HH (corresponding author), LA JOLLA CANC RES FDN, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAWLA D, 1991, BIOCHEM J, V279, P159, DOI 10.1042/bj2790159; COSTER L, 1991, BIOCHEM J, V276, P533, DOI 10.1042/bj2760533; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; ESKO JD, 1987, J BIOL CHEM, V262, P12189; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOLSET SO, 1986, BIOCHEM J, V238, P209, DOI 10.1042/bj2380209; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARGOLIS RK, 1991, J CELL SCI, V99, P237; MELLIS S, 1981, ANAL BIOCHEM, V114, P8398; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PLATT JL, 1987, DEV BIOL, V123, P293, DOI 10.1016/0012-1606(87)90388-5; POTTERPERIGO S, 1992, ARCH BIOCHEM BIOPHYS, V297, P101, DOI 10.1016/0003-9861(92)90646-E; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON HC, 1981, BIOCHEM J, V194, P575, DOI 10.1042/bj1940575; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHOR AM, 1988, IN VITRO CELL DEV B, V24, P659, DOI 10.1007/BF02623603; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHAYMAN JA, 1991, AM J PHYSIOL, V260, pF291, DOI 10.1152/ajprenal.1991.260.3.F291; SHUKLA GS, 1991, J NEUROCHEM, V56, P2125, DOI 10.1111/j.1471-4159.1991.tb03475.x; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; TRICHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	48	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1618	1627						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420936				2022-12-25	WOS:A1993KH62000021
J	LEBLOND, L; MARCEL, YL				LEBLOND, L; MARCEL, YL			UPTAKE OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL ESTER BY HEPG2 CELLS INVOLVES APOLIPOPROTEIN-E LOCALIZED ON THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; RAT HEPATOMA-CELLS; SELECTIVE UPTAKE; MONOCLONAL-ANTIBODIES; HUMAN-PLASMA; A-I; J774 MACROPHAGES; MEDIATED UPTAKE; LINOLEYL ETHER; ADRENAL-CELLS	High density lipoprotein (HDL) cholesterol ester (CE) is taken up by many cells without simultaneous uptake of HDL apoprotein. The studies described herein demonstrate that the selective uptake of cholesterol ester by HepG2 cells is reduced by antibody directed against the receptor-binding domain of apoE (monoclonal antibody (mAb) 1D7) but not by antibody directed against the NH2-terminal portion of the molecule. The reduction, by 1D7, of HDL cholesteryl ester uptake is not due to apoE acquisition by the labeled HDL preparation or by the transfer of [H-3]CE of HDL to apoE-containing lipoproteins and uptake by the apoB/E or apoE receptors. Rather, it appears that mAb 1D7 recognizes apoE localized at the cell surface of HepG2 cells. This conclusion is supported by the fact that: 1) reduction of HDL-CE uptake by HepG2 cells is observed within 15 min after the addition of the antibody-ligand mixture; 2) 1D7 is similarly effective in reducing the selective uptake of HDL-CE when added to the ligand or to the cells; 3) three different anti-apoE mAbs (1D7, 3B7, and 3H1) bind specifically to the surface of the cells. We have also demonstrated that heparin (5 mg/ml) does not reduce the amount of apoE-immunoreactive material bound at the cell surface when added before or after the binding period. 1D7, but not 3B7 or 3H1, binds less in the presence of heparin. The observations are consistent with a localization of apoE on the cell membrane rather than on lipoproteins bound to apoB/E or apoE receptors.	CLIN RES INST MONTREAL, LIPOPROT METAB LAB, MONTREAL H2W 1R7, QUEBEC, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; BACHORIK PS, 1982, BIOCHEMISTRY-US, V21, P5675, DOI 10.1021/bi00265a044; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRANDAN E, 1989, J BIOL CHEM, V264, P10520; DASHTI N, 1984, BIOCHIM BIOPHYS ACTA, V794, P373, DOI 10.1016/0005-2760(84)90003-1; DELAMATRE JG, 1990, J LIPID RES, V31, P191; DELAMATRE JG, 1991, J CELL PHYSIOL, V146, P18, DOI 10.1002/jcp.1041460104; DORY L, 1991, J LIPID RES, V32, P783; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FAUST RA, 1987, ARTERIOSCLEROSIS, V7, P267, DOI 10.1161/01.ATV.7.3.267; FRANCIS GA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P159, DOI 10.1016/0005-2760(91)90215-4; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GRANOT E, 1987, J BIOL CHEM, V262, P3482; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HANDLEY DA, 1981, J CELL BIOL, V90, P778, DOI 10.1083/jcb.90.3.778; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HUI DY, 1984, J BIOL CHEM, V259, P5060; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONES AL, 1984, J LIPID RES, V25, P1151; KAMBOURIS AM, 1990, ARTERIOSCLEROSIS, V10, P582, DOI 10.1161/01.ATV.10.4.582; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOO C, 1985, J BIOL CHEM, V260, P1934; KRONVALL G, 1970, J IMMUNOL, V104, P140; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINNON M, 1986, J BIOL CHEM, V261, P2548; MARCEL YL, 1982, J BIOL CHEM, V257, P13165; MCCALL MR, 1988, J LIPID RES, V29, P1127; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MELLMAN IS, 1980, J EXP MED, V152, P1048, DOI 10.1084/jem.152.4.1048; MILNE RW, 1981, J CLIN INVEST, V68, P111, DOI 10.1172/JCI110225; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; NICHOLS AV, 1965, J LIPID RES, V6, P206; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RAHIM ATMA, 1991, BIOCHIM BIOPHYS ACTA, V1082, P195; RANGANATHAN S, 1990, BIOCHIM BIOPHYS ACTA, V1046, P223, DOI 10.1016/0005-2760(90)90193-2; REAVEN E, 1988, ARTERIOSCLEROSIS, V8, P298, DOI 10.1161/01.ATV.8.3.298; REAVEN E, 1990, J BIOL CHEM, V265, P19100; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; RINNINGER F, 1989, J BIOL CHEM, V264, P6111; RINNINGER F, 1990, BIOCHIM BIOPHYS ACTA, V1043, P318, DOI 10.1016/0005-2760(90)90033-T; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1987, J LIPID RES, V28, P1313; ROBERTS DCK, 1985, BIOCHEM J, V226, P319, DOI 10.1042/bj2260319; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SENAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1046, P81, DOI 10.1016/0005-2760(90)90097-H; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; THRIFT RN, 1986, J LIPID RES, V27, P236; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348	64	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1670	1676						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420942				2022-12-25	WOS:A1993KH62000027
J	BERNARDI, P; VERONESE, P; PETRONILLI, V				BERNARDI, P; VERONESE, P; PETRONILLI, V			MODULATION OF THE MITOCHONDRIAL CYCLOSPORINE A-SENSITIVE PERMEABILITY TRANSITION PORE .1. EVIDENCE FOR 2 SEPARATE ME2+ BINDING-SITES WITH OPPOSING EFFECTS ON THE PORE OPEN PROBABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED MEMBRANE TRANSITION; HEART-MITOCHONDRIA; LIVER-MITOCHONDRIA; CA-2+-DEPENDENT PORE; OXIDATIVE STRESS; INNER MEMBRANE; CA-2+ RELEASE; INHIBITION; MECHANISMS; CALCIUM	This paper reports an investigation on the regulation of the mitochondrial cyclosporin A-sensitive permeability transition pore (MTP). Energized, coupled rat liver mitochondria incubated in sucrose medium in the presence of phosphate maintain a high proton electrochemical gradient (DELTAmuH) and a low permeability to solutes. Addition of a small (10-20 muM) Ca2+ pulse leads to a transient membrane depolarization. After Ca2+ accumulation, a high DELTAmuH is recovered, and mitochondria remain coupled indefinitely. Yet, addition of fully uncoupling concentrations of carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP) brings about MTP opening within seconds. This finding confirms that MTP opening is the consequence rather than the cause of membrane depolarization, and allowed us to study the operation of the MTP in a synchronized population of mitochondria, since pore opening can be triggered by the addition of uncoupler under a series of experimental conditions. We find that three regulatory sites can be defined: (i) an internal Me2+ binding site: when this site is occupied by Ca2+, the pore ''open'' probability increases, while other Me2+ ions (Sr2+, Mn2+) have an inhibitory effect; (ii) an external Me2+ binding site: when this site is occupied by Me2+ ions, including Ca2+, the pore open probability decreases; (iii) an independent cyclosporin A binding site: when this site is occupied by cyclosporin A the pore open probability decreases. We show that at variance from the case of cyclosporin A, MTP inhibition by the phospholipase A2 inhibitors nupercaine and trifluoperazine is Ca2+-competitive and is presumably related to interference by these drugs with Ca2+ binding to the internal regulatory site.	UNIV PADUA, SCH MED, DEPT BIOMED SCI, BIOPHYS & MEMBRANE BIOL LAB, I-35121 PADUA, ITALY	University of Padua	BERNARDI, P (corresponding author), UNIV PADUA, SCH MED, CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404				BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1982, FEBS LETT, V139, P9, DOI 10.1016/0014-5793(82)80475-4; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1992, MECHANICS SWELLING C, P357; BRIERLEY GP, 1978, MOL BIOL MEMBRANES, P295; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NOVGORODOV SA, 1991, BIOCHEM BIOPH RES CO, V180, P33, DOI 10.1016/S0006-291X(05)81250-1; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; SARIS NEL, 1988, J BIOENERG BIOMEMBR, V20, P749, DOI 10.1007/BF00762551; SCARPA A, 1968, BIOCHIM BIOPHYS ACTA, V150, P473, DOI 10.1016/0005-2736(68)90147-8; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537	29	177	185	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1005	1010						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419309				2022-12-25	WOS:A1993KG07700039
J	KULPA, J; DIXON, JE; PAN, GH; SADOWSKI, PD				KULPA, J; DIXON, JE; PAN, GH; SADOWSKI, PD			MUTATIONS OF THE FLP RECOMBINASE GENE THAT CAUSE A DEFICIENCY IN DNA BENDING AND STRAND CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; 2-MU-M CIRCLE PLASMID; STEP-ARREST MUTANTS; SACCHAROMYCES-CEREVISIAE; SECONDARY-STRUCTURE; TARGET SEQUENCE; PROTEIN; YEAST; MECHANISM; BINDING	We have used site-directed mutagenesis to change several amino acids of the C-terminal portion of the FLP recombinase of Saccharomyces cerevisiae. These residues are absolutely conserved among the six FLP-like proteins from various yeast strains. We have examined the ability of the altered proteins to catalyze recombination in vivo and in vitro and to perform various partial steps of the reaction in vitro. Two of the mutations produced a partial defect in DNA binding but the remainder resulted in normal binding. All of these mutations caused impairment of the ability of the protein to induce the type II bend of the FRT site, and some of these proteins were also defective in DNA strand cleavage. None of the mutations affected the ability of the proteins to perform synapsis between two FRT sites, but some were defective in strand ligation. Interestingly, some mutant proteins showed impairment of the initial stages of the recombination reaction on a linear substrate and yet they maintained the ability to resolve a Holliday intermediate in the reaction. We conclude that this conserved region of the FLP protein is important for the early stage(s) of the recombination reaction.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto								ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AGROS P, 1986, EMBO J, V6, P433; AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; AMIN AA, 1990, J MOL BIOL, V214, P55, DOI 10.1016/0022-2836(90)90146-D; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2328; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; MEYERLEON L, 1987, NUCLEIC ACIDS RES, V15, P6469, DOI 10.1093/nar/15.16.6469; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN H, 1991, J BIOL CHEM, V266, P11347; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787; QIAN XH, 1990, J BIOL CHEM, V265, P21779; REYNOLDS AE, 1987, MOL CELL BIOL, V7, P3566, DOI 10.1128/MCB.7.10.3566; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SCHWARTZ CJE, 1990, THESIS U TORONTO; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2	36	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1101	1108						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419317				2022-12-25	WOS:A1993KG07700053
J	LAWSON, JH; BUTENAS, S; RIBARIK, N; MANN, KG				LAWSON, JH; BUTENAS, S; RIBARIK, N; MANN, KG			COMPLEX-DEPENDENT INHIBITION OF FACTOR-VIIA BY ANTITHROMBIN-III AND HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR; BLOOD-COAGULATION; EXTRINSIC PATHWAY; FACTOR XA; MECHANISM; THROMBIN; PLASMA; INACTIVATION; ACTIVATION	The regulation of the factor VIIa-tissue factor complex is essential for control of the hemostatic response. However, the role of the inhibitor antithrombin III in the regulation of factor VIIa has remained in question. The inhibition of factor VIIa activity by antithrombin III and heparin in the presence and absence of tissue factor was evaluated using the fluorescent substrate m-LGR-nds. Our data show that the activity of recombinant human factor VIIa is inhibited by antithrombin III in the presence of heparin at a rate of 1.7 x 10(2) M-1 s-1. In the presence of tissue factor, the rate constant for this reaction increases to 5.6 x 10(3) M-1 s-1. A 1:1 stoichiometric complex between factor VIIa and antithrombin III, with an apparent molecular weight of 110,000, was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A heterogeneous mixture of factor VIIa products with molecular weights between 50,000 and 80,000, most likely representing proteolytically degraded factor VIIa-antithrombin III complexes, was also observed.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [T32 HLO7594, R01 HL4697] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; Damus P S, 1976, Methods Enzymol, V45, P653; DOWNING MR, 1978, BIOCHEMISTRY-US, V17, P2649, DOI 10.1021/bi00606a030; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; ESMON CT, 1989, J BIOL CHEM, V264, P4743; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JESTY J, 1978, ARCH BIOCHEM BIOPHYS, V185, P165, DOI 10.1016/0003-9861(78)90156-X; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KONDO S, 1987, THROMB RES, V46, P325, DOI 10.1016/0049-3848(87)90294-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; MILETICH JP, 1978, J CLIN INVEST, V62, P824, DOI 10.1172/JCI109194; NEMERSON Y, 1988, BLOOD, V71, P1; NORDENMAN B, EUR J BIOCHEM, V78, P295; NOVOTNY WF, 1989, BLOOD S, V74, pA209; OLSON ST, 1989, THROMB HAEMOSTASIS, V62, P381; PIXLEY RA, 1985, BLOOD, V66, P198; RAPAPORT SI, 1989, BLOOD, V73, P359; RAPAPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; ROSENBERG RD, 1989, J CLIN INVEST, V74, P1; SCOTT CF, 1989, BLOOD, V73, P1373; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	31	135	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					767	770						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419351				2022-12-25	WOS:A1993KG07700004
J	MORRIS, AJ; TOLAN, DR				MORRIS, AJ; TOLAN, DR			SITE-DIRECTED MUTAGENESIS IDENTIFIES ASPARTATE-33 AS A PREVIOUSLY UNIDENTIFIED CRITICAL RESIDUE IN THE CATALYTIC MECHANISM OF RABBIT ALDOLASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY FRUCTOSE INTOLERANCE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; MUSCLE ALDOLASE; MAIZE ALDOLASE; MUTATION; PROTEINS; DEFICIENCY; RESOLUTION; EXPRESSION	The expression and purification of the rabbit muscle aldolase A (D-fructose 1,6-bisphosphate:D-glyceraldehyde-3-phosphate lyase, EC 4.1.2.13) from an expression plasmid in bacteria is described. The enzyme is produced in bacteria at a level of 300 mg/liter and is indistinguishable from the enzyme isolated from muscle in assays using fructose 1,6-bisphosphate and fructose 1-phosphate. The recombinant enzyme has the same primary, secondary, and quaternary structure as the muscle enzyme. Aspartic acid 33, found near the active site lysine in the crystal structure, is changed to alanine, serine, and glutamic acid by site-directed mutagenesis, resulting in the mutant proteins, D33A, D33S, and D33E, respectively. The mutant enzymes are purified by substrate affinity elution from carboxylmethyl-Sepharose, the same method as that used for the wild-type enzyme. The secondary and quaternary structure of D33A is identical to wild-type aldolase when analyzed by light scattering, gel filtration, and circular dichroism. Moreover, the hexose substrate can be fixed in the active site by reduction of the Schiff base with sodium borohydride, indicating that the active site is not drastically altered. These single mutations in the active site have a serious effect on the activity of the enzyme. In addition, the rate of carbanion oxidation for D33A is 17-29 times slower when the substrate is fructose 1,6-bisphosphate versus dihydroxyacetone phosphate, whereas in the wild-type there is no significant difference in these rates. This evidence and the conservation of this residue in other class I aldolases indicate that aspartic acid 33 is an essential residue in the catalytic mechanism, possibly involved in abstraction of the carbon 4 hydroxyl proton.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	Boston University				Tolan, Dean/0000-0002-0598-7241	NIDDK NIH HHS [DK38821, DK43521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043521, R29DK038821] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; ANAI M, 1973, ARCH BIOCHEM BIOPHYS, V156, P712, DOI 10.1016/0003-9861(73)90324-X; BALDWIN SA, 1978, BIOCHEM J, V169, P643, DOI 10.1042/bj1690643; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BEERNINK PT, 1992, PROTEIN EXPRES PURIF, V3, P332, DOI 10.1016/1046-5928(92)90009-L; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BERTHIAUME L, 1989, ARCH BIOCHEM BIOPHYS, V272, P281, DOI 10.1016/0003-9861(89)90221-X; BIRKENHAGER JC, 1960, BIOCHIM BIOPHYS ACTA, V40, P182, DOI 10.1016/0006-3002(60)91336-6; BLOSTEIN R, 1963, J BIOL CHEM, V238, P3280; Boyer P.D., 1990, ENZYMES, V19, P99; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS CC, 1991, AM J HUM GENET, V49, P1075; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSS NCP, 1990, LANCET, V335, P306, DOI 10.1016/0140-6736(90)90603-3; CROSS NCP, 1988, CELL, V53, P881, DOI 10.1016/S0092-8674(88)90349-2; DAZZO C, 1990, AM J HUM GENET, V46, P1194; HARTMAN FC, 1974, BIOCHEM BIOPH RES CO, V57, P85, DOI 10.1016/S0006-291X(74)80360-8; HARTMAN FC, 1976, J BIOL CHEM, V251, P3057; HEALY MJ, 1973, BIOCHEMISTRY-US, V12, P35, DOI 10.1021/bi00725a006; HERS H. G., 1961, ENZYMOL BIOL ET CLIN, V1, P4; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; KELLY PM, 1987, PLANT PHYSIOL, V82, P1076; KISHI H, 1987, P NATL ACAD SCI USA, V84, P8623, DOI 10.1073/pnas.84.23.8623; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KUKITA A, 1988, EUR J BIOCHEM, V171, P471, DOI 10.1111/j.1432-1033.1988.tb13813.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; PAPPIN DJC, 1990, ANAL BIOCHEM, V187, P10, DOI 10.1016/0003-2697(90)90410-B; PENHOET E, 1967, BIOCHEMISTRY-US, V6, P2940, DOI 10.1021/bi00861a039; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; RACKER E, 1952, J BIOL CHEM, V196, P347; ROSE IA, 1965, J BIOL CHEM, V240, P1758; ROTTMANN WH, 1984, P NATL ACAD SCI-BIOL, V81, P2738, DOI 10.1073/pnas.81.9.2738; RUTTER WJ, 1964, FED PROC, V23, P1248; SAKAKIBARA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P334, DOI 10.1016/0167-4781(89)90156-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; TAKAHASHI I, 1989, J BIOCHEM, V105, P281, DOI 10.1093/oxfordjournals.jbchem.a122654; TAYLOR JF, 1955, METHOD ENZYMOL, V1, P310, DOI 10.1016/0076-6879(55)01043-4; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROMBETTA G, 1977, BIOCHEM BIOPH RES CO, V74, P1297, DOI 10.1016/0006-291X(77)90583-6; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VLAHOS CJ, 1990, J BIOL CHEM, V265, P20384; VOET D, 1990, BIOCHEMISTRY-US, P433	47	65	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1095	1100						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419316				2022-12-25	WOS:A1993KG07700052
J	STONE, CL; BOSRON, WF; DUNN, MF				STONE, CL; BOSRON, WF; DUNN, MF			AMINO-ACID SUBSTITUTIONS AT POSITION 47 OF HUMAN BETA-1-BETA-1 AND BETA-2-BETA-2 ALCOHOL DEHYDROGENASES AFFECT HYDRIDE TRANSFER AND COENZYME DISSOCIATION RATE CONSTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ZINC-BOUND WATER; KINETIC CHARACTERIZATION; CATALYZED REDUCTION; BINDING-SITE; LIVER; PURIFICATION; ISOENZYMES; ALDEHYDE; ADH	Human liver alcohol dehydrogenase isoenzymes beta1beta1 and beta2beta2, in which position 47 in the coenzyme binding domain is an arginine or histidine, respectively, differ remarkably in steady-state kinetics. To understand which catalytic steps affect these kinetics, apparent coenzyme dissociation and association rate constants, and apparent 4-trans-(NN-dimethylamino)cinnamaldehyde (DACA) hydride transfer rate constants were obtained with stopped-flow kinetics. Enzymes containing site-specific mutations of Arg-47 in beta1beta1 (beta47R) to His (beta2beta2 or beta47H), Lys (beta47K), or Gln (beta47Q) were studied. Apparent coenzyme dissociation rate constants are greatly affected by substitutions at position 47, in which mutant enzymes with a weak base or a neutral residue at this position (beta47H and beta47Q) exhibit faster rate constants than beta47R and beta47K. Substitutions at position 47 have less effect on apparent coenzyme association rate constants. The kinetics of NADH association for beta47H and beta47Q are consistent with a two-step mechanism in which the bimolecular binding step is coupled to a unimolecular process. These findings indicate that the greater role of position 47 in coenzyme dissociation may occur after a coenzyme-induced isomerization. Substitutions at position 47 also strongly influence apparent DACA hydride transfer rate constants; hydride transfer is faster with mutant enzymes containing weak bases like histidine at this position. Steady-state kinetics, however, reveal that the rate-limiting step of both beta47R and beta47H for acetaldehyde reduction and for ethanol oxidation is coenzyme product dissociation. Thus, the different activities of beta1beta1 and beta2beta2 for ethanol oxidation and acetaldehyde reduction are caused primarily by different coenzyme dissociation rates.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Riverside					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA002342, R01AA007117] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32-AA07642, R01-AA07117, R01-AA02342] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSSON P, 1980, EUR J BIOCHEM, V108, P303, DOI 10.1111/j.1432-1033.1980.tb04724.x; ANDERSSON P, 1981, EUR J BIOCHEM, V113, P425, DOI 10.1111/j.1432-1033.1981.tb05082.x; Bosron W F, 1981, Semin Liver Dis, V1, P179, DOI 10.1055/s-2008-1041746; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BOSRON WF, 1980, P NATL ACAD SCI-BIOL, V77, P5784, DOI 10.1073/pnas.77.10.5784; BUHLER R, 1984, FEBS LETT, V173, P360, DOI 10.1016/0014-5793(84)80806-6; BURNELL JC, 1989, BIOCHEMISTRY-US, V28, P6810, DOI 10.1021/bi00443a005; Burnell JC, 1989, HUMAN METABOLISM ALC, V2, P65; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DETRAGLIA MC, 1977, J BIOL CHEM, V252, P3493; DUNN MF, 1973, BIOCHEMISTRY-US, V12, P4882, DOI 10.1021/bi00748a012; DUNN MF, 1982, BIOCHEMISTRY-US, V21, P354, DOI 10.1021/bi00531a024; EHRIG T, 1990, ALCOHOL ALCOHOLISM, V25, P105, DOI 10.1093/oxfordjournals.alcalc.a044985; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HRULEY TD, 1990, J BIOL CHEM, V265, P16366; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; KVASSMAN J, 1979, EUR J BIOCHEM, V100, P115, DOI 10.1111/j.1432-1033.1979.tb02039.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCEVILY A J, 1990, Biochromatography, V5, P13; MEIERTACKMANN D, 1990, ALCOHOL, V7, P413, DOI 10.1016/0741-8329(90)90025-8; MORRIS RG, 1980, BIOCHEMISTRY-US, V19, P725, DOI 10.1021/bi00545a018; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; THEORELL H, 1963, BIOCHEM Z, V338, P537; Tipton K F, 1979, Methods Enzymol, V63, P183; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; YIN SJ, 1984, BIOCHEMISTRY-US, V23, P5847, DOI 10.1021/bi00319a026	31	44	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					892	899						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419368				2022-12-25	WOS:A1993KG07700024
J	JOHNSON, DR; DURONIO, RJ; LANGNER, CA; RUDNICK, DA; GORDON, JI				JOHNSON, DR; DURONIO, RJ; LANGNER, CA; RUDNICK, DA; GORDON, JI			GENETIC AND BIOCHEMICAL-STUDIES OF A MUTANT SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA - PROTEIN N-MYRISTOYLTRANSFERASE, NMT72PLEU99-]PRO, THAT PRODUCES TEMPERATURE-SENSITIVE MYRISTIC ACID AUXOTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PHEROMONE RESPONSE; ADP-RIBOSYLATION FACTOR; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; 2 GENES; ACYL-COA; TRANSFERASE; ASSOCIATION; ACYLATION; SUBUNITS	Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) is an essential enzyme that transfers myristate from CoA to the amino-terminal glycine residue of at least 12 cellular proteins. Its reaction mechanism is Ordered Bi Bi with myristoyl-CoA binding occurring before binding of nascent polypeptides and release of CoA preceding release of the myristoylprotein product. nmt1-72 is a temperature-sensitive allele, identified by Stone et al. (Stone, D. E., Cole, G. M., Lopes, M. B., Goebl, M., and Reed, S. I. (1991) Genes & Dev. 5, 1969-1981) that causes arrest in the G1 phase of the cell cycle due to reduced acylation of Gpa1p. We have recovered this mutant allele and determined that it contains a single point mutation resulting in a Leu99 (CTA) to Pro (CCA) substitution. Addition of greater-than-or-equal-to 500 muM myristate but not palmitate to synthetic or rich media rescues the growth arrest caused by nmt1-72 at 37-39-degrees-C, consistent with the observation that purified nmt72p has reduced affinity for myristoyl-CoA and that exogenous myristate but not palmitate increases cellular myristoyl-CoA pools. Metabolic labeling studies in S. cerevisiae and co-expression of nmt72p with several protein substrates of Nmt1p in Escherichia coli indicate that the Leu99 --> Pro substitution causes a reduction in the acylation of some but not all protein substrates. Since formation of a myristoyl-CoA.Nmt1p complex appears to be required for synthesis/formation of a peptide binding site, these defects in acylation appear to arise either because Leu99 is a component of the enzyme's functionally distinguishable myristoyl-CoA and peptide recognition sites or because Pro99 alters the interaction between myristoyl-CoA and enzyme in a way that precludes formation of a normal peptide binding site. The reduction in affinity for myristoyl-CoA produced by Leu99 --> Pro in nmt72p is less than that produced by the Gly451 --> Asp mutation in nmt181p, which also produces temperature-sensitive myristic acid auxotrophy. Isogenic, haploid strains containing NMT1, nmt1-72, and nmt1-181 do not manifest any obvious differences in steady state levels of the acyltransferases during growth at permissive temperatures or in the biosynthesis of long chain saturated acyl-CoAs. The spectrum of cellular N-myristoylproteins whose level of acylation is affected by nmt1-72 and nmt1-181 is distinct. This is evidenced by: (i) differences in pattern of incorporation of exogenous [H-3]myristate into N-myristoylproteins, (ii) the fact that disruption of STE4 is epistatic to nmt1-72 but not to nmt1-181, (iii) the lack of effect of overexpression of Gpalp on growth of isogenic haploid nmt1-181 strains, (iv) differences in the degree of growth suppression produced by overexpression of Arf1p, and (v) differences in their abilities to acylate a panel of four substrates of Nmt1p in the E. coli co-expression system. Together, these findings suggest that nmt1-72 and nmt1-181 strains may be useful for identifying essential cellular N-myristoylproteins as well as gene products that affect myristoyl-CoA metabolism and/or the delivery of this substrate to Nmt1p.	WASHINGTON UNIV, SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Duronio, Robert/0000-0001-6469-6965	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27179, AI30188] Funding Source: Medline; NIGMS NIH HHS [GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1990, PROG CLIN BIOL RES, V321, P217; DENBREEJEN JN, 1989, BIOCHIM BIOPHYS ACTA, V1002, P277, DOI 10.1016/0005-2760(89)90341-X; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KEITH AD, 1969, J BACTERIOL, V98, P415, DOI 10.1128/JB.98.2.415-420.1969; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KNOLL LJ, 1993, IN PRESS J BIOL CHEM; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MEYER KH, 1974, J BACTERIOL, V117, P345, DOI 10.1128/JB.117.2.345-350.1974; MORTIMER RK, 1969, YEASTS, V1, P385; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; OLINS PO, 1989, J BIOL CHEM, V264, P16973; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; REED SI, 1988, COLD SPRING HARB SYM, V53, P621, DOI 10.1101/SQB.1988.053.01.071; RESNICK MA, 1966, J BACTERIOL, V92, P597, DOI 10.1128/JB.92.3.597-600.1966; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; RUDNICK DA, 1992, IN PRESS P NATL ACAD; RUDNICK DA, 1993, IN PRESS P NATL ACAD; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHWEIZER E, 1970, P NATL ACAD SCI USA, V67, P660, DOI 10.1073/pnas.67.2.660; SIKORSKI RS, 1989, GENETICS, V122, P19; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8	72	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					483	494						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416952				2022-12-25	WOS:A1993KE60300074
J	IIDA, S; SETO, M; YAMAMOTO, K; KOMATSU, H; TOJO, A; ASANO, S; KAMADA, N; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R				IIDA, S; SETO, M; YAMAMOTO, K; KOMATSU, H; TOJO, A; ASANO, S; KAMADA, N; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R			MLLT3 GENE ON 9P22 INVOLVED IN T(9-11) LEUKEMIA ENCODES A SERINE PROLINE-RICH PROTEIN HOMOLOGOUS TO MLLT1 ON 19P13	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA POLYMERASE-II; 11Q23 TRANSLOCATIONS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; LARGEST SUBUNIT; BREAKPOINT; CLONING; T(4-11); T(11-19)(Q23-P13)	Recently, the MLL gene at 11q23 was found to be involved in a subset of leukemias with an 11q23 abnormality. In the present study, we isolated chimeric cDNAs between the MLL and a gene designated MLLT3 at 9p22 from a cDNA library of an IMS-M1 cell line with a t(9;11)(p22;q23) translocation, a representative karyotypic abnormality seen in acute monocytic leukemia. We also isolated a normal MLLT3 cDNA and found an open reading frame encoding at least 318 amino acids with high serine/proline content (24.8%). The chimeric mRNAs were demonstrated to be fused to MLL in frame, as found in t(11;19) and t(4;11) leukemias. The predicted MLLT3 protein demonstrated a significant homology to that of the MLLT1 gene at 19p13 involved in t(11;19) leukemia. The highest homology, up to 74.1%, was found in 86 amino acids of the C-terminus, suggesting that this region is of particular importance for leukemogenesis in t(9;11) leukemia. Northern blot analysis with the MLLT3 cDNA probe against normal tissues revealed multiple transcripts in lymphoid organs. A survey of hematopoietic cell lines demonstrated relatively stronger signals in cells belonging to megakaryocytic and erythroid lineages. As previously found in t(11;19) leukemia, heterogeneous MLL-MLLT3 chimeric mRNAs could be detected by the reverse transcriptase-polymerase chain reaction (RT-PCR) in t(9;11) leukemia samples.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT HEMATOL & CHEMOTHERAPY,CHIKUSA KU,NAGOYA 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MED,MINATO KU,TOKYO 108,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT MED,MINAMI KU,HIROSHIMA 734,JAPAN	Aichi Cancer Center; Aichi Cancer Center; University of Tokyo; Hiroshima University								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AKAO Y, 1992, CANCER RES, V52, P6083; BERGER R, 1980, LEUKEMIA RES, V4, P119, DOI 10.1016/0145-2126(80)90051-X; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRODEUR GM, 1983, CANCER GENET CYTOGEN, V8, P93, DOI 10.1016/0165-4608(83)90041-9; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DYER MJS, 1990, BLOOD, V75, P709; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HAGEMEIJER A, 1982, CANCER GENET CYTOGEN, V5, P95, DOI 10.1016/0165-4608(82)90001-2; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; KANEKO Y, 1986, BLOOD, V67, P484; KANEKO Y, 1982, BLOOD, V60, P389; KATZ F, 1988, BLOOD, V71, P1438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MORGAN GJ, 1992, BLOOD, V80, P2172; MORRISSEY J, 1993, BLOOD, V81, P1124; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1987, BLOOD, V69, P1289; RAIMONDI SC, 1989, BLOOD, V73, P1627; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SETO M, 1992, ONCOGENE, V7, P1401; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, IN PRESS ONCOGENE; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	36	99	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3085	3092						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414510				2022-12-25	WOS:A1993MC09300025
J	MARTIN, F; PRANDINI, MH; THEVENON, D; MARGUERIE, G; UZAN, G				MARTIN, F; PRANDINI, MH; THEVENON, D; MARGUERIE, G; UZAN, G			THE TRANSCRIPTION FACTOR GATA-1 REGULATES THE PROMOTER ACTIVITY OF THE PLATELET GLYCOPROTEIN-IIB GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ERYTHROID-SPECIFIC PROTEIN; AVIAN LEUKEMIA-VIRUS; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; IMMUNOGLOBULIN GENES; HEMATOPOIETIC-CELLS; NUCLEAR FACTOR; CONTROL REGION; GLOBIN GENE	Glycoprotein IIb (GPIIb) is an early and specific marker of the megakaryocytic lineage. We have previously shown that a fragment extending 643 base pairs upstream the transcription start site of the human GPIIb promoter was able to control the tissue-specific expression of the CAT -gene in transfection experiments. Four potential GATA-binding sites, located at positions -463, -376, -243, and -54 are present within this fragment. Gel shift analysis revealed that nuclear extracts from the erythroleukemic cell line HEL contain a DNA-binding protein that recognizes these GATA sites. Using an antiserum raised to an hydrophilic region of the transcription factor GATA-1, the HEL GATA-binding protein was found to be GATA-1. Point mutations of the different GATA sites indicated that they did not equally contribute to GPIIb promoter activity. The -463 GATA motif located in an enhancer region is essential for full transcription activity and was found to be dominant upon the other GATA motifs. When this site is mutated, the -54 GATA site appears to be essential for the remaining CAT activity. These results indicate that the transcription factor GATA-1 plays an important role in the regulation of the transcription of the megakaryocyte specific GPIIb gene.			MARTIN, F (corresponding author), CEN, INSERM, DEPT BIOL MOLEC & STRUCT, HEMATOL LAB, 85X, F-38041 GRENOBLE, FRANCE.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; CLINTON GM, 1991, METHOD ENZYMOL, V200, P463; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; INOUE A, 1989, J BIOL CHEM, V264, P14954; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KAGEN A, 1979, METHOD HORM RADIOIMM, P328; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P1311; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MOLLA A, 1992, BRIT J HAEMATOL, V82, P635, DOI 10.1111/j.1365-2141.1992.tb06937.x; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; UZAN G, 1991, J BIOL CHEM, V266, P8932; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854	46	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21606	21612						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408012				2022-12-25	WOS:A1993MC80900029
J	RAMAMOORTHY, S; COOL, DR; MAHESH, VB; LEIBACH, FH; MELIKIAN, HE; BLAKELY, RD; GANAPATHY, V				RAMAMOORTHY, S; COOL, DR; MAHESH, VB; LEIBACH, FH; MELIKIAN, HE; BLAKELY, RD; GANAPATHY, V			REGULATION OF THE HUMAN SEROTONIN TRANSPORTER - CHOLERA TOXIN-INDUCED STIMULATION OF SEROTONIN UPTAKE IN HUMAN PLACENTAL CHORIOCARCINOMA CELLS IS ACCOMPANIED BY INCREASED SEROTONIN TRANSPORTER MESSENGER-RNA LEVELS AND SEROTONIN TRANSPORTER-SPECIFIC LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BORDER MEMBRANE-VESICLES; HIGH-AFFINITY; RAT-BRAIN; IMIPRAMINE BINDING; ENDOTHELIAL-CELLS; H-3-IMIPRAMINE BINDING; ACTIVE-TRANSPORT; HUMAN-PLATELETS; I-125 RTI-55	Treatment of confluent cultures of JAR human placental choriocarcinoma cells with cholera toxin or forskolin for 16 h markedly stimulated (2.4-fold) serotonin transport activity in these cells. Cycloheximide, an inhibitor of protein synthesis or actinomycin D, an inhibitor of mRNA synthesis effectively blocked this stimulation. Northern blot analysis revealed that treatment with cholera toxin resulted in severalfold increase in the concentrations of the three mRNA species (6.8, 4.9 and 3.0 kilobases in size) which hybridized to the human placental serotonin transporter cDNA. Under similar conditions, the concentrations of the mRNA species which hybridized to the human placental taurine transporter cDNA or to the human beta-actin cDNA were not affected. Analysis of paroxetine-sensitive binding of the cocaine analog 2beta-carbomethoxy-3beta-(4-[I-125]iodophenyl)tropane to the membranes prepared from control and cholera toxin-treated cells indicated that the maximal binding capacity was increased 2.5-fold by cholera toxin, with no significant change in the binding affinity. Thus, stimulation of serotonin transporter activity in the placental choriocarcinoma cells following cholera toxin treatment is likely a result of an increase in cell surface density of the serotonin transporter protein as a consequence of increased steady state serotonin transporter mRNA levels.	MED COLL GEORGIA, DEPT BIOCHEM & MOLEC BIOL, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PHYSIOL & ENDOCRINOL, AUGUSTA, GA 30912 USA; EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Emory University			Melikian, Haley/S-8301-2016	Melikian, Haley/0000-0002-9694-5556	NICHD NIH HHS [HD 27487] Funding Source: Medline; NIDA NIH HHS [DA 07390] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AHTEE L, 1981, LIFE SCI, V29, P2323, DOI 10.1016/0024-3205(81)90566-X; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BLOCK ER, 1987, AM J PHYSIOL, V253, pC672, DOI 10.1152/ajpcell.1987.253.5.C672; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; BOJA JW, 1991, EUR J PHARMACOL, V194, P133, DOI 10.1016/0014-2999(91)90137-F; BOSIN TR, 1989, J PHARMACOL EXP THER, V248, P67; BRILEY MS, 1980, SCIENCE, V209, P303, DOI 10.1126/science.7384806; COOL DR, 1991, J BIOL CHEM, V266, P15750; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; COOL DR, 1990, AM J PHYSIOL, V259, pC196, DOI 10.1152/ajpcell.1990.259.2.C196; COOL DR, 1990, BIOCHEM PHARMACOL, V40, P2161, DOI 10.1016/0006-2952(90)90249-K; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; FATTACCINI CM, 1990, NEUROPHARMACOLOGY, V29, P1, DOI 10.1016/0028-3908(90)90076-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GANAPATHY V, 1989, J PHARMACOL EXP THER, V251, P9; GANAPATHY V, 1993, TROPHOBLAST RES, V7, P35; GRAHAM D, 1988, NEURONAL SEROTONIN, P367; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HRDINA PD, 1987, EUR J PHARMACOL, V138, P159, DOI 10.1016/0014-2999(87)90429-8; KAMAL LA, 1984, LIFE SCI, V34, P2083, DOI 10.1016/0024-3205(84)90373-4; KELLEY LK, 1983, BIOCHIM BIOPHYS ACTA, V734, P91, DOI 10.1016/0005-2736(83)90079-2; KING SC, 1992, BIOCHEM BIOPH RES CO, V183, P487, DOI 10.1016/0006-291X(92)90508-I; KULANTHAIVEL P, 1991, BIOCHEM J, V277, P53, DOI 10.1042/bj2770053; LANGER SZ, 1980, N-S ARCH PHARMACOL, V313, P189, DOI 10.1007/BF00505732; LEE SL, 1986, AM J PHYSIOL, V250, pC766, DOI 10.1152/ajpcell.1986.250.5.C766; LESCH KP, 1993, MOL BRAIN RES, V17, P31, DOI 10.1016/0169-328X(93)90069-2; LOPEZIBOR JJ, 1988, BRIT J PSYCHIAT, V153, P26, DOI 10.1192/S0007125000297262; MARAZZITI D, 1989, N-S ARCH PHARMACOL, V340, P593; MENINI T, 1987, N-S ARCH PHARMACOL, V336, P478; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1992, BIOCHEM J, V286, P89, DOI 10.1042/bj2860089; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1189, DOI 10.1152/ajpcell.1992.262.5.C1189; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RIFAS L, 1984, P NATL ACAD SCI-BIOL, V81, P4558, DOI 10.1073/pnas.81.14.4558; ROSS SB, 1982, BIOL SEROTONERGIC TR, P159; RUDNICK G, 1992, METHOD ENZYMOL, V215, P213; RUDNICK G, 1986, PLATELET RESPONSES M, P119; SEVERSON JA, 1985, J NEUROCHEM, V45, P1382, DOI 10.1111/j.1471-4159.1985.tb07203.x; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WALL SC, 1993, MOL PHARMACOL, V43, P264; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	47	112	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21626	21631						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408014				2022-12-25	WOS:A1993MC80900032
J	URADE, R; TAKENAKA, Y; KITO, M				URADE, R; TAKENAKA, Y; KITO, M			PROTEIN-DEGRADATION BY ERP72 FROM RAT AND MOUSE-LIVER ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; PRE-GOLGI DEGRADATION; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; DISULFIDE-ISOMERASE; CYSTEINE PROTEASE; PHOSPHOLIPASE-C; CLONING; CALRETICULIN; INHIBITION; SEQUENCES	The endoplasmic reticulum (ER) resident protein, ER60, is a member of the protein disulfide-isomerase family and contains two copies of the internal thioredoxin motif, CGHC. Previously, ER60 was identified as a cysteine protease and named ER-60 protease (Urade, R., Nasu, M., Moriyama, T., Wada, K., and Kito, M. (1992) J. Biol. Chem. 267, 15152-15159; Urade, R., and Kito, M. (1992) FEBS Lett. 312, 83-86). Here, ERp72, the other member of the protein disulfide-isomerase family containing three CGHC motifs, was isolated from ER of rat and mouse livers through four sequential chromatographies on DEAE-Toyopearl 650, AF-heparin Toyopearl 650M, and TSK gel G3000SW twice. The purified rat protein was found to be homogeneous on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, not being contaminated by ER-60 protease, as judged on immunoblot analysis using an anti-ER-60 protease antibody. The partial amino acid sequence of rat ERp72 was 93% homologous to that of mouse ERp72. The purified rat ERp72 degraded other ER resident proteins such as protein disulfide-isomerase and calreticulin. The purified mouse ERp72 also degraded those proteins. Though rat ERp72 did not basically require Ca2+ for the reaction, the degradation of protein disulfide-isomerase was enhanced, but the degradation of calreticulin was inhibited in the presence of Ca2+. The proteolytic activity of rat ERp72 was inhibited by cysteine protease inhibitors. Its sensitivity to protease inhibitors was the same as that of ER-60 protease. In addition, the proteolytic activity of rat ERp72 was inhibited by acidic phospholipids, also similar to ER-60 protease. Therefore, we propose that ERp72 be named ER-72 protease.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHANDHURI MM, 1992, BIOCHEM J, V281, P645; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; HUANG SH, 1991, J BIOL CHEM, V266, P5353; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; MACER DRJ, 1988, J CELL SCI, V91, P61; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; OHNO S, 1987, METHOD ENZYMOL, V139, P363; PETER F, 1992, J BIOL CHEM, V267, P10631; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; WAXMAN L, 1981, METHOD ENZYMOL, V80, P664; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1990, CELL REGUL, V2, P753	29	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22004	22009						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408057				2022-12-25	WOS:A1993MC80900085
J	ZACHARY, I; SINNETTSMITH, J; TURNER, CE; ROZENGURT, E				ZACHARY, I; SINNETTSMITH, J; TURNER, CE; ROZENGURT, E			BOMBESIN, VASOPRESSIN, AND ENDOTHELIN RAPIDLY STIMULATE TYROSINE PHOSPHORYLATION OF THE FOCAL ADHESION-ASSOCIATED PROTEIN PAXILLIN IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; BINDING-PROTEIN; PHOSPHOLIPASE-C; EXTRACELLULAR-MATRIX; MITOGENIC RESPONSE; ALPHA-SUBUNITS; GROWTH-FACTORS; EARLY EVENTS; RECEPTOR; ACTIVATION	Treatment of Swiss 3T3 cells with bombesin caused a striking increase (21-fold) in the tyrosine phosphorylation of the cytoskeleton-associated protein paxillin, as judged by anti-phosphotyrosine Western blots of anti-paxillin immunoprecipitates. Vasopressin and endothelin also stimulated paxillin tyrosine phosphorylation. Bombesin-stimulated tyrosine phosphorylation of paxillin was detectable within 1 min and was concentration-dependent (half-maximum effect at 0.09 nM). Bombesin stimulation of paxillin tyrosine phosphorylation could be dissociated from both protein kinase C (PKC) activation and the mobilization of Ca2+ from intracellular stores. Activation of PKC in quiescent Swiss 3T3 cells using the tumor promoter phorbol 12,13-dibutyrate (PDB) increased the tyrosine phosphorylation of paxillin in a time-dependent manner but was less effective than bombesin and stimulated detectable phosphorylation only within 5 min, considerably slower than bombesin-induced tyrosine phosphorylation of paxillin. Furthermore, the selective PKC inhibitor, GF109203X, or down-regulation of PKC using prolonged treatment with PDB markedly inhibited the stimulation of paxillin tyrosine phosphorylation by PDB but had little effect on the response to bombesin. In contrast, cytochalasin D, an agent that selectively disrupts the network of actin microfilaments, completely inhibited bombesin- and PDB-induced paxillin tyrosine phosphorylation. This is the first report to identify paxillin as a substrate for neuropeptide-stimulated tyrosine phosphorylation.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,SYRACUSE,NY 13210	Cancer Research UK; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIGMS NIH HHS [R01 GM047607, GM47607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047607, R01GM047607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; ERUUSALIMSKY J, 1988, J BIOL CHEM, V263, P19188; FORCE T, 1991, J BIOL CHEM, V266, P6650; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STADDON JM, 1991, J BIOL CHEM, V266, P4840; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1993, IN PRESS J CELL SCI; WALSH JH, 1993, IN PRESS J CELL PHYS; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	55	209	209	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22060	22065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408063				2022-12-25	WOS:A1993MC80900093
J	GEFFEN, I; FUHRER, C; LEITINGER, B; WEISS, M; HUGGEL, K; GRIFFITHS, G; SPIESS, M				GEFFEN, I; FUHRER, C; LEITINGER, B; WEISS, M; HUGGEL, K; GRIFFITHS, G; SPIESS, M			RELATED SIGNALS FOR ENDOCYTOSIS AND BASOLATERAL SORTING OF THE ASIALOGLYCOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; HUMAN TRANSFERRIN RECEPTOR; CANINE KIDNEY-CELLS; CYTOPLASMIC DOMAIN; LDL RECEPTOR; MEMBRANE-PROTEIN; EPITHELIAL-CELLS; INTERNALIZATION SIGNAL; RAPID ENDOCYTOSIS; TRANSGENIC MICE	The major subunit of the human asialoglycoprotein receptor contains signals for efficient endocytosis and specific basolateral expression in polarized Madin-Darby canine kidney cells, both of which are located within its 40-residue cytoplasmic domain. The aromatic residue in this segment, tyrosine 5, which is necessary for efficient clustering into clathrin-coated pits at the plasma membrane, is also necessary for exclusive basolateral delivery. Mutation of this residue to alanine resulted in a nonpolar expression of the protein. Replacement of tyrosine 5 with phenylalanine yielded almost wild-type rates of endocytosis as well as specific basolateral expression, indicating that tyrosine phosphorylation is not essential for either sorting step. The close similarity between the two sorting signals was further corroborated by deletion mutants showing that the amino-terminal 10 residues of the cytoplasmic domain are sufficient for basolateral polarity and efficient endocytosis. The kinetics of appearance of newly synthesized wild-type and mutant receptor protein at the apical and basolateral surfaces indicate that these proteins are sorted intracellularly and are transported directly to the respective domains. Mutants affected in basolateral sorting lost polarity, i.e, appeared to similar extents on both surfaces, indicating that there is no significant apical sorting information elsewhere in the protein. The close correlation between endocytosis and basolateral polarity suggests common recognition mechanisms at the plasma membrane and in the trans-Golgi network.	UNIV BASEL, BIOCTR, DEPT BIOCHEM, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND; BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND	University of Basel				Spiess, Martin/0000-0001-7139-0550; Fuhrer, Christian/0000-0001-8216-8883				BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; WANDINGERNESS A, 1990, POLARIZED TRANSPORT, P575; WESSELS HP, 1989, J BIOL CHEM, V264, P17; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	37	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20772	20777						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407903				2022-12-25	WOS:A1993MA28800022
J	LIND, T; LINDAHL, U; LIDHOLT, K				LIND, T; LINDAHL, U; LIDHOLT, K			BIOSYNTHESIS OF HEPARIN HEPARAN-SULFATE - IDENTIFICATION OF A 70-KDA PROTEIN CATALYZING BOTH THE D-GLUCURONOSYLTRANSFERASE AND THE N-ACETYL-D-GLUCOSAMINYLTRANSFERASE REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; GLYCOSYLTRANSFERASES; PURIFICATION	The D-glucuronosyl- (GlcA) and N-acetyl-D-glucosaminyl-(GlcNAc) transferase reactions involved in heparin/heparan sulfate biosynthesis were assayed, measuring transfer of radiolabeled GlcA or GlcNAc monosaccharide units from the corresponding UDP-sugars to the appropriate oligosaccharide acceptors. The assays were applied to enzyme purification from bovine serum. The two activities remained inseparable through a series of different chromatographic steps, resulting in approximately 2000-fold purification. Further purification was achieved by chromatofocusing, which showed an isoelectric point of pH approximately 7.0, similar for both activities. SDS-polyacrylamide gel electrophoresis (PAGE) of subfractions from the chromatofocusing procedure revealed a approximately 70-kDa protein in amounts reflecting enzyme activity. SDS-PAGE followed by extraction of gel segments and renaturation of proteins showed that the GlcA- and GlcNAc-transferase activities were both recovered from the same single segment, corresponding to the 70-kDa component. It is proposed that the two glycosyltransferase reactions are catalyzed by the same Golgi enzyme (see also Lidholt, K., Weinke, J. L., Kiser, C. S., Lugemwa, F. N., Bame, K. J., Cheifetz, S., Massague, J., Lindahl, U., and Esko, J. D. (1992) Proc. NatL Acad. Sci. U. S. A. 89, 2267-2271).	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,BOX 575,S-75123 UPPSALA,SWEDEN	Uppsala University				Lind, Thomas/0000-0003-2791-688X				CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HOOK M, 1975, J BIOL CHEM, V250, P6065; JACOBSSON I, 1979, J BIOL CHEM, V252, P2975; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; Lindahl U., 1989, HEPARIN, P159; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x	16	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20705	20708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407890				2022-12-25	WOS:A1993MA28800007
J	VOLONTE, C; ANGELASTRO, JM; GREENE, LA				VOLONTE, C; ANGELASTRO, JM; GREENE, LA			ASSOCIATION OF PROTEIN-KINASES ERK1 AND ERK2 WITH P75 NERVE GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; AFFINITY NGF RECEPTOR; MYELIN BASIC-PROTEIN; STIMULATES TYROSINE PHOSPHORYLATION; TRK PROTOONCOGENE PRODUCT; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; PURINE ANALOGS; GENE-TRANSFER; INSULIN	Extracellular signal-regulated protein kinases (ERKs) constitute a family of protein serine-threonine kinases implicated in a variety of cell-signaling pathways. In cultured rat pheochromocytoma PC12 cells, ERK1 and ERK2 are activated by nerve growth factor (NGF), which also induces rapid association between ERK1 and the high affinity gp140prototrk tyrosine kinase NGF receptor. In the present work, we investigated the possible association between ERKs and the low affinity NGF receptor, p75. Extracts of PC 12 cells (before and after NGF treatment) were subjected to immunoprecipitation with anti-p75 antibodies or antiserum; the immune complexes were then assessed for the presence of ERK proteins and tyrosine phosphorylation or for ERK activity using a specific substrate peptide. ERK1 and, to a lesser extent, ERK2 were found to be constitutively associated with p75. NGF did not modulate the total amount of ERK proteins co-immunoprecipitated with p75 but did markedly stimulate the level of p75-associated ERK catalytic activity. NGF treatment also enhanced the tyrosine phosphorylation of a p75-associated species that co-migrates with ERK1 in Western blots. Finally, K-252a, a compound that specifically inhibits activation by NGF of gp140prototrk, abolished the latter effect. These findings indicate that NGF, via activation of gp140prototrk, leads to association of enzymatically active ERKs with p75 and raise the possibility that this interaction may play a role in the NGF mechanism of action.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Columbia University			Volonté, Cinzia/N-6474-2013	Volonté, Cinzia/0000-0001-7362-8307				AHN NG, 1991, J BIOL CHEM, V266, P4220; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERG MM, 1992, J BIOL CHEM, V267, P13; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DRINKWATER CC, 1992, P R SOC LOND B, V246, P307; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P1; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; PAVNE DM, 1991, EMBO J, V10, P885; RADEKE MJ, 1991, NEURON, V7, P141, DOI 10.1016/0896-6273(91)90082-B; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSS AH, 1991, CELL REGUL, V2, P685, DOI 10.1091/mbc.2.9.685; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO H, 1990, J BIOL CHEM, V265, P15471; TSAO H, 1991, J BIOL CHEM, V266, P12981; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VOLONTE C, 1992, J BIOL CHEM, V267, P21663; VOLONTE C, 1993, MOL BIOL CELL, V4, P71, DOI 10.1091/mbc.4.1.71; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; VOLONTE C, 1992, J NEUROCHEM, V58, P700, DOI 10.1111/j.1471-4159.1992.tb09774.x; VOLONTE C, 1990, J BIOL CHEM, V265, P11050; VOLONTE C, 1993, IN PRESS J NEUROCHEM; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	63	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21410	21415						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407983				2022-12-25	WOS:A1993MA28800111
J	MA, HW; BLITZER, RD; HEALY, EC; PREMONT, RT; LANDAU, EM; IYENGAR, R				MA, HW; BLITZER, RD; HEALY, EC; PREMONT, RT; LANDAU, EM; IYENGAR, R			RECEPTOR-EVOKED CL- CURRENT IN XENOPUS-OOCYTES IS MEDIATED THROUGH A BETA-TYPE PHOSPHOLIPASE-C - CLONING OF A NEW FORM OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-SUBUNITS; MESSENGER-RNA; G-PROTEINS; RAT-BRAIN; STIMULATION; GENE; ACTIVATION; EXPRESSION; DROSOPHILA; ISOZYMES	Xenopus oocytes exhibit a receptor-evoked Cl- current that is mediated through the activation of phospholipase C (PLC) and release of intracellular Ca2+. The identity of PLC(s) mediating this effect is unknown. We have cloned cDNAs encoding a new form of PLC-beta from a Xenopus oocyte cDNA library. The Xenopus PLC-beta has substantial (33-64%) homology with mammalian beta1, beta2, beta3, and beta4 phospholipase C and is closest to PLC-beta3, with 64% identity and 80% similarity. Injection of antisense oligonucleotides to a specific region of Xenopus PLC-beta results in degradation of its mRNA and significantly reduces Cl- currents evoked by both endogenous angiotensin receptors and expressed mammalian alpha1b-adrenergic receptors and M1-muscarinic receptors as compared to responses in sense oligonucleotide-injected oocytes. Inhibition of the M1-muscarinic response by antisense oligonucleotides was nonadditive with pertussis toxin inhibition. PLC antisense oligonucleotide-injected oocytes show Cl- current responses to IP3 that are indistinguishable from sense oligonucleotide-injected oocytes. Since the receptor responses are pertussis toxin-sensitive, we conclude that we have isolated a new form of PLC-beta involved in the pertussis toxin-sensitive receptor stimulation of the Ca2+ activated Cl- current in Xenopus oocytes.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; VET ADM MED CTR, DEPT PSYCHIAT, BRONX, NY 10468 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA)	MA, HW (corresponding author), CUNY MT SINAI SCH MED, DEPT PHARMACOL, BOX 1215, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.			Premont, Richard/0000-0002-8053-5026	NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; HEALY DP, 1992, AM J PHYSIOL, V263, pE355, DOI 10.1152/ajpendo.1992.263.2.E355; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JHON DY, 1993, J BIOL CHEM, V268, P6654; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIZ R, 1990, CIBA F SYMP, V150, P112; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LEE CW, 1993, IN PRESS J BIOL CHEM, V268; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SAKUTA H, 1991, EUR J PHARM-MOLEC PH, V208, P31, DOI 10.1016/0922-4106(91)90048-M; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763	31	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19915	19918						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397190				2022-12-25	WOS:A1993LY01900001
J	ERICKSON, PR; HERZBERG, MC				ERICKSON, PR; HERZBERG, MC			THE STREPTOCOCCUS-SANGUIS PLATELET AGGREGATION-ASSOCIATED PROTEIN - IDENTIFICATION AND CHARACTERIZATION OF THE MINIMAL PLATELET-INTERACTIVE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGEN; SURFACE; CHAIN; ADHESION; SEQUENCE; STRAINS; CLONING; TISSUE	Streptococcus sanguis expresses a cell wall-bound protein that induces the activation and aggregation of platelets. This platelet aggregation-associated protein (PAAP) contains a collagen-like, platelet-interactive domain within a 23-kDa protein fragment. To isolate the minimal platelet-interactive domain, p23 PAAP was digested with collagenase, and the digest chromatographed to isolate fractions with activity inhibitory to S. sanguis-induced platelet aggregation. The active fraction was then digested with cyanogen bromide, the product chromatographed, and a smaller inhibitory peptide isolated. Finally, this fraction was digested with endoproteinase Lys-C, and the digest fractionated. After each step, inhibitory activity resolved into single chromatographic peaks of 13 kDa (p13 PAAP), 2.7 kDa (p2.7 PAAP), and a minimal 7-mer peptide, respectively. These PAAP fragments showed similar ID50 (19-28 nM), suggesting that each contained a single copy of the platelet-interactive domain. The minimal 7-mer peptide was purified by immunoaffinity chromatography and reverse phase high pressure liquid chromatography. The primary structure was determined to be Pro-Gly-Glu-Gln-Gly-Pro-Lys. This sequence conforms to the predicted structural motif of the platelet-interactive domains of types I and III collagen. This 7-mer peptide is therefore the platelet-interactive domain of the PAAP from S. sanguis. Its structure explains the molecular basis for immunological cross-reactivity and functional similarity to the platelet-interactive domains of collagens.	UNIV MINNESOTA,SCH DENT,DEPT PREVENT SCI,17-164 MOOS HS TOWER,515 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH DENT,GRAD PROGRAM ORAL BIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000224, R01DE005501] Funding Source: NIH RePORTER; NIDCR NIH HHS [1 K15 DE00224, 2 R01 DE05501] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARNES MJ, 1980, THROMB RES, V18, P375, DOI 10.1016/0049-3848(80)90333-3; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CLAWSON CC, 1980, AM J HEMATOL, V9, P43, DOI 10.1002/ajh.2830090106; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DILLON HC, 1982, DENTAL MICROBIOLOGY, P388; ERICKSON PR, 1990, J BIOL CHEM, V265, P14080; ERICKSON PR, 1987, J IMMUNOL, V138, P3360; ERICKSON PR, 1992, J BIOL CHEM, V267, P10018; FACKLAM RR, 1977, J CLIN MICROBIOL, V5, P184; FITZSIMMONS CM, 1986, THROMB HAEMOSTASIS, V56, P95; GORDON JL, 1979, NATURE, V278, P13, DOI 10.1038/278013a0; HERZBERG MC, 1983, INFECT IMMUN, V42, P394, DOI 10.1128/IAI.42.1.394-401.1983; HERZBERG MC, 1979, J BIOL CHEM, V254, P1487; HERZBERG MC, 1983, INFECT IMMUN, V39, P1457, DOI 10.1128/IAI.39.3.1457-1469.1983; HERZBERG MC, 1990, INFECT IMMUN, V58, P4117, DOI 10.1128/IAI.58.12.4117-4125.1990; HERZBERG MC, 1992, INFECT IMMUN, V60, P4809, DOI 10.1128/IAI.60.11.4809-4818.1992; HERZBERG MC, 1985, MOL BASIS ORAL MICRO, P53; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; KARNIGVIAN A, 1980, BIOCHEM BIOPH RES CO, V96, P1579; KELLER PM, 1992, J BIOL CHEM, V267, P6899; MERRIL CR, 1982, ELECTROPHORESIS, V3, P17, DOI 10.1002/elps.1150030104; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MYERS LK, 1989, J EXP MED, V170, P1999, DOI 10.1084/jem.170.6.1999; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1980, THROMB HAEMOSTASIS, V43, P158; SAUS J, 1989, J BIOL CHEM, V264, P6318; SCHWARZ U, 1986, EUR J BIOCHEM, V157, P49, DOI 10.1111/j.1432-1033.1986.tb09636.x; SOBERAY AH, 1987, THROMB HAEMOSTASIS, V57, P222; SOMMER P, 1992, INFECT IMMUN, V60, P360, DOI 10.1128/IAI.60.2.360-365.1992; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SULLAM PM, 1987, INFECT IMMUN, V55, P1743, DOI 10.1128/IAI.55.8.1743-1750.1987; TERLECKYJ B, 1975, INFECT IMMUN, V11, P649, DOI 10.1128/IAI.11.4.649-655.1975; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022	37	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1646	1649						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420939				2022-12-25	WOS:A1993KH62000024
J	LEAVITT, AD; SHIUE, L; VARMUS, HE				LEAVITT, AD; SHIUE, L; VARMUS, HE			SITE-DIRECTED MUTAGENESIS OF HIV-1 INTEGRASE DEMONSTRATES DIFFERENTIAL-EFFECTS ON INTEGRASE FUNCTIONS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; RETROVIRAL INTEGRATION; PROTEIN CLEAVES; VIRAL-DNA; POL GENE; MUTATIONS; SEQUENCES; ENDS	The retroviral integrase (IN) protein is essential for integration of retroviral DNA into the host cell genome. To identify functional domains within the protein and to assess the importance of conserved residues, we performed site-directed mutagenesis of HIV-1 IN and analyzed the mutants in vitro for IN-mediated activities: 3' processing (att site-specific nuclease activity), strand transfer (the joining of att site oligonucleotides to target DNA), disintegration (the reverse of strand transfer), and integration site selection. Changing the conserved residue His-16 either to Cys or to Val in a proposed zinc-finger region had minimal effect on IN activities. Alteration of two highly conserved amino acid residues, Asp-116 --> Ile and Glu-152 --> Gly, each resulted in complete or nearly complete loss of 3' processing, strand transfer, and disintegration, whereas alteration of another conserved residue, Trp235 --> Glu, had no demonstrable effect on any of the activities in vitro. Two mutants, Asp-64 --> Val and Arg-199 --> CysDELTA, each demonstrated differential effects on IN activities. Asp-64 --> Val has no demonstrable strand transfer or disintegration activity yet maintains 3' processing activity at a diminished level. Arg199 --> CysDELTA, which lacks part of the carboxyl terminus of IN, has impaired strand transfer activity without loss of disintegration activity. Use of a target site selection assay showed that all of our mutants with strand transfer activity maintain the same integration pattern as wild type IN. We conclude that not all highly conserved IN residues are essential for IN activities in vitro, zinc coordination by the proposed zinc-finger domain may not be required for the activities assayed, alteration of single residues can yield differential effects on IN activities, and target site selection into naked DNA is not necessarily altered by changes in strand transfer activity.	UNIV CALIF SAN FRANCISCO,DEPT IMMUNOL & MICROBIOL,HSE 401,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BARR PJ, 1991, EXPRESSION SYSTEMS P, P51; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2526; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DONEHOWER LA, 1984, P NATL ACAD SCI-BIOL, V81, P6461, DOI 10.1073/pnas.81.20.6461; DONEHOWER LA, 1988, J VIROL, V62, P3958, DOI 10.1128/JVI.62.11.3958-3964.1988; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FRANCHINI G, 1989, P NATL ACAD SCI USA, V86, P2433, DOI 10.1073/pnas.86.7.2433; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KAHN E, 1991, NUCLEIC ACIDS RES, V19, P851; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LIN TH, 1989, PROTEINS, V5, P156, DOI 10.1002/prot.340050210; MYERS G, 1991, HUMAN RETROVIRUSES A; PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0; PANGANIBAN AT, 1984, P NATL ACAD SCI-BIOL, V81, P7885, DOI 10.1073/pnas.81.24.7885; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; QUINN TP, 1988, J VIROL, V62, P2307, DOI 10.1128/JVI.62.7.2307-2312.1988; ROTH MJ, 1991, J VIROL, V65, P2141, DOI 10.1128/JVI.65.4.2141-2145.1991; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROTH MJ, 1990, J VIROL, V64, P4709, DOI 10.1128/JVI.64.10.4709-4717.1990; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WHITCOMB JM, 1991, J VIROL, V65, P3906, DOI 10.1128/JVI.65.7.3906-3910.1991; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P297, DOI 10.1089/aid.1992.8.297	35	192	201	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2113	2119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420982				2022-12-25	WOS:A1993KH62000092
J	LOPEZCORCUERA, B; ALCANTARA, R; VAZQUEZ, J; ARAGON, C				LOPEZCORCUERA, B; ALCANTARA, R; VAZQUEZ, J; ARAGON, C			HYDRODYNAMIC PROPERTIES AND IMMUNOLOGICAL IDENTIFICATION OF THE SODIUM-COUPLED AND CHLORIDE-COUPLED GLYCINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; PLASMA-MEMBRANE; EXPRESSION CLONING; BRAIN; PURIFICATION; RECONSTITUTION; GLYCOPROTEIN; PROTEINS	We have recently reported the purification of the native sodium- and chloride-coupled glycine transporter from pig brain stem (Lopez-Corcuera, B. Vazquez, J., and Aragon, C. (1991) J. Biol. Chem. 266, 24809-24814). This preparation is essentially homogeneous and contains a unique 100-kDa polypeptide based on electrophoretic migration under denaturing conditions. In this paper we report the hydrodynamic characterization of the native transporter, solubilized in two different detergents, as well as the immunological identification of the protein. On the basis of results obtained from size-exclusion chromatography, we calculated the Stokes radii of transporter 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid (CHAPS) and transporter-cholate complexes to be 5.5 and 6.0 nm, respectively. In addition, from H2O/D2O sucrose density gradient sedimentation analysis, we calculated the molecular weight of protein-detergent complexes to be 115,000 and 160,000 in CHAPS and cholate, respectively, and the molecular weight of the protein moiety as 86,000. Finally, polyclonal antibodies raised against the 100-kDa polypeptide were found to immunoprecipitate specifically glycine transport activity. Taken together, the results reported herein corroborate the identity of the 100-kDa band as the sodium- and chloride-coupled glycine transporter and also suggest that in its native state the transporter is a monomeric protein.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CTR BIOL MOLEC,DEPT BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid			Aragon, Carmen/K-9783-2014; Corcuera, Beatriz López/D-5188-2009; Vazquez, Jesus/B-7697-2015	Aragon, Carmen/0000-0001-8287-9386; Corcuera, Beatriz López/0000-0002-0383-4241; Vazquez, Jesus/0000-0003-1461-5092; Alcantara Martin, Rafael/0000-0001-5152-9922				ACKERS GK, 1967, J BIOL CHEM, V242, P3237; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ARAGON MC, 1987, FEBS LETT, V212, P87, DOI 10.1016/0014-5793(87)81562-4; BERGER SP, 1991, MOL PHARMACOL, V39, P429; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; CLARKE S, 1975, J BIOL CHEM, V250, P5459; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HIRAYAMA BA, 1991, AM J PHYSIOL, V261, pC296, DOI 10.1152/ajpcell.1991.261.2.C296; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P72, DOI 10.1016/0003-2697(83)90651-6; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KERWIN RW, 1979, EUR J PHARMACOL, V54, P93, DOI 10.1016/0014-2999(79)90411-4; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XQ, 1990, J BIOL CHEM, V265, P15316; LIN QR, 1992, FEBS LETT, V305, P110; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1989, BIOCHIM BIOPHYS ACTA, V983, P247, DOI 10.1016/0005-2736(89)90240-X; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAYOR F, 1981, BIOCHEM J, V198, P535, DOI 10.1042/bj1980535; MCCORMICK JI, 1988, P NATL ACAD SCI USA, V85, P7877, DOI 10.1073/pnas.85.21.7877; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RADIAN R, 1986, J BIOL CHEM, V261, P5437; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Small DM, 1968, AM CHEM SOC ADV CHEM, V84, P31; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; [No title captured]	35	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2239	2243						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420992				2022-12-25	WOS:A1993KH62000110
J	MAY, A; NAIRN, RS; OKUMOTO, DS; WASSERMANN, K; STEVNSNER, T; JONES, JC; BOHR, VA				MAY, A; NAIRN, RS; OKUMOTO, DS; WASSERMANN, K; STEVNSNER, T; JONES, JC; BOHR, VA			REPAIR OF INDIVIDUAL DNA STRANDS IN THE HAMSTER DIHYDROFOLATE-REDUCTASE GENE AFTER TREATMENT WITH ULTRAVIOLET-LIGHT, ALKYLATING-AGENTS, AND CISPLATIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINKS; UV-INDUCED MUTATIONS; ESCHERICHIA-COLI; OVARY CELLS; TRANSCRIBED STRAND; PREFERENTIAL REPAIR; PYRIMIDINE DIMERS; 6-4 PHOTOPRODUCTS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS	We have analyzed gene-specific and strand-specific DNA damage and repair in the dihydrofolate reductase gene in hamster cells. Cells were UV-irradiated or treated with two types of chemotherapeutics, alkylating agents or cisplatin. UV-induced pyrimidine dimers were detected using a previoulsy published technique in which the T4 endonuclease V enzyme is used to create nicks at the lesion sites. 6-4 photoproducts were detected in a similar assay using ABC excinuclease after prior reversal of the pyrimidine dimers with photolyase. Adducts formed by the alkylating agents nitrogen mustard and dimethyl sulfate were quantitated by generating strand breaks at abasic sites after neutral depurination. Cisplatin-induced intrastrand adducts were detected with ABC excinuclease, and cisplatin interstrand cross-links were detected using a denaturation-reannealing reaction before electrophoresis. In accord with previous reports by other investigators, we find distinct strand specificity of the repair of pyrimidine dimers after UV; the transcribed strand was much more efficiently repaired than the nontranscribed strand. In contrast, there was little or no strand bias in the repair of the 6-4 photoproducts. For alkylating agents, a slight bias toward repair in the transcribed strand was found after treatment with nitrogen mustard, but there appeared to be no bias in the repair after treatment with dimethyl sulfate. Cisplatin interstrand cross-links are repaired with equal efficiency from the two strands, but the more common cisplatin-induced lesion, the intrastrand adduct, is preferentially repaired from the transcribed strand. In conclusion, there is strand bias in the repair of pyrimidine dimers and cisplatin intrastrand adducts, but the strand specificity of repair may not be a general feature for all DNA lesions, as we found little or no strand bias in the repair of other lesions studied.	NCI,DIV CANC TREATMENT,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; UNIV TEXAS,MD ANDERSON CANC CTR,DIV SCI PK RES,SMITHVILLE,TX 78957	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center			Bohr, Vilhelm/AAP-5931-2020					BARTLETT JD, 1991, MUTAT RES, V255, P247, DOI 10.1016/0921-8777(91)90028-N; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BILL CA, 1991, J BIOL CHEM, V266, P21821; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1989, LAB INVEST, V61, P143; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1985, J BIOL CHEM, V260, P1438; CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P1997, DOI 10.1093/nar/11.7.1997; CAROTHERS AM, 1991, P NATL ACAD SCI USA, V88, P5749, DOI 10.1073/pnas.88.13.5749; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHRISTIANS F C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P2; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; HANAWALT PC, 1989, GENOME, V31, P605, DOI 10.1139/g89-113; HUMPHREYS GO, 1975, BIOCHIM BIOPHYS ACTA, V383, P457, DOI 10.1016/0005-2787(75)90318-4; JONES JC, 1991, J BIOL CHEM, V266, P7101; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; LEADON SA, 1988, MOL CELL BIOL, V8, P5331, DOI 10.1128/MCB.8.12.5331; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEDOUX SP, 1990, J BIOL CHEM, V265, P14875; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PLOOY ACM, 1984, CANCER RES, V44, P2043; SADHU C, 1988, BIOTECHNIQUES, V6, P20; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANCAR A, 1984, J MOL BIOL, V172, P223, DOI 10.1016/S0022-2836(84)80040-6; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SICCHITANO D, 1988, P NATL ACAD SCI USA, V86, P3050; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; VOS JMH, 1987, CELL, V50, P789, DOI 10.1016/0092-8674(87)90337-0; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; VRIELING H, 1989, MOL CELL BIOL, V9, P2868; WASSERMANN K, 1990, J BIOL CHEM, V265, P13906	46	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1650	1657						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420940				2022-12-25	WOS:A1993KH62000025
J	RAMABHADRAN, TV; GANDY, SE; GHISO, J; CZERNIK, AJ; FERRIS, D; BHASIN, R; GOLDGABER, D; FRANGIONE, B; GREENGARD, P				RAMABHADRAN, TV; GANDY, SE; GHISO, J; CZERNIK, AJ; FERRIS, D; BHASIN, R; GOLDGABER, D; FRANGIONE, B; GREENGARD, P			PROTEOLYTIC PROCESSING OF HUMAN AMYLOID BETA-PROTEIN PRECURSOR IN INSECT CELLS - MAJOR CARBOXYL-TERMINAL FRAGMENT IS IDENTICAL TO ITS HUMAN COUNTERPART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CLEAVAGE SITE; IDENTIFICATION; PHOSPHORYLATION; EXPRESSION; BIOGENESIS; PEPTIDE	The predominant component of amyloid plaques of Alzheimer's disease is the amyloid beta protein (Abeta), a 39-42-amino-acid peptide derived by proteolysis of a family of precursors known as amyloid precursor proteins (APP). In mammalian brain and in cultured mammalian cells, the release of APP amino-terminal fragments into the extracellular medium occurs by a proteolytic cleavage within the Abeta domain, thereby precluding amyloidogenesis. Infection of Sf9 insect cells with baculovirus vectors containing APP cDNAs results in high levels of APP expression. The concomitant release of amino-terminal fragments of APP and the production of carboxyl-terminal, cell-associated cleavage products are observed. Here we demonstrate by direct protein microsequencing that the proteolytic processing of APP in the Sf9 cells generates a prominent carboxyl-terminal species that is identical to that produced in human cells, suggesting that the major pathway for proteolytic processing of APP is conserved among metazoans.	CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; SUNY STONY BROOK,DEPT PSYCHIAT & BEHAV SCI,STONY BROOK,NY 11794	Cornell University; NewYork-Presbyterian Hospital; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	RAMABHADRAN, TV (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.				NIA NIH HHS [AG 11508, AG 10491, AG 09464] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009464, P01AG010491, R55AG011508, R01AG011508] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GANDY SE, 1992, J NEUROCHEM, V58, P383, DOI 10.1111/j.1471-4159.1992.tb09322.x; GHISO J, 1989, BIOCHEM BIOPH RES CO, V163, P430, DOI 10.1016/0006-291X(89)92154-2; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNOPS J, 1991, J BIOL CHEM, V266, P7285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; RAMAKRISHNA N, 1991, BIOCHEM BIOPH RES CO, V174, P983, DOI 10.1016/0006-291X(91)91515-E; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TOMLINSON BE, 1984, GREENFIELDS NEUROPAT, P951; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	28	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2009	2012						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420974				2022-12-25	WOS:A1993KH62000078
J	JOHN, J; RENSLAND, H; SCHLICHTING, I; VETTER, I; BORASIO, GD; GOODY, RS; WITTINGHOFER, A				JOHN, J; RENSLAND, H; SCHLICHTING, I; VETTER, I; BORASIO, GD; GOODY, RS; WITTINGHOFER, A			KINETIC AND STRUCTURAL-ANALYSIS OF THE MG2+-BINDING SITE OF THE GUANINE NUCLEOTIDE-BINDING PROTEIN P21(H-RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVATING PROTEIN; H-RAS P21; INDUCED NEURONAL DIFFERENTIATION; PC12 CELLS; ESCHERICHIA-COLI; NUCLEOSIDE PHOSPHOROTHIOATES; TRIPHOSPHATE CONFORMATION; ONCOGENIC RAS-P21; MOLECULAR SWITCH; GENE-PRODUCT	The coordination and binding of the Mg2+ ion in the nucleotide-binding site of p21 have been investigated using site-directed mutagenesis, kinetic methods, and phosphorous NMR. Mg2+ in the p21.nucleotide.Mg2+ complex appears to be in fast equilibrium with the solvent. The dissociation constant between Mg2+ and the p21.GDP complex was determined to be 2.8 muM. It decreases 30- or 16-fold on substituting Ser-17 or Asp-57 with alanine, respectively, whereas the T35A mutation has no effect. All three mutations influence the dissociation constants and the association and dissociation rate constants of the interaction between guanine nucleotides and p21, but to a different degree. We conclude that Thr-35 is only complexed to Mg2+ in the GTP conformation and both Asp-57 and Ser-17 appear to be critical for both GDP and GTP binding. P-31 NMR spectra of the GDP and Gpp(NH)p (guanosine-5'-(beta,gamma-imido)triphosphate) complexes of mutated p21 show a remarkable perturbation of the guanine nucleotide-binding site compared to wild-type protein. The mutant proteins show reduced GTPase rates, which are not stimulated by the GTPase-activating protein GAP. p21(S17A) has been reported to function just as p21(S17N) as a dominant negative inhibitor of normal p21. We find that it inhibits oncogenic p21-induced survival of primary neurons.	MAX PLANCK INST MED RES, BIOPHYS ABT, W-6900 HEIDELBERG 1, GERMANY; UNIV MUNICH, KLINIKUM GROSSHADERN, NEUROL KLIN, W-8000 MUNICH 70, GERMANY	Max Planck Society; University of Munich			Schlichting, Ilme/I-1339-2013; Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Borasio, Gian Domenico/0000-0002-2737-3662				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORASIO GD, 1989, NEURON, V2, P1087; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CLELAND WW, 1982, METHOD ENZYMOL, V87, P159; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEUERSTEIN J, 1987, EUR J BIOCHEM, V162, P49, DOI 10.1111/j.1432-1033.1987.tb10540.x; FRECH M, 1990, J BIOL CHEM, V265, P6353; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1986, TETRAHEDRON LETT, V27, P3599, DOI 10.1016/S0040-4039(00)84859-5; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, G PROTEINS MEDIATORS, P173; JAFFE EK, 1979, J BIOL CHEM, V254, P839; JOHN J, 1989, NATO ADV SCI I A-LIF, V165, P209; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1988, J BIOL CHEM, V263, P11792; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KALBITZER HR, 1987, MET IONS BIOL SYST, V22, P81; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MITSOU MY, 1992, EMBO J, V11, P2391; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; QIU MS, 1991, J CELL BIOL, V115, P795, DOI 10.1083/jcb.115.3.795; RAO BDN, 1989, METHOD ENZYMOL, V176, P279; RAY BD, 1988, BIOCHEMISTRY-US, V27, P8669, DOI 10.1021/bi00423a024; Reed G., 1984, BIOL MAGN RESON, V6, P73; ROSCH P, 1986, BIOCHEM BIOPH RES CO, V135, P549, DOI 10.1016/0006-291X(86)90029-X; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHLICHTING I, 1990, BIOCHEMISTRY-US, V29, P504, DOI 10.1021/bi00454a026; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SMITHERS GW, 1990, ARCH BIOCHEM BIOPHYS, V280, P416, DOI 10.1016/0003-9861(90)90351-X; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	58	218	220	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					923	929						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419371				2022-12-25	WOS:A1993KG07700028
J	BOWMAN, EP; UHLINGER, DJ; LAMBETH, JD				BOWMAN, EP; UHLINGER, DJ; LAMBETH, JD			NEUTROPHIL PHOSPHOLIPASE-D IS ACTIVATED BY A MEMBRANE-ASSOCIATED RHO FAMILY SMALL MOLECULAR-WEIGHT GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GDP/GTP EXCHANGE PROTEINS; BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDES; NADPH OXIDASE; REGULATORY COMPONENT; CHEMOTACTIC PEPTIDE; HL-60 GRANULOCYTES; ADENYLYL CYCLASE; PHOSPHATIDYLCHOLINE; IDENTIFICATION	Phospholipase D in human neutrophil lysates is activated by GTPgammaS (guanosine 5'-O-(3-thiotriphosphate)), implying the participation of a GTP-binding protein. Reconstitution of GTPgammaS-dependent activity requires protein factors in both the plasma membrane and the cytosol (Olson, S. C., Bowman, E. P., and Lambeth, J. D. (1991) J. Biol. Chem. 266,17236-17242). The location of the GTP-binding protein was investigated by preincubating either cytosol or plasma membrane with GTPgammaS, followed by removal of all but tightly bound nucleotide and reconstituting activity with the complementing untreated subcellular fraction. This approach indicated that the GTP-binding protein was membrane-associated. A low magnesium requirement for GTPgammaS prebinding, as well as a failure of aluminum fluoride to activate, suggested a Ras-like small M(r) GTP-binding protein. smg GDP dissociation stimulator, which stimulates the exchange of GDP for GTP on a variety of small GTP-binding proteins, stimulated GTP-dependent phospholipase D activity. Rho GDP dissociation inhibitor, a regulatory protein that binds specifically to and inhibits the functions of Rho family small GTP-binding proteins, inhibited GTPgammaS-dependent activity. Thus, neutrophil phospholipase D is regulated by a membrane-associated small molecular weight GTP-binding protein, likely to be a member of the Rho family.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline; NIGMS NIH HHS [T32 GM08367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO S, 1992, J BIOL CHEM, V267, P25709; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOSNER RW, 1989, BIOCHEM J, V264, P617; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHUANG TH, 1993, J BIOL CHEM, V268, P775; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; IYENGAR R, 1982, P NATL ACAD SCI-BIOL, V79, P5179, DOI 10.1073/pnas.79.17.5179; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; LAMBETH JD, 1993, PROTEIN KINASE; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; QIAN Z, 1989, J BIOL CHEM, V264, P21720; QUILLIAM LA, 1990, SEC MESS PHOSPHOPROT, V13, P59; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAMIR A, 1990, BIOCHEMISTRY-US, V29, P6947, DOI 10.1021/bi00482a002; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WANG P, 1991, J BIOL CHEM, V266, P14877; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081	39	244	246	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21509	21512						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408000				2022-12-25	WOS:A1993MC80900015
J	ROSORIUS, O; ISSINGER, OG; BRAULKE, T				ROSORIUS, O; ISSINGER, OG; BRAULKE, T			PHOSPHORYLATION OF THE CYTOPLASMIC TAIL OF THE 300-KDA MANNOSE 6-PHOSPHATE RECEPTOR IS REQUIRED FOR THE INTERACTION WITH A CYTOSOLIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-II RECEPTOR; GOLGI	The cytoplasmic tail of the human 300-kDa mannose 6-phosphate receptor (MPR 300-CT) is an excellent substrate for casein kinase II in vitro. The phosphorylated MPR 300-CT was cross-linked by means of bis(sulfosuccinimidyl) suberate mainly to a cytosolic protein of 35 kDa (referred to as TIP 35) and to 35- and 91-kDa proteins salt-washed from bovine brain membranes. Gel filtration suggested that TIP 35 is part of a higher molecular mass complex of approximately 130-150 kDa. Inhibition studies, using non-phosphorylated and phosphorylated MPR 300-CT and cross-linking, indicate that the interaction with TIP 35 is phosphorylation-specific. Furthermore, TIP 35 was only cross-linked to the MPR 300-CT phosphorylated by casein kinase II whereas the MPR 300-CT phosphorylated by protein kinase A failed to cross-link to TIP 35. These results indicate that the cytoplasmic tail of the MPR 300 interacts with a cytosolic protein depending on the phosphorylation by a casein kinase II-like kinase. The cross-linking with salt-washed membrane proteins, however, is inhibited by non-phosphorylated MPR 300-CT, suggesting that different structural determinants in the MPR 300-CT interact with cytosol- and membrane-derived proteins.	UNIV GOTTINGEN,INST BIOCHEM 2,GOSSLERSTR 12D,D-37073 GOTTINGEN,GERMANY; UNIV SAARLAND,INST HUMAN GENET,D-66421 HOMBURG,GERMANY	University of Gottingen; Saarland University			Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; DAMKE H, 1991, J BIOL CHEM, V266, P24829; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONFIGURA K, 1985, BIOCHEM J, V225, P543, DOI 10.1042/bj2250543	14	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21470	21473						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407994				2022-12-25	WOS:A1993MC80900005
J	WANG, GL; SEMENZA, GL				WANG, GL; SEMENZA, GL			CHARACTERIZATION OF HYPOXIA-INDUCIBLE FACTOR-I AND REGULATION OF DNA-BINDING ACTIVITY BY HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; MESSENGER-RNA LEVELS; RHIZOBIUM-MELILOTI; PROTEIN-SYNTHESIS; TRANSGENIC MICE; ENHANCER ELEMENT; HEPATOMA-CELLS; OXYGEN SENSOR; PHORBOL ESTER; TRANSCRIPTION	Hypoxia-inducible factor 1 (HIF-1) is a DNA binding activity detected in nuclear extracts from Hep3B cells cultured in 1% O2 but not in extracts from cells cultured in 20% O2. HIF-1 binds to a sequence within the human erythropoietin gene enhancer that is required for hypoxic activation of transcription. Induction of HIF-1 is inhibited by cycloheximide, which also inhibits induction of erythropoietin RNA. We now demonstrate that induction of both HIF-1 and erythropoietin RNA is inhibited by the protein kinase inhibitor 2-aminopurine. HIF-1 binding to DNA was eliminated by phosphatase treatment of nuclear extracts. Actinomycin D also inhibited HIF-1 induction, suggesting that de novo transcription is required. The kinetics of HIF-1 induction by hypoxia paralleled the kinetics of erythropoietin gene transcriptional induction. HIF-1 DNA binding activity decayed rapidly when hypoxic cells were exposed to increased oxygen tension. In vitro, the kinetics of HIF-1 association with, and dissociation from, its binding site were extremely rapid, with a t1/2 for both processes of <1 min. These findings are consistent with the proposed function of HIF-1 as a physiologic regulator of gene expression that responds to changes in cellular oxygen tension. Methylation interference analysis indicated that HIF-1 makes specific contacts with DNA in the major groove.	JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, DEPT PEDIAT, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University								BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1990, J BIOL CHEM, V265, P14100; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DEBENEDETTI A, 1983, J BIOL CHEM, V258, P4556; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAGAWA S, 1991, BLOOD, V77, P278; JELKMANN W, 1991, BIOCHEM BIOPH RES CO, V179, P1441, DOI 10.1016/0006-291X(91)91734-T; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KOURY MJ, 1988, J CLIN INVEST, V82, P154, DOI 10.1172/JCI113564; KOURY ST, 1989, BLOOD, V74, P645; KRANTZ SB, 1991, BLOOD, V77, P419; KURTZ A, 1992, AM J PHYSIOL, V262, pC1204, DOI 10.1152/ajpcell.1992.262.5.C1204; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562	37	707	770	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21513	21518						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408001				2022-12-25	WOS:A1993MC80900016
J	HAUGEN, BR; WOOD, WM; GORDON, DF; RIDGWAY, EC				HAUGEN, BR; WOOD, WM; GORDON, DF; RIDGWAY, EC			A THYROTROPE-SPECIFIC VARIANT OF PIT-1 TRANSACTIVATES THE THYROTROPIN-BETA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GHF-1; POU-SPECIFIC DOMAIN; SUBUNIT GENE; NUCLEOTIDE-SEQUENCE; GLYCOPROTEIN HORMONES; MURINE THYROTROPIN; RAT THYROTROPIN; DNA-BINDING; PITUITARY; PROTEIN	Thyrotropin (TSH) beta is a subunit of TSH, the expression of which is limited to the thyrotrope cells of the anterior pituitary gland. Tissue-specific expression of the mouse TSHbeta gene is conferred by sequences between -270 and -80 of the 5'-flanking region. We have investigated tissue-specific expression of the TSHbeta promoter in two thyrotrope-derived cell types: 1) TtT-97 thyrotropic tumors, which express the endogenous TSHbeta gene, and 2) an alpha-TSH cell line, which was generated from a thyrotropic tumor that has lost the ability to express the TSHbeta gene. The pituitary-specific transcription factor Pit-1 is present in thyrotropes and interacts with three cis-acting elements in the functionally important region of the TSHbeta promoter. Pit-1 protein is present in TtT-97 tumor cells but is absent from alpha-TSH cells. Reintroduction of Pit-1 into alpha-TSH cells by transient transfection does not restore TSHbeta promoter activity. We have identified an alternately spliced variant of Pit-1, called Pit-1T, the mRNA and protein expression of which is limited to thyrotrope-derived cells. Pit-1T contains a 14-amino acid insert in the transactivation domain due to an alternate 3' splice acceptor site. Transiently transfected Pit-1T increases TSHbeta promoter activity in TtT-97 thyrotropic tumor cells, whereas additional Pit-1 has no effect. The alpha-TSH cell line, which lacks all Pit-1 proteins, requires both isoforms in order to stimulate TSHbeta promoter activity. These data suggest that Pit-1T is a thyrotrope-specific splice variant of Pit-1 that is required for TSHbeta promoter stimulation; furthermore, both Pit-1 and Pit-1T are required for TSHbeta promoter activity in thyrotrope cells.			HAUGEN, BR (corresponding author), UNIV COLORADO, HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,BOX B151, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL CANCER INSTITUTE [P30CA046934, R01CA047411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036843] Funding Source: NIH RePORTER; NCI NIH HHS [CA47411, CA46934] Funding Source: Medline; NIDDK NIH HHS [DK36843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER LM, 1989, MOL ENDOCRINOL, V3, P1037, DOI 10.1210/mend-3-7-1037; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COTE GJ, 1992, NUCLEIC ACIDS RES, V20, P2361, DOI 10.1093/nar/20.9.2361; CROYLE ML, 1986, DNA-J MOLEC CELL BIO, V5, P299, DOI 10.1089/dna.1986.5.299; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DELSERT CD, 1992, J BIOL CHEM, V267, P14573; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P679, DOI 10.1089/dna.1988.7.679; GORDON DF, 1990, MOL CELL ENDOCRINOL, V71, P93, DOI 10.1016/0303-7207(90)90246-5; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P17, DOI 10.1089/dna.1988.7.17; GORDON DF, 1992, 74TH ANN M END SOC S, P451; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KIM MK, 1991, THYROID, V1, pS60; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; OHTA K, 1992, BIOCHEM BIOPH RES CO, V189, P851, DOI 10.1016/0006-291X(92)92281-2; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P829, DOI 10.1210/mend-4-6-829; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; VOSS JW, 1991, J BIOL CHEM, V266, P12832; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840	41	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20818	20824						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407911				2022-12-25	WOS:A1993MA28800030
J	MOTTRAM, JC; KINNAIRD, JH; SHIELS, BR; TAIT, A; BARRY, JD				MOTTRAM, JC; KINNAIRD, JH; SHIELS, BR; TAIT, A; BARRY, JD			A NOVEL CDC2-RELATED PROTEIN-KINASE FROM LEISHMANIA-MEXICANA, LMMCRK1, IS POSTTRANSLATIONALLY REGULATED DURING THE LIFE-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; CONTROL GENE CDC2+; CELL DIVISION CYCLE; FISSION YEAST; M-PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; CRITHIDIA-FASCICULATA; TRYPANOSOMA-BRUCEI; HISTONE-H1 KINASE	The p34CDC2 protein kinase is a key component in the regulation of the eukaryotic cell cycle. We have isolated from the protozoan parasite Leishmania mexicana mexicana a CDC2-related kinase gene (Lmmcrk1) encoding a 34-kDa protein kinase (lmmCRK1) which has 56% amino acid identity with the human CDC2 and contains a PCTAIR motif in place of the highly conserved PSTAIR box. lmmCRK1 was detected in all life cycle stages at comparable levels, yet its histone H1 kinase activity was detected in only the promastigote form, indicating that its activity is stage-regulated at a post-translational level. lmmCRK1 did not bind p13suc1 beads and Lmmcrk1 was unable to complement a fission yeast temperature-sensitive cdc2 mutant. These data suggest that Lmmcrk1 is unlikely to be the functional L. mexicana cdc2 homologue. A distinct histone H1 kinase activity that binds p13suc1 beads (SBCRK) was also detected, with activity that correlated with the division status of the developmental forms of the parasite, being present in the dividing stages of the parasite and absent in nondividing metacyclic forms. SBCRK is a candidate for the functional CDC2 homologue, but it does not react with an anti-PSTAIR monoclonal antibody on Western blots when eluted from p13suc1 beads, indicating a divergent PSTAIR box. These data suggest that a family of CDC2-related protein kinases are present in Leishmania. Some share sequence and biochemical properties with CDC2, but significant differences also exist, possibly reflecting the evolutionary distance between Leishmania and higher eukaryotes.	UNIV GLASGOW, DEPT VET PARASITOL, GLASGOW G11 5JS, SCOTLAND	University of Glasgow	MOTTRAM, JC (corresponding author), UNIV GLASGOW, INST GENET, WELLCOME UNIT MOLEC PARASITOL, CHURCH ST, GLASGOW G11 5JS, SCOTLAND.			Mottram, Jeremy/0000-0001-5574-3766; Shiels, Brian/0000-0001-7595-2514	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BERGER SL, 1987, METHOD ENZYMOL, V152, P215; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROWN L, 1992, NUCLEIC ACIDS RES, V20, P5451, DOI 10.1093/nar/20.20.5451; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; Cox F. E., 1982, MODERN PARASITOLOGY; DRAETTA G, 1989, J CELL SCI, P21; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1985, MOL GEN GENET, V201, P543, DOI 10.1007/BF00331353; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEILER HS, 1990, P NATL ACAD SCI USA, V87, P5397, DOI 10.1073/pnas.87.14.5397; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HINZE E, 1992, DEV GROWTH DIFFER, V34, P363; JENNI L, 1986, NATURE, V322, P173, DOI 10.1038/322173a0; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; JOHN PCL, 1989, PLANT CELL, V1, P1185; JOHN PCL, 1991, PROTOPLASMA, V161, P70, DOI 10.1007/BF01328899; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; Killick-Kendrick R., 1986, Journal of the Royal Army Medical Corps, V132, P134; KREK W, 1992, NEW BIOL, V4, P323; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MALLINSON DJ, 1989, PARASITOLOGY, V98, P7, DOI 10.1017/S0031182000059631; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; MOTTRAM JC, 1989, MOL BIOCHEM PARASIT, V37, P115, DOI 10.1016/0166-6851(89)90108-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; NORTH MJ, 1983, MOL BIOCHEM PARASIT, V9, P161, DOI 10.1016/0166-6851(83)90107-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, New Biologist, V2, P389; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; SACKS DL, 1985, AM J TROP MED HYG, V34, P456, DOI 10.4269/ajtmh.1985.34.456; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Sambrook J, 1989, MOL CLONING LABORATO; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TURNER CMR, 1992, PARASITOL TODAY, V8, P3, DOI 10.1016/0169-4758(92)90295-D; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI A, 1991, DEV GROWTH DIFFER, V33, P625; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; [No title captured]	79	58	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21044	21052						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407941				2022-12-25	WOS:A1993MA28800063
J	ROSING, J; BAKKER, HM; THOMASSEN, MCLGD; HEMKER, HC; TANS, G				ROSING, J; BAKKER, HM; THOMASSEN, MCLGD; HEMKER, HC; TANS, G			CHARACTERIZATION OF 2 FORMS OF HUMAN FACTOR-VA WITH DIFFERENT COFACTOR ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; BOVINE FACTOR-V; THROMBIN-CATALYZED ACTIVATION; PHOSPHOLIPID-VESICLES; FACTOR-XA; BINDING-SITE; PROTHROMBINASE COMPLEX; VARYING COMPOSITION; MEMBRANE-BINDING; PROTEIN-C	Factor Va is an essential cofactor in factor Xa-catalyzed prothrombin activation. Purified human factor Va appears to consist of a heavy chain (M(r) almost-equal-to 105,000) and a light chain doublet with M(r) almost-equal-to 74,000 and almost-equal-to 71,000. We separated factor Va by chromatography on a Mono-S column into two fractions, designated factors Va1 and Va2. Factor Va1 contains the light chain with M(r) almost-equal-to 74,000, and factor Va2 exclusively contains the light chain with M(r) almost-equal-to 71,000. The two forms of factor Va express different cofactor activities when prothrombin is activated at low phospholipid concentrations or on membranes containing low amounts of phosphatidylserine in phosphatidylcholine. Compared with factor Va2, much higher amounts of factor Va1 are required for factor Xa.Va complex formation at the membrane surface. Once incorporated into the prothrombinase complex, factors Va1 and Va2 are equally active in prothrombin activation. This indicates that the two forms of factor Va do not differ in their ability to promote the catalytic activity of factor Xa or to interact with prothrombin. Direct binding experiments show that the different cofactor activities are explained by a greatly impaired ability of factor Va1 to bind to negatively charged membranes. Factor V is also separated into two protein peaks after chromatography on a Mono-S column. Upon incubation with thrombin, the first peak yields factor Va1 and the second peak factor Va2. The same two forms of factor Va were generated when freshly prepared plasma samples or platelet suspensions were treated with thrombin. This shows that the heterogeneity of the light chain domain is an intrinsic property of both plasma and platelet factor V. It is hypothesized that the heterogeneity is caused by small differences in the carboxyl-terminal C2 domain of factor V that are introduced as the result of post-ribosomal processing.			ROSING, J (corresponding author), UNIV LIMBURG,INST CARDIOVASC RES,DEPT BIOCHEM,POB 616,6200 MD MAASTRICHT,NETHERLANDS.			Thomassen, Stella/0000-0002-9686-6364; Hemker, Coen/0000-0003-1669-2358				BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ESMON CT, 1979, J BIOL CHEM, V254, P964; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1981, J BIOL CHEM, V256, P1002; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SMITH RL, 1973, J BIOL CHEM, V248, P2418; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, BLOOD, V77, P2641; TANS G, 1991, J BIOL CHEM, V266, P21864; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008	37	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21130	21136						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407949				2022-12-25	WOS:A1993MA28800074
J	SUMBILLA, C; LU, L; LEWIS, DE; INESI, G; ISHII, T; TAKEYASU, K; FENG, Y; FAMBROUGH, DM				SUMBILLA, C; LU, L; LEWIS, DE; INESI, G; ISHII, T; TAKEYASU, K; FENG, Y; FAMBROUGH, DM			CA(2+)-DEPENDENT AND THAPSIGARGIN-INHIBITED PHOSPHORYLATION OF NA+,K+-ATPASE CATALYTIC DOMAIN FOLLOWING CHIMERIC RECOMBINATION WITH CA(2+)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CA2+ TRANSPORT ATPASE; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; ADENOSINE-TRIPHOSPHATASE; LYSYL RESIDUE; HIGH-AFFINITY; BINDING SITE; CALCIUM; EXPRESSION	Two chimeric proteins comprising the Na,K-ATPase catalytic domain (large cytosolic loop) and the two flanking regions of the Ca-ATPase were obtained by transient or stable expression in mammalian cells transfected with recombinant DNA. In the first chimera (CpNC), a large portion (containing the nucleotide-binding site) of the cytosolic loop between putative membrane spans M4 and M5 of the sarcoendoplasmic reticulum Ca2+ (SERCA) 1 (fast muscle) ATPase was replaced by the corresponding portion of the Na,K-ATPase al subunit. In the second chimera (CNpC), an even larger portion (containing the nucleotide-binding site and the phosphorylation site) of the analogous cytosolic loop of the SERCA2 (cardiac muscle) ATPase was replaced by the corresponding portion of the Na,K-ATPase alpha1 subunit. Steady state Ca2+ transport and coupled ATP hydrolysis by the chimeric proteins were negligible as compared to those obtained with SERCA enzymes. Nevertheless, the chimeric proteins were able to utilize ATP to form phosphoenzyme levels equal to those formed by SERCA ATPases. Chimeric and SERCA enzymes exhibited an identical Ca2+ requirement for ATP utilization and sensitivity to thapsigargin (TG) which is a specific inhibitor of SERCA ATPase and not of Na,K-ATPase. Furthermore, both SERCA and chimeric enzymes could be phosphorylated with P(i), and this reaction required removal of Ca2+. In comparative experiments, the functional pattern of seemingly unaffected phosphoenzyme formation and inhibited Ca2+ transport was produced in the SERCA ATPase even by single mutation of Pro337 to Ala, evidently due to defective protein conformation. Retention of Ca2+ and TG sensitivity by the chimeric proteins demonstrates that the Ca2+- and TG-binding domains do not reside within the cytosolic loop replaced by chimeric substitution and strongly support previous studies suggesting that binding of calcium required for enzyme activation occurs within the membrane-bound region of the SERCA ATPases (Clarke et al., 1989a; Sumbilla et al., 1991).	OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Ohio State University; Ohio State University; Johns Hopkins University	SUMBILLA, C (corresponding author), UNIV MARYLAND, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA.							ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BLASIE JK, 1992, ANN NY ACAD SCI, V671, P11, DOI 10.1111/j.1749-6632.1992.tb43780.x; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CHADWICK CC, 1983, BIOCHIM BIOPHYS ACTA, V730, P201, DOI 10.1016/0005-2736(83)90334-6; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DEGANI C, 1973, J BIOL CHEM, V248, P8222; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HERRMANN T, 1986, EUR J BIOCHEM, V158, P550; HORGAN DJ, 1972, ANAL BIOCHEM, V48, P147, DOI 10.1016/0003-2697(72)90178-9; INESI G, 1973, J MOL BIOL, V81, P483, DOI 10.1016/0022-2836(73)90518-4; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; KLEMENS MR, 1988, FEBS LETT, V237, P4, DOI 10.1016/0014-5793(88)80160-1; KLEMENS MR, 1988, BIOCHEM BIOPH RES CO, V155, P236, DOI 10.1016/S0006-291X(88)81074-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; LUCKIE DB, 1991, FEBS LETT, V281, P231, DOI 10.1016/0014-5793(91)80400-W; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MURPHY AJ, 1977, ARCH BIOCHEM BIOPHYS, V180, P114, DOI 10.1016/0003-9861(77)90014-5; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	50	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21185	21192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407954				2022-12-25	WOS:A1993MA28800080
J	SMITH, BL; MACLEOD, MC				SMITH, BL; MACLEOD, MC			COVALENT BINDING OF THE CARCINOGEN BENZO[A]PYRENE DIOL EPOXIDE TO XENOPUS-LAEVIS 5-S DNA RECONSTITUTED INTO NUCLEOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR VIRUS PROMOTER; CORE PARTICLE; RNA GENE; CHROMATIN; RESOLUTION; HISTONES; PROTEINS; ADDUCTS; DISSOCIATION; ETHIDIUM	The sequence-specific interactions of bulky carcinogens with purified DNA might reasonably be expected to be altered when the DNA is organized into chromatin. We have approached this subject by studying the covalent binding of a potent carcinogen, 7r,8t-dihydroxy-9t,10t-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE-I) to nucleosomal and free DNA, using a defined fragment of DNA derived from the 5'-end of the 5 S rRNA gene of Xenopus laevis, reconstituted into nucleosomes by salt exchange with unlabeled chicken mononucleosomes. Micrococcal nuclease and hydroxyl radical ''footprinting'' experiments demonstrated the formation of a uniquely positioned nucleosome covering the transcriptional start point of the gene. The reconstituted nucleosomes or control DNA samples were modified with BPDE-I. DNA was repurified from the nucleosomal and control modification reactions and then irradiated with laser light at 355 nm, causing strand breaks at the positions of adducts. Nucleosomal DNA exhibited a marked decrease in the level of carcinogen binding, especially in the central 80-90 base pairs of the nucleosomal region. Interestingly, although overall binding was inhibited about 2-fold, the sequence-specific pattern of binding to deoxyguanosine residues seen with purified DNA was maintained in the nucleosomal DNA.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, SMITHVILLE, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center			Maddux, Bettye/D-1269-2009	Maddux, Bettye/0000-0001-5890-5249	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007296] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA035581] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000886] Funding Source: NIH RePORTER; NCI NIH HHS [CA 35581] Funding Source: Medline; NCRR NIH HHS [RR00886] Funding Source: Medline; NICHD NIH HHS [T32 HD07296-GT] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOLES TC, 1984, P NATL ACAD SCI-BIOL, V81, P5623, DOI 10.1073/pnas.81.18.5623; BOLES TC, 1986, BIOCHEMISTRY-US, V25, P3039, DOI 10.1021/bi00358a045; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; DITTRICH KA, 1991, CHEM RES TOXICOL, V4, P277, DOI 10.1021/tx00021a003; DITTRICH KA, 1991, CHEM RES TOXICOL, V4, P270, DOI 10.1021/tx00021a002; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; GEACINTOV NE, 1988, POLYCYCL AROMAT COMP, V2, P181; GOTTESFELD JM, 1987, MOL CELL BIOL, V7, P1612, DOI 10.1128/MCB.7.5.1612; Harvey R. G., 1991, POLYCYCLIC AROMATIC; HAUGHTPOWERS J, 1991, J MOL BIOL, V221, P795, DOI 10.1016/0022-2836(91)80176-U; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HOGAN ME, 1981, J BIOL CHEM, V256, P4504; JACK PI, 1982, CARCINOGENESIS, V3, P341, DOI 10.1093/carcin/3.3.341; KOOTSTRA A, 1979, CHEM-BIOL INTERACT, V28, P225, DOI 10.1016/0009-2797(79)90163-7; KOOTSTRA A, 1989, MOL CARCINOGEN, V1, P239, DOI 10.1002/mc.2940010406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MACLEOD MC, 1985, CHEM-BIOL INTERACT, V54, P45, DOI 10.1016/S0009-2797(85)80151-4; MACLEOD MC, 1989, MOL CARCINOGEN, V1, P245, DOI 10.1002/mc.2940010407; MACLEOD MC, 1988, CARCINOGENESIS, V9, P2133, DOI 10.1093/carcin/9.11.2133; MACLEOD MC, 1990, J THEOR BIOL, V142, P113, DOI 10.1016/S0022-5193(05)80016-5; Maniatis T., 1982, MOL CLONING; MAXAMAM, 1980, METHOD ENZYMOL, V65, P466; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5631, DOI 10.1021/bi00237a001; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MEEHAN T, 1979, NATURE, V277, P410, DOI 10.1038/277410a0; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MILLER EC, 1976, CHEM CARCINOGENS, P737; MOYER R, 1989, J BIOL CHEM, V264, P12226; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRUNELL A, 1983, BIOCHEMISTRY-US, V22, P4887, DOI 10.1021/bi00290a004; RAMSAY N, 1986, J MOL BIOL, V189, P179, DOI 10.1016/0022-2836(86)90389-X; REARDON DB, 1990, CARCINOGENESIS, V11, P165, DOI 10.1093/carcin/11.1.165; REARDON DB, 1989, CHEM RES TOXICOL, V2, P12, DOI 10.1021/tx00007a002; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; SLAGA TJ, 1979, CANCER RES, V39, P67; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; UBERBACHER EC, 1989, J BIOMOL STRUCT DYN, V7, P1; van Holde KE., 1989, SPRINGER SERIES MOL; WEISCHET WO, 1978, NUCLEIC ACIDS RES, V5, P139, DOI 10.1093/nar/5.1.139	57	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20620	20629						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397211				2022-12-25	WOS:A1993LY01900100
J	WISSELAAR, HA; KROOS, MA; HERMANS, MMP; VANBEEUMEN, J; REUSER, AJJ				WISSELAAR, HA; KROOS, MA; HERMANS, MMP; VANBEEUMEN, J; REUSER, AJJ			STRUCTURAL AND FUNCTIONAL-CHANGES OF LYSOSOMAL ACID ALPHA-GLUCOSIDASE DURING INTRACELLULAR-TRANSPORT AND MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; SUCRASE-ISOMALTASE COMPLEX; HUMAN BETA-HEXOSAMINIDASE; GLYCOGENOSIS TYPE-II; BRUSH-BORDER; HUMAN-FIBROBLASTS; MEMBRANE-PROTEIN; PRECURSOR FORM; PHOSPHATASE; ENZYMES	The synthesis and posttranslational modification of lysosomal acid alpha-glucosidase were studied in a cell-free translation system and in mammalian cells transfected with acid alpha-glucosidase cDNA constructs. The newly synthesized precursor, sequestered in the endoplasmic reticulum, was demonstrated to be membrane-bound by lack of signal peptide cleavage, and to be catalytically inactive. Sugar chain modification was shown to occur in the Golgi complex and to be dependent on the rate of transport. From the trans-Golgi network different routes were found to be followed by acid alpha-glucosidase. A fraction of precursor molecules, proteolytically released from the membrane anchor, appeared to enter the secretory pathway and was recovered from the cell culture medium in a catalytically active form. A second fraction was transported to the lysosomes and was trimmed in a stepwise process at both the amino- and carboxyl-terminal ends. The intramolecular cleavage sites were determined. Involvement of thiol proteinases was demonstrated. Specificity for the natural substrate glycogen was gained during the maturation process. The phosphomannosyl receptor is assumed to be instrumental in the lysosomal targeting of acid alpha-glucosidase, but a phosphomannosyl receptor-independent transport of membrane-bound precursor molecules to the lysosomes, either directly or via the plasma membrane, cannot be excluded.	ERASMUS UNIV,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS; STATE UNIV GHENT,MICROBIOL LAB,B-9000 GHENT,BELGIUM	Erasmus University Rotterdam; Ghent University								AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CREEK KE, 1984, LYSOSOM BIOL PATHOL, V7, P63; ELFERINK RPJO, 1984, EUR J BIOCHEM, V139, P497, DOI 10.1111/j.1432-1033.1984.tb08033.x; ELFERINK RPJO, 1984, EUR J BIOCHEM, V139, P489, DOI 10.1111/j.1432-1033.1984.tb08032.x; ELFERINK RPJO, 1989, EUR J CELL BIOL, V50, P299; FRANSEN JAM, 1988, EUR J CELL BIOL, V47, P72; FUJITA H, 1991, BIOCHEM BIOPH RES CO, V178, P444, DOI 10.1016/0006-291X(91)90127-S; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HERMANS MMP, 1993, IN PRESS BIOCH J; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HOEFSLOOT LH, 1990, BIOCHEM J, V272, P485, DOI 10.1042/bj2720485; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JEZEQUEL AM, 1965, LAB INVEST, V14, P1894; JONAS AJ, 1990, BIOCHEM J, V272, P323, DOI 10.1042/bj2720323; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLUMPERMAN J, 1991, J CELL SCI, V100, P339; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOSTER JF, 1972, EUR J CLIN INVEST, V2, P467, DOI 10.1111/j.1365-2362.1972.tb00678.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MARTINIUK F, 1990, AM J HUM GENET, V47, P440; MATTER K, 1990, J BIOL CHEM, V265, P3503; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P1184, DOI 10.1073/pnas.82.4.1184; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PHILLIPS MJ, 1967, J ULTRA MOL STRUCT R, V18, P142, DOI 10.1016/S0022-5320(67)80236-3; QUON DVK, 1989, J BIOL CHEM, V264, P3380; REUSER AJJ, 1978, AM J HUM GENET, V30, P132; REUSER AJJ, 1985, J BIOL CHEM, V260, P8336; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; ROSENFELD EL, 1975, PATHOL BIOL, V25, P71; SCHONHOLZER F, 1985, EUR J BIOCHEM, V147, P273, DOI 10.1111/j.1432-1033.1985.tb08747.x; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; STIRLING J, 1988, FEBS LETT, V231, P47, DOI 10.1016/0014-5793(88)80699-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI A, 1987, BIOCHEM INT, V15, P945; TSUJI A, 1988, J BIOCHEM-TOKYO, V104, P276, DOI 10.1093/oxfordjournals.jbchem.a122457; TSUJI A, 1988, BIOCHEM BIOPH RES CO, V151, P1358, DOI 10.1016/S0006-291X(88)80512-6; VANDONGEN JM, 1985, EUR J CELL BIOL, V39, P179; VANDONGEN JM, 1984, HISTOCHEM J, V16, P941, DOI 10.1007/BF01003850; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WILLEMSEN R, 1991, HISTOCHEM J, V23, P467, DOI 10.1007/BF01041377	57	133	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2223	2231						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420990				2022-12-25	WOS:A1993KH62000108
J	UNEMORI, EN; AMENTO, EP; BAUER, EA; HORUK, R				UNEMORI, EN; AMENTO, EP; BAUER, EA; HORUK, R			MELANOMA GROWTH-STIMULATORY ACTIVITY GRO DECREASES COLLAGEN EXPRESSION BY HUMAN FIBROBLASTS - REGULATION BY C-X-C BUT NOT C-C CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; NECROSIS-FACTOR-ALPHA; MOLECULAR CHARACTERIZATION; INFLAMMATORY CYTOKINES; ENDOTHELIAL-CELLS; I COLLAGEN; CLONING; GENE; SECRETION; PROTEINS	Melanoma growth-stimulatory activity (MGSA)/GRO is well characterized as a potent neutrophil chemoattractant. In the present study, we have demonstrated that MGSA induced a dose-dependent decrease in the expression of interstitial collagens by rheumatoid synovial fibroblasts. The decrease was observed over a dose range of 0.6-6.0 nM MGSA. This effect was specific, as MGSA had no demonstrable effect on the expression of collagen-degrading metalloproteinases, nor did it affect the collagenase inhibitor, tissue inhibitor of metalloproteinases. It also had no effect on the proliferation rate of these fibroblasts, unlike its mitogenic effect on melanoma cells. The ability to inhibit collagen expression was also demonstrated by another member of the C-X-C branch of the platelet factor 4 superfamily, interleukin-8 (IL-8), but not by RANTES, MIP-1alpha, or MIP-1beta, which belong to the C-C branch. Steady-state levels of expression of MGSA and IL-8 transcripts in normal adult tissues were dissimilar, suggesting that expression may be an important level at which the activity of these cytokines is regulated. Direct binding experiments with I-125-MGSA on synovial fibroblasts have allowed us to identify an MGSA receptor with a K(D) of 10.1 nM and approximately 75,000 binding sites/fibroblast. I-125-MGSA binding was specific and could not be displaced by unlabeled IL-8. These results suggest that MGSA, as well as IL-8, may play a role other than that of neutrophil chemo-attractant and more specifically, may be important in the regulation of collagen turnover.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; STANFORD UNIV,MED CTR,DEPT DERMATOL,STANFORD,CA 94305	Roche Holding; Genentech; Stanford University	UNEMORI, EN (corresponding author), GENENTECH INC,DEPT IMMUNOL,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.				NIAMS NIH HHS [AR 41045-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041045] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARRE PC, 1991, J CLIN INVEST, V88, P1802, DOI 10.1172/JCI115501; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; Fahey T J 3rd, 1990, Cytokine, V2, P92, DOI 10.1016/1043-4666(90)90002-B; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDS EE, 1989, BIOCHEM J, V259, P585, DOI 10.1042/bj2590585; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, J BIOL CHEM, V268, P541; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LEE J, 1992, J BIOL CHEM, V267, P16283; LOIDL HR, 1984, NUCLEIC ACIDS RES, V12, P9383, DOI 10.1093/nar/12.24.9383; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; SHERRY B, 1991, CURR OPIN IMMUNOL, V3, P56, DOI 10.1016/0952-7915(91)90077-E; TOKUNAGA K, 1987, CANCER RES, V47, P5616; UNEMORI EN, 1992, J INVEST DERMATOL, V99, P337, DOI 10.1111/1523-1747.ep12616665; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; Werb Z., 1989, TXB RHEUMATOLOGY, P300	35	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1338	1342						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419336				2022-12-25	WOS:A1993KG07700086
J	LATCHINIANSADEK, L; THOMAS, DY				LATCHINIANSADEK, L; THOMAS, DY			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE YEAST KEX1 GENE-PRODUCT, A POLYPEPTIDE PRECURSOR PROCESSING CARBOXYPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE PROTEIN; ALPHA-FACTOR; ENKEPHALIN CONVERTASE; KILLER TOXIN; ENZYMES; QUANTITIES; INHIBITORS; PROTEASES; MEMBRANES; SEQUENCE	The Saccharomyces cerevisiae KEX1 gene encodes a protease with carboxypeptidase B-like activity involved in K1 and K2 killer toxins and alpha-factor (mating pheromone) precursors processing. The gene has been expressed using the baculovirus/insect cell system, and the KEX1 encoded protein (Kex1p) was purified to apparent homogeneity from detergent-solubilized membrane preparations of insect cells infected with the recombinant virus. The specific activity of the enzyme was enriched 126-fold as compared with the cell lysate, with a recovery of 29%. The NH2-terminal sequence of the purified active enzyme was identical to the predicted sequence after the removal of the signal peptide. This provides evidence that Kex1p, at least in insect cells, is not made as a proenzyme. The optimum pH for activity was 6.0, and the apparent pI value of the protein was below pH 3.0. The enzyme cleaves arginine or lysine from the COOH terminus of synthetic peptides: benzoyl-Phe-Ala-Arg (K(m) = 284 muM), furylacryloyl (fa)-Ala-Arg (K(m) = 516 muM), and fa-Ala-Lys (K(m) = 962 muM). The kinetic data obtained reveals that Kex1p preferentially cleaves the COOH-terminal arginine of peptides over the COOH-terminal lysine. Insect-derived Kex1p processes alpha-factor-Lys-Arg, its known natural substrate, to mature active alpha-factor, and this maturation event takes place in a sequential manner. Furthermore, the enzyme expresses very high affinity for the 15-amino acid-long peptide, alpha-factor-Lys-Arg (K(i) = 22 muM), and somewhat lower affinity for the heptapeptides [Leu]enkephalin-Arg-Arg, -Arg-Lys, and [Met]enkephalin-Lys-Lys (K(i) = 45, 57, and 81 muM, respectively). The data demonstrate that processing at the COOH terminus of the peptides tested stops after the cleavage of the Arg and/or Lys residues. The specificity of the enzyme for COOH-terminal basic amino acid residues of the peptides used in this study and its high affinity for alpha-factor-Lys-Arg confirms the role that Kex1p plays in polypeptide precursor processing in yeast.	MCGILL UNIV,DEPT BIOL,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University	LATCHINIANSADEK, L (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,6100 AVE ROYALMOUNT,MONTREAL H4P 2R2,PQ,CANADA.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ACHSTETTER T, 1985, EMBO J, V4, P173, DOI 10.1002/j.1460-2075.1985.tb02333.x; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOURBONNAIS Y, 1992, IN PRESS ENZYME; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; DIGNARD D, 1991, MOL GEN GENET, V227, P127, DOI 10.1007/BF00260717; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1983, BIOCHEM BIOPH RES CO, V111, P994, DOI 10.1016/0006-291X(83)91398-0; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LYNCH DR, 1986, ANNU REV BIOCHEM, V55, P773, DOI 10.1146/annurev.bi.55.070186.004013; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; ROSSIER J, 1989, ANAL BIOCHEM, V178, P27, DOI 10.1016/0003-2697(89)90350-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; Summers MD, 1987, TEXAS AGR EXPT STATI; THOMAS L, 1990, J BIOL CHEM, V265, P10821; WAGNER JC, 1987, FEBS LETT, V221, P423, DOI 10.1016/0014-5793(87)80967-5; WALKER JM, 1992, IN PRESS BACULOVIRUS; [No title captured]	35	19	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					534	540						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416959				2022-12-25	WOS:A1993KE60300081
J	CHOU, DKH; JUNGALWALA, FB				CHOU, DKH; JUNGALWALA, FB			N-ACETYLGLUCOSAMINYLTRANSFERASE REGULATES THE EXPRESSION OF NEOLACTOGLYCOLIPIDS INCLUDING SULFOGLUCURONYLGLYCOLIPIDS IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLUCURONIC-ACID; HUMAN COLONIC ADENOCARCINOMA; PURKINJE-CELL ABNORMALITY; L2/HNK-1 CARBOHYDRATE; DEVELOPMENTAL EXPRESSION; HNK-1-REACTIVE ANTIGENS; BIOSYNTHESIS INVITRO; ADHESION MOLECULE; HNK-1 ANTIBODY; MURINE MUTANTS	Lactosylceramide N-acetylglucosaminyltransferase (GlcNAc-Tr) in the synthesis of lactotriosylceramide (LcOse3Cer) was characterized in the nervous system. The microsomal membrane GlcNAc-Tr required a divalent metal ion, preferably Mn2+, and a nonionic detergent. The pH optimum was around 7.0. The enzyme also transferred GlcNAc to neoactotetraosylceramide (nLcOse4Cer), G(M1), and asialo-G(M1), but not to other glycolipids. The K(m) value for lactosylceramide was 21 muM (V(max) = 91 pmol/mg/h), and that for nLcOse4Cer was 35 muM (V(max) = 112 pmol/mg/h). The GlcNAc-Tr for the glycolipids appears to be separate from that for oligosaccharides. The developmental expression of GlcNAc-Tr, both in the cerebral cortex and cerebellum, correlated well with the tissue levels of LcOse3Cer, nLcOse4Cer, sulfoglucuronylglycolipids (SGGLs), and other neolacto series glycolipids (nLSGs). In the cerebral cortex, the specific activity of GlcNAc-Tr decreased sharply from a maximum level at embryonic day 15, and by postnatal day 10 onward, it was undetectable. In the adult cerebral cortex, although significant activities of other glycosyltransferases involved in the subsequent steps of the synthesis of SGGLs were present, the absence of GlcNAc-Tr stymied the formation of LcOse3Cer and therefore the synthesis of nLSGs, including SGGLs. In the cerebellum, the GlcNAc-Tr specific activity declined from the day of birth to postnatal day 3, but later, the activity increased and reached a maximum at postnatal day 15, which correlated with the increasing synthesis of nLSGs. The results indicate that lactosylceramide GlcNAc-Tr is the key regulatory enzyme controlling the differential expression of all nLSGs in the developing nervous system.	EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, DEPT BIOMED SCI, 200 TRAPELO RD, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS24405] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABO T, 1982, J IMMUNOL, V129, P1752; ANDERSEN BB, 1992, J COMP NEUROL, V326, P549, DOI 10.1002/cne.903260405; ARIGA T, 1987, J BIOL CHEM, V262, P848; ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BASU M, 1987, METHOD ENZYMOL, V138, P575; BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; BASU M, 1984, J BIOL CHEM, V259, P2557; BONNERFRASER M, 1987, DEV BIOL, V123, P321; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CHOU DKH, 1992, T AM SOC NEUROCHEM, V23, P139; CHOU DKH, 1993, T AM SOC NEUROCHEM, V24, P264; CHOU DKH, 1993, IN PRESS J NEUROCHEM; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; DIXON M, 1964, ENZYMES, P72; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FIGLEWICZ DA, 1985, J LIPID RES, V26, P140; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HOLMES EH, 1991, ARCH BIOCHEM BIOPHYS, V288, P87, DOI 10.1016/0003-9861(91)90168-I; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1988, ARCH BIOCHEM BIOPHYS, V260, P461, DOI 10.1016/0003-9861(88)90470-5; KOHRIYAMA T, 1988, J NEUROCHEM, V51, P869, DOI 10.1111/j.1471-4159.1988.tb01823.x; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; NAIR SM, 1993, J COMP NEUROL, V332, P282, DOI 10.1002/cne.903320303; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; PESHEVA P, 1988, J NEUROSCI RES, V20, P420, DOI 10.1002/jnr.490200404; PILLER F, 1984, J BIOL CHEM, V259, P3385; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SCHACHTER H, 1989, METHOD ENZYMOL, V179, P351; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SHASHOUA VE, 1986, BIOCHEM BIOPH RES CO, V138, P902, DOI 10.1016/S0006-291X(86)80581-2; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; SVENNERHOLM L, 1991, J NEUROCHEM, V56, P1763, DOI 10.1111/j.1471-4159.1991.tb02078.x; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; 1977, LIPIDS, V12, P455	47	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21727	21733						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408027				2022-12-25	WOS:A1993MC80900048
J	CREEMERS, JWM; SIEZEN, RJ; ROEBROEK, AJM; AYOUBI, TAY; HUYLEBROECK, D; VANDEVEN, WJM				CREEMERS, JWM; SIEZEN, RJ; ROEBROEK, AJM; AYOUBI, TAY; HUYLEBROECK, D; VANDEVEN, WJM			MODULATION OF FURIN-MEDIATED PROPROTEIN PROCESSING ACTIVITY BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; VONWILLEBRAND-FACTOR VWF; SUBSTRATE-SPECIFICITY; KEX2-LIKE ENDOPROTEASE; GENE-EXPRESSION; PROTO-ONCOGENE; YEAST KEX2; ENZYME; CLEAVAGE; CDNA	The proprotein processing activity of mutants of the subtilisin-like enzyme furin was studied in transfected mammalian cells. Our studies indicate that the three residues of the catalytic triad of furin, Asp46, His87, and Ser261, are critical not only for substrate processing but also, for maturation of furin. Furthermore, evidence is provided that maturation of furin occurs through an intramolecular autocatalytic process. Substitution of the asparagine residue (Asn188) of the oxyanion hole by an alanine residue appears to block substrate processing but not furin maturation. Analysis of carboxyl-terminal deletion mutants revealed that the segment encompassing residues Glu449 to Glu469 of the ''middle'' domain, which is more than 100 residues downstream of the predicted catalytic domain, contains residues that seem to be critical for processing activity but that the more carboxyl-terminal cysteine-rich region, the transmembrane region, and the cytosolic tail are dispensable. Finally, we made mutants in the substrate binding region of human furin and, studied their ability to process von Willebrand factor (pro-vWF) substrates, including wild-type pro-vWF as well as pro-vWF mutants in which the P1 (vWFR-1G), P2 (vWFK-2A), or P4 (vWFR-4A) basic residue with respect to the pro region cleavage site had been mutated. It is demonstrated that particular negatively charged residues in or near the substrate binding region of furin are critical for cleavage activity and specificity of the enzyme for multiple basic residues in the substrate. Furthermore, substrate binding region mutants of furin were obtained, which cleaved either the pro-vWFK-2A or pro-vWFR-4A mutant of pro-vWF more efficiently than wild-type pro-vWF.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL LAB,HERESTR 49,B-3000 LOUVAIN,BELGIUM; NEDERLANDS INST ZUIVELONDERZOEK,DEPT BIOPHYS CHEM,6710 BA EDE,NETHERLANDS; CATHOLIC UNIV LEUVEN,CELGEN,MOLEC BIOL LAB,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven			Siezen, Roland J/P-5745-2015	Huylebroeck, Danny/0000-0003-4862-1079				ANDREASSON KI, 1989, FEBS LETT, V248, P43, DOI 10.1016/0014-5793(89)80428-4; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CHRETIEN M, 1967, CAN J BIOCHEM CELL B, V45, P1163, DOI 10.1139/o67-133; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; FEURST TO, 1986, P NATL ACAD SCI USA, V83, P8122; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARYNEN P, 1990, FEBS LETT, V262, P349, DOI 10.1016/0014-5793(90)80226-9; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1992, BLOOD, V79, P2349; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1993, EMBO J, V12, P1853, DOI 10.1002/j.1460-2075.1993.tb05834.x; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIEZEN RJ, 1993, IN PRESS SUBTILISIN; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1967, P NATL ACAD SCI USA, V57, P473, DOI 10.1073/pnas.57.2.473; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDEVEN WJM, 1992, ENZYME, V45, P257; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOS P, 1991, PROTEIN ENG, V4, P479, DOI 10.1093/protein/4.4.479; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P5167, DOI 10.1073/pnas.84.15.5167; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1	52	122	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21826	21834						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408037				2022-12-25	WOS:A1993MC80900061
J	KIM, JS; LOWE, KE; SHANE, B				KIM, JS; LOWE, KE; SHANE, B			REGULATION OF FOLATE AND ONE-CARBON METABOLISM IN MAMMALIAN-CELLS .4. ROLE OF FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE IN METHOTREXATE METABOLISM AND CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L1210 LEUKEMIA-CELLS; RAT-LIVER; TETRAHYDROFOLATE COFACTORS; FACILITATED TRANSPORT; HEPATOMA-CELLS; CYTO-TOXICITY; TUMOR-CELLS; S180 CELLS; POLYGLUTAMATES; INVITRO	Chinese hamster ovary (CHO) cells expressing human and Escherichia coli folylpoly-gamma-glutamate synthetase (FPGS) activities were used as models to study factors regulating the cytotoxicity and metabolism of methotrexate (MTX). CHO cells expressing human FPGS metabolized MTX to polyglutamates characteristic of human cells. Cellular MTX accumulation and metabolism to polyglutamates were dependent on the level of FPGS activity and were unaffected by putative gamma-glutamyl hydrolase inhibitors. The sensitivity of cells continuously exposed to MTX was not influenced by FPGS activity. After short term exposure to MTX, cells expressing higher levels of FPGS were more sensitive to the drug. MTX was not transported into the mitochondria and MTX treatment had no effect on preexisting mitochondrial folates while cytosolic folates were converted to oxidized forms. Mitochondrial folate accumulation was significantly impaired by MTX treatment, suggesting that the mitochondrial folate transport system is specific for reduced folates.	UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720	University of California System; University of California Berkeley					NCI NIH HHS [CA-41991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRUECO JR, 1992, J BIOL CHEM, V267, P19986; BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; COLL RJ, 1991, BIOCHEM PHARMACOL, V42, P833, DOI 10.1016/0006-2952(91)90043-5; COOK JD, 1987, BIOCHEMISTRY-US, V26, P530, DOI 10.1021/bi00376a027; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; FABRE I, 1984, CANCER RES, V44, P3190; FREISHEIM JH, 1984, FOLATE ANTAGONISTS T, V1, P69; GEORGE S, 1987, BIOCHEMISTRY-US, V26, P522, DOI 10.1021/bi00376a026; HAGAN RL, 1991, BIOCHEM PHARMACOL, V41, P781, DOI 10.1016/0006-2952(91)90081-F; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; Jackson R, 1984, FOLATE ANTAGONISTS T, V1, P289; JOHNSON TB, 1988, CANCER RES, V48, P2426; KALMAN T I, 1986, P583; KELLEY JL, 1990, J MED CHEM, V33, P561, DOI 10.1021/jm00164a014; Lenz H.-J., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P504; LI WW, 1992, CANCER RES, V52, P1434; LI WW, 1992, CANCER RES, V52, P3908; LIN BF, 1993, J BIOL CHEM, V268, P21674; LOWE KE, 1993, J BIOL CHEM, V268, P21665; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1985, CANCER RES, V45, P6395; MORAN RG, 1985, MOL PHARMACOL, V27, P156; NIMEC Z, 1983, ARCH BIOCHEM BIOPHYS, V226, P671, DOI 10.1016/0003-9861(83)90337-5; OCONNOR BM, 1991, CANCER RES, V51, P3874; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PIZZORNO G, 1988, CANCER RES, V48, P2149; PIZZORNO G, 1989, CANCER RES, V49, P5275; SAMUELS LL, 1986, CANCER RES, V46, P2230; SAMUELS LL, 1985, CANCER RES, V45, P1488; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SEITHER RL, 1991, J BIOL CHEM, V266, P4112; SHANE B, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P891; SHANE B, 1983, J BACTERIOL, V153, P316, DOI 10.1128/JB.153.1.316-325.1983; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SOKOLOSKI JA, 1989, CANCER RES, V49, P4824; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; WHITEHEAD VM, 1987, BIOCHEM BIOPH RES CO, V144, P292, DOI 10.1016/S0006-291X(87)80509-0; WHITEHEAD VM, 1990, BLOOD, V76, P44; WHITEHEAD VM, 1975, CANCER RES, V35, P2985; WILSON SD, 1984, ANAL BIOCHEM, V142, P529, DOI 10.1016/0003-2697(84)90502-5	44	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21680	21685						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408021				2022-12-25	WOS:A1993MC80900040
J	LIN, J; PAN, LP; CHAN, SI				LIN, J; PAN, LP; CHAN, SI			THE SUBUNIT LOCATION OF MAGNESIUM IN CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART; IDENTIFICATION; COPPER; YEAST; HEME	The magnesium ion in bovine heart cytochrome c oxidase can be depleted up to 75% by heat treatment of the enzyme at 43-degrees-C followed by dialysis against EDTA buffer solution. The magnesium-depleted enzyme so obtained retains 40% of the activity of the native enzyme. This is the first attempt to deplete magnesium ion from bovine heart cytochrome c oxidase without denaturation of the protein. Magnesium depletion exposes at least one carboxyl group on subunit IV for labeling by N-cyclohexyl-N'-(4-dimethylaminonaphthyl)carbodiimide (NCD-4). The NCD-4 labeling of subunit IV of the magnesium-depleted enzyme is significantly enhanced relative to what is observed for the native and heat-treated oxidase, suggesting that the magnesium ion is located in subunit IV with at least one carboxyl ligand. By comparing the activity of the magnesium-depleted enzyme with that of a control sample of heat-treated oxidase, the influence of divalent magnesium on the activity of the enzyme is assessed.	CALTECH, ARTHUR AMOS NOYES LAB CHEM PHYS, 127-72, PASADENA, CA 91125 USA	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022432, R37GM022432] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY RP, 1980, J BIOL CHEM, V255, P3994; CHADWICK CC, 1983, BIOCHIM BIOPHYS ACTA, V730, P201, DOI 10.1016/0005-2736(83)90334-6; DARLEYUSMAR VM, 1984, FEBS LETT, V166, P131, DOI 10.1016/0014-5793(84)80058-7; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; HALL J, 1988, J BIOL CHEM, V263, P8142; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; LUDWIG B, 1980, BIOCHIM BIOPHYS ACTA, V594, P177, DOI 10.1016/0304-4173(80)90008-7; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; MONTECUCCO C, 1986, BIOCHEM J, V234, P241, DOI 10.1042/bj2340241; PAN LP, 1991, J BIOL CHEM, V266, P1367; POWER SD, 1984, J BIOL CHEM, V259, P6575; PROCHASKA LJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P360, DOI 10.1016/0005-2728(81)90175-4; RIZZUTO R, 1991, BIOCHIM BIOPHYS ACTA, V1089, P386, DOI 10.1016/0167-4781(91)90180-T; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; WIKSTROM M, 1981, CYTOCHROME OXIDASE S, P2; WINTER DB, 1980, J BIOL CHEM, V255, P1408; YEWEY GL, 1987, BIOCHEM BIOPH RES CO, V148, P1520, DOI 10.1016/S0006-291X(87)80304-2; ZHANG YZ, 1988, ANN NY ACAD SCI, V550, P3	20	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22210	22214						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408083				2022-12-25	WOS:A1993MC80900114
J	MASUOKA, J; HEGENAUER, J; VANDYKE, BR; SALTMAN, P				MASUOKA, J; HEGENAUER, J; VANDYKE, BR; SALTMAN, P			INTRINSIC STOICHIOMETRIC EQUILIBRIUM-CONSTANTS FOR THE BINDING OF ZINC(II) AND COPPER(II) TO THE HIGH-AFFINITY SITE OF SERUM-ALBUMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; PLASMA; REGRESSION; IONS	Intrinsic stoichiometric equilibrium constants were determined for zinc(II) and copper(II) binding to bovine and human serum albumin. Data were obtained from equilibrium dialysis experiments. Metals were presented to apoprotein as metal chelates in order to avoid metal hydrolysis and to minimize nonspecific metal-protein interactions. Scatchard analysis of the binding data indicated that the high affinity class for both zinc and copper was comprised of one site. Results of binding experiments done at several pH values suggested that while both histidyl and carboxyl groups appear to be involved in copper binding, histidyl residues alone were sufficient for zinc binding. These amino acid residues were used in combination to model several binding sites used in the formulation of equilibria expressions from which stoichiometric constants were calculated. The log10K for bovine serum albumin were calculated to be 7.28 for Zn(II) and 11.12 for Cu(II). Those for human serum albumin were determined to be 7.53 and 11.18 for Zn(II) and Cu(II), respectively. These constants were used in equilibria to simulate speciation of metal-albumin and metal-chelator and to illustrate relative binding affinities. This comparison of binding strengths was possible only through the calculation of an intrinsic stoichiometric binding constant.			MASUOKA, J (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NIDDK NIH HHS [DK 12386-25] Funding Source: Medline; NIGMS NIH HHS [GM 07313] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012386] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTHON G, 1978, J CHEM SOC DALTON, P1433, DOI 10.1039/dt9780001433; BLONDEAU JP, 1975, EUR J BIOCHEM, V55, P375, DOI 10.1111/j.1432-1033.1975.tb02172.x; DIXON JW, 1972, BIOCHEM BIOPH RES CO, V48, P197, DOI 10.1016/0006-291X(72)90362-2; DYKE B, 1987, BIOCHEMISTRY-US, V26, P3228, DOI 10.1021/bi00385a044; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; GIROUX E, 1981, J INORG BIOCHEM, V14, P359, DOI 10.1016/S0162-0134(00)80292-5; HARRIS WR, 1989, J NUTR, V119, P1677, DOI 10.1093/jn/119.11.1677; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEGENAUER J, 1979, BIOCHEMISTRY-US, V18, P3865, DOI 10.1021/bi00585a006; KAMIKUBO K, 1986, JPN J PHARMACOL, V40, P342, DOI 10.1254/jjp.40.342; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; KLOTZ IM, 1948, J AM CHEM SOC, V70, P939, DOI 10.1021/ja01183a015; KRUCK TPA, 1973, CAN J CHEM, V51, P3549, DOI 10.1139/v73-529; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMSTROM BG, 1953, ARCH BIOCHEM BIOPHYS, V46, P345, DOI 10.1016/0003-9861(53)90207-0; MAY PM, 1976, EXPERIENTIA, V32, P1492, DOI 10.1007/BF01924411; OSTERBERG R, 1971, ACTA CHEM SCAND, V25, P3827, DOI 10.3891/acta.chem.scand.25-3827; PETTIT LD, 1976, J CHEM SOC DALTON, P588, DOI 10.1039/dt9760000588; RAO MSN, 1958, J AM CHEM SOC, V80, P3222, DOI 10.1021/ja01546a013; RAO MSN, 1958, J AM CHEM SOC, V80, P3226, DOI 10.1021/ja01546a014; REILMAN MA, 1986, J QUAL TECHNOL, V18, P162, DOI 10.1080/00224065.1986.11979004; RYALL X, 1974, THESIS AUSTR NATIONA; SAROFF HA, 1953, J AM CHEM SOC, V75, P1420, DOI 10.1021/ja01102a044; SASSKORTSAK A, 1967, CAN MED ASSOC J, V96, P361; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Spiro T.G., 1969, STRUCTURE BONDING, V6; TAKAHASHI N, 1987, P NATL ACAD SCI USA, V84, P7403, DOI 10.1073/pnas.84.21.7403; TANFORD C, 1952, J AM CHEM SOC, V74, P211, DOI 10.1021/ja01121a054; TANFORD C, 1955, J AM CHEM SOC, V77, P6414, DOI 10.1021/ja01629a002	30	197	205	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21533	21537						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408004				2022-12-25	WOS:A1993MC80900019
J	RACHIE, NA; SEGER, R; VALENTINE, MA; OSTROWSKI, J; BOMSZTYK, K				RACHIE, NA; SEGER, R; VALENTINE, MA; OSTROWSKI, J; BOMSZTYK, K			IDENTIFICATION OF AN INDUCIBLE 85-KDA NUCLEAR-PROTEIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; S6 KINASE; T-CELLS; CYTOPLASMIC ALKALINIZATION; RIBOSOMAL PROTEIN-S6; INTERFERON-GAMMA; EPITHELIAL-CELLS; SWISS 3T3-CELLS; GENE-EXPRESSION	To identify inducible protein kinases localized exclusively in the nucleus, nuclear and cytosolic extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotted to an Immobilon-P membrane. After denaturation-renaturation, the membranes were incubated in phosphorylation buffer containing [gamma-P-32]ATP. Autoradiographs of the membranes revealed an 85-kDa P-32-labeled band; the intensity of this band was transiently increased in nuclear but not in cytosolic extracts from interleukin-1alpha-treated cells. Incorporation of P-32 label into a blotted protein band suggested the presence of an interleukin-1alpha-responsive 85-kDa nuclear protein kinase. Fractionation of nuclear extracts by Mono Q failed to separate the kinase activity from the substrate, indicating that the 85-kDa band identified on the Immobilon-P membrane represents a protein kinase that undergoes autophosphorylation. Phosphoamino acid analysis of the 85-kDa band showed that this enzyme is a serine/threonine kinase. Purified pp90RSK could not be identified by the denaturation-renaturation method, indicating that the 85-kDa kinase identified here is not pp90RSK. This observation, nuclear but not cytoplasmic localization, and the fact that antibodies to known protein kinases kinase failed to recognize it suggest that the enzyme identified here is a novel protein kinase.	UNIV WASHINGTON, DEPT MED, RM-11, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MICROBIOL, SEATTLE, WA 98195 USA; MED CTR POSTGRAD EDUC, DEPT GASTROENTEROL & METAB, WARSAW, POLAND	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre of Postgraduate Medical Education - Poland				Ostrowski, Jerzy/0000-0003-1363-3766	NIGMS NIH HHS [P01 GM42508, R01 GM45134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508, R01GM045134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; AKAGI S, J HISTOCHEM CYTOCHEM, V36, P1533; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COTO JA, 1992, P NATL ACAD SCI USA, V89, P7752, DOI 10.1073/pnas.89.16.7752; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1991, BLOOD, V77, P1627; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVETT DH, 1988, J CLIN INVEST, V82, P115, DOI 10.1172/JCI113558; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MUNOZ E, 1991, J IMMUNOL, V146, P136; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; MUNOZ E, 1990, BIOCHIM BIOPHYS ACTA, V1052, P173; OPPENHEIMER MN, 1990, EXP HEMATOL, V18, P888; OSTROWSKI J, 1988, J BIOL CHEM, V263, P13786; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PESONEN M, 1984, J CELL BIOL, V99, P803, DOI 10.1083/jcb.99.3.803; QUIGG RJ, 1989, AM J PATHOL, V134, P1125; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH LL, 1988, J BIOL CHEM, V263, P7359; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WEEKS RS, 1988, J IMMUNOL, V140, P1312; WEIEL JE, 1990, ADV SEC MESS PHOSPH, V24, P182	60	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22143	22149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408074				2022-12-25	WOS:A1993MC80900104
J	SIROIS, J; RICHARDS, JS				SIROIS, J; RICHARDS, JS			TRANSCRIPTIONAL REGULATION OF THE RAT PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 GENE IN GRANULOSA-CELLS - EVIDENCE FOR THE ROLE OF A CIS-ACTING C/EBP-BETA PROMOTER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; ENHANCER-BINDING-PROTEIN; PREOVULATORY FOLLICLES; H SYNTHASE; LUTEINIZING-HORMONE; G/H SYNTHASE; COMPLEMENTARY-DNA; INDUCTION; CYCLOOXYGENASE; EXPRESSION	The promoter of the rat prostaglandin endoperoxide synthase 2 (PGS-2) gene has recently been shown to confer gonadotropic hormone (follicle-stimulating hormone (FSH), luteinizing hormone (LH), cAMP) inducibility when ligated to a CAT (chloramphenicol acetyltransferase) reporter gene and transfected into primary cultures of differentiated granulosa cells. To delineate cis-acting elements and trans-activating factors mediating this response, deletions of the active promoter region (-192/-53 base pairs upstream of the transcriptional start site) were tested for their ability to bind protein of granulosa cell nuclear extracts and activate reporter gene activity. Electrophoretic mobility shift assays revealed that the DNA subregion -142/-120 inhibited protein/DNA binding observed between granulosa cell nuclear extracts and the labeled PGS-2 fragment -192/-53. The subregion -142/-120 was shown to contain a consensus sequence for the cis-acting element C/EBPbeta, 5'-TTATGCAAT-3'. Point mutations within the C/EBPbeta element abolished protein/DNA binding and resulted in a 50% loss of forskolin/LH/FSH inducibility of reporter gene activity. C/EBPbeta mRNA and protein were induced rapidly in granulosa cells in vivo by an ovulatory dose of human chorionic gonadotropin (hCG). Collectively, these results indicate that C/EBPbeta appears to play a key role in regulating induction of the PGS-2 gene in granulosa cells prior to ovulation.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030	Baylor College of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CLARK MR, 1978, J BIOL CHEM, V253, P7757; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GADDYKURTEN D, 1991, MOL ENDOCRINOL, V5, P1280, DOI 10.1210/mend-5-9-1280; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES DA, 1993, J BIOL CHEM, V268, P9049; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KULMACZ RJ, 1987, CRC HDB EICOSANOID A, V1, P163; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN AH, 1989, J BIOL CHEM, V264, P17379; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MORRIS JK, 1993, IN PRESS ENDOCRINOLO; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OONK RB, 1989, J BIOL CHEM, V264, P21934; PARK EA, 1993, J BIOL CHEM, V268, P613; PELHAM HRB, 1976, ANAL BIOCHEM, V72, P248; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Sambrook J, 1989, MOL CLONING LABORATO; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	59	219	219	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21931	21938						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408049				2022-12-25	WOS:A1993MC80900075
J	SOLER, C; BEGUINOT, L; SORKIN, A; CARPENTER, G				SOLER, C; BEGUINOT, L; SORKIN, A; CARPENTER, G			TYROSINE PHOSPHORYLATION OF RAS GTPASE-ACTIVATING PROTEIN DOES NOT REQUIRE ASSOCIATION WITH THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; NIH 3T3 CELLS; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; EGF RECEPTOR; KINASE-ACTIVITY; SELF-PHOSPHORYLATION; INSULIN STIMULATION; MOLECULAR-CLONING	The importance of the carboxyl-terminal domain of the epidermal growth factor (EGF) receptor and its five autophosphorylation sites in the in vivo interaction and tyrosine phosphorylation of the ras GTPase-activating protein (rasGAP) has been investigated, using NIH 3T3 cells transfected with mutant EGF receptors. Phosphorylation of rasGAP by EGF receptor mutants, in which one to four autophosphorylation sites (Tyr-1173, -1148, -1086, and -1068) were mutated to phenylalanine, was reduced by 50-60% compared to the wild-type receptor. Elimination of these four autophosphorylation sites by truncation of 123 carboxyl-terminal residues of the EGF receptor paralleled results obtained with point mutants. Substantial inhibition (about 90%) of rasGAP tyrosine phosphorylation by the EGF receptor occurred only when the remaining autophosphorylation site (Tyr-1992) was mutated, in the context of this truncated receptor or in the full-length receptor mutated at all four other autophosphorylation sites. However, a point mutation of only Tyr-992 in the full-length receptor suppressed tyrosine phosphorylation of rasGAP only by 50%. In contrast, an EGF receptor lacking the last 214 amino acid residues (Dc214), which emcompasses all five autophosphorylation sites, phosphorylated rasGAP to the same extent as the wild-type receptor. However, this truncated receptor was significantly impaired in its capacity to phosphorylate phospholipase C-gamma1. Interestingly, while EGF receptor autophosphorylation sites are required for EGF-induced rasGAP association with the receptor, maximal phosphorylation of rasGAP by the truncated receptor Dc214 occurred without detectable formation of receptor.rasGAP complexes. Furthermore, the capacity of mutated EGF receptors to bring about focal transformation was correlated with their capacity to phosphorylate rasGAP.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; DIBIT HS RAFFAELE, ONCOL MOLEC LAB, MILAN, ITALY	Vanderbilt University; Vanderbilt University			Soler, Concepció/L-1185-2014	Soler, Concepció/0000-0001-6502-5012; Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA24071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELIN K, 1991, ONCOGENE, V6, P825; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD ER, 1992, J BIOL CHEM, V267, P14138; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	71	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22010	22019						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408058				2022-12-25	WOS:A1993MC80900086
J	FRITZ, G; DOSCH, J; THIELMANN, HW; KAINA, B				FRITZ, G; DOSCH, J; THIELMANN, HW; KAINA, B			MOLECULAR AND CELLULAR CHARACTERIZATION OF MEX- METHYLATION-RESISTANT PHENOTYPE - GENE AND CDNA CLONING, SERUM DEPENDENCE, AND TUMOR SUPPRESSION OF TRANSFECTANT STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; DNA-REPAIR GENE; ALKYLATING-AGENTS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; METHYLTRANSFERASE ACTIVITY; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; LYMPHOBLASTOID LINES; HUMAN FIBROBLAST	Methylating agents are widely distributed environmental mutagens. To identify mechanisms that protect cells against the toxic effects of methylating compounds Chinese hamster ovary (CHO) cells were transfected with human DNA and selected for resistance to methylating agents. From methylation-resistant transfectants, human DNA was cloned that conferred methylation resistance to CHO cells. A human cDNA was isolated (designated c81) encoding a protein of 410 amino acids which is partially identical to human lamp-2 encoding a lysosomal membrane glycoprotein. Transfection of c81, but not of the neo gene or a c81 antisense construct, into CHO cells gave rise to significant increases of survivors after methylating treatments. c81 mRNA is expressed both in human, CHO parental, and transfected cells, albeit in different amounts. The methylation-resistant transfectants lacked alkyltransferase activity (Mex- phenotype), did not repair O6-methylguanine in vivo, and neither showed reduced initial DNA methylation level nor increase of removal of 3-methyladenine and 7-methylguanine from DNA. They are therefore representatives of the ''tolerance'' phenotype. The transfectants also showed a higher serum requirement, flat growth, and a reduced tumor forming ability. The data suggest a link between altered regulation of cell proliferation and acquired resistance to methylating DNA damaging agents.	FORSCHUNGSZENTRUM JULICH, DEPT GENET, D-76021 KARLSRUHE, GERMANY; GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; Research Center Julich; Helmholtz Association; German Cancer Research Center (DKFZ)			Kaina, Bernd/AAE-4692-2020					ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; [Anonymous], 1985, DNA REPAIR; AQUILINA G, 1989, CARCINOGENESIS, V10, P1219, DOI 10.1093/carcin/10.7.1219; BAKER RM, 1979, P NATL ACAD SCI USA, V76, P5249, DOI 10.1073/pnas.76.10.5249; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; BIANCHI R, 1992, CANCER CHEMOTH PHARM, V29, P277, DOI 10.1007/BF00685945; BOON T, 1977, P NATL ACAD SCI USA, V74, P272, DOI 10.1073/pnas.74.1.272; BRENNAND J, 1986, P NATL ACAD SCI USA, V83, P6292, DOI 10.1073/pnas.83.17.6292; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLVIN M, 1982, PHARM PRINCIPLES CAN, P276; DAY RS, 1980, CARCINOGENESIS, V1, P21, DOI 10.1093/carcin/1.1.21; DAY RS, 1979, NATURE, V279, P797, DOI 10.1038/279797a0; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GEBARA MM, 1987, MOL CELL BIOL, V7, P1459, DOI 10.1128/MCB.7.4.1459; GIAMPIETRI A, 1980, J NATL CANCER I, V64, P297, DOI 10.1093/jnci/64.2.297; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GOTHGOLDSTEIN R, 1987, CARCINOGENESIS, V8, P1449, DOI 10.1093/carcin/8.10.1449; GREEN MHL, 1989, CARCINOGENESIS, V10, P893, DOI 10.1093/carcin/10.5.893; HALL J, 1988, CARCINOGENESIS, V9, P1587, DOI 10.1093/carcin/9.9.1587; IBEANU G, 1992, CARCINOGENESIS, V13, P1989, DOI 10.1093/carcin/13.11.1989; IKENAGA M, 1987, MUTAT RES, V184, P161, DOI 10.1016/0167-8817(87)90073-3; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; ISHIZAKI K, 1986, MUTAT RES, V166, P135, DOI 10.1016/0167-8817(86)90011-8; KAINA B, 1987, CARCINOGENESIS, V8, P1935, DOI 10.1093/carcin/8.12.1935; KAINA B, 1990, P NATL ACAD SCI USA, V87, P2710, DOI 10.1073/pnas.87.7.2710; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KAINA B, 1990, MUTAT RES, V243, P219, DOI 10.1016/0165-7992(90)90094-Z; KAINA B, 1987, MOL CELL BIOL, V7, P2024, DOI 10.1128/MCB.7.5.2024; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; KARRAN P, 1985, CANCER SURV, V4, P583; KATAOKA H, 1986, EMBO J, V5, P3195, DOI 10.1002/j.1460-2075.1986.tb04629.x; KLINGER HP, 1983, J NATL CANCER I, V3, P559; KLUNGLAND A, 1992, EMBO J, V11, P4439, DOI 10.1002/j.1460-2075.1992.tb05544.x; KYRTOPOULOS SA, 1989, CANCER SURV, V8, P423; Maniatis T., 1982, MOL CLONING; MITANI H, 1987, MUTAT RES, V191, P201, DOI 10.1016/0165-7992(87)90154-0; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; PEGG AE, 1990, CANCER RES, V50, P6119; Peto R., 1984, IARC SCI PUBL, V57, P627; PUCCETTI P, 1987, CANCER METAST REV, V6, P93, DOI 10.1007/BF00052845; SAMSON L, 1986, P NATL ACAD SCI USA, V83, P5607, DOI 10.1073/pnas.83.15.5607; SCUDIERO DA, 1984, CANCER RES, V44, P961; SHILOH Y, 1981, CANCER RES, V41, P5114; Singer B., 1983, MOL BIOL MUTAGENS CA; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; SKLAR RM, 1983, CANCER RES, V43, P3316; THIELMANN HW, 1991, CANCER RES, V51, P3456; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199	55	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21102	21112						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407947				2022-12-25	WOS:A1993MA28800071
J	HUGHES, MJ; LINGREL, JB; KRAKOWSKY, JM; ANDERSON, KP				HUGHES, MJ; LINGREL, JB; KRAKOWSKY, JM; ANDERSON, KP			A HELIX-LOOP-HELIX TRANSCRIPTION FACTOR-LIKE GENE IS LOCATED AT THE MI LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSGENIC MICE; INSERTIONAL MUTATION; MAST-CELLS; MOUSE; PROTEINS; FIBROBLASTS; TRANSLOCATION; INTEGRATION; ONCOGENE; BINDING	The mouse microphthalmia phenotype is complex and consists of one or more of the following phenotypic alterations: a lack of pigmentation, small eyes, a mast cell defect, and bone abnormalities. The locus for this allele has been assigned to chromosome 6. A single gene defect that produces such a pleiotropic effect has suggested some involvement at a control point in development. Recently a mutant line of mice carrying a transgene insertion, which represents a new allelic form of mi, was described. The integration site of the transgene from these mi(tg) mice was cloned and analyzed. An exon sequence was discovered adjacent to the insertion. Computer analysis of this nucleotide sequence revealed the presence of a motif indicative of the helix-loop-helix class of transcription factors. The gene was expressed in a number of tissues from wild type animals but was absent in the tissue RNA from mi(tg) mice. Southern blot analysis demonstrated a deletion of some of the genetic material for this gene in the mi(tg) mice. This is consistent with the lack of expression in the mi(tg) mice. Interestingly, when DNA from other mi allelic variants was subjected to a similar analysis, a deletion was also observed in this gene in two other mi lines. Taken together, these data suggest that the gene encoding this new helix-loop-helix DNA-binding protein, and residing in the mi locus, is a strong candidate for the mi gene.	UNIV CINCINNATI, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					PHS HHS [39585] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COSTANTINI F, 1989, PROG NUCLEIC ACID RE, V36, P159; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EBI Y, 1990, BLOOD, V75, P1247; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRANCKE U, 1992, MAMM GENOME, V3, P209, DOI 10.1007/BF00355721; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GRIDLEY T, 1990, DEVELOPMENT, V109, P235; GRUNEBERG H, 1948, J GENET, V49, P1, DOI 10.1007/BF02986377; Hillyard A. L., 1992, LOCUS MAP MOUSE COMP; KRAKOWSKY JM, 1993, TRANSGENIC RES, V2, P14, DOI 10.1007/BF01977676; LEE JJ, 1992, DEVELOPMENT, V115, P277; LYON MF, 1989, GENETIC VARIANTS STR, P236; MAGRAM J, 1991, P NATL ACAD SCI USA, V88, P10327, DOI 10.1073/pnas.88.22.10327; MARK WH, 1985, COLD SPRING HARB SYM, V50, P453, DOI 10.1101/SQB.1985.050.01.057; MCNEISH JD, 1988, SCIENCE, V241, P837, DOI 10.1126/science.3406741; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; MERLINO GT, 1991, GENE DEV, V5, P1395, DOI 10.1101/gad.5.8.1395; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; RADICE G, 1991, DEVELOPMENT, V111, P801; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; TACHIBANA M, 1992, MOL CELL NEUROSCI, V3, P433, DOI 10.1016/1044-7431(92)90055-7; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; WERNKE G R, 1989, Biophysical Journal, V55, p390A; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	41	231	236	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20687	20690						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407885				2022-12-25	WOS:A1993MA28800002
J	KRACHT, M; HEINER, A; RESCH, K; SZAMEL, M				KRACHT, M; HEINER, A; RESCH, K; SZAMEL, M			INTERLEUKIN-1-INDUCED SIGNALING IN T-CELLS - EVIDENCE FOR THE INVOLVEMENT OF PHOSPHATASES PP1 AND PP2A IN REGULATING PROTEIN-KINASE C-MEDIATED PROTEIN-PHOSPHORYLATION AND INTERLEUKIN-2 SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OKADAIC ACID; LYMPHOCYTES-T; GROWTH-FACTOR; CYCLIC-AMP; ACTIVATION; TRANSDUCTION; IL-1; EXPRESSION; MECHANISM	Binding of human recombinant interleukin-1beta (IL-1beta) to the cell surface receptors of EL-4 6.1 murine T-cells results in enhanced phosphorylation of several cellular proteins. Staurosporine abolished the enhanced phosphorylation in response to IL-1 for some of these proteins, suggesting that protein kinase C (PKC) was at least partially responsible. PKC-beta was translocated from the cytosol to the plasma membrane between 2 and 15 min after IL-1 binding. Activation of PKC-beta was enhanced by the protein phosphatase inhibitor okadaic acid. In fact, okadaic acid inhibited dephosphorylation of the PKC-specific peptide GS (Pro-Leu-Ser-Arg-Thr-Leu-Ser-Val-Ala-Ala-Lys-Lys). On the other hand, okadaic acid also led to elevation of IL-1-induced trans/autophosphorylation of PKC-beta. Accordingly, IL-1 induction of interleukin-2 synthesis was markedly enhanced by okadaic acid in EL-4 cells. These data suggest that activation of PKC-beta contributes to enhanced phosphorylation of cellular proteins in IL-1-treated cells and support the importance of protein phosphorylation and dephosphorylation in the regulation of IL-1-induced IL-2 synthesis in EL-4 6.1 T-cells.			KRACHT, M (corresponding author), MED SCH HANNOVER,INST MOLEC PHARMACOL,KONSTANTY GUTSCHOW STR 8,D-30623 HANNOVER,GERMANY.			Kracht, Michael/0000-0002-8501-043X				ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; ALEXANDER DR, 1989, IMMUNOL TODAY, V10, P200, DOI 10.1016/0167-5699(89)90325-3; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEDID M, 1991, J IMMUNOL, V147, P867; CSERMELY P, 1988, J BIOL CHEM, V263, P6487; DINARELLO CA, 1991, BLOOD, V77, P1627; GILLIS S, 1978, J IMMUNOL, V120, P2027; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUY GR, 1992, J BIOL CHEM, V267, P1846; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MARTIN M, 1989, EUR J BIOCHEM, V148, P1; MILLS GB, 1990, J CELL PHYSIOL, V142, P539, DOI 10.1002/jcp.1041420313; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MODIANO JF, 1991, J BIOL CHEM, V266, P10552; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUNOZ E, 1990, J IMMUNOL, V144, P964; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; OSTROWSKI J, 1988, J BIOL CHEM, V263, P13786; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SAWAMURA S, 1989, FEBS LETT, V247, P353, DOI 10.1016/0014-5793(89)81369-9; SHEARMAN MS, 1988, FEBS LETT, V234, P387, DOI 10.1016/0014-5793(88)80122-4; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SZAMEL M, 1989, J IMMUNOL, V143, P2806; TAFFS RE, 1991, J IMMUNOL, V147, P722; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	37	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21066	21072						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407943				2022-12-25	WOS:A1993MA28800066
J	SLACK, BE; NITSCH, RM; LIVNEH, E; KUNZ, GM; BREU, J; ELDAR, H; WURTMAN, RJ				SLACK, BE; NITSCH, RM; LIVNEH, E; KUNZ, GM; BREU, J; ELDAR, H; WURTMAN, RJ			REGULATION BY PHORBOL ESTERS OF AMYLOID PRECURSOR PROTEIN RELEASE FROM SWISS 3T3 FIBROBLASTS OVEREXPRESSING PROTEIN KINASE-C-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; PHOSPHORYLATION; CELLS; IDENTIFICATION; PEPTIDE; BIOGENESIS; EXPRESSION; ACTIVATION; SECRETION	Release of large soluble NH2-terminal fragments of the amyloid precursor protein (APP) of Alzheimer's disease was measured in two Swiss 3T3 fibroblast cell lines (designated SF1.4 and SF3.2), overexpressing the alpha subtype of protein kinase C, and in two control cell lines (SC1 and SC2) (Eldar, H., Zisman, Y., Ullrich, A., and Livneh, E. (1990) J. Biol. Chem. 265, 13290-13296). Basal release of APP was significantly increased in SF1.4 cells, but not in SF3.2 cells, relative to controls. Phorbol 12-myristate 13-acetate, an activator of protein kinase C, elicited a concentration-dependent increase in APP release in all four cell lines. However, the estimated EC50 for this effect was lower in the two cell lines overexpressing protein kinase C-alpha (7 and 6 nM, in SF1.4 and SF3.2 cells, respectively) than in control SC1 and SC2 cells (56 and 22 nM, respectively). The absolute amount of APP released by maximal concentrations of phorbol ester was not altered by overexpression of protein kinase Calpha. The protein kinase C inhibitor H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride) significantly reduced the response to phorbol esters in control (SC1) cells but not in cells (SF1.4) that overexpress protein kinase Calpha. Levels of cell-associated APP were slightly elevated, and rates of APP turnover were unchanged, in SF1.4 cells relative to controls. However, cell-associated APP levels were lower in SF3.2 cells than in controls. The results demonstrate that protein kinase Calpha regulates APP release in Swiss 3T3 fibroblasts, and perhaps in other tissues, including brain, and may be the isozyme that mediates receptor-evoked release of APP.	MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Weizmann Institute of Science	SLACK, BE (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.		Eldar-Finkelman, Hagit/AAF-8329-2019; Slack, Barbara/AAU-9917-2021	Eldar-Finkelman, Hagit/0000-0002-8460-9686; Slack, Barbara/0000-0002-7619-410X	NIMH NIH HHS [MH-28783] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH028783, R01MH028783] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BRUEL A, 1991, NEUROSCI LETT, V133, P89, DOI 10.1016/0304-3940(91)90064-Z; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ELDAR H, 1993, J BIOL CHEM, V268, P12560; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; MASLIAH E, 1990, J NEUROSCI, V10, P2113; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SHASPIRO IP, 1992, SOC NEUR ABSTR, V18, P1442; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	33	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21097	21101						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407946				2022-12-25	WOS:A1993MA28800070
J	TAKIMOTO, CH; VOELLER, DB; STRONG, JM; ANDERSON, L; CHU, E; ALLEGRA, CJ				TAKIMOTO, CH; VOELLER, DB; STRONG, JM; ANDERSON, L; CHU, E; ALLEGRA, CJ			EFFECTS OF 5-FLUOROURACIL SUBSTITUTION ON THE RNA CONFORMATION AND IN-VITRO TRANSLATION OF THYMIDYLATE SYNTHASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT KB CELLS; DIHYDROFOLATE-REDUCTASE; CARCINOMA-CELLS; CYTO-TOXICITY; RIBOSOMAL-RNA; HUMAN-BREAST; INHIBITION; COMBINATION; ACID	In vitro transcribed thymidylate synthase (TS) mRNA which is 100% substituted with 5-fluorouracil (FUra) was analyzed for changes in mRNA secondary structure, for alterations in translational efficiency, and for evidence of translational miscoding in vitro. FUra substitution in TS mRNA results in an altered migration pattern in non-denaturing RNA gels and in decreased hyperchromicity in RNA melting temperature studies, consistent with a change in mRNA secondary structure. However, no change in the translational efficiency of FUra-substituted TS mRNA is seen compared to control TS mRNA in either rabbit reticulocyte lysate or wheat germ extract in vitro translation systems. Analysis of the in vitro translation product of FUra-substituted TS mRNA by Western immunoblotting, isoelectric focusing, 5-fluoro-2'-deoxyuridine 5'-monophosphate binding, and TS catalytic activity experiments shows no difference compared to control TS mRNA. We conclude that the in vitro translation products of FUra-substituted and control TS mRNA are identical. Our findings do not support the hypothesis that changes in the mRNA template are responsible for the RNA-directed cytotoxicity of FUra.	US FDA, CTR DRUG EVALUAT & RES, DIV CLIN PHARMACOL, OFF RES RESOURCES, ROCKVILLE, MD 20850 USA	US Food & Drug Administration (FDA)	TAKIMOTO, CH (corresponding author), NATL NAVAL MED CTR, NCI,DIV CANC TREATMENT,MED ONCOL BRANCH,BLDG 8, RM 5101, BETHESDA, MD 20814 USA.							ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; ARMSTRONG RD, 1986, J BIOL CHEM, V261, P21; CADMAN E, 1979, SCIENCE, V205, P1135, DOI 10.1126/science.472732; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1991, MOL PHARMACOL, V39, P136; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DANENBERG PV, 1990, CANCER RES, V50, P1757; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DOLNICK BJ, 1985, J BIOL CHEM, V260, P3006; DOONG SL, 1988, J BIOL CHEM, V263, P4467; GLAZER RI, 1983, MOL PHARMACOL, V23, P540; GLAZER RI, 1981, MOL PHARMACOL, V19, P117; GLEASON MK, 1976, P NATL ACAD SCI USA, V73, P1528, DOI 10.1073/pnas.73.5.1528; GREENHALGH DA, 1990, BRIT J CANCER, V61, P415, DOI 10.1038/bjc.1990.91; GREM JL, 1990, CANC CHEMOTHERAPY PR, P180; GRUNBERG M, 1964, BIOCHIM BIOPHYS ACTA, V87, P593, DOI 10.1016/0926-6550(64)90277-4; KUFE DW, 1981, J BIOL CHEM, V256, P9802; MARTIN DS, 1983, CANCER RES, V43, P2317; NAKADA D, 1964, J MOL BIOL, V8, P105, DOI 10.1016/S0022-2836(64)80153-4; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; ROSEN B, 1969, J MOL BIOL, V44, P363, DOI 10.1016/0022-2836(69)90181-8; SIERAKOWSKA H, 1989, J BIOL CHEM, V264, P19185; SOWERS LC, 1987, J BIOL CHEM, V262, P15436; SPIEGELMAN S, 1980, P NATL ACAD SCI-BIOL, V77, P4966, DOI 10.1073/pnas.77.8.4966; TAKIMOTO CH, 1987, BIOCHEM PHARMACOL, V36, P3243, DOI 10.1016/0006-2952(87)90640-X; TSENG WC, 1978, CANCER RES, V38, P1250; Uchida J, 1992, Gan To Kagaku Ryoho, V19, P677; WILKINSON DS, 1973, J BIOL CHEM, V248, P63; WILL CL, 1987, J BIOL CHEM, V262, P5433; WILL CL, 1989, J BIOL CHEM, V264, P21413	31	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21438	21442						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407987				2022-12-25	WOS:A1993MA28800115
J	VIGON, I; FLORINDO, C; FICHELSON, S; GUENET, JL; MATTEI, MG; SOUYRI, M; COSMAN, D; GISSELBRECHT, S				VIGON, I; FLORINDO, C; FICHELSON, S; GUENET, JL; MATTEI, MG; SOUYRI, M; COSMAN, D; GISSELBRECHT, S			CHARACTERIZATION OF THE MURINE MPL PROTOONCOGENE, A MEMBER OF THE HEMATOPOIETIC CYTOKINE RECEPTOR FAMILY - MOLECULAR-CLONING, CHROMOSOMAL LOCATION AND EVIDENCE FOR A FUNCTION IN CELL-GROWTH	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE LEUKEMIA-VIRUS; AFFINITY INTERLEUKIN-5 RECEPTOR; IL-6 SIGNAL TRANSDUCER; GM-CSF RECEPTOR; EXPRESSION CLONING; INHIBITORY FACTOR; BINDING-PROTEIN; ERYTHROPOIETIN RECEPTOR; PROGENITOR CELLS	The v-mpl oncogene transduced in the myeloproliferative leukemia virus (MPLV) encodes a truncated form of a putative receptor protein that belongs to the cytokine receptor superfamily. We previously reported the cloning of complete human c-MPL cDNA. In the present report, we show that the murine Mpl proto-oncogene is located at the D-band of murine chromosome 4, in a region in synteny with human chromosome 1p34, where MPL was previously located. RNA blot analysis of murine hematopoietic tissues and cells lines indicated that Mpl is expressed in immature hematopoietic precursor cells. Molecular cloning of murine proto-oncogene c-Mpl cDNAs is also reported. Two cDNA species were isolated. One potentially encodes a transmembrane protein. The extracellular domain of this protein has two repeats of the cytokine receptor domain common to all members of this receptor family. The cytoplasmic domain has no protein kinase or phosphatase motifs, but does contain a sequence that has been shown to be essential for the transmission of a growth signal in several other members of the family. Comparison of murine and human putative proteins indicated that they shared 81% amino acid identity, the most conserved region being the cytoplasmic domain (91% identity). The other Mpl cDNA clones potentially encode a soluble form of this receptor chain. A chimeric receptor containing the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor fused to the transmembrane and cytoplasmic domains of Mpl was able to induce G-CSF responsiveness when transfected into the interleukin 3 (IL-3)-dependent cell line BAF/BO3. This demonstrated that the cytoplasmic Mpl domain is most probably implicated in proliferative signal transduction.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; INST PASTEUR,GENET MAMMIFERES LAB,F-75724 PARIS 15,FRANCE; HOP ENFANTS,GRP HOSP TIMONE,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VIGON, I (corresponding author), HOP COCHIN,ICGM,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75674 PARIS 14,FRANCE.		Souyri, Michele/L-5845-2017					BOUTIN JM, 1988, P NATL ACAD SCI USA, V88, P7744; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LECONIAT M, 1989, HUM GENET, V83, P194; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NADEAU JH, 1986, GENETICS, V114, P1239; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG HM, 1992, J BIOL CHEM, V267, P979; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161; WEYDERT A, 1992, CR ACAD SCI III-VIE, V314, P429; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	44	133	139	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2607	2615						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397366				2022-12-25	WOS:A1993LX34300001
J	BAVIK, CO; LEVY, F; HELLMAN, U; WERNSTEDT, C; ERIKSSON, U				BAVIK, CO; LEVY, F; HELLMAN, U; WERNSTEDT, C; ERIKSSON, U			THE RETINAL-PIGMENT EPITHELIAL MEMBRANE-RECEPTOR FOR PLASMA RETINOL-BINDING PROTEIN - ISOLATION AND CDNA CLONING OF THE 63-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE ELEMENT; IDENTIFICATION; SEQUENCE; GENE; HOMOLOGY; DIFFERENTIATION; GLYCOPROTEIN; RIBOSOMES; INVITRO; CELLS	Retinol, a metabolic precursor of retinal and retinoic acid, is transported in plasma by the plasma retinol-binding protein (RBP). The cellular uptake of retinol from RBP is believed to involve a specific membrane receptor for RBP. In retinal pigment epithelium the RBP receptor appears to be an oligomeric protein complex, and we have previously identified a 63-kDa membrane protein as part of this receptor. The 63-kDa protein (p63) has now been isolated, and we have cloned the corresponding cDNA. In a data base search no sequences similar to p63 were identified. Hydropathy analyses of the 533 amino acids deduced from the cDNA sequence did not indicate an N-terminal signal sequence or obvious transmembrane regions. In vitro translation of synthetic mRNA encoding p63, in the presence of heterologous microsomes, verified that p63 does not become cotranslationally membrane-inserted. Transcripts for p63 are abundantly expressed in retinal pigment epithelium with no detectable expression in several other tissues. Southern blotting analysis of bovine and human genomic DNA revealed several hybridizing fragments suggesting a complex organization of the corresponding genes.	LUDWIG INST CANC RES,STOCKHOLM BRANCH,POB 240,S-17177 STOCKHOLM,SWEDEN; LUDWIG INST CANC RES,CTR BIOMED,UPPSALA BRANCH,S-75122 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research								BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chytil F., 1984, RETINOIDS, V2, P90; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GODOVAC-ZIMMERMANN J, 1985, BIOL CHEM H-S, V366, P431, DOI 10.1515/bchm3.1985.366.1.431; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HELLER J, 1975, J BIOL CHEM, V250, P3613; HELLMAN U, 1989, ELECTROPHORESIS FORU, P89; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEE KH, 1987, SCIENCE, V253, P1053; LEVY F, 1991, J CELL BIOL, V115, P959, DOI 10.1083/jcb.115.4.959; LOPEZ C, 1981, BIOCHEM BIOPH RES CO, V103, P919, DOI 10.1016/0006-291X(81)90898-6; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Meyer D I, 1991, Trends Cell Biol, V1, P154, DOI 10.1016/0962-8924(91)90016-3; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NICHOLSON RC, 1990, EMBO J, V9, P4433; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1976, J BIOL CHEM, V251, P6360; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SUGARA H, 1991, EXP EYE RES, V53, P765; SUNDELIN J, 1985, CHEM PHYS LIPIDS, V38, P175, DOI 10.1016/0009-3084(85)90065-9; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	58	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20540	20546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397208				2022-12-25	WOS:A1993LY01900089
J	PAPINI, E; RAPPUOLI, R; MURGIA, M; MONTECUCCO, C				PAPINI, E; RAPPUOLI, R; MURGIA, M; MONTECUCCO, C			CELL PENETRATION OF DIPHTHERIA-TOXIN - REDUCTION OF THE INTERCHAIN DISULFIDE BRIDGE IS THE RATE-LIMITING STEP OF TRANSLOCATION IN THE CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; MEMBRANE TRANSLOCATION; LIPID INTERACTION; FRAGMENT-B; LOW PH; RECEPTOR; PROTEIN; ENTRY; PURIFICATION; TRANSPORT	The pathway of cell penetration of diphtheria toxin (DT) was studied in Vero cells by following the kinetics of uptake, reduction, degradation, and sub-cellular distribution of I-125-DT in the absence or presence of bafilomycin A1 (baf-A1), a powerful inhibitor of the endosomal H+-ATPase. After a lag phase of 4 min, DT, bound to Vero cells, reached an acidic intracellular compartment, where about one-third of it underwent a transition to a state competent for subsequent reduction and membrane translocation. After further 4 min, this DT fraction was reduced in a baf-A1-insensitive reaction and DT-A, the intracellularly active protomer of DT, was immediately released in the cytosol. The present data indicate that cell-mediated reduction of the toxin is the rate-determining step of the DT cell intoxication process. Subcellular fractionation showed that DT underwent the low pH-driven conformational change in an early endosome, distinct from the subsequent endosomal compartment where reduction took place. DT-B remained endosome-bound and was proteolyzed at low pH as well as the portion of DT which was not reduced after the exposure to low pH in early endosomes.	IST RIC IMMUNOBIOL, I-53100 SIENA, ITALY; UNIV PADUA, DIPARTIMENTO SCI BIOMED, I-35121 PADUA, ITALY	University of Padua	PAPINI, E (corresponding author), UNIV PADUA, CNR, CTR BIOMEMBRANE, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Papini, Emanuele/AAE-6961-2022	Papini, Emanuele/0000-0001-6033-4473				BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BISSON R, 1987, TRENDS BIOCHEM SCI, V12, P181, DOI 10.1016/0968-0004(87)90087-9; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLI AW, 1988, J BIOL CHEM, V263, P16283; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DEMEL R, 1991, EUR J BIOCHEM, V197, P481, DOI 10.1111/j.1432-1033.1991.tb15935.x; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FALNES PO, 1992, J BIOL CHEM, V267, P12284; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HU VW, 1984, J BIOL CHEM, V259, P2226; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; HUDSON TH, 1985, J BIOL CHEM, V260, P2675; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; IMATA T, 1990, J BIOL CHEM, V265, P21940; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MARKWELL MA, 1978, METHOD ENZYMOL, V72, P297; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; OLSNES S, 1985, BIOCHIM BIOPHYS ACTA, V846, P334, DOI 10.1016/0167-4889(85)90003-5; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPINI E, 1987, FEBS LETT, V215, P73, DOI 10.1016/0014-5793(87)80116-3; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; RAPPUOLI R, 1983, J CHROMATOGR, V268, P543, DOI 10.1016/S0021-9673(01)95457-3; RONNBERG BJ, 1989, TOXICON, V27, P1377, DOI 10.1016/0041-0101(89)90069-X; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SANDVIG K, 1986, J BIOL CHEM, V261, P1570; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANDVIG K, 1991, SOURCEBOOK BACTERIAL, P57; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; YAMAMOTO Y, 1978, IEEE J QUANTUM ELECT, V14, P245, DOI 10.1109/JQE.1978.1069769; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; [No title captured]	52	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1567	1574						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420931				2022-12-25	WOS:A1993KH62000013
J	SVOBODA, DL; TAYLOR, JS; HEARST, JE; SANCAR, A				SVOBODA, DL; TAYLOR, JS; HEARST, JE; SANCAR, A			DNA-REPAIR BY EUKARYOTIC NUCLEOTIDE EXCISION NUCLEASE - REMOVAL OF THYMINE DIMER AND PSORALEN MONOADDUCT BY HELA CELL-FREE-EXTRACT AND OF THYMINE DIMER BY XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; PYRIMIDINE DIMER; BUILDING BLOCK; LESIONS; OLIGONUCLEOTIDES; EXONUCLEASE; STRAND; ENZYME; SITE	Using a human cell-free extract, we have recently shown that thymine dimers are removed from DNA in oligonucleotides 27-29 nucleotides in length (Huang, J. C., Svoboda, D. L., Reardon, J. T., and Sancar, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3664-3668). In this study we find that the excision reaction is dependent on ATP, the excised fragments range in length from 27-32 nucleotides, and have 5'-P and 3'-OH termini. We also found that a thymine-psoralen furan side monoadduct is excised from the DNA with a similar incision pattern, indicating that in humans bulky adducts are removed from DNA by the same enzyme system which hydrolyzes mainly the 22-24th and the 5th phosphodiester bonds 5' and 3', respectively, to the lesion. This incision pattern might be common to eukaryotic excision nucleases as thymine dimers were removed from DNA by the same dual incision pattern by Xenopus laevis oocytes.	WASHINGTON UNIV, DEPT CHEM, ST LOUIS, MO 63130 USA; LAWRENCE BERKELEY LAB, DIV CHEM BIODYNAM, BERKELEY, CA 94720 USA	Washington University (WUSTL); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	SVOBODA, DL (corresponding author), UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.			Taylor, John-Stephen/0000-0002-8615-7257	NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; CHENG S, 1988, J BIOL CHEM, V263, P15110; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1991, PHOTOCHEM PHOTOBIOL, V54, P393, DOI 10.1111/j.1751-1097.1991.tb02033.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; EDENBERG H, 1972, BIOCHIM BIOPHYS ACTA, V272, P361, DOI 10.1016/0005-2787(72)90389-9; FRIEDBERG EC, 1985, DNA REPAIR, P213; FUCHS RPP, 1984, J MOL BIOL, V177, P173, DOI 10.1016/0022-2836(84)90063-9; HAYS JB, 1990, MOL CELL BIOL, V10, P3505, DOI 10.1128/MCB.10.7.3505; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KORNBERG A, 1991, DNA REPLICATION, P187; LEGERSKI RJ, 1987, MOL CELL BIOL, V7, P4317, DOI 10.1128/MCB.7.12.4317; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; ROYERPOKORA B, 1981, NUCLEIC ACIDS RES, V9, P4595, DOI 10.1093/nar/9.18.4595; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; TAYLOR JS, 1988, NUCLEIC ACIDS RES, V16, P5123, DOI 10.1093/nar/16.11.5123; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	30	122	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1931	1936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420966				2022-12-25	WOS:A1993KH62000066
J	GUSTAFSSON, C; BJORK, GR				GUSTAFSSON, C; BJORK, GR			THE TRANSFER RNA-(M(5)U54)-METHYLTRANSFERASE OF ESCHERICHIA-COLI IS PRESENT IN 2 FORMS INVIVO, ONE OF WHICH IS PRESENT AS BOUND TO TRANSFER-RNA AND TO A 3'-END FRAGMENT OF 16-S RIBOSOMAL-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; SALMONELLA-TYPHIMURIUM; CATALYTIC MECHANISM; (M5U54)-METHYLTRANSFERASE; SEQUENCE; IDENTIFICATION; EXPRESSION; BINDING; GENES; ACID	The enzyme tRNA-(m5U54)-methyltransferase (EC 2.1.1.35) of Escherichia coli catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to uridine in position 54 of the TPSI-loop of all E. coli tRNA species, forming 5-methyluridine (m5U). In vivo, this enzyme is present both as a native polypeptide of 42 kDa and as a TrmA.RNA complex. The TrmA.RNA complex is not dissociated during strong denaturing conditions such as boiling in 8 M urea or 6 m guanidine HCl, consisting with that the RNA is covalently bound to the protein. After sequencing and Southern blot analyses, the RNA was identified to be a subset of undermodified tRNA species as well as the 3' terminus of 16 S rRNA. However, the complex is not associated with the ribosome and the covalently bound RNA does not affect the tRNA methylating activity of the enzyme.			GUSTAFSSON, C (corresponding author), UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN.		Björk, Glenn/AAE-8219-2022	Gustafsson, Claes/0000-0003-2181-3126				BELLISARIO RL, 1976, P NATL ACAD SCI USA, V73, P1848, DOI 10.1073/pnas.73.6.1848; BERESTEN S, 1992, NUCLEIC ACIDS RES, V20, P1523, DOI 10.1093/nar/20.7.1523; BJORK GR, 1975, J BACTERIOL, V124, P99; BJORK GR, 1975, J BACTERIOL, V124, P92; BJORK GR, 1973, VIROLOGY, V52, P507, DOI 10.1016/0042-6822(73)90346-2; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; DAVANLOO P, 1979, NUCLEIC ACIDS RES, V6, P1571, DOI 10.1093/nar/6.4.1571; DURWALD H, 1968, J MOL BIOL, V34, P331, DOI 10.1016/0022-2836(68)90257-X; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GREENBERG R, 1980, J BIOL CHEM, V255, P8296; GU X, 1992, IN PRESS BIOCHEMISTR; GU XG, 1991, BIOCHEMISTRY-US, V30, P2999, DOI 10.1021/bi00226a003; GU XR, 1990, DNA CELL BIOL, V9, P273, DOI 10.1089/dna.1990.9.273; GUSTAFSSON C, 1991, J BACTERIOL, V173, P1757, DOI 10.1128/jb.173.5.1757-1764.1991; KEALEY JT, 1991, BIOCHEMISTRY-US, V30, P9724, DOI 10.1021/bi00104a022; KERSTEN H, 1981, EUR J BIOCHEM, V114, P451, DOI 10.1111/j.1432-1033.1981.tb05166.x; KUNITANI MG, 1980, BIOCHEMISTRY-US, V19, P1271, DOI 10.1021/bi00548a001; LEHNER AF, 1984, J BACTERIOL, V160, P682, DOI 10.1128/JB.160.2.682-686.1984; MARCU KB, 1976, NATURE, V261, P159, DOI 10.1038/261159a0; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; Nishimura S., 1979, TRANSFER RNA STRUCTU, P551; NY T, 1980, J BACTERIOL, V141, P67, DOI 10.1128/JB.141.1.67-73.1980; NY T, 1977, J BACTERIOL, V130, P635, DOI 10.1128/JB.130.2.635-641.1977; NY T, 1980, J BACTERIOL, V142, P371, DOI 10.1128/JB.142.2.371-379.1980; NY T, 1988, EUR J BIOCHEM, V177, P467, DOI 10.1111/j.1432-1033.1988.tb14396.x; PERSSON BC, 1992, P NATL ACAD SCI USA, V89, P3995, DOI 10.1073/pnas.89.9.3995; ROE BA, 1976, P NATL ACAD SCI USA, V74, P3696; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SPRINGER RA, 1991, CURRENT PROTOCOLS MO; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; TAKATA R, 1978, MOL GEN GENET, V161, P15, DOI 10.1007/BF00266610; WIKSTROM PM, 1988, J MOL BIOL, V203, P141, DOI 10.1016/0022-2836(88)90098-8; WU JC, 1987, J BIOL CHEM, V262, P4778; YEH YC, 1967, J BIOL CHEM, V242, P1307	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1326	1331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419334				2022-12-25	WOS:A1993KG07700084
J	POYNER, DR; COOKE, F; HANLEY, MR; REYNOLDS, DJM; HAWKINS, PT				POYNER, DR; COOKE, F; HANLEY, MR; REYNOLDS, DJM; HAWKINS, PT			CHARACTERIZATION OF METAL ION-INDUCED [H-3] INOSITOL HEXAKISPHOSPHATE BINDING TO RAT CEREBELLAR MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTIC ACID; MYOINOSITOL HEXAKISPHOSPHATE; INOSITOL TETRAKISPHOSPHATE; BRAIN; CELLS; PENTAKISPHOSPHATE; PHOSPHATES; INOSITOLHEXAKISPHOSPHATE; PHOSPHORYLATION; CA-2+	The binding of [H-3]inositol hexakisphosphate ([H-3]InsP6) to rat cerebellar membranes has been characterized with the objective of establishing the role, if any, of a membrane protein receptor. In the presence of EDTA, we have previously identified an InsP6-binding site with a capacity of approximately 20 pmol/mg protein (Hawkins, P. T., Reynolds, D. J. M., Poyner, D. R., and Hanley, M. R. (1990) Biochem. Biophys. Res. Commun. 167, 819-827). However, in the presence of 1 mm Mg2+, the capacity of [H-3]InsP6 binding to membranes was increased approximately 9-fold. This enhancing effect of Mg2+ was reversed by addition of 10 muM of several cation chelators, suggesting that the increased binding required trace quantities of other metal cations. This is supported by experiments where it was possible to saturate binding by addition of excess membranes, despite not significantly depleting radioligand, pointing to removal of some other factor. Removal of endogenous cations from the binding assay by pretreatment with chelex resin also prevents the Mg2+-induced potentiation. Consideration of the specificity of the chelators able to abolish this potentiation suggested involvement of Fe3+ or Al3+. Both these ions (but not several others) were able to increase [H-3]InsP6 binding to chelex-pretreated membranes at concentrations of 1 muM. It is possible to demonstrate synergy between Fe3+ and Mg2+ under these conditions. We propose that [H-3] InsP6 may interact with membranes through non-protein recognition, possibly via phospholipids, in a manner dependent upon trace metals. The implications of this for InsP6 biology are considered.	INST ANIM PHYSIOL & GENET RES,CAMBRIDGE RES STN,CAMBRIDGE CB2 4AT,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND; MRC,CAMBRIDGE CB2 2QH,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Oxford				Hawkins, Phillip/0000-0002-6979-0464; Poyner, David R/0000-0003-1590-112X				ACEVES J, 1985, BRIT J PHARMACOL, V84, P417, DOI 10.1111/j.1476-5381.1985.tb12925.x; BARRACO RA, 1989, EUR J PHARMACOL, V173, P75, DOI 10.1016/0014-2999(89)90010-1; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; Cosgrove D., 1980, INOSITOL PHOSPHATES; COSGROVE DJ, 1969, ANN NY ACAD SCI, V165, P677; CRICHTON RR, 1979, CIBA F S, V65, P57; EGGLETON P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P309, DOI 10.1016/0167-4889(91)90091-B; FRENCH PJ, 1988, BIOCHEM SOC T, V16, P985, DOI 10.1042/bst0160985; GRAF E, 1984, J BIOL CHEM, V259, P3620; GRAF E, 1987, J BIOL CHEM, V262, P11647; GROHLIC D, 1979, INT J BIOCHEM, V10, P803; HANLEY MR, 1988, PHILOS T R SOC B, V320, P381, DOI 10.1098/rstb.1988.0083; HAWKINS PT, 1990, BIOCHEM BIOPH RES CO, V167, P819, DOI 10.1016/0006-291X(90)92099-L; HESLOP JP, 1985, J EXP BIOL, V119, P395; HUGHES PJ, 1990, J BIOL CHEM, V265, P9869; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; Jacobs A., 1977, CIBA F S, V51, P91; MADDAIAH VT, 1964, P SOC EXP BIOL MED, V115, P391, DOI 10.3181/00379727-115-28922; Martell A. E., 1982, CRITICAL STABILITY C, V5, P340; MITCHELL R, 1991, BIOCHEM SOC T, V19, pS116, DOI 10.1042/bst019116s; NICOLETTI F, 1990, MOL PHARMACOL, V37, P689; NICOLETTI F, 1989, J NEUROCHEM, V53, P1026, DOI 10.1111/j.1471-4159.1989.tb07390.x; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PITTET D, 1989, J BIOL CHEM, V264, P18489; REGUNATHAN S, 1992, BIOCHEM PHARMACOL, V43, P1331, DOI 10.1016/0006-2952(92)90510-P; SMITH SE, 1990, EUR J PHARMACOL, V191, P337, DOI 10.1016/0014-2999(90)94166-U; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TUFANO TP, 1981, J AM CHEM SOC, V103, P6617, DOI 10.1021/ja00412a015; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; VOHRA P, 1965, J POULTRY SCI, V43, P1164; WILLIAMS SG, 1970, PLANT PHYSIOL, V45, P376, DOI 10.1104/pp.45.4.376; WISE A, 1982, TOXICOL LETT, V11, P49, DOI 10.1016/0378-4274(82)90104-7; WORLEY PF, 1989, J NEUROSCI, V9, P339; 1989, BIOCHEM J, V258, P1	38	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1032	1038						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419311				2022-12-25	WOS:A1993KG07700043
J	SHIVANNA, BD; MEJILLANO, MR; WILLIAMS, TD; HIMES, RH				SHIVANNA, BD; MEJILLANO, MR; WILLIAMS, TD; HIMES, RH			EXCHANGEABLE GTP BINDING-SITE OF BETA-TUBULIN - IDENTIFICATION OF CYSTEINE-12 AS THE MAJOR SITE OF CROSS-LINKING BY DIRECT PHOTOAFFINITY-LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; PEPTIDE; ALPHA; GENE; LOCALIZATION; ANTIBODIES; MECHANISM; DOMAIN; YEAST	After direct photoaffinity cross-linking of [H-3]GTP to the beta-subunit of tubulin, followed by tryptic digestion and alkaline phosphatase treatment, we employed cis-diol-specific boronate gel chromatography and reversed-phase high-pressure liquid chromatography to purify a peptide containing most of the covalently bound radioactivity. The sequence of this peptide corresponded to that of residues 3-19 of beta-tubulin. Residue 10 of the peptide, which is Cys-12 in beta-tubulin, could not be identified. The fast atom bombardment mass spectrum of this peptide showed the presence of a predominant species with a molecular mass of 2022 kDa (2021 kDa for the C-12 variant), which is 255 Da greater than the molecular mass of the peptide. Fast atom bombardment collision-activated decomposition mass spectrometry analysis produced fragments which are consistent with the beta(3-19) peptide but having a unit of mass of 358 at position 12. Thermolysin digestion of the tryptic peptide restricted the cross-linking site to the 9-amino acid sequence, I(L)QAGQXGNQ. The molecular mass of this peptide was 1174 kDa, which is equal to the mass of the beta(7-15) peptide containing an extra group of mass 255. To explain the molecular masses of the two labeled peptides, which are 26 atomic mass units less than expected, a mechanism of photolabeling is proposed that involves opening of the guanine ring and loss of the C-6 carbonyl function as CO2.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA; UNIV KANSAS, MASS SPECTROMETRY LAB, LAWRENCE, KS 66045 USA	University of Kansas; University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036953] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36953] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALGAIER J, 1988, BIOCHIM BIOPHYS ACTA, V954, P235, DOI 10.1016/0167-4838(88)90078-7; ALVAREZGONZALEZ R, 1983, ANAL BIOCHEM, V135, P69, DOI 10.1016/0003-2697(83)90732-7; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOGLE GS, 1962, PHOTOCHEM PHOTOBIOL, V1, P277, DOI 10.1111/j.1751-1097.1962.tb08103.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURNS RG, 1991, CELL MOTIL CYTOSKEL, V20, P181, DOI 10.1002/cm.970200302; CARLIER MF, 1989, INT REV CYTOL, V115, P139; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; FARR GW, 1992, J MOL BIOL, V227, P307, DOI 10.1016/0022-2836(92)90700-T; GEAHLEN RL, 1979, J BIOL CHEM, V254, P1982; GEAHLEN RL, 1977, P NATL ACAD SCI USA, V74, P4375, DOI 10.1073/pnas.74.10.4375; HESSE J, 1985, FEBS LETT, V179, P91, DOI 10.1016/0014-5793(85)80198-8; HESSE J, 1987, J BIOL CHEM, V262, P15472; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HUYSER ES, 1970, FREE RADICAL CHAIN R, P77; JELLINEK T, 1970, PHOTOCHEM PHOTOBIOL, V11, P349, DOI 10.1111/j.1751-1097.1970.tb06007.x; KIM H, 1987, FASEB J, V46, P2229; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LITTLE M, 1981, BIOSYSTEMS, V14, P239, DOI 10.1016/0303-2647(81)90031-9; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; NATH JP, 1986, BIOCHEM BIOPH RES CO, V135, P1135, DOI 10.1016/0006-291X(86)91046-6; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; PONSTINGL H, 1990, LABORATORY METHODOLO, P151; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; STEINMAUS H, 1971, J ORG CHEM, V36, P3594; STERNLICHT H, 1987, FEBS LETT, V214, P226, DOI 10.1016/0014-5793(87)80061-3; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	36	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					127	132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416920				2022-12-25	WOS:A1993KE60300020
J	YU, FX; LIN, SC; MORRISONBOGORAD, M; ATKINSON, MAL; YIN, HL				YU, FX; LIN, SC; MORRISONBOGORAD, M; ATKINSON, MAL; YIN, HL			THYMOSIN BETA-10 AND THYMOSIN BETA-4 ARE BOTH ACTIN MONOMER SEQUESTERING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; F-ACTIN; ACANTHAMOEBA ACTOBINDIN; DEPOLYMERIZING FACTOR; CAPPING PROTEIN; SKELETAL-MUSCLE; BINDING PROTEIN; PLASMA GELSOLIN; RETINOIC ACID; PROFILIN	The beta-thymosins are a family of related peptides. Recently, thymosin beta4 was identified as a significant actin monomer sequestering protein in cells. To determine if other beta-thymosins also bind actin, and how they may participate in the regulation of actin polymerization, we expressed thymosin beta4 and its major homolog, thymosin beta10, in bacteria and characterized their interactions with actin. Equilibrium sedimentation studies showed that thymosin beta4 behaved as a monomeric protein in solution. Both beta-thymosins bound skeletal muscle actin and inhibited actin polymerization with similar K(d) values (between 0.7-1 muM). They were not inhibited by polyphosphoinositides. Kinetic measurements showed that at high ratios of beta-thymosin to actin, beta-thymosin decreased the rate of barbed end filament growth. However, in spite of a close agreement between the kinetic and steady state K(d) values, the rate of barbed end filament growth was slightly, but reproducibly, larger than expected, and this deviation was particularly noticeable at lower ratios of beta-thymosin to actin. We conclude that unlike profilin, beta-thymosins are primarily actin monomer sequestering proteins, although some aspects of their interactions with actin are still not completely understood.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROL & BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,CTR HLTH,DEPT BIOCHEM,TYLER,TX 75710	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014886] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29113] Funding Source: Medline; NICHD NIH HHS [HD14886] Funding Source: Medline; NIGMS NIH HHS [GM40423] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBB MR, 1991, J BIOL CHEM, V266, P3820; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; COOPER JA, 1986, J BIOL CHEM, V261, P477; ERICKSONVIITANE.S, 1983, ARCH BIOCHEM BIOPHYS, V222, P407; GOLDSCHMIDTCLER.PJ, 1991, J CELL BIOL, V115, P3; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOODALL GJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P402, DOI 10.1016/0003-9861(87)90461-9; HALL AK, 1991, J NEUROCHEM, V56, P462, DOI 10.1111/j.1471-4159.1991.tb08173.x; HALL AK, 1990, MOL BRAIN RES, V8, P129, DOI 10.1016/0169-328X(90)90057-K; HANNAPPEL E, 1989, ARCH BIOCHEM BIOPHYS, V273, P396, DOI 10.1016/0003-9861(89)90498-0; HANNAPPEL E, 1982, P NATL ACAD SCI-BIOL, V79, P1708, DOI 10.1073/pnas.79.6.1708; HARITOS AA, 1987, FEBS LETT, V218, P107, DOI 10.1016/0014-5793(87)81028-1; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12836; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LIN SC, 1990, J MOL NEUROSCI, V2, P35, DOI 10.1007/BF02896924; LIN SC, 1991, J BIOL CHEM, V266, P23347; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; LOW TLK, 1985, METHOD ENZYMOL, V116, P248; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2336; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE J, 1990, J BIOL CHEM, V265, P12801; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WODNARFILIPOWICZ A, 1984, P NATL ACAD SCI-BIOL, V81, P2295, DOI 10.1073/pnas.81.8.2295; YAMAMOTO H, 1990, J BIOCHEM-TOKYO, V108, P505, DOI 10.1093/oxfordjournals.jbchem.a123229; YIN HL, 1981, J BIOL CHEM, V256, P9693; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269; YU FX, 1992, J BIOL CHEM, V267, P14616; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	56	165	171	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					502	509						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416954				2022-12-25	WOS:A1993KE60300076
J	ZIOBER, BL; WILLSON, JKV; HYMPHREY, LE; CHILDRESSFIELDS, K; BRATTAIN, MG				ZIOBER, BL; WILLSON, JKV; HYMPHREY, LE; CHILDRESSFIELDS, K; BRATTAIN, MG			AUTOCRINE TRANSFORMING GROWTH FACTOR-ALPHA IS ASSOCIATED WITH PROGRESSION OF TRANSFORMED PROPERTIES IN HUMAN COLON CANCER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR RECEPTOR ANTIBODIES; HUMAN-BREAST CANCER; TGF-ALPHA; CARCINOMA-CELLS; TRANSGENIC MICE; MONOCLONAL-ANTIBODY; HUMAN-FIBROBLASTS; EPITHELIAL-CELLS; SARCOMA-VIRUS	The GEO colon carcinoma cell line is weakly tumorigenic in athymic mice and shows differentiated properties both in tissue culture and in xenografts. Proliferating monolayer cultures of GEO cells which normally require exogenous epidermal growth factor (EGF) for optimal growth displayed a marked inhibition in growth upon addition of antibodies that block binding to the EGF receptor or neutralize TGF-alpha. These results indicated that GEO cells utilize TGF-alpha in a weak autocrine loop. The availability of a weakly malignant model system in which TGF-alpha had demonstrable, but low level autocrine activity, permitted the investigation of the role of TGF-alpha in tumorigenesis by generating a stronger autocrine loop through the overexpression of the polypeptide. GEO cells were electroporated with an expression vector containing the human TGF-alpha cDNA, and stable clones were isolated that constitutively expressed the TGF-alpha cDNA in a strong autocrine loop. However, the growth rate of the parental cells in EGF-supplemented medium was the same as that of transfected cells with or without growth factor-supplemented medium. Thus, any biological changes generated by the overexpression of TGF-alpha were due to the autocrine nature of the growth mechanism rather than due to any decrease in doubling time leading to a faster growth rate. Transfected GEO cells showed an increase in anchorage-independent growth and formed tumors more readily in athymic nude mice indicating that TGF-alpha plays a role in progression of transformed properties.	BAYLOR COLL MED, DEPT PHARMACOL, HOUSTON, TX 77030 USA; CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA	Baylor College of Medicine; Case Western Reserve University					NCI NIH HHS [CA45967, CA50457, CA54807] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054807, R01CA050457, U01CA045967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKELESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BOYD DD, 1988, CANCER RES, V48, P2469; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; COFFEY RJ, 1987, CANCER RES, V47, P4590; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1989, CANCER CEL, V7, P297; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; GILL GN, 1984, J BIOL CHEM, V259, P7755; HEMAR A, 1991, J IMMUNOL, V146, P2409; IWAMOTO M, 1990, CELL IMMUNOL, V125, P151, DOI 10.1016/0008-8749(90)90070-8; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LEE JC, 1982, J IMMUNOL, V128, P2393; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Maniatis T., 1982, MOL CLONING; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; MULDER KM, 1991, CANCER RES, V51, P2256; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; RAYMOND VW, 1989, CANCER RES, V49, P3608; RODECK U, 1990, J CELL BIOCHEM, V44, P69, DOI 10.1002/jcb.240440202; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROSENTHAL SM, 1991, J CLIN INVEST, V87, P1212, DOI 10.1172/JCI115121; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato J D, 1983, Mol Biol Med, V1, P511; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SIZELAND AM, 1991, MOL CELL BIOL, V11, P4005, DOI 10.1128/MCB.11.8.4005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	56	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					691	698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416972				2022-12-25	WOS:A1993KE60300104
J	FATTAEY, AR; HELIN, K; DEMBSKI, MS; DYSON, N; HARLOW, E; VUOCOLO, GA; HANOBIK, MG; HASKELL, KM; OLIFF, A; DEFEOJONES, D; JONES, RE				FATTAEY, AR; HELIN, K; DEMBSKI, MS; DYSON, N; HARLOW, E; VUOCOLO, GA; HANOBIK, MG; HASKELL, KM; OLIFF, A; DEFEOJONES, D; JONES, RE			CHARACTERIZATION OF THE RETINOBLASTOMA BINDING-PROTEINS RBP1 AND RBP2	ONCOGENE			English	Note							CELLULAR TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGEN; GENE-PRODUCT; TUMOR SUPPRESSOR; CARCINOMA-CELLS; DNA-BINDING; 2 DISTINCT; FACTOR E2F; IDENTIFICATION	The retinoblastoma gene product, pRB, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins. Several cellular proteins have been shown to bind directly to pRB and the genes encoding a number of them have been isolated. The protein product of one of these genes is the transcription factor E2F. We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB. The products of the RBP1 and RBP2 genes are ubiquotosly expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation. In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.	MERCK & CO INC,RES LABS,DEPT CANC RES,W POINT,PA 19486	Merck & Company	FATTAEY, AR (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,BOSTON,MA 02129, USA.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, IN PRESS MOL CELL BI; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PETERSON MG, 1991, NATURE, V354, P369; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG PN, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	48	158	167	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3149	3156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414517				2022-12-25	WOS:A1993MC09300032
J	DUMAS, C; CAMONIS, J				DUMAS, C; CAMONIS, J			CLONING AND SEQUENCE-ANALYSIS OF THE CDNA FOR ARGININE KINASE OF LOBSTER MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MITOCHONDRIAL CREATINE-KINASE; AMINO-ACID SEQUENCES; MESSENGER-RNA; PROTEIN; SHUTTLE; CHICKEN; ENZYME; CLONES; BRAIN	Arginine kinase belongs to an evolutionary conserved family of ATP:guanidino phosphotransferases, whose members play an important role in energy metabolism. In this work, a lambdagt11 lobster muscle library was constructed and screened by using both polyclonal antibodies and two synthetic oligonucleotides. The complete amino acid sequence of arginine kinase (ATP:L-arginine N-phosphotransferase, EC 2.7.3.3) from lobster muscle was determined by cloning and sequencing the DNA complementary to its mRNA. The identity of the clone was confirmed by comparing the amino acid sequence deduced by nucleotide sequence analysis with previously published partial sequences of amino- and carboxyl-terminal regions of the enzyme and some of its fragments (Regnouf, F., Kassab, R., Debuire, B., Richard, C., and Han K. K. (1981) Int. J. Peptide Protein Res. 17, 143-155). The nucleotide sequence of the cDNA was found to contain an open reading frame encoding 355 amino acid residues with a calculated molecular mass of 39,830 daltons. This enzyme exhibits a significant sequence identity to those of representative members of the guanidino kinase family, including creatine kinase. This report represents the first molecular cloning and sequencing of an ATP-guanidino phosphotransferase which is not a creatine kinase isoform.	UNIV PARIS 11,CNRS,UMR 9920,BIOL STRUCT LAB,F-91405 ORSAY,FRANCE; UNIV PARIS 11,CNRS,URA 1122,INFORMAT GENET & DEV GRP,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BENFIELD PA, 1984, J BIOL CHEM, V259, P4979; BENFIELD PA, 1985, GENE, V39, P263, DOI 10.1016/0378-1119(85)90321-X; BERTHOU A, 1975, J MOL BIOL, V95, P331; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BILLADELLO JJ, 1986, BIOCHEM BIOPH RES CO, V138, P392, DOI 10.1016/0006-291X(86)90294-9; BLETHEN SL, 1967, BIOCHEMISTRY-US, V6, P1413, DOI 10.1021/bi00857a025; BREVET A, 1975, BIOCHIM BIOPHYS ACTA, V393, P1, DOI 10.1016/0005-2795(75)90209-3; BUECHTER DD, 1992, J BIOL CHEM, V267, P2173; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; BUTTLAIRE DH, 1974, J BIOL CHEM, V249, P5733; DEBUIRE B, 1977, J BIOCHEM, V81, P611, DOI 10.1093/oxfordjournals.jbchem.a131496; DERTERROSSIAN E, 1969, EUR J BIOCHEM, V11, P482; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; GIRAUDAT J, 1984, P NATL ACAD SCI-BIOL, V81, P7313, DOI 10.1073/pnas.81.23.7313; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; HOSSLE JP, 1988, BIOCHEM BIOPH RES CO, V151, P408, DOI 10.1016/0006-291X(88)90608-0; JARORI GK, 1989, BIOCHEMISTRY-US, V28, P9343, DOI 10.1021/bi00450a015; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; KWIATKOWSKI RW, 1984, NUCLEIC ACIDS RES, V12, P6925, DOI 10.1093/nar/12.18.6925; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Morrison J. F., 1973, ENZYMES, V8, P457, DOI 10.1016/S1874-6047; MUNNEKE LR, 1988, BIOCHEM GENET, V26, P131, DOI 10.1007/BF00555494; NICHOLS R, 1988, ANAL BIOCHEM, V170, P110, DOI 10.1016/0003-2697(88)90096-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRYMAN MB, 1986, BIOCHEM BIOPH RES CO, V140, P981, DOI 10.1016/0006-291X(86)90732-1; PICKERING L, 1985, P NATL ACAD SCI USA, V82, P2310, DOI 10.1073/pnas.82.8.2310; PRADEL LA, 1973, CR ACAD SCI D NAT, V276, P2843; PUTNEY S, 1984, J BIOL CHEM, V259, P14317; RAO BDN, 1981, J BIOL CHEM, V256, P1716; RATTO A, 1988, EUR J BIOCHEM, V173, P667, DOI 10.1111/j.1432-1033.1988.tb14050.x; REGNOUF F, 1981, INT J PEPT PROT RES, V17, P143; REGNOUF F, 1974, EUR J BIOCHEM, V44, P67, DOI 10.1111/j.1432-1033.1974.tb03458.x; RICHARD C, 1984, INT J BIOCHEM, V16, P727, DOI 10.1016/0020-711X(84)90182-4; ROMAN D, 1985, P NATL ACAD SCI USA, V82, P8394, DOI 10.1073/pnas.82.24.8394; ROUSTAN C, 1970, BIOCHIM BIOPHYS ACTA, V206, P369, DOI 10.1016/0005-2744(70)90153-1; ROUXFROMY M, 1988, EUR J BIOCHEM, V176, P343, DOI 10.1111/j.1432-1033.1988.tb14287.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNYDER T, 1991, J BIOL CHEM, V266, P5318; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STEIN LD, 1990, J BIOL CHEM, V265, P6582; TERROSSIAN ED, 1971, EUR J BIOCHEM, V22, P585; THOAI NV, 1970, METHODS ENZYMOLOGY A, V17, P1002; THOMSON AR, 1964, NATURE, V203, P267, DOI 10.1038/203267a0; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; VILLARREALLEVY G, 1987, BIOCHEM BIOPH RES CO, V144, P1116, DOI 10.1016/0006-291X(87)91427-6; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALLIMAN.T, 1973, EUR J BIOCHEM, V38, P180, DOI 10.1111/j.1432-1033.1973.tb03048.x; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WATTS DC, 1973, ENZYMES, V8, P383; WEST BL, 1984, P NATL ACAD SCI-BIOL, V81, P7007, DOI 10.1073/pnas.81.22.7007; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; [No title captured]	58	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21599	21605						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408011				2022-12-25	WOS:A1993MC80900028
J	KOSAKI, A; WEBSTER, NJG				KOSAKI, A; WEBSTER, NJG			EFFECT OF DEXAMETHASONE ON THE ALTERNATIVE SPLICING OF THE INSULIN-RECEPTOR MESSENGER-RNA AND INSULIN ACTION IN HEPG2 HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; LIVER; GENE; RESPONSIVENESS; HORMONE; SUBUNIT; DIFFERENTIATION; TRANSCRIPTION; SENSITIVITY; EXPRESSION	We have shown that culturing HepG2 cells in Ham's F-12 medium supplemented with calf serum, dexamethasone, and triiodothyronine causes an increase in the insulin sensitivity and responsiveness for glucose incorporation into glycogen. This correlates with increased expression of the mRNA encoding the B isoform of the insulin receptor. Of all the components in the medium, we found that dexamethasone exerted the greatest effect. Dexamethasone alone could cause both a switch in expression from the A to the B isoform of the insulin receptor and also an increase in insulin sensitivity for both glucose incorporation into glycogen and 2-deoxyglucose transport. In addition, we found that expression of the B isoform of the insulin receptor is developmentally regulated in the 3T3-L1 adipocyte leading to the suggestion that the alternatively spliced B isoform of the insulin receptor may play an important role in signal transduction in insulin target tissues such as liver, fat, and muscle.	VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161	US Department of Veterans Affairs; Veterans Health Administration (VHA)			Webster, Nick/AAI-8410-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R01DK044643, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651, DK44643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1991, J BIOL CHEM, V266, P21760; ANDERSON CM, 1993, J CLIN ENDOCR METAB, V76, P1380, DOI 10.1210/jc.76.5.1380; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FLEIG WE, 1985, BIOCHIM BIOPHYS ACTA, V847, P352, DOI 10.1016/0167-4889(85)90041-2; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERREROS A, 1989, J BIOL CHEM, V264, P19994; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; KAHN CR, 1985, ANNU REV MED, V36, P429; KARLSSON FA, 1979, ENDOCRINOLOGY, V104, P1383, DOI 10.1210/endo-104-5-1383; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NAKANISHI O, 1985, GENE, V35, P289; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PODSKALNY JM, 1985, EUR J BIOCHEM, V150, P401, DOI 10.1111/j.1432-1033.1985.tb09034.x; RESH MD, 1982, J BIOL CHEM, V257, P6978; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SALHANICK AI, 1989, BIOCHEM J, V261, P985, DOI 10.1042/bj2610985; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SESTI G, 1992, DIABETES, V41, P6, DOI 10.2337/diabetes.41.1.6; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WILLIAMS JF, 1990, ENDOCRINOLOGY, V127, P1706, DOI 10.1210/endo-127-4-1706; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	35	97	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21990	21996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408055				2022-12-25	WOS:A1993MC80900083
J	MALILA, LH; SIIVARI, KM; MAKELA, MJ; JALONEN, JE; LATIPAA, PM; KUNAU, WH; HILTUNEN, JK				MALILA, LH; SIIVARI, KM; MAKELA, MJ; JALONEN, JE; LATIPAA, PM; KUNAU, WH; HILTUNEN, JK			ENZYMES CONVERTING D-3-HYDROXYACYL-COA TO TRANS-2-ENOYL-COA - MICROSOMAL AND PEROXISOMAL ISOENZYMES IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ION-TRAP DETECTOR; BETA-OXIDATION; 3-HYDROXYACYL-COA EPIMERASE; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; 2,4-DIENOYL-COA REDUCTASE; SUBCELLULAR-DISTRIBUTION; ESCHERICHIA-COLI; CHAIN; MITOCHONDRIA	Epimerization of 3-hydroxyacyl-CoA, which has been shown to occur as a two-step dehydration-hydration reaction (Hiltunen, J. K., Palosaari, P. M., and Kunau, W.-H. (1989) J. Biol. Chem. 264, 13536-13540; Smeland, E., Jianxun, L., Chu, C., Cuebas, D., and Schulz, H. (1989) Biochem. Biophys. Res. Commun. 160, 988-992) was studied in rat liver. Subcellular fractionations of rat liver on different density gradients revealed a dual distribution of activity, catalyzing dehydration of D-3-hydroxydecanoyl-CoA to trans-2-decenoyl-CoA (hydratase 2) in both peroxisomal and microsomal compartments. Both hydratase 2 activity peaks were separated by dye ligand chromatography from the extract of the combined heavy and light mitochondrial fractions. The activity eluted at low salt was identified as the microsomal isoform and was purified to apparent homogeneity. The M(r) of the native protein (subunit) was found to be 60,000 (31,500), indicating that it is homodimeric. The enzyme activity was inhibited by IgGs isolated from antisera raised against the denatured subunit. The activity eluted at high salt was tentatively identified to be peroxisomal of origin, and the M(r) of the native protein (subunit) was determined to be 62,000 (33,500). The peroxisomal enzyme was not recognized by the antibody to its microsomal counterpart. Analysis of the reaction products of microsomal enzyme activity by gas chromatography-mass spectrometry showed that the enzyme catalyzed reversibly hydration/dehydration between trans-2-enoyl-CoA and D-3-hydroxyacyl-CoA, but L-3-hydroxydecanoyl-CoA was not dehydrated to DELTA2-enoyl-CoA compounds. Similar reaction characteristics were also determined for the peroxisomal hydratase by using stereospecific auxiliary enzymes. The present data demonstrate that rat liver contains microsomal and peroxisomal proteins possessing hydratase 2 activities. Although their kinetic properties are similar, immunological data, subunit sizes, and chromatographic evidence clearly indicate that they are different enzymes. Comparisons with other hydratases revealed that the microsomal and peroxisomal hydratase 2 described in the present work are proteins that have not been previously purified.	UNIV OULU, BIOCTR OULU, DEPT MED BIOCHEM, KAJAANINTIE 52 A, SF-90220 OULU, FINLAND; UNIV OULU, DEPT CHEM, SF-90570 OULU, FINLAND; RUHR UNIV BOCHUM, FAK MED, INST PHYSIOL CHEM, ZELLBIOCHEM ABT, W-4630 BOCHUM, GERMANY	University of Oulu; University of Oulu; Ruhr University Bochum								BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P161, DOI 10.1016/0003-9861(88)90624-8; BERGMEYER HU, 1970, METHODEN ENZYMATISCH, P533; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; BOCK P, 1980, PEROXISOMES RELATED; BREMER J, 1982, J LIPID RES, V23, P243; CHU CH, 1985, FEBS LETT, V185, P129, DOI 10.1016/0014-5793(85)80755-9; CHU CH, 1984, BIOCHEM BIOPH RES CO, V118, P162, DOI 10.1016/0006-291X(84)91081-7; COOK L, 1992, BIOCHEM J, V287, P91, DOI 10.1042/bj2870091; DICZFALUSY U, 1988, J LIPID RES, V29, P1629; DOMMES V, 1981, J BIOL CHEM, V256, P8259; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GHOOS Y, 1991, ANAL CHIM ACTA, V247, P223, DOI 10.1016/S0003-2670(00)83816-7; GHOSH MK, 1986, ANAL BIOCHEM, V159, P169, DOI 10.1016/0003-2697(86)90323-4; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; GRESSNER AM, 1982, CLIN CHIM ACTA, V124, P315, DOI 10.1016/0009-8981(82)90425-9; GRONN M, 1990, BIOCHIM BIOPHYS ACTA, V1044, P249, DOI 10.1016/0005-2760(90)90310-T; HAGVE TA, 1986, BIOCHIM BIOPHYS ACTA, V875, P165, DOI 10.1016/0005-2760(86)90165-7; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HILTUNEN JK, 1990, PROG CLIN BIOL RES, V321, P265; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HORMAN I, 1989, BIOMED ENVIRON MASS, V18, P1016, DOI 10.1002/bms.1200181111; KARKI T, 1987, FEBS LETT, V215, P228, DOI 10.1016/0014-5793(87)80151-5; KILPONEN JM, 1990, BIOCHEM J, V269, P223, DOI 10.1042/bj2690223; KIMURA C, 1984, J BIOCH, V36, P1463; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JX, 1990, J BIOL CHEM, V265, P13629; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; OSMUNDSEN H, 1983, IODINATED DENSITY GR, P139; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PULLMAN ME, 1973, ANAL BIOCHEM, V54, P188, DOI 10.1016/0003-2697(73)90262-5; RAATIKAINEN MJP, 1992, BIOCHIM BIOPHYS ACTA, V1099, P238; RATHKE MW, 1970, J ORG CHEM, V35, P3966, DOI 10.1021/jo00836a087; RUPPERT JF, 1974, J ORG CHEM, V39, P269, DOI 10.1021/jo00916a043; SCHEPERS L, 1989, BIOCHEM J, V257, P221, DOI 10.1042/bj2570221; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SMELAND TE, 1989, BIOCHEM BIOPH RES CO, V160, P988, DOI 10.1016/S0006-291X(89)80098-1; SMIDT E, 1983, METHOD ENZYMAT AN, V3, P216; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V339, P167; SYMONS LJ, 1987, ANAL BIOCHEM, V164, P382, DOI 10.1016/0003-2697(87)90508-2; THEILACKER WHW, 1955, METHOD ORGAN CHEM, V4, P518; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; WAKABAYASHI K, 1963, BIOCHIM BIOPHYS ACTA, V70, P132, DOI 10.1016/0006-3002(63)90733-9; WHITEHEAD TP, 1983, NATURE, V305, P158, DOI 10.1038/305158a0; YANG SY, 1983, J BIOL CHEM, V258, P9780; YANG SY, 1986, J BIOL CHEM, V261, P2238; YOKOTA S, 1988, HISTOCHEM J, V20, P679, DOI 10.1007/BF01002748	53	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21578	21585						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408009				2022-12-25	WOS:A1993MC80900025
J	MASON, SA; HOUSLEY, PR				MASON, SA; HOUSLEY, PR			SITE-DIRECTED MUTAGENESIS OF THE PHOSPHORYLATION SITES IN THE MOUSE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL ENHANCEMENT; MAMMALIAN-CELLS; CULTURED-CELLS; INTACT-CELLS; PROTEIN; EXPRESSION; HORMONE; BINDING; DNA	The functional significance of receptor phosphorylation in mediating the actions of glucocorticoids remains undefined. The identification of seven phosphorylation sites in the mouse glucocorticoid receptor (Bodwell, J. E., Orti, E., Coull, J. M., Pappin, D. J. C., Smith, L. I., and Swift, F. (1991) J. Biol. Chem. 266, 7549-7555) permits a direct examination of the potential regulatory role of glucocorticoid receptor phosphorylation in transactivation. Using oligonucleotide-directed mutagenesis of the mouse glucocorticoid receptor cDNA, we have substituted alanine or aspartate for the residues phosphorylated in this ligand-dependent transcription factor. COS-1 cells were cotransfected with mutant receptor cDNA expression vectors and a reporter plasmid containing the glucocorticoid-inducible mouse mammary tumor virus promoter linked to chloramphenicol acetyltransferase in order to characterize the effect of these substitutions on receptor-mediated gene expression. Substitution of alanine or aspartate at single phosphorylation sites does not prevent receptor transactivation. Receptors containing multiple substitutions of alanine or aspartate at the major phosphorylation sites in the acidic domain elicit levels of hormone-induced reporter gene expression that are comparable to wild-type receptors. Mutant receptors substituted with alanine at the five phosphorylation sites conserved among the rat, human, and mouse receptors exhibit a 22% decrease in transcriptional activity. Receptors mutated at all seven sites display a similar modest reduction. These results demonstrate that receptor phosphorylation at these seven identified residues is not a major determinant in glucocorticoid receptor transcriptional activity at the mouse mammary tumor virus promoter.	UNIV S CAROLINA,SCH MED,DEPT PHARMACOL,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1991, 73RD ANN M END SOC W, P32; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; HOUSLEY PR, 1982, J BIOL CHEM, V257, P8615; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; ORTI E, 1993, J BIOL CHEM, V268, P7779; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575	42	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21501	21504						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407999				2022-12-25	WOS:A1993MC80900013
J	RESNICOFF, M; SELL, C; AMBROSE, D; BASERGA, R; RUBIN, R				RESNICOFF, M; SELL, C; AMBROSE, D; BASERGA, R; RUBIN, R			ETHANOL INHIBITS THE AUTOPHOSPHORYLATION OF THE INSULIN-LIKE GROWTH FACTOR-I (IGF-1) RECEPTOR AND THE IGF-1-MEDIATED PROLIFERATION OF 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL ALCOHOL SYNDROME; FACTOR-I; HEPATIC REGENERATION; SIGNAL TRANSDUCTION; LIVER-REGENERATION; BINDING-PROTEINS; TYROSINE KINASE; PHOSPHOLIPASE-C; INVITRO; EXPOSURE	The effect of ethanol on cell proliferation was studied in Balb/c 3T3 cells and in stably transfected 3T3 cells constitutively overexpressing the human insulin-like growth factor 1 (IGF-1) receptor (p6 cells). Ethanol inhibited growth of both cell lines when they were cultured in serum-free medium supplemented with individual growth factors, i. e. platelet-derived growth factor and IGF-1 for 3T3 cells, and IGF-1 only for p6 cells. Increases in cell number were prevented in both cell lines even when ethanol was present exclusively during the period of IGF-1 stimulation. The inhibitory effect of ethanol was concentration-dependent, with a 30% inhibition observed at 10 mM ethanol. IGF-1 receptor tyrosine autophosphorylation was completely prevented by ethanol both in intact cells and in immunopurified IGF-1 receptor preparations. The binding of IGF-1 to its receptor on intact cells was unaffected by ethanol. Ethanol also inhibited the stimulation of IGF-1 receptor autophosphorylation and the corresponding growth of p6 cells induced by IGF-2. Transcription of c-myc, c-fos, and c-jun in response to IGF-1 was inhibited by ethanol. These findings demonstrate that ethanol at low concentrations markedly inhibits IGF-1 receptor autophosphorylation and IGF-1-mediated cell growth.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL & CELL BIOL, 606 LIFE SCI BLDG, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University					NCI NIH HHS [CA-56309] Funding Source: Medline; NIAAA NIH HHS [AA-7309, AA-07186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; [Anonymous], 1991, INSULIN LIKE GROWTH; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CARTER EA, 1988, ALCOHOL CLIN EXP RES, V12, P555, DOI 10.1111/j.1530-0277.1988.tb00241.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES CD, 1992, DEV CENTRAL NERVOUS; COOK RT, 1990, ALCOHOL ALCOHOLISM, V25, P33; COOK RT, 1990, ALCOHOL CLIN EXP RES, V14, P695, DOI 10.1111/j.1530-0277.1990.tb01229.x; CURRAN T, 1987, ONCOGENE, V2, P79; DATTA R, 1990, BLOOD, V76, P298; DAVIES DL, 1991, BRAIN RES, V547, P53; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DICICCOBLOOM E, 1988, P NATL ACAD SCI USA, V85, P4066, DOI 10.1073/pnas.85.11.4066; DUGUAY L, 1982, GUT, V23, P8, DOI 10.1136/gut.23.1.8; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FRANK WO, 1979, J LAB CLIN MED, V93, P402; FRIDAY KE, 1991, METABOLISM, V40, P562, DOI 10.1016/0026-0495(91)90044-W; GOLDRING M B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P301; HENDERSON GI, 1989, J CLIN INVEST, V84, P1287, DOI 10.1172/JCI114296; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; HIGGINS PJ, 1986, BIOCHEM PHARMACOL, V35, P3857, DOI 10.1016/0006-2952(86)90676-3; HIGGINS PJ, 1987, ALCOHOL CLIN EXP RES, V11, P550, DOI 10.1111/j.1530-0277.1987.tb00172.x; HOEK JB, 1990, ALCOHOL ALCOHOLISM, V25, P143, DOI 10.1093/oxfordjournals.alcalc.a044989; HOFFMAN PL, 1990, FASEB J, V4, P2612, DOI 10.1096/fasebj.4.9.2161371; HUANG S, 1992, NATURE, V360, P745, DOI 10.1038/360745a0; IMPERIA PS, 1984, P SOC EXP BIOL MED, V175, P219; ISENBERG K, 1992, ALCOHOL CLIN EXP RES, V16, P695, DOI 10.1111/j.1530-0277.1992.tb00663.x; JONES KL, 1975, TERATOLOGY, V12, P1, DOI 10.1002/tera.1420120102; KATO H, 1993, J BIOL CHEM, V268, P2655; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MICHALOPOULOS G, 1992, LAB INVEST, V67, P413; PANTAZIS NJ, 1992, ALCOHOL, V9, P171, DOI 10.1016/0741-8329(92)90048-F; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; POSO H, 1980, MED BIOL, V58, P329; ROONEY TA, 1989, J BIOL CHEM, V264, P6817; RUBIN R, 1989, ARCH BIOCHEM BIOPHYS, V270, P99, DOI 10.1016/0003-9861(89)90012-X; RUBIN R, 1988, BIOCHEM J, V254, P147, DOI 10.1042/bj2540147; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SARA VR, 1990, KAR INS NCS, P179; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHENKER S, 1990, ALCOHOL CLIN EXP RES, V14, P635, DOI 10.1111/j.1530-0277.1990.tb01220.x; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; SVRZIC D, 1990, BIOCHEM BIOPH RES CO, V172, P54, DOI 10.1016/S0006-291X(05)80172-X; TARASCHI TF, 1985, LAB INVEST, V52, P120; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wands J R, 1980, Adv Exp Med Biol, V132, P663; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WERNER H, 1992, RECEPTORS DEV NERVOU, P109; YOSHINOUCHI M, 1993, CELL PROLIFERAT, V26, P139, DOI 10.1111/j.1365-2184.1993.tb00014.x	56	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21777	21782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408032				2022-12-25	WOS:A1993MC80900055
J	CAPPS, GG; ZUNIGA, MC				CAPPS, GG; ZUNIGA, MC			THE CYTOPLASMIC DOMAIN OF THE H-2L(D) CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE IS DIFFERENTIALLY ACCESSIBLE TO IMMUNOLOGICAL AND BIOCHEMICAL PROBES DURING TRANSPORT TO THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; INTRACELLULAR-TRANSPORT; TRANSPLANTATION ANTIGENS; PEPTIDE LIGAND; VIRAL PEPTIDES; G-PROTEIN; T-CELLS; HLA-A; LD; HEMAGGLUTININ	An antiserum was generated against a synthetic peptide corresponding to a portion of the cytoplasmic domains of the H-2L(d) and H-2D(b) class I major histocompatibility complex molecules of the mouse. This antibody preparation, R4, binds exclusively to endoglycosidase H-resistant H-2L(d)/D(b) molecules which are not associated with beta2-microglobulin. Interestingly, acquisition of resistance to endoglycosidase H precedes acquisition of R4 reactivity by 30 min. R4-reactive H-2L(d) and H-2D(b) molecules occur on the cell surface and are phosphorylated in vivo. Other studies show that the tyrosine in the cytoplasmic domain is accessible to radioiodination on only a subset of H-2L(d) molecules, and that the two-dimensional electrophoretic profiles of phosphorylated H-2L(d)/D(b) molecules, of R4-reactive molecules, and of H-2L(d) molecules radiolabeled on this cytoplasmic domain tyrosine are virtually identical. R4-reactive H-2L(d) molecules do not undergo the peptide- and beta2-microglobulin-induced conformational changes characteristic of free class I major histocompatibility complex heavy chains. The accessibility of the H-2L(d) cytoplasmic domain to R4 and to radioiodination late in biosynthesis and its biological significance are discussed.	UNIV CALIF SANTA CRUZ,DEPT BIOL,SINSHEIMER LABS,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; CAPPS GG, 1990, BIOTECHNIQUES, V8, P62; CAPPS GG, 1993, J IMMUNOL, V151, P159; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; JONES PP, 1980, SELECTED METHODS CEL, P398; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; LIPPE R, 1991, J EXP MED, V174, P1159, DOI 10.1084/jem.174.5.1159; MACK D, 1989, J CELL BIOL, V109, P2057, DOI 10.1083/jcb.109.5.2057; MCCLUSKEY J, 1986, EMBO J, V5, P2477, DOI 10.1002/j.1460-2075.1986.tb04524.x; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MYERS NB, 1989, J IMMUNOL, V142, P2751; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; PULLEN JK, 1992, J IMMUNOL, V148, P953; RAVIPRAKASH K, 1990, J BIOL CHEM, V265, P1777; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; SHIROISHI T, 1985, J IMMUNOL, V134, P623; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, COLD SPRING HARB SYM, V1, P299; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZUNIGA MC, 1983, CELL, V34, P535, DOI 10.1016/0092-8674(83)90386-0; ZUNIGA MC, 1986, J CELL BIOL, V102, P1, DOI 10.1083/jcb.102.1.1	37	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21263	21270						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407964				2022-12-25	WOS:A1993MA28800091
J	HARRINGTON, MA; KONICEK, B; SONG, A; XIA, XL; FREDERICKS, WJ; RAUSCHER, FJ				HARRINGTON, MA; KONICEK, B; SONG, A; XIA, XL; FREDERICKS, WJ; RAUSCHER, FJ			INHIBITION OF COLONY-STIMULATING FACTOR-I PROMOTER ACTIVITY BY THE PRODUCT OF THE WILMS-TUMOR LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; SUPPRESSOR WT1; MESSENGER-RNA; BINDING; CSF-1; TRANSCRIPTION; PROTEIN	Colony-stimulating factor-1 (CSF-1) is a member of the immediate early gene family, which is expressed in mitogen-stimulated quiescent fibroblasts. The biological effects of CSF-1 are multifaceted and include stimulation of the proliferation and differentiation of myeloid progenitors and activity of circulating monocytes and tissue-specific macrophages. Ablation of circulating levels of biologically active CSF-1 in mice leads to osteopetrosis and sterility, thus implicating a role for CSF-1 in bone remodeling and implantation. Identification of regulatory elements and cognate transcription factors that bind the csf-1 promoter and mediate such diverse expression patterns is of great interest. We identified a sequence element at -273 to -265 (relative to the transcription initiation site) in the murine csf-1 promoter, which contains overlapping consensus sequences for the Wilms' tumor protein (WT1), EGR-1, SP1, and SP3 proteins. WT1 and EGR-1 proteins produced in vitro bound to this sequence, and co-transfection of wt1 with a csf-1-cat reporter plasmid resulted in repression of promoter activity. Interestingly, nuclear extracts prepared from serum-stimulated C3H10T1/2 cells contained predominantly SP1 and SP3 binding activities, which recognized the -273 to -265 site. Thus repression of the csf-1 promoter by WT1 at this site may involve competition between SP1 family transcriptional activators and the WT1 repressor. Colony-stimulating factor-1 may be a physiologically relevant target gene for regulation by the WT1 transcription factor.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; The Wistar Institute	HARRINGTON, MA (corresponding author), INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,IB 549,975 W WALNUT ST,INDIANAPOLIS,IN 46202, USA.				NCI NIH HHS [CA 52009] Funding Source: Medline; NIDDK NIH HHS [1-P50-DK45191] Funding Source: Medline; NIGMS NIH HHS [GM43972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043972, R29GM043972] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOUD SL, 1991, BLOOD, V78, P103; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARTOCCI A, 1986, J EXP MED, V164, P956, DOI 10.1084/jem.164.3.956; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOWENPOPE DF, 1991, TRENDS GENET, V7, P413, DOI 10.1016/0168-9525(91)90222-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROXMEYER HE, 1988, CRC CR REV ONCOL-HEM, V8, P173, DOI 10.1016/S1040-8428(88)80016-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daiter E, 1992, REPROD MED REV, V1, P83; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FALKENBURG JHF, 1991, BLOOD, V78, P658; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GILBERT HS, 1989, BLOOD, V74, P1231; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HARRINGTON MA, 1990, MOL CELL BIOL, V10, P4948, DOI 10.1128/MCB.10.9.4948; HARRINGTON MA, 1991, GENE, V102, P165, DOI 10.1016/0378-1119(91)90074-L; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HORIGUCHI J, 1988, MOL CELL BIOL, V8, P3951, DOI 10.1128/MCB.8.9.3951; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEIBOVITCH SA, 1989, ONCOGENE RES, V4, P157; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; PAIK S, 1989, LAB INVEST, V61, P522; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; WANG JM, 1988, J IMMUNOL, V141, P575; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	40	170	176	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21271	21275						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407965				2022-12-25	WOS:A1993MA28800092
J	MCDOWELL, LM; COHEN, ER; SCHAEFER, J				MCDOWELL, LM; COHEN, ER; SCHAEFER, J			2-DIMENSIONAL, ROTATIONAL-ECHO DOUBLE-RESONANCE NMR OF CELL-CULTURE METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CROSS-POLARIZATION NMR; SOLID-STATE C-13; KLEBSIELLA-PNEUMONIAE; INTERATOMIC DISTANCE; HELICAL PEPTIDE; INSECT CUTICLE; PSEUDOMONAS SP; MAGIC-ANGLE; REDOR NMR	Two-dimensional, rotational-echo double-resonance C-13 NMR, a new solid-state NMR technique, has been used to show that the relative fluxes of the labeled chemical bond of L-[2-C-13,N-15]serine along four metabolic pathways (direct purine synthesis, direct glycine incorporation into protein, direct non-glycyl incorporation into protein, and nitrogen scrambling with loss of carbon) are 1:2:6:36, respectively, for Klebsiella pneumoniae under conditions of nitrogenase derepression. These determinations were performed on a single sample of lyophilized, double-labeled, intact cells. Analysis of the homogeneity of the distribution of label suggests that the primary role of serine in shortening derepression is in providing specific carbon and nitrogen for RNA synthesis.	WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130	Washington University (WUSTL)								BRILL WJ, 1974, J BACTERIOL, V118, P986, DOI 10.1128/JB.118.3.986-989.1974; CHRISTENSEN AM, 1991, J AM CHEM SOC, V113, P6799, DOI 10.1021/ja00018a013; CHRISTENSEN AM, 1993, BIOCHEMISTRY-US, V32, P2868, DOI 10.1021/bi00062a018; FORREST TM, 1991, J BIOL CHEM, V266, P24485; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; GULLION T, 1991, J MAGN RESON, V92, P439, DOI 10.1016/0022-2364(91)90286-3; GULLION T, 1989, ADV MAGN RESON, V13, P57; HING AW, 1993, IN PRESS BIOCHEMISTR; HOLL SM, 1993, ARCH BIOCHEM BIOPHYS, V302, P255, DOI 10.1006/abbi.1993.1207; HOLL SM, 1992, J AM CHEM SOC, V114, P4830, DOI 10.1021/ja00038a056; JACOB GS, 1985, J BIOL CHEM, V260, P2777; JACOB GS, 1987, J BIOL CHEM, V262, P254; JACOB GS, 1987, J BIOL CHEM, V262, P1552; JACOB GS, 1985, J BIOL CHEM, V260, P5899; LINDSAY HL, 1963, THESIS U WISCONSIN M; MARSHALL GR, 1990, J AM CHEM SOC, V112, P963, DOI 10.1021/ja00159a009; SCHAEFER J, 1984, J MAGN RESON, V59, P150, DOI 10.1016/0022-2364(84)90293-2; SCHAEFER J, 1979, J MAGN RESON, V34, P443, DOI 10.1016/0022-2364(79)90022-2; SCHAEFER J, 1976, J AM CHEM SOC, V98, P1031, DOI 10.1021/ja00420a036; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; SKOKUT TA, 1985, PLANT PHYSIOL, V79, P579, DOI 10.1104/pp.79.3.579; STJOHN RT, 1974, J BACTERIOL, V119, P266; YOCH DC, 1966, J BACTERIOL, V92, P618, DOI 10.1128/JB.92.3.618-622.1966	23	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20768	20771						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407902				2022-12-25	WOS:A1993MA28800021
J	TAN, JC; INDELICATO, SR; NARULA, SK; ZAVODNY, PJ; CHOU, CC				TAN, JC; INDELICATO, SR; NARULA, SK; ZAVODNY, PJ; CHOU, CC			CHARACTERIZATION OF INTERLEUKIN-10 RECEPTORS ON HUMAN AND MOUSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS CYTOKINE PRODUCTION; HIGH-AFFINITY; MOLECULAR-CLONING; B-CELLS; GM-CSF; COLORIMETRIC ASSAY; EXPRESSION CLONING; T-CELLS; IL-10; GROWTH	Human interleukin (IL)-10 is a pleiotropic cytokine acting on a variety of immune cells. Here we show that the protein can be enzymatically iodinated to high specific radioactivity with retention of biological activity. The radiolabeled ligand binds specifically to its receptor in several mouse and human cell lines, notably human B-lymphoma line JY and mouse mast cell line MC/9. Human IL-10 apparently binds as a dimer to a single class of receptor in both the JY and MC/9 cell lines with a K(d) in the 50-200 pM range. Interestingly, mouse IL-10 was capable of blocking binding of human IL-10 to mouse but not human cells. There appears to be at most only a few hundred IL-10 receptors/cell for both mouse and human cell lines examined. Chemical cross-linking of the radioiodinated hIL-10 to JY and MC/9 cells revealed a common protein complex with an apparent molecular mass of about 97 kDa. Additional high molecular weight complexes were detected with JY but not MC/9 cells.	SCHERING PLOUGH RES INST,DEPT BIOTECHNOL MOLEC BIOL,KENILWORTH,NJ 07033	Merck & Company; Schering-Plough Research Institute								ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; CHEN WF, 1991, J IMMUNOL, V147, P528; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOWARD M, 1992, J CLIN IMMUNOL, V12, P239, DOI 10.1007/BF00918147; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEV S, 1992, J BIOL CHEM, V267, P15970; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P915; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; RAZIN E, 1991, J IMMUNOL, V146, P981; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SUDA T, 1990, CELL IMMUNOL, V129, P228, DOI 10.1016/0008-8749(90)90200-B; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZLOTNIK A, 1991, CYTOKINE, V3, P366, DOI 10.1016/1043-4666(91)90039-G	40	130	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21053	21059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407942				2022-12-25	WOS:A1993MA28800064
J	BAUER, JW; KIRCHMAIR, R; EGGER, C; FISCHERCOLBRIE, R				BAUER, JW; KIRCHMAIR, R; EGGER, C; FISCHERCOLBRIE, R			HISTAMINE INDUCES A GENE-SPECIFIC SYNTHESIS REGULATION OF SECRETOGRANIN-II BUT NOT OF CHROMOGRANIN-A AND CHROMOGRANIN-B IN CHROMAFFIN CELLS IN A CALCIUM-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADRENAL-MEDULLA; MESSENGER-RNA LEVELS; INOSITOL PHOSPHATES; SECRETORY PROTEINS; PRIMARY CULTURES; OPIOID-PEPTIDES; NEUROPEPTIDE-Y; ANGIOTENSIN-II; CYCLIC-AMP; GRANULES	The effect of histamine on steady-state mRNA levels of three soluble secretory proteins from chromaffin granules was investigated in cultured bovine adrenal medullary cells. Histamine stimulated secretogranin II mRNA 4-fold, with no or only slight effects on chromogranin A and B transcription. After an initial lag phase, secretogranin II mRNA increased markedly between 4 and 12 h followed by a plateau phase up to 48 h. The effect of histamine on secretogranin II gene-expression was abolished by the H-1 receptor antagonist promethazine but not by the H-2 blocker cimetidine. The histamine-induced elevation of secretogranin II mRNA was partially reduced by the L-type calcium channel blocker nifedipine, indicating a contribution of extracellular calcium in the second messenger signaling pathway involved. At present, the H-1 histaminergic receptor is the first membrane receptor found regulating secretogranin II biosynthesis in chromaffin cells. The selective up-regulation of secretogranin II mRNA but not of chromogranin A and B by histamine is another example illustrating that the synthesis regulation of secretory components co-stored in large vesicles of neuroendocrine cells is specific to the individual gene. Together with results obtained earlier, our data demonstrate a marked variation in the relative composition of peptides secreted from adrenal medulla into circulation following different physiologic conditions.	UNIV INNSBRUCK, DEPT PHARMACOL, PETER MAYR STR 1A, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck								ANOUAR Y, 1991, ENDOCRINOLOGY, V129, P2393, DOI 10.1210/endo-129-5-2393; BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BLASCHKO H, 1967, NATURE, V215, P58, DOI 10.1038/215058a0; BOMMER M, 1987, J NEUROCHEM, V49, P1688, DOI 10.1111/j.1471-4159.1987.tb02426.x; BUNN SJ, 1990, NEUROPEPTIDES, V15, P187, DOI 10.1016/0143-4179(90)90012-N; CHANG RSL, 1979, J PHARMACOL EXP THER, V209, P437; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; EIDEN LE, 1987, NEUROSCIENCE, V21, P1019, DOI 10.1016/0306-4522(87)90056-X; EIDEN LE, 1984, P NATL ACAD SCI-BIOL, V81, P3949, DOI 10.1073/pnas.81.13.3949; EIDEN LE, 1983, LIFE SCI, V33, P687, DOI 10.1016/0024-3205(83)90772-5; FARIN CJ, 1990, J BIOL CHEM, V265, P19116; FASCIOTTO BH, 1990, ENDOCRINOLOGY, V127, P1329, DOI 10.1210/endo-127-3-1329; FISCHERCOLBRIE R, 1990, J BIOL CHEM, V265, P9208; FISCHERCOLBRIE R, 1987, ANN NY ACAD SCI, V493, P120, DOI 10.1111/j.1749-6632.1987.tb27189.x; FISCHERCOLBRIE R, 1992, J NEUROENDOCRINOL, V4, P125, DOI 10.1111/j.1365-2826.1992.tb00355.x; FISCHERCOLBRIE R, 1986, J NEUROCHEM, V47, P318; FISCHERCOLBRIE R, 1985, J NEUROCHEM, V44, P1854, DOI 10.1111/j.1471-4159.1985.tb07179.x; FISCHERCOLBRIE R, 1988, P NATL ACAD SCI USA, V85, P3240, DOI 10.1073/pnas.85.9.3240; FISCHERCOLBRIE R, 1989, J ENDOCRINOL, V121, P487, DOI 10.1677/joe.0.1210487; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GERDES HH, 1989, J BIOL CHEM, V264, P12009; HOFLE G, 1991, REGUL PEPTIDES, V32, P321, DOI 10.1016/0167-0115(91)90025-C; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9245, DOI 10.1073/pnas.83.23.9245; KLEY N, 1987, NEUROENDOCRINOLOGY, V46, P89, DOI 10.1159/000124801; KLEY N, 1986, EMBO J, V5, P967, DOI 10.1002/j.1460-2075.1986.tb04310.x; LASLOP A, 1990, BIOCHIM BIOPHYS ACTA, V1033, P65, DOI 10.1016/0304-4165(90)90195-3; LASLOP A, 1992, NEUROSCIENCE, V49, P443, DOI 10.1016/0306-4522(92)90109-F; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; LIVETT BG, 1986, BRIT J PHARMACOL, V89, P327, DOI 10.1111/j.1476-5381.1986.tb10264.x; MAHATA SK, 1992, NEUROSCIENCE, V48, P669, DOI 10.1016/0306-4522(92)90410-4; MAHATA SK, 1991, EUR J NEUROSCI, V3, P895, DOI 10.1111/j.1460-9568.1991.tb00101.x; MARLEY PD, 1991, BRIT J PHARMACOL, V104, P839, DOI 10.1111/j.1476-5381.1991.tb12515.x; MOULAND AJ, 1991, ENDOCRINOLOGY, V128, P441, DOI 10.1210/endo-128-1-441; NOBLE EP, 1986, BIOCHEM BIOPH RES CO, V135, P566, DOI 10.1016/0006-291X(86)90031-8; NOBLE EP, 1988, BIOCHEM PHARMACOL, V37, P221, DOI 10.1016/0006-2952(88)90721-6; NOLAN JA, 1985, J HISTOCHEM CYTOCHEM, V33, P791, DOI 10.1177/33.8.3894497; PLEVIN R, 1988, J NEUROCHEM, V51, P634, DOI 10.1111/j.1471-4159.1988.tb01085.x; RUSSELL J, 1990, MOL ENDOCRINOL, V4, P505, DOI 10.1210/mend-4-3-505; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SIETZEN M, 1987, NEUROSCIENCE, V22, P131, DOI 10.1016/0306-4522(87)90203-X; SIMON JP, 1989, BIOCHEM J, V262, P1; SOMOGYI P, 1984, BRAIN RES REV, V8, P193, DOI 10.1016/0165-0173(84)90007-9; STAUDERMAN KA, 1990, J NEUROCHEM, V54, P946, DOI 10.1111/j.1471-4159.1990.tb02342.x; STEINER HJ, 1989, HISTOCHEMISTRY, V91, P473, DOI 10.1007/BF00492518; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; THOENEN H, 1972, PHARMACOL REV, V24, P255; WAN DCC, 1989, EUR J PHARM-MOLEC PH, V172, P117, DOI 10.1016/0922-4106(89)90003-5; WILSON SP, 1991, J NEUROCHEM, V56, P945, DOI 10.1111/j.1471-4159.1991.tb02013.x; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WOHLFARTER T, 1988, FEBS LETT, V231, P67, DOI 10.1016/0014-5793(88)80704-X; YAMASHITA M, 1991, BIOCHEM BIOPH RES CO, V177, P1233, DOI 10.1016/0006-291X(91)90673-U	57	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1586	1589						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420933				2022-12-25	WOS:A1993KH62000016
J	RYAN, RO; OIKAWA, K; KAY, CM				RYAN, RO; OIKAWA, K; KAY, CM			CONFORMATIONAL, THERMODYNAMIC, AND STABILITY PROPERTIES OF MANDUCA-SEXTA APOLIPOPHORIN-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-A-IV; INSECT APOLIPOPROTEIN; LOCUSTA-MIGRATORIA; AQUEOUS-SOLUTIONS; SELF-ASSOCIATION; APOA-I; C-II; PLASMA; BEHAVIOR	Apolipophorin III (apoLp-III) is a major protein in hemolymph of adult Manduca sexta. Although it normally exists in a lipid-free state, during sustained flight, apoLp-III functions as an apolipoprotein, reversibly associating with the surface of lipoprotein particles. In an effort to gain a fuller understanding of this dual existence, we have investigated its solution properties using spectroscopic methods. The UV absorption spectrum of apoLp-III is distinctive owing to the absence of tryptophan and the presence of a single tyrosine residue. Circular dichroism experiments revealed an enhancement of apoLp-III alpha-helical content when spectra were obtained in 50% trifluoroethanol versus aqueous buffer. The helical content in buffer was unaffected by protein concentration, suggesting that apoLp-III exists in solution as a monomeric species. At pH values >10 and <4, there was a marked loss of helical content. Increasing the temperature of apoLp-III solutions also caused a loss of secondary structure, with a temperature-induced denaturation midpoint of 52-degrees-C. Upon recooling of heat-denatured apoLp-III, approximately 95% of the secondary structure was restored. In guanidine HCl denaturation studies monitored by CD, a 50% transition midpoint of 0.355 M was determined, corresponding to a DELTAG(D)H2O of 1.29 kcal/mol. Fluorescence studies indicated that guanidine HCl induced an enhancement of tyrosine fluorescence emission at 300 nm when excited at 277 nm. In native apoLp-III, we propose that tyrosine fluorescence is quenched to a large extent due to a hydrophobic stacking interaction of its side chain with that of a neighboring phenylalanine residue. DELTAG(D)H2O was determined from the fluorescence data to be 2.1 kcal/mol, with a transition midpoint occurring at 0.25 M guanidine HCl. The lower concentration of guanidine HCl required to induce half-maximal tyrosine fluorescence enhancement versus the transition midpoint detected by CD may be a reflection of the fact that this residue is located near the COOH-terminal end of the protein and as such may be more susceptible to denaturation. The results presented indicate that apoLp-III assumes a relatively labile conformation in solution that' appears to be partially stabilized by side chain charge-charge interactions within predicted alpha-helical segments.	UNIV ALBERTA,UPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,MRC,PROT STRUCT & FUNCT,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta	RYAN, RO (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; COLE KD, 1987, J BIOL CHEM, V262, P11794; DELAMATRE JG, 1983, J LIPID RES, V24, P1578; EDELSTEIN C, 1980, J BIOL CHEM, V255, P5747; GWYNNE J, 1975, J BIOL CHEM, V250, P2269; GWYNNE J, 1974, J BIOL CHEM, V249, P2411; GWYNNE J, 1975, J BIOL CHEM, V170, P204; HOLDEN HM, 1988, J BIOL CHEM, V263, P3960; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KANOST MR, 1988, J BIOL CHEM, V263, P10568; KAWOOYA JK, 1984, J BIOL CHEM, V259, P733; LEFEVRE M, 1986, J LIPID RES, V27, P1163; LIU H, 1991, BIOCHEM BIOPH RES CO, V179, P734, DOI 10.1016/0006-291X(91)91878-G; MAKINO S, 1974, J BIOL CHEM, V249, P7379; MANTULIN WW, 1980, J BIOL CHEM, V255, P8185; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; NAKAE Y, 1973, J BIOCHEM, V73, P1249, DOI 10.1093/oxfordjournals.jbchem.a130198; Pace C N, 1986, Methods Enzymol, V131, P266; PRASAD SV, 1986, J BIOL CHEM, V261, P558; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REIJNGOULD DJ, 1982, BIOCHEMISTRY-US, V21, P2069; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; ROSSENEU M, 1976, EUR J BIOCHEM, V70, P285, DOI 10.1111/j.1432-1033.1976.tb10980.x; RYAN RO, 1990, J LIPID RES, V31, P1725; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SINGH TKA, 1992, J BIOL CHEM, V267, P9275; STONE WL, 1975, J BIOL CHEM, V250, P8045; TAJIMA S, 1982, J BIOCHEM-TOKYO, V91, P1273, DOI 10.1093/oxfordjournals.jbchem.a133812; TALL AR, 1976, J BIOL CHEM, V251, P3749; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; VITELLO LB, 1976, J BIOL CHEM, V251, P1131; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	45	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1525	1530						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420928				2022-12-25	WOS:A1993KH62000007
J	ALONSO, JC; STIEGE, AC; DOBRINSKI, B; LURZ, R				ALONSO, JC; STIEGE, AC; DOBRINSKI, B; LURZ, R			PURIFICATION AND PROPERTIES OF THE RECR PROTEIN FROM BACILLUS-SUBTILIS 168	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPAIR; GENETIC-RECOMBINATION; XERODERMA-PIGMENTOSUM; MOLECULAR-CLONING; EXCISION REPAIR; EXPRESSION; BINDING; MUTATIONS; STRAINS	Genetic evidence suggests that the Bacillus subtilis recR gene product is involved in DNA repair and recombination. To assign a biochemical function to the recR gene product, the RecR protein was labeled and purified by monitoring the radioactive label. NH2-terminal protein sequence analysis of RecR was consistent with the deduced amino acid sequence of the recR gene. The RecR protein (molecular mass of 25 kDa, isoelectric point 5.4) bound single- and double-stranded DNA in a filter binding assay. RecR-DNA complex formation is enhanced by the presence of a damage in the DNA substrate. The RecR-DNA complex formation proceeds in the absence of divalent cations and nucleotide cofactors, but is markedly stimulated by ATP and divalent cations. In our experimental conditions the apparent equilibrium constants of the optimized RecR-DNA complexes are 3 x 10(-7) M and 9 x 10(-7) M for damaged and undamaged DNA, respectively. The binding reaction is cooperative. Electron microscopy studies show that the presence of divalent cations increases the rate of RecR protein self-assembly. Addition of ATP or dATP promotes the organization of discrete series of quaternary structures on DNA, but ATPgammaS inhibits the DNA binding activity. A possible mechanism for the RecR function in DNA repair is discussed.			ALONSO, JC (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.		Alonso, Juan C./D-2595-2009	Alonso, Juan C./0000-0002-5178-7179				ALONSO JC, 1990, NUCLEIC ACIDS RES, V18, P6771, DOI 10.1093/nar/18.23.6771; ALONSO JC, 1991, BIOCHIMIE, V73, P277, DOI 10.1016/0300-9084(91)90213-K; ALONSO JC, 1991, J BACTERIOL, V173, P3977, DOI 10.1128/JB.173.13.3977-3980.1991; ALONSO JC, 1987, GENE AMST, V65, P325; BERG JM, 1990, J BIOL CHEM, V265, P6513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKARDT H, 1988, ADV MOL GENETICS, P281; CEGLOWSKI P, 1990, MOL GEN GENET, V222, P441, DOI 10.1007/BF00633853; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; GASSEL M, 1989, MOL MICROBIOL, V3, P1269, DOI 10.1111/j.1365-2958.1989.tb00277.x; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; Iordanescu S, 1976, Arch Roum Pathol Exp Microbiol, V35, P111; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KOOISTRA J, 1991, J BACTERIOL, V173, P3644, DOI 10.1128/JB.173.12.3644-3655.1991; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD RG, 1988, MOL GEN GENET, V212, P317, DOI 10.1007/BF00334702; LLOYD RG, 1991, BIOCHIMIE, V73, P313, DOI 10.1016/0300-9084(91)90218-P; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MAHDI AA, 1989, NUCLEIC ACIDS RES, V17, P6781, DOI 10.1093/nar/17.17.6781; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MCPARTLAND A, 1980, CELL, V20, P731, DOI 10.1016/0092-8674(80)90319-0; MORRISON PT, 1989, J BACTERIOL, V171, P3641, DOI 10.1128/jb.171.7.3641-3649.1989; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANDLER SJ, 1992, NUCLEIC ACIDS RES, V20, P839, DOI 10.1093/nar/20.4.839; SAWITZKE JA, 1992, GENETICS, V130, P7; SHEMYAKIN MF, 1979, EUR J BIOCHEM, V98, P417, DOI 10.1111/j.1432-1033.1979.tb13201.x; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TELANDERMUSKAVI.KM, 1981, ENZYMES, V14, P234; THOMAS DC, 1986, J BIOL CHEM, V261, P4496; THOMS B, 1987, J BACTERIOL, V169, P498; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1424	1429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419343				2022-12-25	WOS:A1993KG07700098
J	KAGIWADA, S; MURATA, M; HISHIDA, R; TAGAYA, M; YAMASHINA, S; OHNISHI, S				KAGIWADA, S; MURATA, M; HISHIDA, R; TAGAYA, M; YAMASHINA, S; OHNISHI, S			INVITRO FUSION OF RABBIT LIVER GOLGI MEMBRANES WITH LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; VESICULAR TRANSPORT; RAT-LIVER; PROTEIN; PHOSPHOLIPIDS; APPARATUS; VESICLES; REQUIRES	Fusion of Golgi membranes isolated from rabbit liver with liposomes was studied by lipid mixing of fluorescent lipid analogues and internal content mixing and by electron microscopic observation of transfer of horseradish peroxidase from liposomes into Golgi membranes. A monoclonal antibody was used to confirm fusion of Golgi membranes but not other contaminating vesicles. Fusion was rapid and efficient, reaching about 20% of the maximum after a 5-min incubation using small or large unilamellar dioleoylphosphatidylcholine vesicles. The fusion was dependent on temperature, decreasing at lower temperatures, and becoming nearly zero below 10-degrees-C. The addition of ATP, GTP, cytosolic factors, or N-ethylmaleimide did not affect fusion. Treatments of Golgi membranes with 0.1 M Na2CO3 or 1 M KCl did not cause any changes in fusion. However, treatment with proteases inhibited fusion. These results suggest that Golgi integral membrane protein(s) are involved in fusion. Changing the medium to an isoosmotic substance, sucrose, in place of KCl or NaCl inhibited fusion. The binding assay of fluorescent liposomes to Golgi membranes showed that lowering the temperature or replacing salts with sucrose did not affect binding. However, treatment of Golgi membranes with proteases inhibited binding. Addition of phosphatidylserine or phosphatidylethanolamine to dioleoylphosphatidylcholine liposomes caused a 2-fold increase in binding and fusion. Fusion between Golgi membranes by themselves did not occur. These results provide some information on the mechanism of intracellular vesicular transport.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN; KITASATO UNIV,SCH MED,DEPT ANAT,SAGAMIHARA,KANAGAWA 228,JAPAN	Osaka University; Kitasato University	KAGIWADA, S (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN.							ALKAISSI E, 1983, J IMMUNOL METHODS, V58, P127, DOI 10.1016/0022-1759(83)90269-7; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BREW K, 1975, J BIOL CHEM, V250, P1434; CHLAPOWSKI FJ, 1971, J CELL BIOL, V50, P634, DOI 10.1083/jcb.50.3.634; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DESILVA NS, 1981, J BIOL CHEM, V256, P5845; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FREISCHER S, 1974, METHOD ENZYMOL, V31, P6; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZBAZENET C, 1988, BIOCHIM BIOPHYS ACTA, V943, P35, DOI 10.1016/0005-2736(88)90344-6; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MILLS JT, 1984, P NATL ACAD SCI-BIOL, V81, P1385, DOI 10.1073/pnas.81.5.1385; MOREAU P, 1991, J BIOL CHEM, V266, P4322; Ohnishi Shun-Ichi, 1988, Curr Top Membr Transp, V32, P257, DOI 10.1016/S0070-2161(08)60137-9; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SHEN DF, 1982, BIOCHIM BIOPHYS ACTA, V689, P31, DOI 10.1016/0005-2736(82)90185-7; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SLEIGHT RG, 1985, J BIOL CHEM, V260, P1146; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; STUTZIN A, 1986, FEBS LETT, V197, P274, DOI 10.1016/0014-5793(86)80341-6; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TABAS I, 1979, J BIOL CHEM, V254, P1655; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331	49	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1430	1435						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419344				2022-12-25	WOS:A1993KG07700099
J	NORDSTEDT, C; CAPORASO, GL; THYBERG, J; GANDY, SE; GREENGARD, P				NORDSTEDT, C; CAPORASO, GL; THYBERG, J; GANDY, SE; GREENGARD, P			IDENTIFICATION OF THE ALZHEIMER BETA/A4 AMYLOID PRECURSOR PROTEIN IN CLATHRIN-COATED VESICLES PURIFIED FROM PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; NEXIN-II; DISEASE; RECEPTOR; CDNA; LOCALIZATION; ENDOCYTOSIS; BIOGENESIS; LYSOSOMES	The Alzheimer beta/A4 amyloid precursor protein (APP) can be proteolytically processed by at least two separate pathways in PC12 cells: chloroquine-insensitive secretory cleavage and chloroquine-sensitive intracellular degradation, presumably in the endosomal/lysosomal system. To further investigate the possibility of APP processing in the endosomal/lysosomal system, we have examined whether APP is present in clathrin-coated vesicles (CCVs), which mediate the transport of many proteins to the endosomal compartment. Using a procedure derived from established protocols for the purification of CCVs from mammalian organs, we obtained from PC12 cells highly purified CCVs that displayed the same morphological features as described for CCVs purified from other sources. The CCVs were enriched in full-length mature (fully post-translationally modified) forms of APP, as well as in the carboxyl-terminal APP fragment produced by the secretory cleavage pathway. As CCVs are known to be involved in only two intracellular pathways (trafficking from the plasma membrane to early endosomes, and from the trans-Golgi network to late endosomes/prelysosomes), these findings provide direct evidence that APP is transported to the endosomal/lysosomal system. Furthermore, the presence in CCVs of the carboxyl-terminal fragment resulting from APP secretory cleavage suggests that APP secretory processing occurs in a pre-CCV compartment.	ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT GERIATR MED,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,INST MED NOBEL,DEPT CELL BIOL,S-10401 STOCKHOLM 60,SWEDEN; CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021	Rockefeller University; Karolinska Institutet; Karolinska Institutet; Cornell University; NewYork-Presbyterian Hospital					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09464] Funding Source: Medline; NIGMS NIH HHS [GM-07739] Funding Source: Medline; NINDS NIH HHS [NS-01095] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GANDY SE, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P155; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURKEWITZ AP, 1989, J CELL BIOL, V108, P2127, DOI 10.1083/jcb.108.6.2127; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	38	181	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					608	612						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416966				2022-12-25	WOS:A1993KE60300091
J	UCHIMARU, T; UEBAYASI, M; TANABE, K; TAIRA, K				UCHIMARU, T; UEBAYASI, M; TANABE, K; TAIRA, K			THEORETICAL ANALYSES ON THE ROLE OF MG2+ IONS IN RIBOZYME REACTIONS	FASEB JOURNAL			English	Article						RIBOZYME; METALLOENZYMES; MOLECULAR ORBITAL CALCULATIONS; MAGNESIUM IONS; MECHANISM	MARGINALLY STABLE INTERMEDIATE; BASE-CATALYZED METHANOLYSIS; INTERVENING SEQUENCE; TETRAHYMENA RIBOZYME; RNA CLEAVAGE; HAMMERHEAD RIBOZYMES; MG-2+ BINDING; PHOSPHATE; PHOSPHOROTHIOATE; STEREOCHEMISTRY	To elucidate the role of the Mg2+ ion in ribozyme reactions, we carried out ab initio molecular orbital investigations on dianionic trimethoxyphosphorane A and its Mg2+ complex (overall a neutral molecule) as a model system for the reaction center of Tetrahymena-type ribozyme. Although dianionic oxyphosphorane A concentrates its negative charges on the equatorial phosphoryl oxygens, the coordination of the Mg2+ ion between these two oxygens is unlikely. Geometry optimizations of the complex and the electrostatic potential of A both suggest that Mg2+ coordination preferably occurs in the region between the axial oxygen and the equatorial phosphoryl oxygen. The considerations of electrostatic potential rationalize the geometries of carboxylate-metal and phosphate-metal interactions extracted from the Cambridge Structural Database as well. Consequently, the Mg2+ ion at the active site of Tetrahymena-type ribozyme most likely lies in the regions between the axial and equatorial oxygens. The axial-equatorial coordinations of Mg2+ ions conceivably increase the electronegativities of the axial oxygens and facilitate cleavage of the phosphodiester bond located at the junction of the intron and the exon. It is thus likely that the Mg2+ ions play the key role in the phosphodiester cleavage reactions mediated by ribozymes.	MINIST INT TRADE & IND, NATL INST BIOSCI & HUMAN TECHNOL, AGCY IND SCI & TECHNOL, TSUKUBA 305, JAPAN; NATL INST MAT & CHEM RES, TSUKUBA 305, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)								ALEXANDER RS, 1990, J AM CHEM SOC, V112, P933, DOI 10.1021/ja00159a004; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6365, DOI 10.1021/bi00369a004; CARPENTER JE, 1990, SPARTAN VERSION 1 0; CECH TR, 1990, ANGEW CHEM INT EDIT, V29, P759, DOI 10.1002/anie.199007591; CHRISTOPHER J, 1988, J AM CHEM SOC, V110, P8651; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FRISH MJ, 1988, GAUSSIAN PROGRAM 88; FRISH MJ, 1990, GAUSSIAN PROGRAM 90; GORENSTEIN DG, 1987, CHEM REV, V87, P1047, DOI 10.1021/cr00081a009; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Hehre W. J., 1986, AB INITIO MOL ORBITA; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; Kirby A. J., 1983, ANOMERIC EFFECT RELA; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; REED AE, 1988, CHEM REV, V88, P899, DOI 10.1016/0030-4018(75)90085-1; REED AE, 1988, INORG CHEM, V27, P3969, DOI 10.1021/ic00295a018; REED AE, 1985, J CHEM PHYS, V83, P735, DOI 10.1063/1.449486; RICHARDS FM, 1971, ENZYMES, V4, P647; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STORER JW, 1991, J AM CHEM SOC, V113, P5216, DOI 10.1021/ja00014a012; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; Taira K., 1992, Gene regulation: biology of antisense RNA and DNA., P35; UCHIMARU T, 1991, J AM CHEM SOC, V113, P4351, DOI 10.1021/ja00011a060; UCHIMARU T, 1992, CHEM EXPRESS, V7, P501; UEBAYASI M, 1991, NUCLEIC ACIDS RES S, V25, P107; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	31	62	62	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					137	142		10.1096/fasebj.7.1.8422960	http://dx.doi.org/10.1096/fasebj.7.1.8422960			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422960				2022-12-25	WOS:A1993KH88000020
J	CROMME, FV; SNIJDERS, PJF; VANDENBRULE, AJC; KENEMANS, P; MEIJER, CJLM; WALBOOMERS, JMM				CROMME, FV; SNIJDERS, PJF; VANDENBRULE, AJC; KENEMANS, P; MEIJER, CJLM; WALBOOMERS, JMM			MHC CLASS-I EXPRESSION IN HPV-16 POSITIVE CERVICAL CARCINOMAS IS POSTTRANSCRIPTIONALLY CONTROLLED AND INDEPENDENT FROM C-MYC OVEREXPRESSION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS GENOTYPES; POLYMERASE CHAIN-REACTION; INTRAEPITHELIAL NEOPLASIA; ONCOGENE EXPRESSION; UTERINE CERVIX; HISTOCOMPATIBILITY ANTIGENS; SILVER INTENSIFICATION; INSITU HYBRIDIZATION; COLORECTAL-CANCER; HEAVY-CHAINS	Squamous cell carcinomas of the uterine cervix (n = 23) were selected for the presence of human papillomavirus type 16 (HPV 16) using the polymerase chain reaction (PCR). Localization of transcripts coding for the E7 protein was demonstrated in neoplastic cells with RNA in situ hybridization. Consecutive tissue sections were investigated for expression of the major histocompatibility complex class I (MHC-I) and c-myc using immunohistochemical double staining procedures, since a role has been suggested for the c-myc protein in MHC-I down-regulation and c-myc overexpression has been described in cervical carcinomas. Reduced expression of class I heavy chains was observed in neoplastic cells from 18 out of 23 carcinomas (78%). Varying levels of c-myc overexpression were observed in 12 carcinomas (52%), from which four showed positive MHC-I expression in c-myc overexpressing cells. In the remaining eight c-myc overexpressing carcinomas MHC-I down-regulation was observed. Additional RNA in situ hybridization with class I heavy chain locus-specific RNA-probes revealed presence of class I mRNAs in those neoplastic cells that show negative staining for MHC-I protein. These data strongly indicate that MHC-I down-regulation in cervical carcinomas involves post-transcriptional mechanisms, not directly related to E7 transcription and overexpression of c-myc.	FREE UNIV AMSTERDAM HOSP, INST PATHOL,DEPT PATHOL,MOLEC PATHOL SECT, DE BOELELAAN 1117, 1081 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT GYNAECOL & OBSTET, 1081 HV AMSTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BERGERON C, 1992, AM J SURG PATHOL, V16, P641, DOI 10.1097/00000478-199207000-00002; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROKER TR, 1989, CANCER CEL, V7, P197; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DURST M, 1987, ONCOGENE, V1, P251; FELTNER DE, 1989, J IMMUNOL, V143, P4292; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; IWASAKA T, 1992, GYNECOL ONCOL, V46, P298, DOI 10.1016/0090-8258(92)90220-D; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOLLER BH, 1984, P NATL ACAD SCI-BIOL, V81, P5175, DOI 10.1073/pnas.81.16.5175; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LUNGU O, 1992, JAMA-J AM MED ASSOC, V267, P2493, DOI 10.1001/jama.267.18.2493; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MORRIS A, 1990, ANTICANCER RES, V10, P1161; MULLINK H, 1992, J HISTOCHEM CYTOCHEM, V40, P495, DOI 10.1177/40.4.1532404; MULLINK H, 1987, APPLICATION MONOCLON, P37; MUNGER K, 1989, J VIROL, V64, P519; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; OCADIZ R, 1987, CANCER RES, V47, P4173; OUDEJANS CBM, 1989, J EXP MED, V169, P447, DOI 10.1084/jem.169.2.447; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PILLAI R, 1991, CANCER LETT, V59, P171, DOI 10.1016/0304-3835(91)90183-I; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REDONDO M, 1991, CANCER RES, V51, P2463; RIOU G, 1987, LANCET, V1, P761; RIOU GF, 1988, CANCER SURV, V7, P441; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHRIER PI, 1993, ADV CANCER RES, V60, P181; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; SOONG TW, 1991, CANCER DETECT PREV, V15, P231; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAM NJ, 1986, J IMMUNOL, V137, P2299; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANDENBRULE AJC, 1991, INT J CANCER, V48, P404, DOI 10.1002/ijc.2910480317; VANDENBRULE AJC, 1990, J CLIN MICROBIOL, V28, P2739, DOI 10.1128/JCM.28.12.2739-2743.1990; VANDENBRULE AJC, 1991, AM J PATHOL, V139, P1037; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621; WOODWORTH CD, 1990, CANCER RES, V50, P3709	56	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2969	2975						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414499				2022-12-25	WOS:A1993MC09300010
J	COLLAWN, JF; LAI, A; DOMINGO, D; FITCH, M; HATTON, S; TROWBRIDGE, IS				COLLAWN, JF; LAI, A; DOMINGO, D; FITCH, M; HATTON, S; TROWBRIDGE, IS			YTRF IS THE CONSERVED INTERNALIZATION SIGNAL OF THE TRANSFERRIN RECEPTOR, AND A 2ND YTRF SIGNAL AT POSITION-31-34 ENHANCES ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; AMINO-ACID; RAPID INTERNALIZATION; INSULIN-RECEPTOR; CDNA SEQUENCE; DNA; TAIL; SITE	By functional analysis of mutant human transferrin receptors (TR) expressed in chicken embryo fibroblasts, we previously identified a tetrapeptide sequence, Y20TRF23, within the 61-residue cytoplasmic tail as the signal for high-efficiency endocytosis (Collawn, J. F., Stangel, M., Kuhn, L. A., Esekogwu, V., Jing, S., Trowbridge, I. S., and Tainer, J. A. (1990) Cell 63, 1061-1072). It has been inferred from other studies, however, that the TR internalization signal was localized to a much larger region, residues 7 through 26 (Girones, N., Alvarez, E., Seth, A., Lin, I-M., Latour, D. A., and Davis, R. J. (1991) J. Biol. Chem. 266,19006-19012). Additionally, Tyr20 was reported to not be conserved in the Chinese hamster cytoplasmic tail sequence (Alvarez, E., Girones, N., and Davis, R. J. (1990) Biochem. J. 267, 31-35). In the studies reported here, we examined the effect of insertion of an extra copy of a YTRF sequence at three different locations within the human TR cytoplasmic domain and show that the insertion of another YTRF signal at position 31-34 in the wild-type TR, but not the other two locations, increases the rate of endocytosis 2-fold. Furthermore, introduction of YTRF at position 31-34 in an internalization-defective mutant receptor restores endocytosis to wild-type levels, indicating that YTRF signals at either positions 20-23 or 31-34 are necessary and sufficient to promote TR internalization and function in an independent and additive manner. We also report the complete primary structure of the Chinese hamster TR deduced from its cDNA sequence and show that the Tyr20 as well as the complete YTRF motif is conserved.	SALK INST BIOL STUDIES, DEPT CANC BIOL, SAN DIEGO, CA 92138 USA	Salk Institute					NATIONAL CANCER INSTITUTE [R01CA034787] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA34787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BATES GW, 1973, J BIOL CHEM, V248, P3228; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GERHARDT EM, 1991, GENE, V102, P249, DOI 10.1016/0378-1119(91)90085-P; GIRONES N, 1991, J BIOL CHEM, V266, P19006; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TROWBRIDGE IS, 1988, EXCERPTA MED INT C S, V775, P441	37	97	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21686	21692						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408022				2022-12-25	WOS:A1993MC80900041
J	GUILLOT, D; PENIN, F; DIPIETRO, A; SONTAG, B; LAVERGNE, JP; REBOUD, JP				GUILLOT, D; PENIN, F; DIPIETRO, A; SONTAG, B; LAVERGNE, JP; REBOUD, JP			GTP-BINDING TO ELONGATION-FACTOR EEF-2 UNMASKS A TRYPTOPHAN RESIDUE REQUIRED FOR BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; DIPHTHERIA TOXIN; CDNA SEQUENCE; FACTOR EF-2; FUS-GENE; PROTEINS; FLUORESCENCE; CLONING; PHOSPHORYLATION; EXPRESSION	Elongation factor eEF-2 from rat liver, which contains 7 tryptophan residues, was treated with increasing concentrations of N-bromosuccinimide (NBS) under conditions in which these residues were oxidized specifically. The reagent produced a characteristic lowering in both the absorbance at 280 nm and the intrinsic fluorescence at 332 nm of the factor. Fluorometric titration of tryptophans and correlation to eEF-2 residual activity on GTP hydrolysis and polyphenylalanine synthesis showed that modification of the two most reactive tryptophans completely inactivated the factor. These residues were identified as Trp343 and Trp221 after cleavage of the protein with cyanogen bromide, separation of the fragments by reversed-phase high-pressure liquid chromatography, and N-terminal sequencing of the two fragments which exhibited a decreased absorbance in the NBS-treated protein. Oxidation of the most reactive residue, Trp343, did not induce significant decrease of activity of the factor or of its ability to interact with GTP or GDP. On the contrary, oxidation of Trp221 inactivated the factor, whose residual fluorescence was still partly quenched by GDP but no longer by GTP. Preincubation of eEF-2 with GDP protected Trp221 against NBS oxidation and prevented concomitant inactivation of the factor, whereas preincubation of eEF-2 with GTP increased the sensitivity of the same Trp221 residue to the reagent. Our results show for the first time that Trp221, which is conserved and belongs to a well preserved domain in eukaryotic cells and archaebacteria, plays an essential part in the catalytic activity of eEF-2. They strongly suggest that GTP induces a conformational change of the protein which unmasks this residue, whereas GDP stabilizes a conformation which makes this residue much less accessible.	CNRS,INST BIOL & CHIM PROT,BIOCHIM STRUCT & FONCTIONNELLE LAB,7 PASSAGE VERCORS,F-69367 LYON 07,FRANCE; CNRS,INST BIOL & CHIM PROT,BIOCHIM MED LAB,F-69367 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			PENIN, Francois/A-7315-2008					BANNISTER WH, 1972, INT J BIOCHEM, V3, P560, DOI 10.1016/0020-711X(72)90012-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CONQUET F, 1987, EUR J BIOCHEM, V163, P15, DOI 10.1111/j.1432-1033.1987.tb10730.x; GEOURJON C, 1991, J MOL GRAPHICS, V9, P188, DOI 10.1016/0263-7855(91)80008-N; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; GRINBLAT Y, 1989, NUCLEIC ACIDS RES, V17, P7303, DOI 10.1093/nar/17.18.7303; HELENE C, 1969, BIOCHEM BIOPH RES CO, V37, P393, DOI 10.1016/0006-291X(69)90927-9; HONJO T, 1968, J BIOL CHEM, V243, P3553; HONJO T, 1971, J BIOL CHEM, V246, P4251; ITOH T, 1989, EUR J BIOCHEM, V186, P213, DOI 10.1111/j.1432-1033.1989.tb15197.x; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LECHNER K, 1988, NUCLEIC ACIDS RES, V16, P7817, DOI 10.1093/nar/16.16.7817; LUNDBLAD RL, 1984, CHEM MODIFICATION TR, P41; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NILSSON L, 1988, EUR J BIOCHEM, V171, P293, DOI 10.1111/j.1432-1033.1988.tb13789.x; OGORMAN RB, 1977, J BIOL CHEM, V252, P3565; OLEINIKOV AV, 1989, FEBS LETT, V248, P131, DOI 10.1016/0014-5793(89)80447-8; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PECHMANN H, 1991, FEMS MICROBIOL LETT, V79, P51, DOI 10.1016/0378-1097(91)90526-G; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; RAPP G, 1989, BIOL CHEM H-S, V370, P1071, DOI 10.1515/bchm3.1989.370.2.1071; REBOUD AM, 1972, EUR J BIOCHEM, V26, P347, DOI 10.1111/j.1432-1033.1972.tb01773.x; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; RYAZANOV AG, 1987, FEBS LETT, V214, P331, DOI 10.1016/0014-5793(87)80081-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER J, 1991, EUR J BIOCHEM, V195, P321, DOI 10.1111/j.1432-1033.1991.tb15709.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; Spande T. F., 1967, METHOD ENZYMOL, V11, P528; Spande T.F., 1967, DETERMINATION TRYPTO, P498; TODA K, 1989, J BIOL CHEM, V264, P15489; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; ZENGEL JM, 1984, NUCLEIC ACIDS RES, V12, P2181, DOI 10.1093/nar/12.4.2181	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20911	20916						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407925				2022-12-25	WOS:A1993MA28800045
J	KAMITANI, T; CHANG, HM; ROLLINS, C; WANECK, GL; YEH, ETH				KAMITANI, T; CHANG, HM; ROLLINS, C; WANECK, GL; YEH, ETH			CORRECTION OF THE CLASS-H DEFECT IN GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS IN LTK- CELLS BY A HUMAN CDNA CLONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VARIANT SURFACE GLYCOPROTEINS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GLYCOSYL-PHOSPHATIDYLINOSITOL; MAMMALIAN-CELLS; STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; MOLECULAR-CLONING; PROTEINS	Previous attempts to express glycosylphosphatidylinositol-anchored proteins in Ltk- cells have not been successful because Ltk- cells cannot synthesize N-acetylglucosamine-phosphatidylinositol, the first intermediate in anchor biosynthesis. Using complementation cloning, we have identified a human cDNA that corrects the defect in anchor biosynthesis and allows the expression of glycosylphosphatidylinositol-anchored proteins in Ltk- cells. The nucleotide sequence predicts a novel cytosolic protein of 188 amino acids.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,6431 FANNIN,SUITE 4200,HOUSTON,TX 77030; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA 02114; UNIV TEXAS,HLTH SCI CTR,DEPT ANESTHESIA,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630; Chang, Hui-Ming/0000-0002-5856-3397	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046467] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIAMS NIH HHS [AR-03564] Funding Source: Medline; NIGMS NIH HHS [GM-46467] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, J BIOL CHEM, V267, P24611; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KIMURA S, 1984, IMMUNOGENETICS, V20, P47, DOI 10.1007/BF00373446; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHARROW SO, 1989, J IMMUNOL, V142, P3495; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	39	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20733	20736						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407896				2022-12-25	WOS:A1993MA28800014
J	QUINN, MT; EVANS, T; LOETTERLE, LR; JESAITIS, AJ; BOKOCH, GM				QUINN, MT; EVANS, T; LOETTERLE, LR; JESAITIS, AJ; BOKOCH, GM			TRANSLOCATION OF RAC CORRELATES WITH NADPH OXIDASE ACTIVATION - EVIDENCE FOR EQUIMOLAR TRANSLOCATION OF OXIDASE COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; GTP-BINDING PROTEIN; CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL CYTOCHROME-B; PLASMA-MEMBRANE; SUPEROXIDE GENERATION; CYTOSOLIC COMPONENTS; GUANINE-NUCLEOTIDES; HUMAN-GRANULOCYTES	Activation of the superoxide-generating NADPH oxidase system of human neutrophils involves the assembly of several neutrophil components, some located on the plasma membrane and others in the cytosol. It has recently been established that one of the required components for NADPH oxidase activity is the GTP-binding protein Rac. To further investigate the role of Rac in the NADPH oxidase system, studies were carried out to determine its subcellular distribution in resting and activated human neutrophils. In resting cells, Rac and an associated guanine nucleotide regulatory factor, GDP dissociation inhibitor (GDI), were located only in the cytosol, along with other known oxidase factors, p47-phox and p67-phox. After activation of neutrophils with phorbol 12-myristate 13-acetate or formyl-methionyl-leucyl-phenylalanine, Rac was translocated from the cytosol to the plasma membrane, and this translocation corresponded temporally with the translocation of p47-phox and p67-phox and with the generation of superoxide. GDI remained localized to the cytosol, suggesting activation of the oxidase involved dissociation of the Rac-GDI complex prior to Rac translocation. Determination of the quantities of cytosolic factors associated with the plasma membrane indicated that Rac, p47-phox, and p67-phox are translocated to the plasma membrane simultaneously in equimolar amounts, but that the membrane-associated cytochrome b was present at 3-4-fold molar excess. These findings suggest that Rac may play a role in assembly of the active NADPH oxidase complex.	ONYX PHARMACEUT, RICHMOND, CA 94806 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	QUINN, MT (corresponding author), MONTANA STATE UNIV, DEPT MICROBIOL, BOZEMAN, MT 59717 USA.			Jesaitis, Algirdas/0000-0001-9001-5617	NIAID NIH HHS [AI26711] Funding Source: Medline; NIAMS NIH HHS [AR40929-01] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1977, BLOOD, V50, P517; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; CHUANG T, 1993, FASEB J, V7, P1141; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1990, BLOOD, V76, pA183; JESAITIS AJ, 1983, J BIOL CHEM, V258, P1968; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; QUINN MT, 1992, BLOOD, V79, P2438; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; QUINN MT, 1992, J BIOL CHEM, V267, P7303; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEGAL AW, 1992, BIOCHEM J, V284, P7881; TAMURA M, 1992, J BIOL CHEM, V267, P7529; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1993, J BIOL CHEM, V268, P19901; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	46	293	296	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20983	20987						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407934				2022-12-25	WOS:A1993MA28800054
J	TROTTER, PJ; PEDRETTI, J; VOELKER, DR				TROTTER, PJ; PEDRETTI, J; VOELKER, DR			PHOSPHATIDYLSERINE DECARBOXYLASE FROM SACCHAROMYCES-CEREVISIAE - ISOLATION OF MUTANTS, CLONING OF THE GENE, AND CREATION OF A NULL ALLELE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED ANIMAL-CELLS; ESCHERICHIA-COLI; RAT-LIVER; PHOSPHOLIPID-SYNTHESIS; SUBCELLULAR MEMBRANES; NEUROSPORA-CRASSA; LIPID-SYNTHESIS; YEAST; MITOCHONDRIA; TRANSLOCATION	Phosphatidylserine decarboxylase plays a pivotal role in the synthesis of phospholipid by the mitochondria. The substrate phosphatidylserine is synthesized extramitochondrially and must be translocated to the mitochondria prior to decarboxylation. To understand the properties of the decarboxylase and exploit its unique topology to address basic questions of interorganelle cooperation in membrane assembly, we have begun to examine this enzyme in Saccharomyces cerevisiae. Strains of the yeast defective in enzyme activity were isolated by modified brute force using 1-acyl-2[N-(6-[7-nitrobenz-2-oxa- 1,3-diazo-4-yl)]aminocaproyl] (NBD)-phosphatidyl[1'-C-14]serine as substrate for permeabilized cells. Mutant strains with less than 5% wild type activity exhibited no defective growth phenotype. The gene for the phosphatidylserine decarboxylase (PSD) was cloned using an oligonucleotide probe degenerate for the sequence VGAT(I)/(N)VGSI, which is the longest stretch of sequence identity between the Escherichia coli sequence (I at position 5) and the putative CHO cell sequence (N at position 5). The gene encodes a 500 amino acid protein with 28-43% identity to the bacterial and mammalian sequences. The yeast PSD gene maps to the long arm of chromosome 14 between the kex 2 and RAS 2 loci. Null mutations created by disrupting the PSD gene with TRP1 demonstrate that the gene is not essential for cell growth even when the engineered strains are deprived of choline and ethanolamine. Analysis of lipid synthesis and enzyme activity in null mutants indicates that there are two PSD genes.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA	National Jewish Health								AGRANOFF BW, 1963, BIOCHEM PREP, V10, P46; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1984, GENETICS, V108, P533; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BJERVE KS, 1973, BIOCHIM BIOPHYS ACTA, V296, P549, DOI 10.1016/0005-2760(73)90115-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DENNIS EA, 1972, J LIPID RES, V13, P263; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; GARDINER K, 1989, ELECTROPHORESIS, V10, P296, DOI 10.1002/elps.1150100505; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; GNAMUSCH E, 1992, BIOCHIM BIOPHYS ACTA, V1111, P120, DOI 10.1016/0005-2736(92)90281-P; HANSON BA, 1980, J LIPID RES, V21, P309; HAWROT E, 1975, P NATL ACAD SCI USA, V72, P1112, DOI 10.1073/pnas.72.3.1112; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HOVIUS R, 1992, J BIOL CHEM, V267, P16790; HUBSCHER G, 1962, BIOCHIM BIOPHYS ACTA, V56, P555; JONG SC, 1990, CATALOGUE YEASTS, P106; KANFER J, 1964, J BIOL CHEM, V239, P1720; KANFER JN, 1972, J LIPID RES, V13, P468; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KUGE O, 1991, J BIOL CHEM, V266, P6370; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LI QX, 1988, J BIOL CHEM, V263, P11516; LI QX, 1990, J BIOL CHEM, V265, P4111; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; OHTA A, 1981, J BIOL CHEM, V256, P2219; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SATRE M, 1978, J BIOL CHEM, V253, P479; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SHERMAN F, 1983, METHODS YEAST GENETI, P112; SHERMAN F, 1992, METHOD ENZYMOL, V194, P3; SIMBENI R, 1990, J BIOL CHEM, V265, P281; STOFFEL W, 1972, H-S Z PHYSIOL CHEM, V353, P965, DOI 10.1515/bchm2.1972.353.1.965; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1745, DOI 10.1515/bchm2.1968.349.2.1745; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VIEBROCK A, 1982, EMBO J, V1, P565, DOI 10.1002/j.1460-2075.1982.tb01209.x; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	55	187	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21416	21424						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407984				2022-12-25	WOS:A1993MA28800112
J	GEORGEL, P; DEMELER, B; TERPENING, C; PAULE, MR; VANHOLDE, KE				GEORGEL, P; DEMELER, B; TERPENING, C; PAULE, MR; VANHOLDE, KE			BINDING OF THE RNA POLYMERASE-I TRANSCRIPTION COMPLEX TO ITS PROMOTER CAN MODIFY POSITIONING OF DOWNSTREAM NUCLEOSOMES ASSEMBLED INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PARTICLES; DNA; HISTONES; ELONGATION; INITIATION; SEQUENCES; INHIBIT; SYSTEM; GENE	We have studied the reconstitution of chromatin-like structures in vitro, using purified RNA polymerase I transcription complexes and histone octamers. The plasmid construct used in these studies is a pUC8 derivative in which we have inserted an RNA polymerase I core promoter region of Acanthamoeba castellanii upstream of four repeats of the 5 S rDNA nucleosome positioning sequence (208 base pairs) from Lytechinus variegatus. When histone octamers were reconstituted onto the naked DNA template, the expected nucleosome positioning previously observed using tandem repeats of the same 208-base pair fragment was not obtained (as assayed by restriction enzyme digestion mapping of the inserted region of the plasmid). We show that the location of the RNA polymerase I core promoter region with regard to the tandemly repeated 208-base pair positioning sequence is a major determinant in the positioning of the histone octamers. Reconstituting first with the stalled transcription complex excluded octamers from the promoter region and recovered the expected nucleosome positioning downstream on the four repeats of the 5 S positioning sequence. The observed competition between histone octamers and the transcription complex for the promoter region suggests a great similarity with what has been reported from in vitro studies of RNA polymerase II and III transcription systems. We may be looking at a mechanism of regulation of transcription for the RNA polymerase I.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523; COLORADO STATE UNIV,PROGRAM CELL & MOLEC BIOL,FT COLLINS,CO 80523	Oregon State University; Colorado State University; Colorado State University				Demeler, Borries/0000-0002-2414-9518	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER; NIEHS NIH HHS [5 PO-1 ES 04766] Funding Source: Medline; NIGMS NIH HHS [GM-12296, GM-22580] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; CONSTANZO G, 1990, J MOL BIOL, V216, P363; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; IIDA CT, 1992, IN PRESS NUCLEIC ACI; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P5839; LOSA R, 1987, CELL, V50, P501; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PENNINGS S, 1989, BIOCHEMISTRY-US, V25, P5043; PENNINGS S, 1991, BIOCHEMISTRY-US, V220, P101; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RETIEF JD, 1984, FEBS LETT, V167, P170, DOI 10.1016/0014-5793(84)80855-8; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1986, BIOESSAYS, V4, P172, DOI 10.1002/bies.950040408; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; TRIFONOV EN, 1980, NUCLEIC ACIDS RES, V8, P4041, DOI 10.1093/nar/8.17.4041; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045; ZWICK MG, 1991, NUCLEIC ACIDS RES, V19, P1681, DOI 10.1093/nar/19.7.1681	33	41	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1947	1954						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420969				2022-12-25	WOS:A1993KH62000069
J	ZHENG, MZ; FANG, H; TSURUOKA, T; TSUJI, T; SASAKI, T; HAKOMORI, S				ZHENG, MZ; FANG, H; TSURUOKA, T; TSUJI, T; SASAKI, T; HAKOMORI, S			REGULATORY ROLE OF GM3 GANGLIOSIDE IN ALPHA-5-BETA-1 INTEGRIN RECEPTOR FOR FIBRONECTIN-MEDIATED ADHESION OF FUA169 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE PROTEINS GLYCOSIDASES; MELANOMA-CELLS; SURFACE; RECOGNITION; COLLAGEN; GLYCOPROTEIN; SPECIFICITY; LECTINS; COMPLEX; FAMILY	Mouse mammary carcinoma mutant cell line FUA169, characterized by high G(M3) ganglioside content, was established from parent cell line FM3A/F28-7, which has high lactosyl ceramide (LacCer) content but no G(M3). FUA169 displays no changes in protein glycosylation, and is a typical glycolipid mutant differing from its parent in that it contains high quantities of G(M3) and GlcCer, but no LacCer (see accompanying paper; Tsuruoka, T., Tsuji, T., Nojiri, H., Holmes, E. H., Hakomori, S. (1993) J. Biol. Chem. 268, 2211-2216). In contrast to parent F28-7 cells, FUA169 cells showed clear adhesion to fibronectin (FN). Several lines of evidence indicate that adhesion of FUA169 cells to FN requires the presence of G(M3), which supports the function of integrin receptor. (i) Both FUA 169 and F28-7 cells express the same quantity of FN integrin receptor, which consists of alpha5beta1 (sensitive to RGDS peptide) and alpha4beta1 (sensitive to CS1 peptide). However, adhesion to FN-coated plates, regardless of type of FN, was much higher for FUA169 than for F28-7 cells. (ii) F28-7 cells, which normally lack G(M3) and adhere only weakly to FN, acquired G(M3) during incubation in G(M3)-containing medium, and subsequently adhered strongly to FN. (iii) Cholesterol-lecithin liposomes (cholesterol was C-14-labeled) incorporating alpha5beta1 receptor isolated from human placenta showed clear adhesion to FN-coated plates, and this adhesion was completely inhibited by RGDS peptide and by anti-beta1 mAb ZH1. When liposomes included a moderate quantity of G(M3) (0.22-0.44 mug (0.2-0.4 nmol)/55 mug of phosphatidylcholine, 33 mug of cholesterol, 5 mug of alpha5beta1 in liposome), adhesion was enhanced significantly. In contrast, adhesion was greatly reduced below control level for alpha5beta1 liposomes containing a higher quantity (2.2 mug; >2 nm) of G(M3). Adhesion to FN was also inhibited, but never enhanced, for alpha5beta1 liposomes with similar composition but containing 0.4 nmol (or other quantities) of LacCer or GlcCer instead of G(M3). These findings suggest that the greater adhesion to FN by FUA169 cells, relative to parent F28-7 cells, is due to functional support by G(M3) of alpha5beta1 integrin receptor.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; MEIJI SEIKA KAISHA LTD,KOHOKU KU,YOKOHAMA,KANAGAWA 222,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Meiji Holdings Co., Ltd.; University of Tokyo	ZHENG, MZ (corresponding author), BIOMEMBRANE INST,SEATTLE,WA 98119, USA.				NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; CARTER WG, 1981, J CELL BIOL, V88, P138, DOI 10.1083/jcb.88.1.138; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RAUVALA H, 1981, J CELL BIOL, V88, P127, DOI 10.1083/jcb.88.1.127; RAUVALA H, 1981, J CELL BIOL, V88, P149, DOI 10.1083/jcb.88.1.149; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SEKIGUCHI K, 1985, J BIOL CHEM, V260, P5105; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TSURUOKA T, 1993, J BIOL CHEM, V268, P2211; Yamada KM, 1989, FIBRONECTIN, P47	25	120	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2217	2222						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420989				2022-12-25	WOS:A1993KH62000107
J	MURAKAMI, M; KUDO, I; INOUE, K				MURAKAMI, M; KUDO, I; INOUE, K			MOLECULAR NATURE OF PHOSPHOLIPASES-A2 INVOLVED IN PROSTAGLANDIN-I2 SYNTHESIS IN HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS - POSSIBLE PARTICIPATION OF CYTOSOLIC AND EXTRACELLULAR TYPE-II PHOSPHOLIPASES-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PLATELET PHOSPHOLIPASE-A2; TUMOR-NECROSIS-FACTOR; CULTURED HUMAN; MESSENGER-RNA; PANCREATIC PHOSPHOLIPASE-A2; PROSTACYCLIN PRODUCTION; SERUM PHOSPHOLIPASE-A2; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; INFLAMMATORY EXUDATE	A lysate of unstimulated human umbilical vein endothelial cells (HUVEC) exhibited phospholipase A2 (PLA2) activity, which hydrolyzed phospholipids bearing arachidonate more preferentially than those bearing linoleate at the sn-2 position. An anti-rabbit cytosolic PLA2 monoclonal antibody absorbed the activity, whereas an anti-human type II PLA2 monoclonal antibody did not. HUVEC treated with thrombin generated prostaglandin I2 (PGI2), and the PLA2 activity of the thrombin-stimulated cells was absorbed almost completely by the anti-cytosolic PLA2 antibody. HUVEC treated with tumor necrosis factor (TNF) also generated PGI2. PGI2 generation by TNF-treated cells was suppressed partially by extracellular addition of the anti-type II PLA2 antibody. PLA2 activity in a lysate of TNF-stimulated cells was increased about 2-3-fold, and about half of the increased activity was suppressed by the anti-type II PLA2 antibody. Addition of heparin together with TNF resulted in release of type II PLA2 in the medium. Thus, both cytosolic and type II PLA2s may be involved in agonist-stimulated PGI2 synthesis in HUVEC. Furthermore, exogenously added type II PLA2 was bound to the cell surface and synergistically enhanced PGI2 generation in TNF-stimulated HUVEC. This binding was blocked by either heparin or a monoclonal antibody recognizing the heparin-binding domain of type II PLA2. Taken together, type II PLA2 generated endogenously as well as added exogenously may be captured on the HUVEC surface via heparan sulfate proteoglycan and may contribute to cellular arachidonate metabolism.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ALLIKMETS EY, 1986, TISSUE CELL, V18, P481, DOI 10.1016/0040-8166(86)90014-5; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BUONASSISI V, 1975, BIOCHIM BIOPHYS ACTA, V385, P1, DOI 10.1016/0304-4165(75)90067-7; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; FUJIMORI Y, 1992, J BIOCHEM-TOKYO, V111, P54, DOI 10.1093/oxfordjournals.jbchem.a123718; Gerritsen M E, 1990, Adv Exp Med Biol, V275, P115; GOODMAN R, 1991, AGENTS ACTIONS, V34, P113, DOI 10.1007/BF01993253; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; KAWAKAMI M, 1986, BIOCHEM BIOPH RES CO, V141, P482, DOI 10.1016/S0006-291X(86)80198-X; KERR JS, 1989, BIOCHEM BIOPH RES CO, V165, P1079, DOI 10.1016/0006-291X(89)92712-5; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; McLean L R, 1986, Methods Enzymol, V129, P738; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1005, P270; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1988, J BIOCHEM-TOKYO, V104, P884, DOI 10.1093/oxfordjournals.jbchem.a122577; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; OKA S, 1991, J BIOL CHEM, V266, P9956; ONO T, 1988, J BIOL CHEM, V263, P5732; ONO T, 1984, J BIOCHEM-TOKYO, V96, P785, DOI 10.1093/oxfordjournals.jbchem.a134896; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; ROSENTHANL MD, 1989, ARCH BIOCHEM BIOPHYS, V273, P590; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V174, P268, DOI 10.1016/0006-291X(91)90515-9; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STONER CR, 1991, J IMMUNOL METHODS, V145, P127, DOI 10.1016/0022-1759(91)90318-A; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TAKAYAMA K, 1990, BIOCHEM BIOPH RES CO, V167, P1309, DOI 10.1016/0006-291X(90)90666-B; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1983, CAN J PHYSIOL PHARM, V61, P561, DOI 10.1139/y83-086; VERGER R, 1982, BIOCHEMISTRY-US, V21, P6883, DOI 10.1021/bi00269a040; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	55	237	238	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					839	844						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419361				2022-12-25	WOS:A1993KG07700016
J	SLEPAK, VZ; WILKIE, TM; SIMON, MI				SLEPAK, VZ; WILKIE, TM; SIMON, MI			MUTATIONAL ANALYSIS OF G-PROTEIN ALPHA-SUBUNIT GO-ALPHA EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; BETA-ADRENERGIC-RECEPTOR; ROD OUTER SEGMENTS; REGULATORY PROTEINS; BOVINE BRAIN; ADENYLYL CYCLASE; ADP-RIBOSYLATION; GAMMA-SUBUNITS; GTP; IDENTIFICATION	G protein-mediated signal transduction is dependent on alpha subunit interactions with betagamma subunits, receptors, effectors, magnesium ions, and guanine nucleotides. The interdependence of these interactions can be probed by mutational analysis. We developed large scale screening procedures in recombinant Escherichia coli to identify and characterize novel mutations in G(o)alpha. Random mutations were generated by polymerase chain reaction in the amino-terminal 56 amino acids of G(o)alpha. Guanine nucleotide binding properties of the mutants were assayed in situ and in crude extracts of recombinant E. coli. Betagamma interactions were assayed by pertussis toxin mediated ADP-ribosylation. Efficacy of the screening procedures was evaluated by studying properties of wild-type G(o)alpha and site-directed mutations that were characterized previously in other G proteins. Several novel mutants with altered GTP binding characteristics and reduced ability to interact with betagamma had been isolated from the randomly generated mutant library. ADP-ribosylation of mutants R10G, K21N, and K35E was significantly reduced, whereas two of the mutants bearing multiple amino acid substitutions were refractory to modification. Mutant K35E also exhibited reduced affinity to guanosine 5'-(3-O-thio)triphosphate at submicromolar concentrations of magnesium. These experiments demonstrate the feasibility of using large scale random mutagenesis in the studies of G protein function.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HAGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1991, J BIOL CHEM, V266, P16226; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1992, J BIOL CHEM, V267, P1212; Leung DW, 1989, TECHNIQUE, V1, P11; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNIER T, 1984, J BIOL CHEM, V259, P15447; TABOR S, 1987, J BIOL CHEM, V262, P16212; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU DQ, 1992, J BIOL CHEM, V267, P1811	62	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1414	1423						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419342				2022-12-25	WOS:A1993KG07700097
J	MABLY, JD; SOLE, MJ; LIEW, CC				MABLY, JD; SOLE, MJ; LIEW, CC			CHARACTERIZATION OF THE GARC MOTIF - A NOVEL CIS-ACTING ELEMENT OF THE HUMAN CARDIAC MYOSIN HEAVY-CHAIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; MUSCLE-SPECIFIC TRANSCRIPTION; PROTEIN-BINDING SITE; RNA POLYMERASE-II; ALPHA-ACTIN; THYROID-HORMONE; C-FOS; REGULATORY FACTORS; COMPLETE SEQUENCE	A positive element between positions -924 and -851 and a negative element between -851 and -762 of the 5'-upstream region of the alpha-myosin heavy chain gene were identified through transient transfection assays in primary cultures of neonatal rat heart cells. Subsequent DNase I protection analysis revealed almost identical footprints at two positions (GAAAAATCT at -904 to -896 and GAAAATCT at -823 to -816). We have designated this sequence the GArC motif (for G,AT-rich,C). Gel mobility shift assays demonstrated the formation of specific complexes with GArC oligomers when either rat heart, rat liver, or HeLa cell nuclear extracts were used. Competition studies with unlabeled GArC oligomers resulted in a loss of binding. Oligomers were also made to the Xenopus cytoskeletal actin serum response element and to a segment of the alpha-MyHC gene (AT-core), each with a similar AT-rich core sequence. No detectable loss of binding resulted from the addition of an excess of either of these unlabeled oligomers. Southwestern blot analysis identified several proteins which interacted with the GArC element, suggesting the presence of a group of related trans-acting factors. Analysis of a sequence in the beta-MyHC gene with the same AT-rich core was negative, suggesting a role for the bases surrounding the protected area in binding. We propose that the GArC motif, together with its associated trans-acting factor(s), provides a novel mechanism of transcriptional control in addition to those previously reported for the cardiac myosin heavy chain genes.	UNIV TORONTO,TORONTO HOSP,INST BANTING,CTR CARDIOVASC RES,MOLEC CARDIOL LAB,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto								BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRENOWITZ M, 1989, CURRENT PROTOCOLS MO, P1241; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHODOSH LA, 1989, CURRENT PROTOCOLS MO, P1221; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; COWAN DB, 1991, BIOCHEM J, V274, P687, DOI 10.1042/bj2740687; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUSTAFSON TA, 1986, CIRC RES, V59, P194, DOI 10.1161/01.RES.59.2.194; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIYA K, 1991, J BIOL CHEM, V266, P10023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P707; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SINGH H, 1989, CURRENT PROTOCOLS MO, P1271; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; WANG DL, 1992, BIOCHEM BIOPH RES CO, V183, P1260, DOI 10.1016/S0006-291X(05)80326-2; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839	51	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					476	482						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416951				2022-12-25	WOS:A1993KE60300073
J	MIURA, Y; KIKUCHI, A; MUSHA, T; KURODA, S; YAKU, H; SASAKI, T; TAKAI, Y				MIURA, Y; KIKUCHI, A; MUSHA, T; KURODA, S; YAKU, H; SASAKI, T; TAKAI, Y			REGULATION OF MORPHOLOGY BY RHO P21 AND ITS INHIBITORY GDP/GTP EXCHANGE PROTEIN (RHO GDI) IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; CLOSTRIDIUM-BOTULINUM; SMOOTH-MUSCLE; MOLECULAR-CLONING; GENE-PRODUCT; SMG P21S; PURIFICATION; RIBOSYLATION	rho GDP dissociation inhibitor (GDI) is an inhibitory GDP/GTP exchange protein for a group of small GTP-binding proteins including at least rhoA p21, rhoB p21, rac1 p21, rac2 p21, and G25K. Microinjection of rho GDI into Swiss 3T3 cells made the cells round and refractile. This morphological change was accompanied by the disappearance of stress fibers. The rho GDI action was prevented by comicroinjection of rho GDI with the guanosine 5'-(3-O-thio)triphosphate (GTPgammaS)-bound form of rhoA p21, but not with the GTPgammaS-bound form of rhoA p21 lacking the C-terminal three amino acids, which was not post-translationally modified with lipids. The GTPgammaS-bound form of rac1 p21, the same form of G25K, the same form of smg p21B, or Ki-ras(val12) p21 was ineffective. Microinjection of the bacterial ADP-ribosyltransferase C3 specific for rho p21 into Swiss 3T3 cells induced the similar changes of morphology and stress fibers. This C3 action was not prevented by comicroinjection Of C3 with the GTPgammaS-bound form of rhoA p21, but was prevented by comicroinjection with the same form of a rhoA p21 mutant which was not ADP-ribosylated by C3. These results indicate that the rho GDI-rho p21 system regulates cell morphology presumably through the actomyosin system in Swiss 3T3 cells.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University			KURODA, SHINYA/G-4961-2014					ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KURODA S, 1992, BIOCHEM BIOPH RES CO, V185, P473, DOI 10.1016/S0006-291X(05)81009-5; MARUMIYA S, 1988, J BIOL CHEM, V263, P17255; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; MOSS J, 1990, ADP RIBOSYLATING TOX, P567; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sambrook J, 1989, MOL CLONING LABORATO; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; Weber K, 1972, Methods Enzymol, V26, P3; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	50	125	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					510	515						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416955				2022-12-25	WOS:A1993KE60300077
J	TAKUWA, N; WEI, Z; KUMADA, M; TAKUWA, Y				TAKUWA, N; WEI, Z; KUMADA, M; TAKUWA, Y			CA2+-DEPENDENT STIMULATION OF RETINOBLASTOMA GENE-PRODUCT PHOSPHORYLATION AND P34CDC2 KINASE ACTIVATION IN SERUM-STIMULATED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; CHICKEN-EMBRYO FIBROBLASTS; EPIDERMAL GROWTH-FACTOR; SWISS 3T3 FIBROBLASTS; RAT-LIVER CELLS; SUSCEPTIBILITY GENE; HISTONE-H1 KINASE; DNA-REPLICATION; CALCIUM REQUIREMENTS; TUMOR SUPPRESSOR	In serum-deprived human fibroblasts IMR-90 and WI-38 cells, the addition of fetal calf serum or basic fibroblast growth factor stimulates DNA synthesis in an extracellular Ca2+-dependent manner; the effect of serum on [H-3]thymidine incorporation into DNA is 4-16-fold greater at 2.0 mM CaCl2 as compared with that at 0.03 mM CaCl2. By contrast, in SV40 virus-transformed WI-38 (SV-WI-38) cells DNA synthesis is essentially independent of the extracellular calcium concentration ([Ca]out) and serum growth factors. To explore the role of Ca2+ in mitogenic signal transduction through G1 to S phase cell cycle progression, we studied and compared the effect of [Ca]out on phosphorylation of RB protein, the product of a tumor suppressor retinoblastoma gene. In IMR-90 and WI-38 cells, serum or basic fibroblast growth factor induces an increase in the amount of hyperphosphorylated forms of RB protein in a manner strictly dependent on [Ca]out. In sharp contrast, in SV-WI-38 cells, the extent of RB phosphorylation is little affected by [Ca]out or the presence or absence of serum growth factors. In addition, potent calmodulin antagonists W-7 and calmidazolium, but not an inactive analogue W-12 or W-5, strongly inhibit serum-induced increases in DNA synthesis and RB phosphorylation in IMR-90 and WI-38 cells, whereas in SV-WI-38 cells, the inhibitory effect is much more limited. Under the same treatment conditions, we measured histone H1 kinase activity associated with anti-p34cdc2 immunoprecipitate and found that the serum-induced increase in p34cdc2 kinase activity is strongly dependent on [Ca]out and is potently inhibited by the active calmodulin antagonists in IMR-90 and WI-38 cells, but not in SV-WI-38 cells. In IMR-90 cells that have been incubated with serum in 0.03 mM [Ca]out for 24 h, restoration of [Ca]out to 2.0 mM results in initiation of DNA synthesis after 13 h and concomitant increases in RB phosphorylation and p34cdc2 histone H1 kinase activity. These results suggest that in human fibroblasts, Ca2+/calmodulin regulates the signaling cascade leading to cdc2 kinase activation, RB protein phosphorylation, and DNA synthesis and that this Ca2+-dependent regulation is abrogated in SV40-transformed cells.	UNIV TOKYO,FAC MED,DEPT CARDIOVASC BIOL,TOKYO 113,JAPAN	University of Tokyo	TAKUWA, N (corresponding author), UNIV TOKYO,FAC MED,DEPT PHYSIOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.			TAKUWA, Noriko/0000-0002-4278-2704				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BALK SD, 1971, P NATL ACAD SCI USA, V68, P271, DOI 10.1073/pnas.68.2.271; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOYNTON AL, 1977, CANCER RES, V37, P2657; BOYNTON AL, 1976, P NATL ACAD SCI USA, V73, P1651, DOI 10.1073/pnas.73.5.1651; BOYNTON AL, 1980, BIOCHEM BIOPH RES CO, V95, P745, DOI 10.1016/0006-291X(80)90849-9; BOYNTON AL, 1977, J CELL PHYSIOL, V92, P241, DOI 10.1002/jcp.1040920212; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CHAFOULEAS JG, 1981, P NATL ACAD SCI-BIOL, V78, P996, DOI 10.1073/pnas.78.2.996; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRISS WE, 1982, FED PROC, V41, P2289; CUTRY AF, 1989, J BIOL CHEM, V264, P19700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DICICCOBLOOM E, 1989, BRAIN RES, V491, P403, DOI 10.1016/0006-8993(89)90080-2; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULBECCO R, 1975, P NATL ACAD SCI USA, V72, P1584, DOI 10.1073/pnas.72.4.1584; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HAZELTON B, 1979, J CELL BIOL, V83, P487, DOI 10.1083/jcb.83.2.487; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUPE DJ, 1991, J BIOL CHEM, V266, P10136; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NICHOLSON NB, 1984, J CELL BIOL, V99, P2314, DOI 10.1083/jcb.99.6.2314; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; PAUL D, 1979, J CELL PHYSIOL, V98, P31, DOI 10.1002/jcp.1040980105; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RASMUSSEN CD, 1987, EMBO J, V6, P3961, DOI 10.1002/j.1460-2075.1987.tb02738.x; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIXON RH, 1976, J CELL PHYSIOL, V87, P147, DOI 10.1002/jcp.1040870203; SASAKI Y, 1982, BIOCHEM BIOPH RES CO, V104, P451, DOI 10.1016/0006-291X(82)90658-1; SERRATOSA J, 1988, BIOCHEM BIOPH RES CO, V150, P1162, DOI 10.1016/0006-291X(88)90751-6; SORIANO M, 1985, CELL TISSUE KINET, V18, P475, DOI 10.1111/j.1365-2184.1985.tb00689.x; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKUWA N, 1988, J BIOL CHEM, V263, P9738; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUPPER JT, 1980, J CELL PHYSIOL, V104, P97, DOI 10.1002/jcp.1041040113; VEIGL ML, 1982, FED PROC, V41, P2282; WATTERSON DM, 1976, P NATL ACAD SCI USA, V73, P2711, DOI 10.1073/pnas.73.8.2711; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; ZENDEGUI JG, 1984, MOL CELL BIOL, V4, P883, DOI 10.1128/MCB.4.5.883	64	98	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					138	145						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416921				2022-12-25	WOS:A1993KE60300022
J	LIU, JX; CAMPBELL, M; GUO, JQ; LU, D; XIAN, YM; ANDERSSON, BS; ARLINGHAUS, RB				LIU, JX; CAMPBELL, M; GUO, JQ; LU, D; XIAN, YM; ANDERSSON, BS; ARLINGHAUS, RB			BCR-ABL TYROSINE KINASE IS AUTOPHOSPHORYLATED OR TRANSPHOSPHORYLATES P160 BCR ON TYROSINE PREDOMINANTLY WITHIN THE 1ST BCR EXON	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PHILADELPHIA-CHROMOSOME; CELL-LINE; C-ABL; ONCOGENE PRODUCT; GENE-PRODUCTS; PROTEIN; MICE	The role of BCR gene sequences in Philadelphia (Ph) chromosome-positive leukemia is not well understood. Our previous studies demonstrated that P210 BCR-ABL co-precipitates with P160 BCR following immunoprecipitation with antibodies to the C-terminal domain of P160 BCR, sequences lacking in P210 BCR-ABL. We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. P185 BCR-ABL produced in a cell line derived from a Ph chromosome-positive acute lymphocytic leukemia patient also co-immunoprecipitated with P160 BCR. As with P210 BCR-ABL, P160 BCR tyrosine phosphopeptides were shared with P185 BCR-ABL, indicating that the major sites of tyrosine phosphorylation in vitro are contained within the first exon of P160 BCR. Similarly, BCR-ABL autophosphorylation was found to occur predominantly at tyrosines within BCR exon 1 sequences. These results raise the possibility that the activated ABL protein kinase of BCR-ABL proteins modulates the putative signal transduction activities of P160 BCR by tyrosine phosphorylation of exon 1 sequences.	UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, DEPT HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON BS, 1987, CANCER GENET CYTOGEN, V24, P335, DOI 10.1016/0165-4608(87)90116-6; ARLINGHAUS RB, 1992, MOL CARCINOGEN, V5, P171, DOI 10.1002/mc.2940050302; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHAMPLIN RE, 1985, BLOOD, V65, P1039; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GUO JQ, 1991, CANCER RES, V51, P3048; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAXWELL SA, 1987, CANCER RES, V47, P1731; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NAUMOVSKI L, 1988, CANCER RES, V48, P2876; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRIEST JR, 1980, BLOOD, V56, P15; RON D, 1991, NEW BIOL, V3, P372; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH RG, 1981, J IMMUNOL, V126, P596; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TIMMONS MS, 1989, ONCOGENE, V4, P559	34	57	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					101	109						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423987				2022-12-25	WOS:A1993KN00500012
J	MCCUBREY, JA; SMITH, SR; ALGATE, PA; DEVENTE, JE; WHITE, MK; STEELMAN, LS				MCCUBREY, JA; SMITH, SR; ALGATE, PA; DEVENTE, JE; WHITE, MK; STEELMAN, LS			RETROVIRAL INFECTION CAN ABROGATE THE FACTOR-DEPENDENCY OF HEMATOPOIETIC-CELLS BY AUTOCRINE AND NONAUTOCRINE MECHANISMS DEPENDING ON THE PRESENCE OF A FUNCTIONAL VIRAL ONCOGENE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; V-SRC; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; AUTONOMOUS GROWTH; GENE-EXPRESSION; ABELSON VIRUS; INTERLEUKIN-3; LINE; TRANSFORMATION	The mechanisms responsible for abrogation of the growth factor-dependency of a hematopoietic cell line were investigated. FDC-P1 cells were infected with retroviral constructs containing the neo gene and either a wild-type or a temperature-sensitive v-src oncogene. v-src(wt) abrogated the factor-dependency of these cells since each G418r colony gave rise to factor-independent cells and no autocrine growth factor activity was detected. Moreover, the vast majority (<99%) of cells infected with the v-src(ts) mutant gave rise to conditional factor-independent cells. Therefore a functional v-src gene product was required for growth factor-independence which occurred by a non-autocrine mechanism. A minority of factor-independent cells which arose after v-src(ts) infection, grew at the non-permissive temperature and one-half secreted granulocyte/macrophage-colony stimulating factor (GM-CSF) which supports the growth of the parental cells. Since the v-src(ts) viral stock contained a helper virus, Murine Leukemia Virus (MuLV), the ability of this virus to relieve factor-dependency was examined. A low frequency of factor-independent transformants was recovered after MuLV infection and one-half secreted GM-CSF. Therefore, retroviruses such as MuLV which lack an oncogene, can transform cells by stimulating autocrine growth factor secretion. Subsequent experiments performed with helper-free v-src preparations indicated that they could abrogate factor-dependency directly by a non-autocrine mechanism. These results demonstrate that a hematopoietic cell line can be transformed by two different mechanisms after retroviral infection and may be relevant for understanding hematopoietic cell transformation after persistent viral infection.			MCCUBREY, JA (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858, USA.			McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [NCI RO1CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1993, ONCOGENE, V8, P1221; ANDERSON SM, 1990, ONCOGENE, V5, P317; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1802; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARBERS K, 1981, P NATL ACAD SCI-BIOL, V78, P7609, DOI 10.1073/pnas.78.12.7609; IHLE JN, 1987, J IMMUNOL, V138, P3051; IHLE JN, 1983, J IMMUNOL, V131, P282; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KITAMURA T, 1991, CELL, V66, P165; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1991, ONCOGENE RES, V6, P1; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NICOLA NA, 1986, J BIOL CHEM, V261, P2384; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALASZYNSKI EW, 1984, J IMMUNOL, V132, P1872; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WYKE JA, 1973, VIROLOGY, V53, P152, DOI 10.1016/0042-6822(73)90474-1	44	51	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2905	2915						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414494				2022-12-25	WOS:A1993MC09300003
J	GAYLE, RB; POINDEXTER, K; COSMAN, D; DOWER, SK; GILLIS, S; HOPP, T; JERZY, R; KRONHEIM, S; LUM, V; LEWIS, A; GOODGAME, MM; MARCH, CJ; SMITH, DL; SRINIVASAN, S				GAYLE, RB; POINDEXTER, K; COSMAN, D; DOWER, SK; GILLIS, S; HOPP, T; JERZY, R; KRONHEIM, S; LUM, V; LEWIS, A; GOODGAME, MM; MARCH, CJ; SMITH, DL; SRINIVASAN, S			IDENTIFICATION OF REGIONS IN INTERLEUKIN-1-ALPHA IMPORTANT FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; FIBROBLAST GROWTH-FACTOR; RECEPTOR ANTAGONIST; 3-DIMENSIONAL STRUCTURE; KEY RESIDUES; EXPRESSION; RESOLUTION; SEQUENCE; BINDING; 1-ALPHA	Saturation mutagenesis of the mature human interleukin-1alpha (IL-1alpha) gene has been performed. Following expression in Escherichia coli, the biological and receptor binding activities of the mutant proteins were examined. Most of the molecule could be altered with little effect on either function. More than 3,500 mutants were examined, and only 23 unique amino acid sequences were identified which resulted in an altered ratio of biological to binding activity when compared with wild-type IL-1alpha. These proteins possessed mutations at 38 of the 159 amino acid residues in IL-1alpha. Random mutagenesis at several of these positions identified further substitutions that affected activity. Examination of a model for IL-1alpha localized most of the residues which altered activity along one face of the molecule. This region appears to be distinct from areas of IL-1 which have been postulated to make contact with IL-1 receptor.	EASTMAN KODAK CO,LIFE SCI RES LABS,ROCHESTER,NY 14650	Eastman Kodak	GAYLE, RB (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.			dower, steve/0000-0002-4675-4225				AGO H, 1991, J BIOCHEM-TOKYO, V110, P360, DOI 10.1093/oxfordjournals.jbchem.a123586; AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; AURON PE, 1987, J IMMUNOL, V138, P1447; Ausubel FM., 1988, CURRENT PROTOCOLS MO; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CRAIG S, 1989, INT J PEPT PROT RES, V33, P256; DOWER S K, 1990, P137; DOWER SK, 1990, PROG CLIN BIOL RES, V349, P241; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DURUM SK, 1985, ANNU REV IMMUNOL, V3, P263; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GILLILAND GL, 1987, J BIOL CHEM, V262, P12323; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRENFELL S, 1991, BIOCHEM J, V280, P111, DOI 10.1042/bj2800111; GRONENBORN AM, 1988, FEBS LETT, V231, P135, DOI 10.1016/0014-5793(88)80717-8; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KAMOGASHIRA T, 1988, J BIOCHEM-TOKYO, V104, P837, DOI 10.1093/oxfordjournals.jbchem.a122559; KAMOGASHIRA T, 1988, BIOCHEM BIOPH RES CO, V150, P1106, DOI 10.1016/0006-291X(88)90743-7; KAWASHIMA H, 1992, PROTEIN ENG, V5, P171, DOI 10.1093/protein/5.2.171; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; PEEPLES WJ, 1989, CYTOBIOS, V58, P109; POINDEXTER K, 1991, NUCLEIC ACIDS RES, V19, P1899, DOI 10.1093/nar/19.8.1899; PRIESTLE JP, 1990, PROG CLIN BIOL RES, V349, P297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMS JE, 1993, IL 1 SIGNAL TRANSDUC; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; YAMAYOSHI M, 1990, LYMPHOKINE RES, V9, P405; YANOFSKY SD, 1990, J BIOL CHEM, V265, P13000; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZURAWSKI G, 1991, TRENDS BIOTECHNOL, V9, P250, DOI 10.1016/0167-7799(91)90079-W	42	8	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22105	22111						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408069				2022-12-25	WOS:A1993MC80900099
J	LOWE, KE; OSBORNE, CB; LIN, BF; KIM, JS; HSU, JC; SHANE, B				LOWE, KE; OSBORNE, CB; LIN, BF; KIM, JS; HSU, JC; SHANE, B			REGULATION OF FOLATE AND ONE-CARBON METABOLISM IN MAMMALIAN-CELLS .2. EFFECT OF FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE SUBSTRATE-SPECIFICITY AND LEVEL ON FOLATE METABOLISM AND FOLYLPOLY-GAMMA-GLUTAMATE SPECIFICITY OF METABOLIC CYCLES OF ONE-CARBON METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; POLYGLUTAMATE CHAIN-LENGTH; DEPENDENT ENZYMES; PIG-LIVER; FOLYLPOLYGLUTAMATES; INVITRO; METHOTREXATE; TRANSPORT; MUTANT; EXPRESSION	The effect of folylpoly-gamma-glutamate synthetase (FPGS) levels on folate accumulation was investigated in Chinese hamster ovary cells expressing various levels of human and Escherichia coli FPGS activity. At low medium folate concentrations, folate accumulation was limited by influx and was independent of FPGS activity except in cells expressing extremely low levels of FPGS. Essentially all transported folate was metabolized to retained polyglutamate derivatives, the chain length of which varied with the level of FPGS activity. As medium folate concentration increased through the physiological to the pharmacological range, cellular folate accumulation became proportional to FPGS activity and the chain length of intracellular folates decreased. At high folate concentrations, competition between substrates for FPGS limited the extent of polyglutamylation and less than 5% of transported folate was retained by the cell. Pteroyltriglutainates functioned as effectively as the longer chain length polyglutamates normally found in mammalian cells in the metabolic cycles of de novo purine and thymidylate biosynthesis but were unable to support glycine and methionine synthesis. Transfectants expressing human FPGS and containing folates of glutamate chain length ranging from four to eight were equally effective at supporting glycine synthesis, and transfectants expressing higher levels of FPGS were able to grow in the absence of methionine. Growth in the absence of methionine required high (nonphysiological) intracellular folate levels and longer chain length polyglutamates.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				LIN, BI-FONG/0000-0003-2260-6081	NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41991] Funding Source: Medline; NIGMS NIH HHS [GM073079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; BOARMAN DM, 1992, CANCER RES, V52, P36; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; BOGNAR AL, 1986, METHOD ENZYMOL, V122, P349; CASSADY IA, 1980, BIOCHIM BIOPHYS ACTA, V633, P258, DOI 10.1016/0304-4165(80)90411-0; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; COLL RJ, 1991, BIOCHEM PHARMACOL, V42, P833, DOI 10.1016/0006-2952(91)90043-5; COOK JD, 1987, BIOCHEMISTRY-US, V26, P530, DOI 10.1021/bi00376a027; ETO I, 1982, LIFE SCI, V30, P183, DOI 10.1016/0024-3205(82)90651-8; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FOO SK, 1982, J BIOL CHEM, V257, P13587; GREEN JM, 1988, BIOCHEMISTRY-US, V27, P8014, DOI 10.1021/bi00421a007; HOFFMAN RM, 1982, IN VITRO CELL DEV B, V18, P421; Houghton J A, 1989, Cancer Commun, V1, P167; HOUGHTON JA, 1990, CANCER RES, V50, P3940; HOUGHTON JA, 1990, CANCER RES, V50, P3493; KALMAN T I, 1986, P763; KIM JS, 1993, J BIOL CHEM, V268, P21680; KRUMDIECK CL, 1983, VITAM HORM, V40, P45, DOI 10.1016/S0083-6729(08)60432-X; LU YZ, 1984, BIOCHEMISTRY-US, V23, P6870, DOI 10.1021/bi00321a091; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MATTHEWS RG, 1987, ADV ENZYME REGUL, V26, P157, DOI 10.1016/0065-2571(87)90012-4; MATTHEWS RG, 1980, BIOCHEMISTRY-US, V19, P2040, DOI 10.1021/bi00551a005; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; OCONNOR BM, 1991, CANCER RES, V51, P3874; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PRIEST DG, 1983, BIOCHIM BIOPHYS ACTA, V756, P253, DOI 10.1016/0304-4165(83)90332-X; SAMUELS LL, 1986, CANCER RES, V46, P2230; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SHANE B, 1989, VITAM HORM, V45, P263; SIN BF, 1983, J BIOL CHEM, V268, P21674; SIROTNAK FM, 1985, CANCER RES, V45, P3992; TAYLOR RT, 1975, ARCH BIOCHEM BIOPHYS, V171, P507, DOI 10.1016/0003-9861(75)90060-0; TAYLOR RT, 1979, ARCH BIOCHEM BIOPHYS, V197, P36, DOI 10.1016/0003-9861(79)90215-7; WEITMAN SD, 1992, CANCER RES, V52, P3396; WHITEHEAD VM, 1987, BIOCHEM BIOPH RES CO, V144, P292, DOI 10.1016/S0006-291X(87)80509-0; ZHANG ZG, 1991, CANCER RES, V51, P3476	41	65	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21665	21673						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408019				2022-12-25	WOS:A1993MC80900038
J	OSHIRO, S; NAKAJIMA, H; MARKELLO, T; KRASNEWICH, D; BERNARDINI, I; GAHL, WA				OSHIRO, S; NAKAJIMA, H; MARKELLO, T; KRASNEWICH, D; BERNARDINI, I; GAHL, WA			REDOX, TRANSFERRIN-INDEPENDENT, AND RECEPTOR-MEDIATED ENDOCYTOSIS IRON UPTAKE SYSTEMS IN CULTURED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PLASMA-MEMBRANE; DIFERRIC TRANSFERRIN; K562 CELLS; BOUND IRON; REDUCTASE; LIVER; MECHANISM; RETICULOCYTES; LYSOSOMES	Sepharose beads bound to Fe-55-transferrin (Tf) were used to evaluate Tf-dependent iron uptake not employing receptor-mediated endocytosis (RME). The iron of Fe-55(2)-Tf-Sepharose was reduced and taken up by cultured human fibroblasts in a time- and concentration-dependent fashion (K(m) 7 muM; V(max) 128 pmol/mg/min). This redox system resembled that for Tf-independent iron uptake (Tf-IU, evaluated using Fe-55-citrate) in several ways. 1) NH4Cl did not inhibit iron uptake from Fe-55-citrate and Fe-55(2)-Tf-Sepharose but did inhibit uptake from Fe-55(2)-Tf (RME system). 2) Iron uptake and reduction from Fe-55(2)-Tf-Sepharose and Fe-55-citrate increased with temperature hyperbolically, differing from the sigmoidal curve for RME uptake. 3) The subcellular distributions of iron from Fe-55-citrate and Fe-55(2)-Tf-Sepharose resembled each other and differed from that for Fe-55(2)-Tf. 4) The optimal pH for iron reduction and uptake using Fe-55(2)-Tf-Sepharose or Fe-55-citrate was less than pH 5.5, while that for iron uptake from Fe-55(2)-Tf was pH 7.4. 5) The uptake and reduction of iron from Fe-55(2)-Tf-Sepharose was inhibited by ferric citrate and by transition metals. We conclude that both Tf-independent and non-RME, Tf-dependent iron uptake proceed via a common redox system for iron. The mechanisms of cellular iron uptake can be separately evaluated in fibroblasts using Fe-55-citrate, Fe-55(2)-Tf, and Fe-55(2)-Tf-Sepharose beads.	NICHHD,HUMAN GENET BRANCH,HUMAN BIOCHEM GENET SECT,BLDG 10,RM 95242,BETHESDA,MD 20892; TOKYO MED & DENT UNIV,MED RES INST,DEPT BIOCHEM GENET,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tokyo Medical & Dental University (TMDU)								BATES GW, 1971, J BIOL CHEM, V246, P3679; BATES GW, 1973, J BIOL CHEM, V248, P3228; BERCZI A, 1991, BIOCHIM BIOPHYS ACTA, V1073, P562, DOI 10.1016/0304-4165(91)90231-5; BOTHWELL TH, 1989, METABOLIC BASIS INHE, P1433; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DUNN WA, 1980, J BIOL CHEM, V255, P5971; GABER BP, 1970, BIOCHIM BIOPHYS ACTA, V221, P228, DOI 10.1016/0005-2795(70)90262-X; GOLDENBERG H, 1990, EUR J BIOCHEM, V192, P475, DOI 10.1111/j.1432-1033.1990.tb19250.x; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; HUEBERS H, 1981, P NATL ACAD SCI-BIOL, V78, P621, DOI 10.1073/pnas.78.1.621; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KNISELY AS, 1989, AM J PATHOL, V134, P439; KOJIMA N, 1979, J BIOL CHEM, V254, P8847; LOH TT, 1977, BIOCHIM BIOPHYS ACTA, V471, P118, DOI 10.1016/0005-2736(77)90399-6; MORAND JN, 1986, ANAL BIOCHEM, V159, P157, DOI 10.1016/0003-2697(86)90321-0; MORGAN EH, 1981, BIOCHIM BIOPHYS ACTA, V642, P119, DOI 10.1016/0005-2736(81)90143-7; MORLEY CGD, 1985, INT J BIOCHEM, V17, P553, DOI 10.1016/0020-711X(85)90286-1; MORRE DJ, 1969, BIOCHEM BIOPH RES CO, V37, P813; MORRE JD, 1971, METHOD ENZYMOL, V22, P138; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; NUNEZ MT, 1983, J BIOL CHEM, V258, P1146; OSHIRO S, 1988, J BIOL CHEM, V263, P16032; RAY TK, 1970, BIOCHIM BIOPHYS ACTA, V196, P1, DOI 10.1016/0005-2736(70)90159-8; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; ROME LH, 1981, J BIOL CHEM, V256, P763; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SPIRO TG, 1967, J AM CHEM SOC, V89, P5555, DOI 10.1021/ja00998a008; SPIRO TG, 1967, J AM CHEM SOC, V89, P5559, DOI 10.1021/ja00998a009; STURROCK A, 1990, J BIOL CHEM, V265, P3139; SUN IL, 1987, BIOCHEM INT, V14, P119; SUN IL, 1988, BIOCHIM BIOPHYS ACTA, V938, P17, DOI 10.1016/0005-2736(88)90117-4; SUN IL, 1987, J BIOL CHEM, V262, P15915; THORSTENSEN K, 1990, BIOCHEM J, V271, P1; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; WARD JH, 1982, BIOCHEM J, V208, P19, DOI 10.1042/bj2080019; WEIGEL PH, 1981, J BIOL CHEM, V256, P2615; WORWOOD M, 1973, BIOCHEM J, V134, P183, DOI 10.1042/bj1340183; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505	43	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21586	21591						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408010				2022-12-25	WOS:A1993MC80900026
J	PATANKAR, MS; OEHNINGER, S; BARNETT, T; WILLIAMS, RL; CLARK, GF				PATANKAR, MS; OEHNINGER, S; BARNETT, T; WILLIAMS, RL; CLARK, GF			A REVISED STRUCTURE FOR FUCOIDAN MAY EXPLAIN SOME OF ITS BIOLOGICAL-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; ZONA-PELLUCIDA; LINKED OLIGOSACCHARIDES; METHYLATION ANALYSIS; SACCHARIDE MOIETIES; MASS-SPECTROMETRY; HUMAN SPERMATOZOA; SULFATED GLYCANS; CELL-ADHESION; BINDING	Fucoidan from Fucus vesiculosus inhibits human sperm-zona pellucida binding and blocks the zona pellucida-induced acrosome reaction in human sperm. Fucoidan also potently inhibits selectin-mediated adhesion of leukocytes to vascular endothelium. To understand the molecular basis for fucoidan's inhibition of specific cell adhesion events, we have investigated the structure of this fucan using definitive methods of carbohydrate structural analysis. We report the revised average structure for fucoidan. [GRAPHICS] This average structure differs from the previous model for fucoidan in two respects. First, the core region of the fucan is composed primarily of a polymer of alpha1-3-linked fucose with sulfate groups substituted at the 4 position on some of the fucose residues. Secondly, fucose is also attached to this polymer to form branch points, one for every 2-3 fucose residues within the chain. This revised average structure is consistent with previous studies suggesting a branched random coil as the best model for this polysaccharide. The proposed model is also a closer structural analogue of the sulfated carbohydrate ligands that bind to selectins. This information should be useful for determining whether a relationship exists between selectin-mediated adhesion of leukocytes and human sperm-egg binding.	EASTERN VIRGINIA MED SCH, DEPT BIOCHEM, POB 1980, NORFOLK, VA 23501 USA; EASTERN VIRGINIA MED SCH, DEPT OBSTET & GYNECOL, NORFOLK, VA 23501 USA; OLD DOMINION UNIV, DEPT CHEM & BIOCHEM, NORFOLK, VA 23529 USA	Eastern Virginia Medical School; Eastern Virginia Medical School; Old Dominion University			Oehninger, Sergio/AAZ-8443-2020					AHUJA KK, 1982, EXP CELL RES, V140, P353, DOI 10.1016/0014-4827(82)90124-0; ANNO K, 1970, CARBOHYD RES, V13, P167, DOI 10.1016/S0008-6215(00)84905-8; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BERNARDI G, 1962, J BIOL CHEM, V237, P75; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BJORNDAL HAKAN, 1967, CAR BOHYD RES, V5, P433, DOI 10.1016/S0008-6215(00)81115-5; BLACK WAP, 1952, J SCI FOOD AGR, V3, P122, DOI 10.1002/jsfa.2740030305; BLAKENEY AB, 1983, CARBOHYD RES, V113, P291, DOI 10.1016/0008-6215(83)88244-5; BOLWELL GP, 1979, J CELL SCI, V36, P19; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARK GF, 1992, FASEB J, V6, pA233; CONCHIE J, 1950, J CHEM SOC, P827, DOI 10.1039/jr9500000827; COTE RH, 1959, J CHEM SOC, P2248, DOI 10.1039/jr9590002248; DABROWSKI J, 1989, METHOD ENZYMOL, V179, P122; DEANGELIS PL, 1987, J BIOL CHEM, V262, P13946; DODGSON KS, 1961, BIOCHEM J, V78, P312, DOI 10.1042/bj0780312; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GLABE CG, 1982, J CELL BIOL, V94, P123, DOI 10.1083/jcb.94.1.123; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GUNNARSSON A, 1987, GLYCOCONJUGATE J, V4, P239, DOI 10.1007/BF01048429; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HUANG TTF, 1982, GAMETE RES, V5, P355, DOI 10.1002/mrd.1120050406; JONES R, 1991, DEVELOPMENT, V111, P1155; Klenk E, 1941, H-S Z PHYSIOL CHEM, V270, P185, DOI 10.1515/bchm2.1941.270.3-4.185; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MAHONY MC, 1991, CONTRACEPTION, V44, P657, DOI 10.1016/0010-7824(91)90085-T; OEHNINGER S, 1990, FERTIL STERIL, V53, P143; OEHNINGER S, 1991, FERTIL STERIL, V55, P165; Percival E., 1967, CHEM ENZYMOLOGY MARI, P157; PERCIVAL EGV, 1949, Q REV CHEM SOC, V3, P369, DOI 10.1039/qr9490300369; PETERSON RN, 1984, J EXP ZOOL, V231, P137, DOI 10.1002/jez.1402310118; SHALGI R, 1986, BIOL REPROD, V34, P446, DOI 10.1095/biolreprod34.3.446; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STOFFYN P, 1971, J LIPID RES, V12, P318; THOMASOATES JE, 1989, BIOCHEM SOC T, V17, P243, DOI 10.1042/bst0170243; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; URCH UA, 1991, DEVELOPMENT, V111, P1165; VARKI A, 1980, J BIOL CHEM, V255, P847; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILLIAMS RM, 1993, J EXP ZOOL, V266, P65, DOI 10.1002/jez.1402660110; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZEHAVI U, 1972, J ORG CHEM, V37, P2141, DOI 10.1021/jo00978a017	49	426	452	0	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21770	21776						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408031				2022-12-25	WOS:A1993MC80900054
J	WESSENDORF, JHM; GARFINKEL, S; ZHAN, X; BROWN, S; MACIAG, T				WESSENDORF, JHM; GARFINKEL, S; ZHAN, X; BROWN, S; MACIAG, T			IDENTIFICATION OF A NUCLEAR-LOCALIZATION SEQUENCE WITHIN THE STRUCTURE OF THE HUMAN INTERLEUKIN-1-ALPHA PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN ENDOTHELIAL-CELLS; NIH 3T3 CELLS; LEUKOCYTE INTERLEUKINS; RECEPTOR ANTAGONIST; INTERNALIZATION; EXPRESSION; PROTEINS; BINDING; CDNA	Recent studies have suggested that the signal peptide-less cytokine, interleukin (IL)-1alpha, may play a role as an intracellular regulator of human endothelial cell proliferation in vitro (Garfinkel, S., Haines, D. S., Brown, S., Wessendorf, J., Gillespie, D. H., and Maciag, T. (1992) J. Biol. Chem. 267, 24375-24378). In order to determine the intracellular locale of the IL-1alpha precursor, we fused the open reading frame of the IL-1alpha precursor to the reporter gene beta-galactosidase (Gal) and studied the cellular distribution of the chimera in NIH 3T3 cells after transfection. Immunological and enzymatic analysis demonstrated that the IL-1alpha:beta-Gal fusion protein was associated with the nucleus. To further define the region responsible for this activity, we ligated the mature form of IL-1alpha (IL-1alpha113-271) and the IL-1alpha precursor domain (IL-1alpha1-112) to beta-Gal. Analysis of the intracellular distribution of these chimeric polypeptides following transfection demonstrated a differential distribution of IL-1alpha1-112:beta-Gal in the nucleus and IL-1alpha113-271:beta-Gal in the cytosol. Because the IL-1alpha precursor domain contains a sequence that resembles a nuclear translocation signal (KVLKKRRL, residues 79-86), we prepared an IL-1alpha precursor point mutant in which Lys82 was replaced by Glu. Transfection of NIH 3T3 cells with the IL-1alpha precursor point mutant (IL-1alpha1-271 Glu82:beta-Gal) resulted in a significant reduction in the ability of the IL-1alpha precursor to associate with the nucleus and similar data were obtained as a result of Lys82 mutagenesis in the IL-1alpha precursor domain (IL-1alpha1-112 Glu82:beta-Gal). These data suggest that the IL-1alpha precursor contains a functional nuclear localization sequence within the structure of the precursor domain and Lys82 is critical for its function.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007450] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35627] Funding Source: Medline; NIA NIH HHS [AG07450] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CURTIS BM, 1990, J IMMUNOL, V144, P1295; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GARFINKEL S, 1992, J BIOL CHEM, V267, P24375; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; GRENFELL S, 1991, BIOCHEM J, V280, P111, DOI 10.1042/bj2800111; GUBLER U, 1986, J IMMUNOL, V136, P2492; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MONTESANO R, 1985, J CELL PHYSIOL, V122, P424, DOI 10.1002/jcp.1041220313; MONTESANO R, 1984, J CELL BIOL, V99, P1706, DOI 10.1083/jcb.99.5.1706; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; SAEGUSA Y, 1990, J CELL PHYSIOL, V142, P488, DOI 10.1002/jcp.1041420307; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEITZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166, DOI 10.1016/0006-291X(92)91319-L; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	42	159	163	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22100	22104						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408068				2022-12-25	WOS:A1993MC80900098
J	WILHELM, SM; SHAO, ZH; HOUSLEY, TJ; SEPERACK, PK; BAUMANN, AP; GUNJASMITH, Z; WOESSNER, JF				WILHELM, SM; SHAO, ZH; HOUSLEY, TJ; SEPERACK, PK; BAUMANN, AP; GUNJASMITH, Z; WOESSNER, JF			MATRIX METALLOPROTEINASE-3 (STROMELYSIN-1) - IDENTIFICATION AS THE CARTILAGE ACID METALLOPROTEASE AND EFFECT OF PH ON CATALYTIC PROPERTIES AND CALCIUM AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; RHEUMATOID SYNOVIAL FIBROBLASTS; HUMAN-SKIN; PURIFICATION; PROTEOGLYCAN; TISSUE; COLLAGENASE; COMPONENTS; CELLS; DEGRADATION	Human pro-MMP-3 (pro-matrix metalloproteinase-3) was purified from three sources: articular cartilage and conditioned media from synovial fibroblasts and Chinese hamster ovary cells expressing recombinant pro-MMP-3. All three preparations reacted with two monoclonal antibodies specific for human fibroblast pro-MMP-3. Each preparation of active MMP-3 possessed properties identical to those previously reported for the cartilage acid metalloproteinase (MMP-6; Azzo and Woessner, J. F., Jr. (1986) J. Biol. Chem. 261, 5434-5441): an acid pH optimum of 5.3-5.5 for digestion of cartilage aggrecan; digestion of oxidized insulin B-chain at Ala14-Leu15 and Tyr16-Leu17 in a ratio of 3:1; and heat stability at neutral pH. Further characterization of MMP-3 establishes that the acid pH optimum for cartilage aggrecan is not due to substrate denaturation since the same optimum is found by viscosity assay, by SDS-polyacrylamide gel electrophoresis assay of G1 domain, and by digestion of aggrecan in fresh cartilage fragments in vitro. Fibronectin was also digested optimally at pH 5.5 and NH2-terminal sequence analysis revealed no pH change in a major proteolytic site of cleavage at the Pro689-Leu690 bond. The specificity constant k(cat)/K(m) is maximal at pH 5.5 as determined in a quenched fluorescence peptide assay. This is due to an increase in k(cat) at pH 5.5 without any substantial effect on K(m). The affinity of MMP-3 for calcium is decreased about 10-fold at pH 5.3 compared to neutral pH. Finally, the neutral cartilage metalloproteinase is identified as 72-kDa pro-MMP-2 based on M(r), specificity of insulin B-chain cleavage, and reactivity with a specific polyconal antibody to human MMP-2.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101	University of Miami	WILHELM, SM (corresponding author), MILES INC,MILES RES CTR,INST BONE & JOINT DISORDERS,400 MORGAN LANE,W HAVEN,CT 06516, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR016940, R01AR016940] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-16940] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZZO W, 1986, J BIOL CHEM, V261, P5434; CAMPBELL IK, 1986, J RHEUMATOL, V13, P20; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; EECKHOUT Y, 1990, BIOCHEM J, V272, P529, DOI 10.1042/bj2720529; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; HARRISON R, 1989, ANAL BIOCHEM, V180, P110, DOI 10.1016/0003-2697(89)90096-1; HARRISON RK, 1992, BIOCHEMISTRY-US, V31, P10757, DOI 10.1021/bi00159a016; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HOUSLEY TJ, 1903, J BIOL CHEM, V268, P4481; HUGHES C, 1991, BIOCHEM J, V279, P733, DOI 10.1042/bj2790733; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KUNUGI S, 1982, EUR J BIOCHEM, V124, P157, DOI 10.1111/j.1432-1033.1982.tb05919.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; SAPOLSKY AI, 1976, J CLIN INVEST, V58, P1030, DOI 10.1172/JCI108526; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; Wilhelm S M, 1992, Matrix Suppl, V1, P37; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WOESSNER JF, 1973, FED PROC, V32, P1485; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; WOESSNER JF, 1984, J BIOL CHEM, V259, P3633	36	72	73	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21906	21913						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408046				2022-12-25	WOS:A1993MC80900072
J	FASOLATO, C; HOTH, M; PENNER, R				FASOLATO, C; HOTH, M; PENNER, R			A GTP-DEPENDENT STEP IN THE ACTIVATION MECHANISM OF CAPACITATIVE CALCIUM INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR CALCIUM; BINDING PROTEINS; MAST-CELLS; ENTRY	Calcium influx in electrically non-excitable cells is regulated by the firing state of intracellular calcium stores. Depletion of stores activates plasma membrane channels that are voltage-independent and highly selective for Ca2+ ions. We report here that the activation of plasma membrane Ca2+ currents induced by depletion of Ca2+ stores requires a diffusible cytosolic factor that washes out with time when dialyzing cells in the whole-cell configuration of the patch-clamp technique. The activation of calcium release-activated calcium current (I(CRAC)) by ionomycin- or inositol 1,4,5-trisphosphate-induced store depletion is blocked by guanosine 5'-3-O(thio)triphosphate (GTPgammaS) and guanyl-5'-yl imidodiphosphate, non-hydrolyzable analogs of GTP, suggesting the involvement of a GTP-binding protein. The inhibition by GTPgammaS occurs at a step prior to the activation of I(CRAC) and is prevented by the addition of GTP. We conclude that the activation mechanism of depletion-induced Ca2+ influx encompasses a GTP-dependent step, possibly involving an as yet unidentified small GTP-binding protein.	MAX PLANCK INST BIOPHYS CHEM,DEPT MEMBRANE BIOPHYS,AM FASSBERG,D-37077 GOTTINGEN,GERMANY	Max Planck Society			Fasolato, Cristina/AAE-6024-2019	Fasolato, Cristina/0000-0002-9816-7751; Penner, Reinhold/0000-0002-5366-1537; Hoth, Markus/0000-0001-7080-4643				BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KAHN RA, 1991, J BIOL CHEM, V266, P15595; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PENNER R, 1988, FEBS LETT, V226, P307, DOI 10.1016/0014-5793(88)81445-5; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	20	260	261	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20737	20740						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407897				2022-12-25	WOS:A1993MA28800015
J	FLORESROZAS, H; HURWITZ, J				FLORESROZAS, H; HURWITZ, J			CHARACTERIZATION OF A NEW RNA HELICASE FROM NUCLEAR EXTRACTS OF HELA-CELLS WHICH TRANSLOCATES IN THE 5' TO 3' DIRECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; MESSENGER-RNA; TRANSLATION INITIATION; DEPENDENT ATPASE; DNA HELICASE; PROTEIN; COMPLEX; GENE; DROSOPHILA; FRACTIONS	RNA helicase II, isolated from nuclear extracts of HeLa cells, was purified 1,300-fold and contained a single protein band of 100 kDa when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The enzyme displaced partial duplex RNA exclusively in a 5' to 3' direction. This reaction was supported only by ATP and deoxy-ATP at relatively high concentrations (the K(m) was estimated as 1 mM). The enzyme displayed only ATPase and deoxy-ATPase activity that was stimulated preferentially by poly(C). RNA helicase catalyzed the unwinding of duplex RNA and RNA . DNA hybrids provided that single-stranded (ss) RNA was available for the helicase to bind. In the presence of MgCl2 and ATP or adenosine 5'-O-3-thiotriphosphate) RNA helicase II interacted with ssRNA and yielded a protein-RNA complex only when reaction mixtures were treated with glutaraldehyde after incubation. When the reactions contained non-hydrolyzable ATP analogs or GTP, ssRNA was converted into an electrophoretically slower migrating form by the helicase. The slower migrating RNA form was shown to be an RNA species containing secondary structure that resided within a putative hairpin loop. These observations indicate that RNA helicase II can introduce intramolecular secondary structure in ssRNA.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center								BARRIJAL S, 1992, NUCLEIC ACIDS RES, V20, P5053, DOI 10.1093/nar/20.19.5053; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOVAL BC, 1991, SCIENCE, V252, P1823; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LINDER P, 1988, NUCLEIC ACIDS RES, V16, P10359, DOI 10.1093/nar/16.21.10359; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PRUZAN R, 1990, J BIOL CHEM, V265, P2804; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEO YS, 1991, J BIOL CHEM, V266, P13161; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0	35	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21372	21383						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407977				2022-12-25	WOS:A1993MA28800105
J	NAVARATNAM, N; MORRISON, JR; BHATTACHARYA, S; PATEL, D; FUNAHASHI, T; GIANNONI, F; TENG, BB; DAVIDSON, NO; SCOTT, J				NAVARATNAM, N; MORRISON, JR; BHATTACHARYA, S; PATEL, D; FUNAHASHI, T; GIANNONI, F; TENG, BB; DAVIDSON, NO; SCOTT, J			THE P27 CATALYTIC SUBUNIT OF THE APOLIPOPROTEIN-B MESSENGER-RNA EDITING ENZYME IS A CYTIDINE DEAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; CLONING; SITE	The messenger RNA for apolipoprotein B undergoes a discrete and specific C to U editing of nucleotide 6666. This generates a stop translation codon and defines the carboxyl terminus of apolipoprotein B48. A 27-kDa rat intestinal protein that does not itself edit apolipoprotein B mRNA, but confers editing activity on chick intestinal extracts that do not have intrinsic editing activity, has recently been identified and its cDNA cloned (Teng, B., Burant, C. F., and Davidson, N. O. (1993) Science 260, 1816-1819). Here we show that p27 is homologous in the zinc coordinating region of the active site to cytidine deaminases from Escherichia coli, Bacillus subtilis, yeast, and man and to deoxycytidylate deaminases from T2 and T4 bacteriophages and man. p27 expressed in Xenopus laevis oocyte extracts has cytidine deaminase activity and specifically confers editing activity on chick intestinal extracts. The homologous E. coli cytidine deaminase does not confer editing activity. The zinc-specific chelating agent o-phenanthroline abolishes p27 activity and site-specific apolipoprotein B mRNA editing in rat enterocyte editing extracts. We conclude that p27 is the catalytic subunit of the apolipoprotein B mRNA editing enzyme and is a zinc-containing cytidine deaminase.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,DU CANE RD,LONDON W12 ONN,ENGLAND; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	Imperial College London; University of Chicago			Giannoni, Federico/A-6577-2013; Bhattacharya, Shoumo/F-4127-2010	Giannoni, Federico/0000-0001-5521-512X; Bhattacharya, Shoumo/0000-0002-5571-0478	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002166, R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180, HL-02166] Funding Source: Medline; NIDDK NIH HHS [DK 42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1991, NATURE, V349, P370, DOI 10.1038/349370a0; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; FRICK L, 1987, ENZYMES, V4, P47; GREEVE J, 1991, NUCLEIC ACIDS RES, V13, P3569; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; KUHN K, 1993, BIOCHEM BIOPH RES CO, V190, P1, DOI 10.1006/bbrc.1993.1001; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MAHMOUDIAN M, 1993, IN PRESS ENZYME MICR; MALEY GF, 1983, J BIOL CHEM, V258, P8290; MALEY GF, 1990, J BIOL CHEM, V265, P47; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MCINTOSH EM, 1986, MOL CELL BIOL, V6, P1711, DOI 10.1128/MCB.6.5.1711; MOORE JT, 1993, J BIOL CHEM, V263, P2288; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Scott J, 1989, CURR OPIN CELL BIOL, V1, P1141, DOI 10.1016/S0955-0674(89)80064-X; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHARMEEN L, 1991, P NATL ACAD SCI USA, V88, P8096, DOI 10.1073/pnas.88.18.8096; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SONG BH, 1989, MOL GEN GENET, V216, P462, DOI 10.1007/BF00334391; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; WANG TP, 1950, J BIOL CHEM, V184, P17; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003	35	242	245	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20709	20712						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407891				2022-12-25	WOS:A1993MA28800008
J	WANG, ZY; FREIRE, E; MCCARTY, RE				WANG, ZY; FREIRE, E; MCCARTY, RE			INFLUENCE OF NUCLEOTIDE-BINDING SITE OCCUPANCY ON THE THERMAL-STABILITY OF THE F(1) PORTION OF THE CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; BETA-SUBUNIT; ELECTRON-MICROSCOPY; NONCATALYTIC SITES; EPSILON-SUBUNIT; GAMMA-SUBUNIT; DEFICIENT; MEMBRANES; PROTEINS; ATPASES	The irreversible thermal denaturation of the F1 portion of the chloroplast ATP synthase (CF1) was examined by differential scanning calorimetry, ATPase activity loss, and release of bound nucleotides. In nearly all cases, the loss of ATPase activity closely paralleled the temperature dependence of the excess heat capacity. Although the irreversible nature of the denaturation precluded thermodynamic interpretation, a kinetic analysis was feasible. A two-state kinetic model was found to fit the calorimetric data very well. The activation energies of thermal denaturation calculated from calorimetric data were very close to those determined from Arrhenius plots of the apparent first-order rate constants of loss of ATPase activity versus reciprocal of the temperature. The nucleotide binding site occupancy profoundly influenced the temperature at which thermal denaturation occurred. In particular, the temperature at which the maximum in excess heat capacity occurs (T(m)) was increased about 8-degrees-C by occupancy of tight, noncatalytic ATP binding sites and by an additional 3-4-degrees-C by the presence of nucleotides in the medium during heating. The thermal denaturation of CF1, an enzyme composed of nine polypeptide chains, is highly cooperative in that it obeys the simple two-step kinetic model. Since the removal of the epsilon and delta subunits has little effect on thermal denaturation, the major forces that stabilize CF1 must, thus, be between the alpha, beta, and gamma subunits.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,CTR BIOCALORIMETRY,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NCRR NIH HHS [RR 0438] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AVITAL S, 1991, J BIOL CHEM, V266, P7067; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BOEKEMA EJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P365, DOI 10.1016/0005-2728(88)90044-8; BOYER PD, 1989, FASEB J, V3, P365; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; FARRON F, 1970, BIOCHEMISTRY-US, V9, P3829, DOI 10.1021/bi00821a024; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; KAGAWA Y, 1992, J BIOENERG BIOMEMBR, V24, P441, DOI 10.1007/BF00762360; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA M, 1976, BIOCHEM BIOPH RES CO, V70, P228, DOI 10.1016/0006-291X(76)91132-3; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; McCarty RE, 1988, LIGHT ENERGY TRANSDU, P290; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MORIN PE, 1990, BIOCHEMISTRY-US, V29, P781, DOI 10.1021/bi00455a028; PATRIE WJ, 1984, J BIOL CHEM, V259, P1121; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SMITH KA, 1986, BIOCHEMISTRY-US, V25, P7099, DOI 10.1021/bi00370a051; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VIALE A, 1981, BIOCHIM BIOPHYS ACTA, V637, P496, DOI 10.1016/0005-2728(81)90056-6; XIAO JP, 1989, BIOCHIM BIOPHYS ACTA, V976, P203, DOI 10.1016/S0005-2728(89)80231-2; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001	34	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20785	20790						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407905				2022-12-25	WOS:A1993MA28800024
J	SCHAAP, D; VANDERWAL, J; HOWE, LR; MARSHALL, CJ; VANBLITTERSWIJK, WJ				SCHAAP, D; VANDERWAL, J; HOWE, LR; MARSHALL, CJ; VANBLITTERSWIJK, WJ			A DOMINANT-NEGATIVE MUTANT OF RAF BLOCKS MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION BY GROWTH-FACTORS AND ONCOGENIC P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; DIACYLGLYCEROL KINASE; SUBSTRATE-SPECIFICITY; PURIFICATION; EXPRESSION; ZINC; INVOLVEMENT; REQUIRES; CLONING; EPSILON	p74raf-1, a serine/threonine kinase, is structurally related to the protein kinase C (PKC) family and contains a cysteine motif in its N-terminal domain, which is essential for its regulation. It has been shown that p74raf-1 functions upstream of mitogen-activated protein (MAP) kinase kinase. We have constructed a p74raf-1 mutant (NDELTAraf) that only contains the N-terminal regulatory domain. When transiently expressed in COS-M6 cells, NDELTAraf efficiently blocked the activation of the MAP extracellular signal regulated kinase (ERK2), induced by either epidermal growth factor, phorbol ester, serum, or oncogenic p21ras. Similar constructs with the cysteine motifs from either PKC-alpha or diacylglycerol kinase did not inhibit activation of ERK2. Overexpression of full-length p74raf-1 rescued the inhibition of ERK2 by NDELTAraf in a stimulus dependent manner, indicating that NDELTAraf acts as a competitive inhibitor of wild-type p74raf-1. In contrast, overexpression of either PKC-alpha, -epsilon, or -zeta in NDELTAraf-containing cells could not rescue the inhibition of ERK2. We conclude that p74raf-1 is an essential mediator of epidermal growth factor- and phorbol ester-induced ERK2 activation and that the MAP kinase kinase kinase activity of p74raf-1 cannot be substituted with either PKC-alpha, -epsilon or -zeta.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	SCHAAP, D (corresponding author), NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.			Howe, Louise/0000-0002-1468-7136				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUBBARD SR, 1991, SCIENCE, V254, P1776; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; RAPP UR, 1991, ONCOGENE, V6, P495; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SOZERI O, 1992, ONCOGENE, V7, P2259; WAYS DK, 1992, J BIOL CHEM, V267, P4799	30	153	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20232	20236						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397201				2022-12-25	WOS:A1993LY01900049
J	MARSHALL, MS; HETTICH, LA				MARSHALL, MS; HETTICH, LA			CHARACTERIZATION OF RAS EFFECTOR MUTANT INTERACTIONS WITH THE NF1-GAP RELATED DOMAIN	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; ADENYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; NEUROFIBROMATOSIS GENE; CATALYTIC DOMAIN; GAP; P21; MUTATIONS; TRANSFORMATION	The GTPase activating proteins Ras GAP and the neurofibromatosis-type 1 (NF1) gene product have been implicated as both potential mediators and regulators of the mitogenic effects of the ras proteins. In this study, the interactions of selected Ras effector mutants with the NF1-GAP related domain (NF1-GRD) were investigated. The NF1-GRD was unable to stimulate the GTPase of Ras[Asn33], Ras[Ser35] or Ras[Asn38], all transformation defective mutants. Each of these mutants had reduced but detectable binding to the NF1-GRD (apparent K(D) of 9 muM, 4 muM and 2 muM respectively, vs 0.5 muM for normal Ha-ras). The NF1-GRD was able to fully stimulate the intrinsic GTPase of the transformation-defective Ras[Gly26Ile27] and Ras[Glu45] mutants, each of which bound the NF1-GRD with wild type affinity or better (K(D)=0.13 muM and 0.4 muM respectively). The transforming Ras[Glu30Lys31] protein showed no GTPase stimulation and bound most poorly to the NF1-GRD (apparent K(D) of 16 muM). The interaction of the NF1-GRD with these specific Ras effector mutations is similar to that observed for Ras GAP. When the relative transforming activity of the valine 12 form of each Ras mutant was plotted against the apparent K(D) for NF1-GRD binding, little correlation was observed. These results support the hypothesis that the NF1 gene product does not function as a downstream effector of Ras in the mitogenic pathway.	WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Walther Cancer Institute	MARSHALL, MS (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLDBERG NS, 1991, ARCH DERMATOL, V127, P1705, DOI 10.1001/archderm.127.11.1705; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SIGAL IS, 1988, COLD SPRING HARB SYM, V53, P863, DOI 10.1101/SQB.1988.053.01.099; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					425	431						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426748				2022-12-25	WOS:A1993KN00600022
J	LEWIS, CT; SEYER, JM; CASSELL, RG; CARLSON, GM				LEWIS, CT; SEYER, JM; CASSELL, RG; CARLSON, GM			IDENTIFICATION OF VICINAL THIOLS OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; GUANOSINE TRIPHOSPHATE; MESSENGER-RNA; INACTIVATION; CHICKEN; PROTEIN; 5'-TRIPHOSPHATE; DISULFIDE; CYSTEINE; DITHIOL	Phosphoenolpyruvate carboxykinase (PEPCK) from the cytosol of rat liver has 13 cysteines, at least one of which (Cys288) is known to be very reactive and critical for catalytic activity (Lewis, C. T., Seyer, J. M., and Carlson, G. M. (1989) J. Biol. Chem. 264, 27-33). Previous results provided evidence for the existence of at least 1 pair of vicinal cysteines within or near the active site of PEPCK (Lewis, C. T., Haley, B. E., and Carlson, G. M. (1989) Biochemistry 28, 9248-9255). An intramolecular cystine disulfide is induced to form upon treatment of PEPCK with equimolar 5,5'-dithiobis(2-nitrobenzoate) (Nbs2) or upon irradiation of the enzyme in the presence of the photoaffinity probe 8-azidoGTP. In each case, modification is accompanied by a substantial loss in catalytic activity, and substrates protect against inactivation and modification. We now report the identification of these modified thiols by differential alkylation of cysteines and half-cystines with radioactive iodoacetate, followed by isolation and sequencing of the modified tryptic peptides. The results indicate that the disulfide formed by equimolar NbS2 lies within a 15-residue region of the PEPCK sequence that includes Cys399, Cys407, and Cys413. In addition, Cys407 and/or Cys413 also appear to participate in formation of the disulfide induced by 8-azidoGTP. These thiols lie very near a consensus sequence that has been suggested to represent the binding site for the guanine ring of GTP.	UNIV TENNESSEE,CTR HLTH SCI,COLL MED,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ALVEAR M, 1989, BIOCHIM BIOPHYS ACTA, V994, P7, DOI 10.1016/0167-4838(89)90055-1; ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; BALLARD FJ, 1976, BIOCHEM J, V154, P717, DOI 10.1042/bj1540717; BALLARD FJ, 1969, J BIOL CHEM, V244, P5625; BEALE EG, 1985, J BIOL CHEM, V260, P748; BRINKWORTH RI, 1981, J BIOL CHEM, V256, P795; CARDEMIL E, 1990, BIOCHIM BIOPHYS ACTA, V1040, P71, DOI 10.1016/0167-4838(90)90147-8; CARLSON GM, 1978, BIOCHEMISTRY-US, V17, P5329, DOI 10.1021/bi00618a002; COLOMBO G, 1981, BIOCHEMISTRY-US, V20, P2758, DOI 10.1021/bi00513a009; COLOMBO G, 1978, BIOCHEMISTRY-US, V17, P5321, DOI 10.1021/bi00618a001; COLOMBO G, 1981, BIOCHEMISTRY-US, V20, P2749, DOI 10.1021/bi00513a008; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HEBDA CA, 1982, J BIOL CHEM, V257, P5503; LEWIS CT, 1989, J BIOL CHEM, V264, P27; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; MILLER RS, 1968, J BIOL CHEM, V243, P6030; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIPPA M, 1981, J BIOL CHEM, V256, P451; UTTER MF, 1954, J BIOL CHEM, V207, P803	22	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1628	1636						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420937				2022-12-25	WOS:A1993KH62000022
J	YRUELA, I; ALFONSO, M; DEZARATE, IO; MONTOYA, G; PICOREL, R				YRUELA, I; ALFONSO, M; DEZARATE, IO; MONTOYA, G; PICOREL, R			PRECISE LOCATION OF THE CU(II)-INHIBITORY BINDING-SITE IN HIGHER-PLANT AND BACTERIAL PHOTOSYNTHETIC REACTION CENTERS AS PROBED BY LIGHT-INDUCED ABSORPTION CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION CENTER; ELECTRON-TRANSPORT PROPERTIES; PHOTOSYSTEM-II; RHODOPSEUDOMONAS-VIRIDIS; PHOTOREACTION CENTER; PROTEIN SUBUNITS; B559 COMPLEX; COPPER; QA; CHLOROPLASTS	Light-dependent absorption change at 325 nm, ascribed to Q(A) activity, was strongly reduced in the presence of Cu(II) in oxygen-evolving core complex. This change was much less affected in the presence of the herbicide 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU), indicating that the Cu(II)-binding site is different from that of the DCMU and that Cu(II) blocks Q(A) reduction. Cu(II) did not eliminate the absorption change at 545 nm, ascribed to pheophytin reduction, in Na2S2O4-treated oxygen-evolving core and D1-D2-cytochrome b559 complexes. This indicates that Cu(II) does not affect the electron transport between P680 and pheophytin. Moreover, the activity of the bacterial reaction center probed by the absorption change at 790 nm was inhibited by Cu(II), but the signal at 530 nm, associated to the reduction of bacteriopheophytin in Na2S2O4-treated reaction center, was not inhibited. We conclude that Cu(II) impaired the photosynthetic electron transport between pheophytin and Q(A) in both higher plants and photosynthetic bacteria. Cu(II) would bind to an amino acid(s) highly conserved in non-oxygenic and oxygenic reaction centers, which is(are) necessary for the electron transfer between pheophytin and Q(A). Based on the atomic structure of the bacterial reaction center several schemes of possible Cu(II) binding are shown.	CSIC,ESTAC EXPTL AULA DEI,APARTADO 202,E-50080 ZARAGOZA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Aula Dei (EEAD)			PICOREL, RAFAEL/K-7930-2014; Yruela, Inmaculada/A-9330-2015; Alfonso, Miguel/L-6970-2014; Yruela, Inmaculada/T-1239-2019	PICOREL, RAFAEL/0000-0003-3791-129X; Yruela, Inmaculada/0000-0003-3608-4720; Alfonso, Miguel/0000-0002-8190-5156; Yruela, Inmaculada/0000-0003-3608-4720				ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOWLBY NR, 1988, LIGHT ENERGY TRANSDU, P215; BRAUN P, 1990, BIOCHEMISTRY-US, V29, P10376, DOI 10.1021/bi00497a012; CHAPMAN DJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P423, DOI 10.1016/0005-2728(88)90077-1; CLIJSTERS H, 1985, PHOTOSYNTH RES, V7, P731; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; COLEMAN W, 1990, CURRENT RES PHOTOSYN, P149; COLEMAN WJ, 1990, ANNU REV BIOPHYS BIO, V19, P333; Cramer W. A., 1982, PHOTOSYNTHESIS, V1, P387; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DINER BA, 1991, PHYSIOL PLANTARUM, V81, P423; FOY CD, 1978, ANNU REV PLANT PHYS, V29, P511, DOI 10.1146/annurev.pp.29.060178.002455; HANSSON O, 1990, PHOTOSYNTH RES, V23, P131, DOI 10.1007/BF00035006; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; HSU BD, 1988, PLANT PHYSIOL, V87, P116, DOI 10.1104/pp.87.1.116; MAR T, 1991, BIOCHIM BIOPHYS ACTA, V1056, P190, DOI 10.1016/S0005-2728(05)80286-5; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P17; MOHANTY N, 1989, PLANT PHYSIOL, V90, P175, DOI 10.1104/pp.90.1.175; MONTOYA G, 1991, FEBS LETT, V283, P255, DOI 10.1016/0014-5793(91)80601-X; NAGATSUKA T, 1991, BIOCHIM BIOPHYS ACTA, V1057, P223, DOI 10.1016/S0005-2728(05)80105-7; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; PICOREL R, 1980, BIOCHIM BIOPHYS ACTA, V593, P76, DOI 10.1016/0005-2728(80)90009-2; PLATO M, 1989, FEBS LETT, V249, P70, DOI 10.1016/0014-5793(89)80018-3; SAMSON G, 1988, PHOTOCHEM PHOTOBIOL, V48, P329, DOI 10.1111/j.1751-1097.1988.tb02829.x; SCHATZ GH, 1985, BIOCHIM BIOPHYS ACTA, V810, P283, DOI 10.1016/0005-2728(85)90212-9; SEIBERT M, 1988, PLANT PHYSIOL, V87, P303, DOI 10.1104/pp.87.2.303; SINGH DP, 1987, PLANT PHYSIOL, V83, P12, DOI 10.1104/pp.83.1.12; SULKOWSKI E, 1985, TRENDS BIOTECHNOL, V3, P1, DOI 10.1016/0167-7799(85)90068-X; TANAKAKITATANI Y, 1990, PLANT CELL PHYSIOL, V31, P1039; THORNBER JP, 1987, PHOTOSYNTHETIC BACTE, P133; TREBST A, 1987, Z NATURFORSCH C, V42, P742; VADEBONCOEUR C, 1979, BIOCHEMISTRY-US, V18, P4301, DOI 10.1021/bi00587a007; VANGORKOM HJ, 1982, FUNCTION QUINONES EN, P213; YRUELA I, 1992, PHOTOSYNTH RES, V33, P227, DOI 10.1007/BF00030033; YRUELA I, 1991, J BIOL CHEM, V266, P22847	39	44	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1684	1689						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420944				2022-12-25	WOS:A1993KH62000029
J	HINEK, A; RABINOVITCH, M				HINEK, A; RABINOVITCH, M			THE DUCTUS-ARTERIOSUS MIGRATORY SMOOTH-MUSCLE CELL PHENOTYPE PROCESSES TROPOELASTIN TO A 52-KDA PRODUCT ASSOCIATED WITH IMPAIRED ASSEMBLY OF ELASTIC LAMINAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; BOVINE ELASTIN; BINDING-PROTEIN; MONOCLONAL-ANTIBODY; SOLUBLE ELASTIN; NUCHAL LIGAMENT; CHICK AORTA; GENE; RNA; SEQUENCE	We established the identity of a 52-kDa protein secreted by fetal lamb ductus arteriosus (DA) smooth muscle cells (SMC) and suggest how it might be related to structural changes unique to DA development, i.e. reduced assembly of elastic laminae and associated formation of intimal cushions. We produced a monoclonal antibody (HI-20) to the 52-kDa protein and observed, by electron microscopy, immunogold labeling of elastin in both DA and aorta vessel walls. Western immunoblotting showed that HI-20, as well as antibodies to tropoelastin, reacted with the 52-kDa protein secreted by DA SMC, as well as with 68-kDa tropoelastin. The highly specific antibody to the carboxyl-terminal sequence of tropoelastin failed, however, to recognize the 52-kDa protein, although it reacted well with the 68-kDa tropoelastin. Amino acid analysis and sequencing data confirmed the identity of the affinity-purified 52-kDa protein as truncated tropoelastin with an intact amino terminus. Cell-free translation of mRNA extracted from DA and aorta SMC produced a 68-kDa, but not a 52-kDa, immunoprecipitated tropoelastin. When DA and aorta SMC were pulsed with [C-14]valine, we immunoprecipitated, after only a 15-min chase, both 68-kDa and 52-kDa tropoelastin from cell extracts of DA SMC, but only the 68-kDa tropoelastin was present in aorta SMC. There was no evidence of proteolytic degradation of radiolabeled aorta 68-kDa tropoelastin to a 52-kDa species when mixed with DA SMC conditioned medium. This suggests that the 52-kDa tropoelastin is the result of cell-associated processing or degradation of an original 68-kDa product of translation. Furthermore, pulse-chase experiments showed initial secretion of equivalent amounts of 68-kDa and 52-kDa tropoelastins by cultured DA SMC with increasing accumulation of the 52-kDa species, suggesting its impaired insolubilization. The production, in high concentration, of a 52-kDa tropoelastin product that lacks the carboxyl terminus, may prevent its alignment on the microfibrillar scaffold, resulting in abnormal assembly of elastic laminae in the DA. The accumulation of this soluble tropoelastin may be associated with the previously described property of chemotaxis resulting in the increased SMC migration into the subendothelium associated with DA intimal thickening.	HOSP SICK CHILDREN,RES INST,DIV CARDIOVASC RES,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Hinek, Aleksander/V-8790-2019					BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; BOUDREAU N, 1991, LAB INVEST, V64, P187; BUCHNAN JW, 1978, BIRTH DEFECTS, V124, P349; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHIPMAN SD, 1985, J BIOL CHEM, V260, P2780; CICILA G, 1985, BIOCHEMISTRY-US, V24, P3075, DOI 10.1021/bi00334a001; DAVIDSON JM, 1984, BIOCHEM J, V220, P643, DOI 10.1042/bj2200643; DAVIDSON JM, 1982, J BIOL CHEM, V257, P747; DAVIDSON JM, 1982, ARCH BIOCHEM BIOPHYS, V218, P31, DOI 10.1016/0003-9861(82)90317-4; DEREEDER EG, 1990, ANAT EMBRYOL, V182, P473; DEREEDER EG, 1988, AM J PATHOL, V132, P574; EMANUEL BS, 1985, AM J HUM GENET, V37, P873; FAZIO MJ, 1988, J INVEST DERMATOL, V91, P458, DOI 10.1111/1523-1747.ep12476591; FOSTER JA, 1980, BIOCHEMISTRY-US, V19, P857, DOI 10.1021/bi00546a005; FOSTER JA, 1981, BIOCHEMISTRY-US, V20, P3528, DOI 10.1021/bi00515a035; FOSTER JA, 1986, COLLAGEN REL RES, V6, P387; FRANZBLAU C, 1989, J BIOL CHEM, V264, P15115; GITTENBERGERDEGROOT AC, 1980, J PEDIATR-US, V96, P88, DOI 10.1016/S0022-3476(80)80337-4; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; Hineck A, 1990, ELASTIN CHEM BIOL AS, P369; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; INDIK Z, 1989, AM J MED GENET, V34, P81, DOI 10.1002/ajmg.1320340115; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MECHAM RP, 1984, J CELL BIOL, V98, P1813, DOI 10.1083/jcb.98.5.1813; MECHAM RP, 1977, BIOCHEMISTRY-US, V16, P3825, DOI 10.1021/bi00636a017; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; OLLIVER L, 1987, COLLAGEN REL RES, V7, P77; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PATTERSON DF, 1979, PEDIATR CARDIOL, V2, P45; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; RABINOVITCH M, 1988, DEV BIOL, V130, P250, DOI 10.1016/0012-1606(88)90431-9; RAJU K, 1987, J BIOL CHEM, V262, P5755; ROMERO N, 1986, ARCH BIOCHEM BIOPHYS, V244, P161, DOI 10.1016/0003-9861(86)90105-0; ROSENBLOOM J, 1986, COLLAGEN REL RES, V6, P423; ROSENBLOOM J, 1984, LAB INVEST, V51, P605; Sandberg L B, 1976, Int Rev Connect Tissue Res, V7, P159; SANDBERG LB, 1982, METHOD ENZYMOL, V82, P657; SANDBERG LB, 1985, PATHOL BIOL, V33, P266; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; STARCHER BC, 1976, ANAL BIOCHEM, V74, P441, DOI 10.1016/0003-2697(76)90224-4; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TODOROVICHHUNTER L, 1988, LAB INVEST, V58, P184; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKADA T, 1987, AM J PATHOL, V126, P51; WRENN DS, 1986, BIOCHEMISTRY-US, V25, P5172, DOI 10.1021/bi00366a028; WRENN DS, 1987, J BIOL CHEM, V262, P2244; WRENN DS, 1986, METHOD ENZYMOL, V144, P246; YEH H, 1987, COLLAGEN REL RES, V7, P235; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; YODER MJ, 1978, ANAT REC, V192, P19, DOI 10.1002/ar.1091920103; YOON K, 1985, ARCH BIOCHEM BIOPHYS, V241, P684, DOI 10.1016/0003-9861(85)90595-8; YOON K, 1984, BIOCHEM BIOPH RES CO, V118, P261, DOI 10.1016/0006-291X(84)91095-7; ZHU L, 1993, IN PRESS LAB INVEST	58	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1405	1413						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419341				2022-12-25	WOS:A1993KG07700096
J	KEREM, A; KRONMAN, C; BARNUN, S; SHAFFERMAN, A; VELAN, B				KEREM, A; KRONMAN, C; BARNUN, S; SHAFFERMAN, A; VELAN, B			INTERRELATIONS BETWEEN ASSEMBLY AND SECRETION OF RECOMBINANT HUMAN ACETYLCHOLINESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYBRID CELL-LINE; MOLECULAR-FORMS; ENDOPLASMIC-RETICULUM; DISULFIDE BONDS; EXPRESSION; GOLGI; IGM; BUTYRYLCHOLINESTERASE; CHOLINESTERASE; DEGRADATION	Transport and secretion of recombinant human acetylcholinesterase (HuAChE) were studied in transfected human 293 cells expressing either the oligomerized soluble enzyme or a monomeric mutant derivative in which Cys-580 was substituted by alanine (C580A). In cells expressing the wild-type enzyme, the gradual assembly of newly synthesized intracellular rHuAChE monomers into oligomers occurs within the endoplasmic reticulum. Secretion of mature wild-type enzyme into the medium is efficient and appears to be exclusive to multimeric forms. Consistently, intracellular oligomers, but not monomers, are endoglycosidase H-resistant, indicating that only oligomers undergo terminal glycosylation in the wild-type enzyme. In contrast, in cells expressing the dimerization-defective C580A mutant, newly synthesized rHuAChE monomers undergo terminal glycosylation and are secreted into the medium as efficiently as wild-type multimers. No significant difference between the intracellular transport rates of wild-type rHuAChE oligomers and mutant C580A monomers was revealed by probing with specific lectins. In both systems, transport and processing prior to the trans-Golgi galactosylation compartment appear to be rate-limiting, whereas the following passage to the cell surface is rapid. In conclusion, we suggest that in the presence of a free cysteine at the COOH terminus of the rHuAChE polypeptide, secretion of monomers is not effectuated, whereas in its absence, monomers are exported from the endoplasmic reticulum and are capable of traversing the entire secretory pathway.	ISRAEL INST BIOL RES,DEPT BIOCHEM,POB 19,IL-70450 NESS ZIONA,ISRAEL; TEL AVIV UNIV,SCH LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ALLMAND P, 1981, J NEUROCHEM, V36, P860; AMITAY R, 1991, J BIOL CHEM, V266, P12568; ATACK JR, 1987, J NEUROCHEM, V48, P1845, DOI 10.1111/j.1471-4159.1987.tb05746.x; BROCKMAN SK, 1986, J BIOL CHEM, V261, P1201; CHATONNET A, 1989, BIOCHEM J, V260, P625, DOI 10.1042/bj2600625; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HEIDER H, 1992, BIOCHEM J, V281, P279, DOI 10.1042/bj2810279; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KRONMAN C, 1992, IN PRESS GENE AMST; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LAZAR M, 1984, J BIOL CHEM, V259, P3703; LI Y, 1991, J BIOL CHEM, V266, P23083; LOCKRIDGE O, 1979, J BIOL CHEM, V254, P8324; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RIEGER F, 1980, DEV BIOL, V76, P238, DOI 10.1016/0012-1606(80)90376-0; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; SCHUMACHER M, 1988, J BIOL CHEM, V263, P18979; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; WILCHEK M, 1982, BIOCHEM INT, V4, P629	42	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					180	184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416926				2022-12-25	WOS:A1993KE60300028
J	RUTHER, U; WOODROOFE, C; FATTORI, E; CILIBERTO, G				RUTHER, U; WOODROOFE, C; FATTORI, E; CILIBERTO, G			INDUCIBLE FORMATION OF LIVER-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Article							C-REACTIVE PROTEIN; EXPRESSION; TUMORIGENESIS; GENES	Transgenic mice have been generated with an inducible SV40 t/T antigen construct with the aim of analysing the early changes that take place in the course of liver tumorigenesis. The strictly liver-specific human C-reactive protein (CRP) gene promoter was chosen for the control of the transgene expression because this promoter can be turned on transiently by injection of bacterial lipopolysaccharide. Among 10 independently derived CRP-Tag mouse lines five showed inducible expression of the CRP-Tag transgene in liver. However, only one had a tight control of the transgene with virtually no expression under physiological conditions and high levels of Tag expression after stimulation. Females of this line were used to analyse the progression of liver alterations upon repeated induction of the t/T antigen for different lengths of time. The first signs of transgene-induced liver alterations could be monitored by the activation of the marker enzyme gamma-glutamyltranspeptidase 30 days after the start of the induction program. After 90 days hepatocellular carcinomas were already detectable. Thus, CRP-Tag mice constitute an excellent system to analyse the sequential events that take place during liver carcinogenesis.	IST RIC BIOL MOLEC,DEPT GENET,I-00040 POMEZIA,ITALY; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P5859; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANTER U, 1989, EMBO J, V8, P3733; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HOGAN B, 1986, MANIPULATION MOUSE E; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; NOWELL PC, 1986, CANCER RES, V46, P2203; OGAWA K, 1980, CANCER RES, V40, P725; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SANDGREN EP, 1989, ONCOGENE, V4, P715; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; TONIATTI C, 1990, MOL BIOL MED, V7, P199; TOOZE J, 1990, DNA TUMOR VIRUSES; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					87	93						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423999				2022-12-25	WOS:A1993KN00500010
J	REID, RL; LINDHOLM, PF; MIRESKANDARI, A; DITTMER, J; BRADY, JN				REID, RL; LINDHOLM, PF; MIRESKANDARI, A; DITTMER, J; BRADY, JN			STABILIZATION OF WILD-TYPE P53 IN HUMAN T-LYMPHOCYTES TRANSFORMED BY HTLV-I	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; VIRUS TYPE-I; HUMAN PAPILLOMAVIRUS TYPE-16; CORD BLOOD-LYMPHOCYTES; MONOCLONAL-ANTIBODIES; LEUKEMIA LYMPHOMA; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; INCREASED EXPRESSION; MOLECULAR-CLONING	Adult T-cell leukemia/lymphoma is an aggressive malignancy associated with infection by the human T-lymphotropic virus type-I (HTLV-1). We now demonstrate that p53 expression is elevated in the HTLV-1-transformed T-lymphocyte lines C81, MT-2, MT-4 and HUT 102. In pulse-chase experiments, the p53 protein demonstrated a prolonged half-life of 2 to 8 h in HTLV-1-transformed cells compared with 0.5 to 1.0 h for wild-type p53 in primary human and murine fibroblasts, or human peripheral blood lymphocytes. In cell lines C81 and HUT 102, which exhibited the longest p53 protein half-life, the wild-type-related PAb1620 epitope was detected at reduced levels. The PAb240 mutant-related p53 epitope was not detected in any of the transformed cell lines. By direct sequence analysis of RT-PCR products, the entire p53 cDNA coding sequence was determined to be wild-type in all four cell lines. Stabilization of wild-type p53 may represent its functional inactivation and contribute to lymphocyte transformation by HTLV-I.	NCI,MOLEC VIROL LAB,BLDG 41,ROOM B602,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dittmer, Juergen/G-1160-2011					BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KONDO T, 1987, LANCET, V2, P159; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUBBERT M, 1989, ONCOGENE, V4, P643; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROWLEY JD, 1984, HUMAN T CELL LEUKEMI, P85; SAKASHITA A, 1992, BLOOD, V79, P477; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SANADA I, 1985, BLOOD, V65, P649; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SQUIRES J, 1988, P AM ASSOC CANC RES, V29, P454; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; TOKUDOME S, 1989, CANCER RES, V49, P226; UESHIMA Y, 1981, BLOOD, V58, P420; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	97	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3029	3036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414503				2022-12-25	WOS:A1993MC09300017
J	KWONG, FYP; WU, JSR; SHI, MM; FINCHAM, HE; DAVIES, A; HENDERSON, PJF; BALDWIN, SA; YOUNG, JD				KWONG, FYP; WU, JSR; SHI, MM; FINCHAM, HE; DAVIES, A; HENDERSON, PJF; BALDWIN, SA; YOUNG, JD			ENZYMATIC CLEAVAGE AS A PROBE OF THE MOLECULAR-STRUCTURES OF MAMMALIAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; PARA-CHLOROMERCURIPHENYL SULFONATE; ENDO-BETA-GALACTOSIDASE; GUINEA-PIG; NITROBENZYLTHIOINOSINE-BINDING; SPECIES-DIFFERENCES; LEUKEMIA-CELLS; ADENOSINE; SITES; RAT	We have used enzymic cleavage by trypsin in conjunction with glycosidase digestion to probe the transmembrane topologies and molecular structures of mammalian equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive, nucleoside transport systems. Transporters from four species (human, pig, guinea pig, and rat) and three tissues (erythrocyte, liver, and lung), which differ from each other in size and in their sensitivity to inhibition by the vasodilator dipyridamole, were investigated. Broadly equivalent sites of [H-3]NBMPR photolabeling, carbohydrate attachment, and trypsin cleavage were observed for all systems. Results from these experiments demonstrate that molecular weight differences between rat transporters and those from two other species (human and guinea pig) are due largely to oligosaccharide heterogeneity and that the low dipyridamole sensitivity of rat nucleoside transporters is probably a consequence of relatively minor differences in molecular structure. In marked contrast, carbohydrate removal increases the molecular weight difference between the pig erythrocyte transporter and, for example, that in human erythrocytes. This polypeptide difference is limited largely, if not completely, to one tryptic fragment of the protein. In the case of the human erythrocyte transporter, the site of N-linked glycosylation has been located very close to one end of the protein, and the site of NBMPR photolabeling to within 16 kDa of that site. Trypsin cleavage occurs endofacially. Our results provide evidence of substantial structural conservation among mammalian NBMPR-sensitive nucleoside transporters.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PROT & MOLEC BIOL,LONDON NW3 2PF,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; CHINESE UNIV HONG KONG,DEPT BIOCHEM,SHA TIN,HONG KONG; UNIV ALBERTA,DEPT PATHOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; Chinese University of Hong Kong; University of Alberta	KWONG, FYP (corresponding author), UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT BIOCHEM & CHEM,ROWLAND HILLS ST,LONDON NW3 2PF,ENGLAND.		Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; ASANO T, 1991, J BIOL CHEM, V266, P24632; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; DAGNINO L, 1990, CANCER RES, V50, P6549; DAVIES A, 1987, J BIOL CHEM, V262, P9347; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FEUGEAS JP, 1991, BIOCHIM BIOPHYS ACTA, V1066, P59, DOI 10.1016/0005-2736(91)90250-C; GATI WP, 1986, BIOCHEM J, V236, P665, DOI 10.1042/bj2360665; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; HOPKINS SV, 1971, BIOCHEM PHARMACOL, V20, P3359, DOI 10.1016/0006-2952(71)90440-0; JANMOHAMED NS, 1985, BIOCHEM J, V230, P777, DOI 10.1042/bj2300777; JARVIS SM, 1980, BIOCHIM BIOPHYS ACTA, V597, P183, DOI 10.1016/0005-2736(80)90162-5; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1980, BIOCHEM J, V190, P377, DOI 10.1042/bj1900377; JARVIS SM, 1985, J NEUROCHEM, V44, P183, DOI 10.1111/j.1471-4159.1985.tb07129.x; JARVIS SM, 1986, J BIOL CHEM, V261, P1077; KOLASSA N, 1971, EUR J PHARMACOL, V13, P320, DOI 10.1016/0014-2999(71)90221-4; KWAN KF, 1984, AM J PHYSIOL, V246, pH710, DOI 10.1152/ajpheart.1984.246.5.H710; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1987, BIOCHIM BIOPHYS ACTA, V904, P105, DOI 10.1016/0005-2736(87)90091-5; KWONG FYP, 1986, BIOCHEM J, V240, P349, DOI 10.1042/bj2400349; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SAKAI K, 1981, J CARDIOVASC PHARM, V3, P420, DOI 10.1097/00005344-198105000-00002; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHANAHAN MF, 1987, J BIOL CHEM, V262, P5978; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P594, DOI 10.1016/0006-291X(84)91344-5; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; Steck T.L., 1974, METHODS MEMBRANE BIO, P245; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; TSE CM, 1985, BIOCHIM BIOPHYS ACTA, V818, P316, DOI 10.1016/0005-2736(85)90005-7; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; YOUNG JD, 1983, BIOSCIENCE REP, V3, P309, DOI 10.1007/BF01122895; YOUNG JD, 1989, BIOCHEM SOC T, V17, P444, DOI 10.1042/bst0170444	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22127	22134						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408072				2022-12-25	WOS:A1993MC80900102
J	SOTO, M; REQUENA, JM; GARCIA, M; GOMEZ, LC; NAVARRETE, I; ALONSO, C				SOTO, M; REQUENA, JM; GARCIA, M; GOMEZ, LC; NAVARRETE, I; ALONSO, C			GENOMIC ORGANIZATION AND EXPRESSION OF 2 INDEPENDENT GENE ARRAYS CODING FOR 2 ANTIGENIC ACIDIC RIBOSOMAL-PROTEINS OF LEISHMANIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; ESCHERICHIA-COLI; HEAT-SHOCK; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNAS; SULFOLOBUS-SOLFATARICUS; NUCLEOTIDE-SEQUENCE; DONOVANI-CHAGASI; FAMILY; CDNA	In the present paper we describe the isolation and characterization of four novel genes of the parasitic protozoan Leishmania infantum. These genes are organized as two independent gene clusters, and they are related by nucleotide sequence to eukaryotic genes encoding acidic ribosomal proteins. Each gene cluster contains two tandemly linked genes coding for identical proteins. Each of the proteins coded by the gene clusters (called LiP and LiP') are highly divergent in sequence, showing the characteristic features of eukaryotic P-proteins from the P2 group. In spite of the sequence conservation of the coding regions of each of the genes in the cluster, the 5'- and 3'-untranslated regions are heterogeneous in sequence. The analysis of the expression of these genes indicates that logarithmic phase promastigotes show increased levels of LiP- and LiP'-specific transcripts compared with stationary phase promastigotes. The steady state RNA levels of the LiP and LiP' genes show a similar dependence of the growth phase of the parasite. Using specific probes for the divergent 3'-untranslated regions of each of the genes, it was found that the abundance of the mature transcripts is different even when the transcripts are derived from the same gene cluster. These findings probably indicate that the 3'-untranslated regions may influence the stability or turnover of the transcripts derived from both LiP and LiP' gene clusters.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOLEC SEVERO OCHOA,CANTOBLANCO,E-28049 MADRID,SPAIN; UNIV EXTREMADURA,FAC VET,DEPT MED & SANIDAD ANIM,E-10071 CACERES,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Extremadura			Álvarez, Manuel Soto/Q-5234-2018; Requena, Jose M/I-2022-2019	Álvarez, Manuel Soto/0000-0001-6825-841X; Requena, Jose M/0000-0001-7550-0198; GOMEZ FERNANDEZ, LUIS/0000-0002-4346-4820; GARCIA ALONSO, MERCEDES/0000-0003-3416-1075				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BELTRAME M, 1990, MOL CELL BIOL, V10, P2341, DOI 10.1128/MCB.10.5.2341; CASIANO C, 1991, J BIOL CHEM, V266, P21578; CASIANO C, 1990, J BIOL CHEM, V265, P18757; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE PS, 1991, EXP PARASITOL, V73, P326, DOI 10.1016/0014-4894(91)90104-5; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; GENSKE JE, 1991, MOL CELL BIOL, V11, P240, DOI 10.1128/MCB.11.1.240; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V12, P3777; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; HYUNH TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAASSEN JA, 1985, EUR J BIOCHEM, V149, P609, DOI 10.1111/j.1432-1033.1985.tb08968.x; MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x; Maniatis T., 1982, MOL CLONING; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3575, DOI 10.1093/nar/16.8.3575; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Molyneux D.H., 1983, BIOL TRYPANOSOMA LEI; MOWATT MR, 1988, MOL CELL BIOL, V8, P4055, DOI 10.1128/MCB.8.10.4055; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; NAFZIGER DA, 1991, MOL BIOCHEM PARASIT, V49, P325, DOI 10.1016/0166-6851(91)90076-I; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NEWPORT G, 1988, PARASITOL TODAY, V4, P306, DOI 10.1016/0169-4758(88)90111-1; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; PATERAKI E, 1983, INFECT IMMUN, V42, P496, DOI 10.1128/IAI.42.2.496-500.1983; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; REMACHA M, 1988, J BIOL CHEM, V263, P9094; REQUENA JM, 1988, NUCLEIC ACIDS RES, V16, P1393, DOI 10.1093/nar/16.4.1393; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRA M, 1988, EMBO J, V7, P2895, DOI 10.1002/j.1460-2075.1988.tb03147.x; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOTO M, 1992, EUR J BIOCHEM, V205, P211, DOI 10.1111/j.1432-1033.1992.tb16770.x; SOTO M, 1991, NUCLEIC ACIDS RES, V19, P4554, DOI 10.1093/nar/19.16.4554; STEIN DA, 1990, NUCLEIC ACIDS RES, V18, P1549, DOI 10.1093/nar/18.6.1549; TERHORST C, 1972, EUR J BIOCHEM, V25, P13, DOI 10.1111/j.1432-1033.1972.tb01661.x; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2893, DOI 10.1093/nar/20.11.2893; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2599, DOI 10.1093/nar/20.10.2599; WIGBOLDUS JD, 1987, NUCLEIC ACIDS RES, V15, P10064, DOI 10.1093/nar/15.23.10064; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	54	47	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21835	21843						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408038				2022-12-25	WOS:A1993MC80900062
J	STANCATO, LF; CHOW, YH; HUTCHISON, KA; PERDEW, GH; JOVE, R; PRATT, WB				STANCATO, LF; CHOW, YH; HUTCHISON, KA; PERDEW, GH; JOVE, R; PRATT, WB			RAF EXISTS IN A NATIVE HETEROCOMPLEX WITH HSP90 AND P50 THAT CAN BE RECONSTITUTED IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ROUS-SARCOMA VIRUS; STEROID-RECEPTOR COMPLEXES; MOUSE GLUCOCORTICOID RECEPTORS; HAMSTER OVARY CELLS; PROGESTERONE-RECEPTOR; TRANSFORMING PROTEIN; POLYCLONAL ANTIBODY; BINDING DOMAIN; 90-KDA	Recently, we have demonstrated that the tyrosine kinase pp60v-src can undergo cell-free assembly into a heterocomplex with rabbit hsp90 and p50 when the immunoadsorbed protein is incubated with rabbit reticulocyte lysate (Hutchison, K. A., Brott, B. K., De Leon, J. H., Perdew, G. H., Jove, R., and Pratt, W. B. (1992) J. Biol. Chem. 267, 2902-2908). Using a baculovirus system to express a high level of human c-Raf serine/threonine kinase in Sf9 insect cells, we show here that immunoadsorbed c-Raf undergoes similar lysate-mediated assembly into a heterocomplex with hsp90 and p50. As with pp60v-src and steroid receptors, binding of c-Raf to hsp90 occurs in an ATP-dependent and K+-dependent manner and the resulting heterocomplex is stabilized by molybdate. With a very rapid and gentle procedure of Sf9 cell cytosol preparation and c-Raf immunoadsorption, we show coimmunoadsorption of the insect homologue of hsp90. The same procedures permit detection of a native complex of v-Raf with rat hsp90 and p50 in stably transfected rat 3Y1 fibroblasts, and v-Raf is also assembled into a heterocomplex with rabbit hsp90 and p50 by reticulocyte lysate. Using the 22W mutant of c-Raf in which the NH2-terminal half has been deleted, we show that the catalytic domain of the kinase is sufficient for both formation of the native heterocomplex in mouse NIH 3T3 cells and cell-free reconstitution of the heterocomplex by rabbit reticulocyte lysate. Although the native Raf-heat shock protein heterocomplex is less stable than native pp60v-src and glucocorticoid receptor heterocomplexes, by analogy with these proteins its detection may have important implications regarding the mechanism of Raf trafficking through the cytoplasm.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6322 MED SCI BLDG 1,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA28010, CA55652] Funding Source: Medline; NIEHS NIH HHS [ESO4869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010, R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANG D, 1991, J BIOL CHEM, V266, P24233; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; ERHART JC, 1988, ONCOGENE, V3, P595; FREZ H, 1991, J AM CHEM SOC, V113, P1409; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1992, J BIOL CHEM, V267, P1407; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PARK S, 1992, J BIOL CHEM, V267, P11612; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1988, J BIOL CHEM, V263, P267; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SEFTON BM, 1982, J VIROL, V44, P467, DOI 10.1128/JVI.44.2.467-474.1982; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YEM AW, 1992, J BIOL CHEM, V267, P2868	46	289	298	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21711	21716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408024				2022-12-25	WOS:A1993MC80900045
J	GUDI, T; GUPTA, CM				GUDI, T; GUPTA, CM			HSP 70-LIKE PROTEIN IN RHESUS ERYTHROCYTE CYTOSOL AND ITS INTERACTIONS WITH MEMBRANE SKELETON UNDER HEAT AND PATHOLOGICAL STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; PHOSPHOLIPID ORGANIZATION; STRUCTURAL TRANSITIONS; POLYACRYLAMIDE GELS; PLASMA-MEMBRANE; SPECTRIN; CELLS; INVOLVEMENT; BINDING	The rhesus erythrocytes were examined for the presence of protein(s) similar to the 70-kDa class of heat shock proteins (hsp 70). Also, interactions of these proteins with the erythrocyte membrane were studied under heat stress. These cells in their cytosol contained at least two proteins of about 70 kDa molecular mass; one of which closely resembled the hsp 70 family of proteins. This protein under normal conditions localized mainly in the cytosol, but it had a strong tendency to bind the membrane under heat stress. The binding was almost exclusively restricted to the membrane skeleton and seemed to involve primarily the hydrophobic interactions. A 70-kDa protein immunologically similar to the above protein(s) was detected also in the membranes of rhesus erythrocytes harboring the schizont stage of the simian malarial parasite Plasmodium knowlesi. From these results, we conclude that hsp 70-like proteins in the mature mammalian erythrocytes could perhaps play an important role in protecting the cells under stress by stabilizing the membrane skeleton through their interactions with skeletal proteins.	INST MICROBIAL TECHNOL,CHANDIGARH 160014,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)				Gupta, Dr.Chhitar M/0000-0002-7290-627X				AUJAME L, 1988, BIOCHEM CELL BIOL, V66, P691, DOI 10.1139/o88-079; BANERJI SS, 1987, GENE DEV, V1, P946, DOI 10.1101/gad.1.9.946; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; BURDON RH, 1988, ENDEAVOUR, V12, P133, DOI 10.1016/0160-9327(88)90134-2; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DAVIS JQ, 1986, J BIOL CHEM, V261, P5368; DAVIS JQ, 1985, J BIOL CHEM, V260, P4850; DI YP, 1992, J CELL BIOL, V115, pA350; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GUDI SRP, 1990, BIOCHIM BIOPHYS ACTA, V1023, P63, DOI 10.1016/0005-2736(90)90010-L; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HUBBARD BD, 1979, J CELL BIOL, V80, P166, DOI 10.1083/jcb.80.1.166; JOSHI P, 1987, BIOCHEM J, V246, P103, DOI 10.1042/bj2460103; KUMAR A, 1990, BIOCHIM BIOPHYS ACTA, V1030, P269, DOI 10.1016/0005-2736(90)90303-6; LEE WC, 1992, BRIT J CANCER, V66, P653, DOI 10.1038/bjc.1992.332; LIEM RK, 1989, J BIOL CHEM, V264, P15210; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LYSKO KA, 1981, BIOCHEMISTRY-US, V20, P5570, DOI 10.1021/bi00522a034; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MELBY EC, 1976, HDB LABORATORY ANIMA, V3, P23; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; TOMASOVIC SP, 1989, INT J HYPERTHER, V5, P173, DOI 10.3109/02656738909140446; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WELLER NK, 1988, BIOL CELL, V63, P307, DOI 10.1016/0248-4900(88)90121-9; YOSHINO H, 1987, BIOCHIM BIOPHYS ACTA, V905, P100, DOI 10.1016/0005-2736(87)90013-7	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21344	21350						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407973				2022-12-25	WOS:A1993MA28800101
J	JAULT, JM; DIVITA, G; ALLISON, WS; DIPIETRO, A				JAULT, JM; DIVITA, G; ALLISON, WS; DIPIETRO, A			GLUTAMINE-170 TO TYROSINE SUBSTITUTION IN YEAST MITOCHONDRIAL-F(1) BETA-SUBUNIT INCREASES CATALYTIC SITE INTERACTION WITH GDP AND IDP AND PRODUCES NEGATIVE COOPERATIVITY OF GTP AND ITP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE BINDING-SITES; SCHIZOSACCHAROMYCES-POMBE; ADENOSINE-TRIPHOSPHATASE; NONCATALYTIC SITES; ESCHERICHIA-COLI; ALPHA-SUBUNITS; ATP SYNTHASE; RAT-LIVER; CONFORMATIONAL-CHANGES; HYSTERETIC BEHAVIOR	Glutamine 170 to tyrosine mutation in the beta-subunit from Schizosaccharomyces pombe mitochondrial F1 was found to increase both affinity for ADP, apparent negative cooperativity of ATPase activity, and sensitivity to azide inhibition (Falson, P., Di Pietro, A., Jault, J.-M., Gautheron, D. C., and Boutry, M. (1989) Biochim. Biophys. Acta 975, 119-126). The mutation is shown here to increase the affinity for GDP, IDP, and guanosine 5'-(beta,gamma-imidotriphosphate), which are competitive inhibitors of GTPase and ITPase activities. Various fluorescence approaches also reveal an increased affinity of the catalytic site in mutant as compared with wild-type enzyme for GDP, IDP, and 2'(3')-N-methylanthraniloyl GDP. The mutation alters the maximal rates and pH dependence of GTPase and ITPase activities, whereas wild-type F1 exhibits single optima at pH 7.5-8.0. The pH activity profiles of the mutant enzyme for these substrates are biphasic, with optima at pH 8.5-9.0 and below 6.5. The mutation increases the sensitivity of GTPase and ITPase activities to azide inhibition, which increases with decreasing pH. At pH 6.0-7.0, an apparent negative cooperativity is observed when mutant F1 hydrolyzes GTP or ITP, whereas the wild-type enzyme shows Michaelian kinetics. Addition of bicarbonate at pH 7.0 substantially stimulates GTP or ITP hydrolysis and abolishes the apparent negative cooperativity by the mutant enzyme; on the contrary, the anion produces a slight inhibition of these activities catalyzed by wild-type F1. The overall results suggest that apparent negative cooperativity can be observed with GTP or ITP hydrolysis provided that the release of the respective diphosphate is a rate-limiting step.	UNIV CLAUDE BERNARD LYON 1, INST BIOL & CHIM PROT,CNRS,UPR 412, 7 PASSAGE VERCORS, F-69367 LYON 07, FRANCE; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; MAX PLANCK INST MED RES, BIOPHYS ABT, W-6900 HEIDELBERG 1, GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of California System; University of California San Diego; Max Planck Society			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777	NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1989, BIOCHIMIE, V71, P931, DOI 10.1016/0300-9084(89)90075-8; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIPIETRO A, 1988, BIOCHEM BIOPH RES CO, V152, P1319, DOI 10.1016/S0006-291X(88)80429-7; DIVITA G, 1991, BIOCHEMISTRY-US, V30, P3256, DOI 10.1021/bi00227a013; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P1017, DOI 10.1021/bi00055a004; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; EBEL RE, 1975, J BIOL CHEM, V250, P191; FALSON P, 1989, BIOCHIM BIOPHYS ACTA, V975, P119, DOI 10.1016/S0005-2728(89)80209-9; FALSON P, 1987, BIOCHEM BIOPH RES CO, V148, P1182, DOI 10.1016/S0006-291X(87)80257-7; FALSON P, 1986, J BIOL CHEM, V261, P7151; FALSON P, 1991, EUR J BIOCHEM, V200, P61, DOI 10.1111/j.1432-1033.1991.tb21048.x; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GODINOT C, 1981, BIOCHEM INT, V2, P595; GROMETELHANAN Z, 1992, J BIOENERG BIOMEMBR, V24, P447, DOI 10.1007/BF00762361; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1981, BIOCHIM BIOPHYS ACTA, V635, P412, DOI 10.1016/0005-2728(81)90039-6; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; JAULT JM, 1991, J BIOL CHEM, V266, P8073; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6958; KASHO VN, 1984, J BIOENERG BIOMEMBR, V16, P407, DOI 10.1007/BF00743235; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MULLER DM, 1989, J BIOL CHEM, V264, P16552; PEDERSEN PL, 1976, J BIOL CHEM, V251, P934; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RECKTENWALD D, 1977, FEBS LETT, V76, P25, DOI 10.1016/0014-5793(77)80113-0; ROUX B, 1984, BIOCHEMISTRY-US, V23, P534, DOI 10.1021/bi00298a021; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SCHUSTER SM, 1976, J BIOL CHEM, V251, P6705; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUTTERHEIM E, 1980, BIOCHIM BIOPHYS ACTA, V592, P415, DOI 10.1016/0005-2728(80)90089-4; THOMAS PJ, 1992, J BIOL CHEM, V267, P20331; VERBURG JG, 1990, J BIOL CHEM, V265, P8065; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	52	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20762	20767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407901				2022-12-25	WOS:A1993MA28800020
J	KU, DH; WEN, SC; ENGELHARD, A; NICOLAIDES, NC; LIPSON, KE; MARINO, TA; CALABRETTA, B				KU, DH; WEN, SC; ENGELHARD, A; NICOLAIDES, NC; LIPSON, KE; MARINO, TA; CALABRETTA, B			C-MYB TRANSACTIVATES CDC2 EXPRESSION VIA MYB BINDING-SITES IN THE 5'-FLANKING REGION OF THE HUMAN CDC2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; AVIAN-MYELOBLASTOSIS VIRUS; HUMAN LYMPHOCYTES-T; ONCOGENE PRODUCT; DNA-REPLICATION; PROTEIN; SEQUENCE; RNA; DIFFERENTIATION; PROTOONCOGENE	The c-myb protooncogene is preferentially expressed in hematopoietic cells and is required for cell cycle progression at the G1/S boundary. Because c-myb encodes a transcriptional activator that functions via DNA binding, it is likely that c-myb exerts its biological activity by regulating the transcription of genes required for DNA synthesis and cell cycle progression. One such gene, cdc2, encodes a 34-kDa serine-threonine kinase that appears to be required for G1/S transition in normal human T-lymphocytes. To determine whether c-myb is a transcriptional regulator of cdc2 expression, we subcloned a segment of a cdc2 human genomic clone containing extensive 5'-flanking sequences and part of the first exon. Sequence analysis revealed the presence of two closely spaced Myb binding sites that interact with bacterially synthesized Myb protein within a region extending from nucleotides -410 to -392 upstream of the transcription initiation site. A 465-base pair segment of 5'-flanking sequence containing these sites was linked to the CAT gene and had promoter activity in rodent fibroblasts. Cotransfection of this construct with a full-length human c-myb cDNA driven by the early simian virus 40 promoter resulted in a 6-8-fold enhancement of CAT activity that was abrogated by mutations in the Myb binding sites. These data suggest that c-myb participates in the regulation of cell cycle progression by activating the expression of the cdc2 gene.	THOMAS JEFFERSON UNIV,DEPT MICROBIOL,BLUEMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; CONNECT TISSUE RES INST,PHILADELPHIA,PA; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Lipson, Kenneth/0000-0001-8847-6051	NATIONAL CANCER INSTITUTE [T32CA009678, T32CA009644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044836] Funding Source: NIH RePORTER; NCI NIH HHS [1T32CA09678, CA 09644] Funding Source: Medline; NIDDK NIH HHS [DK44836] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HUTTNER KM, 1981, J CELL BIOL, V91, P153, DOI 10.1083/jcb.91.1.153; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TORELLI G, 1987, CANCER RES, V47, P5266; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	126	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2255	2259						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420994				2022-12-25	WOS:A1993KH62000113
J	OZAWA, K; SZALLASI, Z; KAZANIETZ, MG; BLUMBERG, PM; MISCHAK, H; MUSHINSKI, JF; BEAVEN, MA				OZAWA, K; SZALLASI, Z; KAZANIETZ, MG; BLUMBERG, PM; MISCHAK, H; MUSHINSKI, JF; BEAVEN, MA			CA2+-DEPENDENT AND CA2+-INDEPENDENT ISOZYMES OF PROTEIN-KINASE-C MEDIATE EXOCYTOSIS IN ANTIGEN-STIMULATED RAT BASOPHILIC RBL-2H3 CELLS - RECONSTITUTION OF SECRETORY RESPONSES WITH CA2+ AND PURIFIED ISOZYMES IN WASHED PERMEABILIZED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; DIFFERENTIAL DOWN-REGULATION; 2H3 CELLS; HISTAMINE-RELEASE; LEUKEMIA-CELLS; CALCIUM SIGNAL; IGE RECEPTORS; CALPHOSTIN-C; MAST-CELLS; FAMILY	Rat basophilic RBL-2H3 cells, which exhibit Ca2+-dependent secretion of granules when stimulated with antigen, contained the Ca2+-dependent alpha and beta and the Ca2+-independent delta, epsilon, and zeta isoforms of protein kinase C. These isoforms associated, to variable extents (i.e. delta the most and zeta the least), with the membrane fraction upon antigen stimulation but without external Ca2+; only the Ca2+-independent isoforms did so. Both types of isozymes were probably necessary for optimal responses to antigen as indicated by the following observations. All Ca2+-dependent isozymes were degraded in cells treated with 20 nM phorbol 12-myristate 13-acetate for 6 h, whereas the Ca2+-independent isozymes were not degraded and were retained when the cells were subsequently permeabilized and washed. Cells so treated still exhibited antigen-induced secretion (25-33% of normal) which was suppressed by selective inhibitors of protein kinase C (Ro31-7549 and calphostin C) thereby indicating a possible contribution of the Ca2+-independent isozymes in secretion. Normally, washed permeabilized cells lost all isozymes of protein kinase C and failed to secrete in response to antigen. A full secretory response to antigen could be reconstituted by the subsequent addition of nanomolar concentrations of either beta or delta isozymes of protein kinase C (other isozymes were much less effective) but only in the presence of 1 muM free Ca2+ to indicate distinct roles for Ca2+ and protein kinase C in exocytosis.	NHLBI, CHEM PHARMACOL LAB, BETHESDA, MD 20892 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA; NCI, GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Szallasi, Zoltan/0000-0001-5395-7509; Mischak, Harald/0000-0003-0323-0306				ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P351, DOI 10.1016/S0006-291X(05)81064-2; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEMAN E, 1992, NATURE, V355, P78; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG K-P, 1990, Biofactors, V2, P171; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; ISHIZUKA T, 1992, BIOCHEM BIOPH RES CO, V183, P814, DOI 10.1016/0006-291X(92)90556-Z; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; NAOR Z, 1989, P NATL ACAD SCI USA, V86, P4501, DOI 10.1073/pnas.86.12.4501; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; OSADA S, 1990, J BIOL CHEM, V265, P22434; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SAHARA S, 1992, BIOCHEM BIOPH RES CO, V182, P105, DOI 10.1016/S0006-291X(05)80118-4; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; WHITE KN, 1988, J IMMUNOL, V141, P942; YAMADA K, 1992, J IMMUNOL, V149, P1031	36	395	398	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1749	1756						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420951				2022-12-25	WOS:A1993KH62000039
J	AVVAKUMOV, GV; WARMELSRODENHISER, S; HAMMOND, GL				AVVAKUMOV, GV; WARMELSRODENHISER, S; HAMMOND, GL			GLYCOSYLATION OF HUMAN CORTICOSTEROID-BINDING GLOBULIN AT ASPARGINE-238 IS NECESSARY FOR STEROID BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSCORTIN; CARBOHYDRATE MOIETY; PROTEINS; GLYCOPROTEIN; VARIANTS; CORTISOL; GLYCOPEPTIDES; INHIBITORS; EXPRESSION; MEMBRANES	Human corticosteroid binding-globulin (CBG) is a plasma glycoprotein that binds and regulates the biological activity of glucocorticoids and progesterone. Carbohydrates comprise approximately 25% of its molecular mass being represented by bi- and triantennary N-linked oligosaccharides of the N-acetyllactosamine type. To assess the impact of these carbohydrate chains on CBG production and steroid binding, we mutated a human CBG cDNA so that the six consensus sites for N-glycosylation in the CBG polypeptide were eliminated individually and in various combinations. Expression of the mutant cDNAs in Chinese hamster ovary cells showed that all consensus sites may be utilized during the CBG biosynthesis and that the immunochemical properties of the recombinant glycoproteins are similar to those of CBG isolated from human serum. Removal of sugar chains generally led to a reduction in the secretion of recombinant CBG, but complete removal of N-glycosylation sites did not prevent production or secretion of the protein. Our data indicate that an oligosaccharide linked to Asn238 is essential for steroid binding, and we suggest that an interaction between this sugar chain and the polypeptide may be essential for the creation of a high affinity steroid-binding site. In addition, concanavalin A chromatography of mutants containing only one N-glycosylation site at either Asn74 or Asn238 indicated that processing of the oligosaccharides at these positions is site-specific.	UNIV WESTERN ONTARIO,DEPT OBSTET & GYNECOL,LONDON N6A 4L6,ON,CANADA; UNIV WESTERN ONTARIO,MRC,FETAL & NEONATAL HLTH & DEV GRP,LONDON N6A 4L6,ON,CANADA; UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 4L6,ON,CANADA; UNIV WESTERN ONTARIO,DEPT ONCOL,LONDON N6A 4L6,ON,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)				Hammond, Geoffrey/0000-0002-4639-7336				AKHREM AA, 1981, BIOORG KHIM+, V7, P662; AKHREM AA, 1982, BIOCHIM BIOPHYS ACTA, V714, P177, DOI 10.1016/0304-4165(82)90142-8; AVVAKUMOV GV, 1988, BIOCHIM BIOPHYS ACTA, V938, P1, DOI 10.1016/0005-2736(88)90115-0; AVVAKUMOV GV, 1991, LECTINS CANCER, P263; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BOCCHINFUSO WP, 1991, MOL ENDOCRINOL, V5, P1723, DOI 10.1210/mend-5-11-1723; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOLTON NJ, 1981, J ENDOCRINOL, V90, P125, DOI 10.1677/joe.0.0900125; CARVER JP, 1987, PURE APPL CHEM, V59, P1465, DOI 10.1351/pac198759111465; CHEN WY, 1991, J BIOL CHEM, V266, P8192; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GHOSEDASTIDAR J, 1991, P NATL ACAD SCI USA, V88, P6408, DOI 10.1073/pnas.88.15.6408; HAMMOND GL, 1990, J CLIN ENDOCR METAB, V71, P34, DOI 10.1210/jcem-71-1-34; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; HAMMOND GL, 1991, J STEROID BIOCHEM, V40, P755, DOI 10.1016/0960-0760(91)90300-T; HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65; HOSSNER KL, 1981, ENDOCRINOLOGY, V108, P1780, DOI 10.1210/endo-108-5-1780; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICKELSON KE, 1982, BIOCHEMISTRY-US, V21, P654, DOI 10.1021/bi00533a010; NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; ROBINSON PA, 1985, J ENDOCRINOL, V104, P269, DOI 10.1677/joe.0.1040269; ROSNER W, 1990, ENDOCR REV, V11, P80, DOI 10.1210/edrv-11-1-80; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH CL, 1992, J STEROID BIOCHEM, V42, P671, DOI 10.1016/0960-0760(92)90107-T; STRELCHYONOK OA, 1984, CARBOHYD RES, V134, P133, DOI 10.1016/0008-6215(84)85028-4; STRELCHYONOK OA, 1982, BIOCHIM BIOPHYS ACTA, V705, P167, DOI 10.1016/0167-4838(82)90175-3; STRELCHYONOK OA, 1983, BIOCHIM BIOPHYS ACTA, V755, P514, DOI 10.1016/0304-4165(83)90257-X; STRELCHYONOK OA, 1991, J STEROID BIOCHEM, V40, P795, DOI 10.1016/0960-0760(91)90305-O; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TREUHEIT MJ, 1992, BIOCHEM J, V283, P105, DOI 10.1042/bj2830105; WINTERBURN PJ, 1972, NATURE, V236, P147, DOI 10.1038/236147a0	36	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					862	866						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419363				2022-12-25	WOS:A1993KG07700019
J	SALIH, E; HOWARD, S; CHISHTI, SB; COHEN, SG; LIU, WS; COHEN, JB				SALIH, E; HOWARD, S; CHISHTI, SB; COHEN, SG; LIU, WS; COHEN, JB			LABELING OF CYSTEINE-231 IN ACETYLCHOLINESTERASE FROM TORPEDO-NOBILIANA BY THE ACTIVE-SITE DIRECTED REAGENT, 1-BROMO-2-[C-14] PINACOLONE - EFFECTS OF 2,2'-DIPYRIDYL DISULFIDE AND OTHER SULFHYDRYL-REAGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM CHOLINESTERASE; AMINO-ACID SEQUENCE; REVERSIBLE INHIBITORS; ANIONIC SUBSITES; TRIMETHYL; CALIFORNICA; HYDROLYSIS; PROTEIN; BINDING; PURIFICATION	Acetylcholinesterase (AcChE, EC 3.1.1.7) was isolated from the electric organ of T. nobiliana and treated with the active-site- directed alkylating agent 1-bromo-2-[C-14]pinacolone ([C-14]BrPin), or with BrPin, which acts initially as a competitive inhibitor, K(i) = 0.18 mm, and then inactivates the enzyme, k2 = 1.8 x 10(-4) s-1. AcChE aliquots were digested with trypsin and fractionated by reversed phase high performance liquid chromatography. Inactivation caused a decrease in one absorption peak and an increase in another, identified as the peptide beginning at Ala-222 and extending to Arg-242. 5-Trimethylammonio-2-pentanone, a competitive inhibitor, isosteric with acetylcholine, retarded the inactivation and decreased the quantity of labeled peptide. On sequencing, the C-14 label was found associated with Cys-231. This was confirmed by comparison with synthesized S-pinacolonylcysteine, by study of effects of blocking the sequencing by o-phthalaldehyde, and by inactivation by 2,2'-dipyridyl disulfide (2-PDS), a thiol-specific reagent that acts initially as a competitive inhibitor, K(i) = 0.042 mM, and then inactivates the enzyme, k2 = 5.0 x 10(-4) s-1. This is retarded by 5-trimethylammonio-2-pentanone, and prior inactivation by 2-PDS prevents subsequent reaction of [C-14]BrPin in the active site. BrPin inactivates AcChEs from Electrophorus electricus and from human erythrocyte, but 2-PDS does not. Neither reagent inactivates butyrylcholinesterases from human and horse serum.	BRANDEIS UNIV, DEPT CHEM, WALTHAM, MA 02254 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Brandeis University; Washington University (WUSTL)				Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022828, R01NS019522] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22828, NS 19522] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], ENZYMES 3E; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; BILO J, 1990, NUCLEIC ACIDS RES, V18, P3990; BON S, 1986, FEBS LETT, V209, P206, DOI 10.1016/0014-5793(86)81112-7; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; CHHAJLANI V, 1989, FEBS LETT, V247, P279, DOI 10.1016/0014-5793(89)81352-3; COHEN SG, 1987, BIOORG CHEM, V15, P237, DOI 10.1016/0045-2068(87)90022-8; COHEN SG, 1989, BIOCHIM BIOPHYS ACTA, V997, P167, DOI 10.1016/0167-4838(89)90182-9; COHEN SG, 1984, J MED CHEM, V27, P1643, DOI 10.1021/jm00378a020; COHEN SG, 1982, J BIOL CHEM, V257, P4087; COHEN SG, 1991, BIOCHIM BIOPHYS ACTA, V1076, P112, DOI 10.1016/0167-4838(91)90227-Q; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HASAN FB, 1981, J BIOL CHEM, V256, P7781; HASAN FB, 1980, J BIOL CHEM, V255, P3898; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROSENBERRY TL, 1971, BIOCHEMISTRY-US, V10, P4114, DOI 10.1021/bi00798a016; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; STEINBERG N, 1990, BIOCHEM INT, V21, P1043; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TAYLOR P, 1974, MOL PHARMACOL, V10, P78; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	36	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					245	251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416933				2022-12-25	WOS:A1993KE60300039
J	SHORNICK, LP; HOLTZMAN, MJ				SHORNICK, LP; HOLTZMAN, MJ			A CRYPTIC, MICROSOMAL-TYPE ARACHIDONATE 12-LIPOXYGENASE IS TONICALLY INACTIVATED BY OXIDATION-REDUCTION CONDITIONS IN CULTURED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE LEUKOCYTES; GLUTATHIONE; ACID; LIPOXYGENASE; OXYGENATION; IDENTIFICATION; METABOLITES; INHIBITION; PLATELETS; DISTINCT	Cultured ovine tracheal epithelial cells converted arachidonic acid to prostaglandin E2 (PGE2), but microsome-containing subcellular fractions prepared from these cells under calcium-free conditions converted arachidonic acid to PGE2 and to 12-hydroxyeicosatetraenoic acid (12-HETE) at a high rate (2-4 nmol/mg of protein/15 min). Identification of the membrane-bound 12-HETE-forming activity as a 12-lipoxygenase included 12S-stereospecificity of product formation and trapping of 12-hydroperoxyeicosatetraenoic acid as a reaction product. The 12-lipoxygenase activity was extracted from cell membranes only with detergent (1% Triton X-100), and the activity (membrane-bound or detergent-solubilized) was completely inactivated by mixing with the cytosol-containing subcellular fraction. The inhibitory effect of the cytosolic fraction was reversed by treating the cytosol with GSH-depleting agents (2-cyclohexene-1-one or N-ethylmaleimide) or by mixing it with lipid hydroperoxide (13-hydroperoxyoctadecadienoic acid) at a concentration that had little direct effect on enzyme activity. Inhibition of 12-lipoxygenase activity could also be achieved by treatment of enzyme preparations with GSH at levels (0.1-10 mM) found in epithelial cell cytosol. In addition, treatment of cultured epithelial cells with a GSH-depleting agent (buthionine sulfoximine) and lipid hydroperoxide restored cellular 12-lipoxygenase activity. Little or no detectable 12-lipoxygenase activity was found in freshly isolated ovine tracheal epithelial cells, but the cytosolic 12-lipoxygenase found in freshly isolated bovine tracheal epithelial cells was relatively insensitive to regulation by GSH or lipid hydroperoxide. These observations indicate that a 12-lipoxygenase is expressed in a cryptic, microsomal-type form in primary-culture epithelial cells and that this form of the enzyme may be selectively regulated by changes in cellular oxidation-reduction conditions dependent on cytosolic levels of GSH versus lipid hydroperoxide.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,660 S EUCLID AVE,BOX 8052,ST LOUIS,MO 63110	Washington University (WUSTL)				Shornick, Laurie/0000-0001-6652-1878	NHLBI NIH HHS [HL-40078] Funding Source: Medline; NIDDK NIH HHS [DK-38111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABA A, 1989, J BIOL CHEM, V264, P15790; BROWN LAS, 1992, AM J PHYSIOL, V262, pL305, DOI 10.1152/ajplung.1992.262.3.L305; CHANG WC, 1992, J BIOL CHEM, V267, P3657; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAMBERG M, 1980, BIOCHEM BIOPH RES CO, V95, P1090, DOI 10.1016/0006-291X(80)91584-3; HANSBROUGH JR, 1989, AM J RESP CELL MOL, V1, P237, DOI 10.1165/ajrcmb/1.3.237; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; HOLTZMAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V963, P401, DOI 10.1016/0005-2760(88)90308-6; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; HOLTZMAN MJ, 1991, AIRWAY EPITHELIUM PH, P55; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; JONES GS, 1982, J APPL PHYSIOL, V53, P258, DOI 10.1152/jappl.1982.53.1.258; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LIANG CM, 1989, J BIOL CHEM, V264, P13519; MEISTER A, 1988, J BIOL CHEM, V263, P17205; NADLER JL, 1987, J CLIN INVEST, V80, P1763, DOI 10.1172/JCI113269; PENTLAND AP, 1990, J CLIN INVEST; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SHANNON VR, 1991, AM J PHYSIOL, V261, pL399, DOI 10.1152/ajplung.1991.261.6.L399; SHANNON VR, 1992, IN PRESS AM J PHYSL, V263; SHANNON VR, 1993, IN PRESS AM REV RESP, V147; SHANNON VR, 1993, IN PRESS AM J PHYSL, V264; STENSON WF, 1983, AM J PHYSIOL, V244, pG273, DOI 10.1152/ajpgi.1983.244.3.G273; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UEDA N, 1990, J BIOL CHEM, V265, P2311; WEDNER HJ, 1981, J CLIN INVEST, V68, P535, DOI 10.1172/JCI110285; WU R, 1986, IN VITRO MODELS RESP, P1; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	39	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					371	376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416945				2022-12-25	WOS:A1993KE60300057
J	ELWOOD, NJ; COOK, WD; METCALF, D; BEGLEY, CG				ELWOOD, NJ; COOK, WD; METCALF, D; BEGLEY, CG			SCL, THE GENE IMPLICATED IN HUMAN T-CELL LEUKEMIA, IS ONCOGENIC IN A MURINE T-LYMPHOCYTE CELL-LINE	ONCOGENE			English	Article							ABELSON LEUKEMIA-VIRUS; DNA-BINDING MOTIF; LOOP-HELIX GENES; C-MYC; ERYTHROID-DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; TRANSGENIC MICE; BALB/C MICE; TAL-1 GENE; EXPRESSION	SCL (TAL-1) is implicated in the generation of human T-cell acute lymphoblastic leukaemia. To directly examine the role of this putative oncogene, an SCL retrovirus was constructed and used to infect a v-ABL transformed T-lymphocyte cell line. Thirteen independent SCL-infected and four control cell lines were established and injected subcutaneously into syngeneic mice. Mice injected with SCL-infected clonal cell lines died significantly more rapidly than control animals. By day 200 46% (40/87) of animals injected with SCL-infected cell lines had died due to disseminated transplantable lymphoid tumours. In contrast only 22% of control mice were dead by day 200 (P < 0.0015). Of possible relevance to the enhanced tumourigenesis, some SCL-infected cell lines displayed increased clonogenicity in agar. Increased cell growth was even more striking when ex-vivo tumour-derived cell lines were studied. Thus, SCL can co-operate with v-ABL to hasten T-cell tumourigenesis. This is the first direct evidence demonstrating that SCL can behave as an oncogene.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT SURG,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIAGNOST HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital				Elwood, Ngaire/0000-0002-4740-2416				ABELSON HT, 1970, CANCER RES, V30, P2208; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BOWTELL DDL, 1987, MOL BIOL MED, V4, P229; BOYD AW, 1989, BLOOD, V73, P1896; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1858; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELWOOD NJ, 1991, TODAYS LIFE SCI, V3, P16; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Hariharan I K, 1988, Oncogene Res, V3, P387; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HAUPT Y, 1992, ONCOGENE, V7, P981; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MENDOZA GR, 1976, J IMMUNOL, V117, P1573; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAUMOVSKI L, 1992, BLOOD S1, V80, pA301; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; TANIGAWA T, 1993, IN PRESS P NATL ACAD; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	56	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3093	3101						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414511				2022-12-25	WOS:A1993MC09300026
J	TARUNINA, M; JENKINS, JR				TARUNINA, M; JENKINS, JR			HUMAN P53 BINDS DNA AS A PROTEIN HOMODIMER BUT MONOMERIC VARIANTS RETAIN FULL TRANSCRIPTION TRANSACTIVATION ACTIVITY	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; T-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; ONCOGENE PRODUCT; GENE; SEQUENCE; AMPLIFICATION	Wild-type human p53 protein is able to self-associate and consists predominantly of homotetramers in solution. In earlier work we identified the protein sequence motifs involved in p53 quaternary structure and showed that while monomeric p53 protein retains tumour suppressor function, monomeric tumour mutant p53 lacks dominant transforming activity. In this report we use point mutated and truncated cDNA genes encoding self-association defective human p53 proteins to investigate the relationship between p53 protein quaternary structure and the associated activities of transcription transactivation and target specific DNA binding. We show that p53 binds to a target oligonucleotide as a protein homodimer and that p53 dimerisation is required for detectable DNA binding. We found no evidence for p53 tetramer:DNA complexes and we suggest that the quaternary structure status of p53 may regulate a DNA binding associated activity. Monomeric p53 proteins failed to bind DNA in these assays but exhibited increased transactivating activity. Thus, both transcription transactivation and tumour suppressor functions act independently of p53 protein self-association and DNA binding. We propose that our results validate the p53 dimerisation motif as a target for rational anticancer drug design. We predict that compounds able to block p53 dimer assembly would inhibit the dominant transforming activities of mutant p53 in tumours retaining expression of a mutant allele, while leaving intact the wild-type p53 associated activities of transcription transactivation and transformation suppression in unaffected tissue.	MARIE CURIE RES INST, CELL PROLIFERAT LAB, OXTED RH8 0TL, SURREY, ENGLAND									ADDISON C, 1990, ONCOGENE, V5, P423; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BRAIN R, 1993, UNPUB; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUMAKOV P, 1990, J CELL BIOCH S14C, V106, P269; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAVID YB, 1988, ONCOGENE, V3, P179; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUBERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMEIG F, 1988, VIROLOGY, V194, P132; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	59	101	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3165	3173						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414520				2022-12-25	WOS:A1993MC09300035
J	LEE, SK; NESHEIM, JC; LIPSCOMB, JD				LEE, SK; NESHEIM, JC; LIPSCOMB, JD			TRANSIENT INTERMEDIATES OF THE METHANE MONOOXYGENASE CATALYTIC CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; METHYLOCOCCUS-CAPSULATUS BATH; HYDROXYLASE COMPONENT; RIBONUCLEOTIDE REDUCTASE; RADICAL INTERMEDIATE; IRON CLUSTER; OXO; OXIDATION; CYTOCHROME-P-450; HYDROCARBONS	Three new intermediates of the catalytic cycle of the soluble form of methane monooxygenase (MMO) isolated from Methylosinus trichosporium OB3b have been detected using transient kinetic techniques. MMO consists of hydroxylase (MMOH), reductase, and ''B'' (MMOB) components. MMOH contains an oxygen-bridged [Fe(III).Fe(III)] cluster that catalyzes O2 activation and insertion chemistry. At 4-degrees-C, rapid mixing of O2 with diferrous MMOH ([Fe(II).Fe(II)]) in the presence of a 2-fold excess of MMOB resulted in loss of the g = 16 EPR signal characteristic of the diferrous cluster at an apparent first order rate of 22 +/- 5 s-1 (O2 almost-equal-to 700 muM). Subsequently, an EPR silent, chromophoric (lambda(max) = 330 and 430 nm, epsilon almost-equal-to 7500 M-1 cm-1 at each wavelength) intermediate (compound Q) formed with an average first order rate constant of 1 +/- 0.1 s-1 and then decayed at 0.05 +/- 0.01 s-1. Since compound Q formed much more slowly than diferrous MMOH disappeared, at least one other undetected intermediate (compound P) must have formed before compound Q. MMO substrates had little or no effect on the formation rate of compound Q, but they caused the decay rate to increase linearly with the concentration added. The substrates methane, furan, and nitrobenzene caused compound Q decay to occur with second order rate constants of 19,000 M-1 s-1, 9000 M-1 s-1, and 200 M-1 s-1 (+/- 5%), respectively. When nitrobenzene was used as a substrate, a second chromophoric intermediate (compound T, lambda(max) = 325 nm, with a shoulder at 395 nm, epsilon395 almost-equal-to 6000 M-1 cm-1) formed at the same rate as compound Q decay. Chemical quench studies showed that compound T is an enzyme-product complex that decays with a rate constant of 0.02 +/- 0.005 s-1. This rate is approximately the same as k(cat) for nitrobenzene turnover at 4-degrees-C catalyzed by the reconstituted MMO system, suggesting that product release is the rate-limiting step in catalysis. The characteristics of compound Q suggest that it may be the activated form of the enzyme that directly catalyzes substrate oxidation.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,4-225 MILLARD HALL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [R01 GM040466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCOCK NW, 1970, T FARADAY SOC, V66, P2210, DOI 10.1039/tf9706602210; ANDERSSON KK, 1991, NEW J CHEM, V15, P411; Anthony C., 1982, BIOCH METHYLOTROPHS; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; Dalton H., 1993, P65; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DONG YH, 1993, J AM CHEM SOC, V115, P1851, DOI 10.1021/ja00058a033; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GREEN J, 1989, BIOCHEM J, V259, P167, DOI 10.1042/bj2590167; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LEISING RA, 1990, INORG CHEM, V29, P2553, DOI 10.1021/ic00339a003; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; PRIESTLEY ND, 1992, J AM CHEM SOC, V114, P7561, DOI 10.1021/ja00045a037; RATAJ MJ, 1991, J BIOL CHEM, V266, P18684; REEM RC, 1989, J AM CHEM SOC, V111, P4688, DOI 10.1021/ja00195a024; RUZICKA F, 1990, BIOCHEMISTRY-US, V29, P1696, DOI 10.1021/bi00459a005; SANDERSLOEHR J, 1989, J AM CHEM SOC, V111, P8084, DOI 10.1021/ja00203a003; SEGEL IH, 1975, ENZYME KINETICS, P544; SWINBOURNE ES, 1971, ANAL KINETIC DATA, P90; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4476; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6	34	322	324	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21569	21577						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408008				2022-12-25	WOS:A1993MC80900024
J	MORII, M; TAKEGUCHI, N				MORII, M; TAKEGUCHI, N			DIFFERENT BIOCHEMICAL-MODES OF ACTION OF 2 IRREVERSIBLE H+,K+-ATPASE INHIBITORS, OMEPRAZOLE AND E3810	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED GASTRIC VESICLES; AMINO-ACID-SEQUENCE; (H+ + K+)-ATPASE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; CATALYTIC CYCLE; FLUORESCEIN ISOTHIOCYANATE; LABELED PEPTIDE; K+-SITE	Omeprazole and E3810 were found to inhibit gastric H+,K+-ATPase following different biochemical mechanisms. Effects of the specific binding of the inhibitors on the conformational state of the enzyme were studied by measuring the fluorescence of the enzyme labeled with fluorescein 5'-isothiocyanate. The absolute fluorescence level of the omeprazole-bound enzyme was lower than that of the control enzyme, and reduction of S-S cross-linking between the enzyme and omeprazole increased the fluorescence. Addition of K+ into the control vesicle solution quenched the fluorescence (E1 --> E2K+). The quench was inhibited in the omeprazole-bound enzyme but not in the E3810-bound enzyme. These results suggest that the omeprazole-bound enzyme has a low fluorescence conformation (E2 form). On the other hand, the conformation of the E3810-bound enzyme was the same as that of the control enzyme (E1 form). Phosphoenzyme formation in the absence of K+ was inhibited in both the E3810- and omeprazole-bound enzymes. Binding of 2',3'-o-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate to the enzyme was equally inhibited by E3810 and omeprazole. K+-dependent dephosphorylation from the phosphoenzyme was inhibited in the E3810-bound enzyme but not in the omeprazole-bound enzyme. These experimental results have shown that the inhibition mechanism of H+,K+-ATPase by omeprazole was different from that by E3810; the partial reaction that was the most differently affected by the inhibitors was the conformational change from the E2 to E1 form for omeprazole and the luminal K+-dependent dephosphorylation for E3810.			MORII, M (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,2630 SUGITANI,TOYAMA 93001,JAPAN.							ASANO S, 1990, J BIOL CHEM, V265, P22167; ASANO S, 1987, J BIOL CHEM, V262, P13263; ASANO S, 1992, J BIOL CHEM, V267, P6590; BEIL W, 1986, BRIT J PHARMACOL, V88, P19, DOI 10.1111/j.1476-5381.1986.tb09466.x; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FRYKLUND J, 1988, BIOCHEM PHARMACOL, V37, P254; FUJISAKI H, 1991, BIOCHEM PHARMACOL, V42, P321, DOI 10.1016/0006-2952(91)90719-L; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; KEELING DJ, 1987, BIOCHEM PHARMACOL, V36, P339, DOI 10.1016/0006-2952(87)90291-7; KEELING DJ, 1989, J BIOL CHEM, V264, P5552; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KEELING DJ, 1991, BIOCHEM PHARMACOL, V42, P123, DOI 10.1016/0006-2952(91)90690-7; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; LORENTZON P, 1987, BIOCHIM BIOPHYS ACTA, V897, P41, DOI 10.1016/0005-2736(87)90313-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDLEIN J, 1989, J BIOL CHEM, V264, P18512; MENDLEIN J, 1990, J BIOL CHEM, V265, P15590; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; MORII M, 1989, GASTROENTEROLOGY, V96, P1453, DOI 10.1016/0016-5085(89)90512-X; MORII M, 1990, BIOCHEM PHARMACOL, V39, P661, DOI 10.1016/0006-2952(90)90143-9; MORII M, 1984, BIOCHEMISTRY-US, V23, P6816, DOI 10.1021/bi00321a083; MORII M, 1990, BIOCHEM BIOPH RES CO, V167, P754, DOI 10.1016/0006-291X(90)92089-I; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1982, J BIOL CHEM, V257, P6111; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON E, 1978, BIOCHEMISTRY-US, V17, P3345, DOI 10.1021/bi00609a027; RABON EC, 1990, J BIOL CHEM, V265, P19594; REPHAELI A, 1986, J BIOL CHEM, V261, P2437; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHRIJEN JJ, 1980, BIOCHIM BIOPHYS ACTA, V597, P331, DOI 10.1016/0005-2736(80)90110-8; TAKEGUCHI N, 1983, J BIOL CHEM, V258, P3094; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	43	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21553	21559						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408006				2022-12-25	WOS:A1993MC80900022
J	SIRAWARAPORN, W; PRAPUNWATTANA, P; SIRAWARAPORN, R; YUTHAVONG, Y; SANTI, DV				SIRAWARAPORN, W; PRAPUNWATTANA, P; SIRAWARAPORN, R; YUTHAVONG, Y; SANTI, DV			THE DIHYDROFOLATE-REDUCTASE DOMAIN OF PLASMODIUM-FALCIPARUM THYMIDYLATE SYNTHASE-DIHYDROFOLATE REDUCTASE - GENE SYNTHESIS, EXPRESSION, AND ANTI-FOLATE-RESISTANT MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PYRIMETHAMINE; PROTEINS; MALARIA; PURIFICATION; CYCLOGUANIL; SEQUENCE; PROTOZOA	A 693-base pair gene coding for the 27,132-dalton dihydrofolate reductase (DHFR) domain of the thymidylate synthase-dihydrofolate reductase (TS-DHFR) bifunctional protein of Plasmodium falciparum was designed to have Escherichia coli codon preference and multiple unique restriction sites and was chemically synthesized. The gene was overexpressed (>50% total cellular protein) in E. coli as insoluble inclusion bodies which could be unfolded and refolded to recover soluble enzyme activity. The refolded DHFR was purified by methotrexate-Sepharose affinity chromatography to give the homogeneous enzyme. Active site titration with methotrexate revealed that the purified protein was fully active. The purified DHFR migrates as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with apparent mass of approximately 30 kDa, and gel filtration showed that the protein is a monomer. The yield of purified enzyme was about 5-6 mg/liter of bacterial culture. Kinetic properties of the purified recombinant DHFR were similar to those reported for wild type bifunctional TS-DHFR. Cassette mutagenesis of the synthetic gene was performed to give the S108N and the N51I+S108N mutants which provided DHFRs analogous to pyrimethamine-resistant mutants found in nature.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; MAHIDOL UNIV,FAC SCI,DEPT BIOCHEM,BANGKOK 10400,THAILAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mahidol University			Yuthavong, Yongyuth/E-7392-2010	Yuthavong, Yongyuth/0000-0002-3582-8401	NIAID NIH HHS [AI 19358] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMANN WW, 1949, P SOC EXP BIOL MED, V72, P1; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BRODIN P, 1986, BIOCHEMISTRY-US, V25, P5371, DOI 10.1021/bi00367a004; BRUCECHWATT LJ, 1986, CHEMOTHERAPY MALARIA, P110; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; CLIMIE S, 1990, P NATL ACAD SCI USA, V87, P633, DOI 10.1073/pnas.87.2.633; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; FERONE R, 1980, P NATL ACAD SCI-BIOL, V77, P5802, DOI 10.1073/pnas.77.10.5802; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; FRIEDKIN M, 1962, FED PROC, V21, P176; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; HALL SJ, 1991, MOL BIOCHEM PARASIT, V45, P317, DOI 10.1016/0166-6851(91)90100-K; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; IVANETICH KM, 1991, BIOTECHNIQUES, V10, P704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN KH, 1991, BIOTECHNOLOGY, V11, P750; MARTINEZ HM, 1985, SEQUENCE AAL PROGRAM; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PINTER K, 1988, DNA-J MOLEC CELL BIO, V7, P235, DOI 10.1089/dna.1988.7.235; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEGER DR, 1949, J AM CHEM SOC, V71, P1753, DOI 10.1021/ja01173a061; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILLIAMS JW, 1981, BIOCHEMISTRY-US, V20, P6024, DOI 10.1021/bi00524a016; YOUNG RA, 1979, J BIOL CHEM, V254, P2725	33	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21637	21644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408015				2022-12-25	WOS:A1993MC80900034
J	CARTWRIGHT, IJ; HEBBACHI, AM; HIGGINS, JA				CARTWRIGHT, IJ; HEBBACHI, AM; HIGGINS, JA			TRANSIT AND SORTING OF APOLIPOPROTEIN-B WITHIN THE ENDOPLASMIC-RETICULUM AND GOLGI COMPARTMENTS OF ISOLATED HEPATOCYTES FROM NORMAL AND OROTIC ACID-FED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEIN; HEP G2 CELLS; PLASMA-LIPOPROTEINS; DISULFIDE ISOMERASE; APO-B; SECRETION; LIVER; DEGRADATION; TRANSPORT	Apolipoprotein B (apoB) secretion by isolated rat hepatocytes was dependent on addition of oleate to the incubation medium and inhibited in hepatocytes isolated from livers of orotic acid-fed rats (OA hepatocytes). To investigate the intracellular transit of newly synthesized apoB under different conditions, normal hepatocytes (with or without oleate) or OA hepatocytes (with oleate) were incubated with [S-35]methionine, and subcellular fractions (rough endoplasmic reticulum, smooth endoplasmic reticulum, cis-Golgi, and trans-Golgi and membrane and lumenal contents from these) were isolated at intervals. The specific activities and pool sizes of apoB100 and apoB48 were determined. The observations indicate that there are several points at which intracellular transit of apoB is regulated. Newly synthesized apoB is either translocated to the lumen of the rough endoplasmic reticulum or remains membrane bound and is degraded. The lumenal apoB is either retained and degraded or transferred to the Golgi lumen and secreted. In OA hepatocytes degradation of the membrane-bound form of apoB is inhibited, and the protein accumulates in the trans-Golgi membranes. Although apoB is translocated to the lumen of the rough endoplasmic reticulum in OA hepatocytes, it is not packaged with lipid and is transferred to the Golgi lumen only slowly.	UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,POB 594,FIRTH COURT,SHEFFIELD S10 2UH,ENGLAND	University of Sheffield								BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P384; FUTTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIBBONS GF, 1987, BIOCHEM J, V243, P487, DOI 10.1042/bj2430487; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HAAGSMAN HP, 1981, ARCH BIOCHEM BIOPHYS, V208, P395, DOI 10.1016/0003-9861(81)90524-5; HAMILTON RL, 1986, J LIPID RES, V27, P967; HAY R, 1988, J LIPID RES, V29, P981; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HIGGINS JA, 1987, J LIPID RES, V28, P268; HIGGINS JA, 1976, J CELL SCI, V22, P173; HIGGINS JA, 1984, BIOCHEM J, V219, P261, DOI 10.1042/bj2190261; HIGGINS JA, 1984, J LIPID RES, V25, P1295; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHETTI M, 1962, BIOCHIM BIOPHYS ACTA, V61, P826, DOI 10.1016/0926-6550(62)90066-X; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PULLINGER CR, 1989, J LIPID RES, V30, P1065; ROMERO FJ, 1983, BIOCHEM EDUC, V11, P135, DOI 10.1016/0307-4412(83)90093-6; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SATO R, 1990, J BIOL CHEM, V265, P11880; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SUNDLER R, 1973, BIOCHEM BIOPH RES CO, V55, P961, DOI 10.1016/0006-291X(73)91236-9; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TOKMAKJIAN SD, 1985, J LIPID RES, V26, P478; VON EULER LEO H., 1963, JOUR BIO CHEM, V238, P2464; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; WILKINSON J, 1993, J LIPID RES, V34, P815; WINDMUELLER HG, 1964, J BIOL CHEM, V239, P530; WONG L, 1987, EUR J BIOCHEM, V164, P356; YAO ZM, 1991, J BIOL CHEM, V266, P3300	51	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20937	20952						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407929				2022-12-25	WOS:A1993MA28800049
J	CRENSHAW, DG; HSIEH, TS				CRENSHAW, DG; HSIEH, TS			FUNCTION OF THE HYDROPHILIC CARBOXYL-TERMINUS OF TYPE-II DNA TOPOISOMERASE FROM DROSOPHILA-MELANOGASTER .1. IN-VITRO STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEOTIDE-SEQUENCE; ANTITUMOR DRUGS; YEAST; PHOSPHORYLATION; BINDING; INVIVO; PROTEIN; GYRASE; GENE	The function of the hydrophilic carboxyl-terminal region of Drosophila DNA topoisomerase II was examined by constructing a series of deletion mutants at the 3'-end of the Drosophila Top2 cDNA. The truncated enzymes were then expressed in Saccharomyces cerevisiae. Deletion of up to 240 out of 1447 total amino acids had no apparent effect on the enzyme's ability to catalyze topisomerization reactions. When 273, or more, amino acids were deleted, the enzyme was no longer active. Examples were found where deletion of less than 240 amino acids inactivated the enzyme. Based on the hydrodynamic properties determined for one of these mutants, the lack of activity was most likely due to misfolding of the polypeptides. The active mutants have similar hydrodynamic properties and heat inactivation profiles as the intact enzyme, suggesting that they are dimeric and stably folded. The carboxyl-terminal 240 amino acids also were not required for interaction with the drug VM26. The only difference noted between the shortest, active mutant and the full-length enzyme was a decrease in the stability of the interaction of the truncated enzyme with DNA as evidenced by a decrease in the ionic strength at which catalysis was optimal and at which the transition between a processive and distributive mode of supercoil relaxation occurred.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University			Wu, Wan-lin/G-8937-2012; Hsieh, Tao-shih/G-9305-2012		NIGMS NIH HHS [5T32 GM07184, GM29006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006, T32GM007184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HSIEH TS, 1983, METHOD ENZYMOL, V100, P161; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE MP, 1989, J BIOL CHEM, V264, P13510; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1981, NUCLEIC ACIDS RES, V9, P3979, DOI 10.1093/nar/9.16.3979; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1604; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SHERMAN F, 1986, LABORATORY COURSE MA; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21328	21334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407971				2022-12-25	WOS:A1993MA28800099
J	HOWE, PH; DOBROWOLSKI, SF; REDDY, KB; STACEY, DW				HOWE, PH; DOBROWOLSKI, SF; REDDY, KB; STACEY, DW			RELEASE FROM G(1) GROWTH ARREST BY TRANSFORMING GROWTH-FACTOR-BETA-1 REQUIRES CELLULAR RAS ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL TRANSDUCTION; EPITHELIAL-CELLS; PROTEIN-KINASE; EXPRESSION CLONING; TYROSINE KINASE; MAP KINASE; INHIBITION; RECEPTOR; PHOSPHORYLATION	Transforming growth factor beta1 (TGFbeta1) is a potent inhibitor of epithelial cell growth, although the mechanism of growth inhibition remains unknown. We report here a critical relationship between cellular p21ras activity and TGFbeta1 action. Microinjection of oncogenic Ha-ras protein into TGFbeta1-arrested mink lung epithelial cells overcomes TGFbeta1 growth inhibition and allows progression into S phase. Cells released from TGFbeta1 inhibition following microinjection with anti-p21ras antibody, on the other hand, remain TGFbeta1-arrested and do not enter S phase, indicating a requirement for p21ras activity. These biological data are substantiated biochemically in that TGFbeta1 is shown to decrease the activation state of endogenous p21ras as measured by the level of GTP-bound p21ras. In addition, the phosphorylation and kinase activity of mitogen-activated protein kinase, which depends upon cellular ras activity, is elevated in cells which have been released from growth arrest by TGFbeta1. Together these data demonstrate the involvement of p21ras activity in TGFbeta1-induced growth inhibition and suggest that the inhibitor controls proliferation by modulating the activity of p21ras.	CLEVELAND CLIN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	HOWE, PH (corresponding author), CLEVELAND CLIN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195, USA.				NCI NIH HHS [CA53496, CA 55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055536, R01CA053496, R29CA055536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1992, ONCOGENE, V7, P521; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HOUCK KA, 1989, ONCOGENE, V4, P19; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LONGSTREET M, 1992, ONCOGENE, V7, P1549; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULDER KM, 1992, J BIOL CHEM, V267, P5029; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VRIESSMITS AMM, 1992, NATURE, V357, P602; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	33	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21448	21452						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407989				2022-12-25	WOS:A1993MA28800117
J	KEENEY, S; CHANG, GJ; LINN, S				KEENEY, S; CHANG, GJ; LINN, S			CHARACTERIZATION OF A HUMAN DNA-DAMAGE BINDING-PROTEIN IMPLICATED IN XERODERMA-PIGMENTOSUM-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; COMPLEMENTATION GROUP-E; REPAIR GENE; GROUP-A; POLYACRYLAMIDE GELS; EXCISION REPAIR; HUMAN-CELLS; SACCHAROMYCES-CEREVISIAE; RECOGNITION PROTEIN; HUMAN-PLACENTA	A human DNA damage binding protein implicated in the DNA excision repair disorder xeroderma pigmentosum E was purified to near homogeneity from HeLa cells. The protein is abundant (approximately 10(5) copies/cell) and has a native molecular weight of 154,000-163,000 as estimated by gel filtration and glycerol gradient sedimentation. DNA damage binding activity copurified with polypeptides of 124 and 41 kDa. Based on the native molecular weight, cosedimentation of both polypeptides with DNA damage binding activity on glycerol gradients, and a molar ratio of approximately 1:1 for the two polypeptides, it appears that p124 and p41 are subunits of a heterodimeric protein. Binding to damaged DNA was resistant to K+ concentrations approaching 1 M, but showed anion-specific sensitivity to Cl- concentrations above 0.5 M, suggesting that the majority of the binding energy is contributed by nonionic interactions. In contrast to previous reports, the DNA damage binding protein was shown to recognize cyclobutane pyrimidine dimers in addition to a nonphotoreactivable lesion(s), most likely the pyrimidine-pyrimidone (6-4) photoproduct.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley			Keeney, Scott/GVR-8515-2022	Keeney, Scott/0000-0002-1283-6417	NIEHS NIH HHS [P30ES011896] Funding Source: Medline; NIGMS NIH HHS [GM07232-15, GM30415] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R43ES011896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R01GM030415] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; CHAO CCK, 1991, CANCER RES, V51, P601; CHAO CCK, 1992, BIOCHEM J, V282, P203, DOI 10.1042/bj2820203; CHAO CCK, 1991, MOL CELL BIOL, V11, P2075, DOI 10.1128/MCB.11.4.2075; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EKER APM, 1992, MUTAT RES, V274, P211, DOI 10.1016/0921-8777(92)90067-D; FELDBERG RS, 1980, NUCLEIC ACIDS RES, V8, P1133, DOI 10.1093/nar/8.5.1133; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; FELDBERG RS, 1982, J BIOL CHEM, V257, P6394; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HOEIJMAKERS JHJ, 1990, MUTAT RES, V236, P223, DOI 10.1016/0921-8777(90)90007-R; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KONDO S, 1989, PHOTODERMATOLOGY, V6, P89; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; LEE J C, 1974, Biochemistry, V13, P257, DOI 10.1021/bi00699a005; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; REARDON JT, 1993, J BIOL CHEM, V268, P21301; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RINE J, 1987, GENETICS, V116, P9; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROSS M, 1990, BIOTECHNIQUES, V9, P532; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZELLE B, 1979, MUTAT RES, V62, P363, DOI 10.1016/0027-5107(79)90091-5	45	184	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21293	21300						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407967				2022-12-25	WOS:A1993MA28800095
J	LUO, Y; SHUMAN, S				LUO, Y; SHUMAN, S			RNA-BINDING PROPERTIES OF VACCINIA VIRUS CAPPING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTION TERMINATION; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; GUANYLATE INTERMEDIATE; EARLY GENES; GUANYLYLTRANSFERASE; VIRIONS; ASSOCIATION; SUBUNITS	Vaccinia virus capping enzyme, a heterodimer of 95-kDa and 33-kDa subunits, modifies the 5' RNA end and also acts as a transcription termination factor during synthesis of viral early mRNAs. Termination occurs in response to a specific signal, UUUUUNU, in the nascent RNA chain. We now report that purified capping enzyme binds to defined RNAs in solution to form complexes that are stable during native gel electrophoresis. Multiple enzyme molecules can bind to a single RNA. No particular 5' end structure is required for RNA binding, suggesting that the observed protein-RNA interaction is unrelated to the triphosphatase, guanylyltransferase, or methyltransferase functions of capping enzyme. Although binding does not require a UUUUUNU element in the RNA, complex formation is competed preferentially by poly(U) compared to poly(C). Capping enzyme binds to the synthetic 30-mer homopolymers to form a single protein-RNA complex; affinity for U-30 is 10-fold higher than for A-30. The sites of protein-RNA contact, as detected by UV cross-linking, are located predominantly within the 95-kDa capping enzyme subunit, which is itself sufficient to bind and cross-link to RNA in the absence of the small subunit.			LUO, Y (corresponding author), SLOAN KETTERING INST CANC RES,MOLEC BIOL PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1991, VIROLOGY, V185, P432, DOI 10.1016/0042-6822(91)90793-B; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	26	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21253	21262						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407963				2022-12-25	WOS:A1993MA28800090
J	MAHAFFEY, D; YOO, Y; RECHSTEINER, M				MAHAFFEY, D; YOO, Y; RECHSTEINER, M			UBIQUITIN METABOLISM IN CYCLING XENOPUS EGG EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; ACTIVATING ENZYME; CELL-CYCLE; PROTEIN; DEGRADATION; PURIFICATION; RESOLUTION; MECHANISM; PROTEASES; RECEPTOR	Xenopus egg extract is capable of supporting mitosis in vitro, which makes it ideal for biochemical analysis of the cell cycle. Since several studies have implicated the ubiquitin system in cell cycle progression, we have measured ubiquitin conjugation rates, proteolysis of ubiquitin-lysozyme conjugates, and rates of isopeptidase activity in cycling Xenopus egg extracts. Although ubiquitin conjugation in cytostatic factor arrested extract was half that in activated extract, there were no changes in rates of ubiquitin conjugation during the cell cycle. Ubiquitin conjugates are degraded by a 26 S ATP-stimulated protease. The ability of the 26 S protease to degrade ubiquitin-lysozyme conjugates and a fluorigenic peptide also remained constant across the cell cycle. In contrast to previously characterized systems, isopeptidase activity in Xenopus egg extract is energy-dependent. Glycerol gradient fractionation of Xenopus egg extract separated two ATP-dependent isopeptidases. One co-sedimented with the 26 S protease; the other sedimented slower and was not associated with any additional proteolytic activity. As found for rates of Ub conjugation and conjugate proteolysis, there was little or no variation in isopeptidase activity during the cell cycle.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027159] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NIGMS NIH HHS [GM 27159] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; KANADA F, 1986, BIOCHIM BIOPHYS ACTA, V870, P64; KAWAHARA H, 1992, FEBS LETT, V310, P119, DOI 10.1016/0014-5793(92)81310-I; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MORI S, 1992, J BIOL CHEM, V267, P6429; MUELLER RD, 1985, J BIOL CHEM, V260, P5147; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1992, J BIOL CHEM, V267, P14418; RECHSTEINER MC, 1971, J IMMUNOL, V107, P985; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6	32	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21205	21211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407956				2022-12-25	WOS:A1993MA28800083
J	WERNER, M; CHAUSSIVERT, N; WILLIS, IM; SENTENAC, A				WERNER, M; CHAUSSIVERT, N; WILLIS, IM; SENTENAC, A			INTERACTION BETWEEN A COMPLEX OF RNA POLYMERASE-III SUBUNITS AND THE 70-KDA COMPONENT OF TRANSCRIPTION FACTOR-IIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TATA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE ENCODES; C III; YEAST; GENE; SUPPRESSOR; BOX; INITIATION; MUTATIONS; TFIIB	A system that detects the formation of complexes between different proteins by linking them to separate domains of the GALA transcription activator protein has been used to study protein-protein interactions between four essential and unique subunits of yeast RNA polymerase III (C82, C53, C34 and C31), the 70-kDa component of the initiation transcription factor IIIB (TFIIIB70) and the TATA-binding protein. We found that C82, C34, and C31 are able to combine with each other in vivo and that C34 interacts with TFIIIB70. These results suggest that C34 and TFIIIB70 are specificity determinants of the RNA polymerase III-TFIIIB interaction.	ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 14214 USA	Yeshiva University; Albert Einstein College of Medicine	WERNER, M (corresponding author), CENS, DEPT BIOL CELLULAIRE & MOLEC, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE.		Werner, Michel/B-7316-2009; Troffer-Charlier, Nathalie/B-1857-2017	Werner, Michel/0000-0002-2965-5858; Troffer-Charlier, Nathalie/0000-0001-6812-8375; Willis, Ian/0000-0001-6599-2395				ARCHAMBAULT J, 1990, MOL CELL BIOL, V10, P6123, DOI 10.1128/MCB.10.12.6123; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHIANNILKULCHAI N, 1992, J BIOL CHEM, V267, P23099; CHIANNILKULCHAI N, 1992, MOL CELL BIOL, V12, P4433, DOI 10.1128/MCB.12.10.4433; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HUET J, 1985, J BIOL CHEM, V260, P5304; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1990, CELL, V60, P247; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MANN C, 1992, MOL CELL BIOL, V12, P4314, DOI 10.1128/MCB.12.10.4314; MARTIN C, 1990, MOL CELL BIOL, V10, P1908, DOI 10.1128/MCB.10.5.1908; Miller JH., 1972, EXPT MOL GENETICS; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STETTLER S, 1992, J BIOL CHEM, V267, P21390; THURIAUX P, 1992, MOL CELLULAR BIOL YE, P1; WERNER M, 1992, MOL CELL BIOL, V12, P1087, DOI 10.1128/MCB.12.3.1087; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	38	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20721	20724						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407894				2022-12-25	WOS:A1993MA28800011
J	HSIEH, CL; ARLETT, CF; LIEBER, MR				HSIEH, CL; ARLETT, CF; LIEBER, MR			V(D)J RECOMBINATION IN ATAXIA-TELANGIECTASIA, BLOOM-SYNDROME, AND A DNA-LIGASE I-ASSOCIATED IMMUNODEFICIENCY DISORDER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCID MUTATION; CELLS; GENE; DEFECT; HYPERSENSITIVITY; SPECIFICITY; DEFICIENCY; MECHANISM; DELETION; PATIENT	Ataxia telangiectasia (AT) and Bloom's syndrome (BS) patients are characterized by sensitivity to radiation, increased lymphoid malignancy, and frequent translocations to the antigen receptor loci. Because of these features, there has been a persistent question as to whether the V(D)J recombinase might be abnormal in cells from these patients. Such abnormalities might be due to inappropriate to inaccurate expression of components of the V(D)J recombinase or due to mutation in a component shared between V(D)J recombination and other cellular processes, such as DNA repair. Bloom's syndrome is associated with a ligation deficiency, and this activity may contribute in the end resolution steps of both site-specific and general DNA-processing reactions. In the current study, we have activated V(D)J recombination in normal, AT, and BS fibroblasts and in fibroblasts from a patient with mutations that largely abolish DNA ligase I activity. We find that the signal and coding joint formation of the V(D)J recombination reaction are entirely normal in AT, BS, and DNA ligase I mutant cells. In addition to ruling out abnormalities of the V(D)J recombinase in AT, BS, and DNA ligase I mutant cells, these studies suggest that DNA ligase I is unlikely to be required for signal or coding end joining in the V(D)J recombination reaction.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND	Stanford University; University of Sussex				Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRIDGES BA, 1981, P R SOC LOND B, V212, P268; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V85, P8588; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; HUEBNER K, 1989, CANCER RES, V49, P4071; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEHMANN AR, 1988, CANCER RES, V48, P6343; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LONN U, 1990, CANCER RES, V50, P3141; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, 1993, IN PRESS MOL CELL BI, V13; PETERSON RDA, 1990, NEW ENGL J MED, V322, P124, DOI 10.1056/NEJM199001113220209; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1990, MOL BASIS B CELL DEV, V3, P132; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; WEBSTER ADB, 1992, LANCET, V339, P1508, DOI 10.1016/0140-6736(92)91266-B; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0	37	98	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20105	20109						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397200				2022-12-25	WOS:A1993LY01900030
J	LODISH, HF; KONG, N				LODISH, HF; KONG, N			THE SECRETORY PATHWAY IS NORMAL IN DITHIOTHREITOL-TREATED CELLS, BUT DISULFIDE-BONDED PROTEINS ARE REDUCED AND REVERSIBLY RETAINED IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; GONADOTROPIN-BETA SUBUNIT; HUMAN HEPATOMA-CELLS; ASIALOGLYCOPROTEIN RECEPTOR; FOLDING PATHWAY; BINDING-PROTEIN; RIBONUCLEASE-A; ISOMERASE; BPTI; KINETICS	Addition of 2 mM dithiothreitol (DTT) to HepG2 human hepatoma cells blocks secretion of newly made albumin and causes it to accumulate in the endoplasmic reticulum in the reduced state. Subsequent incubation of the cells in the absence of DTT allows the reduced albumin to form apparently normal disulfide bonds and to be secreted normally. Similarly, DTT treatment causes all newly made subunits of the H1 subunit of the asialoglycoprotein receptor to be retained in the endoplasmic reticulum in the reduced state; following removal of DTT H1 subunits form disulfide bonds via a normal endoplasmic reticulum folding intermediate and mature to the Golgi. Thus, apparently normal formation of disulfide bonds on these two proteins can occur post-translationally, as has been shown previously for the influenza HA hemagglutinin (Braakman, I., Helenius, J., and Helenius, A. (1992) EMBO J. 11, 1717-1722; Braakman, I., Helenius, J., and Helenius, A. (1992) Nature 356, 260-262). Alpha1-antitrypsin contains no disulfide bonds; in the continuous presence of DTT it acquires a normal complement of complex oligosaccharides and is secreted at an only slightly reduced rate. Thus, the secretory pathway functions efficiently even when it is reduced by DTT. Endoplasmic reticulum retention of albumin and H1 during treatment with DTT presumably occurs because, without disulfide bonds, these proteins cannot fold properly, not because of any defect in the overall processes of vesicular transport and protein secretion.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	LODISH, HF (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NIGMS NIH HHS [GM 35012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FREEDMAN RB, 1980, ENZYMOLOGY POST TRAN; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1992, P NATL ACAD SCI USA, V89, P5083, DOI 10.1073/pnas.89.11.5083; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KOIVU J, 1987, J BIOL CHEM, V262, P6159; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MEISTER A, 1988, J BIOL CHEM, V263, P17205; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PETERS T, 1982, J BIOL CHEM, V257, P8847; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; TATU U, 1993, IN PRESS EMBO J; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997	50	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20598	20605						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397210				2022-12-25	WOS:A1993LY01900097
J	VANRENTERGHEM, B; GIBBS, JB; MALLER, JL				VANRENTERGHEM, B; GIBBS, JB; MALLER, JL			RECONSTITUTION OF P21(RAS)-DEPENDENT AND P21(RAS)-INDEPENDENT MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NERVE GROWTH-FACTOR; INDUCED TYROSINE PHOSPHORYLATION; TETRADECANOYL PHORBOL ACETATE; MATURATION-PROMOTING FACTOR; NIH 3T3 CELLS; MAP KINASE; XENOPUS OOCYTES; GENE-PRODUCT; P34CDC2 KINASE; S6 KINASE	In Xenopus oocytes, mitogen-activated protein (MAP) kinase can be activated by progesterone treatment or by microinjection of cyclin A, both of which lead to activation of the cdc2 protein kinase. The tyrosine kinase pp60v-src has previously been shown to accelerate progesterone-induced oocyte maturation and to increase the phosphorylation of ribosomal protein S6 by pp90rsk, most likely by activating MAP kinase. In extracts of resting oocytes, MAP kinase kinase and MAP kinase were activated by addition of pp60v-src or cyclin A. Activation by pp60v-src, was blocked by a dominant-negative p21ras protein (RAS(T)), but activation by cyclin A/cdc2 was unaffected. Thus these two pathways that converge at MAP kinase kinase but are clearly divergent upstream of a p21ras-dependent step can be studied in a cell-free system.	UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Merck & Company					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28353] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DESPHANDE AK, 1987, MOL CELL BIOL, V7, P1285; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P355; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KESSLER SW, 1976, J IMMUNOL, V117, P1482; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOSAKO H, 1993, EMBO J, V12, P7878; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SEGER R, 1992, J BIOL CHEM, V267, P25628; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPIVACK JG, 1984, MOL CELL BIOL, V4, P1631, DOI 10.1128/MCB.4.8.1631; SPIVACK JG, 1985, MOL CELL BIOL, V5, P3629, DOI 10.1128/MCB.5.12.3629; STEFANOVIC D, 1988, EXP CELL RES, V179, P104, DOI 10.1016/0014-4827(88)90352-7; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS J, 1991, J BIOL CHEM, V266, P10906; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	65	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19935	19938						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397192				2022-12-25	WOS:A1993LY01900006
J	GUARNIERI, FG; ARTERBURN, LM; PENNO, MB; CHA, Y; AUGUST, JT				GUARNIERI, FG; ARTERBURN, LM; PENNO, MB; CHA, Y; AUGUST, JT			THE MOTIF TYR-X-X-HYDROPHOBIC RESIDUE MEDIATES LYSOSOMAL MEMBRANE TARGETING OF LYSOSOME-ASSOCIATED MEMBRANE PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; CELL-SURFACE GLYCOPROTEINS; CYTOPLASMIC DOMAIN; ACID-PHOSPHATASE; PLASMA-MEMBRANE; CDNA SEQUENCE; RECEPTOR; ANTIGEN; INTERNALIZATION; PURIFICATION	We have investigated the mechanism by which LAMP-1, a principal protein of the lysosomal membrane, is targeted to lysosomes. Mutagenesis and transfection experiments indicate that the motif Tyr-X-X-hydrophobic residue at the carboxyl terminus of the 11-amino acid cytoplasmic tail of the protein constitutes the lysosomal targeting signal for LAMP-1. This motif directs CD44, a cell surface hyaluronate receptor, to the lysosomal membrane, but only when the signal is placed at the the carboxyl-terminus of a truncated cytoplasmic tail. The signal did not confer lysosomal targeting when it was situated internally or at the carboxyl terminus of the normal CD44 cytoplasmic tail. An apparent paradox is that similar Tyr-containing sequences mediate internalization, but not lysosomal targeting, of several receptors. Of possible relevance is the additional finding that purified LAMP-1 protein lacks the two carboxyl-terminal residues predicted by cDNA, both of which are essential for proper trafficking. A model is proposed in which lysosomal targeting is distinguished from receptor internalization through proteolytic modification of the internalization signal.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA4618] Funding Source: Medline; NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline; NIGMS NIH HHS [5.T32.GM07626] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419; AZORSA DO, 1991, BLOOD, V78, P280; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHA Y, 1990, J BIOL CHEM, V265, P5008; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOTTA H, 1988, CANCER RES, V48, P2955; HUGHES EN, 1981, J BIOL CHEM, V256, P664; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIPPICOTTSCHWAR.J, 1987, CELL, V49, P699; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MENGOD G, 1981, ARCH BIOCHEM BIOPHYS, V209, P718, DOI 10.1016/0003-9861(81)90335-0; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341	37	154	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1941	1946						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420968				2022-12-25	WOS:A1993KH62000068
J	SZTUL, E; COLOMBO, M; STAHL, P; SAMANTA, R				SZTUL, E; COLOMBO, M; STAHL, P; SAMANTA, R			CONTROL OF PROTEIN TRAFFIC BETWEEN DISTINCT PLASMA-MEMBRANE DOMAINS - REQUIREMENT FOR A NOVEL 108,000 PROTEIN IN THE FUSION OF TRANSCYTOTIC VESICLES WITH THE APICAL PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; GTP-BINDING PROTEIN; CANINE KIDNEY-CELLS; TRANS-CELLULAR TRANSPORT; RAT-LIVER; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SECRETORY COMPONENT; IGA RECEPTOR; MORPHOLOGICAL CHARACTERIZATION	We have developed a cell-free system that reconstitutes the last step in transcytosis, i.e. the fusion of transcytotic transport vesicles with the apical plasma membrane (PM). Subcellular fractions containing transcytotic vesicles (the donor) or apical PM (the acceptor) were prepared from rat liver by sucrose density centrifugation. Fusion between the donor and acceptor fractions was measured by the conversion of the 120,000 transmembrane form of the polymeric IgA receptor (pIgA-R), an endogenous protein of transcytotic vesicles, to a processed fragment by a protease endogenous to the apical PM. Fusion occurred only at 37-degrees-C and was critically dependent on the presence of ATP and cytosol. Fusion was inhibited by treating the in vitro fusion reaction with N-ethylmaleimide or by adding antibodies against N-ethylmaleimide-sensitive factor (NSF). We have previously identified a specific transcytotic vesicle-associated protein (TAP) and here show that TAP exists in both cytosolic and membrane-associated pools. Because of its exclusive interaction with transcytotic vesicles, we tested the involvement of TAP in distinct fusion processes. Removal of TAP inhibited fusion in an in vitro transcytotic fusion reaction but had no inhibitory effect in an in vitro endosome-endosome fusion system or in an in vitro intra-Golgi transport reaction. We propose that TAP represents part of the molecular machinery specifically involved in targeting and/or fusion of transcytotic vesicles with the apical PM.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	SZTUL, E (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.							ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; JACKSON GDF, 1978, EUR J IMMUNOL, V8, P123, DOI 10.1002/eji.1830080210; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MAYORGA LS, 1989, J BIOL CHEM, V264, P5392; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MULLOCK BM, 1980, FEBS LETT, V120, P278, DOI 10.1016/0014-5793(80)80316-4; MUSIL LS, 1987, J CELL BIOL, V104, P1725, DOI 10.1083/jcb.104.6.1725; MUSIL LS, 1988, J BIOL CHEM, V263, P15799; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; PESONEN M, 1983, J CELL BIOL, V97, P638, DOI 10.1083/jcb.97.3.638; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROMAN LM, 1984, J CELL BIOL, V98, P1497, DOI 10.1083/jcb.98.4.1497; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SCHAERER E, 1990, J CELL BIOL, V110, P987, DOI 10.1083/jcb.110.4.987; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WATTENBERG B W, 1990, New Biologist, V2, P505; WILSON DW, 1992, METHOD ENZYMOL, V219, P309; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	60	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1876	1885						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420962				2022-12-25	WOS:A1993KH62000059
J	THORBURN, A; THORBURN, J; CHEN, SY; POWERS, S; SHUBEITA, HE; FERAMISCO, JR; CHIEN, KR				THORBURN, A; THORBURN, J; CHEN, SY; POWERS, S; SHUBEITA, HE; FERAMISCO, JR; CHIEN, KR			HRAS-DEPENDENT PATHWAYS CAN ACTIVATE MORPHOLOGICAL AND GENETIC-MARKERS OF CARDIAC-MUSCLE CELL HYPERTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOCARDIAL-CELLS; ATRIAL-NATRIURETIC-FACTOR; PC12 CELLS; ADRENERGIC STIMULATION; INDUCIBLE EXPRESSION; GROWTH-FACTOR; T-ANTIGEN; DIFFERENTIATION; MICROINJECTION; TRANSFORMATION	We have investigated the role of the proto-oncogene HRas in cardiac cell growth and hypertrophy. By direct needle microinjection of activated Ras protein into primary neonatal rat ventricular cardiac myocytes, we find that, unlike many other cell types Ras does not induce DNA synthesis in these cells. However, injection of activated Ras does induce expression of both the c-Fos and atrial natriuretic factor (ANF) genes. Expression of both these genes is associated with the hypertrophic response in ventricular myocytes suggesting that Ras is involved in the hypertrophic signalling pathway. Ras injection also causes morphological changes in the cells so that they increase in profile and show changes in the organization of the contractile apparatus. Further support for a role for Ras in the hypertrophic response was obtained from studies showing that activated Ras stimulates ANF promoter activity in transient transfection assays. We also show that a dominant interfering Ras mutant inhibits the hypertrophic stimulation of the ANF promoter by phenylephrine, indicating a role for Ras in the hypertrophic effect of an alpha-adrenergic agonist.	UNIV CALIF SAN DIEGO, DEPT MED, 0613-C, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, AMER HEART ASSOC, BUGHER FDN CTR MOLEC BIOL, LA JOLLA, CA 92093 USA; UNIV MED & DENT NEW JERSEY, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center				Powers, Scott/0000-0003-2769-1932				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE HR, 1988, J BIOL CHEM, V263, P7352; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SEN A, 1988, J BIOL CHEM, V263, P19132; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	26	204	207	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2244	2249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420993				2022-12-25	WOS:A1993KH62000111
J	RAO, SI; WILKS, A; DEMONTELLANO, PRO				RAO, SI; WILKS, A; DEMONTELLANO, PRO			THE ROLES OF HIS-64, TYR-103, TYR-146, AND TYR-151 IN THE EPOXIDATION OF STYRENE AND BETA-METHYLSTYRENE BY RECOMBINANT SPERM WHALE MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; FERRYL MYOGLOBIN; LIGAND-BINDING; COMPOUND-I; HEME; SPECTROSCOPY; METMYOGLOBIN; ACID	Previous studies demonstrated that at least two mechanisms are involved in the epoxidation of styrene and stilbene by myoglobin and H2O2 (Ortiz de Montellano, P. R., and Catalano, C. E. (1985) J. Biol. Chem. 260, 9265-9271). One mechanism, reaction of the olefin with the ferryl oxygen, preserves the olefin stereochemistry and incorporates an oxygen from H2O2 into the epoxide. The second mechanism, proposed to be a protein-mediated co-oxidation process, results in loss of stereochemistry and incorporation of an atom of molecular oxygen. To examine the role of individual residues in olefin epoxidation, we have examined the catalytic activities of the possible Tyr --> Phe mutants, the His-64 --> Val mutant, and a protein combining all the tyrosine and histidine mutations. The latter protein is less stable than the other mutants and is the only one for which a protein radical is not detected in the reaction with H2O2. The K(m) and V(max) for styrene epoxidation range, respectively, from 0.3-8 mM and 12-35 pmol/min/nmol of protein. Incubation with (H2O2)-O-18 results in 20-30% incorporation of labeled oxygen into the epoxide with all the mutants except Y103F/Y151F, Y146F/Y151F, H64V, and H64V/Y103F/Y146F/Y151F, for which 52, 58, 89, and 96% of the epoxide oxygen, respectively, is labeled. Oxidation of cis-beta-methylstyrene by wild-type myoglobin yielded a 54:46 ratio of cis- and trans-beta-methylstyrene oxides. The cis-isomer accounts for 47-100% of the epoxide produced by the mutant hemoproteins, with the two H64V mutants yielding almost exclusively the cis-epoxide. The oxygen in the cis-epoxide derives primarily or exclusively from H2O2 and that in the trans-epoxide from an alternative source. These results indicate that tyrosine residues may participate in, but are not essential for, protein-mediated epoxidation. In contrast, His-64 appears to be essential for co-oxidative epoxidation because in its absence olefin epoxidation is mediated almost exclusively by ferryl oxygen transfer.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK30297, P-50 DK26743] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297, P30DK026743] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENTOFF AJ, 1993, IN PRESS J AM CHEM S; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P51; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CATALANO CE, 1987, BIOCHEMISTRY-US, V26, P8373, DOI 10.1021/bi00399a052; CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1259, DOI 10.1021/bi00354a010; DAUTREVAUX M, 1969, EUR J BIOCHEM, V11, P267, DOI 10.1111/j.1432-1033.1969.tb00769.x; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEMONTELLANO PRO, 1987, BIOCHEMISTRY-US, V26, P5310, DOI 10.1021/bi00391a014; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; EDMUNDSO.AB, 1965, NATURE, V205, P883, DOI 10.1038/205883a0; FOX JB, 1974, BIOCHEMISTRY-US, V13, P5178, DOI 10.1021/bi00722a020; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GARRISON JM, 1989, J AM CHEM SOC, V111, P4960, DOI 10.1021/ja00195a060; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; HE GX, 1991, J AM CHEM SOC, V113, P5644, DOI 10.1021/ja00015a018; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LABEQUE R, 1987, J AM CHEM SOC, V109, P2828, DOI 10.1021/ja00243a048; LAMAR GN, 1983, J AM CHEM SOC, V105, P782, DOI 10.1021/ja00342a022; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MODI S, 1991, J CHEM SOC CHEM COMM, P830, DOI 10.1039/c39910000830; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RICE RH, 1983, ARCH BIOCHEM BIOPHYS, V221, P417, DOI 10.1016/0003-9861(83)90160-1; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; UCHIDA K, 1989, BIOORG CHEM, V17, P330, DOI 10.1016/0045-2068(89)90035-7; UYEDA M, 1981, BIOCHEMISTRY-US, V20, P2028, DOI 10.1021/bi00510a045; WILBUR DJ, 1976, J BIOL CHEM, V251, P5187; WILKS A, 1992, J BIOL CHEM, V267, P8827; YONETANI T, 1967, J BIOL CHEM, V242, P1974	41	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					803	809						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419357				2022-12-25	WOS:A1993KG07700011
J	SCHODEL, F; PETERSON, D; ZHENG, J; JONES, JE; HUGHES, JL; MILICH, DR				SCHODEL, F; PETERSON, D; ZHENG, J; JONES, JE; HUGHES, JL; MILICH, DR			STRUCTURE OF HEPATITIS-B VIRUS CORE AND E-ANTIGEN - A SINGLE PRECORE AMINO-ACID PREVENTS NUCLEOCAPSID ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGNAL SEQUENCE; EXPRESSION; REGION; GENE; IMMUNOGENICITY; SECRETION; PROTEIN; DETERMINANTS; PARTICLES	The hepatitis B virus core gene codes for two polypeptides: the core protein, which assembles to form particles (HBcAg), and the secreted precore protein (HBeAg). Expression vectors directing the synthesis in Escherichia coli of a recombinant HBeAg corresponding in sequence to serum-derived HBeAg encompassing the 10 precore amino acids remaining after cleavage of the precursor and residues 1-149 of HBcAg (PC-HBeAg) were constructed. Recombinant PC-HBeAg, HBcAg, and C-terminally truncated HBcAg were isolated from E. coli and analyzed by sucrose velocity sedimentation, electron microscopy, anti-HBc/e specific monoclonal antibody analysis, and for immunogenicity. HBcAg and truncated HBcAg formed 27-nm particles and displayed HBc antigenicity. In contrast, PC-HBeAg was nonparticulate and did not band in sucrose gradients. PC-HBeAg was recognized efficiently by HBeAg-specific antibodies and displayed little HBc antigenicity. Immunogenicity studies including T and B cell recognition confirmed that PC-HBeAg demonstrates HBe antigenicity. The presence of the 10 precore amino acids therefore prevented particle formation. To analyze which precore amino acids might be responsible for the prevention of particle formation a cysteine to glutamine substitution at amino acid position -7 was introduced into PC-HBeAg (-7C-->Q)PC-HBeAg. This single amino acid change at position -7 restored particle formation and HBc antigenicity. The evolutionarily conserved cysteine at position -7 thus appears responsible for the prevention of particle assembly in the HBeAg biosynthesis pathway.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM, RICHMOND, VA 23298 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Max Planck Society; Virginia Commonwealth University; Scripps Research Institute			milich, david/W-6493-2019		NIAID NIH HHS [AI20720] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORISOVA GP, 1989, FEBS LETT, V259, P121, DOI 10.1016/0014-5793(89)81509-1; BRUSS V, 1988, VIROLOGY, V163, P268, DOI 10.1016/0042-6822(88)90266-8; CHANG C, 1987, J VIROL, V61, P3322, DOI 10.1128/JVI.61.10.3322-3325.1987; CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0; CLICK RE, 1972, CELL IMMUNOL, V3, P264, DOI 10.1016/0008-8749(72)90165-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; IMAI M, 1982, J IMMUNOL, V128, P69; JEANJEAN O, 1989, VIROLOGY, V170, P99, DOI 10.1016/0042-6822(89)90356-5; MACKAY P, 1981, J MED VIROL, V8, P237, DOI 10.1002/jmv.1890080404; MCLACHLAN A, 1987, J VIROL, V61, P683, DOI 10.1128/JVI.61.3.683-692.1987; MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425; MILICH DR, 1988, J IMMUNOL, V141, P3617; MILICH DR, 1987, J IMMUNOL, V139, P1223; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MIMMS L, 1988, VIRAL HEPATITIS LIVE, P248; MIYANOHARA A, 1986, J VIROL, V59, P176, DOI 10.1128/JVI.59.1.176-180.1986; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; ROOSSINCK MJ, 1986, MOL CELL BIOL, V6, P1393, DOI 10.1128/MCB.6.5.1393; Sambrook J, 1989, MOL CLONING LABORATO; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SCHLICHT HJ, 1991, J VIROL, V65, P6817, DOI 10.1128/JVI.65.12.6817-6825.1991; SCHODEL F, 1992, J VIROL, V66, P106; SCHODEL F, 1989, INFECT IMMUN, V57, P1347; SCHODEL F, 1991, VACCINES, V91, P319; SCHODEL F, 1990, VACCINES, V90, P193; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; STAHL S, 1982, P NATL ACAD SCI-BIOL, V79, P1606, DOI 10.1073/pnas.79.5.1606; STAHL SJ, 1989, P NATL ACAD SCI USA, V86, P6283, DOI 10.1073/pnas.86.16.6283; STANDRING DN, 1988, P NATL ACAD SCI USA, V85, P8405, DOI 10.1073/pnas.85.22.8405; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; TSAI SL, 1992, J CLIN INVEST, V89, P87, DOI 10.1172/JCI115590; WEIMER T, 1987, J VIROL, V61, P3109, DOI 10.1128/JVI.61.10.3109-3113.1987; ZHENG J, 1992, J BIOL CHEM, V267, P9422	37	80	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1332	1337						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419335				2022-12-25	WOS:A1993KG07700085
J	HONG, L; SCHROTH, GP; MATTHEWS, HR; YAU, P; BRADBURY, EM				HONG, L; SCHROTH, GP; MATTHEWS, HR; YAU, P; BRADBURY, EM			STUDIES OF THE DNA-BINDING PROPERTIES OF HISTONE H4 AMINO TERMINUS - THERMAL-DENATURATION STUDIES REVEAL THAT ACETYLATION MARKEDLY REDUCES THE BINDING CONSTANT OF THE H4 TAIL TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; LINKING NUMBER CHANGE; SILENT MATING LOCI; NUCLEOSOME; H-4; HYPERACETYLATION; ACTIVATION; REPRESSION; PEPTIDES; NEUTRON	The effect of acetylation on the DNA binding properties of the rigidly conserved histone H4 amino-terminal tail has been studied in detail using the technique of thermal denaturation. The quantitative DNA-binding parameters for both the non- and fully acetylated H4 amino terminus have been determined from thermal denaturation data for complexes of the peptides bound to mixed sequence 146-base pair DNA. We find that under dilute buffer conditions (5 mM Tris-HCl) the binding constant for the non-acetylated peptide to double-stranded DNA is 5 x 10(11) M-1 and that acetylation of lysine residues in the peptide reduces the binding constant to 1 x 10(5) M-1. The dramatic differences observed in the binding constants for the non- and fully acetylated peptides are probably due to the effect of acetylation on the even distribution of positively charged residues in the H4 amino terminus. In other experiments, the binding of both peptides to a 30-base pair oligonucleotide has been studied in solution with varying concentrations of sodium, magnesium, and phosphate ions. These experiments demonstrate that both magnesium and phosphate ions have strong effects on the binding of the H4 tail to DNA, especially weakening the binding of the acetylated peptide. For instance, the dissociation of the non-acetylated peptide from DNA requires 6 mM magnesium, yet the binding of the acetylated peptide is abolished in only 30 muM magnesium. The modulation of the DNA binding interactions of the H4 amino terminus by physiologically relevant ionic conditions, in addition to the effect of acetylation, can be important in the regulation of chromatin structure and function.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of California System; University of California Davis; Oregon State University; United States Department of Energy (DOE); Los Alamos National Laboratory				Yau, Peter/0000-0002-1984-185X	NIGMS NIH HHS [GM26901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BOHM L, 1981, EUR J BIOCHEM, V119, P67, DOI 10.1111/j.1432-1033.1981.tb05577.x; BRADBURY EM, 1981, DNA CHROMATIN CHROMO; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CHAHAL SS, 1980, NATURE, V287, P76, DOI 10.1038/287076a0; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHRISTENSEN ME, 1984, NUCLEIC ACIDS RES, V12, P4575, DOI 10.1093/nar/12.11.4575; DAVIE JR, 1978, P NATL ACAD SCI USA, V75, P3574, DOI 10.1073/pnas.75.8.3574; DOVE WF, 1962, J MOL BIOL, V5, P467, DOI 10.1016/S0022-2836(62)80119-3; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600; IMAI BS, 1986, J BIOL CHEM, V261, P8784; JOHNS EW, 1967, BIOCHEM J, V105, P611, DOI 10.1042/bj1050611; JOHNSON EM, 1987, J BIOL CHEM, V262, P6943; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MCGHEE JD, 1976, BIOPOLYMERS, V15, P1345, DOI 10.1002/bip.1976.360150710; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; MORGAN JE, 1986, ARCH BIOCHEM BIOPHYS, V246, P225, DOI 10.1016/0003-9861(86)90467-4; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; PERRY M, 1982, J BIOL CHEM, V257, P7336; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; SCHROTH GP, 1990, FEBS LETT, V268, P117, DOI 10.1016/0014-5793(90)80987-T; SMITH RM, 1989, J BIOL CHEM, V264, P10574; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WHITLOCK JP, 1977, J BIOL CHEM, V252, P6516; WOOD MJ, 1991, J BIOL CHEM, V266, P5696; YAU P, 1982, EUR J BIOCHEM, V129, P281, DOI 10.1111/j.1432-1033.1982.tb07050.x; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233	37	308	314	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					305	314						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416938				2022-12-25	WOS:A1993KE60300047
J	CROWE, AJ; HAYMAN, MJ				CROWE, AJ; HAYMAN, MJ			POSTTRANSLATIONAL MODIFICATIONS OF THE ENV-SEA ONCOGENE PRODUCT - THE ROLE OF PROTEOLYTIC PROCESSING IN TRANSFORMATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; TYROSINE KINASE-ACTIVITY; CELL-SURFACE EXPRESSION; MET PROTO-ONCOGENE; C-MET; INSULIN-RECEPTOR; MAMMALIAN-CELLS; RETROVIRUS S13	The transforming gene product of the S13 avian erythroblastosis virus, env-sea, is a member of the growth factor receptor class of tyrosine kinases. The env-sea precursor protein gp155env-sea is proteolytically processed into the mature cleavage products gp85env-sea and gp70env-sea which are subsequently terminally glycosylated. Previous studies have shown that the abnormal glycosylation of gp155env-sea which takes place in the presence of the inhibitor castanospermine inhibits the proteolytic cleavage of gp155env-sea and blocks its transforming ability. To define a role for proteolytic processing of env-sea in transformation, we have introduced mutations at the protease recognition site which efficiently block cleavage without affecting the biosynthesis or transport of the resulting uncleaved protein. We show here that an uncleaved but fully glycosylated sea-encoded protein retains the ability to transform chicken embryo fibroblasts, indicating that proteolytic processing is not essential for transformation by the env-sea tyrosine kinase.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA42573, CA28146, 5T32 CA09176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1982, J CELL PHYSL S, V1, P195; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADAC J, 1986, VIROLOGY, V150, P491, DOI 10.1016/0042-6822(86)90313-2; CHAN AML, 1988, ONCOGENE, V2, P593; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; EINFELD D, 1988, P NATL ACAD SCI USA, V85, P8688, DOI 10.1073/pnas.85.22.8688; GEYER H, 1988, J BIOL CHEM, V263, P11760; GIORDANO S, 1989, ONCOGENE, V4, P1383; HARDWICK JM, 1986, J CELL BIOL, V103, P829, DOI 10.1083/jcb.103.3.829; HAYMAN M, 1978, VIROLOGY, V85, P475, DOI 10.1016/0042-6822(78)90454-3; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HEDO JA, 1983, J BIOL CHEM, V258, P20; HUNTER E, 1989, CURR TOP MICROBIOL, V157, P188; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1988, ONCOGENE, V2, P317; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, IN PRESS EMBO J; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PINTER A, 1984, J VIROL, V49, P452, DOI 10.1128/JVI.49.2.452-458.1984; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SCHWALLER M, 1989, VIROLOGY, V172, P367; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STOKER AW, 1988, J VIROL, V62, P1008, DOI 10.1128/JVI.62.3.1008-1015.1988; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	45	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					181	189						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423995				2022-12-25	WOS:A1993KN00500022
J	TAKAHASHI, M; ASAI, N; IWASHITA, T; ISOMURA, T; MIYAZAKI, K; MATSUYAMA, M				TAKAHASHI, M; ASAI, N; IWASHITA, T; ISOMURA, T; MIYAZAKI, K; MATSUYAMA, M			CHARACTERIZATION OF THE RET PROTOONCOGENE PRODUCTS EXPRESSED IN MOUSE L-CELLS	ONCOGENE			English	Article							PROTOONCOGENE RET; CADHERIN; TYROSINE; NEUROBLASTOMA	The ret proto-oncogene (proto-ret) encodes a receptor type tyrosine kinase with a cadherin-related sequence in the extracellular domain. To investigate whether the proto-Ret protein functions as a cell adhesion molecule like cadherins, we transfected the human proto-ret gene fused to the SV40 promoter or cytomegalovirus (CMV) promoter into mouse L cells in which cadherins are not expressed. Three transfectants with high levels of expression of the proto-Ret proteins were obtained. The proto-Ret proteins were expressed as 150 kDa and 170 kDa glycoproteins in transfectants as observed in human neuroblastoma cells. Cell fractionation experiments revealed that the 170 kDa protein but not the 150 kDa protein was detected predominantly in the plasma membrane fraction, indicating that the 170 kDa protein represents the mature glycosylated form of the proto-Ret protein present on the cell surface. Both 150 kDa and 170 kDa proto-Ret proteins showed tyrosine kinase activity in immunocomplex kinase assay. It is known that cadherins have Ca2+-dependent homophilic binding activity and are resistant to trypsinization in the presence of Ca2+. When L cells expressing the proto-Ret proteins were treated with trypsin in the presence of Ca2+, the 170 kDa protein was resistant to its digestion. On the other hand, it was completely digested in the presence of EGTA, suggesting the possibility that the proto-Ret protein interacts with Ca2+ like cadherins. However, the transfectants did not show clear adhesive properties in cell aggregation assays.	NAGOYA UNIV,SCH MED,DEPT SURG,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT RADIOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University	TAKAHASHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT PATHOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN.		Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1992, P JPN ACAD B-PHYS, V68, P106, DOI 10.2183/pjab.68.106; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187	15	89	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2925	2929						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414495				2022-12-25	WOS:A1993MC09300005
J	NAGIEC, MM; WELLS, GB; LESTER, RL; DICKSON, RC				NAGIEC, MM; WELLS, GB; LESTER, RL; DICKSON, RC			A SUPPRESSOR GENE THAT ENABLES SACCHAROMYCES-CEREVISIAE TO GROW WITHOUT MAKING SPHINGOLIPIDS ENCODES A PROTEIN THAT RESEMBLES AN ESCHERICHIA-COLI FATTY ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; SHUTTLE VECTORS; YEAST; MEMBRANE; STRAINS; SEQUENCE; DNA; TRANSCRIPTION; MANIPULATION; ACTIVATION	Saccharomyces cerevisiae normally requires sphingolipid biosynthesis for growth; however, mutant strains lacking sphingolipids have been isolated by suppression of a genetic defect in sphingolipid long chain base biosynthesis. To begin to understand the nature of the suppressor(s) we isolated and characterized a suppressor gene, SLC1 (sphingolipid compensation). DNA sequence analysis showed that the wild type SLC1 allele differs from the suppressor allele by a single nucleotide which changes Gln-44 in the predicted wild type protein to Leu4-4 in the predicted SLC1-1 suppressor protein. The predicted SLC1 protein sequence is homologous to the 1-acyl-sn-glycerol-3-phosphate acyltransferase of Escherichia coli encoded by the plsC gene. The homology extends to function as well since the SLC1 gene complements the growth defect in an E. coli strain mutated in plsC. These results suggest that the SLC1 protein has a fatty acyltransferase activity. SLC1 thus may be the first eucaryotic sn2-acylglyceride fatty acyltransferase gene to be cloned. SLC strains grown in the absence of long chain base make novel phosphatidylinositol derivatives (Lester, R. L., Wells, G. B., Oxford, G., and Dickson, R. C. (1993) J. Biol. Chem. 268, 845-856) having a C26 fatty acid at the sn-2 position and the same polar head groups as normal sphingolipids. We postulate that the SLC1 suppressor allele encodes a variant enzyme with an altered substrate specificity that enables it to use a C26 in place of a C-16/18 fatty acid precursor to acylate the sn-2 position of inositol-containing. glycerolipids.	UNIV KENTUCKY, MED CTR, DEPT BIOCHEM, 800 ROSE ST, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DORSMAN JC, 1989, NUCLEIC ACIDS RES, V17, P4917, DOI 10.1093/nar/17.13.4917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JOHNSTON SA, 1982, P NATL ACAD SCI USA, V79, P6871; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KUZHANDAIVELU N, 1992, MOL CELL BIOL, V12, P1924, DOI 10.1128/MCB.12.5.1924; LESTER RL, 1993, J BIOL CHEM, V268, P845; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OLSEN MV, 1986, P NATL ACAD SCI USA, V83, P7826; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; STILES JI, 1981, CELL, V25, P277, DOI 10.1016/0092-8674(81)90253-1; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; WELLS GB, 1983, J BIOL CHEM, V258, P200	40	146	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22156	22163						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408076				2022-12-25	WOS:A1993MC80900106
J	PETRONILLI, V; COLA, C; MASSARI, S; COLONNA, R; BERNARDI, P				PETRONILLI, V; COLA, C; MASSARI, S; COLONNA, R; BERNARDI, P			PHYSIOLOGICAL EFFECTORS MODIFY VOLTAGE SENSING BY THE CYCLOSPORINE A-SENSITIVE PERMEABILITY TRANSITION PORE OF MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED MEMBRANE TRANSITION; HEART-MITOCHONDRIA; CA-2+-DEPENDENT PORE; LIVER-MITOCHONDRIA; OXIDATIVE STRESS; DIVALENT-CATIONS; CA-2+ RELEASE; RUTHENIUM RED; CALCIUM; CHANNELS	This paper reports an investigation on the modulation of the mitochondrial permeability transition pore (MTP) by the membrane potential. Energized rat liver mitochondria loaded with a small Ca2+ pulse in sucrose medium supplemented with phosphate favor a high MTP ''closed'' probability because of the high membrane potential and therefore maintain a low permeability to sucrose. Upon depolarization by the addition of fully uncoupling concentrations of carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) mitochondria favor a high MTP ''open'' probability and rapidly undergo a process of osmotic swelling following sucrose diffusion toward the matrix. A titration with FCCP reveals that discrete subpopulations of mitochondria with different gating potentials for MTP opening may exist, since increasing concentrations of FCCP increase the fraction of mitochondria undergoing osmotic swelling. We show that physiological effectors (Ca2+, Mg2+, ADP, palmitate) modify pore opening in a mitochondrial population by shifting the fraction of mitochondria with a functionally open pore at any given membrane potential. Many inducers and inhibitors may therefore affect the pore directly through an effect on the MTP voltage sensing rather than indirectly through an effect on the membrane potential. Thus, many effectors may induce pore opening by shifting the MTP gating potential to higher levels, whereas many inhibitors may induce pore closure by shifting the MTP gating potential to lower levels.	UNIV PADUA, SCH MED,DEPT BIOMED SCI, BIOPHYS & MEMBRANE BIOL LAB,VIA TRIESTE 75, I-35121 PADUA, ITALY; CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, I-35121 PADUA, ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR)			Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEATRICE MC, 1982, J BIOL CHEM, V257, P7161; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1992, MECHANICS SWELLING C, P357; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; KAMISHIMA T, 1992, AM J PHYSIOL, V263, pC69, DOI 10.1152/ajpcell.1992.263.1.C69; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1991, ANNU REV BIOPHYS BIO, V20, P65, DOI 10.1146/annurev.biophys.20.1.65; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	37	294	306	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21939	21945						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408050				2022-12-25	WOS:A1993MC80900076
J	CLEVER, J; DEAN, DA; KASAMATSU, H				CLEVER, J; DEAN, DA; KASAMATSU, H			IDENTIFICATION OF A DNA-BINDING DOMAIN IN SIMIAN VIRUS-40 CAPSID PROTEINS VP2 AND VP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 NUCLEOPROTEIN COMPLEXES; STRUCTURAL PROTEINS; INTRACELLULAR FORMS; AMINO-ACIDS; RESOLUTION; CORE; POLYOMAVIRUS; LOCALIZATION; PURIFICATION; POLYPEPTIDES	We have identified both biochemically and genetically a protein domain within the simian virus 40 virion protein Vp3, and within Vp2 since its carboxyl two-thirds are identical to the full-length Vp3, that binds DNA in a sequence nonspecific manner. Both the Vp2 and Vp3 (Vp2/3) components of SV40 and mutant SV40(202T) bound either SV40 or pBR322 DNA equally well. Wild type and mutant Vp2/3 proteins, expressed as fusion proteins with glutathione S-transferase (GST), were tested for their ability to bind DNA. GST-Vp3 bound DNA at physiological salt concentrations with an apparent K(d) of 2.5 x 10(-8) M and also bound RNA with 4-fold higher affinity. Over 90% of the nucleic acid binding, and all of the activity, was lost upon removal of the carboxyl-terminal 13 and 35 residues, respectively. The DNA binding domain was shown to be distinct and separable from the Vp2/3 nuclear transport signal since mutations within the nuclear transport signal that reduce or abolish nuclear localization of Vp2/3 had no effect on the DNA binding activity of mutant Vp2/3 fusion proteins. The carboxyl-terminal 40 residues of Vp2/3 in the form of a beta-galactosidase fusion protein, F6, are sufficient for DNA binding and may cause compaction of the DNA. The significance of this DNA binding and possible compaction are discussed in relation to the assembly of virion particles.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA050574] Funding Source: NIH RePORTER; NCI NIH HHS [CA50574, CA09148] Funding Source: Medline; NIGMS NIH HHS [GM07104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BAUMGARTNER I, 1979, VIROLOGY, V96, P54, DOI 10.1016/0042-6822(79)90172-7; BELLARD M, 1976, EUR J BIOCHEM, V70, P543, DOI 10.1111/j.1432-1033.1976.tb11046.x; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRADY JN, 1980, J VIROL, V35, P371, DOI 10.1128/JVI.35.2.371-381.1980; CHRISTIANSEN G, 1977, J VIROL, V21, P1079, DOI 10.1128/JVI.21.3.1079-1084.1977; CLEVER J, 1991, VIROLOGY, V181, P78, DOI 10.1016/0042-6822(91)90472-N; CLEVER J, 1992, THESIS U CALIFORNIA; COCAPRADOS M, 1979, J VIROL, V31, P199, DOI 10.1128/JVI.31.1.199-208.1979; CRIMISI C, 1976, J VIROL, V17, P204; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; FENDRICK JL, 1983, J VIROL METHODS, V7, P93, DOI 10.1016/0166-0934(83)90095-2; FERNANDEZMUNOZ R, 1979, J VIROL, V29, P612, DOI 10.1128/JVI.29.2.612-623.1979; Flint S. J, 1981, DNA TUMOR VIRUSES; GARBER EA, 1980, VIROLOGY, V107, P389, DOI 10.1016/0042-6822(80)90306-2; GARCEA RL, 1983, VIROLOGY, V130, P65, DOI 10.1016/0042-6822(83)90118-6; GHARAKHANIAN E, 1990, VIROLOGY, V178, P62, DOI 10.1016/0042-6822(90)90379-6; GHARAKHANIAN E, 1988, P NATL ACAD SCI USA, V85, P6607, DOI 10.1073/pnas.85.18.6607; GHARAKHANIAN E, 1987, VIROLOGY, V157, P440, DOI 10.1016/0042-6822(87)90286-8; GRIFFITH JD, 1975, SCIENCE, V187, P1202, DOI 10.1126/science.187.4182.1202; GRIFFITH JP, 1992, NATURE, V355, P652, DOI 10.1038/355652a0; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG ES, 1972, J VIROL, V9, P923, DOI 10.1128/JVI.9.6.923-929.1972; JAKOBOVITS EB, 1980, VIROLOGY, V102, P107, DOI 10.1016/0042-6822(80)90074-4; KASAMATSU H, 1979, J VIROL, V32, P648, DOI 10.1128/JVI.32.2.648-660.1979; KASAMATSU H, 1976, BIOCHEM BIOPH RES CO, V68, P927, DOI 10.1016/0006-291X(76)91234-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIN W, 1984, J VIROL, V50, P363, DOI 10.1128/JVI.50.2.363-371.1984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILAVETZ B, 1982, J VIROL, V43, P830, DOI 10.1128/JVI.43.3.830-839.1982; MORELAND RB, 1991, J VIROL, V65, P1168, DOI 10.1128/JVI.65.3.1168-1176.1991; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1986, J VIROL, V59, P740, DOI 10.1128/JVI.59.3.740-742.1986; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993	44	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20877	20883						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407920				2022-12-25	WOS:A1993MA28800040
J	GROSS, MD; GOSNELL, M; TSARBOPOULOS, A; HUNZIKER, W				GROSS, MD; GOSNELL, M; TSARBOPOULOS, A; HUNZIKER, W			A FUNCTIONAL AND DEGENERATE PAIR OF EF HANDS CONTAINS THE VERY HIGH-AFFINITY CALCIUM-BINDING SITE OF CALBINDIN-D(28K)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; TROPONIN-C; MOLECULAR-STRUCTURE; PEPTIDE-FRAGMENTS; MASS-SPECTROMETRY; PROTEIN; RADIOIMMUNOASSAY; CALMODULIN; DOMAIN; MUSCLE	Calbindin-D28K, a member of the troponin C superfamily of calcium-binding proteins, had six putative EF hand domains containing one very high affinity and two to three lower affinity calcium-binding sites. The location and binding activity of the calcium-binding sites were examined with a recombinant calbindin-D28K protein. This protein (Calb I-II) only contained EF hand domains 1 and 2 of calbindin-D28K. Binding of calcium and calcium analogs, the lanthanides, by the recombinant protein was determined in fluorescence emission experiments. Calb I-II bound 1 mol of terbium/mol of protein. Terbium was displaced from Calb I-II by other lanthanides and calcium. Fluorescence from terbium was not quenched by holmium. These results and Hill plots of calcium binding activity, determined from intrinsic protein fluorescence measurements, indicated the presence of a single high affinity calcium-binding site on Calb I-II. The properties of the binding site indicated that the very high affinity site of calbindin-D28K was located in EF hand domains 1 and 2 of the protein. In addition, these findings indicated the NH2-terminal pair of EF hands in calbindin-D28K did not depend on interactions with other domains in the protein for high affinity calcium binding activity. The results suggested at least one calcium-binding domain of calbindin-D28K can exist as an independent EF hand pair.	SCHERING PLOUGH RES INST,KENILWORTH,NJ 07033; HOFFMAN LA ROCHE LTD,DEPT BIOL PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	Merck & Company; Schering-Plough Research Institute; Roche Holding	GROSS, MD (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST,SUITE 300,MINNEAPOLIS,MN 55454, USA.							BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BISHOP CW, 1984, J BIOL CHEM, V259, P3355; BREDDERMAN PJ, 1974, BIOCHEMISTRY-US, V13, P1687, DOI 10.1021/bi00705a021; CHRISTAKOS S, 1979, ENDOCRINOLOGY, V104, P1495, DOI 10.1210/endo-104-5-1495; CORSON DC, 1986, BIOCHEMISTRY-US, V25, P1817, DOI 10.1021/bi00355a055; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DRABIKOWSKI W, 1982, J BIOL CHEM, V257, P1584; FULLMER CS, 1987, P NATL ACAD SCI USA, V84, P4772, DOI 10.1073/pnas.84.14.4772; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GROSS MD, 1988, J BIOL CHEM, V263, P14426; GROSS MD, 1987, J BIOL CHEM, V262, P6539; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Hochuli E, 1990, Genet Eng (N Y), V12, P87; Horrocks W. D., 1982, ADV INORG BIOCHEM, P201; HUNZIKER W, 1986, P NATL ACAD SCI USA, V83, P7578, DOI 10.1073/pnas.83.20.7578; HUNZIKER W, 1988, MOL ENDOCRINOL, V2, P465, DOI 10.1210/mend-2-5-465; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LEATHERS VL, 1985, FED PROC, V44, P754; LITWILLER RD, 1986, FASEB J, V45, P481; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; METZLER DE, 1977, BIOCH CHEM REACTIONS, P182; MINGHETTI PP, 1988, MOL ENDOCRINOL, V2, P355, DOI 10.1210/mend-2-4-355; MORGAN DW, 1986, BIOCHEM BIOPH RES CO, V138, P547, DOI 10.1016/S0006-291X(86)80531-9; POTTER JD, 1975, J BIOL CHEM, V250, P4628; REID RE, 1980, J BIOL CHEM, V255, P3642; REID RE, 1981, J BIOL CHEM, V256, P2742; SHIMURA F, 1984, ENDOCRINOLOGY, V115, P1964, DOI 10.1210/endo-115-5-1964; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STORER AC, 1976, BIOCHEM J, V159, P1; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; TAKAGI T, 1986, FEBS LETT, V201, P41, DOI 10.1016/0014-5793(86)80567-1; TSARBOPOULOS A, 1989, BIOMED ENVIRON MASS, V18, P387, DOI 10.1002/bms.1200180605; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WILSON PW, 1985, NUCLEIC ACIDS RES, V13, P8867, DOI 10.1093/nar/13.24.8867; YAMAKUNI T, 1986, NUCLEIC ACIDS RES, V14, P6768, DOI 10.1093/nar/14.16.6768	39	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20917	20922						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407926				2022-12-25	WOS:A1993MA28800046
J	LITVINOV, SV; HILKENS, J				LITVINOV, SV; HILKENS, J			THE EPITHELIAL SIALOMUCIN, EPISIALIN, IS SIALYLATED DURING RECYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MANNOSE 6-PHOSPHATE RECEPTOR; CARCINOMA-ASSOCIATED MUCIN; TRANS-GOLGI NETWORK; CELL-SURFACE; ASIALOGLYCOPROTEIN RECEPTOR; INTRACELLULAR MOVEMENT; PROTEINS; APPARATUS; CDNA	Episialin, the sialomucin encoded by the MUC1 gene is abundantly present at the surface of various epithelial cells. it is a transmembrane molecule that matures through several intermediate forms generated by proteolysis and sequential addition and processing of numerous O-linked glycans. Here we demonstrate that one of the biosynthetic intermediates, the premature form, which is incompletely glycosylated appears at the cell surface. By neuraminidase protection assays we show that cell surface-associated forms of episialin are constitutively internalized (0.9% of surface fraction/min) and recycled, with the intracellular residence time and total cycle time being approximately 66 and 143 min, respectively. During recycling, sialic acid residues are added to the premature form of episialin resulting in complete maturation of the molecule. Complete sialylation of episialin requires several rounds of recycling which continues after sialylation is apparently completed. The recycling of episialin may serve to achieve and maintain a high degree of sialylation.	ANTONI VAN LEEUWENHOEK HOSP,NETHERLANDS CANC INST,DIV TUMOR BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Hilkens, John/0000-0002-0932-7793				BRANDLI AW, 1989, EMBO J, V8, P3207, DOI 10.1002/j.1460-2075.1989.tb08479.x; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; BUSCH G, 1989, EUR J CELL BIOL, V50, P257; CALAFAT J, 1988, CANCER RES, V48, P3822; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUM JR, 1992, J BIOL CHEM, V267, P21375; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1988, Cancer Reviews, V11-12, P25; HILKENS J, 1989, CANCER RES, V49, P786; HULL SR, 1991, J BIOL CHEM, V266, P13580; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JIN M, 1989, J BIOL CHEM, V264, P7675; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; LINSLEY PS, 1988, J BIOL CHEM, V263, P8390; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; REICHNER JS, 1988, J BIOL CHEM, V263, P16316; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; WINDELL CC, 1982, CELL, V28, P61; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2	38	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21364	21371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407976				2022-12-25	WOS:A1993MA28800104
J	SHIRO, Y; IWATA, T; MAKINO, R; FUJII, M; ISOGAI, Y; IIZUKA, T				SHIRO, Y; IWATA, T; MAKINO, R; FUJII, M; ISOGAI, Y; IIZUKA, T			SPECIFIC MODIFICATION OF STRUCTURE AND PROPERTY OF MYOGLOBIN BY THE FORMATION OF TETRAZOLYHISTIDINE-64(E7) - REACTION OF THE MODIFIED MYOGLOBIN WITH MOLECULAR-OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; HEME ENVIRONMENTAL STRUCTURES; LIGAND-BINDING PROPERTIES; DISTAL HISTIDINE; CYANOGEN-BROMIDE; REVERSIBLE OXYGENATION; SUPEROXIDE PRODUCTION; GLYCERA-DIBRANCHIATA; COBALT MYOGLOBINS; RESPIRATORY BURST	Tetrazole-myoglobin (Tet-Mb), a site selectively modified myoglobin with tetrazole anion (-CN4-) covalently attached to the imidazole N(epsilon) of the distal histidine 64(E7) (see Fig. 1; Kamiya, N., Shiro, Y., Iwata, T., Iizuka, T., and Iwasaki, H. (1991) J. Am. Chem. Soc. 113, 1826-1829), exhibited unique properties in the reduction from ferric to ferrous states and in the reaction of its deoxy form with O2. The redox potential of Tet-Mb is obtained to be -193 mV, which is much lower than that of unmodified (native) myoglobin (50 mV), possibly due to the electrostatic interaction between the heme iron and the tetrazole group. The ferrous deoxy form of Tet-Mb was rapidly oxidized to its ferric form in the reaction with O2 at room temperature through an intermediary formation of its oxy form and with the generation of O2-. The oxy form of Tet-Mb can be detected by the optical spectral measurement at -12-degrees-C, the rapid scan measurement at room temperature, and the electron spin resonance measurement of its cobalt-substituted derivative (Tet-Mb(Co2+)) at 77 K. In the kinetic measurement of the O2 binding reaction to Tet-Mb, its association and dissociation rate constants in the bimolecular reaction were 6.1 x 10(7) M-1 s-1 and 2200 s-1, respectively, showing that the tetrazole modification of His-64 extremely accelerates its association and dissociation rates. Taken together with the extremely fast autoxidation rate (53 h-1) obtained, these kinetic results suggested that the channel of O2 from the solvent region to the protein interior is open enough to pass the external ligand. The structure is discussed in relation to those of some genetic mutants. Taking these properties, we demonstrated that Tet-Mb can catalyze O2 consumption to generate O2-, coupled with the NADH-supported enzymatic reduction system of cytochrome P-450cam under an aerobic condition.	GAKUSHUIN UNIV, FAC SCI, DEPT CHEM, TOSHIMA KU, TOKYO 171, JAPAN; HIMEJI INST TECHNOL, FAC SCI, HYOGO 67812, JAPAN	Gakushuin University; University of Hyogo	SHIRO, Y (corresponding author), INST PHYS & CHEM RES, WAKO, SAITAMA 35101, JAPAN.		Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327; Isogai, Yasuhiro/0000-0001-6905-4208				ADACHI S, 1992, BIOCHEMISTRY-US, V31, P8613, DOI 10.1021/bi00151a031; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1971, BIOCHEMISTRY-US, V10, P1604, DOI 10.1021/bi00785a016; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HAGIHARA B, 1971, J BIOCHEM-TOKYO, V69, P355, DOI 10.1093/oxfordjournals.jbchem.a129474; HORI H, 1989, J BIOL CHEM, V264, P5715; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KAMIYA N, 1991, J AM CHEM SOC, V113, P1826, DOI 10.1021/ja00005a056; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; MAKINO R, 1980, J BIOL CHEM, V255, P1883; MAKINO R, 1976, BIOCHEMISTRY-US, V15, P4748, DOI 10.1021/bi00666a033; MAKINO R, 1986, J BIOL CHEM, V261, P1444; Makino R., 1982, OXYGENASES OXYGEN ME, P467; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MORISHIMA I, 1989, BIOCHEMISTRY-US, V28, P7582, DOI 10.1021/bi00445a012; MORISHIMA I, 1985, J AM CHEM SOC, V107, P1063, DOI 10.1021/ja00290a055; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PADLAN EA, 1974, J BIOL CHEM, V249, P4067; PARKHURST LJ, 1980, BIOCHEMISTRY-US, V19, P2688, DOI 10.1021/bi00553a023; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROOME PW, 1983, J BIOL CHEM, V258, P2593; SATO F, 1990, J BIOL CHEM, V265, P2004; SATOH Y, 1981, J BIOL CHEM, V256, P272; SHIMADA H, 1989, BIOCHEM BIOPH RES CO, V158, P110, DOI 10.1016/S0006-291X(89)80184-6; SHIRO Y, 1984, BIOCHEMISTRY-US, V23, P4879, DOI 10.1021/bi00316a010; SHIRO Y, 1989, J AM CHEM SOC, V111, P7707, DOI 10.1021/ja00202a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUGAWARA Y, 1980, EUR J BIOCHEM, V110, P241, DOI 10.1111/j.1432-1033.1980.tb04861.x; TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5; VARADARAJAN R, 1989, SCIENCE, V243, P69, DOI 10.1126/science.2563171; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; YONETANI T, 1974, J BIOL CHEM, V249, P682; YONETANI T, 1967, J BIOL CHEM, V242, P5008; YONETANI T, 1974, J BIOL CHEM, V249, P2168	46	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19983	19990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397193				2022-12-25	WOS:A1993LY01900013
J	DEKKER, LV; MCINTYRE, P; PARKER, PJ				DEKKER, LV; MCINTYRE, P; PARKER, PJ			MUTAGENESIS OF THE REGULATORY DOMAIN OF RAT PROTEIN KINASE-C-ETA - A MOLECULAR-BASIS FOR RESTRICTED HISTONE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; ACTIVATION; EPSILON; FAMILY; EXPRESSION	Protein kinase C-eta (PKC-eta) is a member of the protein kinase C family that is characterized by Ca2+ independence and restricted histone kinase activity (Dekker, L. V., Parker, P. J., and McIntyre, P. (1992) FEBS Lett. 312, 195-199). Here we have investigated the molecular basis of this low histone kinase activity by limited proteolysis and site-directed mutagenesis. It is shown that a 46-kDa C-terminal tryptic fragment, representing the catalytic domain of PKC-eta, can phosphorylate histone. The K(m) value for histone of this catalytic fragment is 25-fold lower than that of intact PKC-eta. Thus, sites in the N-terminal regulatory domain upstream of the trypsin cleavage site (near residue 320) restrict histone kinase activity of intact PKC-eta. Deletion of the ''V(o) domain'' (residues 2-137) generates a PKC-eta mutant that shows the same cofactor dependence and substrate phosphorylation as wild-type PKC-eta, indicating that the relevant sites do not appear to lie in the V(o) domain but between amino acid 137 and the start of the catalytic domain. Deletion of the pseudosubstrate region (residue 155-171) generates a cofactor-independent kinase that has high histone kinase activity. A pseudosubstrate site point mutation in which the alanine residue at position 161 is replaced with a glutamic acid residue shows the same properties as the pseudosubstrate site deletion mutant. K(m) values for histone for both mutants are similar to that observed for the catalytic fragment. Therefore, in addition to its role in conferring cofactor dependence, the pseudosubstrate site also mediates the low histone kinase activity of wild-type PKC-eta. The data are discussed in the light of current models for PKC activation.	SANDOZ INST MED RES,LONDON WC1E 6BN,ENGLAND	Novartis; Sandoz	DEKKER, LV (corresponding author), IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Dekker, Lodewijk/J-6934-2013; Parker, Peter j/D-5192-2013	Dekker, Lodewijk/0000-0001-5247-3297; McIntyre, Peter/0000-0001-9506-5998; parker, peter/0000-0002-6218-2933				BELL RM, 1991, J BIOL CHEM, V266, P4661; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; EHRLICH HA, 1989, PCR TECHNOLOGY; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MARAMUTSU M, 1992, FEBS LETT, V311, P75; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ORR JW, 1992, J BIOL CHEM, V267, P15263; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SCHAAP D, 1989, FEBS LETT, V243, P3512; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19498	19504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396139				2022-12-25	WOS:A1993LW81900055
J	DALESSANDRO, F; COLAMONICI, OR; NORDAN, RP				DALESSANDRO, F; COLAMONICI, OR; NORDAN, RP			DIRECT ASSOCIATION OF INTERLEUKIN-6 WITH A 130-KDA COMPONENT OF THE INTERLEUKIN-6 RECEPTOR SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-II; PLASMACYTOMA GROWTH-FACTOR; CROSS-LINKING; SIGNAL TRANSDUCER; CELLS; PROTEIN; DIFFERENTIATION; EXPRESSION; IL-6; INTERFERON-BETA-2	Affinity cross-linking of membrane bound I-125-interleukin-6 (IL-6) on several cell lines revealed a three-band pattern of IL-6-containing cross-linked complexes with molecular masses of 100, 120, and 150 kDa. To identify the membrane components that were associated with IL-6 in the three complexes, we employed the Denny-Jaffe reagent, a heterobifunctional, cleavable cross-linker that allows the transfer of I-125 from the ligand to its receptor. Samples cross-linked with Denny-Jaffe reagent were analyzed by two-dimensional SDS-polyacrylamide gel electrophoresis in which the cross-linker was cleaved prior to the second dimension. This analysis revealed that IL-6 directly associates with a 130-kDa membrane protein thus allowing the formation of the 150-kDa complex. In addition, both the 100- and 120-kDa cross-linked complexes were shown to include an 80-kDa membrane glycoprotein associated with one and two IL-6 molecules, respectively.	NCI,CLIN PHARMACOL BRANCH,BLDG 10,RM 13N268,BETHESDA,MD 20892; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Chicago								AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; DENNY JB, 1984, P NATL ACAD SCI-BIOL, V81, P5286, DOI 10.1073/pnas.81.17.5286; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GAZDAR AF, 1986, BLOOD, V67, P1542; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HIRATA Y, 1989, J IMMUNOL, V143, P2900; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; JAFFE CL, 1980, BIOCHEMISTRY-US, V19, P4423, DOI 10.1021/bi00560a007; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHWAB G, 1991, BLOOD, V77, P587; SHABO Y, 1989, MOL CELL BIOL, V9, P4109, DOI 10.1128/MCB.9.9.4109; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SIEGALL CB, 1990, MOL CELL BIOL, V10, P2443, DOI 10.1128/MCB.10.6.2443; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; VANCURA S, 1987, P NATL ACAD SCI USA, V84, P3575, DOI 10.1073/pnas.84.11.3575; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	32	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2149	2153						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420983				2022-12-25	WOS:A1993KH62000097
J	OLEINIKOV, AV; PERROUD, B; WANG, B; TRAUT, RR				OLEINIKOV, AV; PERROUD, B; WANG, B; TRAUT, RR			STRUCTURAL AND FUNCTIONAL DOMAINS OF ESCHERICHIA-COLI RIBOSOMAL-PROTEIN L7/L12 - THE HINGE REGION IS REQUIRED FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; C-TERMINAL DOMAIN; MONOCLONAL-ANTIBODIES; LOCALIZATION; SUBUNIT; L7-L12; EPITOPES	Variant forms of Escherichia coli ribosomal protein L7/L12 were constructed, overexpressed, and purified. These included proteins that deleted residues 35-52 (DELTA35-52) and 42 to 52 (DELTA42-52), others that contained single cysteine substitutions at residues 63 and 89, and combinations of the deletions and cysteine substitutions. Chemical modification of the introduced cysteine residues with [C-14]iodoacetamide was used to radiolabel the protein variants in order to quantify their binding to the ribosome. Neither of the deletions in the hinge domain, DELTA35-52 and DELTA42-52, had any effect on L7/L12 dimer formation as detected by cross-linking by dimethyl suberimidate. Perpendicular urea gradient gel electrophoresis showed that both deletion variants retained a compact structural element attributable to the globular C-terminal domain. Reconstitution of core particles depleted of wild type L7/L12 with the deletion proteins showed that DELTA42-52 bound normally in 4 copies per particle, whereas DELTA35-52 bound in only 2.5 copies following isolation of the particles by high speed centrifugation or gel filtration. Ribosomes mixed with an excess of the deletion variants and assayed directly for polyphenylalanine synthesis were completely inactive. The results suggest that the flexibility conferred by the hinge is required for activity, perhaps by allowing the C-terminal domain to occupy a location near the base of the L7/L12 stalk.			OLEINIKOV, AV (corresponding author), UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA.				NIGMS NIH HHS [GM17924] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017924, R01GM017924] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHUEV VN, 1989, J BIOL CHEM, V264, P4498; CASIANO C, 1990, J BIOL CHEM, V265, P18757; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; CREIGHTON TE, 1980, NATURE, V284, P487, DOI 10.1038/284487a0; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; GEORGALIS Y, 1989, J BIOL CHEM, V264, P9210; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GUDKOV AT, 1991, BIOCHIMIE, V73, P1387, DOI 10.1016/0300-9084(91)90168-Z; GUDKOV AT, 1978, EUR J BIOCHEM, V90, P309, DOI 10.1111/j.1432-1033.1978.tb12605.x; GUDKOV AT, 1978, EUR J BIOCHEM, V90, P313, DOI 10.1111/j.1432-1033.1978.tb12606.x; GUDKOV AT, 1982, FEBS LETT, V138, P229, DOI 10.1016/0014-5793(82)80448-1; HAMEL E, 1972, J BIOL CHEM, V247, P805; KOTELIANSKY VE, 1978, EUR J BIOCHEM, V90, P319, DOI 10.1111/j.1432-1033.1978.tb12607.x; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LEIJONMARCK M, 1981, STRUCTURAL ASPECTS R, P761; LI K, 1975, ANAL BIOCHEM, V64, P121, DOI 10.1016/0003-2697(75)90413-3; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; Maniatis T., 1982, MOL CLONING; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; OLSON HM, 1986, J BIOL CHEM, V261, P6924; SCHOP EN, 1982, EUR J BIOCHEM, V128, P371; SOMMER A, 1985, J BIOL CHEM, V260, P6522; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THIELEN APGM, 1984, BIOCHEMISTRY-US, V23, P3317; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; VANAGTHOVEN AJ, 1975, BIOCHEM BIOPH RES CO, V64, P1184, DOI 10.1016/0006-291X(75)90818-9; VERSCHOOR A, 1985, J ULTRA MOL STRUCT R, V92, P180, DOI 10.1016/0889-1605(85)90045-X; ZECHERLE GN, 1992, J BIOL CHEM, V267, P5889; ZECHERLE GN, 1992, BIOCHEMISTRY-US, V31, P9526, DOI 10.1021/bi00155a003	31	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					917	922						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419370				2022-12-25	WOS:A1993KG07700027
J	SCOTT, CW; SPREEN, RC; HERMAN, JL; CHOW, FP; DAVISON, MD; YOUNG, J; CAPUTO, CB				SCOTT, CW; SPREEN, RC; HERMAN, JL; CHOW, FP; DAVISON, MD; YOUNG, J; CAPUTO, CB			PHOSPHORYLATION OF RECOMBINANT TAU BY CAMP-DEPENDENT PROTEIN-KINASE - IDENTIFICATION OF PHOSPHORYLATION SITES AND EFFECT ON MICROTUBULE ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; ABNORMAL PHOSPHORYLATION; BRAIN; TUBULIN; PURIFICATION; EPITOPE; ALZ-50; DEPHOSPHORYLATION	Tau protein is an integral component of paired helical filaments, a pathological feature of Alzheimer's disease. tau extracted from these filaments displays decreased electrophoretic mobility due to aberrant phosphorylation. Here we show that recombinant human tau can be phosphorylated by cAMP-dependent protein kinase resulting in decreased electrophoretic mobility. Phosphorylation of tau by cAMP-dependent protein kinase caused a 92% decrease in the maximum rate of tau-induced microtubule assembly. The sites of phosphorylation were identified by digesting phosphorylated tau with proteases, separating the peptides by reversed-phase HPLC, and analyzing the isolated peptides by liquid-secondary ion mass spectrometry and solid-phase N-terminal sequencing. Five phosphorylation sites were identified, two of which were located within microtubule binding domains. One site was previously shown to be the sole phosphorylation site for CaM kinase II; phosphorylation at this site by CaM kinase II was sufficient to cause decreased electrophoretic mobility (Steiner, B., Mandelkow, E. M., Biernat, J., Gustke, N., Meyer, H. E., Schmidt, B., Mieskes, G., Soling, H. D., Drechsel, D., Kirschner, M. W., Goedert, M., and Mandelkow, E. (1990) EMBO J. 9, 3539-3544). Thus two different second messenger-dependent protein kinases can phosphorylate tau at the same site and induce a shift in tau mobility like that seen in Alzheimer's disease.	ICI PHARMACEUT DIV, DEPT BIOTECHNOL, MACCLESFIELD, CHESHIRE, ENGLAND		SCOTT, CW (corresponding author), ICI AMER INC, DEPT PHARMACOL, ICI PHARMACEUT GRP, WILMINGTON, DE 19897 USA.							BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CAPUTO CB, 1989, BIOCHIM BIOPHYS ACTA, V1012, P299, DOI 10.1016/0167-4889(89)90112-2; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GASESTEL M, 1991, J BIOL CHEM, V266, P14721; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GIBSON BW, 1990, METHOD ENZYMOL, V193, P480, DOI 10.1016/0076-6879(90)93434-M; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7948; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MURPHY DB, 1982, METHOD CELL BIOL, V24, P31; PERRY G, 1991, J NEUROSCI, V11, P1748; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; RICKENBERG HV, 1987, ENZYMES, V18, P419; RODER HM, 1991, J NEUROSCI, V11, P3325; SCOTT CW, 1991, J NEUROSCI RES, V30, P154, DOI 10.1002/jnr.490300116; SCOTT CW, 1992, J NEUROSCI RES, V33, P19, DOI 10.1002/jnr.490330104; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; UEDA K, 1990, J NEUROSCI, V10, P3295; WICHE G, 1991, INT REV CYTOL, V124, P217; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YANG SD, 1991, J PROTEIN CHEM, V10, P171, DOI 10.1007/BF01024781	52	198	200	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1166	1173						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419321				2022-12-25	WOS:A1993KG07700061
J	SWIEZEWSKA, E; DALLNER, G; ANDERSSON, B; ERNSTER, L				SWIEZEWSKA, E; DALLNER, G; ANDERSSON, B; ERNSTER, L			BIOSYNTHESIS OF UBIQUINONE AND PLASTOQUINONE IN THE ENDOPLASMIC RETICULUM-GOLGI MEMBRANES OF SPINACH LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PLANT-MITOCHONDRIA; DOLICHOL; COMPARTMENTATION; PRENYLQUINONES; LOCALIZATION; CHLOROPLASTS; ENVELOPE; SYSTEM; CELLS	The localization of ubiquinone (UQ) and plastoquinone (PQ) biosynthesis in subfractions isolated from spinach leaves has been studied. UQ-9 and UQ-10 were found mainly in mitochondria, whereas PQ was enriched in chloroplasts, but also found in Golgi membranes. Alpha-unsaturated polyprenol-11 was also present at a low concentration in chloroplasts. Autoradiography revealed the presence of nonaprenyl-4-hydroxy-benzoate (NPHB) and nonaprenyl-2-methylquinol (NPMQ) transferase activities involved in quinone biosynthesis in all subfractions, but the specific activities involved in quinone biosynthesis in the total microsomal fraction were 20 times higher than those in mitochondria and chloroplasts. The isolated Golgi vesicles were particularly enriched in both activities. When the incubation medium containing total microsomes or Golgi membranes was supplemented with NADH, NADPH, S-adenosylmethionine, and an ATP-generating system, NPHB and NPMQ were transferred to UQ-9 and PQ, respectively. trans-Prenyltransferase, which synthesizes the side chain of UQ and PQ, was present in the total microsomal fraction. With farnesyl-PP as substrate, no product was formed, but with geranyl-PP, solanesyl-PP was synthesized and transferred to 4-hydroxybenzoate present in the total microsomal fraction. The results show that these membranes from spinach contain farnesyl-PP synthetase. It is concluded that the plant leaf Golgi membranes contain the enzymes for both UQ and PQ biosynthesis and that a specific transport and targeting system is required for selective transfer of UQ to the mitochondria and of PQ to the chloroplast.	KAROLINSKA INST, HUDDINGE HOSP, CLIN RES CTR, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet	SWIEZEWSKA, E (corresponding author), UNIV STOCKHOLM, DEPT BIOCHEM, ARRHENIUS LABS NAT SCI, S-10691 STOCKHOLM, SWEDEN.		Andersson, Bertil/C-9328-2009	Swiezewska, Ewa/0000-0002-3439-8948				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BACH TJ, 1990, RECENT ADV PHYTOCHEM, V24, P1; BACH TJ, 1983, Z NATURFORSCH C, V38, P212; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1975, ANAL BIOCHEM, V69, P114, DOI 10.1016/0003-2697(75)90572-2; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; ELMBERGER PG, 1989, LIPIDS, V24, P919, DOI 10.1007/BF02544535; ERNSTER L, 1991, BIOMED CLIN, V6, P45; ERNSTER L, 1992, BIOFACTORS, V3, P241; ERNSTER L, 1962, J CELL BIOL, V15, P563, DOI 10.1083/jcb.15.3.563; FERON G, 1990, FEBS LETT, V271, P236, DOI 10.1016/0014-5793(90)80414-E; Goodwin T. W., 1977, Lipids and lipid polymers in higher plants., P29; HACHNEL W, 1984, ANNU REV PLANT PHYS, V35, P659; HAMASUR B, 1990, PHYSIOL PLANTARUM, V78, P367, DOI 10.1111/j.1399-3054.1990.tb09050.x; HUNDAL T, 1991, 1ST NORD C PHOT COP; KALEN A, 1990, J BIOL CHEM, V265, P1158; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; KEENAN RW, 1975, ANAL BIOCHEM, V69, P504, DOI 10.1016/0003-2697(75)90153-0; KREUZ K, 1984, EUR J BIOCHEM, V141, P531, DOI 10.1111/j.1432-1033.1984.tb08225.x; LICHTENTHALER HK, 1981, BIOCHIM BIOPHYS ACTA, V641, P99, DOI 10.1016/0005-2736(81)90572-1; LOW P, 1992, LIPIDS, V27, P1, DOI 10.1007/BF02537050; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTKEBRINKHAUS F, 1984, EUR J BIOCHEM, V141, P537, DOI 10.1111/j.1432-1033.1984.tb08226.x; LUTKEBRINKHAUS F, 1987, METHOD ENZYMOL, V148, P486; MITCHELL P, 1991, BIOMEDICAL CLIN ASPE, P3; MOORE DJ, 1979, EUR J CELL BIOL, V20, P195; PENNOCK JF, 1985, METHOD ENZYMOL, V110, P313; SCHINDLER S, 1982, BIOCH METABOLISM PLA, P545; SIEGENTHALER PA, 1976, EUR J BIOCHEM, V61, P575; SOLL J, 1985, ARCH BIOCHEM BIOPHYS, V238, P290, DOI 10.1016/0003-9861(85)90167-5; SOLL J, 1987, METHOD ENZYMOL, V148, P383; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347	34	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1494	1499						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419349				2022-12-25	WOS:A1993KG07700108
J	RAMACHANDRA, M; NAKANO, R; MOHAN, PM; RAWITCH, AB; PADMANABHAN, R				RAMACHANDRA, M; NAKANO, R; MOHAN, PM; RAWITCH, AB; PADMANABHAN, R			ADENOVIRUS DNA-POLYMERASE IS A PHOSPHOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; SV40 T-ANTIGEN; NUCLEAR FACTOR-III; ANIMAL VIRUS-DNA; CELL-CYCLE; REPLICATION INVITRO; EXPRESSION VECTORS; BINDING PROTEIN; PRETERMINAL PROTEIN; VACCINIA VIRUS	Biological activities of many of the eukaryotic DNA replication proteins are modulated by protein phosphorylation. Investigations of the phosphorylation of adenovirus DNA polymerase (AdPol) have been difficult mainly because of its low level of synthesis in adenovirus-infected HeLa cells. However, when AdPol was overproduced using the recombinant vaccinia virus (RV-AdPol) and the baculovirus expression systems, or by a large scale metabolic labeling of adenovirus 2-infected HeLa cells (native AdPol), in vivo phosphorylation of AdPol could be demonstrated. Phosphoamino acid analysis of [P-32]AdPol indicated the presence of phosphoserine independent of the source of AdPol. Comparison of tryptic peptide maps of native AdPol and RV-AdPol revealed that the majority of phosphopeptides were common. Fractionation by high performance liquid chromatography and sequencing of one of the major phosphopeptides revealed serine 67 as a site of phosphorylation. Interestingly, this site is located close to the nuclear localization signal of AdPol and has a consensus substrate recognition sequence for histone H1 (cdc2-related) kinases and mitogen-activated protein kinases. Dephosphorylation of AdPol with calf intestinal alkaline phosphatase resulted in significant decrease in its activity in the in vitro DNA replication initiation assay, suggesting that phosphorylation is important for its biological activity.	UNIV KANSAS, MED CTR, DEPT BIOCHEM MOLEC BIOL, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center			Mohan, PM/C-9594-2018	Mohan, PM/0000-0001-6194-3772; Ramachandra, Murali/0000-0003-4039-1491	NATIONAL CANCER INSTITUTE [R01CA033099] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ADDISON C, 1990, ONCOGENE, V5, P423; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CHEN M, 1990, J BIOL CHEM, V265, P18634; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DANSE JM, 1981, FEBS LETT, V124, P84, DOI 10.1016/0014-5793(81)80059-2; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOBBS L, 1990, VIROLOGY, V178, P43, DOI 10.1016/0042-6822(90)90377-4; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCEMAN BW, 1980, BIOCHEM J, V190, P781, DOI 10.1042/bj1900781; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRASSER FA, 1987, J VIROL, V61, P3373; Green M, 1979, Methods Enzymol, V58, P425; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HOSS A, 1990, J VIROL, V64, P4799; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JENDRISAK JJ, 1975, BIOCHEMISTRY-US, V14, P4639, DOI 10.1021/bi00692a012; JENG YH, 1977, J VIROL, V22, P402, DOI 10.1128/JVI.22.2.402-411.1977; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLEIN H, 1979, J BIOL CHEM, V254, P1051; KRANIAS EG, 1977, J BIOL CHEM, V252, P6750; KRAUSS SW, 1987, J BIOL CHEM, V262, P3432; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LINNE T, 1980, EUR J BIOCHEM, V103, P259, DOI 10.1111/j.1432-1033.1980.tb04310.x; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NAKANO R, 1991, GENE, V105, P173, DOI 10.1016/0378-1119(91)90148-5; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; RAWLINS DR, 1984, CELL, V37, P309, DOI 10.1016/0092-8674(84)90327-1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROACH PJ, 1991, METHOD ENZYMOL, V201, P200; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROSE KM, 1979, J BIOL CHEM, V254, P256; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SASAGURI Y, 1987, VIROLOGY, V160, P389, DOI 10.1016/0042-6822(87)90010-9; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TEMPERLEY SM, 1991, NUCLEIC ACIDS RES, V19, P3243, DOI 10.1093/nar/19.12.3243; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOKUI T, 1991, J BIOL CHEM, V266, P10820; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Vishwanatha J K, 1989, Cancer Commun, V1, P345; WIDES RJ, 1987, MOL CELL BIOL, V7, P864, DOI 10.1128/MCB.7.2.864; WONG SW, 1986, J BIOL CHEM, V261, P7958; ZHAO LJ, 1991, NEW BIOL, V3, P1074; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZHAO LJ, 1991, GENE, V100, P147, DOI 10.1016/0378-1119(91)90360-N	79	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					442	448						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416949				2022-12-25	WOS:A1993KE60300068
J	BRUENGER, E; KOWALAK, JA; KUCHINO, Y; MCCLOSKEY, JA; MIZUSHIMA, H; STETTER, KO; CRAIN, PF				BRUENGER, E; KOWALAK, JA; KUCHINO, Y; MCCLOSKEY, JA; MIZUSHIMA, H; STETTER, KO; CRAIN, PF			5S RIBOSOMAL-RNA MODIFICATION IN THE HYPERTHERMOPHILIC ARCHAEA SULFOLOBUS-SOLFATARICUS AND PYRODICTIUM-OCCULTUM	FASEB JOURNAL			English	Article						PYRODICTIUM-OCCULTUM; SULFOLOBUS-SOLFATARICUS; 5S RIBOSOMAL-RNA ELECTROSPRAY MASS SPECTROMETRY; N4-ACETYL-2'-O-METHYLCYTIDINE	CHROMATOGRAPHY-MASS-SPECTROMETRY; TRANSFER-RNA; LIQUID-CHROMATOGRAPHY; STRUCTURAL CHARACTERIZATION; NUCLEOSIDES; ACIDOCALDARIUS; ARCHAEBACTERIA; RIBOSOMES	The 5S rRNAs from Sulfolobus solfataricus and Pyrodictium occultum were digested to nucleosides and analyzed using directly-combined HPLC/mass spectrometry. P. occultum 5S rRNA contains two modified nucleoside species, N4-acetylcytidine (ac4C) and N4-acetyl-2'-O-methylcytidine (ac4Cm). Oligonucleotides were generated from P. occultum 5S rRNA by RNase T1 hydrolysis, and their molecular weights were determined using electrospray mass spectrometry and compared with those predicted from the P. occultum 5S RNA gene sequence. Deviation in mass between expected and observed molecular weights permitted ac4Cm to be located at position 35, in the nonanucleotide CAA-CACC[ac4Cm]G, and the ac4C in one or both of two (C,U)G trinucleotides. 2'-O-Methylcytidine is unambiguously characterized in S. solfataricus 5S rRNA, confirming earlier tentative assignments at the analogous sequence position (Stahl, D. A., Luehrsen, K. R., Woese, C. R., and Pace, N. R. (1981) Nucleic Acids Res., Vol. 9, pp. 6129-6137; Dams, E., Londei, P.. Cammarano, P., Vandenberghe, A., and De Wachter, R. (1983) Nucleic Acids Res. Vol. 11, pp. 4667-4676). Potential effects of the presence of ac4C and ac4Cm on thermal stabilization of 5S rRNA in thermophiles are discussed.	UNIV UTAH,DEPT MED CHEM,311A SKAGGS HALL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,W-8400 REGENSBURG,GERMANY	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Cancer Center - Japan; University of Regensburg					NIGMS NIH HHS [GM 29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS PF, 1973, ARCH BIOCHEM BIOPHYS, V154, P277, DOI 10.1016/0003-9861(73)90058-1; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CRAIN PF, 1990, MASS SPECTROM REV, V9, P505, DOI 10.1002/mas.1280090504; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DAMS E, 1983, NUCLEIC ACIDS RES, V11, P4667, DOI 10.1093/nar/11.14.4667; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; EDMONDS CG, 1987, J CHEM SOC CHEM COMM, P909, DOI 10.1039/c39870000909; KAINE BP, 1989, SYST APPL MICROBIOL, V12, P8; KAWAI G, 1992, NUCLEOS NUCLEOT, V11, P759, DOI 10.1080/07328319208021740; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KOWALAK JA, 1992, 40TH P ANN C MASS SP, P1127; KOWALAK JA, 1993, IN PRESS J AM SOC MA; KUCHINO Y, 1987, P NATL ACAD SCI USA, V84, P2668, DOI 10.1073/pnas.84.9.2668; LONDEI P, 1986, EUR J BIOCHEM, V157, P455, DOI 10.1111/j.1432-1033.1986.tb09689.x; MCCLOSKEY JA, 1991, ACCOUNTS CHEM RES, V24, P81, DOI 10.1021/ar00003a004; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; STAHL DA, 1981, NUCLEIC ACIDS RES, V9, P6129, DOI 10.1093/nar/9.22.6129; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; TAKEDA N, 1991, J CHROMATOGR-BIOMED, V562, P225, DOI 10.1016/0378-4347(91)80580-6; THOMAS G, 1978, J BIOL CHEM, V253, P1101; WATANABE K, 1980, J BIOCHEM-TOKYO, V87, P1; WOLTERS J, 1988, NUCLEIC ACIDS RES, V16, pR1, DOI 10.1093/nar/16.suppl.r1	24	59	63	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					196	200		10.1096/fasebj.7.1.8422966	http://dx.doi.org/10.1096/fasebj.7.1.8422966			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422966				2022-12-25	WOS:A1993KH88000030
J	STRASSER, A; HARRIS, AW; CORY, S				STRASSER, A; HARRIS, AW; CORY, S			E-MU-BCL-2 TRANSGENE FACILITATES SPONTANEOUS TRANSFORMATION OF EARLY PRE-B AND IMMUNOGLOBULIN-SECRETING CELLS BUT NOT T-CELLS	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; LIGHT CHAIN GENE; HUMAN FOLLICULAR LYMPHOMA; C-MYC ONCOGENE; BCL-2 GENE; CHROMOSOME-TRANSLOCATION; VARIANT TRANSLOCATION; MEMBRANE PROTEIN; ACTIVATION; EXPRESSION	To assess the lymphoid tumorigenic potential of bcl-2, mice of five independent strains expressing a bcl-2 transgene in B and/or T cells were monitored for disease up to 12 months of age. Lymphoma prevalence was minimal in the T lineage but significant, although low (3-15%), in the B lineage. The principal types of tumors were plasmacytomas secreting immunoglobulin and novel lymphomas that expressed markers such as Sca-1, CD4, Thy-1, CD34 and CD45(B220), consistent with an origin very early in B-lymphoid development. Rearrangement of the c-myc gene was common in the plasmacytomas, implying a synergistic role for myc and bcl-2 in their etiology, but was not detected in the lymphomas.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AISENBERG AC, 1988, BLOOD, V71, P969; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ARMITAGE JO, 1988, J NATL CANCER I, V80, P576, DOI 10.1093/jnci/80.8.576; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HILLION J, 1991, ONCOGENE, V6, P169; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; HUA C, 1990, ONCOGENE, V5, P233; KIEM HP, 1990, ONCOGENE, V5, P1815; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; LEE MS, 1987, BLOOD, V70, P90; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUFTI GJ, 1983, BLOOD, V62, P1142; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; PORTLOCK CS, 1979, ANN INTERN MED, V90, P10, DOI 10.7326/0003-4819-90-1-10; RAGHOEBIER S, 1991, BLOOD, V77, P1560; RECHAVI G, 1989, LEUKEMIA, V3, P57; RICHARDSON ME, 1987, BLOOD, V70, P444; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER M, 1991, BLOOD, V78, P1062	64	127	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					1	9						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423986				2022-12-25	WOS:A1993KN00500001
J	CHUMAKOV, AM; MILLER, CW; CHEN, DL; KOEFFLER, HP				CHUMAKOV, AM; MILLER, CW; CHEN, DL; KOEFFLER, HP			ANALYSIS OF P53 TRANSACTIVATION THROUGH HIGH-AFFINITY BINDING-SITES	ONCOGENE			English	Article							LARGE T-ANTIGEN; WILD-TYPE P53; E1B-58KD TUMOR-ANTIGEN; CELL-CYCLE CONTROL; A MOUSE CELLS; SIMIAN VIRUS-40; TRANSFORMED-CELLS; TRANSCRIPTIONAL ACTIVATION; ALTERED PHOSPHORYLATION; SV40-TRANSFORMED CELLS	Alterations or elimination of the p53 protein is frequently occurring during human carcinogenesis. Overexpression of wild-type p53 has a profound growth-inhibitory effect on many cell lines, including strong and apparently non-sequence specific repression of a number of promoters. Consistent with the hypothesis that it acts as transcriptional regulator, wild-type p53 protein binds DNA and activates transcription of several promoters. We have studied DNA binding and transactivation (TA) properties of human wild-type and mutant p53 proteins representing four major mutational hotspots. DNA-gel retardation was used to detect specific p53-DNA complexes in nuclear extracts, with radiolabelled oligonucleotides representing high affinity p53-binding sites (HBS) as a probe. p53-specific complexes were identified by competition with unlabelled 'self' oligos and by double band-shifts in the presence of anti-p53 antibodies. To show transactivation by p53, TK promoter-driven CAT reporter gene was placed 3' of the p53-binding site. CAT activity was assayed after co-transfection of reporters with either wild-type (WT) or mutant p53 expression constructs into human cells that do not express p53 (SKOV3). We found that wild-type p53 has strong transactivating effect on the reporter. All mutants, with the exception of His273, were inactive in TA-assay. p53 is a target of several oncogenes found in DNA tumor viruses. We examined the effect of either SV40 T-ag or 55 kDa EIB protein of Ad5 on DNA binding and transactivation by p53 in transformed COS-1 and 293 cell lines, respectively. COS-1 extracts produced strong p53-dependent band-shift of the HBS oligos, that was doubleshifted by anti-p53 but not anti-T-ag antibodies, indicating that T-ag is not part of the complex. COS-1 cells had a high level of WT p53-dependent expression of transfected CAT reporter, indicating the presence of transactivation-competent p53, acting through the HBS element. In human Ad-transformed 293 cells, endogenous p53 was also transactivation competent and capable of DNA binding. In summary, we found efficient transactivation of HBS motif by WT and His273-p53. Studies of COS-1 and 293 cells suggest that a proportion of p53 in transformed cells display wild-type DNA binding and TA properties and that expression of transcriptionally inactive mutant p53 proteins in these cells does not interfere with WT-dependent transactivation.			CHUMAKOV, AM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI MED CTR, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHEN JD, 1992, ONCOGENE, V7, P1167; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1989, CURR TOP MICROBIOL I, V144, P37; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1990, MOL CELL ENDOCRINOL, V70, P1, DOI 10.1016/0303-7207(90)90053-B; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1989, ONCOGENE, V4, P643; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER CW, 1993, ONCOGENE, V8, P1815; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISHAUS E, 1990, ONCOGENE, V5, P137; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P636; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	53	50	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3005	3011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414502				2022-12-25	WOS:A1993MC09300014
J	HOFMANN, W; ROYER, HD; DRECHSLER, M; SCHNEIDER, S; ROYERPOKORA, B				HOFMANN, W; ROYER, HD; DRECHSLER, M; SCHNEIDER, S; ROYERPOKORA, B			CHARACTERIZATION OF THE TRANSCRIPTIONAL REGULATORY REGION OF THE HUMAN WT1 GENE	ONCOGENE			English	Article							WILMS-TUMOR GENE; ZINC-FINGER PROTEIN; FACTOR-A-CHAIN; PROMOTER REGION; GENITOURINARY DEVELOPMENT; ADENOSINE-DEAMINASE; HOMOZYGOUS DELETION; BINDING PROTEINS; SUPPRESSOR WT1; RECEPTOR GENE	Specific control of the expression of the Wilms tumor gene WT1 is important for normal development of the kidney. In order to characterise the transcriptional control region of the WT1 gene we have isolated genomic clones spanning the upstream region, the first WT1 exon and the 5' end of the Wit1 gene. DNA sequencing revealed that the WT1 promoter lacks a TATA box or CCAAT motif and has a GC content of 71%. Four transcriptional start sites are clustered within a 32 bp region. GC-boxes are present at nucleotide positions - 413, - 160, + 84 and + 158. DNAaseI protection assays with purified Sp1 protein revealed the existence of 11 different binding sites in the WT1 promoter. WT1 and Wit1 promoter activities were tested in COS-7 cells with luciferase reporter gene constructs either containing or lacking an SV40 enhancer. WT1 promoter activity was found in a fragment extending from 449 bp upstream to 201 bp downstream of the WT1 start site. It was 26 fold lower in the absence of the SV40 enhancer than in the presence. Cotransfection with a Sp1 expression vector stimulated both constructs 3-4 fold. Wit1 promoter activity was identified in a DNA fragment extending from 200 bp upstream of the putative Wit1 TATA box to 130 bp downstream. Several potential recognition sites for WT1/EGR, Pax-8, and GAGA-like transcription factors are present in the WT1 promoter.	UNIV HEIDELBERG, INST HUMAN GENET, IMNEVENHEIMER FELD 328, W-6900 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOLEC MED, BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Royer, Hans-dieter/AAH-6293-2019					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AVIVI A, 1992, ONCOGENE, V7, P1957; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRENNER B, 1992, ONCOGENE, V7, P1431; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; COWELL JK, 1991, ONCOGENE, V6, P595; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KUSHNER L, 1992, J UROLOGY, V148, P555, DOI 10.1016/S0022-5347(17)36652-1; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maniatis T., 1982, MOL CLONING COLD SPR; MATSUNAGA E, 1981, HUM GENET, V57, P231; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MIWA H, 1992, LEUKEMIA, V6, P405; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER S, 1993, IN PRESS HUM GENET; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TADOKORO K, 1992, ONCOGENE, V7, P1215; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	68	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3123	3132						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414514				2022-12-25	WOS:A1993MC09300029
J	PRICE, BD; CALDERWOOD, SK				PRICE, BD; CALDERWOOD, SK			INCREASED SEQUENCE-SPECIFIC P53 DNA-BINDING ACTIVITY AFTER DNA-DAMAGE IS ATTENUATED BY PHORBOL ESTERS	ONCOGENE			English	Article							PROTEIN KINASE-C; WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; CELL-CYCLE; GROWTH-REGULATION; MUTANT P53; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; GENE-PRODUCT; 3T3 CELLS	Damage to cellular DNA greatly increases the levels of the tumor-suppressor gene p53 and induces cell cycle arrest in G1. A critical function of wild-type p53 is its ability to bind to specific DNA sequences. The effect of DNA damage on the sequence-specific DNA-binding properties of cellular p53 was investigated using DNA gel mobility-shift assays with nuclear extracts from NIH-3T3 cells. DNA damage (initiated by radiation) induced a rapid, cycloheximide-sensitive increase in the levels of nuclear p53-DNA binding activity and an increase in the half-life of the p53 protein. Increased p53-DNA binding activity could be detected at low (0.2 Gy), non-lethal doses of radiation. The tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA) attenuated the DNA damage-induced increase in p53-DNA binding activity by decreasing the half-life of the p53 protein. The tumor promoter properties of TPA may therefore be mediated by interfering with the cellular p53 response to DNA damage. The increased levels of p53 bound to specific DNA sequences following DNA damage may induce cell cycle arrest. p53-mediated growth arrest could occur by inhibition of DNA replication and/or alterations in transcription of cell cycle genes.			PRICE, BD (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,STRESS PROT GRP RM JF209,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R29CA044940] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA44940] Funding Source: Medline; PHS HHS [R01 47407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRUCE JL, 1993, CANCER RES, V53, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JFOORD OS, 1993, MOL CELL BIOL, V13, P1378; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLZMAN W, 1984, MOL CELL BIOL, V4, P1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHOHAT O, 1987, ONCOGENE, V1, P277; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	54	67	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3055	3062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414506				2022-12-25	WOS:A1993MC09300021
J	SEITE, P; HILLION, J; DAGAY, MF; BERGER, R; LARSEN, CJ				SEITE, P; HILLION, J; DAGAY, MF; BERGER, R; LARSEN, CJ			BCL2 COMPLEX REARRANGEMENT IN FOLLICULAR LYMPHOMA - TRANSLOCATION MBR J(H) AND DELETION IN THE VCR REGION OF THE SAME BCL2 ALLELE	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIANT T(2-18) TRANSLOCATION; BREAKPOINT-CLUSTER REGION; LIGHT CHAIN GENE; B-CELL LYMPHOMA; CHROMOSOMAL TRANSLOCATION; T(14-18) TRANSLOCATION; MALIGNANT-LYMPHOMAS; EXPRESSION; TRANSCRIPTS	Two rearrangements affecting the same allele of the BCL2 gene were characterized by molecular analysis of an untreated follicular lymphoma. The first rearrangement interested the major breakpoint region (mbr) on chromosome 18 and a J(H) segment on chromosome 14. The other one was located at the 5' end of the BCL2 gene, in the so called variant cluster region (vcr), and consisted of a series of deletions that removed part of a DNA region where initiation of transcription normally occurs. Interestingly, both rearrangements involved the same BCL2 allele. The simultaneous presence of mbr (or mcr) translocations and of minor rearrangements in vcr has been previously suggested by restriction map analysis in a significant number of follicular lymphomas. The significance of these abnormalities on the oncogenic process is discussed.	INST GENET MOLEC,INSERM,U301,27 RUE J DODU,F-75010 PARIS,FRANCE; HOP ST LOUIS,ANAT PATHOL LAB,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite				Seite, Paule/0000-0002-7809-7610				ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1990, ONCOGENE, V5, P1653; AMAKAWA R, 1991, BLOOD, V77, P1970; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GAULARD P, 1992, AM J PATHOL, V140, P1089; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HILLION J, 1991, ONCOGENE, V6, P169; JONVEAUX P, 1992, BRIT J HAEMATOL, V81, P620, DOI 10.1111/j.1365-2141.1992.tb03006.x; KIEM HP, 1990, ONCOGENE, V5, P1815; KONISHI H, 1990, CANCER RES, V50, P2698; LARSEN CJ, 1990, NOUV REV FR HEMATOL, V32, P401; LARSEN CJ, 1993, NOUV REV FR HEMATOL, V35, P37; LEROUX D, 1991, GENE CHROMOSOME CANC, V3, P205, DOI 10.1002/gcc.2870030306; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; LIMPENS J, 1991, ONCOGENE, V6, P2271; MIKRAKI V, 1991, GENE CHROMOSOME CANC, V3, P117, DOI 10.1002/gcc.2870030206; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PRICE CGA, 1991, LEUKEMIA, V5, P548; RIMOKH R, 1993, BLOOD, V81, P136; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEITE P, 1993, GENE CHROMOSOME CANC, V6, P39, DOI 10.1002/gcc.2870060108; SEITE P, 1993, LEUKEMIA, V7, P410; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TASHIRO S, 1992, ONCOGENE, V7, P573; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; ZELENETZ AD, 1991, BLOOD, V78, P1552; 1991, GUIDELINES CANCER CY	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3073	3080						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414508				2022-12-25	WOS:A1993MC09300023
J	SIDERS, WM; KLIMOVITZ, JC; MIZEL, SB				SIDERS, WM; KLIMOVITZ, JC; MIZEL, SB			CHARACTERIZATION OF THE STRUCTURAL REQUIREMENTS AND CELL-TYPE SPECIFICITY OF IL-1-ALPHA AND IL-1-BETA SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTE INTERLEUKIN-1; ACTIVATED NEUTRAL PROTEASE; ESCHERICHIA-COLI; IL-1 SECRETION; PRECURSOR; PROTEINS; 1-BETA; CDNA; IDENTIFICATION; EXPRESSION	The murine macrophage cell line, P388D1, was transfected with expression plasmids containing a cDNA for the precursor or mature form of human interleukin (IL)-1alpha or -1beta, and the extent of IL-1 protein secretion was analyzed. The secretion of IL-1beta from cells transfected with a cDNA encoding the mature IL-1beta was approximately 15-fold greater than from cells transfected with a precursor IL-1beta cDNA. Although P388D1 cells transfected with precursor and mature IL-1alpha cDNAs exhibited similar levels of secretion, the precursor IL-1alpha cDNA-transfected cells secreted only the mature form of IL-1alpha. Relatively high levels of IL-1 secretion were also observed in cultures of HeLa cells and the murine EL 4 and human Jurkat T cell lines that were transfected with a mature IL-1alpha or -beta expression plasmid. Secretion was not observed when these cell lines were transfected with precursor IL-1alpha or -beta expression plasmids. Secretion was also minimal when P388D1 cells were transfected with cDNAs encoding mature IL-1beta proteins lacking the NH2- or COOH-terminal 20 amino acids. These results indicate that the mature forms of IL-1 proteins are the preferred substrates for secretion and that the maintenance of a specific conformation of these proteins may be required for optimal secretion.	WAKE FOREST UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, WINSTON SALEM, NC 27157 USA	Wake Forest University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025836] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25836] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BAKOUCHE O, 1987, J IMMUNOL, V138, P4249; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLACK RA, 1989, J BIOL CHEM, V264, P5323; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAVIES WA, 1977, J CELL BIOL, V75, P941, DOI 10.1083/jcb.75.3.941; DINARELLO CA, 1992, CHEM IMMUNOL, V51, P1; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GERY I, 1972, J EXP MED, V136, P128, DOI 10.1084/jem.136.1.128; GIRI JG, 1985, J IMMUNOL, V134, P343; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOSOKAWA R, 1988, J BIOL CHEM, V263, P10045; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMOGASHIRA T, 1988, J BIOCHEM-TOKYO, V104, P837, DOI 10.1093/oxfordjournals.jbchem.a122559; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LANGER T, 1991, CURR TOP MICROBIOL, V167, P3; LILLQUIST JS, 1988, J IMMUNOL, V141, P1975; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SUTTLES J, 1990, J IMMUNOL, V144, P175; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22170	22174						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408078				2022-12-25	WOS:A1993MC80900108
J	CARR, DW; DEMANNO, DA; ATWOOD, A; HUNZICKERDUNN, M; SCOTT, JD				CARR, DW; DEMANNO, DA; ATWOOD, A; HUNZICKERDUNN, M; SCOTT, JD			FOLLICLE-STIMULATING-HORMONE REGULATION OF A-KINASE ANCHORING PROTEINS IN GRANULOSA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-AFFINITY BINDING; SUBUNIT RII; OVARIAN FOLLICLES; II-BETA; DIFFERENTIATION; EXPRESSION; CLONING; MUSCLE; BRAIN	It has been well established that the biochemical and morphological changes during maturation of granulosa cells that are induced by follicle-stimulating hormone (FSH) occur through the elevation of intracellular cAMP and consequent activation of the cAMP-dependent protein kinase (PKA). In this report we show that FSH action alters the expression of A-Kinase Anchoring Proteins (AKAPs), which function to target the subcellular distribution of the type II PKA. Exposure of granulosa cells grown in primary culture with FSH and estradiol for 72 h resulted in the up-regulation of an 80-kDa AKAP and the RIIbeta subunit of PKA, whereas cells grown in control medium containing only estradiol produced a time-dependent increase of a 140-kDa AKAP. RII overlays performed with [P-32]RIIalpha preferentially detected RII-binding bands of 80 and 95 kDa compared to blots probed with [P-32]RIIbeta, suggesting that FSH may alter the subcellular location of PKA in an isoform-specific manner. FSH treatment causes a translocation of RIIalpha from the particulate to the cytosolic fraction coincident with the induction of the 80-kDa AKAP, which is also predominately cytosolic. These data suggest that FSH promotes a redistribution of the type II PKA holoenzyme through the selective induction of an RII isoform-specific AKAP.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201; NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611	Oregon Health & Science University; Northwestern University					NICHD NIH HHS [HD 21921] Funding Source: Medline; NIDDK NIH HHS [DK 44239] Funding Source: Medline; NIGMS NIH HHS [GM 48231] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309; BENZEEV A, 1987, J BIOL CHEM, V262, P5366; BLEY MA, 1991, BIOL REPROD, V44, P880, DOI 10.1095/biolreprod44.5.880; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CORBIN JD, 1975, J BIOL CHEM, V250, P218; HARPER JF, 1985, VITAM HORM, V42, P197; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; HUNZICKERDUNN M, 1985, J BIOL CHEM, V260, P3360; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1992, J BIOL CHEM, V267, P24738; MEIER KE, 1991, J BIOL CHEM, V266, P1914; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; RATOOSH SL, 1987, J BIOL CHEM, V262, P7306; RICHARDS JS, 1980, PHYSIOL REV, V60, P51, DOI 10.1152/physrev.1980.60.1.51; RICHARDS JS, 1987, RECENT PROG HORM RES, V43, P231; RICHARDS JS, 1980, J BIOL CHEM, V255, P5481; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; THREURKAUF W, 1982, J BIOL CHEM, V257, P3284; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	26	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20729	20732						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407895				2022-12-25	WOS:A1993MA28800013
J	JENKINS, AL; BOOTMAN, MD; TAYLOR, CW; MACKIE, EJ; STONE, SR				JENKINS, AL; BOOTMAN, MD; TAYLOR, CW; MACKIE, EJ; STONE, SR			CHARACTERIZATION OF THE RECEPTOR RESPONSIBLE FOR THROMBIN-INDUCED INTRACELLULAR CALCIUM RESPONSES IN OSTEOBLAST-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOSARCOMA CELLS; CA2+ MOBILIZATION; AGONIST PEPTIDES; BONE-RESORPTION; ACTIVATION; MECHANISM; EXPRESSION; PATHWAYS; CLONING; HIRUDIN	The receptor responsible for the increase in intracellular calcium concentration ([Ca2+]i) after the addition of thrombin to the human osteoblast-like cell line Saos-2 has been characterized. Thrombin caused a dose-dependent increase in [Ca2+]i; a half-maximal stimulation was observed with 3.2 +/- 1.1 nM thrombin. The human platelet thrombin receptor is activated by thrombin cleavage to create a new NH2 terminus that acts as a tethered ligand, and peptides based on the tethered ligand can activate the receptor independently of thrombin. Northern analysis indicated the presence of mRNA encoding the platelet receptor in Saos-2 cells, and surface expression of the receptor was demonstrated by immunocytochemistry. A tethered ligand peptide (SFLLRNPNDKYEPF, single-letter amino acid code) was found to increase [Ca2+]i. The maximal response to the peptide was similar to that observed with thrombin, and a half-maximal response was observed with 22 +/- 6 muM peptide. The time course of the increase in [Ca2+]i with the peptide was different than that observed with thrombin; a pronounced shoulder was observed after an initial sharp rise. The phenylalanine in the second position of the agonist peptide and the arginine in the fifth position were shown to be essential for its activity. The requirement for proteolysis of the receptor for the thrombin-dependent increase in [Ca2+]i was demonstrated by two methods. Antibodies that reacted with the cleavage site of the receptor abolished the effect of thrombin on [Ca2+]i. In addition, a mutant of thrombin without catalytic activity as well as chemically inactivated thrombin failed to cause an increase in [Ca2+]i. Similar results were obtained with the rat osteoblast-like cell line UMR-106; a tethered ligand peptide based on the rat sequence induced an increase in [Ca2+]i, and antibodies to the cleavage site of the rat receptor inhibited the effect of thrombin.	UNIV CAMBRIDGE,MRC CTR,DEPT HAEMATOL,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,AFRC,MOLEC SIGNALLING LAB,CAMBRIDGE CB2 3EJ,ENGLAND; UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND; ADDENBROOKES HOSP,RHEUMATOL RES UNIT,CAMBRIDGE CB2 2QQ,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Bootman, Martin/AAB-3330-2019; Taylor, Colin/G-2447-2010	Bootman, Martin/0000-0002-6447-3451; Mackie, Eleanor/0000-0002-8057-5407; Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BABICH M, 1990, ENDOCRINOLOGY, V126, P948, DOI 10.1210/endo-126-2-948; BABICH M, 1991, ENDOCRINOLOGY, V129, P1463, DOI 10.1210/endo-129-3-1463; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; DOOLITTLE RF, 1986, URFS ORFS, P91; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSTAFSON GT, 1983, BIOSCIENCE REP, V3, P255, DOI 10.1007/BF01122457; HOFFMANN O, 1986, PROSTAGLANDINS, V31, P601, DOI 10.1016/0090-6980(86)90168-1; HOWELLS GL, 1993, BRIT J HAEMATOL, V84, P156, DOI 10.1111/j.1365-2141.1993.tb03039.x; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; MACKIE EJ, 1992, J CELL SCI, V103, P765; OFORIDARKO E, 1993, AM J PHYSIOL, V264, pC1266; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PARTRIDGE NC, 1985, PROSTAGLANDINS, V30, P527; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RODAN SB, 1987, CANCER RES, V47, P4961; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; STERN PH, 1990, J BONE MINER RES, V5, P443, DOI 10.1002/jbmr.5650050505; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TATAKIS DN, 1991, BIOCHEM BIOPH RES CO, V174, P181, DOI 10.1016/0006-291X(91)90503-Y; TATAKIS DN, 1989, BIOCHEM BIOPH RES CO, V164, P119, DOI 10.1016/0006-291X(89)91691-4; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	29	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21433	21437						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407986				2022-12-25	WOS:A1993MA28800114
J	GAMETCHU, B; WATSON, CS; WU, SH				GAMETCHU, B; WATSON, CS; WU, SH			USE OF RECEPTOR ANTIBODIES TO DEMONSTRATE MEMBRANE GLUCOCORTICOID RECEPTOR IN CELLS FROM HUMAN LEUKEMIC PATIENTS	FASEB JOURNAL			English	Article						MEMBRANE GLUCOCORTICOID RECEPTOR; LEUKEMIA; LYMPHOCYTOLYSIS; STEROID	S-49 LYMPHOMA-CELLS; ESTROGEN-RECEPTOR; STEROID-BINDING; RAT-LIVER; PROGESTERONE-RECEPTOR; DEOXYRIBONUCLEIC-ACID; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; BREAST-CANCER; IDENTIFICATION	Anti-peptide antibody to the human glucocorticoid receptor (GR) was produced and used to demonstrate that a subset of the GR population resides in the plasma membrane of human leukemic cells. Characterization of the antibody with intracellular GR (iGR) showed its ability to shift [H-3]triamcinolone acetonide-labeled GR (4S protein) from two human leukemic cell lines to a higher density in sucrose gradients; Western and autoradiographic analysis of affinity-labeled ([H-3]dexamethasone 21-mesylate) receptor revealed an immunoreactive and competitively labeled band of 94 kDa. CCRF-CEM cell membrane GR (mGR) resolved as a >7S protein on density gradients and immunoselected cell surface protein labeled by whole cell biotinylation or affinity-labeling with [H-3]dexamethasone 21-mesylate was approximately 145 kDa, demonstrating that mGR was larger in size than iGR, as has been shown previously for the mGR of mouse lymphoma cells. Analysis of mGR in lymphocytes of leukemic patients and the CCRF-CEM cell line indicated differences in levels of expression as shown by FACS and immunocytochemical analyses. We are currently using this system to study the correlation between the quantity of membrane-resident GRs and the glucocorticoid-induced lytic response, a relationship previously shown in the murine (S-49 cell) system.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	GAMETCHU, B (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226, USA.							Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGER U, 1991, CANCER RES, V51, P239; CARLSTEDTDUKE J, 1982, P NATL ACAD SCI-BIOL, V79, P4260, DOI 10.1073/pnas.79.14.4260; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; Coligan JKA, 1991, CURRENT PROTOCOLS IM; GAMETCHU B, 1991, STEROIDS, V56, P411, DOI 10.1016/0039-128X(91)90029-U; GAMETCHU B, 1991, STEROIDS, V56, P402, DOI 10.1016/0039-128X(91)90028-T; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GAMETCHU B, 1984, FED PROC, V43, P1572; GOLDIN A, 1976, CANCER CHEMOTH REP, V55, P309; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOMODELARCHE F, 1984, CANCER RES, V44, P431; HOUSLEY PR, 1982, J BIOL CHEM, V257, P8615; IBARROLA I, 1992, J MEMBRANE BIOL, V125, P185; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P638; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGEAT F, 1985, BIOCHEMISTRY-US, V24, P1029, DOI 10.1021/bi00325a034; MCBLAIN WA, 1980, J BIOL CHEM, V255, P3884; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIRAS ME, 1979, J STEROID BIOCHEM, V11, P1129, DOI 10.1016/0022-4731(79)90163-8; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; SCHREK R, 1961, P SOC EXP BIOL MED, V108, P328; SHERMAN MR, 1983, J BIOL CHEM, V258, P366; SHIH CY, 1987, PROGR CLIN BIOL RES, P439; SHIMADA A, 1985, P NATL ACAD SCI USA, V82, P4803, DOI 10.1073/pnas.82.14.4803; SHYMALA G, 1967, J BIOL CHEM, V244, P1097; SOYUM A, 1968, SCAND J CLIN LAB I S, V21, P77; STEVENS J, 1985, HORMONALLY RESPONSIV, P156; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; SUYEMITSU T, 1975, ENDOCRINOLOGY, V96, P1499, DOI 10.1210/endo-96-6-1499; SZEGO CM, 1981, BIOCHEM ACTION HORM, P307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; WILSON EM, 1988, MOL ENDOCRINOL, V2, P1018, DOI 10.1210/mend-2-11-1018	40	106	107	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1283	1292		10.1096/fasebj.7.13.8405814	http://dx.doi.org/10.1096/fasebj.7.13.8405814			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405814				2022-12-25	WOS:A1993MB37600013
J	KUBES, P; KANWAR, S; NIU, XF; GABOURY, JP				KUBES, P; KANWAR, S; NIU, XF; GABOURY, JP			NITRIC-OXIDE SYNTHESIS INHIBITION INDUCES LEUKOCYTE ADHESION VIA SUPEROXIDE AND MAST-CELLS	FASEB JOURNAL			English	Article						INFLAMMATION; ENDOTHELIUM; MICROCIRCULATION	ENDOTHELIAL-CELLS; RELAXING FACTOR; L-ARGININE; REPERFUSION INJURY; OXYGEN RADICALS; ADHERENCE; NEUTROPHILS; INFLAMMATION; MESENTERY; PLATELET	Recent work has demonstrated that inhibition of nitric oxide production with various nitric oxide synthesis inhibitors (L-NAME, L-NMMA) initiate leukocyte adhesion to postcapillary venules. The objective of this study was to elucidate the mechanism (or mechanisms) that promote the L-NAME-induced leukocyte response. Intravital microscopy was used to examine 25-40 mum venules in the rat mesentery. Nitric oxide synthesis was inhibited with L-NAME and leukocyte adhesion was observed over the first 60 min. The fourfold increase in leukocyte adhesion was independent of alterations in venular red blood cell velocity. The adhesion was superoxide-mediated inasmuch as superoxide dismutase (SOD) abolished the rise in leukocyte adhesion associated with nitric oxide synthesis inhibition. Ketotifen, a mast cell stabilizer, also abolished the rise in leukocyte adhesion induced by L-NAME. Histology revealed that mast cell degranulation occurred only in animals treated with L-NAME but not in animals pretreated with SOD or ketotifen. This observation suggests that mast cells become activated in the absence of nitric oxide production and superoxide contributes to the mast cell activation. The L-NAME-induced leukocyte adhesion could be reproduced by infusing hypoxanthine/xanthine oxidase (a superoxide generating system) or compound 48/80 (an activator of mast cells) and both responses were attenuated by ketotifen. These data suggest that inhibition of nitric oxide synthesis results in a superoxide and mast cell-dependent leukocyte adhesion.			KUBES, P (corresponding author), UNIV CALGARY, FAC MED, DEPT MED PHYSIOL, GASTROINTESTINAL RES GRP, CALGARY T2N 4N1, AB, CANADA.		Kanwar, Shamsher S/F-6096-2019					ARNDT H, 1993, IN PRESS GASTROENTER; ASAKO H, 1992, INFLAMMATION, V16, P45, DOI 10.1007/BF00917514; Chance B., 1973, OXIDASES RELATED RED, P350; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DVORAK AM, 1980, HUM PATHOL, V11, P606, DOI 10.1016/S0046-8177(80)80072-4; FEIGL EO, 1988, NATURE, V331, P490, DOI 10.1038/331490a0; GABOURY J, 1993, IN PRESS AM J PHYSL; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; HOGABOAM C M, 1992, Gastroenterology, V102, pA926; HOGABOAM CM, 1992, BRIT J PHARMACOL, V105, P87, DOI 10.1111/j.1476-5381.1992.tb14215.x; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; INAUEN W, 1990, AM J PHYSIOL, V259, pH925, DOI 10.1152/ajpheart.1990.259.3.H925; JOHNS RA, 1990, CIRC RES, V67, P979, DOI 10.1161/01.RES.67.4.979; KANWAR S, 1993, GASTROENTEROLOGY, V104, pA1044; KELLER AM, 1988, CIRC RES, V63, P1044, DOI 10.1161/01.RES.63.6.1044; KOCH AE, 1991, LAB INVEST, V64, P313; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1990, AM J PHYSIOL, V259, pG859, DOI 10.1152/ajpgi.1990.259.5.G859; KUBES P, 1991, AM J PHYSIOL, V261, pH1872, DOI 10.1152/ajpheart.1991.261.6.H1872; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MAY GR, 1991, BRIT J PHARMACOL, V102, P759, DOI 10.1111/j.1476-5381.1991.tb12246.x; MCCALL T, 1988, BRIT J PHARMACOL, V95, pP517; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RAUD J, 1989, ACTA PHYSIOL SCAND, V135, P95, DOI 10.1111/j.1748-1716.1989.tb08556.x; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RUBANYI GM, 1991, BIOCHEM BIOPH RES CO, V181, P1392, DOI 10.1016/0006-291X(91)92093-Y; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SALVEMINI D, 1991, J CARDIOVASC PHARM, V17, pS258, DOI 10.1097/00005344-199117003-00047; SCHMIDT HHHW, 1990, J PHARMACOL EXP THER, V254, P591; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; SUZUKI M, 1991, MICROVASC RES, V42, P125, DOI 10.1016/0026-2862(91)90081-L; SUZUKI M, 1989, AM J PHYSIOL, V257, pH1740, DOI 10.1152/ajpheart.1989.257.5.H1740; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; VANDEVOORDE J, 1987, CIRC RES, V60, P517, DOI 10.1161/01.RES.60.4.517; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WALLACE JL, 1992, ANN NY ACAD SCI, V664, P400, DOI 10.1111/j.1749-6632.1992.tb39778.x; WASSERMAN SI, 1984, ARTHRITIS RHEUM, V27, P841, DOI 10.1002/art.1780270801; WOLIN MS, 1991, KLIN WOCHENSCHR, V69, P1046, DOI 10.1007/BF01645156	45	324	327	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1993	7	13					1293	1299		10.1096/fasebj.7.13.8405815	http://dx.doi.org/10.1096/fasebj.7.13.8405815			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405815				2022-12-25	WOS:A1993MB37600014
J	WOLF, LE; LAPPE, M; PETERSON, RD; EZRAILSON, EG				WOLF, LE; LAPPE, M; PETERSON, RD; EZRAILSON, EG			HUMAN IMMUNE-RESPONSE TO POLYDIMETHYLSILOXANE (SILICONE) - SCREENING STUDIES IN A BREAST IMPLANT POPULATION	FASEB JOURNAL			English	Article						SILICONE; IMMUNOGLOBULIN-G; ANTI-SILICONE ANTIBODIES; SILOXANE; BREAST IMPLANTS		Although initially it was thought that polydimethylsiloxane (silicone) was biologically inert, recent published studies have demonstrated varying levels of IgG antibody reactive with this structure in humans. The objective of our study was to determine whether silicone implanted in humans results in a measurable immune response directed against a 3700 mol wt hydroxyl terminated silicone molecule and whether that response could be correlated with the level of presumed silicone exposure as inferred by clinical history. In a blind study, sera from 111 patients, with and without breast implants, were sent to a laboratory using an enzyme-linked immunosorbent assay to determine specific anti-silicone IgG antibody levels. Test results showed that patients with implants demonstrated statistically significant elevation in anti-silicone antibodies compared with the unimplanted control, groups. The highest anti-silicone antibody levels were measured in implanted women with either frank implant ruptures or leakage of their silicone gel implants.	PLAZA MED CTR,HOUSTON,TX 77004; UNIV ILLINOIS,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								FISHER JC, 1992, NEW ENGL J MED, V326, P1696, DOI 10.1056/NEJM199206183262511; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; HEGGERS JP, 1983, ANN PLAS SURG, V11, P38, DOI 10.1097/00000637-198307000-00006; HEGGERS JP, 1992, FEB TOX FOR  WASH; KOSSOVSKY N, 1987, J BIOMED MATER RES, V21, P1125, DOI 10.1002/jbm.820210906; LAPPE MA, 1993, IN PRESS MED HYPOTHE; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011	8	73	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1265	1268		10.1096/fasebj.7.13.8405812	http://dx.doi.org/10.1096/fasebj.7.13.8405812			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405812				2022-12-25	WOS:A1993MB37600010
J	SHEN, JR; INOUE, Y				SHEN, JR; INOUE, Y			CELLULAR-LOCALIZATION OF CYTOCHROME-C550 - ITS SPECIFIC ASSOCIATION WITH CYANOBACTERIAL PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; NUCLEOTIDE-SEQUENCE; SYNECHOCOCCUS-VULCANUS; ANACYSTIS-NIDULANS; PHORMIDIUM-LAMINOSUM; PEROXIDASE-ACTIVITY; PROTEIN; POLYPEPTIDE; PARTICLES; SPINACH	Cellular localization of cytochrome (cyt) c550, a low potential, c-type monoheme cytochrome, in a thermophilic cyanobacterium Synechococcus vulcanus was investigated by systematic fractionation of the cells followed by its enzymatic and immunological detection. While cyt c-553, a soluble cyt that donates an electron to P700, was detected in the supernatant of osmotic disruption of lysozyme-treated cells, cyt c550 was detected only in the thylakoid membrane fraction, being tightly bound to thylakoids, and its removal required sonication in the presence of 1 M CaCl2. Upon further fractionation of the thylakoids into photosystem (PS) I and PSII by lauryl dimethylamine N-oxide solubilization, cyt c550 was exclusively concentrated in the crude PSII fraction together with cyt f, with no significant amount being detected in any of the soluble and PSI fractions. Upon further fractionation of the crude PSII by n-dodecyl beta-D-maltoside solubilization followed by column chromatography, cyt c550 was detected exclusively in the purified PSII core complex fraction but not in any other fractions. A 12-kDa protein, one of the extrinsic components of cyanobacterial PSII, exhibited completely the same behavior as that of cyt c550 during these fractionation procedures. These results, coupled with our previous results that cyt c550 binds stoichiometrically to the cyanobacterial PSII core complex and enhances O2 evolution (Shen, J.-R., and Inoue, Y. (1993) Biochemistry 32, 1825-1832), indicate that there is only one species of cyt c550 in cyanobacterial cells and that this cyt is exclusively associated with PSII as a functional component for O2 evolution.			SHEN, JR (corresponding author), INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN.		Shen, Jian-Ren/B-2558-2011					ALAM J, 1984, BIOCHIM BIOPHYS ACTA, V766, P317, DOI 10.1016/0005-2728(84)90247-0; BENDALL DS, 1988, METHOD ENZYMOL, V167, P272; BOWES JM, 1983, BIOCHIM BIOPHYS ACTA, V725, P210, DOI 10.1016/0005-2728(83)90241-4; COHN CL, 1989, ARCH BIOCHEM BIOPHYS, V270, P227, DOI 10.1016/0003-9861(89)90024-6; GUIKEMA JA, 1981, BIOCHIM BIOPHYS ACTA, V637, P189, DOI 10.1016/0005-2728(81)90157-2; HO KK, 1979, BIOCHIM BIOPHYS ACTA, V545, P236; HOGANSON CW, 1990, BIOCHIM BIOPHYS ACTA, V1016, P203, DOI 10.1016/0005-2728(90)90059-D; HOLTON RW, 1967, BIOCHIM BIOPHYS ACTA, V131, P362, DOI 10.1016/0005-2728(67)90150-8; HOLTON RW, 1963, SCIENCE, V142, P234, DOI 10.1126/science.142.3589.234; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KIENZL PF, 1983, FEBS LETT, V162, P76, DOI 10.1016/0014-5793(83)81052-7; KOIKE H, 1985, BIOCHIM BIOPHYS ACTA, V807, P64, DOI 10.1016/0005-2728(85)90053-2; KOIKE H, 1987, BIOCHIM BIOPHYS ACTA, V893, P524, DOI 10.1016/0005-2728(87)90104-6; Koike H., 1983, OXYGEN EVOLVING SYST, P257; KROGMANN DW, 1990, BIOCHIM BIOPHYS ACTA, V2, P687; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MIYAO M, 1987, TOPICS PHOTOSYNTHESI, V9, P289; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V766, P395, DOI 10.1016/0005-2728(84)90255-X; PHILBRICK JB, 1988, MOL GEN GENET, V212, P418, DOI 10.1007/BF00330845; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; STEWART AC, 1985, BIOCHIM BIOPHYS ACTA, V808, P353, DOI 10.1016/0005-2728(85)90145-8; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591	26	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20408	20413						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397205				2022-12-25	WOS:A1993LY01900073
J	FRITSCHE, M; HAESSLER, C; BRANDNER, G				FRITSCHE, M; HAESSLER, C; BRANDNER, G			INDUCTION OF NUCLEAR ACCUMULATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 BY DNA-DAMAGING AGENTS	ONCOGENE			English	Article							CELL-CYCLE PROGRESSION; WILD-TYPE P53; TRANSFORMED-CELLS; MOUSE CELLS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; ANTICANCER AGENTS; TOPOISOMERASE-II	Cancer therapy drugs, such as diamminedichloroplatinum (cisplatin), mitomycin C, etoposide and a number of other compounds, as well as energy-rich radiation, are known to act on cellular DNA. These agents are shown to induce nuclear accumulation of the so-called tumor-suppressor protein p53 in fibroblastoid cells, as well as in epithelioid normal and immortalized cells of murine, simian, and human origin. p53 accumulation starts a few hours after treatment and can remain detectable in surviving cells for at least 20 days. Accumulation occurs because of increased p53 protein stability and depends on ongoing translation. It is not the result of enhanced gene expression. A number of cell cycle inhibitors do not affect p53 protein accumulation, suggesting that the process may start from several points in the cell cycle. Since the increase in the nuclear p53 protein levels occurs within a few hours in most of the treated normal diploid cells, it is unlikely that the accumulated p53 protein is derived from a mutated p53 gene. The results obtained are in accordance with the view that the DNA damage-induced p53 accumulation may either inhibit cell growth, allowing DNA repair processes, or, in the case of severe damage, initiate apoptosis.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,POB 820,W-7800 FREIBURG,GERMANY	University of Freiburg								ABDELLA BR, 1984, ENV HLTH PERSPECT, V64, P3; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARKET J, 1990, ONCOGENE, V5, P893; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; BENNETT WP, 1991, ONCOGENE, V6, P1779; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COLVIN M, 1981, CANCER TREAT REP, V65, P89; COOK PR, 1976, NATURE, V263, P679, DOI 10.1038/263679a0; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dustin P., 1984, MICROTUBULES; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1991, J CANCER RES CLIN, V117, P30; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLAZER RI, 1980, MOL PHARMACOL, V17, P111; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HINDS P, 1987, MOL CELL BIOL, V63, P739; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1988, ONCOGENE HDB, P403; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KASTAN MB, 1991, CANCER RES, V51, P6304; Kato H., 1977, International Rev Cytol, V49, P55; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KEPPLER BK, 1990, NEW J CHEM, V14, P389; KINZEL V, 1990, PROG CLIN BIOL RES, V340, P133; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMANN AR, 1981, J CANCER RES CLIN, V100, P117, DOI 10.1007/BF00403361; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI JC, 1984, P NATL ACAD SCI USA, V81, P5964; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MILLER CW, 1990, CANCER RES, V50, P7950; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARKER WB, 1987, CANCER RES, V47, P979; PERO RW, 1990, CANCER RES, V50, P4619; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; POTMESIL M, 1983, CANCER RES, V43, P3528; REDDY MV, 1987, MUTAT RES, V179, P75; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; ROBERTS JJ, 1957, NATURE, V179, P1181, DOI 10.1038/1791181a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTER V, 1991, ADV CANCER RES, V57, P257; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SELBY CP, 1990, P NATL ACAD SCI USA, V87, P3522, DOI 10.1073/pnas.87.9.3522; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SHOHAT O, 1987, ONCOGENE, V1, P277; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SOUSSI T, 1987, ONCOGENE, V1, P71; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TERADA N, 1991, J IMMUNOL, V147, P698; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; WALKER PR, 1991, CANCER RES, V51, P1078; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; WASSERMANN K, 1990, MOL PHARMACOL, V38, P38; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WINTERSBERGER E, 1984, FEBS LETT, V166, P326, DOI 10.1016/0014-5793(84)80105-2; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	115	875	888	0	24	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					307	318						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426740				2022-12-25	WOS:A1993KN00600009
J	ERIKSSON, S; NORDEN, B; TAKAHASHI, M				ERIKSSON, S; NORDEN, B; TAKAHASHI, M			BINDING OF DNA QUENCHES TYROSINE FLUORESCENCE OF RECA WITHOUT ENERGY-TRANSFER TO DNA BASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR DICHROISM SPECTROSCOPY; ANGLE NEUTRON-SCATTERING; FLOW-ORIENTED SOLUTION; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; GENERAL RECOMBINATION; ELECTRON-MICROSCOPY; NUCLEOTIDE COFACTOR; SELF-ASSOCIATION; LAMBDA-REPRESSOR	The binding of single- as well as double-stranded DNA to RecA, in the presence of the cofactor analog ATPgammaS (adenosine 5'-O-(3-thiotriphosphate)), leads to about 20% quenching of the tyrosine fluorescence of the protein but to no essential change of the tryptophan fluorescence. The excitation spectrum of the fluorescent DNA analog poly(depsilonA), complexed with RecA, shows no sign of energy transfer from the tyrosine residues of RecA to the etheno-modified adenine bases of the polynucleotide. From this observation we reject stacking interaction between tyrosine residues and DNA bases. The RecA filament may bind up to three molecules of single-stranded DNA; however, the observed fluorescence change occurs only upon the binding of the first DNA strand, indicating that the binding mode of this first strand is different from those of the others. The fluorescence change is interpreted in terms of a conformational change of the RecA protein promoted by cooperative binding to DNA. A larger quenching (40%) upon the binding of single-stranded DNA is observed in the absence of cofactor. At high salt condition, which induces ATPase activity in RecA just as DNA binding does, the tyrosine fluorescence is more pronounced than at low salt conditions, indicating that the effect induced by high salt is different from the conformational change induced by DNA binding.	CNRS,INST BIOL MOLEC & CELLULAIRE,CANCEROGENESE & MUTAGENESE MOLEC & STRUCT GRP,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	ERIKSSON, S (corresponding author), CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN.		Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X				BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DICAPUA E, 1980, NUCLEIC ACIDS MOL BI, V283, P26; ERIKSSON S, 1993, J BIOL CHEM, V268, P1811; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600; HORII T, 1991, BIOCHIMIE, V73, P177, DOI 10.1016/0300-9084(91)90200-K; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; ISHIDA T, 1988, NUCLEIC ACIDS RES, V16, P6175, DOI 10.1093/nar/16.13.6175; KHAMIS MI, 1988, BIOCHIM BIOPHYS ACTA, V950, P132, DOI 10.1016/0167-4781(88)90005-X; KIM SK, 1993, IN PRESS CARCINOGENE; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KUBISTA M, 1988, NUCLEOS NUCLEOT, V7, P783, DOI 10.1080/07328318808056330; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; LEDNEVA RK, 1978, NUCLEIC ACIDS RES, V5, P4225, DOI 10.1093/nar/5.11.4225; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Longworth J, 1971, EXCITED STATES PROTE, P319; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MUENCH KA, 1991, J BIOL CHEM, V266, P844; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; NORDEN B, 1990, J MOL BIOL, V216, P223, DOI 10.1016/S0022-2836(05)80311-0; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; NORDEN B, 1992, STRUCTURE FUNCTION, V2, P61; PUGH BF, 1988, J BIOL CHEM, V263, P76; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sasada Y, 1988, Adv Biophys, V24, P57, DOI 10.1016/0065-227X(88)90004-4; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, J BIOL CHEM, V264, P8568; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1987, J BIOL CHEM, V262, P8109; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; TOULME JJ, 1980, BIOCHIM BIOPHYS ACTA, V606, P95, DOI 10.1016/0005-2787(80)90101-X; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEINSTOCK GM, 1982, BIOCHIMIE, V64, P611, DOI 10.1016/S0300-9084(82)80098-9; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050	58	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1805	1810						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420955				2022-12-25	WOS:A1993KH62000048
J	HARRIS, RZ; NEWMYER, SL; DEMONTELLANO, PRO				HARRIS, RZ; NEWMYER, SL; DEMONTELLANO, PRO			HORSERADISH PEROXIDASE-CATALYZED 2-ELECTRON OXIDATIONS - OXIDATION OF IODIDE, THIOANISOLES, AND PHENOLS AT DISTINCT SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; AROMATIC DONOR MOLECULES; COMPOUND-I; OXYGEN-TRANSFER; IRON COMPLEXES; MECHANISM; HEME; LACTOPEROXIDASE; SULFIDES; CHLOROPEROXIDASE	The atypical two-electron oxidation of thioanisole and its p-methyl, p-methoxy, and p-nitro analogues by horseradish peroxidase, contrary to earlier reports, stereoselectively produces the (S) sulfoxides in 60-70% enantiomeric excess. Horseradish peroxidase reconstituted with delta-meso-ethylheme has little peroxidase (guaiacol oxidizing) activity, as previously reported, but exhibits increased sulfoxidation activity. Difference spectroscopy shows that guaiacol binds to delta-meso-ethylheme-reconstituted horseradish peroxidase even though it is essentially not oxidized. In contrast, horseradish peroxidase reconstituted with delta-meso-methylheme is active in both reactions. Studies with (H2O2)-O-18 show that the oxygen in the sulfoxide produced by delta-meso-ethylheme-reconstituted horseradish peroxidase derives, as it does in the reaction catalyzed by the native enzyme, primarily from the peroxide. Preincubation of horseradish peroxidase with phenylhydrazine, which modifies the protein, suppresses peroxidase activity but does not inhibit thioanisole sulfoxidation. On the other hand, the oxidation of iodide is blocked by reconstitution of horseradish peroxidase with delta-meso-ethylheme or preincubation with phenylhydrazine. Noncompetitive kinetics are observed for the inhibition of guaiacol and iodide oxidation by thioanisole and of guaiacol oxidation by iodide. The kinetic data and the differential inhibitory effects of delta-meso-ethylheme reconstitution and phenylhydrazine preincubation indicate that thioanisole and iodide, both of which undergo net two-electron oxidations, are oxidized at sites distinct from each other and from that involved in the oxidation of guaiacol. Spectroscopic substrate binding studies provide support for distinct thioanisole, guaiacol, and iodide-binding sites. An active site model is proposed to rationalize the results.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Newmyer, Sherri/0000-0003-1039-5416	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32488] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1989, J BIOL CHEM, V264, P9250; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; COLONNA S, 1992, J CHEM SOC CHEM COMM, P357, DOI 10.1039/c39920000357; COLONNA S, 1990, BIOCHEMISTRY-US, V29, P10465, DOI 10.1021/bi00498a006; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DOERGE DR, 1986, ARCH BIOCHEM BIOPHYS, V244, P678, DOI 10.1016/0003-9861(86)90636-3; DOERGE DR, 1991, BIOCHEMISTRY-US, V30, P8960, DOI 10.1021/bi00101a007; DUNFORD HB, 1986, ARCH BIOCHEM BIOPHYS, V251, P536, DOI 10.1016/0003-9861(86)90361-9; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ELFARRA AA, 1991, ARCH BIOCHEM BIOPHYS, V286, P244, DOI 10.1016/0003-9861(91)90036-I; FERNANDEZ M, 1991, BIOCHEM BIOPH RES CO, V180, P360, DOI 10.1016/S0006-291X(05)81301-4; GROVES JT, 1986, CYTOCHROME P 450 STR, P1; HARRIS RZ, 1992, BIOCHEMISTRY-US, V31, P2193; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HOSOYA T, 1989, BIOCHEMISTRY-US, V28, P2639, DOI 10.1021/bi00432a042; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; KEDDERIS GL, 1986, J BIOL CHEM, V261, P5910; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KOBAYASHI S, 1987, BIOCHEMISTRY-US, V26, P5019, DOI 10.1021/bi00390a020; KOBAYASHI S, 1986, BIOCHEM BIOPH RES CO, V135, P166, DOI 10.1016/0006-291X(86)90957-5; LEIGH JS, 1975, FEBS LETT, V51, P304, DOI 10.1016/0014-5793(75)80913-6; LEMAR GN, 1992, BIOCHEMISTRY-US, V31, P9158; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P3783; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MEUNIER G, 1985, J BIOL CHEM, V260, P576, DOI 10.1016/S0021-9258(19)85124-4; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MODI S, 1989, J BIOL CHEM, V264, P19677; NARUTA Y, 1990, J CHEM SOC CHEM COMM, P1378, DOI 10.1039/c39900001378; NEWMYER SL, 1992, BIOCHEMISTRY-US, V31, P2195; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; PEREZ U, 1990, BIOCHIM BIOPHYS ACTA, V1038, P98, DOI 10.1016/0167-4838(90)90016-9; PEREZ U, 1990, BIOCHEMISTRY-US, V29, P2757, DOI 10.1021/bi00463a019; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SAKURADA J, 1987, J BIOL CHEM, V262, P4007; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAXENA A, 1990, BIOCHIM BIOPHYS ACTA, V1041, P83, DOI 10.1016/0167-4838(90)90126-Z; SCHEJTER A, 1976, ARCH BIOCHEM BIOPHYS, V174, P36, DOI 10.1016/0003-9861(76)90321-0; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043	48	97	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1637	1645						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420938				2022-12-25	WOS:A1993KH62000023
J	JACKSON, DG; SMITH, DK; LUO, CL; ELLIOTT, JF				JACKSON, DG; SMITH, DK; LUO, CL; ELLIOTT, JF			CLONING OF A NOVEL SURFACE-ANTIGEN FROM THE INSECT STAGES OF TRYPANOSOMA-BRUCEI BY EXPRESSION IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN TRYPANOSOMES; GENE-EXPRESSION; REPETITIVE PROTEIN; MOLECULAR-CLONING; CULTURE FORMS; AMINO-ACIDS; T-BRUCEI; GLYCOPROTEIN; PROCYCLIN; SEQUENCE	Trypanosoma brucei cDNA libraries constructed in the vector pCDM8 were screened selectively for insect (procyclic) stage surface antigen cDNAs by transient expression in mammalian COS-7 fibroblasts and ''panning'' with a rabbit polyclonal antiserum. This strategy yielded two surface antigen cDNAs termed PSSA-1 and PSSA-2. The PSSA-1 cDNA encoded an isotype of procyclin, the major phosphatidylinositol-linked stage-specific glycoprotein antigen of the tsetse fly infective forms of T. brucei. The PSSA-2 cDNA encoded a new and previously unidentified stage-specific surface antigen with the features of a typical transmembrane glycoprotein but with an unusual cytoplasmic tail composed of a proline-rich tandem repeat. Fluorescent antibody staining of PSSA-1 transfected COS cells with a panel of procyclin-specific monoclonal antibodies confirmed that the protein was located on the outer surface of the plasma membrane. Furthermore, the antigen on COS cells was insensitive to treatment with phosphatidylinositol-specific phospholipase C suggesting that the inositol of the glycosylinositol phospholipid-lipid anchor contained the same fatty acyl modification reported recently for the procyclin molecule in cultured procyclic trypanosomes. In contrast the PSSA-2 antigen on COS cells was stained very weakly by whole parasite antisera. Northern blot hybridization revealed that the PSSA-2 antigen was encoded by a single 1.7-kilobase transcript which was present in parasites from the insect procyclic stage of the life cycle but not from the animal bloodstream stage. Southern blot hybridization analysis of DNA from procyclic stage trypanosomes indicated that the gene for PSSA-2 may be present in more than one copy in procyclic trypanosomes.	UNIV ALBERTA, DEPT IMMUNOL, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, DEPT MED MICROBIOL & INFECT DIS, EDMONTON T6G 2H7, ALBERTA, CANADA	University of Alberta; University of Alberta	JACKSON, DG (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.			, david/0000-0002-4133-9364	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGELOPOULOS E, 1970, J PROTOZOOL, V17, P39, DOI 10.1111/j.1550-7408.1970.tb05157.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOOTHROYD JC, 1982, J MOL BIOL, V157, P547, DOI 10.1016/0022-2836(82)90475-2; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRUN R, 1979, ACTA TROP, V36, P289; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; DUNCAN LR, 1991, MOL BIOCHEM PARASIT, V48, P11, DOI 10.1016/0166-6851(91)90159-4; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD MC, 1992, J BIOL CHEM, V267, P5324; FISCHER GF, 1990, J IMMUNOL, V144, P638; GARDINER PR, 1983, J IMMUNOL, V131, P454; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON DG, 1985, BIOCHEM J, V230, P195, DOI 10.1042/bj2300195; JACKSON DG, 1990, BIOCHEM SOC T, V18, P1032, DOI 10.1042/bst0181032; MAEDA N, 1985, J BIOL CHEM, V260, P1123; Maniatis T., 1982, MOL CLONING; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; MOWATT MR, 1988, MOL CELL BIOL, V8, P4055, DOI 10.1128/MCB.8.10.4055; OZAKI LS, 1983, NATURE, V305, P29; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; RICHARDSON JP, 1986, J IMMUNOL, V136, P2259; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; RODITI I, 1990, PARASITOL TODAY, V6, P79, DOI 10.1016/0169-4758(90)90216-Q; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIMMONS D, 1988, J IMMUNOL, V141, P2797; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; VICKERMAN K, 1969, NATURE, V224, P1125, DOI 10.1038/2241125a0; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WONG RSC, 1980, J BIOL CHEM, V255, P5943; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	46	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1894	1900						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420963				2022-12-25	WOS:A1993KH62000061
J	SUN, JD; ODDOUX, C; LAZARUS, A; GILBERT, MT; CATANZARO, DF				SUN, JD; ODDOUX, C; LAZARUS, A; GILBERT, MT; CATANZARO, DF			PROMOTER ACTIVITY OF HUMAN RENIN 5'-FLANKING DNA-SEQUENCES IS ACTIVATED BY THE PITUITARY-SPECIFIC TRANSCRIPTION FACTOR PIT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-HORMONE; PROLACTIN GENE; MESSENGER-RNA; EXPRESSION; RAT; BINDING; CELLS; PROTEIN; SYSTEM; ASSAY	Although the renal juxtaglomerular cell is the source of circulating renin, the renin gene is also expressed at a number of extrarenal sites including lactotrope cells of human and ovine pituitaries. In the present study, we demonstrate that GC cells, a pituitary lactotrope precursor cell line, efficiently express transiently transfected hybrid genes containing human renin 5'-flanking DNA sequences -148/+11. Gel mobility shift competition analyses show that a highly conserved sequence in human and rodent renin 5'-flanking DNAs (human coordinates: -80/-58) binds a nuclear factor from GC cells, most likely the pituitary-specific factor Pit-1. Deletional and mutational analyses demonstrate that this site is a major determinant of renin promoter activity in GC cells. Transfection of a Pit-1 expression construct into HeLa cells, where activity of the human renin promoter is low, stimulates expression of cotransfected renin-luciferase constructs. Moreover, activation of the human renin promoter by co-expression of Pit-1 is dependent on an intact Pit-1 site. Taken together, these data strongly suggest that Pit-1 activates pituitary renin gene expression. This finding raises the possibility that member(s) of the POU family of transcription factors, of which Pit-1 is an archetypal member, may direct renin expression in other tissues, including the kidney.	CORNELL UNIV, MED CTR, COLL MED, CTR CARDIOVASC, 525 E 68TH ST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT PHYSIOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Cornell University								BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURNHAM CE, 1987, P NATL ACAD SCI USA, V84, P5605, DOI 10.1073/pnas.84.16.5605; BURT DW, 1989, GENE, V84, P91, DOI 10.1016/0378-1119(89)90143-1; DESCHEPPER CF, 1986, P NATL ACAD SCI USA, V83, P7552, DOI 10.1073/pnas.83.19.7552; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; HARDMAN JA, 1984, DNA-J MOLEC CELL BIO, V3, P457, DOI 10.1089/dna.1.1984.3.457; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; JONES GJ, 1991, MOL ENDOCRINOL, V5, P1836, DOI 10.1210/mend-5-12-1836; KETTANI S, 1991, HISTOCHEMISTRY, V95, P561, DOI 10.1007/BF00266742; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; NARUSE K, 1981, P NATL ACAD SCI-BIOL, V78, P7579, DOI 10.1073/pnas.78.12.7579; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAINTANDRE JP, 1989, HISTOCHEMISTRY, V91, P291, DOI 10.1007/BF00493003; SCHADLOW VC, 1992, MOL BIOL CELL, V3, P941, DOI 10.1091/mbc.3.8.941; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SEALEY JE, 1986, AM J MED, V81, P1041, DOI 10.1016/0002-9343(86)90402-X; SEALEY JE, 1990, FRONT NEUROENDOCRIN, V11, P213; Sealey JE, 1990, HYPERTENSION PATHOPH, P1287; SHARP ZD, 1989, NUCLEIC ACIDS RES, V17, P2705, DOI 10.1093/nar/17.7.2705; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1505	1508						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420924				2022-12-25	WOS:A1993KH62000002
J	NATARAJAN, V; TAHER, MM; ROEHM, B; PARINANDI, NL; SCHMID, HHO; KISS, Z; GARCIA, JGN				NATARAJAN, V; TAHER, MM; ROEHM, B; PARINANDI, NL; SCHMID, HHO; KISS, Z; GARCIA, JGN			ACTIVATION OF ENDOTHELIAL-CELL PHOSPHOLIPASE-D BY HYDROGEN-PEROXIDE AND FATTY-ACID HYDROPEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERT-BUTYL-HYDROPEROXIDE; GLUTATHIONE REDOX CYCLE; OXYGEN RADICALS; PHORBOL ESTER; ADENOSINE-TRIPHOSPHATE; LIPID-PEROXIDATION; OXIDANT INJURY; LUNG INJURY; MECHANISMS; METABOLISM	We have investigated oxidant-mediated stimulation of phospholipase D (PLD) activity in bovine pulmonary artery endothelial cells (BPAEC), prelabeled with [P-32] orthophosphate or [P-32]lysophospholipids. Treatment of cells incubated in Hanks' balanced salt solution (HBSS) containing 0.5% ethanol with hydrogen peroxide (H2O2) or linoleic acid hydroperoxide (18:2-OOH) enhanced the formation of P-32-labeled phosphatidylethanol (PEt) and phosphatidic acid (PA) in a dose- and time-dependent manner. indicating the activation of PLD. The H2O2- and 18:2-OOH-mediated PLD activation was not associated with cytotoxicity as determined by [H-3]deoxyglucose release. The addition of ferrous chloride (50 muM) augmented H2O2-induced formation of [P-32]PEt and [P-32]PA about 2-fold, whereas the addition of the iron chelator desferoxamine blocked the potentiating effect of ferrous chloride. Replacement of the HBSS medium with Medium 199 containing 20% calf serum also potentiated the effect of H2O2-induced PLD activation. In addition to phosphatidyl-choline (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI) were readily hydrolyzed by PLD in response to H2O2 and 18:2-OOH treatment. The substrate specificity for oxidant-stimulated PLD activity differed from that observed in the presence of bradykinin or exhibited by agonist stimulation with 12-O-tetradecanoylphorbol 13-acetate (TPA) where PC was the major phospholipid hydrolyzed by PLD. The formation of PEt in the presence of H2O2 and 18:2-OOH was not abolished by chelation of either extracellular Ca2+ with EGTA (5 mM) or intracellular Ca2+ with 1,2-bis-(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethyl ester (BAPTA-AM) (25 muM, 30 min). Furthermore, pretreatment of BPAEC with the protein kinase C (PKC) inhibitor staurosporine and down-regulation of PKC by chronic TPA treatment (100 nM, 18 hr) had no effect on H2O2-induced PLD activation, suggesting that PLD activation by H2O2 is independent of PKC activity. It is possible that H2O2- and 18:2-OOH-induced activation of PLD represents an important mechanism to produce PA and diacylglycerol in endothelial cells.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Minnesota System	NATARAJAN, V (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,DIV PULM,1001 W 10TH ST,OPW 425,INDIANAPOLIS,IN 46202, USA.		Garcia, Joe GN/E-8862-2010		NCRR NIH HHS [PHS507 RR5371L] Funding Source: Medline; NHLBI NIH HHS [HL02312, HL 47671] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047671, R55HL047671, K08HL002312] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREOLI SP, 1985, J LAB CLIN MED, V106, P253; ANDREOLI SP, 1990, J LAB CLIN MED, V115, P304; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BARCHOWSKY A, 1987, BIOCHIM BIOPHYS ACTA, V927, P372, DOI 10.1016/0167-4889(87)90102-9; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; Buege J A, 1978, Methods Enzymol, V52, P302; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CHAKRABORTI S, 1989, AM J PHYSIOL, V257, pL430, DOI 10.1152/ajplung.1989.257.6.L430; COOK SJ, 1991, BIOCHEM SOC T, V19, P108; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DUANE PG, 1991, AM J RESP CELL MOL, V4, P408, DOI 10.1165/ajrcmb/4.5.408; ELLIOTT SJ, 1989, J BIOL CHEM, V264, P3806; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARRUKH IS, 1988, AM REV RESPIR DIS, V137, P1343, DOI 10.1164/ajrccm/137.6.1343; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARCIA JGN, 1992, BLOOD, V79, P2056; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GARCIA JGN, 1992, LUNG VASCULAR INJURY, P1; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; GUTTERIDGE JMC, 1979, BIOCHEM J, V184, P469, DOI 10.1042/bj1840469; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HARLAN JM, 1984, J CLIN INVEST, V74, P442, DOI 10.1172/JCI111440; HARLAN JM, 1985, BLOOD, V65, P5136; JANERO DR, 1988, LIPIDS, V23, P452, DOI 10.1007/BF02535519; JOHNSON A, 1989, AM J PHYSIOL, V256, pH1012, DOI 10.1152/ajpheart.1989.256.4.H1012; KAPPUS H, 1992, LIPID PEROXIDATION M, P273; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KISS Z, 1989, J BIOL CHEM, V264, P1483; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; MARTIN TW, 1989, BIOCHEM BIOPH RES CO, V165, P319, DOI 10.1016/0006-291X(89)91072-3; MARTIN WJ, 1984, AM REV RESPIR DIS, V130, P209; MARX JL, 1987, SCIENCE, V235, P529, DOI 10.1126/science.3810154; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MICCADEI S, 1988, ARCH BIOCHEM BIOPHYS, V265, P311, DOI 10.1016/0003-9861(88)90133-6; NATARAJAN V, 1992, IN PRESS J LAB CLIN; PARINANDI NL, 1990, ARCH BIOCHEM BIOPHYS, V280, P45, DOI 10.1016/0003-9861(90)90516-2; PATEL JM, 1991, AM J RESP CELL MOL, V5, P321, DOI 10.1165/ajrcmb/5.4.321; PHILLIPS FC, 1979, LIPIDS, V14, P949, DOI 10.1007/BF02533511; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SARAN M, 1989, FREE RADICAL RES COM, V7, P213, DOI 10.3109/10715768909087944; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SHASBY DM, 1985, BLOOD, V65, P605; SHASBY DM, 1988, BLOOD, V72, P491; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; SUTTORP N, 1986, AM J PHYSIOL, V251, pC671, DOI 10.1152/ajpcell.1986.251.5.C671; TROTTA RJ, 1981, BIOCHIM BIOPHYS ACTA, V678, P230, DOI 10.1016/0304-4165(81)90211-7; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VERCELLOTTI GM, 1991, J LAB CLIN MED, V117, P15; WANG P, 1991, J BIOL CHEM, V266, P14877; WARD PA, 1991, J LAB CLIN MED, V118, P421; WHORTON AR, 1985, J CLIN INVEST, V76, P295, DOI 10.1172/JCI111960	55	212	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					930	937						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419372				2022-12-25	WOS:A1993KG07700029
J	MIAO, F; ABELSON, J				MIAO, F; ABELSON, J			YEAST TRANSFER RNA-SPLICING ENDONUCLEASE CLEAVES PRECURSOR TRANSFER-RNA IN A RANDOM PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBSTRATE RECOGNITION; LIGASE; IDENTIFICATION; EXCISION; INVITRO	Introns interrupt many of the tRNA genes of Saccharomyces cerevisiae at a constant position in the anti-codon loop. Pre-tRNA transcripts must be accurately cleaved at 3' and 5' splice sites by tRNA endonuclease to release these introns. In order to study splice site cleavage order, substrates were prepared in which the ribose 2'-OH at each of the splice sites was phosphorylated. This modification blocked cleavage by the endonuclease. We found that whichever splice site was blocked the endonuclease can cleave the other site, indicating that the two splice sites were cleaved independently. The endonuclease also cleaved both 3'- and 5'-nicked pre-tRNA(Phe). In addition, both kinds of ''2/3 molecules'' (exon+intron) were observed in kinetic studies, indicating that they were true biochemical intermediates. The rates of cleavage at the 3' and 5' splice sites of pre-tRNA were compared in several ways. The results showed that the endonuclease cleaves 3' and 5' sites at almost the same rate in the first cleavage, whereas in the second cleavage the 3' site was cleaved faster, indicating that the rates of the two routes for cleavage were unequal. These results demonstrated that the endonuclease cleaved pre-tRNA in a random order, creating two routes for removal of introns from pre-tRNA.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology								ABELSON JN, 1986, MOL EVOLUTION LIFE, P127; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BALTZINGER M, 1982, BIOCHEMISTRY-US, V21, P2467, DOI 10.1021/bi00539a028; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HO CK, 1990, EMBO J, P1245; HOPPER AK, 1984, PROCESSING RNA, P91; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; Maniatis T., 1982, MOL CLONING; MATHISON L, 1989, MOL CELL BIOL, V9, P4220, DOI 10.1128/MCB.9.10.4220; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; OCONNOR JP, 1990, THESIS U PITTSBURGH; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SANGER F, 1977, P NATL ACAD SCI USA, V75, P190; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; VOLCKAERT G, 1976, ANAL BIOCHEM, V72, P433, DOI 10.1016/0003-2697(76)90551-0; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004	30	10	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					672	677						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416971				2022-12-25	WOS:A1993KE60300101
J	PISTOCCHI, R; KASHIWAGI, K; MIYAMOTO, S; NUKUI, E; SADAKATA, Y; KOBAYASHI, H; IGARASHI, K				PISTOCCHI, R; KASHIWAGI, K; MIYAMOTO, S; NUKUI, E; SADAKATA, Y; KOBAYASHI, H; IGARASHI, K			CHARACTERISTICS OF THE OPERON FOR A PUTRESCINE TRANSPORT-SYSTEM THAT MAPS AT 19 MINUTES ON THE ESCHERICHIA-COLI CHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ORNITHINE DECARBOXYLASE; POLYAMINE TRANSPORT; NUCLEIC-ACIDS; PROTEINS; GENE; IDENTIFICATION; POLYMERASE; CLONING; COMPONENTS	The nucleotide sequence of the operon for the putrescine transport system that maps at 19 min on the Escherichia coli chromosome was determined. It contained four open reading frames encoding potF, -G, -H, and -I proteins. The potF protein (M(r) = 38,000) was inferred to be a putrescine-specific binding protein existing in a periplasmic fraction from the results of Western blot analysis of the cell fractions and from measurements of polyamine binding to the protein. The potG protein (M(r) = 45,000) had consensus amino acid sequences for the nucleotide-binding site. The potH (M(r) = 35,000) and potI (M(r) = 31,000) proteins consisted of six putative transmembrane-spanning segments linked by hydrophilic segments of variable length as shown by hydropathy profiles. The spermidine-putrescine transport system, which is mainly involved in spermidine transport, consisted of potA, -B, -C, and -D proteins (Furuchi, T., Kashiwagi, K., Kobayashi, H., and Igarashi, K. (1991) J. Biol. Chem. 266, 20928-20933). The homologies of the corresponding two proteins between those two systems, F and D, G and A, H and B, and I and C, were 35, 42, 37, and 36%, respectively. The initiation point of the transcription of the operon for the putrescine transport system was determined by primer extension and S1 nuclease mapping. Transcription started from the T residue located either 149 or 150 nucleotides upstream from the initiator AUG codon of potF protein mRNA. By making several subclones and a mutant lacking the potF gene, we showed that the expression of all four proteins was necessary for maximal putrescine transport activity. These results indicate that the putrescine transport system can also be defined as a bacterial periplasmic transport system.	CHIBA UNIV, FAC PHARMACEUT SCI, 1-33 YAYOI CHO, INAGE KU, CHIBA 263, JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187; PISTOCCHI, ROSSELLA/0000-0003-1304-6270				AMEMURA M, 1985, J MOL BIOL, V184, P241, DOI 10.1016/0022-2836(85)90377-8; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; IGARASHI K, 1982, ARCH BIOCHEM BIOPHYS, V219, P438, DOI 10.1016/0003-9861(82)90175-8; IGARASHI K, 1975, J BIOCHEM-TOKYO, V77, P383, DOI 10.1093/oxfordjournals.jbchem.a130736; ITO K, 1990, ARCH BIOCHEM BIOPHYS, V278, P277, DOI 10.1016/0003-9861(90)90260-6; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MUNRO GF, 1974, J BACTERIOL, V118, P952, DOI 10.1128/JB.118.3.952-963.1974; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; PEGG AE, 1988, CANCER RES, V48, P759; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; SANCAR A, 1981, J MOL BIOL, V148, P45, DOI 10.1016/0022-2836(81)90234-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1966, J BIOL CHEM, V241, P3714; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	49	100	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					146	152						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416922				2022-12-25	WOS:A1993KE60300023
J	CAPIEAUX, E; RAPIN, C; THINES, D; DUPONT, Y; GOFFEAU, A				CAPIEAUX, E; RAPIN, C; THINES, D; DUPONT, Y; GOFFEAU, A			OVEREXPRESSION IN ESCHERICHIA-COLI AND PURIFICATION OF AN ATP-BINDING PEPTIDE FROM THE YEAST PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING; SCHIZOSACCHAROMYCES-POMBE; TRANSPORT; FUNGI	The two major hydrophilic domains from the Saccharomyces cerevisiae plasma membrane H+-ATPase fused to glutathione S-transferase have been expressed in Escherichia coli. The GST-L peptide contained the hydrophilic region from Ala340 to Ser660. The GST-SL peptide contained in addition the hydrophilic region Glu162 to Val276. After solubilization of the inclusion bodies with urea, renaturation, and affinity chromatography, 3 mg of highly purified peptides were recovered per liter of E. coli culture. The purified peptides interacted with 2'(3')-O-(2,4,6-trinitrophenyl)adenosine-5'-triphosphate (TNP-ATP), the fluorescence of which was enhanced identically upon binding of either GST-L or GST-SL. ATP competitively displaced the TNP-ATP binding. The observed dissociation constants for TNP-ATP (6.5 muM) and ATP (3 mM) are close to those found for the complete native H+-ATPase protein. The fluorescence of TNP-ATP was sensitive to Mg2+ indicating the existence of a Mg2+-binding site on the peptide. Apparent affinity for this Mg2+ site was found to vary from 50 muM at pH 7.5 to 400 muM at pH 5.5.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; CEN GRENOBLE, DEPT BIOL MOLEC & STRUCT, BIOPHYS MOLEC & CELLULAIRE, F-3804 GRENOBLE, FRANCE	Universite Catholique Louvain; CEA								AMANN EJ, 1983, GENE, V40, P183; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; DUPONT Y, 1983, FEBS LETT, V256, P2346; ERASO P, 1990, TRENDS BIOMEMBR BIOE, V1, P1; GHISLAIN M, 1992, EUR J BIOCHEM, V209, P275, DOI 10.1111/j.1432-1033.1992.tb17286.x; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; HOLZER KP, 1989, J BIOL CHEM, V264, P14389; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; Maniatis T., 1982, MOL CLONING; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MCLENNAN DH, 1985, NATURE, V316, P696; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; RAO US, 1991, J BIOL CHEM, V266, P14740; RONJAT M, 1986, THESIS U GRENOBLE; SCARBOROUGH GA, 1993, IN PRESS MOL ASPECTS; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; VANDIJKCK L, 1990, EUR J BIOCHEM, V189, P675; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309	33	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21895	21900						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408044				2022-12-25	WOS:A1993MC80900070
J	RAO, SM; HOWELLS, RD				RAO, SM; HOWELLS, RD			CIS-ACTING ELEMENTS IN THE 5'-UNTRANSLATED REGION OF RAT TESTIS PROENKEPHALIN MESSENGER-RNA REGULATE TRANSLATION OF THE PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL PYROPHOSPHATE SYNTHETASE; HAPLOID GERM-CELLS; SPERMATOGENIC CELLS; MOLECULAR-CLONING; GENE-EXPRESSION; TRANSGENIC MICE; SOMATIC-CELLS; SERTOLI CELLS; TRANSCRIPTION; PEPTIDE	We found that a rat testis cDNA library contained two types of proenkephalin cDNA, corresponding to somatic and germ cell-specific transcripts. The somatic form is identical in primary sequence to previously characterized transcripts from rat brain and heart. The longer germ cell-specific cDNA contains a novel 5' terminus derived from the somatic intron A. We found that germ cell-specific transcripts translate in vitro with significantly lower efficiency than do somatic-type transcripts. Deletion analysis indicated that translational inefficiency is mediated primarily by the presence of four upstream AUG codons followed by short open reading frames within the leader sequence. Secondary structure in the form of a stem-and-loop upstream of the initiator codon for proenkephalin was found to have a slightly inhibitory effect on translation. These results, coupled with the very low abundance of the somatic transcript, provide a possible explanation for the low levels of opioid peptides found in adult rat testis in spite of the abundant quantity of germ cell-specific proenkephalin transcript.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,185 S ORANGE AVE,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY GRAD SCH BIOMED SCI,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005819] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 05819] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; CRAIN SM, 1990, TRENDS PHARMACOL SCI, V11, P77, DOI 10.1016/0165-6147(90)90322-Y; DONOVAN DM, 1992, P NATL ACAD SCI USA, V89, P2345, DOI 10.1073/pnas.89.6.2345; FOO NC, 1991, ENDOCRINOLOGY, V128, P2118, DOI 10.1210/endo-128-4-2118; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; HARLAN RE, 1987, J COMP NEUROL, V258, P159, DOI 10.1002/cne.902580202; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HOWELLS RD, 1984, P NATL ACAD SCI-BIOL, V81, P7651, DOI 10.1073/pnas.81.23.7651; HOWELLS RD, 1986, P NATL ACAD SCI USA, V83, P1960, DOI 10.1073/pnas.83.6.1960; HOWELLS RD, 1991, NATL I DRUG ABUSE RE, V105, P116; IBANEZ CF, 1991, P NATL ACAD SCI USA, V88, P3676, DOI 10.1073/pnas.88.9.3676; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KEW D, 1989, MOL ENDOCRINOL, V3, P179, DOI 10.1210/mend-3-1-179; KEW D, 1989, MOL ENDOCRINOL, V3, P1191, DOI 10.1210/mend-3-8-1191; KEW D, 1990, P NATL ACAD SCI USA, V87, P1943; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KILPATRICK DL, 1984, P NATL ACAD SCI-BIOL, V81, P7221, DOI 10.1073/pnas.81.22.7221; KILPATRICK DL, 1985, P NATL ACAD SCI USA, V82, P7467, DOI 10.1073/pnas.82.21.7467; KILPATRICK DL, 1986, ENDOCRINOLOGY, V119, P370, DOI 10.1210/endo-119-1-370; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LACAZEMASMONTEIL T, 1987, P NATL ACAD SCI USA, V84, P7261, DOI 10.1073/pnas.84.20.7261; LOW KG, 1990, MOL ENDOCRINOL, V4, P1408, DOI 10.1210/mend-4-9-1408; MANSOUR A, 1987, J NEUROSCI, V7, P2445; NORTH RA, 1986, TRENDS NEUROSCI, V9, P114; PERSSON H, 1990, MOL CELL BIOL, V10, P4701, DOI 10.1128/MCB.10.9.4701; PERSSON H, 1989, P NATL ACAD SCI USA, V86, P6166, DOI 10.1073/pnas.86.16.6166; POLAKIEWICZ RD, 1990, MOL CELL BIOL, V10, P736, DOI 10.1128/MCB.10.2.736; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RAO SM, 1992, REGUL PEPTIDES, V40, P397, DOI 10.1016/0167-0115(92)90526-Z; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; ROSEN H, 1984, J BIOL CHEM, V259, P4309; SCHALLING M, 1990, J CLIN INVEST, V86, P660, DOI 10.1172/JCI114758; TERUYA JH, 1991, BIOL REPROD, V44, P663, DOI 10.1095/biolreprod44.4.663; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; YOSHIKAWA K, 1989, BIOCHEM BIOPH RES CO, V161, P568, DOI 10.1016/0006-291X(89)92637-5; YOSHIKAWA K, 1989, FEBS LETT, V246, P193, DOI 10.1016/0014-5793(89)80281-9; YOSHIKAWA K, 1988, FEBS LETT, V237, P183, DOI 10.1016/0014-5793(88)80197-2; ZINN SA, 1991, J BIOL CHEM, V266, P23850	45	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22164	22169						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408077				2022-12-25	WOS:A1993MC80900107
J	JI, I; JI, TH				JI, I; JI, TH			RECEPTOR ACTIVATION IS DISTINCT FROM HORMONE-BINDING IN INTACT LUTROPIN-CHORIOGONADOTROPIN RECEPTORS AND ASP(397) IS IMPORTANT FOR RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; DOMAIN; ACID	Hormone binding to receptors on the cell surface triggers a sequence of events (receptor activation and signal generation) leading to activation of effectors in the cytoplasm. Receptor activation and signal generation are difficult to study as both are intimately associated with hormone binding. The lutropin-choriogonadotropin (LH/CG) receptor offers a unique model to differentiate and examine receptor activation and signal generation from hormone binding. It belongs to a subfamily of glycoprotein hormone receptors within the G-protein-coupled receptor family. This receptor subfamily has several structural features different from the structures of other G-protein-coupled receptors. These receptors consist of a large extracellular N-terminal half and membrane-associated C-terminal half of similar size. The truncated N-terminal half alone is capable of high affinity hormone binding, whereas the truncated C-terminal half alone is capable of low affinity hormone binding and cAMP induction. However, this distinction between the high affinity hormone binding and low affinity hormone binding associated with cAMP induction has not been established in intact receptors. As a step to identify a structural element which is responsible for receptor activation and signal generation, we have identified an extracellular Asp of the C-terminal half of the LH/CG receptor which is unique and common to the glycoprotein hormone receptors. Evidence is presented for the first time that Asp397 is important for induction of cAMP synthesis but not essential for hormone binding. Since extracellular Asp397 cannot interact with G-protein in the cytoplasm, the inability of the mutant LH/CG receptors with an Asp397 substitution to induce cAMP synthesis is likely to be caused by a defect in the intermediate steps (receptor activation and signal generation) between hormone binding and activation of G-protein. Therefore, our results not only demonstrate that receptor activation and signal generation are distinct from high affinity hormone binding in intact LH/CG receptors, but they also identify an amino acid important for the processes.			JI, I (corresponding author), UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI I, 1990, SERONO S, P355; JI I, 1991, J BIOL CHEM, V266, P14935; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MACFARLAND KC, 1989, SCIENCE, V245, P494; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REBOIS RV, 1984, J BIOL CHEM, V259, P8087; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034	17	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20851	20854						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407915				2022-12-25	WOS:A1993MA28800035
J	TASKEN, K; SKALHEGG, BS; SOLBERG, R; ANDERSSON, KB; TAYLOR, SS; LEA, T; BLOMHOFF, HK; JAHNSEN, T; HANSSON, V				TASKEN, K; SKALHEGG, BS; SOLBERG, R; ANDERSSON, KB; TAYLOR, SS; LEA, T; BLOMHOFF, HK; JAHNSEN, T; HANSSON, V			NOVEL ISOZYMES OF CAMP-DEPENDENT PROTEIN-KINASE EXIST IN HUMAN-CELLS DUE TO FORMATION OF RI-ALPHA-RI-BETA HETERODIMERIC COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I REGULATORY SUBUNIT; GLUTATHIONE-S-TRANSFERASE; AMINO-ACID SEQUENCE; CYCLIC-AMP; HUMAN TESTIS; ADENOSINE-MONOPHOSPHATE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; CDNA STRUCTURE	We report that a human neoplastic B cell line (Reh) contains cAMP-dependent protein kinase (cAK) type I (cAKI), but is practically devoid of cAK type II (cAKII). However, these cells contain a novel cAKI isozyme consisting of an RIalpha-RIbeta heterodimer in association with phosphotransferase activity (RIalphaRIbetaC2) eluting from DEAE-cellulose columns at a salt concentration characteristic of a cAKII. Immunoprecipitation of 8-azido-[P-32]cAMP-labeled extracts and DEAE fractions employing specific antibodies directed against RIalpha and RIbeta clearly demonstrated the presence of RIalpha-RIbeta heterodimers. RIalpha was precipitated with RIbeta antiserum and vice versa. Furthermore, disruption of disulfide bridges by reduction-alkylation abolished this coimmunoprecipitation. In addition, formation of heterodimeric complexes of RIalpha and RIbeta could be demonstrated in vitro using recombinant RI proteins. Finally, the presence of low levels of RIalpha-RIbeta heterodimers could also be demonstrated in human peripheral blood T lymphocytes. RIalpha-RIbeta heterodimers complexed with the catalytic subunit represent a novel isozyme of cAKI (RIalphaRIbetaC2), which enhances the possibilities for diversification of cAMP-mediated effects.	NATL HOSP,INST GEN & RHEUMATOL IMMUNOL,N-0027 OSLO,NORWAY; NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY; NORWEGIAN RADIUM HOSP,DEPT IMMUNOL,N-0310 OSLO,NORWAY; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of California System; University of California San Diego	TASKEN, K (corresponding author), UNIV OSLO,INST MED BIOCHEM,POB 1112,BLINDERN,N-0317 OSLO,NORWAY.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Tasken, Kjetil/0000-0003-2841-4697	NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1986, ENZYMES, V17, P43; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CADD GG, 1990, J BIOL CHEM, V265, P19502; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COBB CE, 1988, METHOD ENZYMOL, V159, P202; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1990, J BIOL CHEM, V265, P7814; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEON DA, 1991, BIOCHEMISTRY-US, V30, P3035, DOI 10.1021/bi00226a008; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LIU AYC, 1982, J BIOL CHEM, V257, P298; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MOGER WH, 1991, ENDOCRINOLOGY, V128, P1414, DOI 10.1210/endo-128-3-1414; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS KV, 1992, MOL ENDOCRINOL, V6, P1756, DOI 10.1210/me.6.10.1756; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SKALHEGG BS, 1992, J BIOL CHEM, V267, P5374; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TASKEN K, 1990, BIOCHEM BIOPH RES CO, V172, P409, DOI 10.1016/0006-291X(90)90688-J; THOMIS DC, 1992, J BIOL CHEM, V267, P10723; WALTER U, 1983, METHOD ENZYMOL, V99, P154; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; ZICK SK, 1982, J BIOL CHEM, V257, P2287	55	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21276	21283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407966				2022-12-25	WOS:A1993MA28800093
J	HAO, MM; FINLAY, CA; LOZANO, G				HAO, MM; FINLAY, CA; LOZANO, G			A FUNCTIONALLY INACTIVE P53 LI-FRAUMENI SYNDROME MUTANT	ONCOGENE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; PROTEINS BIND; GENE-PRODUCT; T-ANTIGEN; DNA; MUTATIONS; CANCER; CELLS	Germline mutations in the tumor-suppressor p53 have been recently identified in Li-Fraumeni syndrome patients. We analysed the function of one of these mutations, an arg-to-trp substitution at amino acid 245 in the murine p53 gene. This p53LFS mutant could not, unlike wild-type p53, suppress foci formation of rat embryo-fibroblasts. Like other p53 mutants it cooperated with activated ras to transform rat embryo fibroblasts. Overexpression of p53LFS thus resulted in a phenotype similar to other mutant p53s. The p53LFS protein was also transcriptionally inactive in contrast to previous studies using a p53LFS/GAL4 fusion protein. To better understand the functional domain disrupted in p53LFS, we developed a dimerization assay and showed that p53LFS still dimerized. In addition, p53LFS retained its ability to bind SV40 large T antigen and not hsc70, both characteristics of wild-type p53. Using immunofluorescence, we localized p53LFS to the nucleus. From these results we conclude that p53LFS represents an unusual p53 mutant in that it retains many characteristics of wild-type p53, however activities critical for growth suppression are lost.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	University of Texas System; UTMD Anderson Cancer Center; Princeton University					NCI NIH HHS [CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047296, R01CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					299	306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426739				2022-12-25	WOS:A1993KN00600008
J	LUDLOW, JW; HOWELL, RL; SMITH, HC				LUDLOW, JW; HOWELL, RL; SMITH, HC			HYPOXIC STRESS INDUCES REVERSIBLE HYPOPHOSPHORYLATION OF PRB AND REDUCTION IN CYCLIN A ABUNDANCE INDEPENDENT OF CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; SEA-URCHIN EGGS; SV40 LARGE-T; TRANSCRIPTION FACTOR; MESSENGER-RNA; CDC2 KINASE; PRODUCT; INDUCTION	The effect of hypoxic stress on the phosphorylation state of the product of retinoblastoma susceptibility gene (pRB) and cyclin A abundance was examined in CV-1P monkey kidney cells. Flow cytometric DNA histogram analysis and [H-3]-thymidine incorporation assays demonstrated that hypoxia inhibited cell cycle progression and cell division. Within 6-12 h of hypoxia, pRB became hypophosphorylated and cyclin A abundance fell below detection limits. Hypophosphorylation of pRB and loss of cyclin A detection occurred without progression of cells through S-phase. These effects were found to be reversible by reoxygenation of the hypoxic cultures. Cells were shown to resume DNA synthesis within 12 - 16 h of reoxygenation concomitant with pRB hyperphosphorylation and an increase in cyclin A detection. These data demonstrate that hypoxic stress blocks the progression of these cells through the phases of the cell cycle and suggests that the effect might arise from the down regulation of key cell cycle controlling elements. The data also raise the possibility that maintaining pRB in a hyperphosphorylated state may be crucial for S-phase progression as well as S-phase entry.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester	LUDLOW, JW (corresponding author), UNIV ROCHESTER, CTR CANC, DIV TUMOR BIOL, BOX 704, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.			Smith, Harold/0000-0001-6257-6791	NCI NIH HHS [CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLEMAN CN, 1988, J NATL CANCER I, V80, P310, DOI 10.1093/jnci/80.5.310; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEWEY WC, 1976, RADIAT RES, V65, P511, DOI 10.2307/3574383; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KOCH CJ, 1971, RADIAT RES, V48, P74, DOI 10.2307/3573396; KOWK TT, 1989, RADIAT RES, V119, P261; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KWOK TT, 1989, INT J RADIAT ONCOL, V16, P1301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOCK RB, 1990, CANCER RES, V50, P3761; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; PELMAN HRB, 1986, CELL, V46, P959; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RICE GC, 1985, INT J RADIAT ONCOL, V11, P1817, DOI 10.1016/0360-3016(85)90038-0; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUTHERLAND RM, 1982, INT J RADIAT ONCOL, V8, P745, DOI 10.1016/0360-3016(82)90726-X; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUPEL P, 1987, RADIAT RES, V2, P707; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; WILSON RE, 1989, J NATL CANCER I, V81, P1235, DOI 10.1093/jnci/81.16.1235; XU HJ, 1989, ONCOGENE, V4, P807; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533	57	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					331	339						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426741				2022-12-25	WOS:A1993KN00600012
J	BOURSIER, JP; ALCOVER, A; HERVE, F; LAISNEY, I; ACUTO, O				BOURSIER, JP; ALCOVER, A; HERVE, F; LAISNEY, I; ACUTO, O			EVIDENCE FOR AN EXTENDED STRUCTURE OF THE T-CELL CORECEPTOR CD8-ALPHA AS DEDUCED FROM THE HYDRODYNAMIC PROPERTIES OF SOLUBLE FORMS OF THE EXTRACELLULAR REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MHC; PERIPHERAL-BLOOD LYMPHOCYTES; HLA CLASS-I; ALPHA-3 DOMAIN; HUMAN CD4; MONOCLONAL-ANTIBODIES; SURFACE-ANTIGENS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; 2ND CHAIN	We expressed soluble forms of the human T-cell coreceptor CD8alpha extracellular region, CD8alpha161, and the amino-terminal immunoglobulin-like domain, CD8alpha114, in Chinese hamster ovary cells and Escherichia coli, respectively. Both molecules were readily purified to homogeneity in milligram amounts and were recognized by a large panel of monoclonal antibodies. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis indicated that approximately 70% of CD8alpha161 was secreted as a disulfide-linked dimer, but CD8alpha114 was not disulfide-linked. To investigate the structural features of CD8alpha161 and CD8alpha114 under native conditions, we performed gel filtration and sucrose gradient sedimentation analysis. In spite of being partially or totally noncovalently bound, both recombinant molecules were stably associated homodimers, as no monomers could be detected at a fairly low protein concentration (approximately 1 muM). This suggests that the CD8alpha amino-terminal domain alone strongly contributes to chain association. Determination of the Stokes radius (R(s)) and sedimentation coefficient (s20,w) gave results consistent with CD8alpha114 having a globular shape and CD8alpha161 being an asymmetric molecule. Taking into account the contribution of hydration to the frictional coefficient, we obtained for CD8alpha161 an axial ratio of approximately 5, when modeled as a prolate ellipsoid. These results indicate that the elongated structure of CD8alpha161 is essentially contributed by the hinge region and help to explain how the CD8alpha is able to bridge the distance between the T-cell surface and its binding site in the alpha3 domain of major histocompatibility complex class I molecules on the target cell.	INST PASTEUR,DEPT IMMUNOL,MOLEC IMMUNOL LAB,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Alcover, Andres/0000-0002-9507-3450				ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ALCOVER A, 1992, IN PRESS MOL IMMUNOL; BARTHOLMES P, 1979, EUR J BIOCHEM, V95, P323, DOI 10.1111/j.1432-1033.1979.tb12968.x; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; Buttin G, 1978, Curr Top Microbiol Immunol, V81, P27; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHARMOT D, 1984, LEUKOCYTE TYPING, V2, P45; CLASSON BJ, 1992, INT IMMUNOL, V4, P215, DOI 10.1093/intimm/4.2.215; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CRON RQ, 1989, J IMMUNOL, V142, P3754; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DISANTO JP, 1988, EMBO J, V7, P3465, DOI 10.1002/j.1460-2075.1988.tb03221.x; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON P, 1986, NATURE, V323, P74, DOI 10.1038/323074a0; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAVATHAS P, 1984, P NATL ACAD SCI-BIOL, V81, P7688, DOI 10.1073/pnas.81.24.7688; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MACDONALD HR, 1982, IMMUNOL REV, V68, P88; MALISSEN B, 1982, EUR J IMMUNOL, V12, P739, DOI 10.1002/eji.1830120908; MARSHALL AG, 1978, BIOPHYSICAL CHEM, P181; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MEUNIER JC, 1972, FEBS LETT, V24, P63, DOI 10.1016/0014-5793(72)80827-5; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1983, J BIOL CHEM, V258, P4675; Sober H. H., 1968, HDB BIOCH; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P7101, DOI 10.1073/pnas.78.11.7101; SZMELCMAN S, 1990, J ACQ IMMUN DEF SYND, V3, P859; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG J, 1992, NATURE, V348, P411; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	66	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2013	2020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420975				2022-12-25	WOS:A1993KH62000079
J	ERIKSSON, S; NORDEN, B; MORIMATSU, K; HORII, T; TAKAHASHI, M				ERIKSSON, S; NORDEN, B; MORIMATSU, K; HORII, T; TAKAHASHI, M			ROLE OF TYROSINE RESIDUE-264 OF RECA FOR THE BINDING OF COFACTOR AND DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; LINEAR DICHROISM; GENERAL RECOMBINATION; ELECTRON-MICROSCOPY; NUCLEOTIDE COFACTOR; LAMBDA-REPRESSOR; ATP HYDROLYSIS; PROTEIN; COMPLEXES	The tyrosine fluorescence of the RecA protein is quenched by about 15% upon binding of the cofactor analog adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS). This quenching is not observed with a modified RecA in which the tyrosine residue at position 264 (Tyr-264) is replaced for alanine by site-directed mutagenesis, a modification which also results in a decrease of binding affinity of cofactor. This indicates that Tyr-264 is responsible for the fluorescence change and that the residue is close to or within the cofactor binding site. Upon DNA binding, a change of tyrosine fluorescence is observed both with the modified protein and with wild type RecA, indicating that DNA binding affects the environment of other tyrosine residues than Tyr-264. However, the change is significantly smaller in the modified protein, suggesting that both Tyr-264 as well as other residue(s) may be affected by the DNA binding. Changed fluorescence properties of the remaining tyrosine residues as a result of a slightly different DNA binding mode of the modified protein are also possible. Tyr-264 may be an important residue for the allosteric effect induced by the cofactor for the binding of DNA to RecA. In the recent crystal structure of RecA-ADP published by Story and Steitz (Story, R. M., and Steitz, T. A. (1992) Nature 355, 374-376), ADP is stacked with Tyr-103 and does not interact with Tyr-264. The fact that we observe no interaction of ATPgammaS with Tyr-103 (as evidenced from absence of fluorescence change) but instead with Tyr-264 may suggest an important conformational difference between the RecA complexes with, respectively, ADP and ATP.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; CNRS,INST BIOL MOLEC & CELLULAIRE,CANCEROGENESE & MUTAGENESE MOLEC & STRUCT LAB,F-67084 STRASBOURG,FRANCE	Osaka University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	ERIKSSON, S (corresponding author), CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN.		Morimatsu, Katsumi/G-5029-2013; Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X; Horii, Toshihiro/0000-0002-3000-2045				BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; COTTERIL SM, 1982, BIOCHEMISTRY-US, V1, P4332; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; ERIKSSON S, 1993, J BIOL CHEM, V268, P1805; FREITAG NE, 1991, J BIOL CHEM, V266, P7058; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; IKAWA S, 1989, J BIOL CHEM, V264, P21167; KAWASHIMA H, 1984, MOL GEN GENET, V193, P288, DOI 10.1007/BF00330682; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; NORDEN B, 1990, J MOL BIOL, V216, P223, DOI 10.1016/S0022-2836(05)80311-0; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; PRASAD BVV, 1987, J MOL BIOL, V193, P579; PUGH BF, 1988, J BIOL CHEM, V263, P76; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1987, J BIOL CHEM, V262, P8109; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINSTOCK GM, 1982, BIOCHIMIE, V64, P611, DOI 10.1016/S0300-9084(82)80098-9; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050	45	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1811	1816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420956				2022-12-25	WOS:A1993KH62000049
J	LIND, LK; SHUKLA, VK; NYHUS, KJ; PAKRASI, HB				LIND, LK; SHUKLA, VK; NYHUS, KJ; PAKRASI, HB			GENETIC AND IMMUNOLOGICAL ANALYSES OF THE CYANOBACTERIUM SYNECHOCYSTTIS SP PCC-6803 SHOW THAT THE PROTEIN ENCODED BY THE PSBJ GENE REGULATES THE NUMBER OF PHOTOSYSTEM-II CENTERS IN THYLAKOID MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; CHLOROPLAST GENOME; DELETION MUTAGENESIS; NUCLEOTIDE-SEQUENCE; CYTOCHROME-B559; DNA; CONSTRUCTION; ORGANIZATION; INHIBITION; EVOLUTION	The psbJ gene is a member of the psbEFLJ gene cluster in the cyanobacterium Synechocystis sp. PCC 6803 as well as in the chloroplasts of green plants. The putative product of the psbJ gene is a 4-kDa protein with one membrane-spanning domain. We have raised rabbit antibodies against a T7 gene 10-psbJ fusion protein, overexpressed in Escherichia coli. These antibodies recognized a polypeptide of expected size in the thylakoid membrane from wild type Synechocystis cells. We have also created a targeted mutant of Synechocystis 6803 in which the fourth codon of the psbJ open reading frame was modified to a translational stop codon. Thylakoid membranes from these mutant cells lacked the protein recognized by the antibodies. In the mutant cells, the partial electron transfer reaction mediated by the photosystem I complex was unaffected, whereas the rate of the photosystem II (PSII)-mediated reaction was 46% of that in wild type cells. Herbicide binding assays indicated that the PSII to chlorophyll ratio in the mutant cells was 49% of that in wild type cells. These results indicate that while the PsbJ protein is not essential for the photochemical activity it controls the amount of functionally assembled PSII complex in the thylakoid membrane.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)					NIGMS NIH HHS [GM45797] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; CANTRELL A, 1988, PHOTOSYNTH RES, V16, P65, DOI 10.1007/BF00039486; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CUSHMAN JC, 1988, CURR GENET, V13, P173, DOI 10.1007/BF00365652; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; FONG SE, 1992, CURR GENET, V21, P527, DOI 10.1007/BF00351664; Hallick RB, 1989, PLANT MOL BIOL REP, V7, P266, DOI [10.1007/BF02668635, DOI 10.1007/BF02668635]; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MacKinney G, 1941, J BIOL CHEM, V140, P315; NYHUS KJ, 1992, J BIOL CHEM, V267, P12489; NYHUS KJ, 1989, TECHNIQUES NEW DEV P, P469; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; PAKRASI HB, 1990, Z NATURFORSCH C, V45, P423; PAKRASI HB, 1992, CURRENT TOPICS PHOTO, V11, P231; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J, 1989, MOL CLONING LABORATO; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAE GS, 1992, BIOCHEMISTRY-US, V31, P4066, DOI 10.1021/bi00131a024; TISCHER W, 1977, BIOCHIM BIOPHYS ACTA, V460, P113, DOI 10.1016/0005-2728(77)90157-8; VANRENSEN JJS, 1978, Z NATURFORSCH C, V33, P413, DOI 10.1515/znc-1978-5-617; VERMAAS W, 1990, BIOCHEMISTRY-US, V29, P5325, DOI 10.1021/bi00474a017; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	34	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1575	1579						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420932				2022-12-25	WOS:A1993KH62000014
J	LESTER, RL; WELLS, GB; OXFORD, G; DICKSON, RC				LESTER, RL; WELLS, GB; OXFORD, G; DICKSON, RC			MUTANT STRAINS OF SACCHAROMYCES-CEREVISIAE LACKING SPHINGOLIPIDS SYNTHESIZE NOVEL INOSITOL GLYCEROPHOSPHOLIPIDS THAT MIMIC SPHINGOLIPID STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PHOSPHOLIPIDS	Mutant strains of Saccharomyces cerevisiae, termed SLC, make no detectable sphingolipids when cultured without a sphingolipid long chain base such as phytosphingosine (Dickson, R. C., Wells, G. B., Schmidt, A., and Lester, R. L. (1990) Mol. Cell. Biol. 10, 2176-2181). When grown with phytosphingosine they make sphingolipids in normal amounts. SLC strains carry a secondary suppressor mutation that bypasses the need to synthesize a long chain base. Hypothetically, the suppressor mutation could function by mutating a gene whose protein product required a sphingolipid for function, by increasing the level of one or more endogenous lipids, or by making new lipid(s). Here we demonstrate that SLC strains make novel inositol glycerophospholipids when cultured without a long chain base. The novel lipids are phosphatidylinositol (PI), mannosyl-PI, and inositol-P-(mannosyl-PI), containing 1 mol of C26 fatty acid, ordinarily found in yeast sphingolipids but not usually found in glycerophospholipids; the C26 fatty acid appears to be located at the SN-2 position of the glycerol. In addition, mono-fattyacyl versions of these three compounds were also identified. The polar head groups and hydrophobic portions of these novel lipids are strikingly similar to S. cerevisiae sphingolipids found in wild-type cells. We speculate that the novel lipids structurally mimic sphingolipids and thereby compensate for some sphingolipid function(s) necessary for growth.			LESTER, RL (corresponding author), UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,LEXINGTON,KY 40536, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BRENNAN PJ, 1988, MICROBIAL LIPIDS, V1, P204; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANSON BA, 1980, J LIPID RES, V21, P309; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LESTER RL, 1992, IN PRESS ADV LIPID R, V25; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; PATTON GM, 1982, J LIPID RES, V23, P190; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; Rattray J. B. M., 1988, MICROBIAL LIPIDS, P555; SKIPSKI VP, 1969, METHOD ENZYMOL, V14, P545; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TREVELYAN WE, 1968, J I BREWING, V74, P365, DOI 10.1002/j.2050-0416.1968.tb03142.x; WELLS GB, 1983, J BIOL CHEM, V258, P200; WILEY MG, 1992, LIPIDS, V27, P295, DOI 10.1007/BF02536479; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2	23	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					845	856						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419362				2022-12-25	WOS:A1993KG07700017
J	PILLET, L; TREMEAU, O; DUCANCEL, F; DREVET, P; ZINNJUSTIN, S; PINKASFELD, S; BOULAIN, JC; MENEZ, A				PILLET, L; TREMEAU, O; DUCANCEL, F; DREVET, P; ZINNJUSTIN, S; PINKASFELD, S; BOULAIN, JC; MENEZ, A			GENETIC-ENGINEERING OF SNAKE TOXINS - ROLE OF INVARIANT RESIDUES IN THE STRUCTURAL AND FUNCTIONAL-PROPERTIES OF A CURAREMIMETIC TOXIN, AS PROBED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; ALPHA-BUNGAROTOXIN BINDING; AMINO-ACID-SEQUENCE; INITIAL PROTEIN REFINEMENT; RABIES VIRUS GLYCOPROTEIN; CRYSTAL-STRUCTURE; SYNTHETIC PEPTIDES; ERABUTOXIN-B; 3-DIMENSIONAL STRUCTURE; 0.140-NM RESOLUTION	To study the site by which erabutoxin a (Ea) from Laticauda semifasciata binds to the nicotinic acetylcholine receptor, we mutated most residues that are shared with other curaremimetic toxins and studied the structural and biological consequences of introduced mutations. By site-directed mutagenesis, we changed Ser-8 into Gly (EaS8G), Lys-27 into Glu (EaK27E), Trp-29 into Phe (EaW29F) and His (EaW29H), Asp-31 into His (EaD31H), Phe-32 into Leu (EaF32L), Arg-33 into Lys (EaR33K) and Glu (EaR33E), Gly-34 into Ser (EaG34S), Glu-38 into Gln (EaE38Q) and Lys (EaE38K), Gly-49 into Val (EaG49V), and Leu-52 into Ala (EaL52A). All mutants were homogeneous as judged by various analytical procedures. EaE38Q, EaG49V, and EaL52A bound the nicotinic acetylcholine receptor with apparent K(d) values close to 10(-10) M, virtually identical to wild Ea. Therefore, Glu-38, Gly-49, and Leu-52 are not important elements in the expression of curaremimetic function in Ea. Mutations of Phe-32 and Gly-34 provoked a 7-fold affinity decrease, suggesting that these residues moderately contribute to function. The 176-fold affinity decrease due to mutation of Ser-8 may reflect some structural change that operates in the polypeptide chain of the mutant, as detected by circular dichroism. Decreases in affinity by a factor of 175, 67, 46, and 318 were seen upon mutations of Lys-27 into Glu, Trp-29 into Phe, Asp-31 into His, and Arg-33 into Glu, with no concomitant change in secondary structure. These residues appear to be important elements of the curaremimetic function of Ea. Thus, a picture of the contribution of conserved residues to the function of a curaremimetic toxin is proposed on the basis of experimental evidence.	CEA, CTR ETUD SACLAY, DEPT INGN & ETUD PROT, F-91190 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BOQUET P, 1979, HDB EXP PHARM, V52, P751; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG CC, 1971, BIOCHIM BIOPHYS ACTA, V251, P334, DOI 10.1016/0005-2795(71)90120-6; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chiappinelli V., 1991, SNAKE TOXINS, P223; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DONNELLYROBERTS DL, 1991, MOL BRAIN RES, V11, P107; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DUCANCEL F, 1991, TOXICON, V29, P516, DOI 10.1016/0041-0101(91)90026-N; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Endo T., 1991, P165; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P1687; HARVEY AL, 1984, BRIT J PHARMACOL, V82, P709, DOI 10.1111/j.1476-5381.1984.tb10810.x; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HORI H, 1976, BIOCHEM J, V153, P217, DOI 10.1042/bj1530217; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOUBERT FJ, 1975, H-S Z PHYSIOL CHEM, V356, P53, DOI 10.1515/bchm2.1975.356.1.53; KARLIN A, 1973, P NATL ACAD SCI USA, V70, P3636, DOI 10.1073/pnas.70.12.3636; KARLSSON E, 1991, TOXICON, V29, P521, DOI 10.1016/0041-0101(91)90027-O; KIM HS, 1982, BIOCHEM J, V207, P215, DOI 10.1042/bj2070215; LABHARDT AM, 1988, EUR J BIOCHEM, V149, P5; LAPLANTE SR, 1990, INT J PEPT PROT RES, V36, P227; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; LENTZ TL, 1991, BIOCHEMISTRY-US, V30, P10949, DOI 10.1021/bi00109a020; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; LOW BW, 1987, ASIA PAC J PHARMACOL, V2, P115; LOW BW, 1979, HDB EXPT PHARMACOLOG, V52, P213; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MCLANE KE, 1991, BIOCHEMISTRY-US, V30, P4925, DOI 10.1021/bi00234a013; MENEZ A, 1982, TOXICON, V20, P95, DOI 10.1016/0041-0101(82)90172-6; MENEZ A, 1976, BIOCHIM BIOPHYS ACTA, V453, P121, DOI 10.1016/0005-2795(76)90256-7; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MENEZ A, 1978, BIOCHIMIE, V60, P505; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; MENEZ A, 1992, SNAKE TOXINS ANTIGEN, P293; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MORI N, 1991, J PHARM PHARMACOL, V43, P785, DOI 10.1111/j.2042-7158.1991.tb03482.x; MULACJERICEVIC B, 1986, FEBS LETT, V199, P68, DOI 10.1016/0014-5793(86)81225-X; NEGRERIE M, 1990, BIOCHEMISTRY-US, V29, P8258, DOI 10.1021/bi00488a009; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; RALSTON S, 1987, BIOCHEMISTRY-US, V26, P3261, DOI 10.1021/bi00386a004; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; RUAN KH, 1990, P NATL ACAD SCI USA, V87, P6156, DOI 10.1073/pnas.87.16.6156; RYDEN L, 1973, INT J PEPT PROT RES, V5, P261; SAITOH T, 1980, FEBS LETT, V116, P30, DOI 10.1016/0014-5793(80)80522-9; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; TSERNOGLOU D, 1978, MOL PHARMACOL, V14, P710; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WEBER M, 1974, MOL PHARMACOL, V10, P1; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON PT, 1988, MOL PHARMACOL, V34, P643; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WOODY RW, 1978, BIOPOLYMERS, V17, P1451, DOI 10.1002/bip.1978.360170606; YANG CC, 1974, BIOCHIM BIOPHYS ACTA, V365, P1, DOI 10.1016/0005-2795(74)90245-1; YU C, 1990, EUR J BIOCHEM, V193, P789, DOI 10.1111/j.1432-1033.1990.tb19401.x; ZINNJUSTIN S, 1992, IN PRESS BIOCHEMISTR; [No title captured]	75	153	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					909	916						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419369				2022-12-25	WOS:A1993KG07700026
J	HILL, JR; MORRIS, DR				HILL, JR; MORRIS, DR			CELL-SPECIFIC TRANSLATIONAL REGULATION OF S-ADENOSYLMETHIONINE DECARBOXYLASE MESSENGER-RNA - DEPENDENCE ON TRANSLATION AND CODING CAPACITY OF THE CIS-ACTING UPSTREAM OPEN READING FRAME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED LYMPHOCYTES; EUKARYOTIC RIBOSOMES; INITIATION; EXPRESSION; SEQUENCES; GENE; EFFICIENCY; MODEL; SITE	The mRNA encoding S-adenosylmethionine decarboxylase (AdoMetDC) has a 330-nucleotide 5'-transcript leader containing an open reading frame (uORF) that codes for the hexapeptide MAGDIS. The uORF restricts the intracellular distribution of AdoMetDC mRNA primarily to monosomes in normal T-lymphocytes and in T-cell lines. In contrast, non-lymphoid cells normally carry an average of seven to nine ribosomes per AdoMetDC mRNA molecule (Hill, J. R., and Morris, D. R. (1992) J. Biol. Chem. 267, 21886-21893). Several alterations abolish the negative regulatory effect of the uORF in T-cells. These include removing the site of translational initiation; weakening the context of the translational initiation site; changing the coding capacity of the fourth, fifth, and sixth codons; increasing the length of the uORF at either the 5' or 3' end; or changing the primary order of the codons. In contrast, altering the nucleic acid sequence of the uORF at degenerative positions without changing the amino acid coding capacity did not cause deregulation. The uORF does not regulate translation in the trans-configuration. Our results support a model in which translation of the uORF generates a nascent hexapeptide that interacts with its translating ribosome to suppress translation of AdoMetDC mRNA in a cell-specific manner. Structural features of the carboxyl-terminal 3 amino acids of the putative hexapeptide govern the interaction of the peptide with a component of the translation machinery.	UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Morris, David/G-4503-2011		NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266, P01GM042508] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NIGMS NIH HHS [GM42508, GM07266-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, NEW BIOL, V3, P511; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HILL JR, 1992, J BIOL CHEM, V267, P21886; KANDROR K V, 1988, Molekulyarnaya Biologiya (Moscow), V22, P31; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MACH M, 1986, J BIOL CHEM, V261, P1697; Maniatis T., 1982, MOL CLONING; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; WHITE MW, 1988, PHYSL POLYAMINES, P331; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; [No title captured]	30	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					726	731						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416975				2022-12-25	WOS:A1993KE60300109
J	SIMONS, M; MORGAN, KG; PARKER, C; COLLINS, E; ROSENBERG, RD				SIMONS, M; MORGAN, KG; PARKER, C; COLLINS, E; ROSENBERG, RD			THE PROTOONCOGENE C-MYB MEDIATES AN INTRACELLULAR CALCIUM RISE DURING THE LATE G1-PHASE OF THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSION; EXPRESSION; MUSCLE; CA-2+; G1; PROLIFERATION; CALMODULIN; MITOSIS; HEPARIN; LINES	The intracellular concentration of ionized calcium is involved in regulating mitosis. However, little is known about intracellular levels of calcium during G1. We have demonstrated in vascular smooth muscle cells a mid-G, decrease in ionized calcium concentration followed by a 2-fold rise at the G1/S interface (44 nM +/- 0.6 nM versus 98 nM +/- 1.1 nM, p < 0.01). The elevation of intracellular calcium is preceded by an increase in c-myb mRNA levels and is abolished with antisense but not mirsense c-myb oligonucleotides. Furthermore, cells stably transfected with c-myb show a similar 2-fold augmentation in intracellular calcium concentrations, as compared with untransfected cells, which is also abolished by antisense c-myb oligonucleotides. The c-myb-induced rise in intracellular calcium is dependent upon the presence of extracellular calcium and is not suppressed by L type calcium channel blockers. We conclude that c-myb induces an elevation in intracellular calcium levels of vascular smooth muscle cells at the G1/S interface which provides a novel role for this proto-oncogene as well as a potentially important control point for cell cycle regulation.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BETH ISRAEL HOSP,PROGRAM SMOOTH MUSCLE RES,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	SIMONS, M (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,BLDG E25-229,CAMBRIDGE,MA 02139, USA.		Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL41484, HL31704, HL33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014, R01HL031704, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; IIDA H, 1990, J BIOL CHEM, V265, P21216; KEITH CH, 1985, NATURE, V316, P848, DOI 10.1038/316848a0; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCINTOSH JR, 1989, SCIENCE, V246, P622; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; PAPAGEORGIOU P, 1991, AM J PHYSIOL, V260, pH507, DOI 10.1152/ajpheart.1991.260.2.H507; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PAUL D, 1979, J CELL PHYSIOL, V98, P31, DOI 10.1002/jcp.1040980105; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; REILLY CF, 1989, J BIOL CHEM, V264, P6990; REILLY CF, 1990, J CELL PHYSIOL, V142, P342, DOI 10.1002/jcp.1041420217; Sambrook J, 1989, MOL CLONING LABORATO; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SISKEN JE, 1985, ADV MICROSCOPY, P73; SMITH IL, 1991, 7TH ANN M ONC F ADV, P6; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0	32	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					627	632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416967				2022-12-25	WOS:A1993KE60300094
J	LANGGUT, W; REISSER, T; KERSTEN, H; NISHIMURA, S				LANGGUT, W; REISSER, T; KERSTEN, H; NISHIMURA, S			MODULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVITY AND RELATED RESPONSES BY THE 7-DEAZAGUANINE DERIVATIVE, QUEUINE	ONCOGENE			English	Article							TRANSFER-RNA; PROTO-ONCOGENES; TYROSINE KINASE; C-FOS; PHOSPHORYLATION; ACTIVATION; PROTEINS; ENZYME; CELLS; BASE	Epidermal growth factor (EGF) induces autophosphorylation of its cognate receptor at tyrosine residues. Here we show that queuine (q), a widely distributed modified guanine analogue occurring free or as a tRNA wobble base, modulates this EGF receptor activity in vitro and in intact cells. Autophosphorylation of the immunopurified receptor from human A431 epidermoid carcinoma cells was enhanced three to fourfold in the presence of physiological concentrations of q. Using a membrane fraction of A431 cells, a twofold increase in autophosphorylation activity in the presence of q was observed, however, only when the receptor was activated by the ligand. In intact A431 cells, q enhanced the initial ligand-induced autophosphorylation of the EGF receptor three to fourfold. However, upon longer treatment of the cells with EGF in the presence of q, significantly less autophosphorylated receptor was detectable compared with stimulation of cells in the absence of q. A similar q-dependent modulation of EGF receptor autophosphorylation was observed also in human cervical carcinoma cells HeLa-S3. Treatment of q-deficient HeLa cells with EGF induced the c-fos gene expression, transiently increased the activity of the anoxic stress protein LDH k, and stimulated proliferation. Treatment of HeLa cells with EGF in the presence of q resulted in a delayed c-fos gene expression and an accelerated increase and decrease of LDH k activity. The stimulatory effect of low doses of EGF on HeLa cell proliferation was completely antagonized in the presence of q. The results suggest that the mitogenic signalling initiated by the EGF receptor is modulated by q.	NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	National Cancer Center - Japan	LANGGUT, W (corresponding author), UNIV ERLANGEN NURNBERG,FAK MED,INST BIOCHEM,FAHRSTR 17,W-8520 ERLANGEN,GERMANY.							ANDERSON GR, 1981, J BIOL CHEM, V256, P583; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; DIETZ AA, 1967, ANAL BIOCHEM, V20, P246, DOI 10.1016/0003-2697(67)90030-9; EMMERICH B, 1985, CANCER RES, V45, P4308; FRENCH BT, 1991, P NATL ACAD SCI USA, V88, P370, DOI 10.1073/pnas.88.2.370; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GOGH NM, 1988, ANAL BIOCHEM, V173, P93; HELIN K, 1991, J BIOL CHEM, V266, P8363; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KATZE JR, 1979, P NATL ACAD SCI USA, V76, P3271, DOI 10.1073/pnas.76.7.3271; KERSTEN H, 1988, Biofactors, V1, P27; Kersten H., 1990, CHROMATOGRAPHY MODIF, V45, pB69; LANGGUT W, 1990, FEBS LETT, V265, P33, DOI 10.1016/0014-5793(90)80877-L; LANGGUT W, 1993, BIOFACTORS, V4, P117; LANGGUT W, 1990, Biofactors, V2, P245; LANGGUT W, 1989, CHEM BIOL PTERIDINES, P356; MAHR U, 1990, Biofactors, V2, P185; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, EUR J BIOCHEM, V254, P3062; SZABO L, 1988, BIOFACTORS, V1, P242; TODDERUD G, 1989, Biofactors, V2, P11; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3141	3147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414516				2022-12-25	WOS:A1993MC09300031
J	WILLIAMS, AC; BROWNE, SJ; YEUDAL, WA; PATERSON, IC; MARSHALL, CJ; LANE, DP; PARASKEVA, C				WILLIAMS, AC; BROWNE, SJ; YEUDAL, WA; PATERSON, IC; MARSHALL, CJ; LANE, DP; PARASKEVA, C			MOLECULAR EVENTS INCLUDING P53 AND K-RAS ALTERATIONS IN THE IN-VITRO PROGRESSION OF A HUMAN COLORECTAL ADENOMA CELL-LINE TO AN ADENOCARCINOMA	ONCOGENE			English	Article							POLYPOSIS COLI PATIENTS; HUMAN COLONIC ADENOMA; GENE-MUTATIONS; CYTOGENETIC ABNORMALITIES; POSSIBLE INVOLVEMENT; HUMAN CHROMOSOME-1; TUMOR PROGRESSION; LUNG-CANCER; HUMAN DNA; CARCINOMA	The aim of the current study was to identify genetic abnormalities in human colorectal adenoma and carcinoma derived cell lines, and to determine whether the genetic changes which occur in vitro are relevant to the in vivo situation. Loss of 1p(33-35) region was shown to be the most common chromosome 1 abnormality and loss of heterozygosity (LOH) of the DCC gene and/or adjacent sequences was detected in all adenoma derived cells as well as the carcinoma cell lines. The level of p53 protein was also investigated as increased cellular p53 protein had previously been associated with mutation of the p53 gene. A further aim was to investigate genetic changes in our in vitro model of tumour progression, where the adenoma derived PC/AA cell line has previously been converted in vitro to two distinct tumorigenic phenotypes, producing either an adenocarcinoma or a mucinous carcinoma in athymic nude mice. Progression to the adenocarcinoma phenotype was shown to involve a specific chromosome 1 rearrangement, loss of both normal copies of chromosome 18 (although DCC gene sequences were retained), loss of the remaining wild type allele of k-ras resulting in homozygosity for the k-ras codon 12 mutation and increased cellular p53 protein as detected by SDS-PAGE Western blotting. The increase in p53 protein was shown not to be due to the acquisition of a mutation in the p53 gene. Interestingly, progression of the adenoma derived PC/AA cell line to the mucinous malignant phenotype did not involve any of these molecular rearrangements, suggesting that different genetically distinct pathways are involved in colorectal carcinogenesis. These studies show that the genetic changes in our in vitro model of human colorectal tumour progression are similar to those observed in in vivo studies.	UNIV BRISTOL,DEPT ORAL MED PATHOL & MICROBIOL,BRISTOL BS2 8HW,AVON,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,LONDON SW3 6JB,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Bristol; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	WILLIAMS, AC (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.		Lane, David P/C-4920-2008; Paterson, Ian/G-8688-2011	Paterson, Ian/0000-0001-9156-401X; Williams, Ann/0000-0002-6009-7137; Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; DELATTRE O, 1987, NUCLEIC ACIDS RES, V15, P1343, DOI 10.1093/nar/15.3.1343; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1993, ONCOGENE, V8, P307; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HAGUE A, 1992, INT J ONCOL, V1, P201; HALVORSEN TB, 1988, J CLIN PATHOL, V41, P1068, DOI 10.1136/jcp.41.10.1068; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEISTER I, 1990, CANCER RES, V50, P7232; LEVI S, 1991, CANCER RES, V51, P3497; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MANNING AM, 1991, ONCOGENE, V6, P1471; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MULERIS M, 1990, CANCER GENET CYTOGEN, V44, P107, DOI 10.1016/0165-4608(90)90203-M; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4747, DOI 10.1093/nar/16.10.4747; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARASKEVA C, 1990, INT J CANCER, V46, P753, DOI 10.1002/ijc.2910460434; PARASKEVA C, 1992, INT J CANCER, V51, P661, DOI 10.1002/ijc.2910510426; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; PARASKEVA C, 1989, CANCER RES, V49, P1282; QUNITILLA M, 1986, NATURE, V322, P78; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAKAI E, 1992, ONCOGENE, V7, P927; SEABRIGH.M, 1971, LANCET, V2, P971; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; SUNDBLAD AS, 1982, CANCER, V50, P2504, DOI 10.1002/1097-0142(19821201)50:11<2504::AID-CNCR2820501141>3.0.CO;2-A; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; YOUNG J, 1992, CANCER RES, V52, P285	58	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3063	3072						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414507				2022-12-25	WOS:A1993MC09300022
J	DO, KY; CUMMINGS, RD				DO, KY; CUMMINGS, RD			2,6-BRANCHED MANNOSE AND THE REGULATION OF POLY-N-ACETYLLACTOSAMINE BIOSYNTHESIS IN N-LINKED OLIGOSACCHARIDES OF CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; CONCANAVALIN-A-SEPHAROSE; STRUCTURAL DETERMINANTS; HUMAN-GRANULOCYTES; SUGAR CHAINS; CARBOHYDRATE MOIETY; HUMAN-ERYTHROCYTES; PLASMA-MEMBRANE; HIGH-AFFINITY; SIALIC-ACID	Poly-N-acetyllactosamine (PL) sequences (repeating (3Galbeta1-4GlcNAcbeta1)n) in complex-type N-linked oligosaccharides often occur in branched tri- and tetraantennary chains containing alpha-linked mannosyl residues disubstituted by N-acetyllactosaminyl units at C-2 and C-6 (2,6-branched mannose). We report here our studies on the factors affecting PL biosynthesis and the branching of N-linked oligosaccharides in glycoproteins from Chinese hamster ovary (CHO) cells. For our studies, we utilized a mutant CHO cell line designated Lec8 CHO, which lacks the ability to galactosylate its glycoproteins and consequently synthesizes glycoproteins containing terminal GlcNAc residues and lacking poly-N-acetyl-lactosamine and sialic acid. Glycoproteins in extracts of [H-3]glucosamine- or [H-3]mannose-labeled Lec8 CHO cells were galactosylated by exogenous beta1-4-galactosyltransferase and analyzed by chromatography on leukoagglutinating phytohemagglutinin-Sepharose, a lectin reactive with glycoproteins containing 2,6-branched mannosyl residues. Approximately 10% of the radiolabeled glycoproteins were bound, and these were primarily of high molecular mass. Structural analyses of the bound glycoproteins demonstrated that they quantitatively contained 296-branched mannose. We then determined whether the ''small i'' N-acetylglucosaminyltransferase (iGNT), which initiates PL biosynthesis, could specifically recognize glycoproteins in vitro and whether recognition was dependent on the presence of 2,6-branched mannose. When the galactosylated glycoproteins in extracts of Lec8 CHO cells were incubated with UDP-[H-3]GlcNAc, the endogenous iGNT quantitatively added GlcNAc in beta1-3-linkage to terminal galactosyl residues in the leukoagglutinating phytohemagglutinin-bound glycoproteins. These results demonstrate for the first time that 2,6-branched mannosyl residues are restricted to a subset of CHO glycoproteins and that the iGNT in vitro preferentially recognizes glycoproteins containing the 2,6-branched mannose determinant.	UNIV OKLAHOMA HLTH SCI CTR, HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,POB 26901, BSEB-325, OKLAHOMA CITY, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center					NCI NIH HHS [CA-37626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BERGER EG, 1985, P NATL ACAD SCI USA, V82, P4736, DOI 10.1073/pnas.82.14.4736; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CHILDS RA, 1983, BIOCHEM BIOPH RES CO, V110, P424, DOI 10.1016/0006-291X(83)91166-X; CRAWLEY SC, 1990, ANAL BIOCHEM, V185, P112, DOI 10.1016/0003-2697(90)90264-A; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; CUMMINGS RD, 1993, IN PRESS GUIDE TECHN; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; EASTON EW, 1991, J BIOL CHEM, V266, P21674; EGGE H, 1985, J BIOL CHEM, V260, P4927; ENDO T, 1990, BIOCHEMISTRY-US, V29, P9126, DOI 10.1021/bi00491a005; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; FUKUDA MN, 1978, J BIOL CHEM, V253, P6814; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LI E, 1978, J BIOL CHEM, V253, P7762; LI E, 1980, ARCH BIOCHEM BIOPHYS, V199, P393, DOI 10.1016/0003-9861(80)90295-7; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MATSUMOTO A, 1982, ARCH BIOCHEM BIOPHYS, V217, P682, DOI 10.1016/0003-9861(82)90550-1; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; ORBERGER G, 1992, EUR J BIOCHEM, V205, P257, DOI 10.1111/j.1432-1033.1992.tb16776.x; PIERCE M, 1986, J BIOL CHEM, V261, P772; PILLER F, 1983, J BIOL CHEM, V258, P2293; PLAAS AHK, 1992, TRENDS GLYCOSCI GLYC, V4, P445; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SEGUCHI T, 1991, ARCH BIOCHEM BIOPHYS, V284, P245, DOI 10.1016/0003-9861(91)90292-Q; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; SZILAGYI PJ, 1985, ANAL BIOCHEM, V148, P260, DOI 10.1016/0003-2697(85)90655-4; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WANG WC, 1991, J BIOL CHEM, V266, P23185; YAMAMOTO K, 1984, EUR J BIOCHEM, V143, P133, DOI 10.1111/j.1432-1033.1984.tb08352.x; YAMASHITA K, 1989, J BIOL CHEM, V264, P2415; YOSHIMA H, 1980, J BIOL CHEM, V255, P793; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZHU BCR, 1984, J BIOL CHEM, V259, P3962	70	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22028	22035						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408060				2022-12-25	WOS:A1993MC80900088
J	NOMURA, T; SAKAI, N; SARAI, A; SUDO, T; KANEIISHII, C; RAMSAY, RG; FAVIER, D; GONDA, TJ; ISHII, S				NOMURA, T; SAKAI, N; SARAI, A; SUDO, T; KANEIISHII, C; RAMSAY, RG; FAVIER, D; GONDA, TJ; ISHII, S			NEGATIVE AUTOREGULATION OF C-MYB ACTIVITY BY HOMODIMER FORMATION THROUGH THE LEUCINE-ZIPPER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; PROTO-ONCOGENE PRODUCT; B-CELL LYMPHOMAS; V-MYB; MYELOMONOCYTIC CELLS; GLUCOCORTICOID RECEPTOR; CONSTITUTIVE EXPRESSION; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; GENE	The trans-activating and transforming capacities of the c-myb proto-oncogene product (c-Myb) are negatively regulated through a leucine zipper structure in its negative regulatory domain. We show here that in contransfection assays, maximal Myb-induced trans-activation occurs with relatively low amounts of wild-type c-Myb, while higher levels of c-Myb result in reduced Myb-induced trans-activation. By contrast, this apparent negative autoregulation is not observed with a c-Myb mutant containing an impaired leucine zipper. Data presented here suggest that this negative autoregulation of trans-activation by wild-type c-Myb is a consequence of homodimer formation by c-Myb through its leucine zipper and of the inability of c-Myb dimers to bind DNA. These findings point to a novel mechanism of regulation of a transcription factor.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA; INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Institute Medical & Veterinary Science Australia	NOMURA, T (corresponding author), RIKEN,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN.		Ishii, Shunsuke/A-5271-2016; Ramsay, Robert G/C-3291-2015	Ishii, Shunsuke/0000-0002-6530-2478; Ramsay, Robert G/0000-0001-5003-0433				ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HU YL, 1991, ONCOGENE, V6, P1549; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACGREGOR PF, 1990, ONCOGENE, V5, P451; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANIKAWA J, 1993, IN PRESS P NATL ACAD; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	66	73	74	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21914	21923						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408047				2022-12-25	WOS:A1993MC80900073
J	CRENSHAW, DG; HSIEH, TS				CRENSHAW, DG; HSIEH, TS			FUNCTION OF THE HYDROPHILIC CARBOXYL-TERMINUS OF TYPE-II DNA TOPOISOMERASE FROM DROSOPHILA-MELANOGASTER .2. IN-VIVO STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERTWINED CATENATED DIMERS; CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; YEAST; REPLICATION; SEGREGATION; TRANSCRIPTION; CONDENSATION; COMPONENT	Genetic complementation, protein distribution, and in vivo enzymatic activity by carboxyl-terminal truncation mutations of the Drosophila enzyme were examined. Removal of more than 273 of the 1447 amino acids composing the full-length topoisomerase inactivates the enzyme in vivo and in vitro; removal of 227 amino acids or less has no apparent effect on the ability of the enzyme to substitute for a conditional lethal, or null mutation, of the Saccharomyces cerevisiae top2 gene. Four catalytically active mutants, from which 227 or 240 amino acids are deleted, define an intervening, critical region. Each mutant in this critical region displays different in vivo complementation activity ranging from complete complementation to non-complementation. Deletion analysis revealed a potent nuclear localization signal within the most distal 60 amino acids, although this is apparently not the only functional signal sequence encoded in the enzyme. Subcellular fractionation and indirect immunofluorescence demonstrate that the truncated enzymes localize to the nucleus, albeit with reduced efficiency compared to wild type. The ability of these mutants, including a mutant in the critical region which does not complement, to catalyze the decatenation of replicated plasmids and the segregation of replicated chromosomes was also examined.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University			Wu, Wan-lin/G-8937-2012; Hsieh, Tao-shih/G-9305-2012		NIGMS NIH HHS [5T32 GM07184, GM29006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184, R01GM029006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHARRON M, 1991, CHROMOSOMA, V100, P97, DOI 10.1007/BF00418242; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HSIEH T, 1983, J BIOL CHEM, V258, P8413; IDE GJ, 1981, CURR GENET, V4, P85, DOI 10.1007/BF00365686; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBS CW, 1988, J CELL BIOL, V107, P1401; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOHR D, 1988, YEAST PRACTICAL APPR, P125; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; SHERMAN F, 1986, LABORATORY COURSE MA; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; YANAGIDA M, 1987, NUCLEIC ACIDS MOL BI, V1, P196; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	46	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21335	21343						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407972				2022-12-25	WOS:A1993MA28800100
J	JONES, GA; CARPENTER, G				JONES, GA; CARPENTER, G			THE REGULATION OF PHOSPHOLIPASE C-GAMMA-1 BY PHOSPHATIDIC-ACID - ASSESSMENT OF KINETIC-PARAMETERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; MIXED MICELLES; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELLS; ACTIVATION; DIACYLGLYCEROL; PHOSPHATIDYLCHOLINE; STIMULATION	A survey of lipids revealed that the anionic phospholipid phosphatidic acid activates both control and tyrosine-phosphorylated PLC-gamma1. The mechanism by which phosphatidic acid activates both forms of PLC-gamma1 was investigated using kinetic analysis. In the presence of phosphatidic acid, the substrate concentration response for control PLC-gamma1 changes from sigmoidal to hyperbolic, while the cooperativity index decreases from 2.5 for control to 1.0 for tyrosine-phosphorylated PLC-gamma1. The primary influence of phosphatidic acid on the control enzyme is on the cooperativity index and not the association of PLC-gamma1 with substrate micelles, as phosphatidic acid had little effect on the micellar association constant, K(s). Phosphatidic acid also increases the activity of the tyrosine phosphorylated form of the enzyme. This increase is reflected in a decrease in the K(m) from 0.3- to 0.03-mol fraction phosphatidylinositol 4,5-bisphosphate. Phosphatidic acid has no effect on the K(s) of the tyrosine-phosphorylated enzyme. From this data it is concluded that phosphatidic acid appears to activate PLC-gamma1 by acting as an allosteric modifier.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, RM 647, LIGHT HALL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [T32CA009582, P01CA043720] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720, CA09582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAKER ME, 1989, MOL CELL ENDOCRINOL, V61, P129, DOI 10.1016/0303-7207(89)90197-4; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DIEZ E, 1992, J BIOL CHEM, V267, P18342; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FISHER GJ, 1991, J CELL PHYSIOL, V146, P309, DOI 10.1002/jcp.1041460216; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARDEN TK, 1990, AM REV RESPIR DIS, V141, pS119, DOI 10.1164/ajrccm/141.3_Pt_2.S119; HASHIZUME T, 1992, BIOCHEM INT, V26, P491; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HOLMSEN H, 1989, BIOCHEM J, V260, P589, DOI 10.1042/bj2600589; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JONES G, 1992, IN PRESS PROG GROWTH; KASZKIN M, 1992, CANCER RES, V52, P5627; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KONDO T, 1992, J BIOL CHEM, V267, P23609; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LIN YP, 1990, J BIOL CHEM, V265, P166; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MITCHELL KT, 1986, ANAL BIOCHEM, V158, P447, DOI 10.1016/0003-2697(86)90574-9; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAI JK, 1988, J BIOL CHEM, V263, P12472; QIAN Z, 1991, FASEB J, V5, P315, DOI 10.1096/fasebj.5.3.2001791; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16864; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Segel I.H., 1975, ENZYME KINETICS; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALSH JP, 1986, J BIOL CHEM, V261, P6239	45	181	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20845	20850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407914				2022-12-25	WOS:A1993MA28800034
J	REEVES, R; NISSEN, MS				REEVES, R; NISSEN, MS			INTERACTION OF HIGH-MOBILITY GROUP-I(Y) NONHISTONE PROTEINS WITH NUCLEOSOME CORE PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; GROUP-I PROTEIN; HMG-I; CHROMOSOMAL-PROTEINS; THERMAL-DENATURATION; GENE-REGULATION; SATELLITE DNA; CDC2 KINASE; BETA GENE; SEQUENCE	Mammalian high mobility group (HMG)-I(Y) chromosomal proteins bind with high affinity to the minor groove of A.T-rich sequences of DNA both in vitro and in vivo. Electrophoretic mobility shift assays demonstrate that in vitro both native and recombinant human HMG-I proteins also bind, but with lower affinity, to preferred regions on isolated avian nucleosome core particles containing approximately 146 base pairs of random sequence DNA. Up to four discrete HMG-I . core particle complexes can be detected by electrophoretic mobility shift assays when increasing molar ratios of protein are associated with cores. Both protein-DNA and protein-protein interactions are involved in HMG-I binding to cores. The interaction of HMG-I with core DNA is demonstrated by both thermal denaturation and DNase I footprinting experiments. Chemical cross-linking studies employing reversible photoactivatable cross-linkers, combined with one- and two-dimensional electrophoretic analyses, indicate that in vitro HMG-I binds to cores in close proximity to histones H2A and H2B and H3. In situ cross-linking of K562 human erythroleukemia cell nuclei demonstrate that native HMG-I(Y) binds in a similar manner to nucleosomal histones in vivo. Proteolytic removal of the positively charged amino-terminal tails of the octamer histones abolishes binding of HMG-I to core particles. However, core binding is not mediated by the negatively charged carboxyl-terminal tail of the HMG-I protein since an in vitro produced mutant protein lacking this region binds to core particles in a manner similar to full-length HMG-I. Together these results demonstrate that HMG-I, both in vitro and in vivo, binds to preferred regions on the front face of core nucleosomes.	WASHINGTON STATE UNIV, DEPT GENET & CELL BIOL, PULLMAN, WA 99164 USA	Washington State University	REEVES, R (corresponding author), WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026356] Funding Source: NIH RePORTER; NIAID NIH HHS [5-R01-AI26356] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BRAWLEY JV, 1992, BIOCHEMISTRY-US, V31, P364, DOI 10.1021/bi00117a008; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CORTADAS J, 1979, EUR J BIOCHEM, V99, P179, DOI 10.1111/j.1432-1033.1979.tb13244.x; COWMAN MK, 1980, BIOCHEMISTRY-US, V19, P532, DOI 10.1021/bi00544a022; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; DREW HR, 1993, J MOL BIOL, V230, P824, DOI 10.1006/jmbi.1993.1204; EDEN FC, 1978, BIOCHEMISTRY-US, V17, P5838, DOI 10.1021/bi00619a035; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; EVANS JNS, 1992, B MAG RESON, V14, P171; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FULMER AW, 1979, BIOCHEMISTRY-US, V18, P659, DOI 10.1021/bi00571a017; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LEVINGER L, 1982, P NATL ACAD SCI-BIOL, V79, P7152, DOI 10.1073/pnas.79.23.7152; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; LUTTER LC, 1989, METHOD ENZYMOL, V170, P264; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; MCGHEE JD, 1980, NUCLEIC ACIDS RES, V8, P2751, DOI 10.1093/nar/8.12.2751; MEANS GE, 1971, CHEM MODIFICATION PR, P219; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OLIVA R, 1986, BIOCHEMISTRY-US, V25, P6508, DOI 10.1021/bi00369a025; PATON AE, 1983, J BIOL CHEM, V258, P3221; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; SHICK VV, 1985, J MOL BIOL, V185, P329, DOI 10.1016/0022-2836(85)90407-3; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; SKALNIK DG, 1992, BIOCHEM BIOPH RES CO, V187, P563, DOI 10.1016/0006-291X(92)91231-E; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STERNER R, 1982, J BIOL CHEM, V257, P13872; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SWERDLOW PS, 1983, NUCLEIC ACIDS RES, V11, P387, DOI 10.1093/nar/11.2.387; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; van Holde KE., 1989, SPRINGER SERIES MOL; VANHOLDE KE, 1980, BIOPHYS J, V32, P271, DOI 10.1016/S0006-3495(80)84956-3; WEISCHET WO, 1978, NUCLEIC ACIDS RES, V5, P139, DOI 10.1093/nar/5.1.139; WOLFFE A, 1992, CRHOMATIN STRUCTURE; WU KC, 1983, J MOL BIOL, V170, P93, DOI 10.1016/S0022-2836(83)80228-9	68	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21137	21146						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407950				2022-12-25	WOS:A1993MA28800075
J	VARGAWEISZ, P; VANHOLDE, K; ZLATANOVA, J				VARGAWEISZ, P; VANHOLDE, K; ZLATANOVA, J			PREFERENTIAL BINDING OF HISTONE H1 TO 4-WAY HELICAL JUNCTION DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRUCIFORM DNA; PROTEIN; TRANSCRIPTION; GENES; HMG	Histone H1 is a major chromatin protein, which stabilizes the nucleosome, has an essential role in organizing nucleosomes into higher order structures, and may have a role as a repressor of transcription (van Holde, K. E. (1989) Chromatin, Springer Publishing Co., New York). Here we show that H1 forms a defined complex with a synthetic four-way junction of DNA strands even in the presence of an excess of linear nonspecific competitor DNA. The four-way junction also competes efficiently against two duplex DNA molecules, which together have the same sequence information as the four-way junction molecule. Another major chromatin protein, high mobility group protein 1, also binds four-way junction structures specifically (Bianchi, M. E., Beltrame, M., and Paonessa, G. (1989) Science 243, 1056-1059), and this similar behavior may indicate a related function of these proteins. Our finding may suggest that four-way DNA junction is a structural equivalent to the main H1 binding site in the nucleosome: a crossover of double helical DNA at the point where the DNA enters and exits the nucleosome (Allan, J., Hartman, P. G., Crane-Robinson, C., and Aviles, F. X. (1980) Nature 288, 675-679).			VARGAWEISZ, P (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.		Zlatanova, Jordanka/B-3273-2009	Varga-Weisz, Patrick/0000-0001-7409-8686	NIEHS NIH HHS [5 PO-1-ES04766] Funding Source: Medline; NIGMS NIH HHS [GM-12296] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004766] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUCKETT DR, 1992, EUR J BIOCHEM, V207, P285, DOI 10.1111/j.1432-1033.1992.tb17049.x; ELBOROUGH KM, 1988, NUCLEIC ACIDS RES, V16, P3603, DOI 10.1093/nar/16.9.3603; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; van Holde KE., 1989, SPRINGER SERIES MOL; ZLATANOVA J, 1992, J CELL SCI, V103, P889; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	13	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20699	20700						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407888				2022-12-25	WOS:A1993MA28800005
J	FAVREAU, LV; PICKETT, CB				FAVREAU, LV; PICKETT, CB			TRANSCRIPTIONAL REGULATION OF THE RAT NAD(P)H-QUINONE REDUCTASE GENE - CHARACTERIZATION OF A DNA-PROTEIN INTERACTION AT THE ANTIOXIDANT RESPONSIVE ELEMENT AND INDUCTION BY 12-O-TETRADECANOYLPHORBOL 13-ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; PLANAR AROMATIC-COMPOUNDS; CONTROLLING INDUCIBLE EXPRESSION; AH RECEPTOR COMPLEX; PHENOLIC ANTIOXIDANTS; FUNCTIONAL-ANALYSIS; OXIDATIVE STRESS; DT-DIAPHORASE; BASAL LEVEL; IDENTIFICATION	We have previously identified a novel xenobiotic responsive element, which has been termed the antioxidant responsive element (ARE), in the 5'-flanking region of the rat quinone reductase gene (Favreau, L. V., and Pickett, C. B. (1991) J. Biol. Chem. 266,4556-4561). This element is responsible for basal level expression of the gene as well as transcriptional activation by phenolic antioxidants and metabolizable planar aromatic compounds. In this communication, we demonstrate that hydrogen peroxide can act as an inducer through the ARE sequence, a phenomenon recently demonstrated for the glutathione S-transferase Ya subunit gene (Rushmore, T. H., Morton, M. R., and Pickett, C. B. (1991) J. Biol. Chem. 266, 116321 1639). To further characterize the quinone reductase ARE, we demonstrate by DNase I footprinting that in crude Hep G2 nuclear extracts a trans-acting factor exists which interacts with a region of DNA found within the 31-nucleotide ARE sequence. Furthermore, electrophoretic mobility shift assays demonstrate the presence of a specific DNA-protein complex which can be competed only by double-stranded oligonucleotides containing the ARE sequences from the quinone reductase and glutathione S-transferase Ya subunit genes. Methylation interference and protection assays indicate that several guanine residues found in the sequence GTGACTTGGC are involved in the binding of the nuclear factor(s) to the DNA. Although electrophoretic mobility shift assays indicate that the rat quinone reductase ARE does not contain a high affinity recognition site for in vitro translated c-Jun and c-Fos, 12-O-tetradecanoylphorbol 13-acetate can act as an inducer through the ARE sequence in Hep G2 cells.	MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,POB 1005,POINTE CLAIRE H9R 4P8,PQ,CANADA	Merck & Company								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAYNEY RM, 1989, J BIOL CHEM, V264, P21793; BEATTY P, 1976, BIOCHEM BIOPH RES CO, V68, P197, DOI 10.1016/0006-291X(76)90029-2; DELONG MJ, 1986, P NATL ACAD SCI USA, V83, P787; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HUGGINS CB, 1978, P NATL ACAD SCI USA, V5, P4524; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; LI Y, 1992, J BIOL CHEM, V267, P15097; LIND C, 1974, BIOCHEM BIOPH RES CO, V56, P392, DOI 10.1016/0006-291X(74)90855-9; LIU QY, 1992, J BIOL CHEM, V267, P12049; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; OKUDA A, 1989, J BIOL CHEM, V264, P16919; Pickett C.B., 1989, ANNU REV BIOCHEM, V58, P734; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000	32	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19875	19881						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396148				2022-12-25	WOS:A1993LW81900106
J	QUINLAN, MP				QUINLAN, MP			EXPRESSION OF ANTISENSE E1A IN 293 CELLS RESULTS IN ALTERED CELL MORPHOLOGIES AND CESSATION OF PROLIFERATION	ONCOGENE			English	Article							ADENOVIRUS-INDUCED ALTERATIONS; PRIMARY EPITHELIAL-CELLS; LONG TERMINAL REPEAT; MAMMARY-TUMOR VIRUS; CHROMOSOME-ABERRATIONS; GENE-EXPRESSION; MAMMALIAN-CELLS; E1A-12S PROTEIN; DNA FRAGMENTS; FRAGILE SITES	To determine whether continued E1A expression is required to maintain immortalization, 293 cells, a cell line that has been immortalized and transformed by adenovirus E1A and E1B, respectively, were transfected by an antisense E1A expression vector. In the presence of low serum, 293 cells underwent a transient, viable, nonproliferative phase wherein cells with altered morphologies were detected. However, only those clones which did not integrate the antisense sequences and exhibited a morphology similar to the original 293 cells were able to survive. High serum concentrations resulted in fewer clones, which rapidly discarded the antisense DNA. Similar experiments with an antisense CAT vector did not give rise to cells with either altered morphologies or growth rates. Furthermore, CAT antisense DNA was integrated into the 293 cell DNA. Hela cells, which were not immortalized or transformed by E1, were unaffected by the expression of antisense E1A and integrated the antisense DNA into genomic DNA. Consistently, the addition of synthetic antisense, but not sense oligonucleotides resulted in a transient inhibition of 293 cell DNA synthesis. These data demonstrate that even after extended periods of time in culture, cells immortalized by E1A still require E1A expression to activate the cell cycle and prevent them from senescing.			QUINLAN, MP (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER; NCI NIH HHS [CA50540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BELLETT AJD, 1982, CHROMOSOMA, V84, P571, DOI 10.1007/BF00292856; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DIPAOLO JA, 1983, JNCI, V70, P114; DURNAM D, 1986, CANCER CELL, V4, P349; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GORBUNOVA LV, 1982, MOL GEN GENET, V187, P473, DOI 10.1007/BF00332631; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; LEBEAU MM, 1986, BLOOD, V67, P849; LUKASH LL, 1985, J CELL SCI, V78, P97; MCDOUGALL JK, 1971, J GEN VIROL, V12, P43, DOI 10.1099/0022-1317-12-1-43; MIROSHNICHENKO OI, 1989, GENE, V84, P83, DOI 10.1016/0378-1119(89)90142-X; MURRAY JD, 1982, J VIROL, V44, P1072, DOI 10.1128/JVI.44.3.1072-1075.1982; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J, 1989, MOL CLONING LABORATO; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; Stout J T, 1987, Methods Enzymol, V151, P519; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WEBER JM, 1990, J GEN VIROL, V71, P585, DOI 10.1099/0022-1317-71-3-585; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOUNG HA, 1977, J VIROL, V21, P139, DOI 10.1128/JVI.21.1.139-146.1977; YUNIS JJ, 1987, SOMAT CELL MOLEC GEN, V13, P397, DOI 10.1007/BF01534938	51	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					257	265						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426736				2022-12-25	WOS:A1993KN00600004
J	DACOSTA, KA; COCHARY, EF; BLUSZTAJN, JK; GARNER, SC; ZEISEL, SH				DACOSTA, KA; COCHARY, EF; BLUSZTAJN, JK; GARNER, SC; ZEISEL, SH			ACCUMULATION OF 1,2-SN-DIRADYLGLYCEROL WITH INCREASED MEMBRANE-ASSOCIATED PROTEIN-KINASE-C MAY BE THE MECHANISM FOR SPONTANEOUS HEPATOCARCINOGENESIS IN CHOLINE-DEFICIENT RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-GLYCOGEN SYNTHASE; FED METHYL-DEFICIENT; DEVOID DIET; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-C; FATTY-ACIDS; TRANSFORMED FIBROBLASTS; METHOTREXATE TREATMENT; LINKED DIGLYCERIDES; SIGNAL TRANSDUCTION	Choline deficiency, via deprivation of labile methyl groups, is associated with a greatly increased incidence of hepatocarcinoma in experimental animals. This dietary deficiency also causes fatty liver, because choline is needed for hepatic secretion of lipoproteins. We hypothesized that fatty liver might be associated with the accumulation of 1,2-sn-diradylglycerol and subsequent activation of protein kinase C. Several lines of evidence indicate that cancers might develop secondary to abnormalities in protein kinase C-mediated signal transduction. We observed that rats fed a choline-deficient diet for 1, 6, or 27 weeks had increased hepatic concentrations of 1,2-diradylglycerol. At 1 and 6 weeks, hepatic plasma membrane from choline-deficient rats had increased concentrations of 1,2-sn-diacylglycerol and 1-alkyl, 2-acylglycerol, with the latter accounting for 20-26% of membrane 1,2-sn-diradylglycerol (as compared with only 2-5% in controls). Protein kinase C activity was increased in hepatic plasma membrane at 1 week of choline deficiency. By Western blotting there was an increase in the amount of protein kinase C zeta and a decrease in the amount of protein kinase C delta in liver at 1 week. By 6 weeks of choline deficiency, hepatic plasma membrane and cytosolic protein kinase C (PKC) activities were increased significantly, with increased amounts of hepatic plasma membrane protein kinase C alpha, and delta detected by Western blotting. Glycogen synthase activity in liver was diminished after 1 week of choline deficiency; this enzyme is inhibited by PKC-mediated phosphorylation. We suggest that choline deficiency perturbed PKC-mediated transmembrane signaling within liver and that this contributed to the development of hepatic cancer in these animals.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT NUTR, CHAPEL HILL, NC 27599 USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA; BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Tufts University; United States Department of Agriculture (USDA); Boston University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				/0000-0001-8438-3122	NICHD NIH HHS [HD16727] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016727] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD Z, 1984, J BIOL CHEM, V259, P8743; ANDERSCH MA, 1947, AM J CLIN PATHOL, V17, P571, DOI 10.1093/ajcp/17.7_ts.571; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BANNI S, 1990, CARCINOGENESIS, V11, P2053, DOI 10.1093/carcin/11.11.2053; BASS DA, 1988, J BIOL CHEM, V263, P19610; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BLANK ML, 1984, J CHROMATOGR, V298, P473, DOI 10.1016/S0021-9673(01)92744-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUSZTAJN JK, 1989, FEBS LETT, V243, P267, DOI 10.1016/0014-5793(89)80142-5; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS G, 1991, CANCER RES, V51, P3281; CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CAMICI M, 1984, J BIOL CHEM, V259, P3429; CAMICI M, 1984, J BIOL CHEM, V259, P2466; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHANDAR N, 1987, CARCINOGENESIS, V8, P669, DOI 10.1093/carcin/8.5.669; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; COOPER RH, 1985, J BIOL CHEM, V260, P3281; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DAWSON WD, 1987, J CELL PHYSIOL, V132, P104, DOI 10.1002/jcp.1041320114; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIXON TF, 1954, J CLIN PATHOL, V7, P341, DOI 10.1136/jcp.7.4.341; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FORD DA, 1989, J BIOL CHEM, V264, P13818; GHOSHAL AK, 1983, AM J PATHOL, V113, P309; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1989, SCIENCE, V246, P1050; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HSIEH LL, 1989, CANCER RES, V49, P3795; HSIEH LL, 1989, J CELL BIOCHEM, V41, P179, DOI 10.1002/jcb.240410403; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KATO M, 1989, FEBS LETT, V247, P247, DOI 10.1016/0014-5793(89)81345-6; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KRAUSS RS, 1989, ONCOGENE, V4, P991; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LI DH, 1990, CANCER RES, V50, P3991; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; LOMBARDI B, 1971, FED PROC, V30, P139; LOMBARDI B, 1968, J LIPID RES, V9, P437; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; POMFRET EA, 1990, J NUTR BIOCHEM, V1, P533, DOI 10.1016/0955-2863(90)90039-N; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RIDER LG, 1988, J IMMUNOL, V140, P200; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROGUE P, 1990, J BIOL CHEM, V265, P4161; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SELHUB J, 1991, CANCER RES, V51, P16; SHINOZUKA H, 1980, CANCER RES, V40, P3846; SINGH U, 1990, J NUTR BIOCHEM, V1, P434, DOI 10.1016/0955-2863(90)90120-A; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snyder F, 1975, Prog Biochem Pharmacol, V10, P1; TACCONI M, 1985, J NEUROCHEM, V45, P805, DOI 10.1111/j.1471-4159.1985.tb04064.x; TAKAHASHI S, 1979, CANCER LETT, V7, P265, DOI 10.1016/S0304-3835(79)80053-1; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TURINSKY J, 1990, J BIOL CHEM, V265, P7933; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WILKISON WO, 1989, ONCOGENE, V4, P625; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; Zeisel S.H., 1988, MODERN NUTR HLTH DIS, P440; ZEISEL SH, 1989, BIOCHEM J, V259, P725, DOI 10.1042/bj2590725	85	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2100	2105						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420980				2022-12-25	WOS:A1993KH62000090
J	JAULT, JM; ALLISON, WS				JAULT, JM; ALLISON, WS			SLOW BINDING OF ATP TO NONCATALYTIC NUCLEOTIDE BINDING-SITES WHICH ACCELERATES CATALYSIS IS RESPONSIBLE FOR APPARENT NEGATIVE COOPERATIVITY EXHIBITED BY THE BOVINE MITOCHONDRIAL F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART F1-ATPASE; ADENOSINE-TRIPHOSPHATASE; BETA-SUBUNIT; THERMOPHILIC BACTERIUM; CHEMICAL MODIFICATION; HYSTERETIC BEHAVIOR; ANION ACTIVATION; ENZYME-ACTIVITY; RAT-LIVER; MECHANISM	The bovine heart mitochondrial F1-ATPase depleted of nucleotides (nd-MF1) hydrolyzes 50 muM ATP in three kinetic phases at 30-degrees-C. An initial ''burst'' rapidly transforms into an intermediate, slower rate, which slowly accelerates to the final, steady-state rate. The intermediate phase disappears progressively as the concentration of ATP in the assay medium is increased and is absent at 2 mM. Activation in the intermediate phase is lost when nd-MF1 is inactivated by 5'-p-fluorosulfonylbenzoyladenosine, which modifies three noncatalytic sites. Correlation of [H-3]ATP binding to nd-MF1, after treatment either with 50 muM Mg[H-3]ATP plus a regenerating system or 10 mM free [H-3]ATP, with stimulation of the intermediate phase suggests that this phase is abolished when at least two noncatalytic sites are filled with ATP. Prior incubation of nd-MF1 with MgPP(i) stimulates hydrolysis of 30 muM to 2 mM ATP and abolishes the intermediate phase. Following incubation with Mg[P-32]PP(i), 3.3 mol of [P-32]PP(i)/mol of enzyme are bound, 1 and 0.5 mol of which are released by cold chases with MgATP and MgITP, respectively. Since the cold chases diminish activation only slightly, the stimulatory effect is not caused by PP(i) binding to catalytic sites. A Lineweaver-Burk plot of initial rates of the intermediate phase for hydrolysis of 30 muM to 2 mm ATP by nd-MF1 is biphasic, extrapolating to apparent K(m) values of 120 and 440 muM. The latter value is the same as the apparent K(d) determined from dependence of the rate of activation of the intermediate phase on ATP concentration in the assay medium. After prior incubation of nd-MF1 with MgPP(i) or free ATP, Lineweaver-Burk plots are linear with the highest K(m) disappearing. Thus, this K(m) reflects rate acceleration when ATP binds to noncatalytic sites. From these results it is concluded that slow binding of ATP to noncatalytic sites during hydrolysis of low concentrations of substrate, which accelerates catalysis, is responsible for apparent negative cooperativity exhibited by MF1.	UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777	NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1986, METHOD ENZYMOL, V126, P741; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; EBEL RE, 1975, J BIOL CHEM, V250, P191; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FALSON P, 1986, J BIOL CHEM, V261, P7151; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; ISSARTEL JP, 1987, J BIOL CHEM, V262, P13538; JAULT JM, 1991, J BIOL CHEM, V266, P8073; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1989, BIOCHIM BIOPHYS ACTA, V975, P50, DOI 10.1016/S0005-2728(89)80200-2; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; PEDERSEN PL, 1976, J BIOL CHEM, V251, P934; PEINNEQUIN A, 1992, BIOCHEMISTRY-US, V31, P2088, DOI 10.1021/bi00122a028; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RECKTENWALD D, 1977, FEBS LETT, V76, P25, DOI 10.1016/0014-5793(77)80113-0; ROVERI OA, 1985, FEBS LETT, V192, P123, DOI 10.1016/0014-5793(85)80056-9; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	43	122	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1558	1566						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420930				2022-12-25	WOS:A1993KH62000012
J	YU, B; PEREIRA, ME; WILK, S				YU, B; PEREIRA, ME; WILK, S			CHANGES IN THE STRUCTURE AND CATALYTIC ACTIVITIES OF THE BOVINE PITUITARY MULTICATALYTIC PROTEINASE COMPLEX FOLLOWING DIALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; CHEMICAL MODIFICATION; MACROPAIN PROTEASOME; RAT-LIVER; PURIFICATION; SPECIFICITY; SUBUNITS; COMPONENTS; UBIQUITIN; MHC	The multicatalytic proteinase complex (proteasome) contains at least four distinct active sites catalyzing the degradation of selected chromogenic substrates (trypsin-like, chymotrypsin-like, and peptidylglutamyl peptide hydrolyzing activities) and proteins such as beta-casein. Oxidized insulin B chain was recently proposed as a model substrate for protein degradation by the multicatalytic proteinase complex (Dick, L. R., Moomaw, C. R., DeMartino, G. N., and Slaughter, C. A. (1991) Biochemistry 30, 2725-2734). We studied the dialysis-induced activation of the hydrolysis of oxidized insulin B chain by this enzyme. Removal of EDTA from purified preparations of bovine pituitary multicatalytic proteinase complex by dialysis against Tris-HCl buffers led to marked changes in the catalytic properties and structure of the enzyme. Dialysis produced a time-dependent activation of oxidized insulin B chain hydrolysis with predominant cleavage at the Glu13-Ala14 bond. A new chromogenic assay was developed for measurement of this activity. Activation was accompanied by a virtually total inactivation of the chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a loss of the 24-kDa subunit and the appearance of a new band at 21 kDa. Amino-terminal amino acid analysis established that the 21-kDa band was autolytically derived from the 24-kDa subunit. Evidence for partial dissociation and/or aggregation indicated that autolysis destabilizes the complex. By altering the profile of catalytic activities of the multicatalytic proteinase complex, autolysis may serve as a mechanism for regulation of this macromolecule.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Pereira, Maria/GZA-9681-2022		NIMH NIH HHS [MH 00350] Funding Source: Medline; NINDS NIH HHS [NS-17392] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKI M, 1992, FEBS LETT, V301, P65, DOI 10.1016/0014-5793(92)80211-X; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FRENTZEL S, 1992, FEBS LETT, V302, P121, DOI 10.1016/0014-5793(92)80420-L; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KUEHN L, 1992, ARCH BIOCHEM BIOPHYS, V295, P55, DOI 10.1016/0003-9861(92)90487-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; SATO S, 1990, BIOCHIM BIOPHYS ACTA, V1041, P269, DOI 10.1016/0167-4838(90)90283-L; SHIVANANDAPPA T, 1991, CURR EYE RES, V10, P871, DOI 10.3109/02713689109013883; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V158, P548, DOI 10.1016/S0006-291X(89)80084-1; TANAKA K, 1986, J BIOL CHEM, V261, P5197; WAGNER BJ, 1991, CURR EYE RES, V10, P485, DOI 10.3109/02713689109001756; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; WILK S, 1990, NEUROPEPTIDES, V16, P163, DOI 10.1016/0143-4179(90)90129-M; WILK S, 1991, BIOMED BIOCHIM ACTA, V50, P471; YU B, 1991, J BIOL CHEM, V266, P17396; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	39	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2029	2036						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420977				2022-12-25	WOS:A1993KH62000081
J	FERREIRA, GC; DAILEY, HA				FERREIRA, GC; DAILEY, HA			EXPRESSION OF MAMMALIAN 5-AMINOLEVULINATE SYNTHASE IN ESCHERICHIA-COLI - OVERPRODUCTION, PURIFICATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; IRON-RESPONSIVE ELEMENT; SIGNAL SEQUENCE; MESSENGER-RNA; ACID SYNTHASE; NUCLEOTIDE-SEQUENCE; X-CHROMOSOME; RAT-LIVER; GENE; IDENTIFICATION	5-Aminolevulinate synthase catalyzes the first step of the heme biosynthetic pathway in nonplant higher eukaryotes. A cDNA encoding for the mouse erythroid 5-aminolevulinate synthase (Schoenhaut, D. S., and Curtis, P. J. (1986) Gene (Amst.) 48, 55-63) has been expressed in Escherichia coli, using the alkaline phosphatase promoter, to a level of 50-60% of the total bacterial protein. Aminolevulinate synthase was overexpressed in an active form and, therefore, was able to rescue hemA mutants, which are unable to grow in the absence of 5-aminolevulinate. A simple purification from the aminolevulinate synthase-overproducing bacterial strain yielded approximately 50 mg of protein, in a high state of purity, per liter of bacterial culture. Moreover, the expressed aminolevulinate synthase could be easily concentrated up to 6-8 mg/ml. Significantly, recombinant aminolevulinate synthase retained physical and catalytic properties identical to those of natural sources. These include the dimeric structure, subunit molecular mass, and pyridoxal 5'-phosphate as an essential cofactor. Removal of the pyridoxal 5'-phosphate led to complete loss of activity. However, the apoenzyme could be readily reconstituted by incubation with 20 muM 5'-pyridoxal phosphate. The K(m) values are 51 mM for glycine and 55 muM for succinyl-CoA, in the same range of the K(m) values determined for the nonrecombinant enzyme. This report describes the overexpression of a mammalian 5-aminolevulinate synthase in E. coli and its purification from an overproducing strain. The ready availability of the pure, cloned, sequenced erythroid 5-aminolevulinate synthase makes it possible now for questions pertinent to the enzyme's structure, mechanism, and regulation to be addressed.	UNIV S FLORIDA,INST BIOMOLEC SCI,TAMPA,FL 33612; UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602; UNIV GEORGIA,CTR MET ENZYME STUDIES,ATHENS,GA 30602	State University System of Florida; University of South Florida; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	FERREIRA, GC (corresponding author), UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,BOX 7,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.		Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217	NIDDK NIH HHS [DK 35898, R56 DK032303] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams E, 1979, Methods Enzymol, V62, P407; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BORTHWICK IA, 1986, METHOD ENZYMOL, V123, P395; BOTTOMLE.SS, 1969, BLOOD-J HEMATOL, V34, P857; CORNISHBOWDEN A, 1981, FUUNDAMENTALS ENZYME, P99; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; ELFERINK CJ, 1988, J BIOL CHEM, V263, P13012; FANICAGA.M, 1973, EUR J BIOCHEM, V40, P19, DOI 10.1111/j.1432-1033.1973.tb03164.x; FERREIRA GC, 1987, J BIOL CHEM, V262, P4407; FERREIRA GC, 1992, J BIOL CHEM, V267, P5460; FERREIRA GC, 1988, BIOCHEM J, V250, P597, DOI 10.1042/bj2500597; FERREIRA GC, 1991, FASEB J, V5, pA1544; FUJITA H, 1991, J BIOL CHEM, V266, P17494; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; INOUYE H, 1982, J BACTERIOL, V149, P434, DOI 10.1128/JB.149.2.434-439.1982; JORDAN PM, 1986, METHOD ENZYMOL, V123, P435; JORDAN PM, 1972, ENZYMES, P339; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; Karpeisky M., 1986, VITAMIN B6 PYRIDOXAL, P76; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KIKUCHI G, 1958, J BIOL CHEM, V233, P1214; KOLLEN RG, 1985, TRANSAMINASES, P545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LI JM, 1989, J BACTERIOL, V171, P2547, DOI 10.1128/jb.171.5.2547-2552.1989; LIEN LF, 1982, ENZYME, V28, P120; MARCEAU M, 1988, J BIOL CHEM, V263, P16934; NANDI AL, 1978, ARCH BIOCHEM BIOPHYS, V188, P266; OHASHI A, 1979, J BIOCHEM-TOKYO, V85, P239, DOI 10.1093/oxfordjournals.jbchem.a132317; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SHORTLE D, 1986, J CELL BIOCHEM, V30, P281, DOI 10.1002/jcb.240300402; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; URBANGRIMAL D, 1986, EUR J BIOCHEM, V156, P511, DOI 10.1111/j.1432-1033.1986.tb09610.x; WHITING MJ, 1976, J BIOL CHEM, V251, P1340; YAMAUCHI K, 1980, J BIOL CHEM, V255, P1746	43	57	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					584	590						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416963				2022-12-25	WOS:A1993KE60300088
J	KANDA, H; TAJIMA, H; LEE, GH; NOMURA, K; OHTAKE, K; MATSUMOTO, K; NAKAMURA, T; KITAGAWA, T				KANDA, H; TAJIMA, H; LEE, GH; NOMURA, K; OHTAKE, K; MATSUMOTO, K; NAKAMURA, T; KITAGAWA, T			HEPATOCYTE GROWTH-FACTOR TRANSFORMS IMMORTALIZED MOUSE-LIVER EPITHELIAL-CELLS	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SCATTER FACTOR; HEPATOCELLULAR-CARCINOMA; MET PROTOONCOGENE; MOLECULAR-CLONING; HEPATIC-FAILURE; HEPATOPOIETIN-A; KINASE-ACTIVITY; MELANOMA-CELLS; C-MET	Transforming activity of hepatocyte growth factor (HGF) was demonstrated utilizing immortalized but not fully transformed mouse hepatocytes (MLE-10). Rat HGF cDNA, expressed under the control of a cytomegalovirus promoter, was transfected together with the neomycin resistance gene (PSV2neo) into MLE-10 cells by the calcium phosphate method, and propagated G418-resistant colonies were harvested colony by colony. After checking for integration and expression of exogenous HGF, five cell lines (MLE-10-HGF-1 approximately 5) were established. Three cell lines transfected with the vector only (MLE-10-CMV-1 approximately 3) were also established in the same manner. All MLE-10-HGF cell lines grew much faster than the MLE-10-CMV and original MLE-10 cells in culture and produced large colonies in soft agar, which colony production was blocked by the addition of anti-HGF antibody to the agar. After addition of HGF, original and MLE-10-CMV lines produced colonies in soft agar. The high-HGF-production lines (MLE-10-HGF-4 and -5) also gave rise to tumors within 2 weeks when implanted into the nude mice subcutis. In contrast, all MLE-10-CMV and original MLE-10 cells were negative in these growth assays. A rough parallelism between the level of HGF expression and the growth rate in both soft agar and nude mice subcutis was evident among MLE-10-HGF cell lines. Those with higher HGF production tended to grow in a scattered fashion in culture. High-affinity HGF receptor, HGFR/met, was expressed in MLE-10 and all the derived cell lines. Since HGF and/or HGFR/met gene expression is seen in various tumors and the serum HGF level is elevated in patients with hepatic disease, the present results indicate a possible significance of HGF and its receptor system in carcinogenesis, most probably via autocrine and/or paracrine mechanisms.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University	KANDA, H (corresponding author), JAPANESE FDN CANC RES,INST CANC,DEPT PATHOL,KAMI IKEBUKURO 1-37-1,TOSHIMA KU,TOKYO 170,JAPAN.							BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HALABAN R, 1992, ONCOGENE, V7, P2195; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANDA H, 1983, CARCINOGENESIS, V14, P1061; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LINDROOS P, 1992, CARCINOGENESIS, V13, P139, DOI 10.1093/carcin/13.1.139; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, ONCOGENE, V6, P501; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIMODA A, 1992, ACTA HEPATOL JPN, V33, P766; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAHARA E, 1990, J CANCER RES CLIN, V116, P121, DOI 10.1007/BF01612665; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TOMIYA T, 1992, HEPATOLOGY, V15, P1, DOI 10.1002/hep.1840150102; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOSHINAGA Y, 1992, JPN J CANCER RES, V83, P1257, DOI 10.1111/j.1349-7006.1992.tb02755.x; ZARNEGAR R, 1989, CANCER RES, V49, P3314	51	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3047	3053						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414505				2022-12-25	WOS:A1993MC09300020
J	CHEN, HW; CHAN, WY; CHEN, CL; MANSFIELD, BC; CHOU, JY				CHEN, HW; CHAN, WY; CHEN, CL; MANSFIELD, BC; CHOU, JY			THE CARBOXYL-TERMINAL DOMAIN OF THE HUMAN PREGNANCY-SPECIFIC GLYCOPROTEIN SPECIFIES INTRACELLULAR RETENTION AND STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARCINOEMBRYONIC ANTIGEN; INTERCELLULAR-ADHESION MOLECULE; ENDOPLASMIC-RETICULUM; GENE FAMILY; MESSENGER-RNAS; CDNA SEQUENCE; CELL-ADHESION; BREFELDIN-A; BETA-1-GLYCOPROTEIN; PROTEINS	The pregnancy-specific glycoproteins (PSGs), which are members of the immunoglobulin superfamily, are the major pregnancy-associated proteins synthesized by the human placenta. Thirty or more PSG members have been identified which are encoded by at least 11 linked genes. The PSG proteins share 85-95% sequence homology in the coding region, but show variability at the carboxyl-terminal (COOH) domains. In the present study, we examined the effects of PSG COOH domains on protein secretion and stability. Using PSGs containing short (11-12 residues) hydrophilic (PSG1e, PSG11s, and PSG16a), short (22 residues) hydrophobic (PSG6r), and long (81 residues) hydrophobic (PSG11w) COOH domains, we showed that most PSG members were secretory proteins except PSG11w which was largely retained in cells. When the PSG11w COOH domain was replaced with a short COOH domain of PSG1e, the resulting PSG-N11w/C1e chimera became secreted into the medium. On the other hand, chimeras that harbored the PSG11w COOH domain, PSG-N1e/C11w and PSG-N16a/C11w, remained in cells, demonstrating that the COOH domain of PSG11w confers intracellular retention. Deletion analysis showed that mutant (PSG11w-C2) that contained the first 21 amino acids of PSG11w COOH domain or mutant (PSG11w-C3) that contained a deletion of hydrophobic residues 372-392 in the PSG11w COOH domain remained largely in cells. In contrast, the PSG11w-C1 mutant which contained the first 12 residues of the PSG11w COOH domain became a secretory protein. Studies of PSG synthesis and processing in the presence of Brefeldin A, a drug that impedes protein transport from endoplasmic reticulum to the Golgi system, showed that PSG11w resided and degraded in the endoplasmic reticulum. The endoplasmic reticulum localization of PSG11w and the cell-associated mutant PSGs was further demonstrated by their sensitivity to endoglycosidase H and indirect immunofluorescence analysis.	NICHHD,HUMAN GENET BRANCH,BLDG 10,RM 95242,BETHESDA,MD 20892; UNIV FLORIDA,COLL VET MED,DEPT LARGE ANIM CLIN SCI,GAINESVILLE,FL 32611; GEORGETOWN UNIV,MED CTR,DEPT PEDIAT,WASHINGTON,DC 20007; MASSEY UNIV,DEPT MICROBIOL & GENET,PALMERSTON NORTH,NEW ZEALAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); State University System of Florida; University of Florida; Georgetown University; Massey University			Chan, Wai Yee/R-7442-2018	Chan, Wai Yee/0000-0002-9714-0936; Mansfield, Brian/0000-0002-8533-2789				ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BROPHY BK, 1992, BIOCHIM BIOPHYS ACTA, V1131, P119, DOI 10.1016/0167-4781(92)90110-L; CHAN WY, 1988, DNA-J MOLEC CELL BIO, V7, P545, DOI 10.1089/dna.1.1988.7.545; CHAN WY, 1991, MOL CELL BIOCHEM, V106, P61; CHOU JY, 1992, SEMIN REPROD ENDOCR, V10, P116, DOI 10.1055/s-2007-1018867; CHOU JY, 1990, ENDOCRINOLOGY, V127, P2127, DOI 10.1210/endo-127-5-2127; GHODA L, 1990, J BIOL CHEM, V265, P11823; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GUSSOW D, 1987, IMMUNOL TODAY, V8, P220, DOI 10.1016/0167-5699(87)90170-8; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JN, 1979, BRIT J OBSTET GYNAEC, V86, P888, DOI 10.1111/j.1471-0528.1979.tb10717.x; LESLIE KK, 1990, P NATL ACAD SCI USA, V87, P5822, DOI 10.1073/pnas.87.15.5822; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIN TM, 1974, J CLIN INVEST, V54, P576, DOI 10.1172/JCI107794; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACDONALD DJ, 1983, AM J OBSTET GYNECOL, V147, P430, DOI 10.1016/S0002-9378(16)32239-6; MASSON GM, 1983, BRIT J OBSTET GYNAEC, V90, P146, DOI 10.1111/j.1471-0528.1983.tb08899.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; PLOUZEK CA, 1991, BIOCHEM BIOPH RES CO, V176, P1532, DOI 10.1016/0006-291X(91)90461-F; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROONEY BC, 1988, GENE, V71, P439, DOI 10.1016/0378-1119(88)90061-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SORENSEN S, 1984, TUMOUR BIOL, V5, P275; STREYDIO C, 1988, BIOCHEM BIOPH RES CO, V154, P130, DOI 10.1016/0006-291X(88)90660-2; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; TAMSEN L, 1983, J PERINAT MED, V11, P19, DOI 10.1515/jpme.1983.11.1.19; TATARINOV Y S, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P66; TATARINOV YS, 1978, GYNECOL OBSTET INVES, V9, P65, DOI 10.1159/000300972; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WATANABE S, 1988, BIOCHEM BIOPH RES CO, V152, P762, DOI 10.1016/S0006-291X(88)80103-7; WATANABE S, 1988, J BIOL CHEM, V263, P2049; WATANABE T, 1992, BIOCHEMISTRY-US, V31, P3051, DOI 10.1021/bi00127a004; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WURZ H, 1981, J PERINAT MED, V9, P67, DOI 10.1515/jpme.1981.9.2.67; ZIMMERMANN W, 1989, BIOCHEM BIOPH RES CO, V163, P1197, DOI 10.1016/0006-291X(89)91105-4	59	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22066	22075						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408064				2022-12-25	WOS:A1993MC80900094
J	KAJI, EH; LODISH, HF				KAJI, EH; LODISH, HF			IN-VITRO UNFOLDING OF RETINOL-BINDING PROTEIN BY DITHIOTHREITOL - ENDOPLASMIC RETICULUM-ASSOCIATED FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DISULFIDE-ISOMERASE; SACCHAROMYCES-CEREVISIAE; TRANSPORT; GOLGI; BONDS; HEMAGGLUTININ; PURIFICATION; MATURATION; CATALYSTS	HepG2 cells in the presence of DTT synthesize fully reduced serum retinol-binding protein (RBP) within the endoplasmic reticulum (ER). Upon removal of DTT, RBP forms disulfide bonds and a folding intermediate, compact II, accumulates within the ER. Compact II RBP co-migrates on nonreducing gel electrophoresis with the secreted form of RBP but is differentiated from secreted RBP by its sensitivity to DTT-induced unfolding (see accompanying article; Kaji, E. H., and Lodish, H. F. (1993) J. Biol. Chem. 268, 22188-22194). Here, we have reconstituted DTT-induced unfolding of compact II RBP in a broken cell system and demonstrate that ER-associated factors enhance the unfolding of RBP by DTT. Protein disulfide isomerase is likely to be one such factor since it enhances the rate of RBP unfolding by DTT in vitro; protein disulfide isomerase-induced unfolding requires the absence of retinoids, similar to the DTT-induced unfolding in vivo. ATP enhances the unfolding of RBP in the absence but not in the presence of retinol, both in intact and broken cells. Thus, protein disulfide isomerase and other ATP-dependent factors can unfold partly folded (or misfolded) RBP in the ER, suggesting how improperly folded proteins might be correctly refolded in vivo.	WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOJI EH, 1993, J BIOL CHEM, V268, P22188; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RAZ A, 1970, J BIOL CHEM, V245, P1903; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; TOKUNAGA M, 1992, J BIOL CHEM, V267, P17553; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	40	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22195	22202						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408081				2022-12-25	WOS:A1993MC80900112
J	MURPHY, JE; XU, X; KANTROWITZ, ER				MURPHY, JE; XU, X; KANTROWITZ, ER			CONVERSION OF A MAGNESIUM BINDING-SITE INTO A ZINC-BINDING SITE BY A SINGLE AMINO-ACID SUBSTITUTION IN ESCHERICHIA-COLI ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIWIRE AREA DETECTOR; MECHANISM	The replacement of aspartic acid by histidine at position 153 in Escherichia coli alkaline phosphatase results in a mutant enzyme that is remarkably similar to certain mammalian alkaline phosphatases that are activated by magnesium in a time-dependent fashion. These mammalian alkaline phosphatases have histidine at the position corresponding to 153 of the E. coli sequence. Here we report the three-dimensional structure of the mutant E. coli alkaline phosphatase with histidine at position 153. The structure reveals that the octahedral magnesium binding site has been converted to a tetrahedral zinc binding site with an imidazole ring nitrogen of His-153 as one of the ligands to the zinc. The alteration in metal binding caused by the mutation could explain the origin of the magnesium activation observed with the mammalian alkaline phosphatases. The structure also reveals differences in the mode of phosphate binding, explaining the enhanced phosphate affinity and the reduced activity of the mutant enzyme in the presence of zinc.	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RA, 1976, BIOCHEMISTRY-US, V15, P3710, DOI 10.1021/bi00662a011; ANDERSON RA, 1975, P NATL ACAD SCI USA, V72, P2989, DOI 10.1073/pnas.72.8.2989; BRUNEL C, 1973, BIOCHIM BIOPHYS ACTA, V309, P104, DOI 10.1016/0005-2744(73)90322-7; BUTTERWORTH PJ, 1968, BIOCHEM J, V107, P467, DOI 10.1042/bj1070467; CATHALA G, 1975, J BIOL CHEM, V250, P6046; HAMLIN R, 1981, J APPL CRYSTALLOGR, V14, P85, DOI 10.1107/S0021889881008856; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JANEWAY CML, 1993, BIOCHEMISTRY-US, V32, P1601, DOI 10.1021/bi00057a026; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SOWADSKI J M, 1983, Journal of Molecular Biology, V170, P575, DOI 10.1016/S0022-2836(83)80162-4; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9	13	53	54	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21497	21500						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407998				2022-12-25	WOS:A1993MC80900012
J	BRITO, RMM; KRUDY, GA; NEGELE, JC; PUTKEY, JA; ROSEVEAR, PR				BRITO, RMM; KRUDY, GA; NEGELE, JC; PUTKEY, JA; ROSEVEAR, PR			CALCIUM PLAYS DISTINCTIVE STRUCTURAL ROLES IN THE N-TERMINAL AND C-TERMINAL DOMAINS OF CARDIAC TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; MAGNESIUM BINDING-SITES; CHICKEN SKELETAL-MUSCLE; CA2+ BINDING; CONFORMATIONAL-CHANGES; CHEMICAL-SHIFTS; RESOLUTION; PROTEINS; AFFINITY	One- and two-dimensional NMR techniques were used to compare the structural consequences of Ca2+ binding to both the low and high affinity Ca2+ binding sites in recombinant cardiac troponin C (cTnC3). In the absence of Ca2+, the short beta-sheet located between the high affinity Ca2+/Mg2+ binding sites in the C-terminal domain was found to be absent or loosely formed as judged by the inter-residue NOEs and chemical shifts of resonances in the Ca2+ binding loops. In contrast, the N-terminal domain beta-sheet located between site II and the naturally inactive site I was present even in the absence of bound Ca2+. Calcium-binding mutant proteins having either an inactive Ca 2, binding site III (CBM-III) or an inactive Ca2+ binding site IV (CBM-IV) (Negele, J. C., Dotson, D., Liu, W., Sweeney, H. L., and Putkey, J. A. (1992) J. Biol. Chem. 267,825-831) were used to study the structural consequences of Ca2+ binding to each of the high affinity sites located in the C-terminal domain. Only a single active Ca2+ binding site was found necessary for formation of the short beta-sheet between Ca2+ binding sites III and IV. However, the absence of bound Ca2+ at site III was found to produce greater instability in the C- terminal domain as judged from the mobility of the C-terminal aromatic hydrophobic cluster. Thus, Ca2+ binding to the high affinity sites in the C-terminal domain results in an ordering of the aromatic hydrophobic cluster, as well as formation of a short beta-sheet between Ca2+ binding sites III and IV. These results demonstrate that Ca2+ binding plays distinctive structural roles in the N- and C-terminal domains of cTnC.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System				Brito, Rui/0000-0001-9128-2557	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041232] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39218] Funding Source: Medline; NIGMS NIH HHS [GM41232] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; BROCKERHOFF SE, 1992, PROTEIN SCI, V1, P504; CAREW EB, 1980, BIOPHYS J, V30, P351, DOI 10.1016/S0006-3495(80)85099-5; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEVINE BA, 1983, CIBA F SYMP, V93, P72; MACURA S, 1982, J MAGN RESON, V47, P351, DOI 10.1016/0022-2364(82)90128-7; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; NAGY B, 1979, J BIOL CHEM, V254, P2732; NEGELE JC, 1992, J BIOL CHEM, V267, P825; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1976, J BIOL CHEM, V251, P7551; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHAW GS, 1991, BIOCHEMISTRY-US, V30, P8339, DOI 10.1021/bi00098a009; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; TSUDA S, 1988, BIOCHEMISTRY-US, V27, P4120, DOI 10.1021/bi00411a032; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20966	20973						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407932				2022-12-25	WOS:A1993MA28800052
J	HOFFMAN, GG; LEE, S; CHRISTIANO, AM; CHUNGHONET, LC; CHENG, W; KATCHMAN, S; UITTO, J; GREENSPAN, DS				HOFFMAN, GG; LEE, S; CHRISTIANO, AM; CHUNGHONET, LC; CHENG, W; KATCHMAN, S; UITTO, J; GREENSPAN, DS			COMPLETE CODING SEQUENCE, INTRON-EXON ORGANIZATION, AND CHROMOSOMAL LOCATION OF THE GENE FOR THE CORE-I PROTEIN OF HUMAN UBIQUINOL-CYTOCHROME-C REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VII COLLAGEN; PROCESSING PEPTIDASE; BC1 COMPLEX; 1ST INTRON; MITOCHONDRIAL; DNA; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; SUBUNIT	Core I protein is a nuclear-encoded component of the ubiquinol-cytochrome c reductase complex of the mitochondrial respiratory chain. We have located the gene for the human core I protein in the p21 region of chromosome 3, just upstream of the COL7A1 gene which encodes type VII collagen. The core I gene, which has been sequenced in its entirety, is comprised of 10,417 base pairs, from the major transcription start site to the polyadenylation signal, and contains 13 exons. The predicted polypeptide contains 480 amino acids, of which the first 34 are predicted to constitute a typical mitochondrial leader peptide containing 6 positively charged arginine residues. The predicted human protein shows significant homology with core I protein from Saccharomyces cerevisiae, rather high homology (64% similarity, 46% identity) with the processing enhancing protein, which functions as core I protein in Neurospora crassa, and, surprisingly, highest homology with the small subunit of the mitochondrial processing peptidase of rat (74% similarity, 55% identity). The predicted human sequence is 87% identical to the reported bovine core I sequence predicted from cDNA cloning, up to residue 298, but the two predicted sequences are widely divergent after that point.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,1300 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM CELL & MOLEC BIOL,MADISON,WI 53706; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Jefferson University; Jefferson University			Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BURGESON RE, 1990, ANN NY ACAD SCI, V580, P32, DOI 10.1111/j.1749-6632.1990.tb17915.x; CAPALDI RA, 1988, J BIOENERG BIOMEMBR, V20, P291, DOI 10.1007/BF00769634; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHRISTIANO AM, 1992, HUM MOL GENET, V1, P475, DOI 10.1093/hmg/1.7.475; DYNAN W, 1986, TRENDS GENET, V6, P196; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GREENSPAN DS, 1993, CYTOGENET CELL GENET, V62, P35, DOI 10.1159/000133440; GREENSPAN DS, 1993, HUM MOL GENET, V2, P273, DOI 10.1093/hmg/2.3.273; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HOSOKAWA Y, 1989, J BIOL CHEM, V264, P13483; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KENNAWAY N G, 1988, Journal of Bioenergetics and Biomembranes, V20, P325, DOI 10.1007/BF00769636; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LEE ST, 1988, J BIOL CHEM, V263, P13414; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RYYNANEN J, 1992, J CLIN INVEST, V89, P163, DOI 10.1172/JCI115557; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x	41	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21113	21119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407948				2022-12-25	WOS:A1993MA28800072
J	SIERON, AL; FERTALA, A; ALAKOKKO, L; PROCKOP, DJ				SIERON, AL; FERTALA, A; ALAKOKKO, L; PROCKOP, DJ			DELETION OF A LARGE DOMAIN IN RECOMBINANT HUMAN PROCOLLAGEN-II DOES NOT ALTER THE THERMAL-STABILITY OF THE TRIPLE-HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-IV; OSTEOGENESIS IMPERFECTA; COLLAGEN; GENE; MUTATIONS; FIBROBLASTS; DISEASES; PATIENT; COL2A1; CHAINS	A construct of the human gene for procollagen II (COL2A1) was prepared with an internal deletion of 5 kilobases that removed 12 exons coding for 291 amino acids from near the NH2 terminus of the triple helix. The construct was then used to transfect stably a human tumor cell line (HT-1080), and clones secreting internally deleted proalpha1(II) chain of procollagen II were isolated. The protein was purified, and the thermal stability of the triple-helical domain was assayed by brief protease digestion. The thermal stability of the internally deleted protein was the same as that of intact collagen II even though the triple helix was 39% shorter. Additionally, the thermal stability of the collagenase A fragment was the same as that of the collagenase A fragment of normal collagen II even though it was 38% shorter. Analysis of the results suggested that the thermal stabilities of large fragments of collagen II depended primarily on their contents of -Gly-Pro-Hyp-triplets corrected for length.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Sieron, Aleksander L/G-1700-2013	Sieron, Aleksander L./0000-0002-3894-9508	NIAMS NIH HHS [AR 39740, AR 38188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188, P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; CONSTANTINOU CD, 1987, EUR J BIOCHEM, V263, P247; DEAK SB, 1985, COLLAGEN REL RES, V5, P305; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Fertala Andrzej, 1993, Matrix, V13, P15; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; GERMANN HP, 1988, BIOPOLYMERS, V27, P157, DOI 10.1002/bip.360270112; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAW MF, 1983, MOL CELL BIOL, V3, P2110, DOI 10.1128/MCB.3.11.2110; LEE B, 1991, AM J HUM GENET, V48, P511; PELTONEN L, 1980, P NATL ACAD SCI-BIOL, V77, P162, DOI 10.1073/pnas.77.1.162; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Ramachandran G.N., 1967, TREATISE COLLAGEN, P103; RICH A, 1955, NATURE, V176, P915, DOI 10.1038/176915a0; RIGBY BJ, 1975, COMP BIOCHEM PHYS B, V52, P89, DOI 10.1016/0305-0491(75)90120-0; RIGBY BJ, 1967, BIOCHIM BIOPHYS ACTA, V133, P272, DOI 10.1016/0005-2795(67)90067-0; RYHANEN L, 1983, ARCH BIOCHEM BIOPHYS, V223, P562, DOI 10.1016/0003-9861(83)90621-5; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2207, DOI 10.1093/nar/13.7.2207; SOKOLOV B P, 1989, Medical Science Research, V17, P911; SOKOLOV BP, 1987, BIOKHIMIYA, V53, P1828; SUNADA H, 1981, COLLAGEN REL RES, V1, P177; VISSING H, 1991, J BIOL CHEM, V266, P5244; VONHIPPEL PH, 1967, TREATISE COLLAGEN CH, V1, P316; WEISS JB, 1976, INT REV CONNECT TISS, V7, P102; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	40	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21232	21237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407960				2022-12-25	WOS:A1993MA28800087
J	TAKAHASHI, M; MATSUSHITA, Y; IIJIMA, Y; TANZAWA, K				TAKAHASHI, M; MATSUSHITA, Y; IIJIMA, Y; TANZAWA, K			PURIFICATION AND CHARACTERIZATION OF ENDOTHELIN-CONVERTING ENZYME FROM RAT LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIG ENDOTHELIN-1; VASOCONSTRICTOR ACTIVITY; CELLS; PHOSPHORAMIDON; CONVERSION; EXPRESSION; PROTEINS; RECEPTOR; INVITRO; CLONING	Endothelin-converting enzyme, a key enzyme in the production of a potent vasoconstricting peptide, endothelin, was purified to homogeneity from rat lung microsomes. A sensitive and convenient assay method using the I-125-endothelin-1 receptor binding assay was developed for purification studies. The enzyme was solubilized with Triton X-100 and was purified at high yield by sequential column chromatography on wheat germ agglutinin-agarose, zinc-chelating Sepharose, and Blue B-agarose. Electrophoretic analysis of the purified enzyme revealed one protein band with M(r) 130,000. High performance liquid chromatographic analysis of the enzyme reaction revealed that purified enzyme quantitatively converted big endothelin-1 to endothelin-1, indicating that the enzyme specifically cleaved the bond between Trp21 and Val22. The enzyme was inhibited by metal chelators and phosphoramidon, but not by thiorphan and captopril. Lung endothelin-converting enzyme preferred big endothelin-1 to big endothelin-2 or -3 as a substrate, and kinetic analysis revealed that the Michaelis constant and a maximal velocity for big endothelin-1 were 0.20 muM and 3.1 nmol/min.mg protein, respectively. Lung endothelin-converting enzyme is a typical neutral metalloproteinase and is similar to the enzyme from endothelial cells.	SANKYO CO LTD,NEW LEAD RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN	Daiichi Sankyo Company Limited	TAKAHASHI, M (corresponding author), SANKYO CO LTD,FERMENTAT RES LABS,1-2-58 HIROMACHI,SHINAGAWA KU,TOKYO 140,JAPAN.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KASHIWABARA T, 1989, FEBS LETT, V247, P73, DOI 10.1016/0014-5793(89)81243-8; KIMURA S, 1989, J CARDIOVASC PHARM, V13, pS5, DOI 10.1097/00005344-198900135-00003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA Y, 1990, FEBS LETT, V272, P166, DOI 10.1016/0014-5793(90)80475-X; MATSUMURA Y, 1990, EUR J PHARMACOL, V185, P103, DOI 10.1016/0014-2999(90)90216-S; MATSUMURA Y, 1992, FEBS LETT, V305, P86, DOI 10.1016/0014-5793(92)80870-M; MATSUMURA Y, 1991, BIOCHEM BIOPH RES CO, V178, P531, DOI 10.1016/0006-291X(91)90140-3; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; OHNAKA K, 1991, BIOCHEM INT, V23, P499; OHNAKA K, 1992, BIOCHEM BIOPH RES CO, V185, P611, DOI 10.1016/0006-291X(92)91668-G; OKADA K, 1991, BIOCHEM BIOPH RES CO, V180, P1019, DOI 10.1016/S0006-291X(05)81167-2; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; OPGENORTH TJ, 1992, FASEB J, V6, P2653, DOI 10.1096/fasebj.6.9.1612289; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SUZUKI N, 1989, J IMMUNOL METHODS, V118, P245, DOI 10.1016/0022-1759(89)90012-4; TAKADA J, 1991, BIOCHEM BIOPH RES CO, V176, P860, DOI 10.1016/S0006-291X(05)80265-7; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	22	136	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21394	21398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407980				2022-12-25	WOS:A1993MA28800108
J	CHANG, ZF; HUANG, DY				CHANG, ZF; HUANG, DY			THE REGULATION OF THYMIDINE KINASE IN HL-60 HUMAN PROMYELOLEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYCLE REGULATION; GENE; PURIFICATION; PROTEINS; ENZYME; DNA; ACID; NITROCELLULOSE; FRAGMENTS	It has been well established that the regulation of thymidine kinase (TK) expression is highly growth-dependent. In this report, we present evidence that TK expression in undifferentiated HL-60 cells is not stringently controlled in a growth-dependent manner, except for a very moderate activation of TK in response to growth stimulation. Moreover, we have demonstrated for the first time that TK becomes phosphorylated, and the fluctuation of TK activity in these cells is related to the extent of phosphorylation of seryl residues of the TK polypeptide. This is further reinforced by the observation that the presence of Ser/Thr phosphatases inhibitor in the crude extract increases TK activity. Our data suggest that post-translational modification by phosphorylation is implicated in TK regulation in HL-60 cells.			CHANG, ZF (corresponding author), CHANG GUNG MED COLL,DEPT BIOCHEM,TAOYUAN,TAIWAN.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; CHANG ZF, 1990, BIOCHEM BIOPH RES CO, V169, P780, DOI 10.1016/0006-291X(90)90399-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; ITO M, 1990, J BIOL CHEM, V265, P6954; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LS, 1976, J BIOL CHEM, V251, P2600; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHLOSSER CA, 1981, P NATL ACAD SCI-BIOL, V78, P1119, DOI 10.1073/pnas.78.2.1119; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHIOTANI T, 1989, CANCER RES, V49, P1090; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	33	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1266	1271						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419329				2022-12-25	WOS:A1993KG07700075
J	HO, MN; HILL, KJ; LINDORFER, MA; STEVENS, TH				HO, MN; HILL, KJ; LINDORFER, MA; STEVENS, TH			ISOLATION OF VACUOLAR MEMBRANE H+-ATPASE-DEFICIENT YEAST MUTANTS - THE VMA5 AND VMA4 GENES ARE ESSENTIAL FOR ASSEMBLY AND ACTIVITY OF THE VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRIFLUOPERAZINE RESISTANCE; ADENOSINE-TRIPHOSPHATASE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CELL-CYCLE; SUBUNIT; DNA; ACIDIFICATION; IDENTIFICATION	The vacuolar membrane H+-ATPase of the yeast Saccharomyces cerevisiae is a multisubunit enzyme complex composed of an integral membrane V0 sector, and a peripherally associated V1 sector. Deletion of one of several structural genes for vacuolar H+-ATPase subunits was previously demonstrated to prevent proper assembly of the remaining V1 subunits onto the vacuolar membrane (Kane, P. M., Kuehn, M. C., Howald-Stevenson, I., and Stevens, T. H. (1992) J. Biol. Chem. 267, 447-454). A genetic screen was designed to identify new genes whose products were essential for the synthesis, assembly, and/or function of the yeast vacuolar H+-ATPase. Mutants were identified based on phenotypes associated with vacuolar membrane H+-ATPase loss of function (vma), including an inability to grow on media buffered at neutral pH. Representatives in five complementation groups were identified, including four novel mutants vma5, vma21, vma22, and vma23, all of which were defective in vacuolar ATPase enzyme activity. We report here the characterization of two genes, VMA4 and VMA5, that encode peripheral subunits of the vacuolar H+-ATPase. We determined that VMA5 encodes the 42-kDa subunit of the vacuolar H+-ATPase. The VMA4 gene, originally described by Foury (Foury, F. (1990) J. Biol. Chem. 265, 18554-18560), was determined to encode the 27-kDa subunit of the purified yeast vacuolar H+-ATPase. Characterization of the vma5 and vma4 mutants revealed that the 42- and 27-kDa subunits are essential for the assembly of the peripheral membrane portion of the H+-ATPase onto the vacuolar membrane.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NIGMS NIH HHS [GM38006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; FOURY F, 1990, J BIOL CHEM, V265, P18554; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRATA R, 1990, J BIOL CHEM, V265, P6726; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON H, 1990, J BIOL CHEM, V265, P20390; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; RINE J, 1979, GENETICS, V93, P877; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SHIH CK, 1990, MOL CELL BIOL, V10, P3397, DOI 10.1128/MCB.10.7.3397; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	42	115	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					221	227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416931				2022-12-25	WOS:A1993KE60300035
J	KHANANSHVILI, D; PRICE, DC; GREENBERG, MJ; SARNE, Y				KHANANSHVILI, D; PRICE, DC; GREENBERG, MJ; SARNE, Y			PHE-MET-ARG-PHE-NH2 (FMRFA)-RELATED PEPTIDES INHIBIT NA+-CA2+ EXCHANGE IN CARDIAC SARCOLEMMA VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; MEMBRANE-VESICLES; ENDOGENOUS NEUROPEPTIDE; FMRFAMIDE; MUSCLE; TRANSLOCATION; MODULATION; TRANSPORT; MECHANISM; CURRENTS	The molluscan cardioexcitatory tetrapeptide FMRF-amide (Phe-Met-Arg-Phe-NH2) and related peptides inhibit Na+-Ca2+ exchange in calf cardiac sarcolemma vesicles. FMRFa itself has a low inhibitory potency (IC50 = 750 muM) which completely resides in its COOH-terminal RFa portion. The physiologically active analog FLRFa is 10-fold more potent (IC50 = 60 muM). Two other substitutions of the Met2 in FMRFa, by either Ile or Lys increase inhibitory potency 7- and 50-fold, respectively. The inhibitory potency increases 300-500-fold if the NH2-terminal Phe1 in FMRFa is substituted by either Val or His (IC50 = 1-2 muM). The inhibitory activity of W(n)LRFa (IC50 = 40 muM) is lost when either the NH2-terminal amino group is acylated or the NH2-terminal Trp1 is deleted. These data suggest that the COOH-terminal portion is essential for the basic low potency inhibition of Na+-Ca2+ exchange, whereas the NH2-terminal portion is important for the potentiation of the inhibitory activity. Although the IC50 values of various peptides range widely (10(-6)-10(-3) M), all of them induce a complete inhibition. The dose-response pattern of the peptide-induced inhibition is identical for the Na+-Ca2+ exchange and its partial reaction, the Ca2+-Ca2+ exchange. The inhibitory effect is reversible and affects both Na(i)(or Ca(i))-dependent Ca-45 uptake and Na(o)-dependent Ca-45 efflux, suggesting that the bidirectional movements of ions are altered. A mild pretreatment of vesicles with trypsin augments the Na+-Ca2+ exchange 1.5-fold but diminishes the inhibitory potency 3-4-fold, suggesting that the inhibition is mediated by an extravesicular membrane protein. The characteristics of the peptide-induced inhibition resemble the effect of opiates on Na+-Ca2+ exchange. FLRFa and dextrorphan (a non-opioid stereoisomer of an opiate agonist) are mutually exclusive inhibitors, suggesting that they may bind to the same site. This putative site lacks the pharmacological properties of opiate receptors and may be located either on the Na+-Ca2+ exchanger or at its vicinity. Endogenous analogs of FMRFa may regulate intracellular calcium via Na+-Ca2+ exchange.	UNIV FLORIDA, WHITNEY LAB, ST AUGUSTINE, FL 32086 USA	State University System of Florida; University of Florida	KHANANSHVILI, D (corresponding author), TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL.			Khananshvili, Daniel/0000-0002-4202-9966				BAUER PJ, 1981, ANAL BIOCHEM, V110, P61, DOI 10.1016/0003-2697(81)90112-3; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; BREZDEN BL, 1991, J PHYSIOL-LONDON, V443, P727, DOI 10.1113/jphysiol.1991.sp018860; BREZINA V, 1987, J PHYSIOL-LONDON, V382, P267, DOI 10.1113/jphysiol.1987.sp016367; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CARVALHO AP, 1991, ANN NY ACAD SCI, V639, P300, DOI 10.1111/j.1749-6632.1991.tb17318.x; COTTRELL GA, 1982, NATURE, V296, P87, DOI 10.1038/296087a0; DORKEY GJ, 1981, NATURE, V293, P656; EGAN TM, 1989, J PHYSIOL-LONDON, V411, P639, DOI 10.1113/jphysiol.1989.sp017596; GARCIA ML, 1988, BIOCHEMISTRY-US, V27, P2410, DOI 10.1021/bi00407a024; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; JACOBY MB, 1987, NEUROSCI LETT, V83, P128, DOI 10.1016/0304-3940(87)90228-X; KACZOROWSKI GJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P287, DOI 10.1016/0304-4157(89)90022-1; KAVALIERS M, 1985, NEUROPEPTIDES, V6, P485, DOI 10.1016/0143-4179(85)90110-6; KAVALIERS M, 1985, PEPTIDES, V6, P847, DOI 10.1016/0196-9781(85)90312-2; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; KHANANSHVILI D, 1991, J BIOL CHEM, V266, P13764; KHANANSHVILI D, 1991, ANN NY ACAD SCI, V639, P85, DOI 10.1111/j.1749-6632.1991.tb17291.x; Khananshvili D, 1990, CURR OPIN CELL BIOL, V2, P731, DOI 10.1016/0955-0674(90)90117-W; KHANANSHVILI D, 1992, LIFE SCI, V52, P275; LI Z, 1990, J BIOL CHEM, V266, P1014; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; NOBLE D, 1991, ANN NY ACAD SCI, V639, P334, DOI 10.1111/j.1749-6632.1991.tb17323.x; PAINTER SD, 1982, J COMP PHYSIOL, V148, P491, DOI 10.1007/BF00619787; PHILIPSON KD, 1990, CALCIUM HEART, P85; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; PRICE DA, 1989, BIOL BULL, V177, P198, DOI 10.2307/1541933; RAFFA RB, 1988, PEPTIDES, V9, P915, DOI 10.1016/0196-9781(88)90141-6; REEVES JP, 1988, METHOD ENZYMOL, V157, P505; REEVES JP, 1989, SODIUM CALCIUM EXCHA, P27; SAGY M, 1987, J CARDIOVASC PHARM, V9, P682, DOI 10.1097/00005344-198706000-00007; SEGEL IH, 1975, ENZYME KINETICS, P479; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023; Stein W., 2012, TRANSPORT DIFFUSION; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; THOMPSON KJ, 1992, J NEUROPHYSIOL, V67, P280, DOI 10.1152/jn.1992.67.2.280	38	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					200	205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416928				2022-12-25	WOS:A1993KE60300031
J	LEE, HC				LEE, HC			POTENTIATION OF CALCIUM-INDUCED AND CAFFEINE-INDUCED CALCIUM RELEASE BY CYCLIC ADP-RIBOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; TUMOR PROMOTER; METABOLITE; NAD+; THAPSIGARGIN; MICROSOMES; TISSUES; ENZYME; CELLS	Cyclic ADP-ribose (cADPR) is a naturally occurring metabolite of NAD+ that is as potent as inositol 1,4,5-trisphosphate (IP3) in mobilizing Ca2+ in sea urchin eggs. Previous pharmacological evidence suggests that cADPR acts through a system similar to the Ca2+-induced Ca2+ release (CICR). Here I showed that in the presence of low concentrations of cADPR addition of Ca2+ to egg homogenates stimulated further release of Ca2+ in a concentration-dependent manner. In the absence of cADPR, no induced release was seen, and the added Ca2+ was, instead, sequestered by a thapsigargin-sensitive transport system. High concentrations of strontium (>50 muM) could also induce Ca2+ release. The effective concentrations of Sr2+, however, were reduced 10-20-fold in the presence of low concentrations of cADPR. Barium, at up to 0.4 mM, did not stimulate Ca2+ release with or without cADPR. The potentiation between divalent cations and cADPR was mutual since the Ca2+ releasing activity of cADPR was also increased in the presence of strontium. Ionomycin and thapsigargin both released Ca2+ but neither potentiated Ca2+ release induced by divalent cations. Caffeine also released Ca2+ in a concentration-dependent manner, and its potency was greatly increased by low concentrations of cADPR, while no such simulation was seen with IP3. Conversely, low concentrations of caffeine that were not sufficient to release Ca2+ increased the effectiveness of cADPR 10-fold. Isocaffeine, an isomer of caffeine, was four to five times less effective, demonstrating the specificity of the caffeine effect. These results suggest that cADPR can function as an endogenous regulator of CICR in eggs.			LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009		NICHD NIH HHS [HD17484] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DUPONT G, 1990, CELL REGUL, V1, P853, DOI 10.1091/mbc.1.11.853; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1991, J BIOL CHEM, V266, P2276; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S	20	233	237	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					293	299						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416936				2022-12-25	WOS:A1993KE60300045
J	LEVY, H; TAL, T; SHAISH, A; ZAMIR, A				LEVY, H; TAL, T; SHAISH, A; ZAMIR, A			CBR, AN ALGAL HOMOLOG OF PLANT EARLY LIGHT-INDUCED PROTEINS, IS A PUTATIVE ZEAXANTHIN BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUNALIELLA-BARDAWIL; INDUCIBLE PROTEIN; XANTHOPHYLL CYCLE; NUCLEAR; LEAVES; GENE; CHLOROPLASTS; CAROTENOIDS; DISSIPATION; EXPRESSION	The cbr gene, previously cloned from the unicellular green alga Dunaliella bardawil, is transcriptionally and translationally activated in parallel to accelerated carotenogenesis in response to light stress conditions. The product of cbr, structurally similar to Elips (early light-induced proteins of higher plants), is associated with a minor light harvesting complexes of photosystem II component (Levy, H., Gokhman, I., and Zamir, A. (1992) J. Biol. Chem. 267, 18831-18836). This study examines the relationship between the induction of Cbr and another plant response to light stress, the deepoxidation of violaxanthin to zeaxanthin. A parallel between the two processes was observed in cells exposed to high light, starved for sulfate, or treated with norflurazon, a herbicide inducing photooxidative damage by inhibiting de novo carotenoid biosynthesis. When highly illuminated cells were returned to normal light, Cbr decayed in parallel to the reepoxidation of zeaxanthin to violaxanthin. Evidence for the physical association of Cbr and zeaxanthin was provided by nondenaturing gel electrophoresis. In cells transferred from low to high light, zeaxanthin was associated with the faster migrating of two electrophoretically resolved fractions of light harvesting complexes of photosystem II that also contained Cbr. In cells growing under normal light, violaxanthin was bound equally to the two fractions. Based on these results we propose that Cbr/early light-induced proteins bind zeaxanthin to form photoprotective complexes within the light-harvesting antennae.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ADAMSKA I, 1992, J BIOL CHEM, V267, P24732; BARTELS D, 1992, EMBO J, V11, P2771, DOI 10.1002/j.1460-2075.1992.tb05344.x; BENAMOTZ A, 1982, J PHYCOL, V18, P529, DOI 10.1111/j.1529-8817.1982.tb03219.x; BILGER W, 1989, PLANT PHYSIOL, V91, P542, DOI 10.1104/pp.91.2.542; BRAUMANN T, 1981, BIOCHIM BIOPHYS ACTA, V637, P8, DOI 10.1016/0005-2728(81)90204-8; CRONSHAGEN U, 1990, EUR J BIOCHEM, V193, P361, DOI 10.1111/j.1432-1033.1990.tb19347.x; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1990, PLANT PHYSIOL, V92, P293, DOI 10.1104/pp.92.2.293; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P500; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GRIMM B, 1989, PLANT MOL BIOL, V13, P585; HHERRIN D, 1992, J BIOL CHEM, V267, P8260; KOLNAUS W, 1987, MOL GEN GENET, V209, P234; LAROCHE J, 1991, PLANT PHYSIOL, V97, P147, DOI 10.1104/pp.97.1.147; LERS A, 1991, J BIOL CHEM, V266, P13698; LERS A, 1990, PLANT PHYSIOL, V93, P389, DOI 10.1104/pp.93.2.389; LEVY H, 1992, J BIOL CHEM, V267, P18831; MCGADEY J, 1970, HISTOCHEMISTRY, V23, P180, DOI 10.1007/BF00305851; MEYER G, 1984, EUR J BIOCHEM, V138, P201, DOI 10.1111/j.1432-1033.1984.tb07900.x; MUKAI Y, 1992, PLANT CELL PHYSIOL, V33, P859; SHAISH A, 1991, J PHYCOL, V27, P652, DOI 10.1111/j.0022-3646.1991.00652.x; SHAISH A, 1993, IN PRESS PLANTA; SUSEK RE, 1992, AUST J PLANT PHYSIOL, V19, P387, DOI 10.1071/PP9920387; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7	26	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20892	20896						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407922				2022-12-25	WOS:A1993MA28800042
J	LYONS, CE; PAYETTE, KL; PRICE, JL; HUANG, RCC				LYONS, CE; PAYETTE, KL; PRICE, JL; HUANG, RCC			EXPRESSION AND STRUCTURAL-ANALYSIS OF A TELEOST HOMOLOG OF A MAMMALIAN ZONA-PELLUCIDA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLINE ENVELOPE PROTEINS; ESTROGEN-RESPONSIVE ELEMENT; TROUT SALMO-GAIRDNERI; WINTER FLOUNDER; RAINBOW-TROUT; MESSENGER-RNA; ONCORHYNCHUS-MYKISS; SPLICE JUNCTIONS; SPERM RECEPTOR; EGG MEMBRANE	Gene expression in oviparous vertebrates during vitellogenesis is hormonally regulated. Our laboratory has characterized a unique gene (wf female), which is seasonally expressed in the liver of the female winter flounder Pseudopleuronectes americanus. The wf female mRNA is coexpressed with vitellogenin mRNA and reaches a high level during vitellogenesis. The wf female gene is 2554 base pairs in length and encodes a putative protein of 509 amino acids. The gene consists of eight exons separated by seven introns of different sizes. Within exon 1, there are six PQQ-rich repeats. Four of them encode a putative (PQQ)4PKY polypeptide, similar to the repeats found in the extracellular domains of other proteins. Exons 2-7 share homology with the zona pellucida protein genes rc55 of rabbit and zp-2 of mouse, and the positions of intron boundaries are conserved in the wf female and mouse zp-2 genes. In addition, the transcriptional regulatory cis elements (estrogen response element, CCAAT and TATAAA boxes), as found in vertebrate genes, are also conserved for the wf female promoter and mapped upstream from the initiation site of the wf female primary transcript.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NIGMS NIH HHS [5T 33 GM07231] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGLER JJ, 1987, 3RD P INT S REPR PHY, P209; AMANZE D, 1990, DEVELOPMENT, V109, P495; BAKER ME, 1988, BIOCHEM J, V255, P1057, DOI 10.1042/bj2551057; BEGOVAC PC, 1989, J EXP ZOOL, V251, P56, DOI 10.1002/jez.1402510108; BLEIL JD, 1981, DEV BIOL, V86, P189, DOI 10.1016/0012-1606(81)90329-8; BRIVIO MF, 1991, MOL REPROD DEV, V28, P85, DOI 10.1002/mrd.1080280114; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURTON MP, 1984, CAN J ZOOL, V62, P2563, DOI 10.1139/z84-374; CALLARD IP, 1990, PROG CLIN BIOL RES, V342, P343; CALLARD IP, 1987, FUNDAMENTALS COMP VE, V1, P257; CHEN TT, 1983, CAN J BIOCHEM CELL B, V61, P802, DOI 10.1139/o83-102; CHEN TT, 1989, PHYSIOL ZOOL, V62, P25, DOI 10.1086/physzool.62.1.30159996; COTELLI F, 1988, J ULTRA MOL STRUCT R, V99, P70, DOI 10.1016/0889-1605(88)90034-1; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOURLIE B, 1984, J BIOL CHEM, V259, P4960; GROOT EP, 1985, CAN J ZOOL, V63, P552, DOI 10.1139/z85-082; HAGENMAIER HE, 1976, H-S Z PHYSIOL CHEM, V357, P1435, DOI 10.1515/bchm2.1976.357.2.1435; HAMAZAKI TS, 1989, DEV BIOL, V133, P101, DOI 10.1016/0012-1606(89)90301-1; HAMODRAKAS SJ, 1992, STRUCTURE CELLULAR S, P115; HOLLAND LJ, 1992, J BIOL CHEM, V267, P7053; HUANG RCC, 1990, UCLA SYM BI, V116, P109; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; HYLLNER SJ, 1991, J ENDOCRINOL, V131, P229, DOI 10.1677/joe.0.1310229; HYLLNER SJ, 1992, J ENDOCRINOL, V135, P303, DOI 10.1677/joe.0.1350303; IUCHI I, 1976, BIOCHIM BIOPHYS ACTA, V453, P240, DOI 10.1016/0005-2795(76)90269-5; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KAIGHN ME, 1964, DEV BIOL, V9, P56, DOI 10.1016/0012-1606(64)90014-4; KAO SM, 1991, J BACTERIOL, V173, P7650, DOI 10.1128/jb.173.23.7650-7664.1991; KINLOCH RA, 1990, DEV BIOL, V142, P414, DOI 10.1016/0012-1606(90)90363-N; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAURSEN RA, 1992, STRUCTURE CELLULAR S, P55; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; LIN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2825, DOI 10.1073/pnas.78.5.2825; LYONS CE, 1993, THESIS J HOPKINS U; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MILLAR SE, 1991, MOL CELL BIOL, V11, P6197, DOI 10.1128/MCB.11.12.6197; MOLLER CC, 1989, DEV BIOL, V132, P103, DOI 10.1016/0012-1606(89)90209-1; Mommsen T.P., 1988, P347; OHZU E, 1981, ANNOT ZOOL JAPON, V54, P241; OPPENBERNTSEN DO, 1990, DEV BIOL, V137, P258, DOI 10.1016/0012-1606(90)90252-E; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREZ LE, 1991, COMP BIOCHEM PHYS B, V100, P821, DOI 10.1016/0305-0491(91)90297-Q; PRICE JL, 1990, FISH PHYSIOL BIOCHEM, V8, P187, DOI 10.1007/BF00004457; PRICE JL, 1986, PHYSIOL ZOOL, V59, P679, DOI 10.1086/physzool.59.6.30158614; Sambrook J, 1989, MOL CLONING LABORATO; SCHWOEBEL E, 1991, J BIOL CHEM, V266, P7214; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wallace R A, 1985, Dev Biol (N Y 1985), V1, P127; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474; YOUNG EG, 1956, J BIOL CHEM, V219, P161; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564	61	98	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21351	21358						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407974				2022-12-25	WOS:A1993MA28800102
J	ZERLIN, M; JULIUS, MA; GOLDFARB, M				ZERLIN, M; JULIUS, MA; GOLDFARB, M			NEP - A NOVEL RECEPTOR-LIKE TYROSINE KINASE EXPRESSED IN PROLIFERATING NEUROEPITHELIA	ONCOGENE			English	Article							CYTOPLASMIC SIGNALING PROTEINS; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; OLIGODENDROCYTE DEVELOPMENT; PHOSPHOTYROSINE ANTIBODY; BINDING-SITE; FAMILY; DIFFERENTIATION; DOMAINS; CELLS	We have isolated a murine cDNA, nep, which encodes a novel receptor-like protein tyrosine kinase. The kinase region of NEP protein bears 50% amino acid sequence identity to the neurotrophin receptors (TRKs). While the intracytoplasmic portion of NEP also contains a short kinase insert region and C-terminal tail reminiscent of the TRK proteins, the putative extracellular domain of NEP is unrelated to any known proteins. The nep gene is strongly expressed within proliferating neuroepithelia of mouse embryos, commencing at the early somite stage (embryonic day 8.0) and persisting in the proliferative ventricular zones of the brain and spinal cord, suggesting that one function of NEP kinase is to signal proliferation of neuroepithelial cells in response to an as yet unknown ligand. The nep gene is also expressed in embryonic sensory ganglia, striated muscle and epidermis, as well as in several adult tissues, including the ventricle linings and glia subpopulations tn the brain.	CTR MOLEC MED & IMMUNOL,NEWARK,NJ 07103; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University								BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1991, DEVELOPMENT, V112, P397; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLBOOK F, 1991, NEURON, V6, P845; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LETWIN K, 1988, ONCOGENE, V3, P621; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	39	60	63	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2731	2739						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397369				2022-12-25	WOS:A1993LX34300014
J	LEE, MS; YANG, JH; SALEHI, Z; ARNSTEIN, P; CHEN, LS; JAY, G; RHIM, JS				LEE, MS; YANG, JH; SALEHI, Z; ARNSTEIN, P; CHEN, LS; JAY, G; RHIM, JS			NEOPLASTIC TRANSFORMATION OF A HUMAN KERATINOCYTE CELL-LINE BY THE V-FOS ONCOGENE	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; HUMAN EPIDERMAL-KERATINOCYTES; PROTO-ONCOGENE; TRANSCRIPTION; EXPRESSION; PRODUCT; ACID; DNA; CARCINOMA; LEUKEMIAS	To analyze the role of the fos oncogene in the growth of human epithelial cells, we have transfected a nontumorigenic human epidermal keratinocyte line (RHEK1) immortalized by the Ad12-SV40 hybrid virus with a plasmid carrying the v-fos gene together with plasmid pSV2-neo which confers resistance to neomycin. Individual neomycin-resistant clones were isolated and characterized with respect to morphological alteration. Of 16 independent clones analyzed, two appeared morphologically transformed and formed foci in culture. Only the two clones with a transformed phenotype were found by Southern blot hybridization analysis to contain the transfected v-fos gene. These clones formed colonies in soft agar and induced tumors when transplanted into nude mice. Analysis of fos specific mRNA and protein demonstrated that the transfected v-fos gene was expressed in these two clonal lines. These findings suggest that expression of the v-fos gene might facilitate the process of neoplastic transformation of human epithelial cells in culture. This appears to represent the first demonstration of the transforming potential of the v-fos gene in human cells.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; JEROME H HOLLAND LAB, VIROL LAB, ROCKVILLE, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jay, Gregory/C-6346-2013					BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1973, 24TH P S COLST RES S, V24, P353; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; GANTT R, 1987, CANCER RES, V47, P1390; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KHARBANDA S, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P23; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEE CK, 1979, P SOC EXP BIOL MED, V162, P214, DOI 10.3181/00379727-162-40650; LEVY JA, 1978, J VIROL, V26, P11, DOI 10.1128/JVI.26.1.11-15.1978; LEVY JA, 1973, J NATL CANCER I, V51, P525; MAVILIO F, 1987, BLOOD, V69, P160; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; PINTO A, 1987, BLOOD, V70, P1450; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1989, ONCOGENE, V4, P1403; RHIM JS, 1981, P NATL ACAD SCI-BIOL, V78, P313, DOI 10.1073/pnas.78.1.313; RHIM JS, 1969, P SOC EXP BIOL MED, V132, P1091; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SKOUV J, 1986, CARCINOGENESIS, V7, P331, DOI 10.1093/carcin/7.2.331; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TERRIER P, 1988, BRIT J CANCER, V57, P43, DOI 10.1038/bjc.1988.6; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9	40	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					387	393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426745				2022-12-25	WOS:A1993KN00600018
J	EICHHOLTZ, T; DEBONT, DBA; DEWIDT, J; LISKAMP, RMJ; PLOEGH, HL				EICHHOLTZ, T; DEBONT, DBA; DEWIDT, J; LISKAMP, RMJ; PLOEGH, HL			A MYRISTOYLATED PSEUDOSUBSTRATE PEPTIDE, A NOVEL PROTEIN-KINASE-C INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE; POTENT INHIBITORS; PHOSPHOLIPASE-C; PHORBOL ESTERS; PHOSPHORYLATION; ACTIVATION; EXPRESSION; CELLS; INDUCTION; SUBSTRATE	Synthetic peptides corresponding to the pseudosubstrate domains of protein kinase C (PKC) have been used as specific inhibitors of PKC in in vitro assays and permeabilized cell systems. However, their use in vivo was hampered by the impermeability of the plasma membrane for such peptides. Here, we show that N-myristoylation of the PKC pseudosubstrate nonapeptide Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln permits its use as an inhibitor of PKC in intact cells. The myristoylated peptide, myr-psiPKC, inhibits phosphorylation of the myristoylated alanine-rich C kinase substrate protein, as induced by 12-O-tetradecanoylphorbol-13-acetate, and the activation of phospholipase D by bradykinin, which strictly depends on PKC. Half-maximal inhibition is obtained at concentrations of 8 and 20 muM, respectively. An N-myristoylated peptide derived from an inhibitor protein of the cAMP-dependent protein kinases, Myr-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile, was ineffective. These results show that myr-psiPKC is a selective and cell-permeable inhibitor of PKC.	NETHERLANDS CANC INST, DEPT CELLULAR BIOCHEM, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS; LEIDEN UNIV, GORLAEUS LABS, DEPT ORGAN CHEM, 2300 RA LEIDEN, NETHERLANDS	Netherlands Cancer Institute; Leiden University; Leiden University - Excl LUMC			Liskamp, Rob M/I-5889-2012	Liskamp, Rob M/0000-0001-8897-8975				ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; ATHERTON E, 1983, J CHEM SOC CHEM COMM, P1060, DOI 10.1039/c39830001060; Atherton E., 1990, SOLID PHASE PEPTIDE; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BUCHLER W, 1988, FEBS LETT, V228, P27, DOI 10.1016/0014-5793(88)80577-5; CASTRO B, 1975, TETRAHEDRON LETT, P1219; COSTE J, 1990, PEPTIDES CHEM STRUCT, P885; DEBONT HBA, 1989, INT J PEPT PROT RES, V33, P115; DEBONT HBA, 1990, TETRAHEDRON LETT, V31, P2497, DOI 10.1016/S0040-4039(00)97399-4; EICHHOLTZ T, 1990, FEBS LETT, V261, P147, DOI 10.1016/0014-5793(90)80657-5; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1990, CELL SIGNAL, V2, P187, DOI 10.1016/0898-6568(90)90022-3; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IOANNIDES CG, 1990, CELL IMMUNOL, V131, P242, DOI 10.1016/0008-8749(90)90250-U; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1990, BIOCHEM PHARMACOL, V39, P49, DOI 10.1016/0006-2952(90)90647-4; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMAGE R, 1987, TETRAHEDRON LETT, V28, P2287, DOI 10.1016/S0040-4039(00)96103-3; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SMITH MK, 1990, J BIOL CHEM, V265, P1837; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANNISPEN JW, 1985, RECL TRAV CHIM PAY B, V104, P99; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602	41	262	298	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1982	1986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420972				2022-12-25	WOS:A1993KH62000074
J	ZHOU, JM; BOYER, PD				ZHOU, JM; BOYER, PD			EVIDENCE THAT ENERGIZATION OF THE CHLOROPLAST ATP SYNTHASE FAVORS ATP FORMATION AT THE TIGHT-BINDING CATALYTIC SITE AND INCREASES THE AFFINITY FOR ADP AT ANOTHER CATALYTIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; CHANGE MECHANISM; COUPLING FACTOR; PHOTOPHOSPHORYLATION; COOPERATIVITY; ACTIVATION; HYDROLYSIS; KINETICS	Previous results have not established whether the attainment of a rapid photophosphorylation rate as ADP concentration is increased in the micromolar range (apparent K(m) = approximately 30 muM) results from the filling of a second or a third catalytic site. Measurements reported here show that the ATP synthase of chloroplast thylakoids, with 2-4 muM medium ADP present during steady-state photophosphorylation, has one catalytic site filled with tightly bound nucleotides, but other catalytic sites are largely empty. Thus, the rapid increase in the photophosphorylation rate with higher ADP concentrations results from the filling of a second catalytic site. Even with 30 muM added ADP in the dark, the binding of more than one ADP per synthase was not detectable. The sensitivity of the assay was such that the K(d) for binding of ADP at a second catalytic site of the de-energized synthase is >150 muM, considerably above the apparent K(m) for rapid photophosphorylation. This result can be explained by an increase in the affinity of a second catalytic site for ADP upon energization. Other experiments assessed the effect of ADP binding at a second catalytic site on the equilibrium between bound ATP and ADP and P(i) at the tight catalytic site. When the rate of photophosphorylation is limited by a low ADP concentration, about equal amounts of ATP and ADP are bound at one catalytic site on the synthase. In contrast, when the rate is limited by a low P(i) concentration with 100 muM ADP present, the equilibrium of bound reactants is shifted so that close to one ATP per synthase is present. This is as expected if the binding of ADP at a second catalytic site allows the protonmotive force to promote ATP formation from ADP and P(i) at a tight binding catalytic site. A scheme for the binding change mechanism incorporating these results is presented.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM-11094] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011094] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFLALO C, 1982, EUR J BIOCHEM, V126, P61, DOI 10.1111/j.1432-1033.1982.tb06746.x; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1977, ANN REV BIOCH, V46, P97; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; CZARNECKI JJ, 1985, BIOCHIM BIOPHYS ACTA, V809, P51, DOI 10.1016/0005-2728(85)90166-5; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; FELDMAN RI, 1983, J BIOL CHEM, V258, P2178; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; GRABER P, 1990, BIOELECTROCHEMISTRY, V3, P277; KOHLBRENNER WE, 1982, J BIOL CHEM, V257, P3441; KOMATSUTAKAKI M, 1992, J BIOL CHEM, V267, P2360; LECKBAND D, 1988, BIOCHEMISTRY-US, V27, P3629, DOI 10.1021/bi00410a016; MAGNUSSON RP, 1976, BIOCHEM BIOPH RES CO, V70, P1283, DOI 10.1016/0006-291X(76)91041-X; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P82; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; ROSEN G, 1979, J BIOL CHEM, V254, P654; SELMAN BR, 1981, J BIOL CHEM, V256, P1722; SHAVIT N, 1980, METHOD ENZYMOL, V69, P323; SMITH DJ, 1976, P NATL ACAD SCI USA, V73, P4314, DOI 10.1073/pnas.73.12.4314; SMITH LT, 1983, J BIOL CHEM, V258, P887; STROOP SD, 1985, BIOCHEMISTRY-US, V24, P2304, DOI 10.1021/bi00330a027; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; ZHOU JM, 1992, BIOCHEMISTRY-US, V31, P3166, DOI 10.1021/bi00127a017	26	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1531	1538						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420929				2022-12-25	WOS:A1993KH62000008
J	HEFFERNAN, M; LOTAN, R; AMOS, B; PALCIC, M; TAKANO, R; DENNIS, JW				HEFFERNAN, M; LOTAN, R; AMOS, B; PALCIC, M; TAKANO, R; DENNIS, JW			BRANCHING BETA-1-6N-ACETYLGLUCOSAMINETRANSFERASES AND POLYLACTOSAMINE EXPRESSION IN MOUSE F9 TERATOCARCINOMA CELLS AND DIFFERENTIATED COUNTERPARTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; ACID-INDUCED DIFFERENTIATION; ASN-LINKED OLIGOSACCHARIDES; MOLECULAR-WEIGHT GLYCOPROTEINS; BLOOD-GROUP-I; RETINOIC-ACID; MEMBRANE-GLYCOPROTEINS; GENE-EXPRESSION; HUMAN-BREAST; TUMOR	Beta-all-trans-retinoic acid (RA)-induced endodermal differentiation of mouse F9 teratocarcinoma cells is accompanied by changes in glycoprotein glycosylation, including expression of i antigen (i.e. polylactosamine) and leukophytohemagglutinin-reactive oligosaccharides (i.e.-GlcNAcbeta1-6Manalpha1-6-branched N-linked). We have used the F9 teratocarcinoma cells as a model to study developmental regulation of glycosyltransferase activities which are responsible for the biosynthesis of beta1-6GlcNAc-branched N- and O-linked oligosaccharides and polylactosamine. Growth of F9 cells in the presence of 10(-6) M RA for 4 days increased core 2 GlcNAc transferase and GlcNAc transferase V activities by 13- and 6-fold, respectively, whereas the activities of GlcNAc transferase I, beta1-3GlcNAc transferase (i), beta1-4Gal transferase, and beta1-3Gal transferase increased 2-4-fold. Induction of glycosyltransferase activities by RA was dose-dependent and showed a biphasic response with approximately half of the increase observed 3 days after RA treatment and the remainder occurred by day 4. PYS-2, a parietal endoderm cell line, showed levels of glycosyltransferase activities similar to those of RA-treated F9 cells. Glycosyltransferase activities in the RA-resistant F9 cell line (RA-3-10) were low and showed only a small induction by RA. These observations suggest that differentiation of F9 cells is closely associated with induction of multiple glycosyltransferase activities, with most pronounced increases in GlcNAc transferase V and 2', 5'-tetradenylate (core 2) GlcNAc transferase. The increase in GlcNAc transferase V was also reflected by the 4-6-fold increase in the binding of I-125-leukophytohemagglutinin to several cellular glycoproteins, which occurred after 3 days of RA treatment. The endo-beta-galactosidase-sensitive polylactosamine content of membrane glycoproteins and, in particular, the LAMP-1 glycoprotein was markedly increased after RA treatment of F9 cells. Consistent with these observations, fucosylated polylactosamine (i.e. dimeric Le(x))) was also increased in RA-treated cells. Analysis of the aryl oligosaccharides produced by F9 cells cultured in the presence of aryl alpha-D-GalNAc showed that RA treatment enhanced the synthesis of disialyl core 2 O-linked oligosaccharides and increased the polylactosamine content of the aryl oligosaccharides by >20-fold. The results suggest that differentiation of F9 cells into endoderm is closely associated with increased GlcNAc transferase V and core 2 GlcNAc transferase activities, enzymes which control the level of beta1-6GlcNAc-branched N- and O-linked oligosaccharides, the preferred substrates for polylactosamine addition.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ON,CANADA; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV ALBERTA,DEPT FOOD SCI,EDMONTON T6G 2P5,ALBERTA,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; University of Alberta			Dennis, James/E-7268-2013					AMOS B, 1990, J BIOL CHEM, V265, P19192; AMOS B, 1990, INT J CANCER, V46, P86, DOI 10.1002/ijc.2910460117; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P547; CHILDS RA, 1983, BIOCHEM J, V215, P491, DOI 10.1042/bj2150491; COSSU G, 1985, DIFFERENTIATION, V29, P63, DOI 10.1111/j.1432-0436.1985.tb00293.x; CRAWLEY SC, 1990, ANAL BIOCHEM, V185, P1; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DE LUCA LM, 1991, FASEB J, V5, P2924; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DEUTSCH V, 1983, EXP CELL RES, V149, P237, DOI 10.1016/0014-4827(83)90395-6; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FERNANDES B, 1991, CANCER RES, V51, P718; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HEFFERNAN M, 1989, CANCER RES, V49, P6077; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; Hogan B. L. M, 1983, CANCER SURV, V2, P115; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KERBEL RS, 1980, J NATL CANCER I, V64, P1221; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEHMAN JM, 1974, J CELL PHYSIOL, V84, P13, DOI 10.1002/jcp.1040840103; LOPEZ LC, 1989, MOL CELL BIOL, V9, P2370, DOI 10.1128/MCB.9.6.2370; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; ROGERS MB, 1990, J CELL BIOL, V110, P1767, DOI 10.1083/jcb.110.5.1767; ROSENMAN SJ, 1989, EXP CELL RES, V180, P326, DOI 10.1016/0014-4827(89)90061-X; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SINGHAL AK, 1990, CANCER RES, V50, P1375; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRIKLAND S, 1980, CELL, V21, P393; TORRES CR, 1984, J BIOL CHEM, V259, P3308; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; WANG SY, 1984, J BIOL CHEM, V259, P5899; WARREN L, 1978, BIOCHIM BIOPHYS ACTA, V516, P97, DOI 10.1016/0304-419X(78)90005-7; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZHUANG D, 1991, Glycobiology, V1, P425, DOI 10.1093/glycob/1.4.425	51	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1242	1251						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419327				2022-12-25	WOS:A1993KG07700072
J	NADEAU, K; DAS, A; WALSH, CT				NADEAU, K; DAS, A; WALSH, CT			HSP90 CHAPERONINS POSSESS ATPASE ACTIVITY AND BIND HEAT-SHOCK TRANSCRIPTION FACTORS AND PEPTIDYL PROLYL ISOMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; PURIFICATION; DNAK; SITE; DISSOCIATION; CYCLOPHILIN; HYDROLYSIS; RECEPTORS; COMPLEXES	Heat shock proteins of the 82-90 kDa class (hsp82 and hsp90) are abundant, conserved, and ubiquitous from prokaryotes to eukaryotes. Although proposed to be chaperones, they had not been reported to possess enzymatic activity until our recent observation that pure trypanosomatid hsp83 had potent ATPase activity (Nadeau, K., Sullivan, M., Engman, D., and Walsh, C. T. (1992) Protein Sci. 1, 970-979). We have now purified the hsp90 homolog from Escherichia coli (HtpG) and from Saccharomyces cerevisiae (hsp82) to homogeneity and observe ATPase activity with k(cat) values of 3 min-1 and 140 min-1. In addition, examinations of purified rat hsp90 and human hsp90 detect ATPase activity with a k(cat) of 0.6 min-1 and 10 min-1. Each of these hsp90s undergoes autophosphorylation on serine or threonine residues. In prokaryotes and eukaryotes, the induction of hsps during heat shock is controlled, respectively, by the binding of an alternate sigma32 or a transcriptional activator (heat shock factor or HSF) at heat shock promoter elements. Here we show that E. coli HtpG immobilized to Affi-Gel beads selectively retains sigma32 while the yeast hsp90 and rat hsp90 retain HSF. The peptidyl prolyl isomerase hsp59 of the FK506 binding class is known to bind to hsp90. We also detect binding of the other family of PPIases, the cyclophilins, to immobilized hsp90, consistent with a functional convergence of protein foldases.			NADEAU, K (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NIGMS NIH HHS [GM 20011] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AUSEBEL FM, 1989, CURRENT PROTOCOLS MO; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHAPPELL TG, 1987, CELL, V45, P3; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROSS C, 1991, TRENDS BIOCHEM SCI, V16, P135; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LARSON J, 1990, NATURE, V355, P372; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Morimoto RI, 1990, STRESS PROTEINS BIOL; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6907; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SPENCE J, 1989, J BIOL CHEM, V264, P4398; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	47	224	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1479	1487						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419347				2022-12-25	WOS:A1993KG07700106
J	PIZZORNO, G; CASHMORE, AR; MOROSON, BA; CROSS, AD; SMITH, AK; MARLINGCASON, M; KAMEN, BA; BEARDSLEY, GP				PIZZORNO, G; CASHMORE, AR; MOROSON, BA; CROSS, AD; SMITH, AK; MARLINGCASON, M; KAMEN, BA; BEARDSLEY, GP			5,10-DIDEAZATETRAHYDROFOLIC ACID (DDATHF) TRANSPORT IN CCRF-CEM AND MA104 CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE ACTIVITY; CARRIER-MEDIATED TRANSPORT; HUMAN LYMPHOBLASTOID CELLS; FOLATE ANALOG TRANSPORT; DENOVO PURINE SYNTHESIS; LEUKEMIA HL-60 CELLS; METHOTREXATE TRANSPORT; L1210 CELLS; MEMBRANE-TRANSPORT; RESISTANT	5,10-Dideazatetrahydrolic acid (DDATHF) is representative of a new class of antifolates acting through inhibition of de novo purine synthesis. We report here the transport characteristics of the diastereomers of DDATHF, which differ in configuration at C6, and comparison studies with other folate and antifolate analogs. (6R)-DDATHF showed high affinity for the influx system of CCRF-CEM cells with a K(m) of 1.07 muM and an influx V(max) of 4.04 pmol/min/10(7) cells. Comparative studies with methotrexate yielded an influx K(m) of 4.98 muM and a V(max) of 6.64 pmol/min/10(7) cells, and with 5-formyltetrahydrofolate an influx K(m) of 2.18 muM and a V(max) of 6.84 pmol/min/10(7) cells. Uptake of (6R)-DDATHF was competitively inhibited by (6S)-DDATHF, methotrexate (MTX), and 5-formyltetrahydrofolate, all with K(i) values similar to their influx K(m). The (6S)-DDATHF diastereomer had an influx K(m) of 1.04 muM, similar to that of (6R)-DDATHF; however, the V(max) of 1.72 pmol/min/10(7) cells was 2.3-fold lower than for (6R)-DDATHF. The transport properties of DDATHF were also studied in a mutant cell line (CEM/MTX), resistant to MTX based on impaired drug transport. In this system (6R)-DDATHF showed an influx K(m) of 1.49 muM and a decreased influx V(max) of 0.60 pmol/min/10(7) cells. A similar effect was shown for MTX (K(m) of 7.48 muM, V(max) of 1.02 pmol/min/10(7) cells). The number of binding sites in CCRF-CEM cells was similar for (6R)-DDATHF, (6S)-DDATHF, and MTX, 0.74, 0.71, and 0.76 pmol/10(7) cells, respectively. These values were slightly higher in the CEM/MTX cell line (1.07 and 1.09 pmol/10(7) cells for (6R)-DDATHF and MTX, respectively). Treatment of CCRF-CEM cells with either the N-hydroxysuccinimide ester of MTX or the corresponding N-hydroxysuccinimide ester of (6R)-DDATHF caused substantial inhibition (>90%) of the influx of (6R)-[H-3]DDATHF and [H-3]MTX, respectively. These results suggest strongly that DDATHF and MTX share a common influx mechanism through the reduced folate transport system. The internalization of DDATHF by monkey kidney epithelial MA104 cells, which express a high affinity folate receptor, was also studied. Competitive binding studies using purified folate receptor and radiolabeled 5-methyltetrahydrofolate showed that (6S)- and (6R)-DDATHF both had I50 values lower than 5-methyltetrahydrofolate (12 nM). Further studies indicate that both DDATHF isomers are actively intracellularly concentrated through this route and are also rapidly converted to high chain length polyglutamates. Transport via this system was inhibited in folate-depleted cells by 10 nM folic acid. At a concentration of 10 nM, receptor-mediated uptake results in greater drug accumulation in receptor-positive cells compared to receptor-negative cells.	YALE UNIV,SCH MED,DEPT PEDIAT,DEPT PEDIAT & PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	Yale University; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [CA57320, CA42367] Funding Source: Medline; NCRR NIH HHS [RR01237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042367] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALT FW, 1978, J BIOL CHEM, V253, P1357; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BARNETT CJ, 1989, CHEM BIOL PTERIDINES, P102; BEARDSLEY G P, 1986, P953; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BEARDSLEY GP, 1989, CHEM BIOL PTERIDINES, P1001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHELLO PL, 1982, BIOCHEM PHARMACOL, V31, P1527, DOI 10.1016/0006-2952(82)90376-8; COWAN KH, 1984, J BIOL CHEM, V289, P10789; DEDHAR S, 1985, BIOCHEM J, V225, P609, DOI 10.1042/bj2250609; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEMBO M, 1976, BIOCHIM BIOPHYS ACTA, V448, P505, DOI 10.1016/0005-2736(76)90303-5; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DOLNICK BJ, 1979, J CELL BIOL, V83, P394, DOI 10.1083/jcb.83.2.394; FISCHER GA, 1962, BIOCHEM PHARMACOL, V11, P1233, DOI 10.1016/0006-2952(62)90200-9; FLINTOFF WF, 1980, BIOCHEMISTRY-US, V19, P4321, DOI 10.1021/bi00559a027; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1982, J BIOL CHEM, V257, P1890; HABER DA, 1981, J BIOL CHEM, V256, P9501; HAKALA MT, 1965, BIOCHIM BIOPHYS ACTA, V102, P198, DOI 10.1016/0926-6585(65)90213-X; HENDERSON GB, 1987, BIOCHEM PHARMACOL, V36, P3007, DOI 10.1016/0006-2952(87)90216-4; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; HENDERSON GB, 1986, CANCER RES, V46, P1633; HILLCOAT BL, 1967, P NATL ACAD SCI USA, V58, P1632, DOI 10.1073/pnas.58.4.1632; JACKSON RC, 1975, CANCER BIOCHEM BIOPH, V1, P151; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MELARA PW, 1980, J BIOL CHEM, V255, P7024; MINI E, 1985, CANCER RES, V45, P325; MORAN RG, 1989, J BIOL CHEM, V264, P21047; NIETHAMMER D, 1975, EUR J CANCER, V11, P845, DOI 10.1016/0014-2964(75)90083-3; PIZZORNO G, 1988, CANCER RES, V48, P2149; PIZZORNO G, 1989, CANCER RES, V49, P5275; PIZZORNO G, 1991, MOL PHARMACOL, V39, P85; PRIEST DG, 1980, ANAL BIOCHEM, V103, P51, DOI 10.1016/0003-2697(80)90234-1; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1976, CANCER RES, V36, P1151; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1979, BIOCHEM PHARMACOL, V28, P2993, DOI 10.1016/0006-2952(79)90599-9; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; WARREN RD, 1978, CANCER RES, V38, P668; WEIMAN SD, 1992, CANCER RES, V52, P3396; WHITE JC, 1978, J BIOL CHEM, V253, P242; ZWIENER RJ, 1993, IN PRESS CANCER CHEM	53	39	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1017	1023						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419310				2022-12-25	WOS:A1993KG07700041
J	WESTENBERG, DJ; GUNSALUS, RP; ACKRELL, BAC; SICES, H; CECCHINI, G				WESTENBERG, DJ; GUNSALUS, RP; ACKRELL, BAC; SICES, H; CECCHINI, G			ESCHERICHIA-COLI FUMARATE REDUCTASE FRDC AND FRDD MUTANTS - IDENTIFICATION OF AMINO-ACID-RESIDUES INVOLVED IN CATALYTIC ACTIVITY WITH QUINONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES R-26; BACTERIAL REACTION CENTERS; SUCCINATE-DEHYDROGENASE; ELECTRON-TRANSPORT; PROTON-TRANSFER; REPLACEMENT; COMPLEX; PATHWAY; COMPONENT; ACCEPTOR	Escherichia coli fumarate reductase (FRD) is a four-subunit enzyme that catalyzes the terminal step in anaerobic respiration to fumarate. The hydrophobic FrdC and FrdD subunits anchor the FrdA and FrdB catalytic subunits to the inner surface of the cytoplasmic membrane and are required for the enzyme to interact with quinones. Thirty-five single-site mutations were constructed in the FrdC and FrdD polypeptides by site-directed mutagenesis. Each mutant enzyme was characterized for its ability to catalyze quinone oxidation and reduction and to support growth of E. coli DW35 (DELTAfrdABCD sdhC=kan) under selective conditions requiring functional enzyme. Replacement of FrdC(E29) with Asp, Leu, Lys, or Phe had a deleterious effect both on quinol oxidase and quinone reductase activities. Substitution of FrdC(H82) with Arg, Leu, Tyr, or Glu also decreased menaquinol oxidase activity, but had variable effects on the reverse reaction, the reduction of ubiquinone. Data are presented to support the hypothesis that the positive charge at FrdC(H82) is required for stabilization of the quinone radical intermediate and the negative charge at FrdC(E29) for deprotonation of menaquinol. Other critical amino acids identified in FrdC included Ala-32, Phe-38, Trp-86, Phe-87, and in FrdD residues Phe-57, Gln-59, Ser-60, and His-80. The established roles of such residues in the Q(A) and Q(B) sites of the photosynthetic reaction center would suggest a similar type of structure operative in the FRD complex. In such a model, Glu-29, Ala-32, His-82, Trp-86 of FrdC and His-80 of FrdD are considered participants in a Q(B)-type site, and FrdD Phe-57, Gln-59, and Ser-60 components in an apolar Q(A)-type site.	DVA MED CTR,DIV MOLEC BIOL,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Francisco			Westenberg, David J/I-2211-2016	Westenberg, David J/0000-0003-3510-0311	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16251] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; BLUM P, 1989, J BACTERIOL, V171, P538, DOI 10.1128/jb.171.1.538-546.1989; CAMMACK R, 1986, BIOCHEM SOC T, V14, P1207, DOI 10.1042/bst0141207; CECCHINI G, 1986, P NATL ACAD SCI USA, V83, P8898, DOI 10.1073/pnas.83.23.8898; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; CECCHINI G, 1984, FLAVINS FLAVOPROTEIN, P555; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; COLEMAN WJ, 1990, CURRENT RES PHOTOSYN, V1; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GIRDLESTONE J, 1981, BIOCHEMISTRY-US, V20, P152, DOI 10.1021/bi00504a025; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; JOHNSONMK, 1988, J BIOL CHEM, V263, P14732; JONES HM, 1987, J BACTERIOL, V169, P3340, DOI 10.1128/jb.169.7.3340-3349.1987; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KROGER A, 1978, BIOCHIM BIOPHYS ACTA, V505, P129, DOI 10.1016/0304-4173(78)90010-1; LATOUR DJ, 1987, J GEN MICROBIOL, V97, P597; LEMIRE BD, 1982, J BACTERIOL, V152, P1126; MCLENDON G, 1991, MET IONS BIOL SYST, V27, P183; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SALACH J, 1972, EUR J BIOCHEM, V26, P267, DOI 10.1111/j.1432-1033.1972.tb01765.x; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; Silhavy T.J., 1984, EXPT GENE FUSIONS; TAKAHASHI E, 1990, CURRENT RES PHOTOSYN, V1; UNDEN G, 1983, FEMS MICROBIOL LETT, V20, P181; WEINER JH, 1986, P NATL ACAD SCI USA, V83, P2056, DOI 10.1073/pnas.83.7.2056; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; ZAGURSKY RJ, 1985, FOCUS, V7, P4	34	87	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					815	822						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419359				2022-12-25	WOS:A1993KG07700013
J	CARLOS, S; HUNT, DF; ROCCHINI, C; ARNOTT, DP; AUSIO, J				CARLOS, S; HUNT, DF; ROCCHINI, C; ARNOTT, DP; AUSIO, J			POSTTRANSLATIONAL CLEAVAGE OF A HISTONE H1-LIKE PROTEIN IN THE SPERM OF MYTILUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIC-PROTEINS; MICROHETEROGENEITY; VARIABILITY; MOLLUSKS	Starting with total RNA from spermatogenic cells of Mytilus trossulus and using random priming, we have cloned and sequenced the c-DNAs corresponding to two variants of the sperm-specific protein PLII* (phi2B). DNA sequencing in conjunction with mass spectrometry and protein sequence data have allowed us to establish that of the three sperm-specific proteins present in the sperm of Mytilus (PL-II*(phi2B), PL-III (phi1), PL-IV (phi3)), the first and the last one are the result of post-translational cleavage of a common precursor. This common precursor is a member of the histone H1 family, and it exhibits inter- and intraspecific microheterogeneity.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	University of Victoria; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368				AUSIO J, 1989, EUR J BIOCHEM, V182, P569, DOI 10.1111/j.1432-1033.1989.tb14865.x; AUSIO J, 1982, BIOCHEMISTRY-US, V21, P5910, DOI 10.1021/bi00266a028; AUSIO J, 1982, EXP CELL RES, V141, P39, DOI 10.1016/0014-4827(82)90065-9; AUSIO J, 1986, COMP BIOCHEM PHYS B, V85, P439, DOI 10.1016/0305-0491(86)90025-8; AUSIO J, 1992, BIOL BULL, V182, P31, DOI 10.2307/1542178; AUSUBEL MF, 1987, CURRENT PROTOCOLS MO, V1; BLOCH DP, 1966, PROTOPLASMATOLOGIA, V5, P1; CARLOS S, 1993, J BIOL CHEM, V268, P185; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; DIXON GH, 1986, CHROMOSOMAL PROTEINS, P287; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; IATROU K, 1977, CELL, V10, P433, DOI 10.1016/0092-8674(77)90030-7; JUTGLAR L, 1991, J BIOL CHEM, V266, P8184; KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499; MOGENSEN C, 1991, FEBS LETT, V282, P273, DOI 10.1016/0014-5793(91)80493-M; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PHELAN JJ, 1974, J BIOL CHEM, V249, P1099; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5643; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; SUBIRANA JA, 1983, SPERM CELL, P197; ZALENSKII AO, 1986, MOL BIOL+, V20, P677	22	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					195	199						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416927				2022-12-25	WOS:A1993KE60300030
J	FORSTER, A; RABBITTS, TH				FORSTER, A; RABBITTS, TH			A METHOD FOR IDENTIFYING GENES WITHIN YEAST ARTIFICIAL CHROMOSOMES - APPLICATION TO ISOLATION OF MLL FUSION CDNAS FROM ACUTE-LEUKEMIA TRANSLOCATIONS	ONCOGENE			English	Article							HUMAN ACUTE-LEUKEMIA; DROSOPHILA-TRITHORAX; SELECTION; 11Q23; REARRANGEMENT; REGIONS; PROBES	The majority of chromosomal translocations breakpoints are within regions of the genome where few DNA probes are available. The use of yeast artificial chromosomes (YACs) containing long stretches of human DNA allows dispersed DNA markers to be used to identify the position of breakpoints but does not readily allow subcloning of the precise breakpoint within the YAC DNA nor the cDNAs containing the affected genes. We describe a procedure allowing rapid isolation of cDNAs corresponding to genes within a YAC clone. Random cDNA is hybridised to PCR-generated biotinylated fragments of total DNA from a yeast strain harbouring a YAC clone. The hybrids can be recovered to facilitate subsequent cloning of the cDNA molecules. The application of this method to the cloning of cDNA molecules carrying sequences involved in the translocation t(4;11)(q21;q23) is illustrated.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BARR FG, 1993, NAT GENET, V3, P133; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1993, IN PRESS NATURE; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	22	2	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3157	3160						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414518				2022-12-25	WOS:A1993MC09300033
J	WATANABE, M; MURAMATSU, MA; HIRAI, H; SUZUKI, T; FUJISAWA, J; YOSHIDA, M; ARAI, KI; ARAI, N				WATANABE, M; MURAMATSU, MA; HIRAI, H; SUZUKI, T; FUJISAWA, J; YOSHIDA, M; ARAI, KI; ARAI, N			HTLV-I ENCODED TAX IN ASSOCIATION WITH NF-KAPPA-B PRECURSOR P105 ENHANCES NUCLEAR-LOCALIZATION OF NF-KAPPA-B P50 AND P65 IN TRANSFECTED CELLS	ONCOGENE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATOR; BINDING-PROTEINS; TRANS-ACTIVATION; CDNA CLONES; LEUKEMIA; EXPRESSION; GENES; INDUCTION	NF-kappaB is a heterodimeric protein composed of two subunits, p50 and p65, and is sequestered in the cytoplasm as an inactive form through the association with an inhibitory protein, IkappaB. In the present study, the effect of HTLV-1 encoded Tax on the exogenously expressed NF-kappaB p105, which encodes a precursor of p50, was investigated using a COS-7 expression system. When p105 was expressed in COS-7 cells, the precursor p105 and the processed p50 were retained in the cytosolic fraction by associating each other, and p50 was not detected in the nuclear fraction. In the cells co-expressing p105 and Tax, the p50/p105 ratio in the cytosolic fraction reduced with an induction of p50 in the nuclear fraction, which gave rise to a significant increase in NF-kappaB binding activity. Enhancement of NF-kappaB binding activity was not observed by adenovirus encoded EIA and bovine papilloma virus encoded E2, and correlated well with the ability of Tax to associate with p105. When p105DELTAX which lacks the repeats of the ankyrin motif was expressed in this system, p105DELTAX and processed p50 were detected in the nuclear fraction and p50/p105DELTAX ratio was not affected by co-expression with Tax. In the same expression system, exogenously expressed NF-kappaB p65 was retained in the cytoplasm by p105 and further expression of Tax allowed entry of p65 in the nucleus. These results suggest that, in this model system, p105 acts as an IkappaB to sequester p50 and p65 in the cytoplasm and that Tax by inhibiting IkappaB activity of p105, enhances nuclear localization of p50 and p65. These findings raise a possibility for a novel mechanism for the induction of NF-kappaB in the nucleus by Tax.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,DEPT CELLULAR & MOLEC BIOL,TOKYO 108,JAPAN; DNAX INC,MOLEC & CELLULAR BIOL INST,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ARAI N, 1992, PHARMACOL THERAPEUT, V55, P303, DOI 10.1016/0163-7258(92)90054-4; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CRENON I, 1993, ONCOGENE, V8, P867; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; HEIKE T, 1989, EMBO J, V8, P1411, DOI 10.1002/j.1460-2075.1989.tb03522.x; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSAME M, 1986, LANCET, V1, P1031; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sambrook J, 1989, MOL CLONING LABORATO; SAWADA M, 1990, J VIROL, V64, P4002, DOI 10.1128/JVI.64.8.4002-4006.1990; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHURMAN L, 1989, J IMMUNOL, V143, P3806; SODROSKI JG, 1984, SCIENCE, V226, P177; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUBOI A, 1991, INT IMMUNOL, V3, P807, DOI 10.1093/intimm/3.8.807; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	38	64	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2949	2958						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414497				2022-12-25	WOS:A1993MC09300008
J	BLACHE, P; KERVRAN, A; LENGUYEN, D; DUFOUR, M; COHENSOLAL, A; DUCKWORTH, W; BATAILLE, D				BLACHE, P; KERVRAN, A; LENGUYEN, D; DUFOUR, M; COHENSOLAL, A; DUCKWORTH, W; BATAILLE, D			ENDOPEPTIDASE FROM RAT-LIVER MEMBRANES, WHICH GENERATES MINIGLUCAGON FROM GLUCAGON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; THIOL-DEPENDENT METALLOENDOPEPTIDASE; PARTIAL-PURIFICATION; PLASMA-MEMBRANE; CA-2+ PUMP; PROTEASE; PROTEINS; HORMONE; SEQUENCE; CDNA	An endopeptidase activity that cleaves glucagon, producing miniglucagon or glucagon (19-29), a Ca2+ pump inhibitory peptide, was isolated from rat liver membranes. The purified enzyme has a molecular mass of approximately 100 kDa and a pH optimum of approximately 8. It is inhibited by, both sulfhydryl-blocking reagents and metal-chelating reagents and activated by thiol compounds. The partial N-terminal amino acid sequence of the 100-kDa protein does not correspond to any known protein. An antiserum was raised against a synthetic octapeptide corresponding to the N-terminal sequence. Immunoblot analysis of crude liver membranes revealed a single band at 100 kDa. Immunoreactivity was found in liver, pancreas, and heart, which are glucagon and miniglucagon target tissues, and in gastric mucosa and kidney. Low levels were detected in spleen, whereas immunoreactivity was undetectable in skeletal muscle and intestinal mucosa. The endopeptidase activity was inhibited by insulin, glucagon-like peptide-1, and glucagon-like peptide-1 (7-36) amide, whereas other peptides that contain dibasic sites had no effect on its activity, indicating that the endopeptidase does not display strict selectivity toward basic doublets.	UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	BLACHE, P (corresponding author), CCIPE, INSERM, U264, RUE CARDONILLE, F-34094 MONTPELLIER 5, FRANCE.		blache, philippe/C-2009-2008					AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; BATAILLE D, 1992, BIOMED RES-TOKYO, V13, P137; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BLACHE P, 1989, CR ACAD SCI III-VIE, V308, P467; BLACHE P, 1990, J BIOL CHEM, V265, P21514; BLACHE P, 1992, BIOMED RES-TOKYO, V13, P51; BLACHE P, 1985, REGUL PEPTIDES, V53, P20; BLACHE P, 1988, BIOMED RES S3, V9, P19; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; DUCKWORTH WC, 1990, J BIOL CHEM, V265, P2984; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HAGOPIAN WA, 1987, J CLIN INVEST, V79, P409, DOI 10.1172/JCI112827; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KOLE HK, 1992, ARCH BIOCHEM BIOPHYS, V297, P199, DOI 10.1016/0003-9861(92)90662-G; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGUYEN D, 1988, PEPTIDE CHEM 1987, P391; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISBIN RI, 1984, METHODS DIABETIC R A, V1, P389; MULLER D, 1991, EUR J BIOCHEM, V202, P285, DOI 10.1111/j.1432-1033.1991.tb16374.x; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; PAVOINE C, 1991, AM J PHYSIOL, V260, pC993, DOI 10.1152/ajpcell.1991.260.5.C993; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEETZ MJ, 1988, J BIOL CHEM, V263, P19210; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TAO Z, 1991, NEUROPEPTIDES, V20, P125, DOI 10.1016/0143-4179(91)90062-N; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499	33	21	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21748	21753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408029				2022-12-25	WOS:A1993MC80900051
J	DANIEL, LW; HUANG, CF; STRUM, JC; SMITHERMAN, PK; GREENE, D; WYKLE, RL				DANIEL, LW; HUANG, CF; STRUM, JC; SMITHERMAN, PK; GREENE, D; WYKLE, RL			PHOSPHOLIPASE-D HYDROLYSIS OF CHOLINE PHOSPHOGLYCERIDES IS SELECTIVE FOR THE ALKYL-LINKED SUBCLASS OF MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STIMULATED HUMAN FIBROBLASTS; MOLECULAR-SPECIES ANALYSIS; HUMAN-NEUTROPHILS; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNAL TRANSDUCTION; HL-60 GRANULOCYTES; PHOSPHATIDIC-ACID; ALPHA-THROMBIN; MAST-CELLS	Madin-Darby canine kidney (MDCK) cells were used to study the synthesis of diglycerides from choline phospholipids (PC) in response to 12-O-tetradecanoylphorbol-13-acetate (TPA). In this system, diglyceride formation was blocked in the presence of ethanol (0.5%), and a corresponding amount of phosphatidylethanol (PEt) was formed, indicating that phospholipase D is responsible for the diglyceride production. Analysis of the subclasses of phosphatidylethanol revealed 1-O-alkyl-(alkyl), 1-O-alk-1'-enyl-(alkenyl), and 1-acyl species of PEt (38.0,8.3, and 53.7%, respectively). The molecular species of the alkyl-PEt most closely matched the alkyl-PC. No change in the relative amounts of alkyl- versus acyl-PEt was observed with time after stimulation. Comparison of the alkyl content of PEt (38.0%) and the parent PC (15.2%) indicated a marked selectivity for the alkyl subclass of PC. A cell-free assay (Huang, C., Wykle, R. L., Daniel, L. W., and Cabot, M. C. (1992) J. Biol. Chem. 267, 16859-16865) for phospholipase D was also used to confirm the selectivity of the enzyme for alkyl-PC versus acyl-PC. The predominant molecular species of PEt contained saturated acyl or alkyl chains in position-1 and monounsaturated residues in position-2 accounting for approximately 50% of the total PEt. 1-O-Octadecyl-2-oleoyl-sn-glycerol, a representative alkyl molecular species, was synthesized and tested for its effect upon protein kinase C derived from MDCK cells. This alkyl-diglyceride (DG) neither stimulated protein kinase C nor inhibited its activation by diacylglycerol. In summary, TPA-stimulated phospholipase D is selective for the alkyl-PC subclass in MDCK cells. The alkyl-DG subsequently formed does not appear to function as a second-messenger in activating protein kinase C.			DANIEL, LW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NCI NIH HHS [CA43297, CA48995] Funding Source: Medline; NHLBI NIH HHS [HL26818] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043297, R01CA048995] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BASS DA, 1989, J BIOL CHEM, V264, P19610; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLANK ML, 1984, J CHROMATOGR, V298, P473, DOI 10.1016/S0021-9673(01)92744-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CHABOT MC, 1989, CANCER RES, V49, P4441; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; EXTON JH, 1990, J BIOL CHEM, V265, P1; FORD DA, 1989, J BIOL CHEM, V264, P13818; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KENNERLY DA, 1990, J IMMUNOL, V144, P3912; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MARASCO CJ, 1990, J MED CHEM, V33, P985, DOI 10.1021/jm00165a016; MARX MH, 1988, J MED CHEM, V31, P858, DOI 10.1021/jm00399a029; MUELLER HW, 1984, J LIPID RES, V25, P383; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; OFLAHERTY JT, 1984, BIOCHEM BIOPH RES CO, V123, P64, DOI 10.1016/0006-291X(84)90380-2; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; PAI JK, 1988, J BIOL CHEM, V263, P12472; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PARKER J, 1987, J BIOL CHEM, V262, P5385; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS JE, 1987, J IMMUNOL, V138, P1542; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; STRUM JC, 1992, J BIOL CHEM, V267, P1576; Sugiura T., 1987, PLATELET ACTIVATING, P55; SURLES JR, 1985, J MED CHEM, V28, P73, DOI 10.1021/jm00379a015; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337	53	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21519	21526						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408002				2022-12-25	WOS:A1993MC80900017
J	DRIGGERS, WJ; LEDOUX, SP; WILSON, GL				DRIGGERS, WJ; LEDOUX, SP; WILSON, GL			REPAIR OF OXIDATIVE DAMAGE WITHIN THE MITOCHONDRIAL-DNA OF RINR-38 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; DEGENERATIVE DISEASES; MUTATIONS; OXYGEN; BIOCHEMISTRY; MUTAGENESIS; DIAGNOSIS; DELETION; INCREASE	A growing body of evidence suggests that a variety of chronic diseases, including cancer and diabetes, are associated with damage to mitochondrial DNA. Since mitochondria are constantly exposed to high levels of reactive oxygen species, it is likely that oxidative damage to mitochondrial DNA may be responsible for some of these maladies. To determine whether mitochondria can repair this damage, a quantitative Southern blot technique was utilized to identify repair in specific DNA fragments. A 10.8-kilobase mitochondrial restriction fragment was studied employing a probe containing the entire mouse mitochondrial genome. Alloxan was employed to generate oxygen radicals. Insulinoma cells were exposed to alloxan for 1 h, and total cellular DNA was isolated immediately or after intervals of up to 8 h. Alkali treatment was used to identify abasic sites and sugar lesions, endonuclease III was used to identify lesions associated with thymine and cytosine damage, and formamidopyrimidine-DNA glycosylase was employed to recognize formamidopyrimidines and 8-oxoguanines in DNA. The results showed that all forms of damage studied were repaired by 4 h, indicating that mitochondria are able to efficiently repair damage to their DNA caused by reactive oxygen species.	UNIV SO ALABAMA,DEPT STRUCT & CELLULAR BIOL,MSB 2042,MOBILE,AL 36688	University of South Alabama					NATIONAL CANCER INSTITUTE [P01CA047995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003456] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47995] Funding Source: Medline; NIEHS NIH HHS [ES 03456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DEMPLE B, 1991, OXIDATIVE STRESS OXI, P127; FREI B, 1985, J BIOL CHEM, V260, P7394; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GERBITZ KD, 1990, J CLIN CHEM CLIN BIO, V28, P241; GERBITZ KD, 1992, DIABETOLOGIA, V35, P1181, DOI 10.1007/BF00401375; HARDING AE, 1991, TRENDS NEUROSCI, V14, P132, DOI 10.1016/0166-2236(91)90081-5; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MEYERS KA, 1988, CARCINOGENESIS, V9, P285; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; MIQUEL J, 1977, FREE RADICALS BIOL, V3, P133; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; PACKER L, 1974, P NATL ACAD SCI USA, V71, P4763, DOI 10.1073/pnas.71.12.4763; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; REID RA, 1983, TRENDS BIOCHEM SCI, V8, P190, DOI 10.1016/0968-0004(83)90205-0; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; SATOH MS, 1988, J BIOL CHEM, V263, P6854; SIES H, 1989, NATURWISSENSCHAFTEN, V76, P57, DOI 10.1007/BF00396705; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X; WALLACE DC, 1990, PEDIATR RES, V28, P525, DOI 10.1203/00006450-199011000-00023; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; YEN TC, 1992, BIOCHEM INT, V26, P457	39	164	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22042	22045						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408062				2022-12-25	WOS:A1993MC80900090
J	MORGENSTERN, KA; HENZEL, WJ; BAKER, JB; WONG, S; PASTUSZYN, A; KISIEL, W				MORGENSTERN, KA; HENZEL, WJ; BAKER, JB; WONG, S; PASTUSZYN, A; KISIEL, W			ISOLATION AND CHARACTERIZATION OF AN INTRACELLULAR SERINE PROTEINASE-INHIBITOR FROM A MONKEY KIDNEY EPITHELIAL-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; HUMAN PROTEASE NEXIN; ELASTASE INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; PROTEOLYTIC ACTIVATION; ANTIGEN PRESENTATION; ENDOTHELIAL-CELLS; ANTITHROMBIN-III; CDNA CLONING; THROMBIN	A recent report described a thrombin inhibitory activity in the soluble fraction of human placenta and the cytosolic fraction of K562 cells. Isolation and characterization of the functionally inactive 35-38-kDa placental form of this protein revealed that it was a novel serine proteinase inhibitor (Coughlin, P. B., Tetaz, T., and Salem, H. H. (1993) J. Biol. Chem. 268, 9541-9547). In the present study, we observed a 67-kDa sodium dodecyl sulfate (SDS)-stable complex when I-125-thrombin was incubated with the cytosolic fraction of a monkey kidney epithelial cell line, BSC-1. This complex was not observed in either the particulate cell fraction extracted with 0.2% Triton X-100 or medium conditioned by cells, suggesting that the thrombin-complexing factor is confined to the cytoplasm. The cytoplasmic antithrombin activity was purified to apparent homogeneity from the cytosol of BSC-1 cells previously pulsed with [S-35]methionine by a combination of heparin-agarose chromatography, Mono Q fast protein liquid chromatography, and anhydrotrypsin-Affi-Gel 10 affinity chromatography. Analysis of the affinity-purified preparation by SDS-polyacrylamide gel electrophoresis and fluorography revealed a single protein with an apparent molecular mass of 38 kDa. The purified 38-kDa protein inhibited the amidolytic activities of thrombin, trypsin, urokinase, and factor Xa but not that of elastase. Incubation of the 38-kDa protein with excess thrombin identified approximately 60% of the labeled 38-kDa protein in an SDS-stable 67-kDa complex. The purified 38-kDa inhibitor was cleaved with cyanogen bromide and the isolated peptides subjected to microsequencing. Amino acid sequence obtained for a region within this protein exhibited significant homology with human antithrombin III and plasminogen activator inhibitors 1 and 2. This homologous peptide contained the full complement of residues designated as highly conserved in helix F of the greater serine proteinase inhibitor superfamily. In addition, an internal sequence of GGGGDIHQGF was found in the monkey cytoplasmic inhibitor, which is identical to that reported for an internal sequence of the human placental inhibitor. These findings confirm the existence of a novel cytoplasmic serine proteinase inhibitor in mammalian cells and provide additional details of its molecular properties. The physiological function of this novel serine proteinase inhibitor in cytoplasm is unknown.	UNIV NEW MEXICO, SCH MED, DEPT PATHOL, BLOOD SYST RES FDN LAB, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, DEPT BIOCHEM, ALBUQUERQUE, NM 87131 USA; GENENTECH INC, PROT CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, CARDIOVASC RES, S SAN FRANCISCO, CA 94080 USA	University of New Mexico; University of New Mexico; Roche Holding; Genentech; Roche Holding; Genentech				Henzel, William/0000-0003-2940-3797				AKO H, 1972, BIOCHEM BIOPH RES CO, V47, P1402, DOI 10.1016/0006-291X(72)90228-8; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; ASTRUP T, 1978, PROGR CHEM FIBRINOLY, V3, P1; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BAKER JB, 1986, RECEPTORS, V3, P153; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON T, 1991, PRINCIPLES TRANSFUSI, P307; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DESA MFG, 1988, J CELL BIOL, V107, P1517, DOI 10.1083/jcb.107.4.1517; DJONDJUROV LP, 1984, EXP CELL RES, V152, P134, DOI 10.1016/0014-4827(84)90237-4; DUBIN A, 1992, J BIOL CHEM, V267, P6576; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRONKE RS, 1989, BLOOD, V73, P472; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; ISHII SI, 1983, METHOD ENZYMOL, V91, P378; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; KAZAMA Y, 1993, BLOOD, V81, P676; KIRSCHNER RJ, 1980, J BIOL CHEM, V255, P5468; KISIEL W, 1985, BLOOD, V66, P1302; KOPITAR M, 1985, THROMB HAEMOSTASIS, V54, P750; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODERMANN H, 1984, J MOL BIOL, V177, P531; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHEWS CK, 1990, BIOCHEMISTRY-US, P16; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; MOTIZUKI M, 1986, EUR J BIOCHEM, V158, P345, DOI 10.1111/j.1432-1033.1986.tb09757.x; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; PARHAM P, 1991, NATURE, V351, P271, DOI 10.1038/351271a0; PONTREMOLI S, 1990, P NATL ACAD SCI USA, V87, P3705, DOI 10.1073/pnas.87.10.3705; POTEMPA J, 1990, NATO ADV SCI I A-LIF, V191, P163; POTEMPA J, 1988, J BIOL CHEM, V263, P7364; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1985, J EXP MED, V162, P2142, DOI 10.1084/jem.162.6.2142; REMOLDODONNELL E, 1989, J EXP MED, V169, P1071, DOI 10.1084/jem.169.3.1071; ROBERTSON M, 1991, NATURE, V353, P300, DOI 10.1038/353300a0; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHACHTER M, 1979, PHARMACOL REV, V31, P1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SCOTT RW, 1983, J BIOL CHEM, V258, P439; SHARIFI BG, 1986, J NEUROCHEM, V46, P461, DOI 10.1111/j.1471-4159.1986.tb12990.x; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TRACY PB, 1986, BIOCH PLATELETS, P296; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANDENAKKER WMR, 1990, FEBS LETT, V276, P123, DOI 10.1016/0014-5793(90)80523-L; WAGNER SL, 1988, BIOCHEMISTRY-US, V27, P2173, DOI 10.1021/bi00406a053; WAGNER SL, 1989, J BIOL CHEM, V264, P611; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; YE RD, 1988, J BIOL CHEM, V263, P4869; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495	73	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21560	21568						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408007				2022-12-25	WOS:A1993MC80900023
J	OSBORNE, CB; LOWE, KE; SHANE, B				OSBORNE, CB; LOWE, KE; SHANE, B			REGULATION OF FOLATE AND ONE-CARBON METABOLISM IN MAMMALIAN-CELLS .1. FOLATE METABOLISM IN CHINESE-HAMSTER OVARY CELLS EXPRESSING ESCHERICHIA-COLI OR HUMAN FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE SYNTHETASE; DEPENDENT ENZYMES; INVITRO SYNTHESIS; FOLC GENE; PROTEINS; ANALOGS; ACID; FOLYLPOLYGLUTAMATES; IDENTIFICATION; METHOTREXATE	Chinese hamster ovary (CHO) cell transfectants expressing various levels of human and Escherichia coli folylpoly-gamma-glutamate synthetase (FPGS) activity and possessing different folylpolyglutamate chain length distributions have been developed as models for folate and antifolate metabolism. The synthesis of pteroyltriglutamate was sufficient for normal cellular retention of folate and also overcame the phenotypic requirement for purines and thymidine of AUXB1, a CHO cell mutant lacking FPGS activity and lacking folylpolyglutamates. Only low levels of FPGS are required to enable cellular metabolism of folates to forms that are retained by mammalian cells. The higher levels found in mammalian cells are required for the synthesis of the long chain polyglutamate derivatives characteristic of mammalian cells. At low medium folate concentrations, folate accumulation by transfectants expressing human FPGS was not responsive to FPGS levels as the limiting step in metabolism was beyond the triglutamate, the chain length required for retention. The rate-limiting step in folate metabolism in cells expressing the E. coli enzyme was the conversion of diglutamate to triglutamate, and, at low FPGS levels, the E. coli enzyme was about 50-fold less effective than the human FPGS in enabling cellular folate accumulation. These data suggest that cellular accumulation of any folate analog whose mono- or diglutamate derivative is a poor substrate for FPGS would be very responsive to the level of FPGS activity.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NCI NIH HHS [CA-41991] Funding Source: Medline; NIGMS NIH HHS [GM073079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; BOGNAR AL, 1986, METHOD ENZYMOL, V122, P349; BORMAN LS, 1989, J CELL PHYSIOL, V140, P335, DOI 10.1002/jcp.1041400220; BRODY T, 1989, PTERIDINS, V1, P159; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; COLL RJ, 1991, BIOCHEM PHARMACOL, V42, P833, DOI 10.1016/0006-2952(91)90043-5; COOK JD, 1987, BIOCHEMISTRY-US, V26, P530, DOI 10.1021/bi00376a027; FERNANDES DJ, 1983, CANCER RES, V43, P1117; FERONE R, 1986, J BIOL CHEM, V261, P6363; FERONE R, 1986, J BIOL CHEM, V261, P6356; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FOO SK, 1982, J BIOL CHEM, V257, P13587; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GEORGE S, 1987, BIOCHEMISTRY-US, V26, P522, DOI 10.1021/bi00376a026; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGAN RL, 1991, BIOCHEM PHARMACOL, V41, P781, DOI 10.1016/0006-2952(91)90081-F; KIM JS, 1993, J BIOL CHEM, V268, P21680; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN BF, 1993, J BIOL CHEM, V268, P21674; LOWE KE, 1993, J BIOL CHEM, V268, P21665; Maniatis T., 1982, MOL CLONING; MATHERLY LH, 1990, CANCER RES, V50, P3262; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1987, CANCER RES, V47, P5975; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; OCONNOR BM, 1991, CANCER RES, V51, P3874; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAMUELS LL, 1985, CANCER RES, V45, P1488; SHANE B, 1986, METHOD ENZYMOL, V122, P323; SHANE B, 1989, VITAM HORM, V45, P263; SHANE B, 1982, AM J CLIN NUTR, V35, P599, DOI 10.1093/ajcn/35.3.599; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUSSMAN DJ, 1986, SOMAT CELL MOLEC GEN, V12, P531, DOI 10.1007/BF01671939; SUSSMAN DJ, 1986, ANAL BIOCHEM, V158, P371, DOI 10.1016/0003-2697(86)90563-4; TAYLOR RT, 1985, MUTAT RES, V151, P293, DOI 10.1016/0027-5107(85)90082-X; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1979, ARCH BIOCHEM BIOPHYS, V197, P36, DOI 10.1016/0003-9861(79)90215-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER C, 1986, FOLATES PTERINS, V3, P251; WEITMAN SD, 1992, CANCER RES, V52, P3396	44	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21657	21664						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408018				2022-12-25	WOS:A1993MC80900037
J	CHUN, SY; STROBEL, S; BASSFORD, P; RANDALL, LL				CHUN, SY; STROBEL, S; BASSFORD, P; RANDALL, LL			FOLDING OF MALTOSE-BINDING PROTEIN - EVIDENCE FOR THE IDENTITY OF THE RATE-DETERMINING STEP IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGNAL SEQUENCE; LEADER PEPTIDE; EXPORTED PROTEIN; ATP HYDROLYSIS; MUTATIONS; CHEMOTAXIS; RIBOSE; GROEL; SECB	The folding of maltose-binding protein, a periplasmic protein in Escherichia coli, was shown to proceed through the same rate-limiting step whether folding occurred in the cell under physiological conditions or in vitro in the absence of other proteins. Four species of maltose-binding protein containing aminoacyl substitutions identified as decreasing the rate of folding of the protein in vivo were purified, and their denaturant-induced folding transitions were analyzed by monitoring the intrinsic fluorescence of tryptophan. In all four cases the rate of folding in vitro was slower than that of the wild-type maltose-binding protein; thus the same step determines the rate of folding in vivo and in vitro. Furthermore, examination of the three-dimensional structure of maltose-binding protein as determined by x-ray crystallography (F. Quiocho, personal communication; Spurlino, J. C., Lu, G.-Y., and Quiocho, F. A. (1991) J. Biol. Chem. 266, 5202-5219) indicates that all 4 of the residues identified as crucial to folding lie in one structural element of the native protein. We conclude that the rate-limiting step both in vivo and in vitro involves formation of this element of structure.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, PROGRAM GENET & CELL BIOL, PULLMAN, WA 99164 USA; UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA	Washington State University; Washington State University; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029798, R37GM029798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; COVER WH, 1987, J BACTERIOL, V169, P1794, DOI 10.1128/jb.169.5.1794-1800.1987; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAROSSA RA, 1991, MOL MICROBIOL, V5, P529, DOI 10.1111/j.1365-2958.1991.tb00724.x; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTINEAU P, 1990, J MOL BIOL, V214, P337, DOI 10.1016/0022-2836(90)90165-I; MATOUSCHEK A, 1991, METHOD ENZYMOL, V202, P82; Matthews CR, 1991, CURR OPIN STRUC BIOL, V1, P28; MATTHEWS CR, 1987, METHOD ENZYMOL, V154, P498; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Pace C N, 1986, Methods Enzymol, V131, P266; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RASMUSSEN BA, 1985, J BACTERIOL, V164, P665, DOI 10.1128/JB.164.2.665-673.1985; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RYAN JP, 1986, J BIOL CHEM, V261, P3389; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; SCHMID FX, 1979, J MOL BIOL, V133, P285, DOI 10.1016/0022-2836(79)90536-9; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TESCHKE CM, 1991, J BIOL CHEM, V266, P11789; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VYAS NK, 1991, J BIOL CHEM, V266, P5226	48	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20855	20862						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407916				2022-12-25	WOS:A1993MA28800036
J	STROOP, SD; THOMPSON, DL; KUESTNER, RE; MOORE, EE				STROOP, SD; THOMPSON, DL; KUESTNER, RE; MOORE, EE			A RECOMBINANT HUMAN CALCITONIN RECEPTOR FUNCTIONS AS AN EXTRACELLULAR CALCIUM SENSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOSOLIC FREE CALCIUM; EXPRESSION CLONING; RAT OSTEOCLASTS; G-PROTEINS; PATHWAYS; PEPTIDE; CYCLASE; BINDING; CELLS	Calcitonin, a peptide hormone active in calcium homeostasis, is used in the treatment of bone loss disorders because it inhibits osteoclast function. A human calcitonin receptor was cloned and expressed in baby hamster kidney cells. Three independent stable transfectants respond to calcitonin via increased intracellular calcium ([Ca2+]i) and cyclic adenosine 3',5'-monophosphate (cAMP). We made the interesting observation that these cells also respond to millimolar increases in extracellular calcium via a rapid and sustained elevation in [Ca2+]i, whereas three calcitonin receptor-negative baby hamster kidney cell lines, two of which express recombinant receptors related to the calcitonin receptor, show no sensitivity to changes in extracellular calcium. The increase of [Ca2+]i in response to both calcitonin and extracellular calcium is a function of the average number of calcitonin receptors per cell. These studies suggest a dual role for the calcitonin receptor as a hormone receptor and an extracellular calcium sensor.			STROOP, SD (corresponding author), ZYMOGENET INC,4225 ROOSEVELT WAY NE,SEATTLE,WA 98105, USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALAM ASM, 1992, BIOSCIENCE REP, V5, P369; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; Deftos LJ, 1990, PRIMER METABOLIC BON, P53; FINDLAY DM, 1981, BIOCHEM J, V196, P513, DOI 10.1042/bj1960513; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MACINTYRE I, 1988, HDB EXPT PHARM, V83, P411; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv-8-4-377; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MOORE EE, 1992, J BONE MINER RES, V7, pS146; MORTON CR, 1986, BRAIN RES, V372, P149, DOI 10.1016/0006-8993(86)91468-X; Munson P.L, 1976, HDB PHYSL, V7, P443; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584; RAPISARDA E, 1984, PHARMACOL RES COMMUN, V16, P1151, DOI 10.1016/S0031-6989(84)80080-6; SEXTON PM, 1987, KIDNEY INT, V32, P862, DOI 10.1038/ki.1987.287; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; STROOP SD, 1993, IN PRESS J RECEPTOR; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; ZAIDI M, 1990, BIOSCIENCE REP, V10, P493, DOI 10.1007/BF01116610; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; ZAIDI M, 1990, BIOCHEM BIOPH RES CO, V167, P807, DOI 10.1016/0006-291X(90)92097-J	31	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19927	19930						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397191				2022-12-25	WOS:A1993LY01900004
J	SATO, H; SEIKI, M				SATO, H; SEIKI, M			REGULATORY MECHANISM OF 92-KDA TYPE-IV COLLAGENASE GENE-EXPRESSION WHICH IS ASSOCIATED WITH INVASIVENESS OF TUMOR-CELLS	ONCOGENE			English	Article							NF-KAPPA-B; NECROSIS FACTOR-ALPHA; RHEUMATOID SYNOVIAL FIBROBLASTS; HUMAN IMMUNODEFICIENCY VIRUS; BASEMENT-MEMBRANE COLLAGEN; DNA-BINDING PROTEIN; GROWTH-FACTOR-BETA; NUCLEAR FACTOR; STROMELYSIN PROMOTER; TRANSCRIPTION FACTOR	92-kDa Type IV collagenase, a member of matrix metalloproteinases, is believed to play a critical role in physiological tissue-remodeling processes and also in many pathological conditions such as tumor invasion. We analyzed the 5'-flanking sequence of the 92 kDa type IV collagenase gene that controls the expression of the gene by ligating it to the chloramphenicol acetyltransferase gene. Deletion and mutation analysis revealed that three motifs, homologous to the binding sites for AP-1, NF-kappaB, and Sp-1 proteins, contributed positively to induction by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and tumor necrosis factor alpha (TNFalpha). The AP-1 site was indispensable but not sufficient for the induction and required synergistic cooperation with either the kappaB or the Sp-1 site. In OST cells, a nuclear factor which bound to Sp-1 was constitutively expressed, and those bound to AP-1 and kappaB elements were rapidly induced by TNFalpha treatment. Comparison of the findings with those for the promoters of other TPA-inducible matrix metalloproteinases, interstitial collagenase and stromelysin 1, revealed that the signal to the AP-1 sites is common for the TPA-inducibility of the genes but that the signals to the KB or Sp-1 sites, which are not present in interstitial collagenase and stromelysin 1 promoters, are the unique determinant for the inducibility of the 92 kDa type IV collagenase gene.			SATO, H (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT MOLEC VIROL & ONCOL, KANAZAWA, ISHIKAWA 920, JAPAN.		SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FRISCH SM, 1990, ONCOGENE, V5, P75; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIZEL SB, 1981, P NATL ACAD SCI-BIOL, V78, P2474, DOI 10.1073/pnas.78.4.2474; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PYKE C, 1992, CANCER RES, V52, P1336; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1992, ONCOGENE, V7, P77; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	60	711	725	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					395	405						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426746				2022-12-25	WOS:A1993KN00600019
J	COX, DA; MATLIB, MA				COX, DA; MATLIB, MA			A ROLE FOR THE MITOCHONDRIAL NA+-CA2+ EXCHANGER IN THE REGULATION OF OXIDATIVE-PHOSPHORYLATION IN ISOLATED HEART-MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMITOCHONDRIAL CA-2+-SENSITIVE ENZYMES; SODIUM-CALCIUM EXCHANGE; RAT-HEART; 2-OXOGLUTARATE DEHYDROGENASE; PYRUVATE-DEHYDROGENASE; CARDIAC MITOCHONDRIA; MYOCARDIAL ISCHEMIA; ADENINE-NUCLEOTIDES; LIVER-MITOCHONDRIA; INHIBITORY-ACTION	The role of the Na+-Ca2+ exchanger of heart mitochondria in cellular functioning is not yet clear. The objectives of this study were to investigate the effects of stimulation and inhibition of the Na+-Ca2+ exchanger on the matrix free Ca2+ concentration in isolated heart mitochondria and to determine the consequences of these changes on the rate of NADH production via Krebs cycle turnover and the oxidative phosphorylation rate (OPR) supported by alpha-ketoglutarate dehydrogenase, a Ca2+-regulated matrix enzyme. Activation of Na+-Ca2+ exchange by increasing extramitochondrial Na+ concentration was found to decrease the matrix free [Ca2+] in a concentration-dependent manner. Inhibitors of mitochondrial Na+-Ca2+ exchange activity inhibited the decrease in matrix free [Ca2+] mediated by Na+. Increasing concentrations of Na+ were also found to inhibit both the rate of NADH production and OPR. Inhibitors of mitochondrial Na+-Ca2+ exchange also blocked the effects of Na+ on the rate of NADH production and OPR in a similar concentration range. The results indicate that alterations in matrix free [Ca2+] induced by changes in mitochondrial Na+-Ca2+ exchange activity are translated into changes in the rate of NADH production and the overall rate of oxidative phosphorylation.	UNIV CINCINNATI, DEPT PHARMACOL & CELL BIOPHYS, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA	University of Cincinnati					NHLBI NIH HHS [R01-HL34664] Funding Source: Medline; PHS HHS [TO7382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034664] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYSAL K, 1991, ARCH BIOCHEM BIOPHYS, V291, P383, DOI 10.1016/0003-9861(91)90150-H; Carafoli E., 1978, CURR TOP MEMBR TRANS, V10, P151; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHIESI M, 1988, BIOCHEM PHARMACOL, V37, P4399, DOI 10.1016/0006-2952(88)90623-5; COX DA, 1983, IN PRESS J CARDIOVAS; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; CROMPTON M, 1978, EUR J BIOCHEM, V91, P599, DOI 10.1111/j.1432-1033.1978.tb12713.x; DAS AM, 1990, CARDIOVASC RES, V24, P411, DOI 10.1093/cvr/24.5.411; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; EDOUTE Y, 1979, J MOL CELL CARDIOL, V11, P831, DOI 10.1016/0022-2828(79)90408-5; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; GOSHIMA K, 1981, J MOL CELL CARDIOL, V13, P489, DOI 10.1016/0022-2828(81)90265-0; GROVER GJ, 1989, J CARDIOVASC PHARM, V14, P331, DOI 10.1097/00005344-198908000-00022; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; HAYAT LH, 1982, BIOCHEM J, V202, P509, DOI 10.1042/bj2020509; KATZ AM, 1988, AM J CARDIOL, V62, pA3, DOI 10.1016/S0002-9149(88)80077-8; LEE CO, 1975, J GEN PHYSIOL, V65, P695, DOI 10.1085/jgp.65.6.695; LOTSCHER HR, 1980, EUR J BIOCHEM, V110, P211, DOI 10.1111/j.1432-1033.1980.tb04857.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATLIB MA, 1985, BIOCHEM BIOPH RES CO, V128, P290, DOI 10.1016/0006-291X(85)91677-8; MATLIB MA, 1983, EUR J PHARMACOL, V89, P327, DOI 10.1016/0014-2999(83)90518-6; MATLIB MA, 1991, AM J HYPERTENS, V4, pS435, DOI 10.1093/ajh/4.7.435S; MATLIB MA, 1984, METHOD PHARMACOL, V5, P25; MCCORMACK JG, 1984, BIOCHEM J, V218, P235, DOI 10.1042/bj2180235; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; MCCORMACK JG, 1985, BIOCHEM J, V231, P581, DOI 10.1042/bj2310581; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1979, BIOCHEM J, V180, P533, DOI 10.1042/bj1800533; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MCCORMACK JG, 1985, BIOCHEM SOC T, V13, P664, DOI 10.1042/bst0130664; MELA L, 1977, CURR TOP MEMBR TRANS, V9, P321; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NAGAO T, 1980, J MOL CELL CARDIOL, V12, P29, DOI 10.1016/0022-2828(80)90109-1; PUSKIN JS, 1976, BIOCHEMISTRY-US, V15, P3834, DOI 10.1021/bi00662a029; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; RUTTER GA, 1989, ANN NY ACAD SCI, V573, P206, DOI 10.1111/j.1749-6632.1989.tb14998.x; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; SOMLYO AP, 1986, J CARDIOVASC PHARM, V8, pS42, DOI 10.1097/00005344-198600088-00009; TAGAMI M, 1985, JPN HEART J, V26, P823; TANZ RD, 1982, J MOL CELL CARDIOL, V14, P655, DOI 10.1016/0022-2828(82)90163-8; THORN MB, 1953, BIOCHEM J, V54, P540, DOI 10.1042/bj0540540; VAGHY PL, 1982, J BIOL CHEM, V257, P6000; VANECHTELD CJA, 1991, J MOL CELL CARDIOL, V23, P297, DOI 10.1016/0022-2828(91)90066-U; WAN B, 1989, J BIOL CHEM, V264, P13430; WATTS J, 1987, EUR J PHARMACOL, V138, P335, DOI 10.1016/0014-2999(87)90471-7; WEISHAAR R, 1979, AM J CARDIOL, V43, P1137, DOI 10.1016/0002-9149(79)90144-9; WILLIAMSON JR, 1979, ANNU REV PHYSIOL, V41, P485, DOI 10.1146/annurev.ph.41.030179.002413; WOLSKA BM, 1991, J MOL CELL CARDIOL, V23, P217, DOI 10.1016/0022-2828(91)90108-X; YAMADA EW, 1981, J BIOL CHEM, V256, P203	54	139	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					938	947						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419373				2022-12-25	WOS:A1993KG07700030
J	SUGISAKI, H; TAKANAMI, M				SUGISAKI, H; TAKANAMI, M			THE 5'-TERMINAL REGION OF THE APOCYTOCHROME-B TRANSCRIPT IN CRITHIDIA-FASCICULATA IS SUCCESSIVELY EDITED BY 2 GUIDE RNAS IN THE 3' TO 5' DIRECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE SUBUNIT-III; MESSENGER-RNA; KINETOPLASTID MITOCHONDRIA; TRYPANOSOMA-BRUCEI; CYTOCHROME-OXIDASE; MAXICIRCLE DNA; MINICIRCLES; MOLECULES; SEQUENCE; DOMAINS	We analyzed the chimeric guide RNA (gRNA-mRNA molecules in Crithidia fasciculata that are predicted to transiently exist in editing of the 5'-terminal domain of apocytochrome b (CYb) mRNA, by polymerase chain reaction amplification and DNA sequencing, and obtained evidence suggesting that among the 14 editing sites numbered from 3' to 5', the sequence in the 3'-half of the sites (3' block) was specified by one guide RNA species (gRNA-I) and that in the remaining half of the sites (5' block) by the other guide RNA species (gRNA-II) and that the direction of editing in each block was 3' to 5'. The predicted transition site of editing by two gRNAs was between the first and second U residues from the 3' end within editing site 7. We found that a stretch of the edited sequence in the 3' block of mRNA could form a stable duplex with a stretch immediately upstream of the guide sequence in gRNA-II. The result leads to a successive editing model that the 3' block of pre-edited mRNA is first edited by gRNA-I, and after completion of editing, the 5' portion of gRNA-II pairs with the edited mRNA for editing of the 5' block.			SUGISAKI, H (corresponding author), KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN.							BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; POLLARD VW, 1991, MOL CELL BIOL, V11, P1668, DOI 10.1128/MCB.11.3.1668; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SLOOF P, 1987, NUCLEIC ACIDS RES, V15, P51, DOI 10.1093/nar/15.1.51; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	24	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					887	891						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419367				2022-12-25	WOS:A1993KG07700023
J	DEWAARD, P; VANDERWAL, H; HUIJBERTS, GNM; EGGINK, G				DEWAARD, P; VANDERWAL, H; HUIJBERTS, GNM; EGGINK, G			HETERONUCLEAR NMR ANALYSIS OF UNSATURATED FATTY-ACIDS IN POLY(3-HYDROXYALKANOATES) - STUDY OF BETA-OXIDATION IN PSEUDOMONAS-PUTIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; ESCHERICHIA-COLI; FLUORESCENT PSEUDOMONADS; REVISED PATHWAY; OLEOVORANS; POLYESTERS; C-13; SENSITIVITY; PROTEINS; COMPLEX	Poly(3-hydroxyalkanoates) (PHAs) were isolated from Pseudomonas putida KT2442 cultivated on petroselenic acid, oleic acid, and linoleic acid to study beta-oxidation of unsaturated fatty acids. Both saturated and unsaturated medium chain length 3-hydroxy fatty acids were found to be constituents of these polymers. With the aid of proton-detected multiple quantum coherence and proton-detected multiple bond coherence NMR spectra the structures of the unsaturated monomers were identified as 3-hydroxy-5-cis-tetradecanoate for PHA produced on oleic acid, and 3-hydroxy-6-cis-dodecanoate and 3-hydroxy-5-cis-8-cis-tetradecadienoate for PHA produced on linoleic acid. The identified structures, which are derived from fatty acid degradation intermediates, indicate a degradation of oleic acid via the enoyl-CoA isomerase-dependent route and a degradation of linoleic acid via the dienoyl-CoA reductase-dependent route.	AGROTECHNOL RES INST,POB 17,6700 AA WAGENINGEN,NETHERLANDS									BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1988, J AM CHEM SOC, V110, P7926, DOI 10.1021/ja00231a081; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRANDL H, 1988, APPL ENVIRON MICROB, V54, P1977, DOI 10.1128/AEM.54.8.1977-1982.1988; BREMSER W, 1985, MAGN RESON CHEM, V23, P271, DOI 10.1002/mrc.1260230413; BRUHWILER D, 1986, J MAGN RESON, V69, P546, DOI 10.1016/0022-2364(86)90174-5; Doi Y., 1990, MICROBIAL POLYESTERS; Eggink G, 1990, NATO ASI SERIES; HUISMAN GW, 1989, APPL ENVIRON MICROB, V55, P1949, DOI 10.1128/AEM.55.8.1949-1954.1989; HUJIBERTS GNM, 1992, APPL ENVIRON MICROB, V58, P536; IMAMURA S, 1990, J BIOCHEM, V107, P184, DOI 10.1093/oxfordjournals.jbchem.a123023; JIN SJ, 1990, BIOCHEMISTRY-US, V29, P8540, DOI 10.1021/bi00489a006; LAGEVEEN RG, 1988, APPL ENVIRON MICROB, V54, P2924, DOI 10.1128/AEM.54.12.2924-2932.1988; PREUSTING H, 1990, MACROMOLECULES, V23, P4220, DOI 10.1021/ma00221a007; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; TIMM A, 1990, APPL ENVIRON MICROB, V56, P3360, DOI 10.1128/AEM.56.11.3360-3367.1990; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; WITHOLT B, 1972, J BACTERIOL, V109, P350, DOI 10.1128/JB.109.1.350-364.1972; YANG SY, 1986, J BIOL CHEM, V261, P2238; YANG SY, 1986, J BIOL CHEM, V261, P5390; YOU SY, 1989, J BIOL CHEM, V264, P16489; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P346, DOI 10.1016/0022-2364(90)90265-B	25	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					315	319						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416939				2022-12-25	WOS:A1993KE60300048
J	SIMBULAN, CMG; SUZUKI, M; IZUTA, S; SAKURAI, T; SAVOYSKY, E; KOJIMA, K; MIYAHARA, K; SHIZUTA, Y; YOSHIDA, S				SIMBULAN, CMG; SUZUKI, M; IZUTA, S; SAKURAI, T; SAVOYSKY, E; KOJIMA, K; MIYAHARA, K; SHIZUTA, Y; YOSHIDA, S			POLY(ADP-RIBOSE) POLYMERASE STIMULATES DNA POLYMERASE-ALPHA BY PHYSICAL ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); ADENOSINE DIPHOSPHORIBOSYL TRANSFERASE; MESSENGER-RNA LEVELS; CALF THYMUS; ADP-RIBOSYLATION; TOPOISOMERASE-I; BINDING DOMAIN; PROTEIN FACTOR; STRAND BREAKS; RAT-LIVER	The direct effect of the eukaryotic nuclear DNA-binding protein poly(ADP-ribose) polymerase on the activity of DNA polymerase alpha was investigated. Homogenously purified poly(ADP-ribose) polymerase (5 to 10 mug/ml) stimulated the activity of immunoaffinity-purified calf or human DNA polymerase alpha by about 6 to 60-fold in a dose-dependent manner. It had no effect on the activities of DNA polymerase beta, DNA polymerase gamma, and primase, indicating that its effect is specific for DNA polymerase alpha. Apparently, poly(ADP-ribosyl)ation of DNA polymerase alpha was not necessary for the stimulation. The stimulatory activity is due to poly(ADP-ribose) polymerase itself since it was immunoprecipitated with a monoclonal antibody directed against poly(ADP-ribose) polymerase. Kinetic analysis showed that, in the presence of poly(ADP-ribose) polymerase, the saturation curve for DNA template primer became sigmoidal; at very low concentrations of DNA, it rather inhibited the reaction in competition with template DNA, while, at higher DNA doses, it greatly stimulated the reaction by increasing the V(max) of the reaction. By the automodification of poly(ADP-ribose) polymerase, however, both the inhibition at low DNA concentration and the stimulation at high DNA doses were largely lost. Furthermore, stimulation by poly(ADP-ribose) polymerase could not be attributed to its DNA-binding function alone since its fragment, containing only the DNA-binding domain, could not exert full stimulatory effect on DNA polymerase, as of the intact enzyme. Poly(ADP-ribose) polymerase is coimmunoprecipitated with DNA polymerase alpha, using anti-DNA polymerase alpha antibody, clearly showing that poly(ADP-ribose) polymerase may be physically associated with DNA polymerase alpha. In a crude extract of calf thymus, a part of poly(ADP-ribose) polymerase activity existed in a 400-kDa, as well as, a larger 700-kDa complex containing DNA polymerase alpha, suggesting the existence in vivo of a complex of these two enzymes.	NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,CANC CELL BIOL LAB,SHOWA KU,NAGOYA,AICHI 466,JAPAN; KOCHI MED SCH,DEPT MED CHEM,NANKOKU,KOCHI 78151,JAPAN	Nagoya University; Kochi University			Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342				Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ANACHKOVA B, 1989, CYTOBIOS, V59, P19; BAKSI K, 1987, EXP CELL RES, V172, P110, DOI 10.1016/0014-4827(87)90098-X; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BOULIKAS T, 1988, EMBO J, V7, P57, DOI 10.1002/j.1460-2075.1988.tb02783.x; BOULIKAS T, 1990, J BIOL CHEM, V265, P14638; BUKI KG, 1991, BIOCHEM BIOPH RES CO, V180, P496, DOI 10.1016/S0006-291X(05)81092-7; BURZIO L, 1972, FEBS LETT, V20, P29, DOI 10.1016/0014-5793(72)80009-7; CESARONE CF, 1990, BIOCHIM BIOPHYS ACTA, V1087, P241, DOI 10.1016/0167-4781(90)90211-J; CESARONE CF, 1990, BIOCHEM BIOPH RES CO, V171, P1037, DOI 10.1016/0006-291X(90)90788-O; COHEN JJ, 1982, BIOCHEMISTRY-US, V21, P4931, DOI 10.1021/bi00263a016; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; DEMURCIA G, 1983, EMBO J, V2, P543, DOI 10.1002/j.1460-2075.1983.tb01460.x; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EKI T, 1991, J BIOL CHEM, V266, P3087; FERRO AM, 1984, J BIOL CHEM, V259, P547; FRY M, 1987, J BIOL CHEM, V262, P8861; GILL DM, 1972, J BIOL CHEM, V247, P5964; GOULIAN M, 1990, J BIOL CHEM, V265, P13221; ITAYA A, 1988, EUR J BIOCHEM, V174, P261, DOI 10.1111/j.1432-1033.1988.tb14092.x; ITOH S, 1979, J BIOL CHEM, V254, P3647; JACOBSON EL, 1983, J BIOL CHEM, V258, P103; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KASID UN, 1986, CARCINOGENESIS, V7, P327, DOI 10.1093/carcin/7.2.327; KASID UN, 1989, J BIOL CHEM, V264, P18687; KAWASAKI K, 1986, BIOCHEMISTRY-US, V25, P3044, DOI 10.1021/bi00358a046; LEHMANN AR, 1974, EXP CELL RES, V83, P63, DOI 10.1016/0014-4827(74)90688-0; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; OHTSUKI M, 1984, FEBS LETT, V168, P275, DOI 10.1016/0014-5793(84)80261-6; PRITCHARD CG, 1983, J BIOL CHEM, V258, P9810; SAPP M, 1985, J BIOL CHEM, V260, P1550; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; STONE PR, 1975, EXP CELL RES, V91, P95, DOI 10.1016/0014-4827(75)90145-7; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TANAKA Y, 1986, EUR J BIOCHEM, V155, P19, DOI 10.1111/j.1432-1033.1986.tb09453.x; THIBODEAU J, 1989, BIOCHEM CELL BIOL, V67, P653, DOI 10.1139/o89-097; TUBO RA, 1987, J BIOL CHEM, V262, P5857; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; USHIRO H, 1987, J BIOL CHEM, V262, P2352; YAGURA T, 1983, NUCLEIC ACIDS RES, V11, P6369, DOI 10.1093/nar/11.18.6369; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5; YOSHIDA S, 1979, J BIOCHEM-TOKYO, V85, P1387, DOI 10.1093/oxfordjournals.jbchem.a132465; YOSHIDA S, 1989, J BIOCHEM-TOKYO, V106, P389, DOI 10.1093/oxfordjournals.jbchem.a122863; YOSHIDA S, 1983, BIOCHIM BIOPHYS ACTA, V741, P348, DOI 10.1016/0167-4781(83)90155-0	49	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					93	99						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416979				2022-12-25	WOS:A1993KE60300016
J	VOIGT, J; NAGEL, K				VOIGT, J; NAGEL, K			REGULATION OF ELONGATION FACTOR-G GTPASE ACTIVITY BY THE RIBOSOMAL STATE - THE EFFECTS OF INITIATION-FACTORS AND DIFFERENTIALLY BOUND TRANSFER-RNA, AMINOACYL-TRANSFER RNA, AND PEPTIDYL-TRANSFER RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC 3-SITE MODEL; ESCHERICHIA-COLI; MESSENGER-RNA; TRANSLATION; CYCLE	The elongation factor G (EF-G) is responsible for the translocation of the ribosome along the mRNA chain. Under in vitro conditions, EF-G exhibits a very active uncoupled GTPase activity which is dependent on the presence of ribosomes and is modulated by mRNA-dependent binding of tRNA. In the absence of tRNA, uncoupled EF-G GTPase is inhibited by initiation factors IF1 and IF3, but not by initiation factor IF2. In the presence of N-fMet-tRNA(fMet) and poly(A,U,G) or in the presence of N-acetyl-Phe-tRNA(Phe) and poly(U), initiation factor IF2 causes an additional decrease of the uncoupled EF-G GTPase activity. This effect, however, is dependent on the presence of IF1 and IF3 and is obviously due to the mRNA- and initiation factor-dependent binding of N-fMet-tRNA(fMet) and N-acetyl-Phe-tRNA(Phe), respectively, to the ribosomal P-site. Non-enzymatic binding of N-fMet-tRNA(fMet) and N-acetyl-Phe-tRNA(Phe), however, causes a stimulation of uncoupled EF-G GTPase activity. The same effects are observed for Met-tRNA, Phe-tRNA(Phe) and uncharged tRNA. These findings are discussed in the light of the three-site model of the ribosome and the mechanism of translocation.			VOIGT, J (corresponding author), TECH UNIV BRAUNSCHWEIG,INST BOT,MENDELSSOHNSTR 4,W-3300 BRAUNSCHWEIG,GERMANY.		Voigt, Juergen/H-2163-2011	Voigt, Juergen/0000-0002-8104-6443				CABRER B, 1976, J BIOL CHEM, V251, P1718; CHINALI G, 1980, J BIOL CHEM, V255, P7455; CHINALI G, 1982, EUR J BIOCHEM, V125, P415, DOI 10.1111/j.1432-1033.1982.tb06699.x; CHINALI G, 1973, EUR J BIOCHEM, V32, P463, DOI 10.1111/j.1432-1033.1973.tb02629.x; CHINALI G, 1973, BIOCHEM BIOPH RES CO, V54, P33, DOI 10.1016/0006-291X(73)90884-X; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; DAHLFORS AAR, 1990, J MOL BIOL, V216, P311; DUBNOFF JS, 1971, P NATL ACAD SCI USA, V68, P318, DOI 10.1073/pnas.68.2.318; DUBNOFF JS, 1971, METHOD ENZYMOL, V20, P248; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GUPTA SL, 1971, BIOCHEMISTRY-US, V10, P4410, DOI 10.1021/bi00800a010; HAENNI AL, 1966, BIOCHIM BIOPHYS ACTA, V114, P135, DOI 10.1016/0005-2787(66)90261-9; HASELKORN R, 1973, ANN REV BIOCH, V41, P397; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; KAJI A, 1969, COLD SPRING HARB SYM, V34, P167, DOI 10.1101/SQB.1969.034.01.024; KAZIRO Y, 1969, COLD SPRING HARB SYM, V34, P385, DOI 10.1101/SQB.1969.034.01.045; KAZIROY, 1968, J BIOCHEM-TOKYO, V64, P423; KURIKI Y, 1974, J BIOL CHEM, V249, P7166; KURIKI Y, 1972, BIOCHEM BIOPH RES CO, V48, P700, DOI 10.1016/0006-291X(72)90405-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCASLENARD J, 1967, P NATL ACAD SCI USA, V57, P1050, DOI 10.1073/pnas.57.4.1050; MIALL SH, 1972, BIOCHEMISTRY-US, V11, P4826, DOI 10.1021/bi00775a028; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MODOLELL J, 1973, J BIOL CHEM, V248, P488; NAAKTGEBOREN N, 1977, EUR J BIOCHEM, V72, P49, DOI 10.1111/j.1432-1033.1977.tb11223.x; NAGEL K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P145, DOI 10.1016/0167-4781(92)90478-I; NISHIZUKA Y, 1966, P NATL ACAD SCI USA, V55, P212, DOI 10.1073/pnas.55.1.212; NOLL M, 1972, NATURE-NEW BIOL, V238, P225, DOI 10.1038/newbio238225a0; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; SABOL S, 1970, NATURE, V228, P1269, DOI 10.1038/2281269a0; SANDER G, 1975, BIOCHEMISTRY-US, V14, P1805, DOI 10.1021/bi00680a001; SUBRAMAN.AR, 1968, P NATL ACAD SCI USA, V61, P761, DOI 10.1073/pnas.61.2.761; SUBRAMANIAN AR, 1970, NATURE, V228, P1273, DOI 10.1038/2281273a0; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; THACH SS, 1971, P NATL ACAD SCI USA, V68, P1791, DOI 10.1073/pnas.68.8.1791; VOIGT J, 1990, EUR J BIOCHEM, V194, P579, DOI 10.1111/j.1432-1033.1990.tb15655.x; Wahba A J, 1974, Methods Enzymol, V30, P3	37	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					100	106						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416917				2022-12-25	WOS:A1993KE60300017
J	KLEMPNAUER, KH				KLEMPNAUER, KH			METHYLATION-SENSITIVE DNA-BINDING BY V-MYB AND C-MYB PROTEINS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CELLULAR HOMOLOG; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANS-ACTIVATION; GENE; DIFFERENTIATION; EXPRESSION; PRODUCT	The retroviral oncogene v-myb and its cellular homolog c-myb encode nuclear DNA-binding phosphoproteins (v-MYB and c-MYB) that function as transcriptional regulators. v-MYB and c-MYB recognize a nucleotide sequence motif, PyAAC(G)/(T)G, that is present in the promoter region of the myb-inducible mim-1 gene and is required for regulation of mim-1 expression by v-MYB and c-MYB. Since the myb-binding motif contains a CpG dinucleotide that constitutes a potential target for methylation, we have investigated whether recognition of the binding site by myb proteins is sensitive to CpG methylation of the binding motif. The results presented here demonstrate that bacterially expressed v-MYB as well as authentic v-MYB and c-MYB bind to the myb binding site in a methylation-sensitive manner. Our observations raise the interesting possibility that myb function can be regulated by methylation of myb binding sites.			KLEMPNAUER, KH (corresponding author), MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY.							BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; EVAN GI, 1984, MOL CELL BIOL, V4, P591; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3552; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	41	33	34	2	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					111	115						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423989				2022-12-25	WOS:A1993KN00500013
J	ISHIKAWA, H; ASANO, M; KANDA, T; KUMAR, S; GELINAS, C; ITO, Y				ISHIKAWA, H; ASANO, M; KANDA, T; KUMAR, S; GELINAS, C; ITO, Y			2 NOVEL FUNCTIONS ASSOCIATED WITH THE REL ONCOPROTEINS - DNA-REPLICATION AND CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article							NF-KAPPA-B; V-REL; C-REL; BINDING-PROTEIN; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; SUBUNIT; FAMILY; HOMOLOGY; ELEMENTS	The v-Rel oncoprotein and its cellular homolog c-Rel belong to the Rel/kappaB family of transcription factors. Members of this family share extensive sequence similarity in their N-terminal halves, a region referred to as the Rel Homology Region (RHR), bind to NF-kappaB DNA motifs and form heterodimers with one another. Whereas c-Rel activates transcription of kappaB-linked genes, v-Rel behaves as a dominant-interfering mutant of c-Rel- and kappaB-mediated transcription activation. Here we describe two novel activities of the Rel oncoproteins. One induces kappaB-site dependent stimulation of polyomavirus (Py) DNA replication and maps to the N-terminus of the RHR, a region where no transcription activation function was detected. This activity is common to v-Rel, c-Rel, p52 (p49/lyt10), RelA (p65) and the p50 subunit of NF-kappaB. The second promotes transcriptional activation in undifferentiated F9 cells and maps 3' to the RHR, a region essential for the transforming activity of v-Rel.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Kyoto University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center			Kanda, Teru/J-7313-2019	Kanda, Teru/0000-0002-1391-3349				BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM KJ, 1979, J IMMUNOL, V122, P549; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEE JH, 1991, ONCOGENE, V6, P665; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORRISON LE, 1992, ONCOGENE, V7, P1137; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WASYLYK C, 1990, ONCOGENE, V5, P1055	58	28	28	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2889	2896						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414493				2022-12-25	WOS:A1993MC09300001
J	GIMBLE, FS; THORNER, J				GIMBLE, FS; THORNER, J			PURIFICATION AND CHARACTERIZATION OF VDE, A SITE-SPECIFIC ENDONUCLEASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-I INTRON; UPSTREAM ACTIVATION SITE; MESSENGER-RNA MATURASE; FLANKING EXONS; MITOCHONDRIAL INTRON; DNA ENDONUCLEASE; ADENOSINE-TRIPHOSPHATASE; ENCODED PROTEINS; READING FRAME; S-CEREVISIAE	The 119-kDa primary translation product of the VMA1 gene of Saccharomyces cerevisiae undergoes a self-catalyzed rearrangement (''protein splicing'') that excises an internal 50-kDa segment of the polypeptide and joins the amino-terminal and carboxyl-terminal segments to generate the 69-kDa subunit of the vacuolar membrane-associated H+-ATPase. We have shown previously that the internal segment is a site-specific endonuclease (Gimble, F. S., and Thorner, J. (1992) Nature 357, 301-306). Here we describe methods for the high level expression and purification to near homogeneity of both the authentic VMA1-derived endonuclease (or VDE) from yeast (yield 18%) and a recombinant form of VDE made in bacteria (yield 29%). Detailed characterization of these preparations demonstrated that the yeast-derived and bacterially produced enzymes were indistinguishable, as judged by: (a) behavior during purification; (b) apparent native molecular mass (50 kDa); (c) immunological reactivity; and (d) catalytic properties (specific activity; cleavage site recognition; and optima for pH, temperature, divalent cation and ionic strength). The minimal site required for VDE cleavage was delimited to a 30-base pair sequence within its specific substrate (the VMA1DELTAvde allele).	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL, RM 401,BARKER HALL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANZIANO PQ, 1982, CELL, V30, P925, DOI 10.1016/0092-8674(82)90297-5; BELFORT M, 1990, ANNU REV GENET, V24, P363; BELLPEDERSEN D, 1990, NUCLEIC ACIDS RES, V18, P3763, DOI 10.1093/nar/18.13.3763; BELLPEDERSEN D, 1989, GENE, V82, P119, DOI 10.1016/0378-1119(89)90036-X; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER MCD, 1992, NUCLEIC ACIDS RES, V20, P5484, DOI 10.1093/nar/20.20.5484; BURGER G, 1985, J MOL BIOL, V186, P231, DOI 10.1016/0022-2836(85)90100-7; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; CUMMINGS DJ, 1989, CURR GENET, V16, P407, DOI 10.1007/BF00340720; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DELASALLE H, 1982, CELL, V28, P721, DOI 10.1016/0092-8674(82)90051-4; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DUJARDIN G, 1982, NATURE, V298, P628, DOI 10.1038/298628a0; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Innis MA, 1990, PCR PROTOCOLS GUIDE; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LEMIEUX B, 1988, MOL GEN GENET, V212, P48, DOI 10.1007/BF00322443; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1986, CELL, V46, P323, DOI 10.1016/0092-8674(86)90651-3; MONTEILHET C, 1990, NUCLEIC ACIDS RES, V18, P1407, DOI 10.1093/nar/18.6.1407; MORAN JV, 1992, NUCLEIC ACIDS RES, V20, P4069, DOI 10.1093/nar/20.15.4069; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGUEIL B, 1991, MOL GEN GENET, V225, P340, DOI 10.1007/BF00269867; SERAPHIN B, 1992, GENE, V113, P1, DOI 10.1016/0378-1119(92)90663-A; Sherman F., 1986, METHODS YEAST GENETI; SHIBATA T, 1984, J BIOL CHEM, V259, P499; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SNYDER M, 1988, MOL CELL BIOL, V8, P2184, DOI 10.1128/MCB.8.5.2184; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANARSDELL SW, 1987, TRANSCRIPTIONAL CONT, P325; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WATABE H, 1983, J BIOL CHEM, V258, P4663; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976	60	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21844	21853						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408039				2022-12-25	WOS:A1993MC80900063
J	LEVINE, A; YEIVIN, A; BENASHER, E; ALONI, Y; RAZIN, A				LEVINE, A; YEIVIN, A; BENASHER, E; ALONI, Y; RAZIN, A			HISTONE-H1-MEDIATED INHIBITION OF TRANSCRIPTION INITIATION OF METHYLATED TEMPLATES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; CPG BINDING-PROTEIN; DNA METHYLATION; CHROMATIN STRUCTURE; ACTIVE CHROMATIN; HISTONE BINDING; PROMOTER; GENE; INVOLVEMENT; EXPRESSION	The detailed mechanism underlying the inhibition of transcription by DNA methylation is still obscure. Chromatin structure has frequently been proposed as a role player in this mechanism. Histone H1 is a known key element in the formation and stabilization of chromatin fibers. We describe here experiments designed to examine the effect of DNA methylation on the binding of histone H1 to DNA and the consequent inhibitory effect of the bound histone H1 on in vitro transcription. The results of these experiments showed a clear preferential binding of histone H1 to methylated DNA as compared with unmethylated DNA. The in vitro transcription assay indicated that transcription of methylated templates was inhibited at a lower histone H1/DNA ratio than of unmethylated templates, and that the extent of inhibition depends on the density of methyl groups in the promoter region. This inhibition of in vitro transcription was alleviated efficiently by methylated competitor DNA, whereas, under similar conditions, almost no effect was observed with unmethylated competitor. Experiments designed to pinpoint the stage in the transcription process that was suppressed by the preferred binding of histone H1 to methylated template revealed that inhibition occurred at the initiation and not at the elongation level.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Weizmann Institute of Science			Levine, Alex/A-6867-2008		NCI NIH HHS [CA 14995] Funding Source: Medline; NIGMS NIH HHS [GM 20483] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALL DJ, 1983, P NATL ACAD SCI-BIOL, V80, P5490, DOI 10.1073/pnas.80.18.5490; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUSHLAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CONKLIN K, 1984, DNA METHYLATION BIOC, P243; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; HIGURASHI M, 1991, J BIOL CHEM, V266, P8619; HOLLER M, 1991, GENE DEV, V5, P1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; RENZ M, 1975, P NATL ACAD SCI USA, V72, P733, DOI 10.1073/pnas.72.2.733; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	35	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21754	21759						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408030				2022-12-25	WOS:A1993MC80900052
J	AGGELER, R; CAI, SX; KEANA, JFW; KOIKE, T; CAPALDI, RA				AGGELER, R; CAI, SX; KEANA, JFW; KOIKE, T; CAPALDI, RA			THE GAMMA-SUBUNIT OF THE ESCHERICHIA-COLI F(1)-ATPASE CAN BE CROSS-LINKED NEAR THE GLYCINE-RICH LOOP REGION OF A BETA-SUBUNIT WHEN ADP+MG(2+) OCCUPIES CATALYTIC SITES BUT NOT WHEN ATP+MG(2+) IS BOUND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; CHLOROPLAST COUPLING FACTOR; NUCLEOTIDE BINDING-SITES; ATP-SYNTHASE; CRYOELECTRON MICROSCOPY; TRYPSIN DIGESTION; MOLECULAR SWITCH; EPSILON-SUBUNIT; PROTEINS; F1-ATPASE	A mutant of the Escherichia coli F1-ATPase, gammaS8C, has been reacted with a novel bifunctional reagent, N-maleimido-N'-(4-azido-2,3,5,6-tetrafluorobenzamido) cystamine (TFPAM-SS1). Modification of Cys-8 via the maleimide, followed by photolysis to convert the azido group to a reactive nitrene, led to cross-linking of the gamma subunit to a beta subunit. When this cross-linking was conducted with ADP + Mg2+ in catalytic sites, the predominant cross-linked product had a M(r) of 108,000. If cross-linking was done with uncleaved ATP + Mg2+ in catalytic sites, cross-linked products of 102,000 and 84,000 were formed. Cross-linking under both conditions led to inhibition of ATPase activity. TFPAM-SS1 could be cleaved by using reducing agents to break the disulfide bond that links the maleimide and tetrafluorophenylazide moieties. Cleavage of this disulfide bond after formation of 102,000 and 84,000 species led to full recovery of ATPase activity. When the 108-kDa cross-linked product was cleaved, full activity was not restored, presumably because of insertion of the tetrafluorophenylazide into a functionally important site on the beta subunit. After cleavage of the disulfide bond, the free thiols could be reacted with [C-14]N-ethylmaleimide, thereby radioactively tagging the sites of insertion of the tetrafluorophenylnitrene moiety. In this way, the site of cross-linking from Cys-8 of gamma to the beta subunit in the presence of ADP + Mg2+ was localized to within the sequence Val 145-Lys-155, which contains the glycine-rich loop. This loop region is a part of the catalytic site of the enzyme.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	University of Oregon; University of Oregon					NHLBI NIH HHS [HL24236] Funding Source: Medline; NIGMS NIH HHS [GM27137] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027137] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BRAGG PD, 1987, BIOCHIM BIOPHYS ACTA, V894, P127, DOI 10.1016/0005-2728(87)90182-4; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CERIONE RA, 1982, BIOCHEMISTRY-US, V21, P745, DOI 10.1021/bi00533a026; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAVILANESRUIZ M, 1988, BIOCHEMISTRY-US, V27, P603, DOI 10.1021/bi00402a016; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; KEANA JFW, 1990, J ORG CHEM, V55, P3640, DOI 10.1021/jo00298a048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1979, BIOCHEM J, V180, P103, DOI 10.1042/bj1800103; SNYDER B, 1984, BIOCHEMISTRY-US, V23, P5787, DOI 10.1021/bi00319a018; TUTTASDORSCHUG R, 1989, BIOCHEMISTRY-US, V28, P5107, DOI 10.1021/bi00438a030; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WISE JG, 1981, J BIOL CHEM, V256, P383; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	34	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20831	20837						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407913				2022-12-25	WOS:A1993MA28800032
J	KIM, TK; ROEDER, RG				KIM, TK; ROEDER, RG			TRANSCRIPTIONAL ACTIVATION IN YEAST BY THE PROLINE-RICH ACTIVATION DOMAIN OF HUMAN CTF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; PREINITIATION COMPLEX; GAL4 DERIVATIVES; BINDING PROTEINS; GLUTAMINE-RICH; TFIID COMPLEX; INVITRO; DNA; COACTIVATORS	Among eukaryotic transcriptional activators, those with acidic activation domains have been shown to stimulate transcription in organisms ranging from yeast to human. In vivo and in vitro assays have been employed to demonstrate transcriptional enhancement in yeast by the proline-rich activation domain of human CTF1. This result suggests that proline-rich activation domains may, like typical acidic activation domains, functional universally.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HOEY T, 1993, CELL, V72, P2447; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KELLEHER RJ, 1990, CELL, V61, P2309; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MARTINEZ E, 1991, MOL CELL BIOL, V11, P1544; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Miller J.H., 1972, EXPT MOL GENETICS; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	43	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20866	20869						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407918				2022-12-25	WOS:A1993MA28800038
J	KOHNO, H; FURUKAWA, T; YOSHINAGA, T; TOKUNAGA, R; TAKETANI, S				KOHNO, H; FURUKAWA, T; YOSHINAGA, T; TOKUNAGA, R; TAKETANI, S			COPROPORPHYRINOGEN OXIDASE - PURIFICATION, MOLECULAR-CLONING, AND INDUCTION OF MESSENGER-RNA DURING ERYTHROID-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME PATHWAY ENZYMES; III OXIDASE; UROPORPHYRINOGEN DECARBOXYLASE; SACCHAROMYCES-CEREVISIAE; RHODOBACTER-SPHAEROIDES; ERYTHROLEUKEMIA-CELLS; FERROCHELATASE; SEQUENCE; GENE; ACTIVATION	Coproporphyrinogen oxidase (EC 1.3.3.3), the enzyme involved in the sixth step of heme biosynthesis, was purified to apparent homogeneity from bovine liver; it has a molecular mass of 37,000 daltons. Partial amino acid sequences were determined. Two degenerate oligonucleotides based on the sequences of trypsin-digested peptides were used in a polymerase chain reaction to amplify a 198-base pair fragment of coproporphyrinogen oxidase DNA, using bovine kidney cells cDNA as a starting template. This fragment was used as a hybridization probe to isolate full-length coproporphyrinogen oxidase clones from a mouse erythroleukemia (MEL) cell cDNA library. Sequence analysis revealed that coproporphyrinogen oxidase comprises 354 amino acid residues (M(r) 40,647), with a putative leader sequence of 31 amino acid residues, the result being a mature protein of 323 amino acid residues (M(r) 37,255). RNA blot analysis revealed a 3.0-kilobase coproporphyrinogen oxidase mRNA in mouse liver and in MEL cells. Treatment of MEL cells with dimethyl sulfoxide led to an increase in coproporphyrinogen oxidase mRNA within 10 h, the induction reached a maximum at 24 h, and was in parallel with the induction of ferrochelatase mRNA. The cDNA allows for the expression of active coproporphyrinogen oxidase, the activity of which is mainly present in mitochondria of transfected cultured cells, thereby indicating that mammalian coproporphyrinogen oxidase is mitochondrial enzyme.	KANSAI MED UNIV,DEPT HYG,MORIGUCHI,OSAKA 570,JAPAN; KYOTO UNIV,FAC MED,DEPT PUBL HLTH,KYOTO 606,JAPAN	Kansai Medical University; Kyoto University								ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; BATLLE AMD, 1965, BIOCHEM J, V97, P731, DOI 10.1042/bj0970731; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; CONDER LH, 1991, BIOCHEM J, V275, P321, DOI 10.1042/bj2750321; COOMBER SA, 1992, MOL MICROBIOL, V6, P3159, DOI 10.1111/j.1365-2958.1992.tb01772.x; DEVERNEUIL H, 1983, J BIOL CHEM, V258, P2454; ELDER GH, 1978, BIOCHEM J, V172, P345, DOI 10.1042/bj1720345; ELDER GH, 1978, BIOCHEM J, V169, P215, DOI 10.1042/bj1690215; FUJITA H, 1991, BIOCHIM BIOPHYS ACTA, V1090, P311, DOI 10.1016/0167-4781(91)90195-R; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; GRANDCHAMP B, 1985, J BIOL CHEM, V260, P9630; GRANDCHAMP B, 1978, BIOCHEM J, V176, P97, DOI 10.1042/bj1760097; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKAHASHI Y, 1990, BIOCHIM BIOPHYS ACTA, V1037, P321, DOI 10.1016/0167-4838(90)90032-B; POULSON R, 1974, J BIOL CHEM, V249, P6367; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO S, 1961, J BIOL CHEM, V236, P1173; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SASSA S, 1983, REGULATION HEMOGLOBI, P359; TAIT GH, 1969, BIOCHEM BIOPH RES CO, V37, P116, DOI 10.1016/0006-291X(69)90888-2; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; YOSHINAGA T, 1980, J BIOL CHEM, V255, P4722; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	29	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21359	21363						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407975				2022-12-25	WOS:A1993MA28800103
J	LANZA, F; MORALES, M; DELASALLE, C; CAZENAVE, JP; CLEMETSON, KJ; SHIMOMURA, T; PHILLIPS, DR				LANZA, F; MORALES, M; DELASALLE, C; CAZENAVE, JP; CLEMETSON, KJ; SHIMOMURA, T; PHILLIPS, DR			CLONING AND CHARACTERIZATION OF THE GENE ENCODING THE HUMAN PLATELET GLYCOPROTEIN-V - A MEMBER OF THE LEUCINE-RICH GLYCOPROTEIN FAMILY CLEAVED DURING THROMBIN-INDUCED PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE GLYCOPROTEIN; VONWILLEBRAND-FACTOR; GEL-ELECTROPHORESIS; IB-ALPHA; PROTEIN; IDENTIFICATION; RECEPTOR; IIB; IX	Glycoprotein V (GPV) is a major platelet membrane 82-kDa glycoprotein, missing in the Bernard-Soulier syndrome, that is cleaved when platelets are treated with thrombin. We report the cloning and sequencing of the GPV cDNA and gene obtained by a combination of polymerase chain reaction amplification of platelet mRNA and genomic library screening. The single-copy gene for GPV is contained within 6.5 kilobase pairs (kb) of genomic sequence and has a simple structure with a single intron of 958 base pairs in the 5'-untranslated sequence; the coding sequence is contained within a single exon. The promoter region contains a canonical TATA box, and putative GATA, Ets-1, and Sp1 cis-acting elements. Reverse transcription-polymerase chain reaction analysis on RNAs from cells of different hematopoietic origins revealed that GPV was specifically transcribed from platelets and from cells of the megakaryocytic lineage (megakaryocytes, HEL cells). A single transcript of 4.5 kb for GPV was detected in human platelets by Northern blot analysis. The entire amino acid sequence of GPV was deduced from the cDNA and genomic sequences. Mature GPV was composed of 544 amino acids which contained a single transmembrane domain, a short cytoplasmic domain (16 residues), and a large extracellular domain with 8 potential N-glycosylation sites. Analysis of the extracellular domain revealed the presence of 15 tandem Leu-rich repeats of 24 amino acids with homology to GPIbalpha and identified a cleavage site for thrombin near the COOH terminus with similarity to the Aalpha chain of fibrinogen, but no hirudin-like sequence was found.	UNIV BERN,THEODOR KOCHER INST,CH-3001 BERN,SWITZERLAND; COR THERAPEUT INC,S SAN FRANCISCO,CA 94080	University of Bern	LANZA, F (corresponding author), CTR REG TRANSFUS SANGUINE,INSERM,U311,10 RUE SPIELMANN,F-67085 STRASBOURG,FRANCE.		Cazenave, Jean-Pierre/AAE-2935-2019; Lanza, Francois/H-9252-2016	Lanza, Francois/0000-0002-5802-4748				BERNDT MC, 1981, J BIOL CHEM, V256, P59; BERNDT MC, 1983, BLOOD, V62, P800; BIENZ D, 1986, BLOOD, V68, P720; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; DU XP, 1987, BLOOD, V69, P1524; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8995; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; JANDROTPERRUS M, 1987, THROMB HAEMOSTASIS, V58, P915; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5614; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MOSHER DF, 1979, BLOOD, V53, P437; Muszbek L, 1984, THROMBIN, P83; NURDEN AT, 1981, J CLIN INVEST, V67, P1431, DOI 10.1172/JCI110172; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; ROTH GJ, 1991, BLOOD, V77, P5; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHIMOMURA T, 1990, BLOOD, V75, P2349; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; VICENTE V, 1990, J BIOL CHEM, V265, P274; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WICKI AN, 1989, THROMB HAEMOSTASIS, V61, P448; ZAFAR RS, 1989, THROMB RES, V53, P31, DOI 10.1016/0049-3848(89)90113-8	45	121	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20801	20807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407908				2022-12-25	WOS:A1993MA28800027
J	PAULS, TL; DURUSSEL, I; COX, JA; CLARK, ID; SZABO, AG; GAGNE, SM; SYKES, BD; BERCHTOLD, MW				PAULS, TL; DURUSSEL, I; COX, JA; CLARK, ID; SZABO, AG; GAGNE, SM; SYKES, BD; BERCHTOLD, MW			METAL-BINDING PROPERTIES OF RECOMBINANT RAT PARVALBUMIN WILD-TYPE AND F102W MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CALCIUM-BINDING; CONFORMATIONAL-CHANGES; ONCOMODULIN; CALMODULIN; MAGNESIUM; PROTEIN; EXPRESSION; FLUORESCENCE; IONS	Rat parvalbumin (PV), an EF-hand type Ca2+-binding protein, was expressed in Escherichia coli and mutated by replacing a Phe at position 102 with a unique Trp in order to introduce a distinct fluorescent label into the protein. Mass spectroscopy and NMR data indicate that the recombinant wild-type (PV(WT)) and F102W mutant (PV(F102W)) proteins have the expected molecular weight and retain the native structure. Both proteins contain two non-cooperative Ca2+/Mg2+-binding sites with intrinsic affinity constants, K(Ca) and K(Mg), of 2.4 +/- 0.9 x 10(7) M-1 and of 2.9 +/- 0.2 x 10(4) M-1, respectively, for PV(WT), and K(Ca) and K(Mg) of 2.7 +/- 1.1 x 10(7) M-1 and of 4.4 +/- 0.3 x 10(4) M-1, respectively, for PV(F102W). Based on the highly similar metal binding properties of PV(WT) and PV(F102W) the latter protein was used to study cation-dependent conformational changes. Trp fluorescence emission and UV difference spectra of PV(F102W) indicated that the Trp residue at position 102 is confined to a hydrophobic core and conformationally strongly restricted. Upon Ca2+ or Mg2+ binding the structural organization of the region around the Trp is hardly affected, but there are significant changes in its electrostatic environment. The conformational change upon binding of Ca2+ and Mg2+, as monitored by UV difference spectrophotometry, increases linearly from 0 to 2 cations bound, indicating that the binding of both ions contributes equally to the structural organization in this protein.	UNIV ZURICH,INST VET BIOCHEM,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND; UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND; NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Zurich; University of Geneva; National Research Council Canada; University of Alberta			Berchtold, Martin/L-1695-2014	Berchtold, Martin/0000-0001-8995-9047				BERCHTOLD MW, 1989, BIOCHIM BIOPHYS ACTA, V1009, P201, DOI 10.1016/0167-4781(89)90104-8; BLUM HE, 1977, J BIOL CHEM, V252, P2834; BRODIN P, 1986, BIOCHEMISTRY-US, V25, P5371, DOI 10.1021/bi00367a004; BURGER D, 1984, BIOCHEMISTRY-US, V23, P1966, DOI 10.1021/bi00304a013; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CORSON DC, 1986, BIOCHEMISTRY-US, V25, P1817, DOI 10.1021/bi00355a055; COX JA, 1990, J BIOL CHEM, V265, P6633; Cox JA, 1977, CALCIUM BINDING PROT, P266; Cox JA, 1990, STIMULUS RESPONSE CO, P83; GOODMAN M, 1977, J MOL EVOL, V9, P131, DOI 10.1007/BF01732745; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; HANER M, 1984, ANAL BIOCHEM, V138, P229, DOI 10.1016/0003-2697(84)90793-0; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HEIZMANN CW, 1984, EXPERIENTIA, V40, P910, DOI 10.1007/BF01946439; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; HUTNIK CML, 1990, J BIOL CHEM, V265, P11456; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LUANRILLIET Y, 1992, EUR J BIOCHEM, V208, P133, DOI 10.1111/j.1432-1033.1992.tb17166.x; MACMANUS JP, 1984, BIOCHEM J, V220, P261, DOI 10.1042/bj2200261; MACMANUS JP, 1989, J BIOL CHEM, V264, P3470; MEECH SR, 1983, J PHOTOCHEM, V23, P193, DOI 10.1016/0047-2670(83)80061-6; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MOESCHLER HJ, 1980, EUR J BIOCHEM, V111, P73; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MUTUS B, 1988, BIOCHEMISTRY-US, V27, P5615, DOI 10.1021/bi00415a033; MUTUS B, 1985, BIOCHEM BIOPH RES CO, V131, P500, DOI 10.1016/0006-291X(85)91830-3; PALMISANO WA, 1990, J BIOL CHEM, V265, P14450; PAULS TL, 1993, METHOD ENZYMOL, V217, P102; PECHERE JF, 1974, CR ACAD SCI D NAT, V278, P2577; PUTKEY JA, 1987, METHOD ENZYMOL, V139, P303; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SZABO AG, 1989, CHEM PHYS LETT, V163, P565, DOI 10.1016/0009-2614(89)85188-7; WILLIS KJ, 1992, BIOCHEMISTRY-US, V31, P8924, DOI 10.1021/bi00152a032; Wnuk W., 1982, CALCIUM CELL FUNCTIO, V2, P243	38	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20897	20903						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407923				2022-12-25	WOS:A1993MA28800043
J	SANTELL, L; RUBIN, RL; LEVIN, EG				SANTELL, L; RUBIN, RL; LEVIN, EG			ENHANCED PHOSPHORYLATION AND DEPHOSPHORYLATION OF A HISTONE-LIKE PROTEIN IN RESPONSE TO HYPEROSMOTIC AND HYPOOSMOTIC CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; HEAT-SHOCK PROTEIN; PLASMINOGEN-ACTIVATOR RELEASE; KINASE-C; VOLUME REGULATION; ADRENERGIC-RECEPTOR; AGONIST OCCUPANCY; STRESS PROTEINS; MESSENGER-RNA; HUMAN HSP27	Placement of endothelial cells under hypoosmotic or hyperosmotic conditions results in the reduction and increase, respectively, in the phosphorylation of a M(r) = 16,500 protein (P17). The changes were dose-dependent with a 3.3 +/- 0.3-fold increase occurring at 485 mosm/kg H2O and negligible phosphorylation observed at 202 mosm/kg H2O. The phosphorylation and dephosphorylation were rapid and prolonged; modified phosphorylation levels were maintained as long as the anisotonic conditions were present. However, return to isotonic medium reversed the phosphorylation back to normal within 1 h. Cellular fractionation studies showed that P17 was associated only with the nuclear compartment under isotonic, hypertonic, or hypotonic conditions. Two forms of P17 with pI values of 9.2 and 9.6 were resolved by isoelectric focusing; both forms showed enhanced phosphorylation by hyperosmotic treatment. Phosphorylation occurred on serines exclusively. These studies demonstrate that a nuclear protein with characteristics similar to histones is affected by cell shrinkage or swelling through changes in its phosphorylation state.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	SANTELL, L (corresponding author), SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; BURG MB, 1992, J AM SOC NEPHROL, V3, P121; BUXBAUM JD, 1989, J BIOL CHEM, V264, P9344; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN P, 1989, J BIOL CHEM, V264, P21435; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1; EXTON JH, 1985, J CLIN INVEST, V75, P1753, DOI 10.1172/JCI111886; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GECK P, 1992, ANN NY ACAD SCI, V652, P166; GUESDON F, 1991, J IMMUNOL, V147, P3402; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEVIN EG, 1989, J BIOL CHEM, V264, P16030; LEVIN EG, 1983, P NATL ACAD SCI-BIOL, V80, P6804, DOI 10.1073/pnas.80.22.6804; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVIN EG, 1991, J IMMUNOL, V146, P3772; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LUNDGREN DW, 1992, J BIOL CHEM, V267, P6841; MANDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; SANTELL L, 1992, BIOCHEM J, V284, P705, DOI 10.1042/bj2840705; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21443	21447						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407988				2022-12-25	WOS:A1993MA28800116
J	KINOSHITA, M; ROSS, AC				KINOSHITA, M; ROSS, AC			VITAMIN-A STATUS AND IMMUNOGLOBULIN-G SUBCLASSES IN RATS IMMUNIZED WITH TETANUS TOXOID	FASEB JOURNAL			English	Article						RETINOL; IMMUNODEFICIENCY; RAT; IGG ISOTYPES; B-LYMPHOCYTES; MEMORY CELLS	MEMORY T-CELLS; IFN-GAMMA; DEFICIENT MICE; LECTIN BINDING; B-CELLS; DIFFERENTIATION; CHILDREN; GLYCOSYLATION; GLYCOPROTEIN; RETINOIDS	Vitamin A deficiency severely compromises the magnitude of the primary and secondary antibody response to tetanus toxoid (TT) but does not impair the development of immunologic memory. To further characterize this immunodeficiency in antibody production, we have quantified the immunoglobulin G (IgG) subclasses (IgG1, IgG2a, IgG2b, and IgG2c) during the primary and secondary response to TT in normal, vitamin A-deficient, and retinol-repleted rats. In the primary response in normal rats, anti-TT IgG1 and IgG2b predominated. In vitamin A-deficient rats the production of anti-TT IgG2b was severely impaired, with little change in either IgG1 or IgG2a. In the secondary response vitamin A-deficient rats produced low levels of all anti-TT IgG subclasses. However, when vitamin A-deficient rats were repleted with retinol 2 days before reimmunization their secondary anti-TT IgG response was normal both in magnitude and IgG subclass distribution. This result implies that although vitamin A deficiency during the primary antibody response impaired anti-TT IgG2b production, it did not inhibit Ig heavy chain recombination or the differentiation of lymphocytes that formed memory B cells for each subclass; furthermore, these cells were activated in the secondary response after vitamin A status was improved. Thus, these experiments further support the concept that memory cell formation remains normal during vitamin A deficiency despite low levels of antibody production.	MED COLL PENN,DEPT BIOCHEM,DIV EDUC,2900 QUEEN LANE,PHILADELPHIA,PA 19129	Drexel University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041479] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK041479, R01 DK-41479] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSIE A, 1991, CELL IMMUNOL, V135, P95, DOI 10.1016/0008-8749(91)90257-C; BOWMAN TA, 1990, J NUTR, V120, P1264, DOI 10.1093/jn/120.10.1264; BROWN KH, 1980, AM J CLIN NUTR, V33, P212, DOI 10.1093/ajcn/33.2.212; BRUGGEMANN M, 1988, EUR J IMMUNOL, V18, P317, DOI 10.1002/eji.1830180222; BRUGGEMANN M, 1988, GENE, V74, P473, DOI 10.1016/0378-1119(88)90180-1; CAI DC, 1991, EXP CELL RES, V192, P366, DOI 10.1016/0014-4827(91)90053-W; CARMAN JA, 1991, J IMMUNOL, V147, P1247; CARMAN JA, 1989, J IMMUNOL, V142, P388; CLEMENT LT, 1992, J CLIN IMMUNOL, V12, P1, DOI 10.1007/BF00918266; DE LUCA LM, 1991, FASEB J, V5, P2924; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; HENDERSON RH, 1988, B WORLD HEALTH ORGAN, V66, P535; KINOSHITA M, 1993, J IMMUNOASSAY, V14, P149, DOI 10.1080/15321819308019846; KINOSHITA M, 1991, FASEB J, V5, P2473, DOI 10.1096/fasebj.5.10.2065894; KIRVEN MJ, 1991, MOL CELL BIOCHEM, V101, P101; LOTAN R, 1987, CANCER BIOCHEM BIOPH, V9, P211; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MERKENSCHLAGER M, 1989, NATURE, V341, P392, DOI 10.1038/341392b0; MILER I, 1983, IMMUNITY HUMAN FOETU; MINCHIN SA, 1990, J IMMUNOL, V145, P2427; Nauss KM, 1986, VITAMIN A DEFICIENCY, P207; REYNOLDS CW, 1981, J IMMUNOL, V126, P1581; Ross A. Catharine, 1994, P521; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SMITH SM, 1987, P NATL ACAD SCI USA, V84, P5878, DOI 10.1073/pnas.84.16.5878; STEINMETZ JE, 1981, BEHAV RES METH INSTR, V13, P702, DOI 10.3758/BF03202100; 1989, OPPORTUNITIES BIOL, P224	29	9	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1993	7	13					1277	1282		10.1096/fasebj.7.13.8405813	http://dx.doi.org/10.1096/fasebj.7.13.8405813			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MB376	8405813				2022-12-25	WOS:A1993MB37600012
J	GERSHON, PD; MOSS, B				GERSHON, PD; MOSS, B			STIMULATION OF POLY(A) TAIL ELONGATION BY THE VP39 SUBUNIT OF THE VACCINIA VIRUS-ENCODED POLY(A) POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; EARLY GENES; TRANSCRIPTION; POLYADENYLATION; SPECIFICITY; TERMINATION; DOWNSTREAM; SEQUENCE; VIRIONS; PROTEIN	The VP55 subunit of the vaccinia virus-encoded poly(A) polymerase can add a maximum of 35 adenylates to the 3'-end of an RNA primer in a rapid and highly processive manner, whereas the VP55-VP39 heterodimer catalyzes the formation of poly(A) tails several hundred nucleotides in length. Here, we describe the overexpression of the VP39 subunit, its purification to near homogeneity, and its ability to associate physically with VP55 and to stimulate polyadenylation. Although VP39 possessed no independent poly(A) polymerase activity, RNA primers with oligo(A) tails greater than 30 adenylates in length could be extended nearly 40-fold more rapidly in the presence of VP39. VP39 enhanced the polyadenylation rate by converting the slow, nonprocessive polyadenylation occurring after the rapid burst in the presence of monomeric VP55, to a rapid, semiprocessive reaction. The effect of VP39 was dramatic when poly(A) primers were used as, 60 mm NaCl, VP39 enhanced the polyadenylation rate 500-fold, and at 90 mm NaCl VP39 was absolutely required. Nevertheless, the VP39-containing polymerase remained selective for polyadenylation of an mRNA 3'-end in the presence of excess poly(A). These data suggest that the role of VP39 in polyadenylation is to increase the affinity of the polymerase for the growing poly(A) tail.	NIAID,VIRAL DIS LAB,BLDG 4,RM 229,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				BOYLE A, 1987, CURRENT PROTOCOLS MO; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; CHELEY S, 1991, BIOTECHNIQUES, V10, P730; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1975, J BIOL CHEM, V250, P4722; Moss B, 1991, CURRENT PROTOCOLS MO; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	22	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2203	2210						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420988				2022-12-25	WOS:A1993KH62000105
J	DOWD, TL; GUPTA, RK				DOWD, TL; GUPTA, RK			NMR-STUDIES OF THE EFFECT OF HYPERGLYCEMIA ON INTRACELLULAR CATIONS IN RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SPONTANEOUSLY HYPERTENSIVE RAT; CYTOSOLIC FREE CALCIUM; MAGNETIC-RESONANCE; PROXIMAL TUBULES; GLUCOSE; SODIUM; ION; CELLS; SPECTROSCOPY	Alterations in intracellular cation concentrations in the kidney during hyperglycemia may play a role in a number of complications associated with diabetes mellitus such as renal hypertrophy and hypertension. In this study, we have investigated the effect of 25 mM glucose on intracellular pH and free Mg2+, free Ca2+, and Na+ concentrations in the perfused kidneys of Sprague-Dawley rats using P-31, F-19, and Na-23 triple-quantum filtered NMR. No significant alteration occurred in the intracellular free Mg2+ concentration, pH, or ATP concentration during hyperglycemia. However, a sizable (approximately 50%) increase in the intracellular Na+ concentration was inferred from Na-23 triple-quatum filtered NMR after 30-45 min of perfusion with 25 mM glucose. Intracellular free Ca2+, measured to be 390 +/- 15 nM at 5 mM glucose, increased significantly (95%; p < 0.001) to a value of 765 +/- 28 nm after 30 min of perfusion with 25 mM glucose. This effect of glucose was reversible. Only small increases (less-than-or-equal-to 20%) in free Ca2+ were found with addition of comparable concentrations of a nontransportable sugar (20 mM mannitol), indicating that glucose entry into the cell (through the Na+/glucose cotransporter) plays a role in causing the free Ca2+ increase. No effect on free Ca2+ was, however, seen with 1 mM ouabain, which caused a sizable increase in intracellular Na+, indicating that Na+/Ca2+ exchange does not play a significant role in the maintenance of low intracellular free Ca2+ in the kidney and that the observed increase in free Ca2+ is probably due to a decrease in the Ca2+/Mg2+-ATPase activity during hyperglycemia. Increased concentrations of Na+ and free Ca2+ during hyperglycemia may be involved in the mechanism of renal hypertrophy and hypertension, frequently associated with diabetes mellitus.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	DOWD, TL (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032030] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIDDK NIH HHS [DK32030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLIS JL, 1991, J MAGN RESON, V93, P71, DOI 10.1016/0022-2364(91)90032-O; AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; BADARGOFFER RS, 1990, J NEUROCHEM, V55, P878, DOI 10.1111/j.1471-4159.1990.tb04573.x; BERRIDGE MJ, 1986, CANCER SURV, V5, P413; BODENHAUSEN G, 1977, J MAGN RESON, V27, P511, DOI 10.1016/0022-2364(77)90016-6; BRAUNSCHWEILER L, 1983, MOL PHYS, V48, P535, DOI 10.1080/00268978300100381; DAVIS FB, 1985, DIABETES, V34, P639, DOI 10.2337/diabetes.34.7.639; DOWD T, 1989, RENAL PHYSIOL BIOCH, V12, P161; DOWD TL, 1992, J BIOL CHEM, V267, P3637; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ENDRE ZH, 1989, MAGNET RESON MED, V11, P267, DOI 10.1002/mrm.1910110215; FINE LG, 1985, P NATL ACAD SCI USA, V82, P1736, DOI 10.1073/pnas.82.6.1736; GUPTA RK, 1980, P NATL ACAD SCI-BIOL, V77, P2487, DOI 10.1073/pnas.77.5.2487; HISE MK, 1988, ENDOCRINOLOGY, V123, P1553, DOI 10.1210/endo-123-3-1553; JELICKS LA, 1990, J BIOL CHEM, V265, P1394; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; KUMAR AM, 1988, KIDNEY INT, V33, P792, DOI 10.1038/ki.1988.69; LEE CO, 1980, NATURE, V287, P859, DOI 10.1038/287859a0; LEVY J, 1989, AM J MED S6A, V87, pA7; LIEBLING MS, 1987, ANN NY ACAD SCI, V508, P149, DOI 10.1111/j.1749-6632.1987.tb32901.x; LLIBRE J, 1988, HYPERTENSION, V12, P399, DOI 10.1161/01.HYP.12.4.399; MORGENSEN CE, 1973, DIABETES, V22, P706; MORRILL GA, 1985, BIOCHIM BIOPHYS ACTA, V844, P377, DOI 10.1016/0167-4889(85)90140-5; NISHIITS.JM, 1967, BIOCHEM J, V103, P852, DOI 10.1042/bj1030852; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; REAVEN GM, 1991, AM J HYPERTENS, V4, P610, DOI 10.1093/ajh/4.7.610; ROSS BD, 1973, AM J PHYSIOL, V225, P1165, DOI 10.1152/ajplegacy.1973.225.5.1165; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SEYERHANSEN K, 1977, DIABETOLOGIA, V13, P141, DOI 10.1007/BF00745142; SHINE N, 1987, ANN NY ACAD SCI, V508, P99, DOI 10.1111/j.1749-6632.1987.tb32898.x; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; TUTTLE KR, 1991, SEMIN NEPHROL, V11, P220; WEINMAN EJ, 1975, KIDNEY INT, V8, P493	35	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					991	996						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419377				2022-12-25	WOS:A1993KG07700037
J	ENGELBORGHS, Y; DUMORTIER, C; DHOORE, A; VANDECANDELAERE, A; FITZGERALD, TJ				ENGELBORGHS, Y; DUMORTIER, C; DHOORE, A; VANDECANDELAERE, A; FITZGERALD, TJ			EVIDENCE FOR AN ALTERNATIVE PATHWAY FOR COLCHICINE BINDING TO TUBULIN, BASED ON THE BINDING-KINETICS OF THE CONSTITUENT RINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE STOPPED FLOW; ANALOG 2-METHOXY-5-(2'; PODOPHYLLOTOXIN; DISSOCIATION; MECHANISM; COMPLEX; TROPONE; BRAIN	The kinetics of tropolone methyl ether binding to tubulin were measured by following the loss of colchicine binding capacity upon preincubation of tubulin with tropolone methyl ether. At 25-degrees-C a bimolecular association rate constant of 2.7 (+/-0.2) m-1 min-1 was determined, and from the temperature dependence an activation energy of 37 (+/- 8) kJ.mol-1 was calculated. By displacement experiments a dissociation rate constant of 2.9 (+/- 0.6) x 10(-2) min-1 was determined at 25-degrees-C. The effect of 3',4',5'-trimethoxyacetophenone (TMA) is 2-fold. TMA reduces the apparent association rate constant of colchicine, indicating that it equilibrates very rapidly and reversibly with the colchicine binding site. From this reduction the binding constant for TMA can be obtained. At 25-degrees-C a value of 112 (+/- 13) M-1 is estimated. The binding of TMA is practically thermoneutral. Preincubation of tubulin with TMA over 30 min not only reduces the subsequent binding rate constant of colchicine but also the amplitude. This indicates that TMA also binds slowly in a second mode or site. Stopped-flow kinetic studies reveal that fast TMA binding competes for the initial binding of colchicine. From these results it is concluded that colchicine binds initially with its trimethoxybenzene ring and in a subsequent step with the tropolone ring.	FLORIDA A&M UNIV,COLL PHARM,TALLAHASSEE,FL 32307	State University System of Florida; Florida A&M University	ENGELBORGHS, Y (corresponding author), KATHOLIEKE UNIV LEUVEN,CHEM & BIOL DYNAM LAB,CELESTIJNENLAAN 200D,B-3001 LOUVAIN,BELGIUM.							ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P6465, DOI 10.1021/bi00268a023; ANDREU JM, 1991, BIOCHEMISTRY-US, V30, P3777, DOI 10.1021/bi00229a027; ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; BANE S, 1984, J BIOL CHEM, V259, P7391; BANERJEE A, 1987, FEBS LETT, V219, P103, DOI 10.1016/0014-5793(87)81199-7; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIAZ JF, 1991, J BIOL CHEM, V266, P2890; ENGELBORGHS Y, 1987, J BIOL CHEM, V262, P5204; ENGELBORGHS Y, 1986, ANN NY ACAD SCI, V466, P709, DOI 10.1111/j.1749-6632.1986.tb38453.x; ENGELBORGHS Y, 1977, FEBS LETT, V80, P81, DOI 10.1016/0014-5793(77)80411-0; FITZGERALD TJ, 1976, BIOCHEM PHARMACOL, V25, P1383; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; HARRISSON CMH, 1976, NATURE, V260, P470; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; LAMBEIR A, 1981, J BIOL CHEM, V256, P3279; MACGREGOR RB, 1987, BIOCHEMISTRY-US, V26, P4008, DOI 10.1021/bi00387a040; MEDRANO FJ, 1989, BIOCHEMISTRY-US, V28, P5598; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SILENCE K, 1992, BIOCHEMISTRY-US, V31, P11133, DOI 10.1021/bi00160a025; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	24	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					107	112						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416918				2022-12-25	WOS:A1993KE60300018
J	KING, IN; DESOYZA, T; CATANZARO, DF; LAVIN, TN				KING, IN; DESOYZA, T; CATANZARO, DF; LAVIN, TN			THYROID-HORMONE RECEPTOR-INDUCED BENDING OF SPECIFIC DNA-SEQUENCES IS MODIFIED BY AN ACCESSORY FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; RAT-LIVER; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; ESCHERICHIA-COLI; GENE-REGULATION; RETINOIC ACID; MALIC ENZYME; BINDING; PROTEIN	Transcriptional regulation by thyroid and steroid hormone receptors requires their recognition and binding of specific DNA sequences. However, little is known about the mechanisms whereby DNA bound receptors regulate transcription. In the present study, we examined the effects of thyroid hormone receptor (TR) binding on DNA conformation using various TR recognition sites contained within sets of circularly permuted flanking sequences. We show that under conditions where TR binds predominantly as monomer, the conformation of a number of binding sites is changed in a manner consistent with receptor induced bending. Despite similar affinities for receptor binding, not all binding sites tested showed evidence for receptor-induced bending. Notably, the conformation of a sequence from the frog vitellogenin 2 gene, which confers a positive transcriptional response when bound by estrogen receptor (ER), but a negative response when bound by TR, appeared to be unaffected by binding of either TR or ER. The observations suggest that the ability of the receptor to alter DNA architecture is strongly dependent on sequence characteristics other than those required for receptor binding. While both partly purified TR from rat liver and TR translated in vitro were able to induce DNA bending, the bend centers and bend angles produced by these different sources of receptor differed. However, addition of a receptor-depleted fraction from the rat liver TR preparation to in vitro translated receptor stimulated TR binding and appeared to form heterodimers with TR. This resulted in changes in both bend centers and bend angles to resemble more closely those produced by native receptor. Together, these results suggest that receptor-induced DNA bending may be specific to TRs and that the position and degree of bending is further modulated by the formation of heterodimers between TRs and accessory protein(s).	CORNELL UNIV,MED CTR,COLL MED,CTR CARDIOVASC,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,CTR CARDIOVASC,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10021	Cornell University; Cornell University					NIDDK NIH HHS [DK39998] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039998] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LAVIN TN, 1981, MOL PHARMACOL, V20, P28; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEE DH, 1989, P NATL ACAD SCI USA, V86, P476, DOI 10.1073/pnas.86.2.476; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MAGNUSON MA, 1983, J BIOL CHEM, V258, P2712; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PEREZMARTIN J, 1989, J BIOL CHEM, V264, P21334; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROBERTSON M, 1987, NATURE, V327, P464, DOI 10.1038/327464a0; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SHEY DJ, 1986, NATURE, V323, P459; SILVA ES, 1977, J BIOL CHEM, V252, P6799; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	44	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					495	501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416953				2022-12-25	WOS:A1993KE60300075
J	WU, JH; ROSEN, BP				WU, JH; ROSEN, BP			METALLOREGULATED EXPRESSION OF THE ARS OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ARSENICAL RESISTANCE OPERON; ESCHERICHIA-COLI; ANION PUMP; PROTEIN; DNA; REPRESSOR; BINDING; PROMOTER; CONTACTS	The plasmid-borne arsenical resistance (ars) operon encodes an arsenical-translocating ATPase and confers resistance to antimonials and arsenicals in Escherichia coli by extrusion of the toxic compounds from the cytosol. The trans-acting regulatory ArsR protein was shown to bind to a fragment of DNA containing the ars promoter. Hybrid formation of the ArsR protein with a ArsR-beta-lactamase chimeric protein suggested that the active form of the ArsR repressor is a dimer. From footprinting analysis the binding site was defined as a region of imperfect dyad symmetry just upstream of the -35 site. In vivo the operon was derepressed by oxyions of +III oxidation state of arsenic, antimony, and bismuth, as well as arsenate (As(V)), whereas in vitro ArsR protein-operator interaction was reduced by each of those compounds except arsenate, as determined by gel retardation and DNase I and hydroxyl radical footprinting experiments. This indicates that arsenate is not a true inducer and must be reduced to arsenite in vivo to induce. An operator mutant obtained by deletion of the in vitro ArsR-protected DNA sequence exhibited constitutive ars promoter activity, demonstrating that the binding site is the functional target for the ArsR repressor in vivo.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,540 E CANFIELD AVE,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GICQUELSANZEY B, 1982, EMBO J, V1, P591, DOI 10.1002/j.1460-2075.1982.tb01213.x; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HSU CM, 1989, J BIOL CHEM, V264, P17349; JI G, 1992, IN PRESS P NATL ACAD; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KIM SH, 1992, SCIENCE, V255, P1217, DOI 10.1126/science.1546321; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Miller J.H., 1972, EXPT MOL GENETICS; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; REIDL J, 1989, J BACTERIOL, V171, P4888, DOI 10.1128/jb.171.9.4888-4899.1989; Sambrook J, 1989, MOL CLONING LABORATO; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; SMITH JD, 1973, COMPREHENSIVE INORGA, V2, P547; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TISA LS, 1990, J BIOL CHEM, V265, P190; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WU J, 1991, MOL MICROBIOL, V5, P1331, DOI 10.1111/j.1365-2958.1991.tb00779.x	29	151	156	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					52	58						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416957				2022-12-25	WOS:A1993KE60300010
J	CHEN, AJ; ZHANG, DL; POULTER, CD				CHEN, AJ; ZHANG, DL; POULTER, CD			(S)-GERANYLGERANYLGLYCERYL PHOSPHATE SYNTHASE - PURIFICATION AND CHARACTERIZATION OF THE 1ST PATHWAY-SPECIFIC ENZYME IN ARCHAEBACTERIAL MEMBRANE LIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1'-4 COUPLING REACTION; QUANTITATION; SYNTHETASE; GENE	The first pathway-specific step in the biosynthesis of the core membrane diether lipids in archaebacteria is the alkylation of the primary hydroxyl group in (S)-glyceryl phosphate by geranylgeranyl diphosphate. The reaction is catalyzed by (S)-3-O-geranylgeranylglyceryl phosphate ((S)-GGGP) synthase. The cytosolic enzyme was purified to homogeneity from the moderately thermophilic archaebacterium Methanobacterium thermoautotrophicum by a combination of ammonium sulfate precipitation, four chromatographic steps (DE52, Q-Sepharose, phenyl-Superose, and Protein Pak), and native polyacrylamide gel electrophoresis. SDS-polyacrylamide gel electrophoresis of gel-purified GGGP synthase gave a single band at 29 kDa. The enzyme requires Mg2+ for optimal activity, although prenyltransfer is also seen in buffers containing Mn2+ or Zn2+. A well defined pH optimum occurs between 6.0 and 7.5. Maximal activity is seen at 50-65-degrees-C. The Michaelis constants for GGGP synthase are V(max) = 4.1 +/- 0.5 mumol min-1 mg-1, K(M)GGPP = 4.1 +/- 1.1 muM, and K(M)GP = 41 +/- 5 muM.	UNIV UTAH, DEPT CHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021328, R01GM021328] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21328] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMICO V, 1977, EXPERIENTIA, V33, P989, DOI 10.1007/BF01945922; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; BEVERIDGE TJ, 1993, J BACTERIOL, V175, P1191, DOI 10.1128/JB.175.4.1191-1197.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN AJ, 1993, J BIOL CHEM, V268, P11002; DEROSA M, 1982, PHYTOCHEMISTRY, V21, P595, DOI 10.1016/0031-9422(82)83147-6; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; DEROSA M, 1976, PHYTOCHEMISTRY, V15, P1995, DOI 10.1016/S0031-9422(00)88872-X; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GEBLER JC, 1992, ARCH BIOCHEM BIOPHYS, V296, P308, DOI 10.1016/0003-9861(92)90577-J; HEATHCOCK CH, 1985, SCIENCE, V229, P862, DOI 10.1126/science.3927485; KAKINUMA K, 1990, J AM CHEM SOC, V112, P2740, DOI 10.1021/ja00163a041; LAM WL, 1992, J BIOL CHEM, V267, P5829; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; MAYER MP, 1993, IN PRESS GENE AMST; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1978, ACCOUNTS CHEM RES, V11, P307, DOI 10.1021/ar50128a004; SAGAMI H, 1984, BIOCHEM INT, V8, P661; TORNABENE TG, 1979, J MOL EVOL, V13, P73, DOI 10.1007/BF01732755; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1981, SCI AM, V244, P98, DOI 10.1038/scientificamerican0681-98; ZHANG DL, 1993, J ORG CHEM, V58, P3919, DOI 10.1021/jo00067a025; ZHANG DL, 1993, J AM CHEM SOC, V115, P1270, DOI 10.1021/ja00057a008; ZHANG DL, 1993, ARCH BIOCHEM BIOPHYS, V304, P133, DOI 10.1006/abbi.1993.1331	28	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21701	21705						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408023				2022-12-25	WOS:A1993MC80900043
J	KAJI, EH; LODISH, HF				KAJI, EH; LODISH, HF			UNFOLDING OF NEWLY MADE RETINOL-BINDING PROTEIN BY DITHIOTHREITOL - SENSITIVITY TO RETINOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; ROUGH ENDOPLASMIC-RETICULUM; DISULFIDE BOND FORMATION; SECRETION; GOLGI; TRANSPORT; CELLS; BIOSYNTHESIS; ISOMERASE; PATHWAY	In cultured hepatoma HepG2 cells, serum retinol-binding protein (RBP) is secreted more rapidly in the presence of retinol than in its absence (Tosetti, F., Ferrari, N., Pfeffer, U., Brigati, C., and Vidali, G. (1992) Exp. Cell Res. 200, 467-472). In the presence of millimolar concentration of DTT, HepG2 cells synthesize fully reduced RBP within the endoplasmic reticulum (ER) which, upon removal of DTT, forms disulfide bonds post-translationally. Secretion of this post-translationally folded RBP is also dependent on the presence of retinol. Using nonreducing gel electrophoresis, we resolved disulfide-bonded RBP folding intermediates. In addition, two other intracellular folding intermediates, compact I and II, which co-migrate with mature RBP were resolved by their different sensitivity to DTT-induced unfolding. Retinol, as well as retinoic acid, stabilized both compact I and II RBP intermediates to DTT-induced unfolding, suggesting that RBP assumes different conformations in the ER in the presence and absence of a ligand. However, only RBP synthesized in the presence of retinol is rapidly secreted, indicating that the ER export quality control system recognizes RBP containing retinol, but not retinoic acid, as fully folded and competent for export. Folding of RBP so that it is stabilized to DTT reduction is not a sufficient condition for ER exit.	WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1989, PROTEINS STRUCTURES; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P8870; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MELHUS H, 1992, J BIOL CHEM, V267, P12036; MORGAN EH, 1985, J BIOL CHEM, V260, P4793; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PETERS T, 1982, J BIOL CHEM, V257, P8847; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOSETTI F, 1992, EXP CELL RES, V200, P467, DOI 10.1016/0014-4827(92)90197-G; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	32	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22188	22194						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408080				2022-12-25	WOS:A1993MC80900111
J	ROSEJOHN, S; SCHOOLTINK, H; SCHMITZVANDELEUR, H; MULLBERG, J; HEINRICH, PC; GRAEVE, L				ROSEJOHN, S; SCHOOLTINK, H; SCHMITZVANDELEUR, H; MULLBERG, J; HEINRICH, PC; GRAEVE, L			INTRACELLULAR RETENTION OF INTERLEUKIN-6 ABROGATES SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-II; LEUKEMIA-INHIBITORY FACTOR; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; HUMAN-MONOCYTES; UP-REGULATION; HEPG2 CELLS; RECEPTOR; PROTEIN; GP130	Three forms of interleukin-6 (IL-6) have been constructed and stably transfected into human hepatoma cells (HepG2). Wild type IL-6 containing a signal peptide was rapidly secreted as a biologically active protein. IL-6 lacking the signal peptide accumulated within the cytoplasm of transfected cells. Surprisingly, IL-6 carrying a COOH-terminal extension of the amino acids Lys-Asp-Glu-Leu (KDEL) was not completely retained in the endoplasmic reticulum (ER). Complete retention in the ER was achieved when the 14 COOH-terminal amino acids of protein disulfide isomerase which include the KDEL signal were added to the COOH terminus of IL-6. This finding clearly demonstrates that the addition of the protein sorting signal KDEL alone is not sufficient for full retention of IL-6 in the ER. IL-6 accumulated in the cytoplasm and IL-6 retained in the ER failed to induce liver-specific acute-phase protein synthesis in the host cells, indicating that there is no intracellular role for IL-6 in signal transduction. Retention of IL-6 in the ER led to the prevention of surface expression of the IL-6 receptor protein gp80, making these cells unresponsive to IL-6. This phenomenon can be exploited in the future to generate transgenic animals which will become completely cytokine unresponsive in the tissues in which they express an ER retained cytokine.			ROSEJOHN, S (corresponding author), RHEIN WESTFAL TH AACHEN, DEPT BIOCHEM, PAUWELSSTR 30, W-5100 AACHEN, GERMANY.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ANDRES DA, 1990, J BIOL CHEM, V265, P5952; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HEINRICH PC, 1991, MOL ASPECTS INFLAMMA, P129; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLY RB, 1990, NATURE, V345, P480, DOI 10.1038/345480a0; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BA, 1992, J CELL BIOL, V118, P1057, DOI 10.1083/jcb.118.5.1057; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; ROSEJOHN S, 1987, BIOCHEM BIOPH RES CO, V147, P219, DOI 10.1016/S0006-291X(87)80109-2; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE J, 1991, J CELL SCI, V100, P415; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHIEL X, 1990, EUR J IMMUNOL, V20, P883, DOI 10.1002/eji.1830200425; SCHOOLTINK H, 1992, FEBS LETT, V297, P263, DOI 10.1016/0014-5793(92)80552-R; SCHOOLTINK H, 1991, BIOCHEM J, V277, P659, DOI 10.1042/bj2770659; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGAYA Y, 1988, J IMMUNOL, V140, P2614; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG FM, 1983, P NATL ACAD SCI-BIOL, V80, P5875, DOI 10.1073/pnas.80.19.5875; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	64	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22084	22091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408066				2022-12-25	WOS:A1993MC80900096
J	AHUJA, SK; MURPHY, PM				AHUJA, SK; MURPHY, PM			MOLECULAR PIRACY OF MAMMALIAN INTERLEUKIN-8 RECEPTOR TYPE-B BY HERPESVIRUS SAIMIRI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FORMYL PEPTIDE RECEPTOR; XENOPUS OOCYTES REQUIRES; OPEN READING FRAME; FUNCTIONAL EXPRESSION; PROTEIN; VIRUS; ENCODES; TRANSFORMATION; ANGIOGENESIS; INFECTION	Viruses are known to acquire and modify the genes of their hosts to attain a survival advantage in the host environment. Herpesvirus saimiri (HVS) is a T-lymphotropic virus that causes fatal lymphoproliferative diseases in several non-human primates. The gene ECRF3 of HVS was most likely acquired from a primate host. ECRF3 encodes a putative seven-transmembrane-domain receptor that is remotely related (approximately 30% amino acid identity) to the known mammalian alpha and beta chemokine receptors, namely interleukin-8 receptor (IL8R) types A and B and the MIP-1alpha/RANTES receptor, respectively. Chemokines regulate the trafficking, activation, and, in some cases, proliferation of myeloid and lymphoid cell types. We now show that ECRF3 encodes a functional receptor for the alpha chemokines IL-8, GRO/melanoma growth stimulatory activity (MGSA), and NAP-2 but not for beta chemokines, a specificity identical to that of IL8RB. Paradoxically, IL8RA shares 77% amino acid identity with IL8RB but is not a receptor for GRO/MGSA or NAP-2. This is the first functional characterization of a viral seven-transmembrane-domain receptor. It suggests a novel role for alpha chemokines in the pathogenesis of HVS infection by transmembrane signaling via the product of ECRF3.	NIAID,HOST DEFENSES LAB,BLDG 10,RM 11N113,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P389; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; KROLL B, 1991, FEBS LETT, V291, P208, DOI 10.1016/0014-5793(91)81285-G; KUNA P, 1993, J IMMUNOL, V150, P1932; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MURPHY PM, 1991, J BIOL CHEM, V266, P12560; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; MURPHY PM, 1990, J IMMUNOL, V145, P2227; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SZOMOLANYI E, 1987, J VIROL, V61, P3485, DOI 10.1128/JVI.61.11.3485-3490.1987; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	42	210	216	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20691	20694						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407886				2022-12-25	WOS:A1993MA28800003
J	CHEN, XL; SPARKS, JD; YAO, Z; FISHER, EA				CHEN, XL; SPARKS, JD; YAO, Z; FISHER, EA			HEPATIC POLYSOMES THAT CONTAIN APOPROTEIN-B MESSENGER-RNA HAVE UNUSUAL PHYSICAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; APOLIPOPROTEIN-B; GENE-EXPRESSION; STOP CODON; THYROID-HORMONE; DIABETIC RATS; EDITING SITE; LIVER; LIPOPROTEINS; TISSUE	To characterize the association of the mRNA for apoprotein B (apoB) with ribosomes, rat hepatic cytoplasmic extracts were fractionated by density gradient centrifugation. On linear sucrose gradients, the sedimentation velocity of the 14.4-kilobase apoB mRNA was retarded compared to the mRNAs for other hepatic proteins, which were concentrated in fractions containing the bulk of the polysomes. This unusual distribution of apoB mRNA could not be explained by co-translational association of nascent apoB peptides with lipids, based on experiments using either detergents to delipidate proteins or puromycin to release nascent peptides from polysomes. The results were also not the result of the editing of apoB mRNA, since the sucrose gradient distributions of both edited and nonedited forms were similar. In contrast, the distribution of a 3'-truncated apoB mRNA (apoB-42, 5.8 kilobases) expressed in rat hepatoma cells resembled that of mRNA of a typical hepatic protein. As opposed to the sedimentation velocity results, on equilibrium density gradients most hepatic apoB mRNA was found in the fraction that contained polysomes. Based on these data, the elongation rate of nascent apoB, and the calculated translational yield of apoB mRNA, we conclude that the majority of rat hepatic apoB mRNA must be part of polysomal complexes with unusual physical properties related to the presence of sequence(s) in the 3'-region of the message. These sequences may either be primary determinants of structural features or binding sites for protein factors that effect conformational changes.	MED COLL PENN,DEPT BIOCHEM,2900 QUEEN LANE,PHILADELPHIA,PA 19129; UNIV ROCHESTER,SCH MED & DENT,DEPT PATHOL & LAB MED,ROCHESTER,NY 14642; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	Drexel University; University of Rochester; University of Alberta				Sparks, Janet/0000-0002-0072-766X; Fisher, Edward/0000-0001-9802-143X	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005418] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RR05418] Funding Source: Medline; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BACKUS JW, 1990, BIOCHEM BIOPH RES CO, V170, P513, DOI 10.1016/0006-291X(90)92121-F; BALIGA BS, 1968, J MOL BIOL, V34, P199, DOI 10.1016/0022-2836(68)90247-7; BALLINGER DG, 1983, CELL, V33, P103, DOI 10.1016/0092-8674(83)90339-2; BENNETT VD, 1987, J BIOL CHEM, V262, P14806; BIRNIE GD, 1973, BIOCHIM BIOPHYS ACTA, V331, P283, DOI 10.1016/0005-2787(73)90441-3; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BLOBEL G, 1967, J MOL BIOL, V26, P293, DOI 10.1016/0022-2836(67)90298-7; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRACEY LT, 1987, P NATL ACAD SCI USA, V84, P9020, DOI 10.1073/pnas.84.24.9020; BUCKINGHAM ME, 1975, FEBS LETT, V53, P355, DOI 10.1016/0014-5793(75)80054-8; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHEN X, 1992, 65TH SCI SESS AM HEA; CHEN XL, 1993, FASEB J, V7, pA796; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAWSON PA, 1989, J LIPID RES, V30, P403; ELOVSON J, 1981, P NATL ACAD SCI USA, V78, P156; FAN H, 1970, J MOL BIOL, V50, P665; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GEHRKE L, 1981, J BIOL CHEM, V256, P2514; GEHRKE L, 1981, J BIOL CHEM, V258, P2522; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GLICKMAN RM, 1972, J CLIN INVEST, V51, P356, DOI 10.1172/JCI106821; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HERBERT PN, 1983, METABOLIC BASIS INHE, P597; HIGUCHI K, 1988, P NATL ACAD SCI USA, V85, P1772, DOI 10.1073/pnas.85.6.1772; HILL JR, 1992, J BIOL CHEM, V267, P21886; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MATSUSHIMA T, 1989, J LIPID RES, V30, P841; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PEAVY DE, 1985, AM J PHYSIOL, V248, pE656, DOI 10.1152/ajpendo.1985.248.6.E656; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT J, 1990, CURRENT OPINION LIPI, V1, P96; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SPARKS CE, 1981, J LIPID RES, V22, P519; SPARKS JD, 1986, ATHEROSCLEROSIS, V61, P205, DOI 10.1016/0021-9150(86)90139-5; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; WU JH, 1990, J BIOL CHEM, V265, P12312; YAO ZM, 1991, J BIOL CHEM, V266, P3300; ZOLFAGHARI R, 1992, ARTERIOSCLER THROMB, V12, P295, DOI 10.1161/01.ATV.12.3.295	53	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21007	21013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407938				2022-12-25	WOS:A1993MA28800058
J	CRUZ, MA; HANDIN, RI; WISE, RJ				CRUZ, MA; HANDIN, RI; WISE, RJ			THE INTERACTION OF THE VON-WILLEBRAND FACTOR-A1 DOMAIN WITH PLATELET GLYCOPROTEIN-IB-IX - THE ROLE OF GLYCOSYLATION AND DISULFIDE BONDING IN A MONOMERIC RECOMBINANT A1 DOMAIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; FACTOR-VIII; FACTOR VWF; MULTIMERIC STRUCTURE; MONOCLONAL-ANTIBODY; FIBRINOGEN BINDING; IIB/IIIA COMPLEX; ESCHERICHIA-COLI; COLLAGEN; CARBOHYDRATE	The interaction of von Willebrand factor (vWF) with platelet glycoprotein Ib/IX plays an important role in primary hemostasis. Previous studies have localized the GpIbalpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain. In order to assess the role of A1 domain structure in vWF binding functions, a cDNA encoding residues 475-709 of vWF was expressed in Escherichia coli (non-glycosylated) and in Chinese hamster ovary (CHO) cells (glycosylated). These recombinant proteins contain a single intrachain disulfide bond between C509 and C695 and were purified as monomers with apparent molecular weights of 36,000 (E. coli) and 39,000 (CHO). S-35-Labeled-vWF-A1 proteins bound directly to GpIb/IX receptors on platelets. The non-glycosylated form had a slightly higher affinity (K(d) = 1.4 +/- 0.4 muM) than the glycosylated vWF-A1 protein (K(d) = 4.5 +/- 0.9 muM) but had similar binding capacity of 28,000 GpIb/IX-specific binding sites per platelet. Additionally, both recombinant vWF-A1 proteins bound to heparin but neither bound to immobilized type I and III collagen. Both E. coli- and CHO-derived vWF-A1 proteins inhibited ristocetin-induced platelet agglutination with IC50 values of 300 and 700 nM, respectively. Reduction of the only disulfide bond between C509 and C695 abolished platelet binding activity at concentration up to 2 muM of protein. Confirmation of the importance of the 509-695 disulfide bond was obtained from a full-length vWF mutant containing substitutions at C509 and C695 (C509/695S) which failed to bind to the platelet GpIb/IX receptor. These studies document that vWF-A1 domain can bind to GpIb/IX and heparin but not collagen, and that binding to GpIb/IX requires an intact disulfide bond between C509 and C695. Furthermore, glycosylation increases the solubility but reduces binding affinity of recombinant vWF A1.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,LMRC-610,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [P01-HL33014, R37-HL34787] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014, R37HL034787] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN JP, 1975, J LAB CLIN MED, V85, P318; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CAREW JA, 1992, J CLIN INVEST, V90, P2258, DOI 10.1172/JCI116112; CHRISTOPHE O, 1991, BLOOD, V78, P2310; COLLER BS, 1983, BLOOD, V61, P99; CRUZ MA, 1992, J BIOL CHEM, V267, P1303; CRUZ MA, 1993, THROMB HAEMOSTASIS, V69, P980; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; FEDERICI AB, 1988, BLOOD, V71, P947; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1743; GINSBURG D, 1992, BLOOD, V79, P2507; GIRMA JP, 1987, BLOOD, V70, P605; GRALNICK HR, 1992, P NATL ACAD SCI USA, V89, P7880, DOI 10.1073/pnas.89.17.7880; GRALNICK HR, 1981, BLOOD, V58, P387; GRALNICK HR, 1983, P NATL ACAD SCI-BIOL, V80, P2771, DOI 10.1073/pnas.80.9.2771; GRANILK HR, 1985, J CLIN INVEST, V75, P19; KAO KJ, 1980, J BIOL CHEM, V255, P134; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MILLER JL, 1990, BRIT J HAEMATOL, V74, P313, DOI 10.1111/j.1365-2141.1990.tb02589.x; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PIETU G, 1989, BIOCHEM BIOPH RES CO, V164, P1339; PRIOR C, 1992, BIO-TECHNOL, V10, P66, DOI 10.1038/nbt0192-66; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SIXMA JJ, 1991, EUR J BIOCHEM, V688, P1; SODETZ JM, 1979, J BIOL CHEM, V254, P754; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TURITTO VT, 1984, J CLIN INVEST, V74, P1730, DOI 10.1172/JCI111591; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WISE RJ, 1991, J BIOL CHEM, V266, P21948; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; WISE RJ, 1993, HUM GENET, V91, P367	47	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21238	21245						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407961				2022-12-25	WOS:A1993MA28800088
J	FERNANDEZPOL, JA; KLOS, DJ; HAMILTON, PD				FERNANDEZPOL, JA; KLOS, DJ; HAMILTON, PD			A GROWTH FACTOR-INDUCIBLE GENE ENCODES A NOVEL NUCLEAR-PROTEIN WITH ZINC-FINGER STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-BINDING DOMAINS; FACTOR RECEPTOR GENE; CARCINOMA CELL-LINE; FACTOR-BETA; DNA-BINDING; ONCOGENE EXPRESSION; ACID-BINDING; TRIIODOTHYRONINE; IDENTIFICATION; MODULATION	Growth factors rapidly induce numerous genes that encode regulatory proteins, many of which have been identified by cDNA cloning. In this study, differential hybridization was used to screen a cDNA library constructed from human mammary carcinoma MDA-468 cells that were stimulated with transforming growth factor beta-1 (TGF-beta1) in the presence of cycloheximide. One of the cDNA clones that was induced by TGF-beta1 was found to have a nucleotide sequence that predicts a 9,450-Da protein with homology to regulatory DNA-binding proteins. This clone was designated metallopan-stimulin-1 (MPS-1) because it encodes a metalloprotein whose mRNA is expressed in a wide variety of actively proliferating cells and tumor tissues. MPS-1 protein contains one ''zinc finger'' domain of the C4 type, similar to those present in proteins of the steroid/thyroid hormone receptor superfamily and other DNA-binding proteins. The mRNA for MPS-1 was induced in MDA-468 cells by fetal calf serum, TGF-beta1, TGF-beta2, and cAMP analogues. The MPS-1 gene is expressed at relatively high levels in several human carcinoma cell lines, particularly those derived from ectodermal layers, and at higher levels in melanomas (ontogenically of neural origin). In contrast, the MPS-1 mRNA is expressed at low levels in normal WI-38 human lung diploid fibroblasts in culture. We hypothesize that MPS-1 protein may play a role as a potentially important mediator of cellular proliferative responses to various growth factors and other environmental signals.	ST LOUIS UNIV, DEPT MED, DIV NUCL MED, ST LOUIS, MO 63106 USA	Saint Louis University	FERNANDEZPOL, JA (corresponding author), DVA MED CTR, MOLEC ONCOL LAB 115JC, 915 N GRAND BLVD, ST LOUIS, MO 63106 USA.							ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1989, PROG INORG CHEM, V37, P143; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FERNANDEZ-POL J A, 1991, Critical Reviews in Oncogenesis, V2, P173; FERNANDEZPOL JA, 1987, CANCER RES, V47, P4260; FERNANDEZPOL JA, 1989, J BIOL CHEM, V264, P4151; FERNANDEZPOL JA, 1989, J CELL BIOCHEM, V41, P159, DOI 10.1002/jcb.240410306; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Gribskov M., 1991, SEQUENCE ANAL PRIMER; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JANSEN R, 1989, GENE ANAL TECH, V6, P79, DOI 10.1016/0735-0651(89)90020-4; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELTON RW, 1989, DEVELOPMENT, V106, P759; RYCHLIK W, 1990, OLIGOTM PRIMER ANAL; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684	37	55	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21198	21204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407955				2022-12-25	WOS:A1993MA28800082
J	MUTA, T; ODA, T; IWANAGA, S				MUTA, T; ODA, T; IWANAGA, S			HORSESHOE-CRAB COAGULATION FACTOR-B - A UNIQUE SERINE-PROTEASE ZYMOGEN ACTIVATED BY CLEAVAGE OF AN ILE-ILE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; AMINO-ACID-SEQUENCE; LIMULUS-POLYPHEMUS HEMOCYTES; DORSAL-VENTRAL PATTERN; 4 TANDEM REPEATS; HUMAN FACTOR-XI; FACTOR-C; PLASMA PREKALLIKREIN; PROCLOTTING ENZYME; PROTEINS	Horseshoe crab factor B is an intracellular serine protease zymogen involved in the bacterial endotoxin-responsive hemolymph coagulation cascade. cDNAs for factor B were isolated utilizing a polymerase chain reaction product using two primers derived from the partial amino acid sequence. The cloned cDNA of 1928 base pairs encoded 400 amino acid residues of factor B precursor. The first 23 amino acid residues constitute a presumed prepropeptide that may be processed by both a signal peptidase and a processing protease, similar to mammalian vitamin K-dependent protease precursors. The mature protein consists of 377 amino acids with a calculated molecular mass of 40,570 Da. The overall structure is highly homologous to that of limulus proclotting enzyme (35.9% identity), the substrate for active factor B in the cascade. Like the proclotting enzyme, mature factor B is composed of an amino-terminal ''clip''-like domain and a carboxyl-terminal serine protease domain homologous to that of human plasma prekallikrein (36.5%). Internal sequences encode a unique activation peptide. Surprisingly, the cleavage sites of the zymogen factor B for activation by limulus active factor C were found to be an Arg-Ser and an Ile-Ile bond, the latter of which has not been found in any other protease zymogens. These cleavages result in the release of the activation peptide, which consists of 21 residues with a carboxyl-terminal isoleucine. These results indicate that the intracellular clotting system of the limulus hemocyte, like mammalian plasma clotting cascade, proceeds with the sequential activation of three serine protease zymogens: factor C, factor B, and proclotting enzyme.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University								AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1991, LIMULUS POLYPHEMUS I, P3; ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1987, HEMOSTASIS THROMBOSI, P242; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Halkier T, 1991, MECH BLOOD COAGULATI, P302; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; IWANAGA S, 1986, J PROTEIN CHEM, V5, P255, DOI 10.1007/BF01025424; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYATA T, 1986, J BIOCHEM-TOKYO, V100, P213, DOI 10.1093/oxfordjournals.jbchem.a121696; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MIYATA T, 1989, J BIOCHEM-TOKYO, V101, P1321; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; Morita T, 1985, Prog Clin Biol Res, V189, P53; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; SCULLY MF, 1991, BRIT J HAEMATOL, V79, P537, DOI 10.1111/j.1365-2141.1991.tb08078.x; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SODERHALL K, 1992, ANN REV FISH DISEASE, V1, P3; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TOKUNAGA F, 1991, J BIOCHEM, V109, P150, DOI 10.1093/oxfordjournals.jbchem.a123337; TOKUNAGA F, 1987, EUR J BIOCHEM, V167, P405, DOI 10.1111/j.1432-1033.1987.tb13352.x; TULINSKY A, 1991, THROMB HAEMOSTASIS, V66, P16; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	43	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21384	21388						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407978				2022-12-25	WOS:A1993MA28800106
J	YANO, T; SANDER, CA; CLARK, HM; DOLEZAL, MV; JAFFE, ES; RAFFELD, M				YANO, T; SANDER, CA; CLARK, HM; DOLEZAL, MV; JAFFE, ES; RAFFELD, M			CLUSTERED MUTATIONS IN THE 2ND EXON OF THE MYC GENE IN SPORADIC BURKITT-LYMPHOMA	ONCOGENE			English	Article							HUMAN C-MYC; CASEIN KINASE-II; PHOSPHORYLATION SITE; NUCLEOTIDE-SEQUENCE; SOMATIC MUTATION; PROTEIN-KINASE; 1ST EXON; ONCOGENE; TRANSCRIPTION; REGION	The primary tumors from 15 untreated patients with Burkitt's lymphoma were analysed for abnormalities in the coding region of the MYC gene by single stranded conformational polymorphism (SSCP) analysis followed by DNA sequencing. Fourteen of the 15 tumors had one or more clonal mutations. Forty one mutations were found in the second exon; only one occurred in the third exon. Seven tumors had mutations that clustered in a region spanning amino acids 38-63. Four of these possessed mutations that altered prolines at positions 57 (3), 60 (1), and 63 (1). Seven tumors were mutated in the central portions of the second exon. These occurred at position 95 (2), position 115 (2), position 137 (1), and position 138 (3). Analysis of the published sequences from five lymphoma cell lines and one primary tumor showed a similar clustering of mutations, with all six having mutations in codons between positions 38-63. The regions where mutations occurred have been associated with a variety of properties, including transcriptional activation and cellular transformation. The number and location of mutations showed no correlation with either chromosome 8 or chromosome 14 breakpoints or with the Epstein-Bar virus positivity of the tumors. This unexpected, frequent occurrence of clustered mutations in the second exon of the MYC gene suggests a rote for the mutated MYC proteins in the pathogenesis of Burkitt's lymphoma, possibly through altered interactions of this domain with other cellular factors.	NCI,PATHOL LAB,HEMATOPATHOL SECT,BLDG 10,ROOM 2N110,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jaffe, Elaine/G-8981-2014					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GILLESPIE DAF, 1989, MOL CELL BIOL, V9, P865, DOI 10.1128/MCB.9.2.865; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JOHNSTON JM, 1991, BLOOD, V78, P2419; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; Nisson P E, 1991, PCR Methods Appl, V1, P120; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, COLD SH Q B, V56, P163; SAKSELA K, 1992, ONCOGENE, V7, P347; SETH A, 1991, J BIOL CHEM, V266, P23521; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANO T, 1992, BLOOD, V79, P1282, DOI 10.1182/blood.V79.5.1282.bloodjournal7951282; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	41	93	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2741	2748						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397370				2022-12-25	WOS:A1993LX34300015
J	KOLCH, W; HEIDECKER, G; TROPPMAIR, J; YANAGIHARA, K; BASSIN, RH; RAPP, UR				KOLCH, W; HEIDECKER, G; TROPPMAIR, J; YANAGIHARA, K; BASSIN, RH; RAPP, UR			RAF REVERTANT CELLS RESIST TRANSFORMATION BY NONNUCLEAR ONCOGENES AND ARE DEFICIENT IN THE INDUCTION OF EARLY RESPONSE GENES BY TPA AND SERUM	ONCOGENE			English	Article							PROTEIN KINASE-C; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; V-RAF; TYROSINE PHOSPHORYLATION; NEGATIVE AUTOREGULATION; EXTRACELLULAR SIGNALS; NUCLEOTIDE-SEQUENCE; FLAT REVERTANTS; AUTO-REGULATION	A revertant cell line was generated from v-raf transformed NIH/3T3 fibroblasts. These cells, termed CHP25, express a functional v-raf oncogene. However, they are non-tumorigenic, do not form colonies in soft agar and possess a flat morphology. CHP25 cell are resistant to re-transformation by sis, ras, tyrosine kinase as well as serine/threonine kinase-encoding oncogenes suggesting that Raf functions downstream of most membrane associated signal transducers. In contrast to v-raf transformed cells, in which the endogenous Raf-1 protein kinase is constitutively activated, v-Raf in CHP25 cells does not activate endogenous Raf-1 kinase. Since mitogen regulation of Raf-1 kinase in CHP25 cells is intact, we conclude that CHP25 cells are blocked at the level of Raf-1 substrate phosphorylation. Consistent with this interpretation CHP25 cells show specific alterations of early gene induction. The serum induction of c-fos and junD as well as the serum and TPA (12-O-tetradecanoylphorbol-13-acetate) induction of junB and egr-1 are almost completely abolished. Only v-fos can transform CHP25, whereas c-fos, v-myc, c-jun and junB are ineffective. These data suggest that the lesion responsible for the revertant phenotype of CHP25 cells is the inability to activate the AP-1 complex. We conclude that Raf-1 signaling is essential for transformation of NIH/3T3 cells by peripheral oncogenes and for regulation of a subset of early response genes by TPA and serum growth factors.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kolch, Walter/ABF-2102-2021	Troppmair, Jakob/0000-0002-0611-3837; Kolch, Walter/0000-0001-5777-5016				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIARDIELLO F, 1988, CANCER RES, V48, P2483; Cleveland J L, 1988, Oncogene Res, V3, P357; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DESSUREAULT J, 1990, J CELL BIOCHEM, V43, P293, DOI 10.1002/jcb.240430309; GERFAUX J, 1990, MOL CARCINOGEN, V3, P103, DOI 10.1002/mc.2940030208; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1992, IN PRESS ADV CANCER; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VARNUM BC, 1989, ONCOGENE, V4, P119; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YAMADA H, 1990, MOL CELL BIOL, V10, P1822, DOI 10.1128/MCB.10.4.1822; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	71	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					361	370						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426742				2022-12-25	WOS:A1993KN00600015
J	JONAS, A; STEINMETZ, A; CHURGAY, L				JONAS, A; STEINMETZ, A; CHURGAY, L			THE NUMBER OF AMPHIPATHIC ALPHA-HELICAL SEGMENTS OF APOLIPOPROTEIN-A-I, APOLIPOPROTEIN-E, AND APOLIPOPROTEIN-A-IV DETERMINES THE SIZE AND FUNCTIONAL-PROPERTIES OF THEIR RECONSTITUTED LIPOPROTEIN PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; DISCOIDAL COMPLEXES; STRUCTURAL DOMAINS; MULTIGENE FAMILY; AQUEOUS-SOLUTION; LIPID-BINDING; PROTEIN; PHOSPHATIDYLCHOLINE; EVOLUTION	The objective of this work was to determine the role of the amphipathic alpha-helical structural units of human apolipoproteins A-I, E, and A-IV in defining the sizes and reactivities with lecithin:cholesterol acyltransferase (LCAT) of their reconstituted lipoprotein particles. We prepared reconstituted high density lipoprotein (rHDL) particles with each of the three apolipoproteins in two weight ratios with lipid: 2.7/0.07/1 and 1.35/0.04/1, palmitoyloleoylphosphatidylcholine/cholesterol/apolipoprotein, by the sodium cholate dialysis procedure; and examined the rHDL product sizes and distributions by nondenaturing gradient gel electrophoresis. The rHDL particles were also incubated with low density lipoprotein (LDL), and with LDL plus LCAT, to observe any structural modifications due to phospholipid transfers to LDL and to cholesterol esterification by LCAT. In addition, we examined the average structural properties of the original rHDL by several fluorescence methods and circular dichroism spectroscopy, and determined their reaction kinetics with LCAT. The results indicate that the diameters of the largest rHDL particles, containing two apolipoproteins per particle, correlate with the maximum number of putative amphipathic alpha-helical segments in their sequences, and that smaller particles of this class may arise from the removal of one or more alpha-helical segments from contact with lipid. Furthermore, the larger particles may be converted into the smaller ones upon loss of phospholipid to LDL, and may form one or two well defined products when reacted with LCAT. In general, the subclasses of particles have distinct spectroscopic properties, consistent with a different apolipoprotein folding in particles containing different proportions of phospholipid to apolipoprotein. Furthermore, the different apolipoprotein structures lead to significant differences in reactivity with LCAT.	UNIV MARBURG,DIV ENDOCRINOL,W-3550 MARBURG,GERMANY	Philipps University Marburg	JONAS, A (corresponding author), UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801, USA.				NHLBI NIH HHS [HL-16059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P319, DOI 10.1016/S0065-3233(08)60022-4; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEUNG MC, 1987, J LIPID RES, V28, P913; DVORIN E, 1985, J LIPID RES, V26, P38; EDELSTEIN C, 1972, J BIOL CHEM, V247, P5842; GIANTURCO SH, 1987, PLASMA LIPOPROTEINS, P183; GONG EL, 1989, BIOCHIM BIOPHYS ACTA, V1006, P317, DOI 10.1016/0005-2760(89)90019-2; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1085, P71, DOI 10.1016/0005-2760(91)90233-8; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; LI WH, 1988, J LIPID RES, V29, P245; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MATZ CE, 1982, J BIOL CHEM, V257, P4541; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1984, BIOCHIM BIOPHYS ACTA, V793, P325, DOI 10.1016/0005-2760(84)90246-7; Pownall H. J., 1987, PLASMA LIPOPROTEINS, P95; POWNALL HJ, 1986, METHOD ENZYMOL, V128, P515; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; RITTER MC, 1977, J BIOL CHEM, V252, P1208; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STEINMETZ A, 1989, J CHROMATOGR-BIOMED, V487, P154, DOI 10.1016/S0378-4347(00)83018-2; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; UTERMANN G, 1975, H-S Z PHYSIOL CHEM, V356, P1113, DOI 10.1515/bchm2.1975.356.2.1113; WALD JH, 1990, J BIOL CHEM, V265, P20037; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZORICH N, 1985, J BIOL CHEM, V260, P8831; ZORICH NL, 1987, BIOCHIM BIOPHYS ACTA, V919, P181, DOI 10.1016/0005-2760(87)90206-2	40	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1596	1602						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420935				2022-12-25	WOS:A1993KH62000018
J	KOHDA, D; ODAKA, M; LAX, I; KAWASAKI, H; SUZUKI, K; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F				KOHDA, D; ODAKA, M; LAX, I; KAWASAKI, H; SUZUKI, K; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F			A 40-KDA EPIDERMAL GROWTH-FACTOR TRANSFORMING GROWTH FACTOR-ALPHA-BINDING DOMAIN PRODUCED BY LIMITED PROTEOLYSIS OF THE EXTRACELLULAR DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EGF RECEPTOR; PROTEIN-STRUCTURE DETERMINATION; TYROSINE KINASE-ACTIVITY; TWO-DIMENSIONAL H-1-NMR; LIGAND-BINDING; SIGNAL TRANSDUCTION; NMR-SPECTROSCOPY; CELLS; MOUSE; EXPRESSION	Elucidation of the three-dimensional structure of the complex of the epiderma. growth factor (EGF) and its receptor is essential for understanding the molecular mechanisms of the EGF-receptor interaction and EGF-induced receptor-receptor interaction. NMR is useful to investigate interactions in solution between macromolecules at atomic resolution, but has a limitation in molecular masses of target proteins: less than 300 residues. We have prepared a fragment with apparent molecular mass of 40 kDa in SDS gels from the soluble extracellular domain of the EGF receptor (sEGFR, 619 residues) by sequential limited proteolysis with proteinase K and bromelain. This fragment is a monomeric structural domain consisting of 202 amino acid residues (Cys302-Arg503 and 18-kDa sugar chains, and binds EGF and transforming growth factor-alpha (TGFalpha). This 40-kDa domain has a dissociation constant of about 1 muM for human TGFalpha, which is similar to that of the parental sEGFR. sEGFR oligomerizes in response to EGF and TGFalpha, while the 40-kDa domain does not, suggesting that the sequences other than this domain is required for receptor oligomerization. The 40-kDa ligand-binding domain described in this report is suitable for analysis by various physico-chemical approaches such as NMR.	TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYSIOL,18-22 HONKOMAGOME 3-CHOME,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,TOKYO 113,JAPAN; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; New York University; Max Planck Society			Odaka, Masafumi/C-2378-2013; Kawasaki, Hiroshi/C-3048-2011; Kohda, Daisuke/I-4990-2019	Kawasaki, Hiroshi/0000-0002-2517-159X; Kohda, Daisuke/0000-0001-8234-3776				BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HIGUCHI Y, 1988, J BIOCHEM-TOKYO, V103, P905, DOI 10.1093/oxfordjournals.jbchem.a122385; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P554, DOI 10.1093/oxfordjournals.jbchem.a122307; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P741, DOI 10.1093/oxfordjournals.jbchem.a122338; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1991, J BIOL CHEM, V266, P13828; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; OKEEFE EJ, 1981, J SUPRAMOL STR CELL, V15, P15, DOI 10.1002/jsscb.1981.380150103; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1990, J BIOL CHEM, V265, P22059; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZIDOVETZKI R, 1986, EMBO J, V5, P247, DOI 10.1002/j.1460-2075.1986.tb04205.x; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	38	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1976	1981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420971				2022-12-25	WOS:A1993KH62000073
J	CHAUHAN, SS; POPESCU, NC; RAY, D; FLEISCHMANN, R; GOTTESMAN, MM; TROEN, BR				CHAUHAN, SS; POPESCU, NC; RAY, D; FLEISCHMANN, R; GOTTESMAN, MM; TROEN, BR			CLONING, GENOMIC ORGANIZATION, AND CHROMOSOMAL LOCALIZATION OF HUMAN CATHEPSIN-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR EXCRETED PROTEIN; BONE-RESORPTION; MESSENGER-RNAS; ACID-PROTEASE; GROWTH-FACTOR; CELL LINES; GENE; EXPRESSION; SEQUENCES; MURINE	Cathepsin L is a lysosomal cysteine protease whose expression and secretion is induced by malignant transformation, growth factors, and tumor promoters. Many human tumors express high levels of cathepsin L, which is a broad spectrum protease with potent elastase and collagenase activities. Two published human cathepsin L cDNA sequences differ only in their 5'-untranslated regions. In this study, we demonstrate the concurrent expression of two distinct human cathepsin L mRNAs (hCATL-A and hCATL-B) in adenocarcinoma, hepatoma, and renal cancer cell lines. Cloning of the human cathepsin L gene by polymerase chain reaction amplification of genomic DNA and subsequent sequencing reveals that hCATL-A and hCATL-B mRNAs are encoded by a single gene. The 3' end of the first intron contains the 5' portion of hCATL-B and is contiguous to the second exon of the gene. These data suggest either the possibility of alternative splicing or the presence of a second promoter within the first intron of the hCATL gene. We mapped the hCATL gene to chromosome 9q21-22. Sequencing of both the mouse and human cathepsin L genes demonstrates almost complete conservation of exon and intron position, but significant divergence in intron structure, possibly reflecting differences in regulation of expression of the mouse and human cathepsin L genes.	UNIV NANCY 1, VET ADM MED CTR, CTR GERIATR RES EDUC & CLIN, INST GERONTOL, F-54506 VANDOEUVRE LES NANCY, FRANCE; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NCI, BIOL LAB, BETHESDA, MD 20892 USA	Geriatric Research Education & Clinical Center; Universite de Lorraine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Troen, Bruce R./ABB-4959-2021					AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; BANDO Y, 1986, J BIOCHEM-TOKYO, V100, P35, DOI 10.1093/oxfordjournals.jbchem.a121703; Bohley P., 1979, BIOL FUNCTIONS PROTE, P17; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; CHAUHAN SS, 1991, CANCER RES, V51, P1478; COMINGS DE, 1972, NATURE, V238, P455, DOI 10.1038/238455a0; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DELAISSE JM, 1986, BIOCHEM PHARMACOL, V35, P3091, DOI 10.1016/0006-2952(86)90391-6; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; ETHERINGTON DJ, 1988, BRIT J EXP PATHOL, V69, P281; FAN YS, 1989, CYTOGENET CELL GENET, V51, P996; FEN Z, 1991, ONCOGENE, V6, P953; GAL S, 1986, J BIOL CHEM, V261, P1760; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; GOTTESMAN MM, 1980, CELL, V19, P449, DOI 10.1016/0092-8674(80)90519-X; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; ISHIDOH K, 1989, FEBS LETT, V259, P71, DOI 10.1016/0014-5793(89)81497-8; JOHNSON DA, 1986, J BIOL CHEM, V261, P4748; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; LOPEZ CF, 1991, EUR J BIOCHEM, V201, P119; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MAYER RJ, 1986, FEBS LETT, V198, P181, DOI 10.1016/0014-5793(86)80403-3; MCCOY K, 1988, J CELL BIOL, V106, P1879, DOI 10.1083/jcb.106.6.1879; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAKAJIMA H, 1990, BIOCHEM BIOPH RES CO, V166, P637, DOI 10.1016/0006-291X(90)90856-I; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RABIN MS, 1986, P NATL ACAD SCI USA, V83, P357, DOI 10.1073/pnas.83.2.357; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; ROMERO P, 1989, ONCOGENE, V4, P93; ROZHIN J, 1989, BIOCHEM BIOPH RES CO, V164, P556, DOI 10.1016/0006-291X(89)91755-5; SABINA RL, 1990, J BIOL CHEM, V265, P9423; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1991, J CELL SCI, V98, P317; STAHL J, 1990, J BIOL CHEM, V265, P8833; TANABE O, 1988, J IMMUNOL, V141, P3875; Troen B R, 1987, Methods Enzymol, V151, P416, DOI 10.1016/S0076-6879(87)51033-3; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; TROEN BR, 1988, J BIOL CHEM, V263, P254; UEDA K, 1987, J BIOL CHEM, V262, P505; WRIGHT WW, 1989, ANN NY ACAD SCI, V564, P173, DOI 10.1111/j.1749-6632.1989.tb25896.x; YAGEL S, 1989, CANCER RES, V49, P3553	51	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1039	1045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419312				2022-12-25	WOS:A1993KG07700044
J	KOHRER, K; EMR, SD				KOHRER, K; EMR, SD			THE YEAST VPS17 GENE ENCODES A MEMBRANE-ASSOCIATED PROTEIN REQUIRED FOR THE SORTING OF SOLUBLE VACUOLAR HYDROLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; CARBOXYPEPTIDASE-Y; LYSOSOMAL-ENZYMES; KEX2 PROTEASE; ALKALINE-PHOSPHATASE; BIOGENESIS; TRANSPORT; TRANSFORMATION; SYSTEM	vps17 mutants missort and secrete several vacuolar hydrolases. To analyze the role of the VPS17 gene in vacuolar protein delivery, we have cloned this gene by complementation of the vacuolar protein sorting defects of a vps17-5 mutant. Disruption of the VPS17 gene had no effect on the viability of haploid yeast cells, although they show an obvious defect in vacuolar morphology. vps17-disrupted cells contain numerous small vacuole-like compartments and also exhibit a severe defect in the sorting of carboxypeptidase Y (CPY), a soluble vacuolar hydrolase. 95% of CPY is missorted and secreted from the mutant cells. Vacuolar sorting of two other soluble hydrolases, proteinase A and proteinase B, is also affected, but to a lesser extent. Delivery and maturation of the vacuolar membrane protein alkaline phosphatase does not appear to be affected in a DELTAvps17 strain. The DNA sequence of the VPS17 clone indicates that the gene encodes a 551-amino-acid protein with a calculated molecular mass of 63.1 kDa. The protein sequence is hydrophilic and contains no obvious N-terminal signal sequence or hydrophobic membrane-spanning domains, indicating that the Vps17p does not enter the secretory pathway. Using a Vps17p-specific polyclonal antiserum, we have demonstrated that the Vps17 protein is not modified with N-linked carbohydrates at any of its four potential N-linked glycosylation sites. The Vps17 protein, however, fractionates to a particulate fraction after centrifugation at 100,000 x g. Vps17p can be released from this particulate fraction by treatment with either Triton X-100 or urea, indicating that the Vps17p is peripherally associated with a crude membrane fraction. Based on these results, we propose that the Vps17p functions on the cytoplasmic surface of some intracellular organelle, possibly the Golgi complex or an intermediate in Golgi to vacuole transport, to facilitate the sorting and delivery of soluble vacuolar hydrolases. Vacuolar membrane protein traffic, however, appears to occur by a mechanism that is independent of Vps17p function.	CALTECH, DIV BIOL 14775, PASADENA, CA 91125 USA	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CLARK DW, 1982, J BACTERIOL, V152, P865; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, TRENDS BIOCHEM SCI, V14, P347, DOI 10.1016/0968-0004(89)90170-9; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAIGER H, 1982, BIOCHEM BIOPH RES CO, V104, P950, DOI 10.1016/0006-291X(82)91341-9; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILIMZIG M, 1985, TRENDS GENET, V1, P158; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; WOOLFORD CA, 1990, GENETICS, V125, P739	74	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					559	569						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416961				2022-12-25	WOS:A1993KE60300085
J	TUCK, SF; GRAHAMLORENCE, S; PETERSON, JA; DEMONTELLANO, PRO				TUCK, SF; GRAHAMLORENCE, S; PETERSON, JA; DEMONTELLANO, PRO			ACTIVE-SITES OF THE CYTOCHROME-P450(CAM) (CYP101) F87W AND F87A MUTANTS - EVIDENCE FOR SIGNIFICANT STRUCTURAL REORGANIZATION WITHOUT ALTERATION OF CATALYTIC REGIOSPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GENE; REARRANGEMENT; COMPLEXES	Ferricyanide oxidation of the aryl-iron complexes formed by the reaction of cytochrome P450 enzymes with arylhydrazines causes in situ migration of the aryl group from the iron to the porphyrin nitrogen atoms. The regiochemistry of this migration, defined by the ratio of the four possible N-arylprotoporphyrin IX isomers, provides a method for mapping the topologies of cytochrome P450 active sites. The method has been validated by using it to examine the active site of cytochrome P450cam (CYP101), for which a crystal structure is available. In agreement with the crystal structure, reaction with phenylhydrazine gives a 5:25:70 ratio of the N(A):N(C):N(D) (subscript indicates pyrrole ring) N-phenylprotoporphyrin IX isomers. Naphthylhydrazine, however, yields exclusively the N(C) regioisomer and 4-(phenyl)phenylhydrazine the N(A):N(C):N(D) isomers in a 14:40:46 ratio. These isomer ratio differences are readily explained by topological differences between the upper and lower reaches of the active site. Having validated the aryl-iron shift as a topological probe, we used it to investigate the structural changes caused by mutation of Phe-87, a residue that provides the ceiling over pyrrole ring D in the crystal structure of cytochrome P450cam. Mutation of Phe-87 to a tryptophan causes no detectable change in the regiochemistry of camphor hydroxylation and only minor changes in the N-aryl isomer ratios. However, mutation of Phe-87 to an alanine, which was expected to open up the region above pyrrole ring D, severely decreased the proportion of the N(D) in favor of the N(A) isomer. Less rather than more space is therefore available over pyrrole ring D in the F87A mutant despite the fact that the regiochemistry of camphor hydroxylation remains unchanged. These results provide evidence for significant structural reorganization in the upper regions of the substrate binding site without alteration of the camphor hydroxylation regiospecificity in the F87A mutant.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515, R01GM043479] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM43479, GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON LA, 1983, BIOCHIM BIOPHYS ACTA, V748, P341, DOI 10.1016/0167-4838(83)90178-4; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HUNSBERGER IM, 1956, J ORG CHEM, V21, P394, DOI 10.1021/jo01110a004; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; MORRIS GM, 1991, BIOCHEM SOC T, V19, P793, DOI 10.1042/bst0190793; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON SD, 1987, MAMMALIAN CYTOCHROME, V2, P19; OMURA T, 1964, J BIOL CHEM, V239, P2370; PAULSEN MD, 1991, J BIOMOL STRUCT DYN, V9, P187, DOI 10.1080/07391102.1991.10507906; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; Sambrook J, 1989, MOL CLONING LABORATO; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1992, ARCH BIOCHEM BIOPHYS, V292, P42, DOI 10.1016/0003-9861(92)90048-2; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TUCK SF, 1992, J BIOL CHEM, V267, P5614; TUCK SF, 1992, BIOCHEMISTRY-US, V31, P6911, DOI 10.1021/bi00145a007; TUCK SF, 1992, J BIOL CHEM, V267, P13175; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	28	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					269	275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416934				2022-12-25	WOS:A1993KE60300042
J	BRIMACOMBE, R; MITCHELL, P; OSSWALD, M; STADE, K; BOCHKARIOV, D				BRIMACOMBE, R; MITCHELL, P; OSSWALD, M; STADE, K; BOCHKARIOV, D			CLUSTERING OF MODIFIED NUCLEOTIDES AT THE FUNCTIONAL CENTER OF BACTERIAL RIBOSOMAL-RNA	FASEB JOURNAL			English	Article						MODIFIED NUCLEOTIDE; RIBOSOMAL RNA; SITE-DIRECTED CROSS-LINKING; TRANSFER RNA BINDING; RIBOSOME STRUCTURE	ESCHERICHIA-COLI RIBOSOME; DIRECTED CROSS-LINKING; MESSENGER-RNA; DECODING SITE; A-SITES; P-SITES; TERTIARY STRUCTURE; 23S RNA; 16S RNA; 3' END	An aryl trifluoromethyl diazirine photoreactive derivative was attached to the 2-thiocytidine residue at position 32 of tRNA(I)Arg and this derivatized tRNA was bound to Escherichia coli 70S ribosomes. After irradiation at 350 nm the site of cross-linking to the 16S RNA was analyzed by our standard procedures and found to lie within the secondary structural element comprising bases 956-983; this region contains two modified nucleotides at positions 966 and 967. Similarly, an aryl azido photoreactive derivative was attached to the phenylalanine residue of Phe-tRNA(Phe), and the derivatized aminoacyl tRNA was bound to the ribosome either at the A- or the P-site. In both cases, after irradiation at 250 nm, the cross-link site was localized to position 2439 of the 23S RNA; in the secondary structure of the latter the neighboring nucleotide 2442 is base-paired to a modified nucleotide at position 2069. Taken together with other cross-linking data, these results now directly implicate a total of 27 out of the 29 modified nucleotides in E. coli 16S and 23S RNA as lying within or close to the functional center of the ribosome.			BRIMACOMBE, R (corresponding author), MAX PLANCK INST MOLEC GENET, IHNESTR 73, W-1000 BERLIN 33, GERMANY.			Mitchell, Phil/0000-0002-3178-0439				BOCHKARIOV DE, 1992, ANAL BIOCHEM, V204, P90, DOI 10.1016/0003-2697(92)90144-V; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P4303, DOI 10.1093/nar/9.17.4303; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1992, BIOCHIMIE, V74, P319, DOI 10.1016/0300-9084(92)90109-R; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; CARBON P, 1979, EUR J BIOCHEM, V100, P399, DOI 10.1111/j.1432-1033.1979.tb04183.x; CHEN JK, 1985, BIOCHEMISTRY-US, V24, P4777, DOI 10.1021/bi00339a011; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; DORING T, 1991, NUCLEIC ACIDS RES, V19, P3517, DOI 10.1093/nar/19.13.3517; DORING T, 1992, NUCLEIC ACIDS RES, V20, P1593, DOI 10.1093/nar/20.7.1593; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; HASELMAN T, 1989, NUCLEIC ACIDS RES, V17, P2215, DOI 10.1093/nar/17.6.2215; KUECHLER E, 1988, METHOD ENZYMOL, V164, P361; LARSEN N, 1992, P NATL ACAD SCI USA, V89, P5044, DOI 10.1073/pnas.89.11.5044; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MITCHELL P, 1990, NUCLEIC ACIDS RES, V18, P4325, DOI 10.1093/nar/18.15.4325; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; PODKOWINSKI J, 1989, NUCLEIC ACIDS RES, V17, P8767, DOI 10.1093/nar/17.21.8767; PRESCOTT C, 1991, NUCLEIC ACIDS RES, V19, P5281, DOI 10.1093/nar/19.19.5281; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; SHEN ZH, 1989, NUCLEIC ACIDS RES, V17, P4535, DOI 10.1093/nar/17.12.4535; SMITH JE, 1992, BIOCHEMISTRY-US, V31, P10825, DOI 10.1021/bi00159a025; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STIEGE W, 1988, NUCLEIC ACIDS RES, V16, P2369, DOI 10.1093/nar/16.6.2369; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; VANCHARLDORP R, 1981, NUCLEIC ACIDS RES, V9, P2717, DOI 10.1093/nar/9.12.2717; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	41	116	116	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					161	167		10.1096/fasebj.7.1.8422963	http://dx.doi.org/10.1096/fasebj.7.1.8422963			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422963				2022-12-25	WOS:A1993KH88000024
J	NAKAMURA, K; HORI, T; SATO, N; SUGIE, K; KAWAKAMI, T; YODOI, J				NAKAMURA, K; HORI, T; SATO, N; SUGIE, K; KAWAKAMI, T; YODOI, J			REDOX REGULATION OF A SRC FAMILY PROTEIN-TYROSINE KINASE P56(LCK) IN T-CELLS	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIGEN RECEPTOR; IL-2 RECEPTOR; KAPPA-B; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAINS; BINDING-ACTIVITY; CD4 RECEPTOR; HTLV-I; ACTIVATION	Protein tyrosine phosphorylation was examined after T cells were exposed to oxidative stress in vitro to investigate the possible involvement of redox regulation in T-cell signaling. Oxidative reagents such as hydrogen peroxide (H2O2) and diamide, which oxidize the free sulfhydryl groups in the cells, markedly induced tyrosine phosphorylation of multiple cellular proteins, especially a 55-kDa protein, of cultured peripheral blood T lymphocytes (PBL blasts). The 55-kDa molecule phosphorylated by diamide turned out to be a src family protein tyrosine kinase, p56lck. The immune complex kinase assay showed that the kinase activity of p56lck of diamide-treated PBL blasts was enhanced. The tryptic peptide mapping of p56lck demonstrated that diamide induced the phosphorylation both at Tyr-394 (autophosphorylation site) and at Tyr-505 (negative regulatory site). Taken together, the tyrosine phosphorylation and presumably kinase activity of p56lck were swiftly enhanced by oxidative stress, indicating that T cells have a redox-sensitive signaling mechanism, which is partly mediated by the lymphocyte-specific protein tyrosine kinase p56lck.	KYOTO UNIV, INST VIRUS RES, DEPT BIOL RESPONSES, KYOTO 60601, JAPAN; KYOTO UNIV, CTR RADIAT BIOL, DEPT LATE EFFECT STUDIES, KYOTO 60601, JAPAN; LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	Kyoto University; Kyoto University; La Jolla Institute for Immunology			Kawakami, Toshiaki/O-1616-2015					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1989, ONCOGENE, V4, P265; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LUO K, 1990, ONCOGENE, V5, P921; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YODOI J, 1985, J IMMUNOL, V134, P1623; YODOI J, 1991, ADV CANCER RES, V57, P381	43	195	198	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3133	3139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414515				2022-12-25	WOS:A1993MC09300030
J	SLEPAK, VZ; QUICK, MW; ARAGAY, AM; DAVIDSON, N; LESTER, HA; SIMON, MI				SLEPAK, VZ; QUICK, MW; ARAGAY, AM; DAVIDSON, N; LESTER, HA; SIMON, MI			RANDOM MUTAGENESIS OF G-PROTEIN ALPHA-SUBUNIT G(O)ALPHA - MUTATIONS ALTERING NUCLEOTIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE SYSTEM; BOVINE BRAIN; GUANINE-NUCLEOTIDES; ADP-RIBOSYLATION; MECHANISM; RECEPTOR; CELLS; MUTANT; TOXIN; MG-2+	Nucleotide binding properties of the G protein alpha subunit G(o)alpha were probed by mutational analysis in recombinant Escherichia coli. Thousands of random mutations generated by polymerase chain reaction were screened by in situ [S-35]GTPgammaS (guanosine 5'-(3-O-thio)triphosphate) binding on the colony lifts following transformation of bacteria with modified G(o)alpha cDNA. Clones that did not bind the nucleotide under these conditions were characterized by DNA sequence analysis, and the nucleotide binding properties were further studied in crude bacterial extracts. A number of novel mutations reducing the affinity of G(o)alpha for GTPgammaS or Mg2+ were identified. Some of the mutations substitute amino acid residues homologous to those known to interact with guanine nucleotides in p21ras proteins. Other mutations show that previously unstudied residues also participate in the nucleotide binding. Several mutants lost GTPgammaS binding but retained the capacity to interact with the betagamma subunit complex as determined by pertussis toxin-mediated ADP-ribosylation. One of these, mutant S47C, was functionally expressed in Xenopus laevis oocytes along with the G protein-coupled thyrotropin-releasing hormone (TRH) receptor. Whereas wild-type G(o)alpha increased TRH-promoted chloride currents, S47C significantly decreased the hormone-induced Cl- response, suggesting that this mutation resulted in a dominant negative phenotype.	CALTECH,DIV BIOL,147-75,PASADENA,CA 91125	California Institute of Technology			Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126				ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEE E, 1992, J BIOL CHEM, V267, P1212; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PADRELL E, 1991, J BIOL CHEM, V266, P9771; QUICK M W, 1992, Biotechniques, V13, P362; QUICK MW, 1993, METHODS NEUROSCIENCE; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21889	21894						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408043				2022-12-25	WOS:A1993MC80900069
J	CHANG, CCY; HUH, HY; CADIGAN, KM; CHANG, TY				CHANG, CCY; HUH, HY; CADIGAN, KM; CHANG, TY			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF HUMAN ACYL-COENZYME-A CHOLESTEROL ACYLTRANSFERASE CDNA IN MUTANT CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CYCLOHEXIMIDE SENSITIVITY; COA; PROTEIN; ATHEROSCLEROSIS; MACROPHAGE; RECONSTITUTION; METABOLISM; LIPOSOMES; DEFICIENT	Accumulation of cholesterol esters as cytoplasmic lipid droplets within macrophages and smooth muscle cells is a characteristic feature of early lesions of atherosclerotic plaque. Intracellularly, an essential element in forming cholesterol ester from cholesterol is the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT). ACAT is a membrane protein located in the endoplasmic reticulum. The ACAT protein has never been purified to homogeneity, and no antibodies directed against ACAT have been reported. The gene(s) encoding this enzyme had not been isolated. This laboratory had previously reported the isolation of Chinese hamster ovary cells expressing human ACAT activity. From DNAs of these cells, we have cloned a 1.2-kb exonic human genomic DNA. This led to the eventual cloning of a 4-kb cDNA clone (K1) from a human macrophage cDNA library. Transfection of K1 in ACAT-deficient mutant Chinese hamster ovary cells complemented the mutant defect and resulted in the expression of human ACAT activity. K1 contained an open reading frame of 1650 bp encoding an integral membrane protein of 550 amino acids. Protein homology analysis showed that the predicted K1 protein shared homologous peptide sequences with other enzymes involved in the catalysis of acyl adenylate formation followed by acyl thioester formation and acyl transfer. These results indicate that K1 encodes a structural gene for ACAT. The cDNA reported here should facilitate future molecular studies on ACAT.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College				Chang, Ta-Yuan/0000-0002-3249-0468; Cadigan, Ken/0000-0003-2431-1703	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R37HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCKLAND R, 1989, NATURE, V338, P547, DOI 10.1038/338547a0; CADIGAN KM, 1988, J LIPID RES, V29, P1683; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1700, DOI 10.1021/bi00355a039; CHANG TY, 1982, BIOCHEMISTRY-US, V21, P5316, DOI 10.1021/bi00264a030; CHANG TY, 1983, ENZYMES, V16, P523; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HASAN MT, 1991, SOMAT CELL MOLEC GEN, V17, P413; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETROU S, 1993, TRENDS BIOCHEM SCI, V18, P41, DOI 10.1016/0968-0004(93)90050-W; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P194, DOI 10.1016/0165-6147(91)90546-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUCKLING KE, 1985, J LIPID RES, V26, P647	41	320	341	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20747	20755						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407899				2022-12-25	WOS:A1993MA28800018
J	LIU, SH; MA, JT; YUEH, AY; LEESMILLER, SP; ANDERSON, CW; NG, SY				LIU, SH; MA, JT; YUEH, AY; LEESMILLER, SP; ANDERSON, CW; NG, SY			THE CARBOXYL-TERMINAL TRANSACTIVATION DOMAIN OF HUMAN SERUM RESPONSE FACTOR CONTAINS DNA-ACTIVATED PROTEIN-KINASE PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TERNARY COMPLEX-FORMATION; VIRUS-40 T-ANTIGEN; RNA POLYMERASE-II; C-FOS PROMOTER; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; ESCHERICHIA-COLI; BINDING ACTIVITY; KU-AUTOANTIGEN	The serum response factor (SRF) is a 67-kDa phosphoprotein that, together with auxiliary factors, modulates transcription of immediate early genes containing serum response elements in their promoters. Here we show that the carboxyl-terminal domain of human SRF is phosphorylated in vivo and is recognized in vitro by the double-stranded DNA-activated serine/threonine-specific protein kinase, DNA-PK. SRF phosphorylation by DNA-PK was stimulated by its cognate binding site. Protein microsequence analysis of a 22-amino acid synthetic SRF peptide and phosphopeptide analysis of genetically altered glutathione S-transferase-SRF fusion proteins identified Ser-435 and Ser-446 of human SRF as sites phosphorylated by DNA-PK. Both serines are followed by glutamine. Changing Gln-436 and Gln-447 to other residues reduced or eliminated phosphorylation by DNA-PK, confirming that these glutamines are important determinants for kinase recognition. The carboxyl-terminal transcription activation domain was mapped within a 71-amino acid region that contains both DNA-PK phosphorylation sites. Amino acid substitutions that interfered with phosphorylation by DNA-PK at Ser-435/446 in GAL4-SRF fusion proteins were reduced in transactivation potency. From these data we suggest that DNA-PK phosphorylation may modulate SRF activity in vivo.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL TSING HUA UNIV, INST LIFE SCI, HSINCHU 30043, TAIWAN; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	Academia Sinica - Taiwan; National Tsing Hua University; United States Department of Energy (DOE); Brookhaven National Laboratory			Yueh, Andrew/D-2079-2010	Lees-Miller, Susan/0000-0001-5809-2516				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drapeau G R, 1977, Methods Enzymol, V47, P189; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FLANNERY AV, 1989, PROTEOLYTIC ENZYMES, P145; Foulkes, 1991, HORMONAL CONTROL REG, P257; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MACGREGOR GR, 1989, METHODS MOL BIOL, V7; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; NG SY, 1989, NUCLEIC ACIDS RES, V17, P601, DOI 10.1093/nar/17.2.601; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; REASON AJ, 1992, J BIOL CHEM, V267, P16911; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1990, CURRENT PROTOCOLS MO; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231	56	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21147	21154						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407951				2022-12-25	WOS:A1993MA28800076
J	SRISODSUK, M; REINIKAINEN, T; PENTTILA, M; TEERI, TT				SRISODSUK, M; REINIKAINEN, T; PENTTILA, M; TEERI, TT			ROLE OF THE INTERDOMAIN LINKER PEPTIDE OF TRICHODERMA-REESEI CELLOBIOHYDROLASE-I IN ITS INTERACTION WITH CRYSTALLINE CELLULOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; NUCLEAR MAGNETIC-RESONANCE; BINDING DOMAINS; MONOCLONAL-ANTIBODIES; LIMITED PROTEOLYSIS; BACTERIAL CELLULASE; FUNCTIONAL DOMAINS; CATALYTIC ACTIVITY; ADSORPTION; PROTEINS	Cellobiohydrolase I (CBH I), the major component of Trichoderma reesei cellulolytic system, is comprised of a catalytic core domain joined to a cellulose binding-domain (CBD) by an extended O-glycosylated interdomain linker peptide. Two internal deletions were introduced to the linker in order to investigate its function particularly in the hydrolysis of crystalline cellulose. Deletion of the first one-third of the linker, including a putative hinge region, reduces the binding capacity of CBH I in high enzyme coverage but does not affect its enzymatic activity on crystalline cellulose. The longer deletion removing practically all of the linker dramatically reduces the rate of crystalline cellulose degradation even though the enzyme still binds to the substrate. We conclude that sufficient spatial separation of the two domains is required for efficient function of CBH I. It is evident that the presence of a functional CBD is increasingly important for CBH I toward higher enzyme to cellulose ratios. Our data suggest that the putative hinge removed by the first deletion facilitates CBD-driven binding and dense packing of the wild type enzyme on the cellulose surface.	VTT, BIOTECH LAB, POB 202, SF-02151 ESPOO, FINLAND	VTT Technical Research Center Finland			Teeri, Tuula T/E-7509-2013; Penttilä, Merja E/A-4710-2013	Penttila, Merja/0000-0002-6929-1032				ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; ABUJA PM, 1988, BIOCHEM BIOPH RES CO, V156, P180, DOI 10.1016/S0006-291X(88)80821-0; ABUJA PM, 1989, BIOCHEM BIOPH RES CO, V165, P615, DOI 10.1016/S0006-291X(89)80010-5; AHO S, 1991, EUR J BIOCHEM, V200, P643, DOI 10.1111/j.1432-1033.1991.tb16227.x; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BURTON J, 1989, BIOPHYS CHEM, V33, P39, DOI 10.1016/0301-4622(89)80005-5; BUSHUEV VN, 1989, J BIOL CHEM, V264, P4498; Claeyssens M, 1988, BIOCH GENETICS CELLU, P393; CLAEYSSENS M, 1989, TRICHODERMA REESEI C, P1; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; FAGERSTAM LG, 1984, FEBS LETT, V167, P309, DOI 10.1016/0014-5793(84)80148-9; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; GILKES NR, 1992, J BIOL CHEM, V267, P6743; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GUM EK, 1976, BIOCHIM BIOPHYS ACTA, V446, P371; HENRISSAT B, 1988, FEBS LETT, V231, P177, DOI 10.1016/0014-5793(88)80726-9; Hestrin S., 1963, METHODS CARBOHYDRATE, V3, P4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HO SN, 1990, DNA PROTEIN ENG TECH, V2, P50; HOSHINO E, 1992, J BIOCHEM, V111, P600, DOI 10.1093/oxfordjournals.jbchem.a123804; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KIM DW, 1992, J FERMENT BIOENG, V73, P461, DOI 10.1016/0922-338X(92)90138-K; Knowles J., 1988, Biochemistry and genetics of cellulose degradation, P153; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; KYRIACOU A, 1988, ENZYME MICROB TECH, V10, P675, DOI 10.1016/0141-0229(88)90059-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTERN IE, 1987, 19TH LUNT LECT MOL G, P34; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; MILLER RC, 1988, BIOCH GENETICS CELLU, P235; MISCHAK H, 1989, BIOCHIM BIOPHYS ACTA, V990, P1, DOI 10.1016/S0304-4165(89)80003-0; OOSHIMA H, 1983, BIOTECHNOL BIOENG, V25, P3103, DOI 10.1002/bit.260251223; PENTTILA M, 1987, GENE, V61, P155, DOI 10.1016/0378-1119(87)90110-7; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SALOVUORI I, 1987, TECHNICAL RES CTR FI, V34; Sambrook J, 1989, MOL CLONING LABORATO; SCHMUCK M, 1986, BIOTECHNOL LETT, V8, P397, DOI 10.1007/BF01026739; SHEN H, 1991, J BIOL CHEM, V266, P11335; STAHLBERG J, 1991, BIO-TECHNOL, V9, P286, DOI 10.1038/nbt0391-286; TEERI TT, 1987, ANAL BIOCHEM, V164, P60, DOI 10.1016/0003-2697(87)90367-8; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TEERI TT, 1982, J BIOTECHNOL, V24, P169; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTILBEURGH H, 1986, FEBS LETT, V204, P223, DOI 10.1016/0014-5793(86)80816-X	46	156	172	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20756	20761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407900				2022-12-25	WOS:A1993MA28800019
J	LOBELL, RB; ARM, JP; RAIZMAN, MB; AUSTEN, KF; KATZ, HR				LOBELL, RB; ARM, JP; RAIZMAN, MB; AUSTEN, KF; KATZ, HR			INTRACELLULAR DEGRADATION OF FC-GAMMA-RIII IN MOUSE BONE-MARROW CULTURE-DERIVED PROGENITOR MAST-CELLS PREVENTS ITS SURFACE EXPRESSION AND ASSOCIATED FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; MOLECULAR-CLONING; GROWTH-FACTOR; W/WV MICE; RECEPTORS; DIFFERENTIATION; ANTIBODIES; INVITRO; CHAIN; INTRAPERITONEAL	Although mouse interleukin-3-dependent, bone marrow culture-derived progenitor mast cells (BMMC) and a Kirsten sarcoma virus (KiSV)-immortalized mouse mast cell line (MC4w) both express on their surfaces receptors for the Fc portion of IgG (FcgammaR), only MC4w degranulate upon FcgammaR perturbation. As shown by surface iodination and SDS-polyacrylamide gel electrophoresis analysis of deglycosylated proteins immuno-precipitated with the FcgammaR-specific monoclonal antibody 2.4G2, a 26-kDa protein, identified as FcgammaRIII by immunoblotting with antibody to FcgammaRIII, was predominantly expressed on the surface of MC4w but minimally on BMMC. However, both BMMC and MC4w expressed mRNA for FcgammaRIII as determined by RNA blot analysis, and both translated FcgammaRIII as assessed by intrinsic radiolabeling and SDS-polyacrylamide gel electrophoresis analysis of deglycosylated monoclonal antibody 2.4G2 immunoprecipitates. Pulse-chase analysis showed that intrinsically radiolabeled FcgammaRIII was stable in MC4w cells but was degraded rapidly in BMMC and that newly synthesized FcgammaRIII remained sensitive to digestion by endoglycosidase H in BMMC but rapidly became resistant in MC4w. These data suggest that the deficiency in surface FcgammaRIII expression on BMMC is due to the degradation of FcgammaRIII in the endoplasmic reticulum. Immunoprecipitation of surface FcgammaR and Fc receptors for IgE (FcepsilonRI) from digitonin-extracted cells followed by immunoblotting with antibody to FcepsilonRI gamma-chain showed that gamma-chain is associated with surface FcepsilonRI and FcgammaR in MC4w, but only with FcepsilonRI in BMMC, which lack surface FcgammaRIII. Inasmuch as BMMC are progenitors of serosal mast cells, which, like MC4w, express surface FcgammaRIII and undergo FcgammaR-mediated activation, the data suggest that maturation of BMMC enables FcgammaRIII to bypass degradation in the endoplasmic reticulum, resulting in the acquisition of functional FcgammaRIII/gamma-chain complexes on the cell surface.	BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	LOBELL, RB (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,250 LONGWOOD AVE,RM 607,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI032101, R01AI022531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-22531, AI-32101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARM JP, 1991, J BIOL CHEM, V266, P15966; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; DAERON M, 1986, ANN INST PASTEUR IMM, VD137, P233; FOX PC, 1982, J IMMUNOL, V129, P314; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; KATZ HR, 1990, J IMMUNOL, V145, P3412; KATZ HR, 1992, J IMMUNOL, V148, P868; KENNY AJ, 1987, MAMMALIAN ECTOZYMES, P332; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; OVARY Z, 1970, IMMUNOLOGY, V19, P715; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; SCHRADER JW, 1981, J IMMUNOL, V126, P452; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPRINGER TA, 1982, HYBRIDOMA, V1, P257, DOI 10.1089/hyb.1.1982.1.257; TERTIAN G, 1981, J IMMUNOL, V127, P788; TIGELAAR RE, 1971, J IMMUNOL, V106, P661; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580	28	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1207	1212						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419324				2022-12-25	WOS:A1993KG07700067
J	BARR, DP; SHAH, MM; AUST, SD				BARR, DP; SHAH, MM; AUST, SD			VERATRYL ALCOHOL-DEPENDENT PRODUCTION OF MOLECULAR-OXYGEN BY LIGNIN PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE-ROT FUNGUS; PHANEROCHAETE-CHRYSOSPORIUM; OXALIC-ACID; OXIDATION; PURIFICATION; METHOXYBENZENES; BIODEGRADATION; BASIDIOMYCETE; CULTURE; OXIDASE	Veratryl alcohol- and H2O2-dependent production of oxygen by lignin peroxidase isozyme H2 (LiPH2) from Phanerochaete chrysosporium was investigated. Veratryl alcohol oxidation by LiPH2 decreased with increasing concentrations of H2O2 while oxygen evolution increased. The absorption spectrum of the LiPH2 in these experiments indicated that it was in the compound Il state. We propose that O2 production results from the one electron oxidation of H2O2 by the veratryl alcohol cation radical to yield superoxide, as the addition of superoxide dismutase stimulated oxygen production. It has been reported previously that oxygen is consumed in reaction mixtures containing lignin peroxidase, H2O2, veratryl alcohol, and oxalate (Popp, J. L., Kalyanaraman, B., and Kirk, T. K. (1990) Biochemistry 29, 10475-10480). In the presence of oxalate, we observed oxygen consumption that was dependent on the H2O2 concentration. The ability of other methoxybenzenes to mediate oxygen production appeared to be related to their redox potential. It was concluded that cation radicals can oxidize H2O2 by one electron which results in the production of superoxide and the evolution of molecular oxygen. Thus, the rates of LiPH2-catalyzed O2 Consumption or O2 production are dependent on the relative concentrations of H2O2 and oxalate.	UTAH STATE UNIV,CTR BIOTECHNOL,LOGAN,UT 84322	Utah System of Higher Education; Utah State University					NIEHS NIH HHS [ES04922] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKAMATSU Y, 1990, FEBS LETT, V269, P261, DOI 10.1016/0014-5793(90)81169-O; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; BARLEV SS, 1981, BIOCHEM BIOPH RES CO, V99, P373, DOI 10.1016/0006-291X(81)91755-1; BARR DP, 1992, ARCH BIOCHEM BIOPHYS, V298, P480, DOI 10.1016/0003-9861(92)90438-3; BUMPUS JA, 1985, SCIENCE, V228, P1434, DOI 10.1126/science.3925550; FERNANDO T, 1990, APPL ENVIRON MICROB, V56, P1666, DOI 10.1128/AEM.56.6.1666-1671.1990; GOLD MH, 1984, ARCH BIOCHEM BIOPHYS, V234, P353, DOI 10.1016/0003-9861(84)90280-7; KELLEY RL, 1986, ARCH MICROBIOL, V144, P248, DOI 10.1007/BF00410957; KENNEDY DW, 1990, APPL ENVIRON MICROB, V56, P2346; KERSTEN PJ, 1990, P NATL ACAD SCI USA, V87, P2936, DOI 10.1073/pnas.87.8.2936; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; KHADAR V, 1990, BIOCHEMISTRY-US, V29, P8535; KIRK TK, 1978, ARCH MICROBIOL, V117, P277, DOI 10.1007/BF00738547; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; POPP JL, 1991, ARCH BIOCHEM BIOPHYS, V288, P145, DOI 10.1016/0003-9861(91)90176-J; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; RYAN TP, 1989, APPL MICROBIOL BIOT, V31, P302, DOI 10.1007/BF00258414; SAWYER DT, 1984, OXYGEN RADICALS CHEM, P25; SHAH MM, 1992, J BIOL CHEM, V267, P21564; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TIEN M, 1984, P NATL ACAD SCI-BIOL, V81, P2280, DOI 10.1073/pnas.81.8.2280; TUISEL H, 1990, ARCH BIOCHEM BIOPHYS, V279, P158, DOI 10.1016/0003-9861(90)90476-F; WARIISHI H, 1991, J BIOL CHEM, V266, P20694	25	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					241	244						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416932				2022-12-25	WOS:A1993KE60300038
J	BROWN, DT; SITTMAN, DB				BROWN, DT; SITTMAN, DB			IDENTIFICATION THROUGH OVEREXPRESSION AND TAGGING OF THE VARIANT TYPE OF THE MOUSE H1E AND H1C GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; HISTONE SUBTYPES; MODIFIED FORMS; H-1 HISTONES; CHROMATIN; DNA; DIFFERENTIATION; TRANSCRIPTION; PROLIFERATION; ORGANIZATION	Multiple, nonallelic forms of histone H1 are found in most mammalian tissues. Attempts to determine a functional significance to this diversity is hindered by a paucity of primary amino acid sequence data. Although numerous H1 genes have been cloned, the type of variant they encode cannot be determined by sequence analysis alone. We used transformation and overexpression methods to determine that two cloned mouse H1 genes, MH143 and MH175, encode H1c and H1e, respectively. Since these genes have been completely sequenced, these results establish the amino acid sequence of these variants. Assignment was accomplished by mutagenically ''tagging'' the genes by incorporation of a codon for methionine, which is not found in the major somatic H1 variants. These genes were placed under the control of the mouse metallothionein I promoter and introduced into 3T3 cells. Products of these mutagenized genes were detected by [S-35]methionine labeling and identified by high performance liquid chromatography and sodium dodecyl sulfate-acid polyacrylamide gel electrophoresis. We were also able to induce major alterations in the normal stoichiometry of chromatin-associated H1 variants through overproduction of H1c and H1e. This had little effect on the growth properties of these transformants.	UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, 2500 N STATE ST, JACKSON, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; AUBERT D, 1991, J CELL BIOL, V113, P497, DOI 10.1083/jcb.113.3.497; BROWN DT, 1988, MOL CELL BIOL, V8, P4406, DOI 10.1128/MCB.8.10.4406; CHENG GH, 1989, P NATL ACAD SCI USA, V86, P7002, DOI 10.1073/pnas.86.18.7002; COLE KD, 1990, GENE, V89, P265, DOI 10.1016/0378-1119(90)90015-J; COLE RD, 1989, METHOD ENZYMOL, V170, P524; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; KINGSTON RE, 1988, CURRENT PROTOCOLS MO, V1, P901; KISTLER WS, 1975, BIOCHEM BIOPH RES CO, V63, P378, DOI 10.1016/0006-291X(75)90699-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW MF, 1983, MOL CELL BIOL, V3, P2110, DOI 10.1128/MCB.3.11.2110; LEA MA, 1987, CANCER BIOCHEM BIOPH, V9, P199; LENNOX RW, 1989, METHOD ENZYMOL, V170, P532; LENNOX RW, 1988, BIOCHEM CELL BIOL, V66, P636, DOI 10.1139/o88-073; LENNOX RW, 1984, HISTONE GENES STRUCT, P373; MARION C, 1985, BIOCHEMISTRY-US, V24, P6328, DOI 10.1021/bi00344a002; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SEYEDIN SM, 1979, BIOCHEMISTRY-US, V18, P1371, DOI 10.1021/bi00574a038; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; VANHOLDE KE, 1989, CHROMATIN, P91; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WELLS D, 1989, NUCLEIC ACIDS RES, V17, pR311, DOI 10.1093/nar/17.suppl.r311; Wu R.S., 1984, P457; YANG YS, 1987, J BIOL CHEM, V262, P17118; YANG YS, 1989, THESIS U MISSISSIPPI; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E; Zweidler A, 1984, HISTONE GENES STRUCT, P339	39	31	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					713	718						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416974				2022-12-25	WOS:A1993KE60300107
J	SCHULDINER, S; LIU, YJ; EDWARDS, RH				SCHULDINER, S; LIU, YJ; EDWARDS, RH			RESERPINE BINDING TO A VESICULAR AMINE TRANSPORTER EXPRESSED IN CHINESE-HAMSTER OVARY FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC ACID; BRAIN SYNAPTIC VESICLES; CHROMAFFIN GRANULES; GLUTAMATE UPTAKE; PROTON PUMPS; RAT-BRAIN; GLYCINE; NEUROTOXIN; STORAGE; GABA	The potent antihypertensive drug reserpine inhibits the transport of biogenic amines into adrenal chromaffin granules and synaptic vesicles. Reserpine acts by binding almost irreversibly to the vesicular amine transporter, and this interaction has been used both to study the mechanism of transport and to purify the protein responsible. Recent isolation of a cDNA for the rat chromaffin granule amine transporter (CGAT) by selection in the neurotoxin 1-methyl-4-phenylpyridinium now permits an analysis of the interaction with reserpine at a molecular level. Using membranes from stable transformants expressing the transporter, we show that reserpine binds specifically and quantitatively to CGAT. As with the native protein in bovine chromaffin granules, a pH gradient accelerates reserpine binding, and amine substrates compete for binding with reserpine. However, 1-methyl-4-phenylpyridinium and tetrabenazine, the other principal inhibitor of vesicular amine transport, compete very poorly with reserpine for binding, suggesting that they interact with CGAT at distinct sites.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, DEPT NEUROL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHULDINER, S (corresponding author), HEBREW UNIV JERUSALEM, INST LIFE SCI, IL-91904 JERUSALEM, ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CARLSON MD, 1989, J BIOL CHEM, V264, P7369; CARLSSON A, 1966, ACTA PHARMACOL TOX, V24, P112; CHRISTENSEN H, 1991, EUR J PHARM-MOLEC PH, V207, P73, DOI 10.1016/S0922-4106(05)80040-9; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DARCHEN F, 1988, BIOCHEM PHARMACOL, V37, P4381, DOI 10.1016/0006-2952(88)90621-1; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Frize E.D., 1954, NEW ENGL J MED, V251, P1006; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; LIU Y, 1992, P NATL ACAD SCI USA, P539; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; NAITO S, 1983, J BIOL CHEM, V258, P696; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHIMKE RT, 1986, CANCER, V57, P1912, DOI 10.1002/1097-0142(19860515)57:10<1912::AID-CNCR2820571004>3.0.CO;2-O; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; STERNBACH Y, 1992, IN PRESS P NATL ACAD; Stitzel R.E., 1977, PHARMACOL REV, V28, P179; STONE DK, 1989, J BIOENERG BIOMEMBR, V21, P605, DOI 10.1007/BF00808116; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0	32	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					29	34						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416935				2022-12-25	WOS:A1993KE60300007
J	SERRE, MC; ZHENG, L; JAYARAM, M				SERRE, MC; ZHENG, L; JAYARAM, M			DNA SPLICING BY AN ACTIVE-SITE MUTANT OF FLP RECOMBINASE - POSSIBLE CATALYTIC COOPERATIVITY BETWEEN THE INACTIVE PROTEIN AND ITS DNA SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; MECHANISM; STEP; STEREOCHEMISTRY; SYNAPSIS	Each strand transfer catalyzed by the Flp recombinase is the composite of two transesterification reactions. The active nucleophilic species in the two reactions are the catalytic site tyrosine (Tyr-343) of Flp and the 5'-hydroxyl from the Flp-nicked DNA substrate, respectively. A ''half recombination site'' is capable of undergoing this pair of transesterifications in the presence of Flp. When the substrate is a half-site containing a chiral phosphorothioate at the exchange point, the Flp reaction yields a product in which the phosphate chirality is retained. A mutant of Flp that lacks the active site tyrosine, Flp(Y343F), is incapable of mediating strand transfer in a full-recombination site but can execute strand transfer in a half-site. The efficiency of this reaction is about 2% of that of the wild type reaction. The activity of Flp(Y343F) is critically dependent on the length of the half-site spacer. Furthermore, in this reaction, the strand cleavage and strand exchange steps cannot be uncoupled. These results strongly suggest a direct attack by the 5'-hydroxyl of the half-site spacer on the phosphodiester at the normal strand transfer point.			SERRE, MC (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.		Serre, Marie-Claude/B-4159-2008	SERRE, Marie-Claude/0000-0002-7899-9833				ALTMAN S, 1990, J BIOL CHEM, V265, P20053; AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIG NL, 1988, ANNU REV GENET, V22, P77; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FLOSS HG, 1984, TOP STEREOCHEM, V15, P253, DOI 10.1002/9780470147245.ch4; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; Maniatis T., 1982, MOL CLONING; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PACE NR, 1990, J BIOL CHEM, V265, P3587; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIAN XH, 1992, J BIOL CHEM, V267, P7794; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					455	463						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416950				2022-12-25	WOS:A1993KE60300070
J	TOMIYA, N; AWAYA, J; KURONO, M; HANZAWA, H; SHIMADA, I; ARATA, Y; YOSHIDA, T; TAKAHASHI, N				TOMIYA, N; AWAYA, J; KURONO, M; HANZAWA, H; SHIMADA, I; ARATA, Y; YOSHIDA, T; TAKAHASHI, N			STRUCTURAL ELUCIDATION OF A VARIETY OF GALNAC-CONTAINING N-LINKED OLIGOSACCHARIDES FROM HUMAN URINARY KALLIDINOGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCANASE-RELEASED OLIGOSACCHARIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; PITUITARY GLYCOPROTEIN HORMONES; SIALYLATED OLIGOSACCHARIDES; LUTROPIN; FOLLITROPIN; THYROTROPIN; KALLIKREIN; BOVINE; OVINE	Fifteen different structures of terminal GalNAc-containing N-linked oligosaccharides from human urinary kallidinogenase have been identified. These N-linked oligosaccharides were mostly neutral, because sialic acid content was lower than 0.13 mol of sialic acid/mol of sugar chain, and sulfate was not detected. The oligosaccharides were released from pepsin-digested protein by glycoamidase A (from almond) digestion. The reducing ends of the oligosaccharide chains were aminated with a fluorescent reagent, 2-aminopyridine. The resulting mixture of pyridylamino derivatives of the oligosaccharides were separated by high performance liquid chromatography on an ODS-silica column, and 15 oligosaccharides were isolated. The structure of each oligosaccharide fraction was analyzed by two-dimensional sugar mapping, component sugar analysis, high resolution proton nuclear magnetic resonance and methylation analysis. It was found that each N-linked oligosaccharide associated with human urinary kallidinogenase contains unsubstituted GalNAc residues at the nonreducing terminal. These 15 oligosaccharides include 5 biantennary, 7 triantennary, and 3 tetraantennary oligosaccharides.	NAKANO VINEGAR CO LTD,NAKANO CENT RES INST,GLYCOLAB,2-6 NAKAMURA CHO,HANDA,AICHI 475,JAPAN; SANWA KAGAKU KENKYUSHO CO LTD,MIE RES LAB,HOKUSEI,MIE 51104,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN; NAGOYA UNIV,SCH MED,SHOWA KU,NAGOYA,AICHI 464,JAPAN	Sanwa Kagaku Kenkyusho Co., Ltd.; University of Tokyo; Nagoya University								BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1987, J BIOL CHEM, V262, P12018; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1987, J BIOL CHEM, V262, P12030; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; JOSEF K, 1988, PROTEIN SEQUENCES DA, V1, P177; LU HS, 1989, INT J PEPT PROT RES, V33, P237; MILLS IH, 1975, J PHYSIOL-LONDON, V251, P281, DOI 10.1113/jphysiol.1975.sp011092; NUSTAD K, 1975, BRIT J PHARMACOL, V53, P229, DOI 10.1111/j.1476-5381.1975.tb07353.x; NYAME K, 1989, J BIOL CHEM, V264, P3235; ROBLERO J, 1976, AM J PHYSIOL, V231, P1383, DOI 10.1152/ajplegacy.1976.231.5.1383; ROCKLIN RD, 1983, J LIQ CHROMATOGR, V6, P1577, DOI 10.1080/01483918308064876; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; TAKAHASHI N, 1987, BIOCHEMISTRY-US, V26, P1137, DOI 10.1021/bi00378a023; TAKAHASHI N, 1992, PROTEIN NUCLEIC ACID, V37, P2117; TAKAHASHI S, 1988, J BIOCHEM-TOKYO, V104, P22, DOI 10.1093/oxfordjournals.jbchem.a122415; TOMIYA N, 1987, ANAL BIOCHEM, V163, P489, DOI 10.1016/0003-2697(87)90253-3; TOMIYA N, 1988, BIOCHEMISTRY-US, V27, P7146, DOI 10.1021/bi00418a072; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TSUDA E, 1988, BIOCHEMISTRY-US, V27, P5646, DOI 10.1021/bi00415a038; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; WEISSHAAR G, 1990, EUR J BIOCHEM, V192, P741, DOI 10.1111/j.1432-1033.1990.tb19285.x	31	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					113	126						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416919				2022-12-25	WOS:A1993KE60300019
J	DUFORT, D; DROLET, M; NEPVEU, A				DUFORT, D; DROLET, M; NEPVEU, A			A PROTEIN-BINDING SITE FROM THE MURINE C-MYC PROMOTER CONTRIBUTES TO TRANSCRIPTIONAL BLOCK	ONCOGENE			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; RNA POLYMERASE-II; 3' END FORMATION; GENE-EXPRESSION; ANTITERMINATION PROTEIN; SNRNA PROMOTER; LAC PROMOTER; 1ST EXON; ELONGATION; TERMINATION	Recent studies have revealed that expression of several eukaryotic genes can be regulated at the level of transcription elongation. As a first step to elucidate the mechanism by which transcription elongation is modulated, several groups have identified sequences necessary for transcriptional block within the c-myc gene. These studies indicated that transcriptional block depends not only on sequences surrounding the sites of block, but also on sequences within the promoter: some deletions within the c-myc promoter eliminated transcriptional block and, with chimeric constructs, transcriptional block was observed when some heterologous promoters but not others were fused to the c-myc termination region. Using a chimeric construct containing the H-2K(b) major histocompatibility class gene promoter linked to the c-myc first exon, we show that transcriptional block is increased by the addition of a 25 bp DNA sequence from the c-myc promoter. Similar results are obtained whether this sequence is inserted upstream or downstream of the transcription initiation site. We further show that nuclear factors interact with this sequence in vitro. Interestingly, when a mutated version of this sequence was tested, we observed decreased nuclear factor binding in vitro as well as reduced transcriptional block in nuclear run-on transcription assays. These results suggest that interactions of protein factors with specific nucleotide sequences near the transcription initiation site can affect elongation of transcription at sites located further down stream.	MCGILL UNIV,DEPT ONCOL,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University			/AAB-8315-2020	Dufort, Daniel/0000-0002-6477-596X				ASSELIN C, 1989, ONCOGENE, V4, P549; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BESSE M, 1986, EMBO J, V5, P1377, DOI 10.1002/j.1460-2075.1986.tb04370.x; DEVEGVAR HEN, 1986, CELL, V47, P259; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	35	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					165	171						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423994				2022-12-25	WOS:A1993KN00500020
J	SHIN, S; STEFFEN, DL				SHIN, S; STEFFEN, DL			FREQUENT ACTIVATION OF THE LCK GENE BY PROMOTER INSERTION AND ABERRANT SPLICING IN MURINE LEUKEMIA VIRUS-INDUCED RAT LYMPHOMAS	ONCOGENE			English	Article							TYROSINE-PROTEIN-KINASE; INBRED MOUSE STRAINS; SIGNAL TRANSDUCTION; CD4 RECEPTOR; P56LCK; SITES; MICE; RNA	We have analysed DNA and RNA from 36 T-cell lymphomas induced in Fischer rats by Moloney murine leukemia virus for alterations affecting the structure or expression of the lck gene. At least five primary tumors (14%) have a proviral insertion upstream of lck. In at least four of the tumors, proviral insertion increases lck mRNA levels an average of eight-fold. Overexpression of lck results from transcription initiating in the viral promoter and extending into lck sequences. Three different structures of hybrid transcript were detected. In all three, the hybrid RNAs are spliced to a normal lck splice acceptor in the first exon of lck, resulting in removal of three out of frame ATG codons which would be expected to increase the translation efficiency of the hybrid message. In one tumor, the viral splice donor is used, in one tumor, proviral insertion generates a splice donor sequence one base pair downstream of the long terminal repeat boundary, and in two tumors, a cryptic splice donor in the upstream lck sequences is used. The significance of these unusual splicing patterns and of the higher frequency of proviral insertions adjacent to lck in rats relative to mice is discussed.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA30674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERGER SL, 1987, METHOD ENZYMOL, V152, P215; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; CLOYD MW, 1980, J EXP MED, V151, P542, DOI 10.1084/jem.151.3.542; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GISSELBRECHT S, 1981, INT J CANCER, V27, P531, DOI 10.1002/ijc.2910270417; GREEN N, 1980, J EXP MED, V152, P2498; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LAWRENCE CB, 1989, EUGENE SOFTWARE PACK; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUCENSKI ML, 1987, J VIROL, V61, P2929, DOI 10.1128/JVI.61.9.2929-2933.1987; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SITBON M, 1985, VIROLOGY, V140, P144, DOI 10.1016/0042-6822(85)90453-2; STEFFEN D, 1984, P NATL ACAD SCI-BIOL, V81, P2097, DOI 10.1073/pnas.81.7.2097; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIJAYA S, 1987, J VIROL, V61, P1164, DOI 10.1128/JVI.61.4.1164-1170.1987; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					141	149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423992				2022-12-25	WOS:A1993KN00500017
J	LIU, BX; WEI, W; BROEK, D				LIU, BX; WEI, W; BROEK, D			THE CATALYTIC DOMAIN OF THE MOUSE SOS1 GENE-PRODUCT ACTIVATES RAS PROTEINS IN-VIVO AND IN-VITRO	ONCOGENE			English	Article							SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; CDC25 GENE; IDENTIFICATION; PATHWAY; CLONING; CDNAS	Nucleotide exchange factors (NEFs) which are structurally related to the yeast Saccharomyces cerevisiae CDC25 gene product have recently been identified in mammals. One of these NEFs, cdc25, has been shown to activate RAS in yeast and to promote nucleotide exchange on RAS proteins in vitro. The cdc25 from mammals is expressed at high levels in brain tissue but not in a variety of other tissues examined. The vertebrate sos1 and sos2 gene products have a domain structurally related to the catalytic domain of the yeast CDC25NEF. The expression pattern of sos1 and sos2 is widespread, showing detectable levels of expression in all tissues examined, although the levels vary dramatically in various tissues. In this report we demonstrate that the catalytic domain of SOS1NEF can complement the loss of CDC25 function in yeast, can bind tightly to the nucleotide-free form of H-ras in vitro and can promote nucleotide exchange on the H-ras protein in vitro.	UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; Innis MA, 1990, PCR PROTOCOLS GUIDE; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUET E, 1993, IN PRESS J BIOL CHEM; KIM JH, 1991, MOL CELL BIOL, V11, P3894, DOI 10.1128/MCB.11.8.3894; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	18	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3081	3084						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414509				2022-12-25	WOS:A1993MC09300024
J	ADACHI, K; KONITZER, P; KIM, JY; WELCH, N; SURREY, S				ADACHI, K; KONITZER, P; KIM, JY; WELCH, N; SURREY, S			EFFECTS OF BETA-6 AROMATIC-AMINO-ACIDS ON POLYMERIZATION AND SOLUBILITY OF RECOMBINANT HEMOGLOBINS MADE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; ESCHERICHIA-COLI; SUBUNIT DISSOCIATION; DEOXYHEMOGLOBIN-S; KINETICS; FLUORESCENCE; GELATION; HB; SUBSTITUTION; MUTAGENESIS	Valine, leucine, tryptophan, and phenylalanine substitutions at the beta6 position of hemoglobin (Hb) were made using a yeast expression system coupled with a polymerase chain reaction-based mutagenesis strategy. The oxygen affinity and absorption spectra of these mutants were similar to recombinant Hb A except for Hb betaE6W which had a higher absorbance at approximately 280 nm. The deoxy forms of Hb betaE6L and Hb S showed characteristic delay times prior to polymerization. Tetrameric deoxy-Hbs containing tryptophan or phenylalanine at the beta6 position had higher solubilities and polymerized less readily compared with deoxy-Hb S. However, when oversaturated, these Hbs polymerized without a delay time. These results suggest that Hb betaE6W and Hb betaE6F form polymers upon deoxygenation by a linear polymerization mechanism without nuclei formation. During polymerization, bulky hydrophobic amino acids, like phenylalanine and tryptophan at the beta6 position, might interact with the acceptor pocket on the surface of an adjacent Hb molecule but may not be able to form stable hydrophobic interactions like beta6 valine and leucine. Difficulty in insertion of the bulky side chains of these aromatic amino acids into the hydrophobic acceptor pocket on an adjacent tetramer may inhibit nuclei formation prior to polymerization.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; Childrens Hospital of Philadelphia	ADACHI, K (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV HEMATOL,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL 32908, P60 HL 38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL032908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1980, J MOL BIOL, V144, P467, DOI 10.1016/0022-2836(80)90332-0; ADACHI K, 1979, J BIOL CHEM, V254, P2273; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1987, J BIOL CHEM, V262, P12920; ADACHI K, 1988, J BIOL CHEM, V263, P5607; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; Antonini E., 1971, FRONT BIOL, V21, P19; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P452; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; COGHLAN D, 1992, EUR J BIOCHEM, V207, P931, DOI 10.1111/j.1432-1033.1992.tb17126.x; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERRONE FA, 1980, BIOPHYS J, V32, P361, DOI 10.1016/S0006-3495(80)84962-9; FERRONE FA, 1985, J MOL BIOL, V183, P591, DOI 10.1016/0022-2836(85)90174-3; FESTA RS, 1979, TRANSFUSION, V19, P107, DOI 10.1046/j.1537-2995.1979.19279160278.x; FRONTICELLI C, 1978, J BIOL CHEM, V253, P2288; GILL SJ, 1979, J MOL BIOL, V130, P175, DOI 10.1016/0022-2836(79)90425-X; HERNAN RA, 1992, BIOCHEMISTRY-US, V31, P8619, DOI 10.1021/bi00151a032; HIRSCH RE, 1983, BIOCHEM BIOPH RES CO, V116, P712, DOI 10.1016/0006-291X(83)90583-1; HIRSH RE, 1991, BLOOD, V78, P199; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1986, J MOL BIOL, V189, P553, DOI 10.1016/0022-2836(86)90324-4; IP SHC, 1976, BIOCHEMISTRY-US, V15, P654, DOI 10.1021/bi00648a032; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KUEZERA K, 1990, P NATL ACAD SCI USA, V87, P8481; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Oosawa F., 1975, THERMODYNAMICS POLYM; PERUTZ M, 1968, NATURE, V288, P726; PERUTZ MF, 1950, NATURE, V166, P677, DOI 10.1038/166677a0; RUSSU IM, 1982, BIOCHEMISTRY-US, V21, P5044, DOI 10.1021/bi00263a030; SASAKI J, 1978, J BIOL CHEM, V253, P87; SCHECHTER AN, 1980, HEMOGLOBIN, V4, P335, DOI 10.3109/03630268008996215; SCHROEDER WA, 1984, HDB HPLC SEPARATION, V11, P287; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WEBER G, 1953, ADV PROTEIN CHEM, V8, P415, DOI 10.1016/S0065-3233(08)60096-0; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	47	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21650	21656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408017				2022-12-25	WOS:A1993MC80900036
J	SCHNEIDER, A; MCNALLY, KP; AGABIAN, N				SCHNEIDER, A; MCNALLY, KP; AGABIAN, N			SPLICING AND 3'-PROCESSING OF THE TYROSINE TRANSFER-RNA OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-TRANSFER RNAS; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; INTRON; IDENTIFICATION; ENDONUCLEASE; SEQUENCE; INVIVO; TRANSCRIPTION; ORGANIZATION	Trypanosoma brucei belongs to a family of protozoa that is characterized as having diverged early in the evolution of eukaryotes. Many unusual forms of RNA processing have been discovered in these cells, one of which is trans-splicing, and, although a great number of genes have been sequenced, no evidence for cis-splicing has yet been found. This study shows that tRNA(Tyr) of T. brucei contains an 11-nucleotide intron. tRNA of the size predicted for unspliced precursor was detected by Northern analysis using an oligonucleotide probe complementary to the putative intervening region. Direct sequence analysis of mature tRNA(Tyr) showed that the predicted intron region is absent from this form of the molecule. Mutated versions of the gene encoding tRNA(Tyr) were introduced into trypanosomes by DNA transformation and shown to be expressed in vivo. Introduction into the genome of a tRNA(Tyr) gene containing an amber suppressor mutation led to a significant accumulation of unspliced precursor molecules. Analysis of the tRNA(Tyr) species from both the wild type and transformed cells revealed unspliced and spliced processing intermediates. The relative abundance of each of these intermediates suggests that 3'-processing and splicing occur independently and that, in the wild type, splicing tends to precede 3'-processing and CCA addition.	UNIV CALIF SAN FRANCISCO,INTERCAMPUS PROGRAM MOLEC PARASITOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021975] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21975] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELSON J, 1992, SCIENCE, V255, P1390, DOI 10.1126/science.1542787; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CAMPBELL DA, 1989, MOL BIOCHEM PARASIT, V37, P257, DOI 10.1016/0166-6851(89)90157-6; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P9479, DOI 10.1093/nar/17.22.9479; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DEROBERTIS EM, 1979, NATURE, V278, P137, DOI 10.1038/278137a0; EID JE, 1991, GENE DEV, P2024; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; HANCOCK K, 1992, J BIOL CHEM, V267, P23963; HANCOCK K, 1992, NUCLEIC ACIDS RES, V20, P4567; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JOHNSON PF, 1983, NATURE, V302, P681, DOI 10.1038/302681a0; KJEMS J, 1989, J BIOL CHEM, V264, P17834; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MOTTRAM JC, 1991, NUCLEIC ACIDS RES, V19, P3995, DOI 10.1093/nar/19.14.3995; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; PERELMAN D, 1990, MOL CELL BIOL, V10, P3284, DOI 10.1128/MCB.10.6.3284; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SPRINZL M, 1987, NUCLEIC ACIDS RES, V15, pR53, DOI 10.1093/nar/15.suppl.r53; STANGE N, 1988, EMBO J, V7, P3823, DOI 10.1002/j.1460-2075.1988.tb03267.x; STROBEL MC, 1986, MOL CELL BIOL, V6, P2663, DOI 10.1128/MCB.6.7.2663; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; SZWEYKOWSKAKULINSKA Z, 1991, NUCLEIC ACIDS RES, V19, P707, DOI 10.1093/nar/19.4.707; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0	33	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21868	21874						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408041				2022-12-25	WOS:A1993MC80900066
J	WRAY, JW; ABELES, RH				WRAY, JW; ABELES, RH			A BACTERIAL ENZYME THAT CATALYZES FORMATION OF CARBON-MONOXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BIOSYNTHESIS	We have isolated and purified an enzyme (E-2) from Klebsiella pneumoniae, which catalyzes the formation of CO from CH3-S-CH2-CH2-CO-C(OH)=CH-O- (III). This compound is an intermediate in the conversion of 5'-methylthioadenosine to methionine. Concomitant with CO formation, methylthiopropionic acid and formate are produced and O2 is consumed. E-2 also catalyzes the formation of CO, formate, and butyrate from CH3-CH2-CH2-CO-C(OH)=CH-O-(IIIa), the desthio analog of III. Experiments with isotopic IIIa have shown that formate is derived from 1-C, and CO from 2-C. E-2 has a M(r) = 18,500 and requires Mg2+, and no chromophoric cofactor has been detected.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012633, T32GM007596, R37GM012633] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM07596-15, GM12633-30] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAKRISHNAN R, 1993, IN PRESS J BIOL CHEM, V268; CHEESBROUGH TM, 1984, P NATL ACAD SCI-BIOL, V81, P6613, DOI 10.1073/pnas.81.21.6613; COREY EJ, 1971, J ORG CHEM, V36, P3553, DOI 10.1021/jo00822a019; DIEKERT G, 1986, ARCH MICROBIOL, V144, P386, DOI 10.1007/BF00409889; ELIEL EL, 1972, J ORG CHEM, V7, P505; HINO S, 1987, ARCH MICROBIOL, V148, P167, DOI 10.1007/BF00414807; MEYERS RW, 1993, IN PRESS J BIOL CHEM, V268; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; SEEBACH D, 1975, J ORG CHEM, V40, P231, DOI 10.1021/jo00890a018; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Waterman M R, 1978, Methods Enzymol, V52, P456	13	57	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21466	21469						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8407993				2022-12-25	WOS:A1993MC80900004
J	YORK, D; FILUTOWICZ, M				YORK, D; FILUTOWICZ, M			AUTOREGULATION-DEFICIENT MUTANT OF THE PLASMID R6K-ENCODED PI-PROTEIN DISTINGUISHES BETWEEN PALINDROMIC AND NONPALINDROMIC BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION INITIATOR PROTEIN; R6K DNA-REPLICATION; NUCLEOTIDE-SEQUENCES; ESCHERICHIA-COLI; ORIGIN; BACTERIOPHAGE-M2; ARRANGEMENT; TOPOGRAPHY; ACTIVATION; COMPLEXES	The autogenously regulated gene pir of Escherichia coli plasmid R6K encodes the replication protein pi. This protein binds to two sites in the operator region of the pir gene: a 22-base pair nonpalindromic sequence and a pair of palindromic 9-base pair sequences. These pi-binding sites are similar, suggesting that pi uses a single DNA-binding domain in recognizing them. We devised a plasmid system permitting isolation of mutants of the pi protein which are altered in autoregulation. A Ser87 to Asn substitution in one such mutant, designated pi87, reduces the protein's ability to repress the pir gene promoter in vivo. DNase I protection and gel retardation assays were carried out with highly purified pi87 protein. In these studies pi87 exhibited altered binding to the palindromic but not to the nonpalindromic part of the operator of the pir gene. Chemical cross-linking and gel filtration analyses have shown that the dimerization properties of wild type pi and pi87 proteins are similar in solution. We propose that the interaction of pi protein with the palindromic part of the pir operator is essential for autoregulation; we also propose that there is a fundamental difference in the mechanisms of pi protein recognition of palindromic and nonpalindromic sequences.	UNIV WISCONSIN, DEPT BACTERIOL, EB FRED HALL, 1550 LINDEN DR, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040314] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; FILUTOWICZ M, 1986, J MOL BIOL, V187, P225, DOI 10.1016/0022-2836(86)90230-5; FILUTOWICZ M, 1987, J CELL SCI, P15; Filutowicz M., 1985, PLASMIDS BACTERIA, P125; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1982, P NATL ACAD SCI-BIOL, V79, P5475, DOI 10.1073/pnas.79.18.5475; GERMINO J, 1983, P NATL ACAD SCI-BIOL, V80, P6848, DOI 10.1073/pnas.80.22.6848; GIRALDO R, 1989, NATURE, V342, P866, DOI 10.1038/342866a0; GREENER A, 1992, GENETICS, V130, P27; GREENER A, 1990, MOL GEN GENET, V224, P24, DOI 10.1007/BF00259447; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KAMIO Y, 1988, J BACTERIOL, V170, P4411, DOI 10.1128/jb.170.9.4411-4414.1988; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KLINE BC, 1988, CAN J MICROBIOL, V34, P526, DOI 10.1139/m88-090; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KOBAYASHI H, 1991, MOL GEN GENET, V226, P65, DOI 10.1007/BF00273588; KOBAYASHI H, 1989, MOL GEN GENET, V220, P8, DOI 10.1007/BF00260848; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; MCEACHERN MJ, 1985, P NATL ACAD SCI USA, V82, P1480, DOI 10.1073/pnas.82.5.1480; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MILLER JH, 1972, EXPT MOL GENETICS, P125; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SHAFFERMAN A, 1982, J MOL BIOL, V161, P57, DOI 10.1016/0022-2836(82)90278-9; STALKER DM, 1982, J MOL BIOL, V161, P33, DOI 10.1016/0022-2836(82)90276-5; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YORK D, 1992, GENE, V116, P7, DOI 10.1016/0378-1119(92)90622-V	41	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21854	21861						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408040				2022-12-25	WOS:A1993MC80900064
J	FAN, Z; MENDELSOHN, J; MASUI, H; KUMAR, R				FAN, Z; MENDELSOHN, J; MASUI, H; KUMAR, R			REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN NIH3T3 HER14 CELLS BY ANTIRECEPTOR MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; HUMAN-BREAST CANCER; FACTOR-ALPHA; A431 CELLS; CARCINOMA-CELLS; EGF RECEPTOR; SIGNAL TRANSDUCTION; INDUCED ACTIVATION; PROTEIN; PHOSPHORYLATION	The mechanism(s) by which monoclonal antibodies (mAbs) against the epidermal growth factor (EGF) receptor regulate receptor function have been investigated with NIH3T3/HER14 fibroblasts expressing human EGF receptors. Bivalent 225 mAb or monovalent 225 Fab' inhibited transforming growth factor (TGF)-alpha-induced EGF receptor tyrosine phosphorylation and cell proliferation. Culture of HER14 cells with 225 mAb or 225 Fab' did not activate EGF receptor tyrosine kinase when assayed after lysis of cells in SDS sample buffer. However, when cells were cultured with bivalent 225 mAb, but not with monovalent 225 Fab', and were subsequently lysed and further incubated in Triton X-100 lysis buffer containing proteinase and phosphatase inhibitors, receptor phosphorylation was observed. Phosphorylation was confined to tyrosine residues and was inhibited by addition of genistein after lysis, indicating that it was due to the activation of protein tyrosine kinase. The activity of bivalent 225 mAb was unphysiologic, in contrast with TGF-alpha, in that receptor kinase activation occurred only after cell lysis and with delayed kinetics; serine and threonine phosphorylation did not occur; and down-regulation of EGF receptors was slower. Selective mAb-mediated phosphorylation of tyrosine residues on EGF receptors was sufficient to activate phosphorylation of a SH2 group-bearing substrate, phospholipase C-gamma, indicating that serine/threonine phosphorylation is not required for EGF receptor kinase activity. These studies provide novel insights into the capacity of bivalent mAb to modulate EGF receptor function.	MEM SLOAN KETTERING CANC CTR,RECEPTOR BIOL LAB,BOX 156,1275 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [U19CA037641, R37CA042060, R01CA042060, U01CA037641] Funding Source: NIH RePORTER; NCI NIH HHS [CA37641, CA42060] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARAKAKI N, 1992, BIOCHEM BIOPH RES CO, V185, P22, DOI 10.1016/S0006-291X(05)80949-0; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; ATLAS I, 1992, CANCER RES, V52, P3335; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DEFIZE LHK, 1987, CELL DIFFER DEV, V20, P87, DOI 10.1016/0045-6039(87)90423-4; DEMIGNOT S, 1989, J IMMUNOL METHODS, V121, P209, DOI 10.1016/0022-1759(89)90162-2; DIFIZE LH, 1986, EMBO J, V5, P1187; EK B, 1982, J BIOL CHEM, V257, P486; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FERNANDEZPOL JA, 1985, J BIOL CHEM, V260, P5003; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOOI HC, 1985, BIOSCIENCE REP, V5, P83; HOFER DR, 1991, CANCER RES, V51, P2780; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; MACHICAO F, 1982, FEBS LETT, V149, P96, DOI 10.1016/0014-5793(82)81079-X; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MASUI H, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P394; Mendelsohn J, 1987, Trans Assoc Am Physicians, V100, P173; MENDELSOHN J, 1988, CELLULAR MOL BIOL TU, P307; MENDELSOHN J, 1989, MOL DIAGNOSTICS HUMA, V7, P359; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PARHAM P, 1983, J IMMUNOL, V131, P2895; REISS M, 1991, CANCER RES, V51, P6254; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODECK U, 1987, CANCER RES, V47, P3692; RUBIN RA, 1983, J BIOL CHEM, V258, P5177; SANSOM CE, 1990, BRIT J CANCER, V62, P505; Sato J D, 1983, Mol Biol Med, V1, P511; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; SPAARGAREN M, 1990, BIOCHEM BIOPH RES CO, V171, P882, DOI 10.1016/0006-291X(90)91228-K; SUNADA H, 1985, ANAL BIOCHEM, V149, P438, DOI 10.1016/0003-2697(85)90595-0; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TORTI M, 1992, J BIOL CHEM, V267, P8293; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VERHEIJDEN GF, 1991, NATO ASI SERIES H, V52, P31; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	50	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21073	21079						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407944				2022-12-25	WOS:A1993MA28800067
J	GONZALEZGRONOW, M; GAWDI, G; PIZZO, SV				GONZALEZGRONOW, M; GAWDI, G; PIZZO, SV			PLASMINOGEN ACTIVATION STIMULATES AN INCREASE IN INTRACELLULAR CALCIUM IN HUMAN SYNOVIAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CELLS; DEGRADATION; INTERLEUKIN-1; PURIFICATION; MODULATION; MECHANISMS; ARTHRITIS; UROKINASE; COLLAGEN	Both plasminogen (Pg) and urinary-type Pg activator (u-PA), but not tissue-type Pg activator (t-PA), bind to normal and rheumatoid arthritis (RA) human synovial fibroblasts in culture with high affinity and in a dose-dependent manner. Single cell intracellular Ca2+ responses to Pg and u-PA were studied using Fura-2 and digital imaging fluorescence microscopy. Pg activation by u-PA on the surface of RA synovial fibroblasts induces a significant rise in cytosolic free Ca2+ concentration ([Ca2+]i) within 90 s. Pg kringle 4 and the alpha2,3-linked sialic acid in the carbohydrate chain bound to Thr245 are involved in mediating the increases in [Ca2+)i. This response is not observed in normal synovial fibroblasts, suggesting that RA synovial fibroblasts have altered responses to the binding and activation of Pg on their surfaces.			GONZALEZGRONOW, M (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043339, R01HL031932] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43339, HL-31932] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMANO J, 1989, BIOCHEMISTRY-US, V28, P2374; ANDREWS HJ, 1990, BIOCHIM BIOPHYS ACTA, V1051, P84, DOI 10.1016/0167-4889(90)90177-F; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BROMMER EJP, 1992, ANN RHEUM DIS, V51, P965, DOI 10.1136/ard.51.8.965; CASTOR CW, 1971, J LAB CLIN MED, V77, P65; COLLEN D, 1987, J CELL BIOCHEM, V33, P77, DOI 10.1002/jcb.240330202; COLLIER S, 1988, J RHEUMATOL, V15, P1129; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FIBBI G, 1986, BIOCHIM BIOPHYS ACTA, V885, P301, DOI 10.1016/0167-4889(86)90245-4; GANZ PR, 1990, BIOCH CELL BIOL, V69, P442; GONZALEZGRONOW M, 1977, J BIOL CHEM, V252, P2175; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KUMMER JA, 1992, ARTHRITIS RHEUM, V35, P884; LACK CH, 1958, NATURE, V182, P948, DOI 10.1038/182948a0; LO SK, 1989, J CLIN INVEST, V84, P793, DOI 10.1172/JCI114238; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1985, J BIOL CHEM, V260, P4303; MOCHAN E, 1984, BIOCHIM BIOPHYS ACTA, V800, P312, DOI 10.1016/0304-4165(84)90412-4; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; ROBBINS KC, 1977, HAEMOSTASIS BIOCH PH, P208; SCHAFER AI, 1986, J CLIN INVEST, V78, P73, DOI 10.1172/JCI112576; SOTTRUPJENSEN L, 1978, FIBRINOLYSIS THROMBO, V3, P199; STACK MS, 1992, BIOCHEM J, V284, P81, DOI 10.1042/bj2840081; UHL J, 1991, BIOCHIM BIOPHYS ACTA, V1097, P283, DOI 10.1016/0925-4439(91)90082-K; VAES G, 1978, BIOCHEM J, V172, P261, DOI 10.1042/bj1720261; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WINTERS KJ, 1990, BLOOD, V76, P1546	34	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20791	20795						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407906				2022-12-25	WOS:A1993MA28800025
J	OSTANIN, K; VANETTEN, RL				OSTANIN, K; VANETTEN, RL			ASP(304) OF ESCHERICHIA-COLI ACID-PHOSPHATASE IS INVOLVED IN LEAVING GROUP PROTONATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSYL-PROTEIN PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; BOVINE HEART; PH; PHOSPHORYLATION; DEPENDENCE; MECHANISM; CATALYSIS; RESIDUE	Site-directed mutagenesis was used to explore the role of potential proton donors in the mechanism of the Escherichia coli acid phosphatase that is encoded by the appA gene. Asp304 appeared to be the only carboxylic acid residue that is conserved in the protein sequences of the high molecular weight acid phosphatases. The mutations Asp304Ala and Asp304Glu were introduced into appA and the corresponding proteins were overexpressed in E. coli and purified to homogeneity. Only small decreases were observed for the K(m) values of the substrates p-nitrophenyl phosphate, fructose 1,6-diphosphate, and tripolyphosphate. However, V(max) was greatly decreased, and the magnitude of effect depended markedly on substrate. Both mutant proteins exhibited significantly lower V(max) values with fructose 1,6-diphosphate, which possesses a much poorer leaving group than do the other two substrates. The importance of the leaving group was further tested by using a number of phenyl and alkyl phosphate derivatives as substrates. A linear correlation was observed between log V(max) and the pK(a) of the substrate leaving group for catalysis by the Asp304Ala mutant enzyme. These results are consistent with partition experiments using ethylene glycol as an alternate nucleophile, which indicated that for the Asp304Ala protein, the formation of a phosphoenzyme intermediate is the rate-determining step, in contrast to the situation for the wild type enzyme and the His303Ala mutant. In the latter case, the rate-limiting step of the reaction is interpreted to be the breakdown of phosphoenzyme. It is concluded that Asp304, rather than His303, is involved in protonation of the substrate leaving group.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27713] Funding Source: Medline; NIGMS NIH HHS [GM 27003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BENDER ML, 1962, J AM CHEM SOC, V84, P2570, DOI 10.1021/ja00872a022; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; DASSA E, 1982, J BIOL CHEM, V257, P6669; DASSA J, 1990, J BACTERIOL, V172, P5497, DOI 10.1128/jb.172.9.5497-5500.1990; DAVIDSON RE, 1990, THESIS PURDUE U W LA; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; HINBERG I, 1972, CAN J BIOCHEM CELL B, V50, P1360, DOI 10.1139/o72-179; HINBERG I, 1972, CAN J BIOCHEM CELL B, V50, P1334, DOI 10.1139/o72-178; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN K, 1992, J BIOL CHEM, V267, P19163; LIN K, 1992, J BIOL CHEM, V267, P6556; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P422, DOI 10.1016/0005-2744(78)90044-X; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P407, DOI 10.1016/0005-2744(78)90043-8; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; SAINI MS, 1979, BIOCHIM BIOPHYS ACTA, V568, P370, DOI 10.1016/0005-2744(79)90305-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAULER A, 1990, J BIOL CHEM, V265, P15617; VANETTEN RL, 1977, BIOCHIM BIOPHYS ACTA, V484, P386, DOI 10.1016/0005-2744(77)90094-8; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516	27	55	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20778	20784						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407904				2022-12-25	WOS:A1993MA28800023
J	BAKER, AH; RIDGE, SA; HOY, T; CACHIA, PG; CULLIGAN, D; BAINES, P; WHITTAKER, JA; JACOBS, A; PADUA, RA				BAKER, AH; RIDGE, SA; HOY, T; CACHIA, PG; CULLIGAN, D; BAINES, P; WHITTAKER, JA; JACOBS, A; PADUA, RA			EXPRESSION OF THE COLONY-STIMULATING FACTOR-I RECEPTOR IN B-LYMPHOCYTES	ONCOGENE			English	Article							FMS PROTO-ONCOGENE; FACTOR-I RECEPTOR; C-FMS; CSF-1 RECEPTOR; CELL-LINES; HUMAN-MONOCYTES; PRODUCT; ACTIVATION; TRANSCRIPTION; KINASE	The FMS proto-oncogene encodes for the colony-stimulating factor 1 receptor (CSF-1R), whose expression within the haematopoietic system has previously been thought to be restricted to cells of the mononuclear phagocyte lineage. We have studied the expression of the CSF-1R in peripheral blood mononuclear cells by indirect immunofluorescence and flow cytometry. FMS expression was detected on both monocytes and B lymphocytes from all samples analysed, including 14 haematologically normal individuals and 31 patients (23 in remission following cytotoxic therapy for lymphoma, six with B-cell chronic lymphocytic leukaemia and two with chronic myelomonocytic leukaemia). The level of FMS expression on B lymphocytes was lower than the level of expression detected on monocytes isolated from the same sample. FMS mRNA expression in B lymphocytes has been confirmed by a reverse transcription-polymerase chain reaction (RT-PCR)-based technique and Northern blot analysis. Thus, FMS may play a role in the normal function of B lymphocytes and, because of its potential oncogenic activity, may contribute to the pathogenesis of malignancies of this cell type.	UNIV WALES COLL MED, DEPT HAEMATOL, LEUKAEMIA RES FUND PRELEUKAEMIA UNIT, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University			PADUA, Rose Ann/E-8621-2019; Baker, Andy/AAO-5250-2021; Padua, Rose Ann/GVT-5961-2022	PADUA, Rose Ann/0000-0001-9964-7864; Baker, Andy/0000-0003-1441-5576; 				ASHMUN RA, 1989, BLOOD, V73, P827; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAS SK, 1982, J BIOL CHEM, V257, P13679; DECINO P, 1988, ONCOGENE RES, V3, P33; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DOWNING JR, 1991, ONCOGENE, V6, P607; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HORIGUCHI J, 1987, BLOOD, V69, P1259; JANOWSKAWIECZOREK A, 1991, BLOOD, V77, P1796; KHALILI K, 1984, J MOL BIOL, V175, P453, DOI 10.1016/0022-2836(84)90179-7; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MELCHERS F, 1984, CELL, V37, P715, DOI 10.1016/0092-8674(84)90407-0; MULLER R, 1983, MOL CELL BIOL, V3, P1062; OSTER W, 1987, BLOOD, V70, P1700; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REISBACH G, 1989, BLOOD, V74, P959; REISBACH G, 1987, CELL IMMUNOL, V109, P246, DOI 10.1016/0008-8749(87)90308-X; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; RIDGE SA, 1990, BLOOD S, V1, pA244; ROBERTS WM, 1992, BLOOD, V79, P586; ROBERTS WM, 1991, BLOOD S, V1, pA340; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Sambrook J, 1989, MOL CLONING LABORATO; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORG R, 1991, EXP HEMATOL, V19, P882; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TOBAL K, 1990, LEUKEMIA, V4, P486; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; [No title captured]	46	25	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426743				2022-12-25	WOS:A1993KN00600016
J	PULVERER, BJ; HUGHES, K; FRANKLIN, CC; KRAFT, AS; LEEVERS, SJ; WOODGETT, JR				PULVERER, BJ; HUGHES, K; FRANKLIN, CC; KRAFT, AS; LEEVERS, SJ; WOODGETT, JR			COPURIFICATION OF MITOGEN-ACTIVATED PROTEIN-KINASES WITH PHORBOL ESTER-INDUCED C-JUN KINASE-ACTIVITY IN U937 LEUKEMIC-CELLS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; ENHANCER ACTIVITY; MAP KINASES; PHOSPHORYLATION; INSULIN; GENES; DIFFERENTIATION; EXPRESSION; TYROSINE; TPA	Phorbol esters, such as phorbol myristate acetate (PMA), cause differentiation of U937 human mono-myelocytic cells along the macrophage pathway. Within 15 min of PMA treatment DNA binding of the c-jun transcription factor is increased and is accompanied by rapid changes in the phosphate content of the c-jun protein. Phorbol esters stimulate phosphorylation of serines 63 and 73 located within the Al transactivation domain of c-Jun that have previously been shown to positively regulate activity. A protein kinase activity is detectable in extracts of phorbol ester-treated U937 cells that specifically targets these two serines. Using novel assays, the protein kinase activity has been purified over 1000-fold. The major portion of protein kinase activity co-chromatographs over three columns with pp42/44 mitogen-activated protein kinases as judged by immunological methods. The significance of these results with respect to mitogen-induced transcription of AP-1-responsive genes is discussed.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ALABAMA, DEPT HAEMATOL ONCOL, BIRMINGHAM, AL 35294 USA; CHESTER BEATTY LABS, INST CANC RES, LONDON SW3 6JB, ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Alabama System; University of Alabama Birmingham; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODE N, 1992, J BIOL CHEM, V267, P16878; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KRAFT AS, 1989, CANCER RES, V49, P1287; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Woodgett J R, 1990, Semin Cancer Biol, V1, P389	45	78	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					407	415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426747				2022-12-25	WOS:A1993KN00600020
J	DAVID, LL; SHEARER, TR; SHIH, M				DAVID, LL; SHEARER, TR; SHIH, M			SEQUENCE-ANALYSIS OF LENS BETA-CRYSTALLINS SUGGESTS INVOLVEMENT OF CALPAIN IN CATARACT FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT LENS; PROTEOLYSIS; PROTEIN	Abnormal activation of the protease calpain in the lens may be a cause of cataracts. Cataracts were induced in 10-day-old rats by a single overdose of sodium selenite. The water-insoluble protein from the opaque lens nucleus was separated by two-dimensional electrophoresis, electroblotted onto membranes, and the NH2-terminal sequence of partially degraded beta-crystallin polypeptides determined. Selenite cataractous lenses contained four major structural proteins, betaB1, betaB3, betaA3/A1, and betaA4 crystallins, missing from 5 to 49 amino acids from their NH2 termini. Incubation of intact beta-crystallins with calpain II in vitro produced identical cleavage sites. This provided further evidence for the role of calpain in the production of light scattering insoluble protein in cataractous lenses and also suggested that a similar process may lead to lens protein insolubilization during aging.	OREGON HLTH SCI UNIV,DEPT OPHTHALMOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	DAVID, LL (corresponding author), OREGON HLTH SCI UNIV,DEPT ORAL MOLEC BIOL,611 SW CAMPUS DR,PORTLAND,OR 97201, USA.				NATIONAL EYE INSTITUTE [R01EY003600, R01EY007755, R29EY007755] Funding Source: NIH RePORTER; NEI NIH HHS [EY07755, EY03600] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AZUMA M, 1992, FEBS LETT, V307, P313, DOI 10.1016/0014-5793(92)80703-J; AZUMA M, 1992, OPHTHALMIC RES, V24, P8, DOI 10.1159/000267138; BATEMAN OA, 1992, EXP EYE RES, V55, P127, DOI 10.1016/0014-4835(92)90100-7; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; DAVID L, UNPUB; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DAVID LL, 1987, INVEST OPHTH VIS SCI, V28, P1148; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; DAVID LL, 1992, BIOCHIM BIOPHYS ACTA, V1139, P210, DOI 10.1016/0925-4439(92)90136-B; DENDUNNEN JT, 1985, BIOCHIM BIOPHYS ACTA, V824, P295, DOI 10.1016/0167-4781(85)90035-1; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PETERSON CA, 1986, GENE, V45, P139, DOI 10.1016/0378-1119(86)90248-9; PIERSCIONEK B, 1988, CURR EYE RES, V7, P11, DOI 10.3109/02713688809047015; SHEARER TR, 1991, INVEST OPHTH VIS SCI, V32, P533; Takahashi K., 1990, INTRACELLULAR CALCIU, P56; VANRENS GLM, 1991, GENE, V102, P179, DOI 10.1016/0378-1119(91)90149-6	17	114	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1937	1940						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420967				2022-12-25	WOS:A1993KH62000067
J	LILIENBAUM, A; PAULIN, D				LILIENBAUM, A; PAULIN, D			ACTIVATION OF THE HUMAN VIMENTIN GENE BY THE TAX HUMAN T-CELL LEUKEMIA VIRUS-I - MECHANISMS OF REGULATION BY THE NF-KAPPA-B TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEINS; DNA-BINDING; MAMMALIAN-CELLS; INTERLEUKIN-6 GENE; REL ONCOGENE; EXPRESSION; PROMOTER; HTLV-1; SEQUENCE; PROLIFERATION	The molecular basis for transactivation of the human vimentin gene by the Tax protein from he human T-cell leukemia virus (HTLV-1) is analyzed in this report. We first demonstrate that the factor NF-kappaB binds to the vimentin promoter. Using gel retardation assays, we found the putative NF-kappaB protein. Specific antibodies and competition experiments between the NF-kappaB-binding site in the interleukin-2Ralpha and HIV-1 promoters and the vimentin promoter show that the three sites have identical affinity for the factor. We further show that the mechanisms of activation of NF-kappaB by the Tax protein involve a cellular inducer. Nuclear extract from lymphoid cells expressing Tax can induce in vitro a NF-kappaB binding activity in nonlymphoid cytosolic extract. This inducer, if preexisting in an inactive state in T-cells which are not expressing Tax, cannot be switched to an active state by addition of partially purified Tax protein. While found in the nucleus of Tax-expressing cells in our experiments, this inducer might be cytoplasmic as well. In a first attempt to identify and characterize the inducer, we present the results of fractionation assays of nuclear extract.	UNIV PARIS 07,BIOL MOLEC DIFFERENTIAT LAB,F-75221 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite	LILIENBAUM, A (corresponding author), INST PASTEUR,SCME,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CEREGHINI S, 1988, I PASTEUR PRACTICAL, P10; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOLDMAN R, 1985, ANN NY ACAD SCI, V455, P1, DOI 10.1111/j.1749-6632.1985.tb50400.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LILIENBAUM A, 1988, STRUCTURE FUNCTION C, V171, P151; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1991, J BIOCHEM BIOPH METH, V22, P233, DOI 10.1016/0165-022X(91)90071-4; MARRIOTT SJ, 1991, NEW BIOL, V3, P678; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Maxam A M, 1980, Methods Enzymol, V65, P499; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; PAULIN D, 1990, REPROD NUTR DEV, V30, P423, DOI 10.1051/rnd:19900316; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN S M, 1989, New Biologist, V1, P275; RUBEN S M, 1990, New Biologist, V2, P894; SAX CM, 1988, NUCLEIC ACIDS RES, V16, P8057, DOI 10.1093/nar/16.16.8057; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shibuya H, 1989, INT IMMUNOL, V1, P43, DOI 10.1093/intimm/1.1.43; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; TRAUB P, 1985, ANN NY ACAD SCI, V455, P68, DOI 10.1111/j.1749-6632.1985.tb50404.x; ZABEL U, 1991, J BIOL CHEM, V266, P252	55	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2180	2188						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420985				2022-12-25	WOS:A1993KH62000102
J	WEMMER, DE; WEDEMAYER, GJ; GLAZER, AN				WEMMER, DE; WEDEMAYER, GJ; GLAZER, AN			PHYCOBILINS OF CRYPTOPHYCEAN ALGAE - NOVEL LINKAGE OF DIHYDROBILIVERDIN IN A PHYCOERYTHRIN-555 AND A PHYCOCYANIN-645	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROOMONAS SP CRYPTOPHYCEAE; CRYPTOMONAD BILIPROTEIN; I PHYCOERYTHRIN; ENERGY-TRANSFER; MULTIPLE FORMS; ALPHA-SUBUNITS; C-PHYCOCYANIN; ATTACHMENT; DIVERSITY; SEQUENCE	Cryptomonad strain IVF2 phycoerythrin 555 carries phycoerythrobilins attached through single thioether bonds at alpha-Cys-18, beta-Cys-82, and beta-Cys-158 and a doubly linked 15,16-dihydrobiliverdin (DBV) at beta-DiCys-50,61 (for sequence numbering, see Sidler, W., Nutt, H., Kumpf, B., Frank, G., Suter, F., Brenzel, A., Wehrmeyer, W., and Zuber, H. (1990) Biol. Chem. Hoppe-Seyler 371, 573-547). Analysis of the beta-DiCys-50,61-linked DBV by H-1 homonuclear and H-1-C-13 heteronuclear NMR spectroscopy establishes that the thioether bond from Cys-50 is to the 3''-carbon of the DBV ring A and that from Cys-61 is to the 18'-carbon of ring D, i.e. the peptide-linked bilin is an 8,12-bis(2-carboxyethyl)-3-(2-(cysteinyl-S)-ethyl)-18-(1-(cysteinyl-S)-ethyl)-2,,7,13,17-tetramethylbiladiene-ab-1,19(16H, 21H)-dione. DBV is also present at beta-DiCys-50,61 in cryptomonad strain UW374 phycocyanin 645 (Wedemayer, G. J., Kidd, D. G., Wemmer, D. E., and Glazer, A. N. (1992) J. Biol. Chem. 267, 7315-7331). NMR spectroscopy shows that the thioether bonds to this DBV are also at 3'' and 18'. Linkage of tetrapyrroles to polypeptides through the 3''-carbon has not hitherto been reported.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,DIV CHEM BIODYNAM,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NIGMS NIH HHS [GM28994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BISHOP JE, 1986, J BIOL CHEM, V261, P6790; BROOKS C, 1973, ARCH MIKROBIOL, V88, P193, DOI 10.1007/BF00421845; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; GINGRICH JC, 1982, J CELL BIOL, V95, P170, DOI 10.1083/jcb.95.1.170; Glazer A. N, 1986, CURRENT COMMUNICATIO, P31; GLAZER AN, 1975, ARCH MICROBIOL, V104, P29, DOI 10.1007/BF00447296; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; GLAZER AN, 1971, ARCH MIKROBIOL, V80, P1, DOI 10.1007/BF00410574; GLAZER AN, 1973, J BIOL CHEM, V248, P663; GLAZER AN, 1975, J BIOL CHEM, V250, P5487; HILL DRA, 1989, PHYCOLOGIA, V28, P455, DOI 10.2216/i0031-8884-28-4-455.1; HILLER RG, 1987, BIOCHIM BIOPHYS ACTA, V923, P98, DOI 10.1016/0304-4165(87)90131-0; JENKINS J, 1990, FEBS LETT, V273, P191, DOI 10.1016/0014-5793(90)81082-Y; KELLER MD, 1987, J PHYCOL, V23, P633; KLOTZ AV, 1986, J BIOL CHEM, V261, P6797; LUNDELL DJ, 1984, J BIOL CHEM, V259, P5472; MACCOLL R, 1983, ARCH MICROBIOL, V135, P194, DOI 10.1007/BF00414479; MACCOLL R, 1990, BIOCHEMISTRY-US, V29, P430, DOI 10.1021/bi00454a018; MACCOLL R, 1983, BIOCHEMISTRY-US, V22, P5568, DOI 10.1021/bi00293a018; MACCOLL R, 1992, J LUMIN, V51, P21, DOI 10.1016/0022-2313(92)90015-2; MACCOLL R, 1983, J BIOL CHEM, V258, P4327; MACCOLL R, 1976, ARCH BIOCHEM BIOPHYS, V177, P265, DOI 10.1016/0003-9861(76)90436-7; MACCOLL R, 1973, J BIOL CHEM, V248, P7080; MARTIN CD, 1987, BIOCHIM BIOPHYS ACTA, V923, P88, DOI 10.1016/0304-4165(87)90130-9; MORSCHEL E, 1975, ARCH MICROBIOL, V105, P153, DOI 10.1007/BF00447130; MORSCHEL E, 1977, ARCH MICROBIOL, V113, P83, DOI 10.1007/BF00428585; NOLAN DN, 1967, BIOCHEM J, V103, pP39; OHEOCHA C, 1959, NATURE, V184, P1049, DOI 10.1038/1841049a0; OHEOCHA C, 1964, Proc R Ir Acad B, V63, P191; ONG LJ, 1991, J BIOL CHEM, V266, P9515; REITH M, 1990, PLANT MOL BIOL, V15, P585, DOI 10.1007/BF00017833; SCHEER H, 1977, Z NATURFORSCH C, V32, P513; SHELDRICK WS, 1976, J CHEM SOC PERK T 2, P1457, DOI 10.1039/p29760001457; SIDLER W, 1985, BIOL CHEM H-S, V366, P233, DOI 10.1515/bchm3.1985.366.1.233; SIDLER W, 1990, BIOL CHEM HOPPESEYLE, V371, P573; SIDLER WA, 1987, PROGR PHOTOSYNTHESIS, V2, P153; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; WEDEMAYER GJ, 1991, J BIOL CHEM, V266, P4731; WEDEMAYER GJ, 1992, J BIOL CHEM, V267, P7315; WILBANKS SM, 1989, J BIOL CHEM, V260, P17860	43	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1658	1669						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420941				2022-12-25	WOS:A1993KH62000026
J	LENDENFELD, T; GHALI, D; WOLSCHEK, M; KUBICEKPRANZ, EM; KUBICEK, CP				LENDENFELD, T; GHALI, D; WOLSCHEK, M; KUBICEKPRANZ, EM; KUBICEK, CP			SUBCELLULAR COMPARTMENTATION OF PENICILLIN BIOSYNTHESIS IN PENICILLIUM-CHRYSOGENUM - THE AMINO-ACID PRECURSORS ARE DERIVED FROM THE VACUOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA; ISOPENICILLIN-N; ASPERGILLUS-NIDULANS; LYSINE BIOSYNTHESIS; DELTA-(L-ALPHA-AMINOADIPYL)-L-CYSTEINYL-D-VALINE; PROTEINS; MEMBRANE; STRAINS; ACYLTRANSFERASE; SYNTHETASE	The cellular localization of the origin of alpha-aminoadipate used in penicillin biosynthesis and the first enzymic step in Penicillium chrysogenum involved, delta-(alpha-aminoadipyl)-L-cysteinyl-D-valine synthetase (ACVS), has been studied. Subcellular fractions were obtained from protoplasts of a high penicillin-producing strain upon lysis by Triton X-100, and vacuoles purified from them. They were identified by the aid of alpha-mannosidase as a marker enzyme, by the presence of polyphosphate, and their ability to sequester [C-14]lysin, added to the protoplasts prior to subcellular fractionation. 15.6 and 26.5%, respectively, of 6-[C-14]alpha-aminoadipate, and 8.5 and 10.3%, respectively, of [C-14]valine added accordingly were also found in the vacuole, and the higher proportion was found in vacuoles isolated from penicillin-producing mycelia. ACVS protein was detected in the membrane as well as the soluble fraction of the purified vacuoles. We propose therefore that ACVS is located either within or bound to the vacuolar membrane, and that the precursor amino acids for penicillin biosynthesis are withdrawn from the vacuolar amino acid pool.	VIENNA TECH UNIV,INST BIOCHEM TECHNOL & MIKROBIOL,MIKROBIELLE BIOCHEM ABT,A-1060 VIENNA,AUSTRIA	Technische Universitat Wien								Abraham EP, 1981, RECENT ADV CHEM BETA, P125; AFFENZELLER K, 1991, J GEN MICROBIOL, V137, P1653, DOI 10.1099/00221287-137-7-1653; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BOWMAN BJ, 1987, EXP MYCOL, V11, P197, DOI 10.1016/0147-5975(87)90005-3; BOWMAN EJ, 1982, J BACTERIOL, V151, P1326, DOI 10.1128/JB.151.3.1326-1337.1982; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARR LG, 1986, GENE AMST, V83, P291; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CRAMER CL, 1980, J BACTERIOL, V142, P945, DOI 10.1128/JB.142.3.945-952.1980; DIEZ B, 1990, J BIOL CHEM; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fawcett P, 1975, Methods Enzymol, V43, P471; FAWCETT PA, 1976, BIOSYNTHESIS, V4, P248; FRIEDRICH CG, 1978, ARCH MICROBIOL, V119, P43, DOI 10.1007/BF00407926; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HONLINGER C, 1988, J ANTIBIOT, V41, P255; HONLINGER C, 1989, FEMS MICROBIOL LETT, V65, P71, DOI 10.1016/0378-1097(89)90368-6; HONLINGER C, 1989, BIOCHIM BIOPHYS ACTA, V993, P204, DOI 10.1016/0304-4165(89)90165-7; HORAK J, 1986, BIOCHIM BIOPHYS ACTA, V864, P223, DOI 10.1016/0304-4157(86)90001-8; JAKLITSCH WM, 1987, EXP MYCOL, V11, P141, DOI 10.1016/0147-5975(87)90047-8; JAKLITSCH WM, 1986, CAN J MICROBIOL, V32, P473, DOI 10.1139/m86-087; KELLER U, 1984, APPL ENVIRON MICROB, V47, P710, DOI 10.1128/AEM.47.4.710-714.1984; KURYLOWICZ W, 1987, ARCH IMMUNOL THER EX, V35, P699; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langdon RG, 1966, METHODS ENZYMOL, V9, DOI DOI 10.1016/0076-6879(66)09030-X; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MARTIN JF, 1991, J IND MICROBIOL, V9, P73; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MULLER WH, 1991, EMBO J, V10, P489, DOI 10.1002/j.1460-2075.1991.tb07971.x; MULLER WH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P210, DOI 10.1016/0304-4165(92)90118-E; RAMOS FR, 1985, ANTIMICROB AGENTS CH, V27, P380, DOI 10.1128/AAC.27.3.380; REVILLA G, 1986, J BACTERIOL, V168, P947, DOI 10.1128/jb.168.2.947-952.1986; Roos W, 1986, CELL METABOLISM GROW, P45; SMITH DJ, 1990, BIO-TECHNOL, V8, P39, DOI 10.1038/nbt0190-39; VANLIEMPT H, 1989, J BIOL CHEM, V264, P3680; VAUGHN LE, 1981, MOL CELL BIOL, V1, P797, DOI 10.1128/MCB.1.9.797; VEENSTRAA EA, 1989, GENETICS MOL BIOL IN, P262; WHITEMAN PA, 1990, FEBS LETT, V262, P342, DOI 10.1016/0014-5793(90)80224-7; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499	40	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					665	671						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416970				2022-12-25	WOS:A1993KE60300100
J	CALLAGHAN, T; ANTCZAK, M; FLICKINGER, T; RAINES, M; MYERS, M; KUNG, HJ				CALLAGHAN, T; ANTCZAK, M; FLICKINGER, T; RAINES, M; MYERS, M; KUNG, HJ			A COMPLETE DESCRIPTION OF THE EGF-RECEPTOR EXON STRUCTURE - IMPLICATIONS IN ONCOGENIC ACTIVATION AND DOMAIN EVOLUTION	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; AVIAN-LEUKOSIS VIRUS; TYROSINE KINASE-ACTIVITY; HUMAN-BRAIN TUMORS; C-ERBB ACTIVATION; INDUCED ERYTHROBLASTOSIS; SIGNAL TRANSDUCTION; SELF-PHOSPHORYLATION; CATALYTIC DOMAINS; PHOSPHOLIPASE-C	In this paper, we report that the chicken Epidermal Growth Factor Receptor (EGF-R), encoded by the proto-oncogene c-erbB, is comprised of 28 exons and spans over 75 Kb. The four previously identified domains which make up the extracellular ligand binding region of the receptor are coded for by two copies of a 300 amino acid repeat. We have demonstrated that the 3' end of each repeat coincides with the 3' end of the last exon making up the repeat. This alignment suggests that an exon-duplication may have occurred in the ligand-binding region of the gene. The transmembrane domain is encoded within a single exon and the exon boundaries of the catalytic domain closely match those defined by structural homology with other kinases. Along with the 54 chicken splice sites, the region 5' to the first exon was also sequenced. The proposed promoter region is greater than 70% GC, contains five repeats of the consensus Spl binding sequence and does not have a CCATT or TATA box. In addition to the presence of these characteristic housekeeping features, expression analysis confirms the promoter activity of this region and four sets of TCC repeats similar to those found in the human EGF-R promoter have been identified. To our knowledge this represents the first complete description of the exon-intron structure of the EGF-receptor family. The elucidation of the EGF-R exon structure provides insight into the domain evolution of the receptor-kinases and the mechanisms for the oncogenic conversion of EGF-R in erythroleukemias and glioblastomas.			CALLAGHAN, T (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [P-30 CA43703, NCI CA 39207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039207, R37CA039207, P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDRE C, 1992, ONCOGENE, V7, P685; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BEUG H, 1982, J CELL PHYSIOL, P195; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOKKEL E, 1992, ONCOGENE, V7, P1423; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; HALEY J, 1987, ONCOGENE RES, V1, P375; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MAIHLE NJ, 1991, P NATL ACAD SCI USA, V88, P1825, DOI 10.1073/pnas.88.5.1825; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MEINSENHELDER J, 1989, CELL, V57, P1109; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; PAWSON T, 1988, ONCOGENE, V3, P491; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SERGEANT A, 1982, EMBO J, V1, P237, DOI 10.1002/j.1460-2075.1982.tb01153.x; STECK PA, 1988, CANCER RES, V48, P5433; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TOH H, 1985, NATURE, V314, P199, DOI 10.1038/314199a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WHITE MRA, 1992, ONCOGENE, V7, P677; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	70	45	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2939	2948						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414496				2022-12-25	WOS:A1993MC09300007
J	ISMAIL, M; BROCK, JH				ISMAIL, M; BROCK, JH			BINDING OF LACTOFERRIN AND TRANSFERRIN TO THE HUMAN PROMONOCYTIC CELL-LINE U937 - EFFECT ON IRON UPTAKE AND RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL BRUSH-BORDER; HUMAN-MONOCYTES; RECEPTOR; LACTOTRANSFERRIN; FERRITIN; MACROPHAGES; ENDOCYTOSIS; LYMPHOCYTES; SURFACE; GROWTH	We have compared the ability of lactoferrin and transferrin to interact with and donate iron to the monocytic cell line U937. About 10 times more lactoferrin was bound than transferrin, but most lactoferrin bound nonspecifically, and the degree of specific binding was similar for both proteins (2-3 x 10(6) sites/cell). The binding affinity for lactoferrin (83 nM) was about 4-fold lower than for transferrin (21 nM). Lactoferrin did not inhibit binding of transferrin, or vice versa. Binding of lactoferrin was not inhibited by 30 mM glucose or fucose nor by incubating the cells with heparinase. Transferrin, but not lactoferrin, was internalized, and 3 mM primaquine caused intracellular accumulation of transferrin but not lactoferrin. The cells rapidly acquired iron from transferrin, but uptake from lactoferrin was 10-fold slower and probably resulted from transfer of Fe-59 from lactoferrin to unlabeled transferrin during culture. Lactoferrin, but not transferrin, released iron to the extracellular medium when bound to U937 cells. Lactoferrin inhibited cellular uptake of iron from Fe-nitrilotriacetate but not from transferrin. It is concluded that transferrin, but not lactoferrin, acts as an iron donor to U937 cells. Lactoferrin may regulate uptake of potentially toxic non-transferrin-bound iron.	UNIV GLASGOW,WESTERN INFIRM,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND	University of Glasgow				ISMAIL, MAZNAH/0000-0002-2378-0519				AISEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P314, DOI 10.1016/0005-2795(72)90283-8; AMOURIC M, 1984, IN VITRO CELL DEV B, V20, P543; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BATES GW, 1973, J BIOL CHEM, V248, P3228; BAYNES R, 1986, SCAND J CLIN LAB INV, V46, P695, DOI 10.3109/00365518609083733; BENNETT RM, 1981, BIOCHEM BIOPH RES CO, V101, P88, DOI 10.1016/S0006-291X(81)80014-9; BIRGENS HS, 1983, BRIT J HAEMATOL, V54, P383, DOI 10.1111/j.1365-2141.1983.tb02113.x; BIRGENS HS, 1988, EUR J HAEMATOL, V41, P52; BRITIGAN BE, 1991, J IMMUNOL, V147, P4271; BROCK JH, 1981, IMMUNOLOGY, V43, P393; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DJEHA A, 1992, BRIT J HAEMATOL, V80, P235, DOI 10.1111/j.1365-2141.1992.tb08906.x; GOAVEC M, 1985, CR ACAD SCI III-VIE, V301, P689; GORDEUK VR, 1988, J CLIN INVEST, V82, P1934, DOI 10.1172/JCI113812; HASHIZUME S, 1983, BIOCHIM BIOPHYS ACTA, V763, P377, DOI 10.1016/0167-4889(83)90099-X; HU WL, 1990, BIOCHEMISTRY-US, V29, P535, DOI 10.1021/bi00454a030; IMBER MJ, 1983, BIOCHEM J, V212, P249, DOI 10.1042/bj2120249; INTRAGUMTORNCHA.T, 1988, BLUT, V60, P249; ITURRALDE M, 1992, BIOCHIM BIOPHYS ACTA, V1133, P241, DOI 10.1016/0167-4889(92)90043-B; JOHANSSON BG, 1969, ACTA CHEM SCAND, V23, P683, DOI 10.3891/acta.chem.scand.23-0683; KAWAKAMI H, 1990, AM J PHYSIOL, V258, pG535, DOI 10.1152/ajpgi.1990.258.4.G535; LEE GR, 1983, SEMIN HEMATOL, V20, P61; MAZURIER J, 1989, EUR J BIOCHEM, V179, P481, DOI 10.1111/j.1432-1033.1989.tb14578.x; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; MCABEE DD, 1991, J BIOL CHEM, V266, P23624; METZBOUTIGUE MH, 1978, BIOCHIMIE PARIS, V60, P38; MOGUILEVSKY N, 1987, BRIT J HAEMATOL, V66, P129, DOI 10.1111/j.1365-2141.1987.tb06902.x; ORIA R, 1988, BIOCHEM J, V252, P221, DOI 10.1042/bj2520221; ORIA R, 1983, J DAIRY RES, V60, P363; PIPPARD MJ, 1989, IRON IMMUNITY CANCER, P361; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHARD E, 1989, FEBS LETT, V255, P201, DOI 10.1016/0014-5793(89)81091-9; ROIRON D, 1989, EUR J BIOCHEM, V186, P367, DOI 10.1111/j.1432-1033.1989.tb15218.x; ROIRONLAGROUX D, 1990, BIOCHEM BIOPH RES CO, V170, P837, DOI 10.1016/0006-291X(90)92167-X; SANCHEZ L, 1992, ARCH DIS CHILD, V67, P657, DOI 10.1136/adc.67.5.657; SIPE DM, 1991, J BIOL CHEM, V266, P8002; SUN IL, 1991, BIOCHEM BIOPH RES CO, V176, P498, DOI 10.1016/0006-291X(91)90952-4; VANSNICK JL, 1974, J EXP MED, V140, P1068, DOI 10.1084/jem.140.4.1068; VANSNICK JL, 1977, J EXP MED, V146, P817, DOI 10.1084/jem.146.3.817; YAMADA Y, 1987, BLOOD, V70, P264	41	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21618	21625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408013				2022-12-25	WOS:A1993MC80900031
J	KATAYANAGI, K; ISHIKAWA, M; OKUMURA, M; ARIYOSHI, M; KANAYA, S; KAWANO, Y; SUZUKI, M; TANAKA, I; MORIKAWA, K				KATAYANAGI, K; ISHIKAWA, M; OKUMURA, M; ARIYOSHI, M; KANAYA, S; KAWANO, Y; SUZUKI, M; TANAKA, I; MORIKAWA, K			CRYSTAL-STRUCTURES OF RIBONUCLEASE-HI ACTIVE-SITE MUTANTS FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; RNASE-H; 3-DIMENSIONAL STRUCTURE; DNA-POLYMERASE; IDENTIFICATION; RETROVIRUSES; REPLICATION; MUTAGENESIS; INITIATION; RESOLUTION	In order to investigate the relationships between the three-dimensional structure and the enzymic activity of E. coli RNase HI, three mutant proteins, which were completely inactivated by the replacements of three functional residues, Asp10 by Asn (D10N), Glu48 by Gln (E48Q), and Asp70 by Asn (D70N), were crystallized. Their three-dimensional structures were determined by x-ray crystallography. Although the entire backbone structures of these mutants were not affected by the replacements, very localized conformational changes were observed around the Mg2+-binding site. The substitution of an amide group for a negatively charged carboxyl group in common induces the formation of new hydrogen bond networks, presumably due to the cancellation of repulsive forces between carboxyl side chains with negative charges. These conformational changes can account for the loss of the enzymic activity in the mutants, and suggest a possible role for Mg2+ in the hydrolysis. Since the 3 replaced acidic residues are completely conserved in sequences of reverse transcriptases from retroviruses, including human immunodeficiency virus, the concepts of the catalytic mechanism deduced from this structural analysis can also be applied to RNase H activity in reverse transcriptases.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN; HOKKAIDO UNIV,FAC SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Suzuki, Mamoru/G-6576-2016	Suzuki, Mamoru/0000-0001-7071-5093; Ariyoshi, Mariko/0000-0002-1361-2642				BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HUBER R, 1985, J APPL CRYSTALLOGR, V18, P165, DOI 10.1107/S0021889885010044; ISHIKAWA K, 1993, J MOL BIOL, V230, P529, DOI 10.1006/jmbi.1993.1169; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JOU RW, 1991, J AM CHEM SOC, V113, P6685, DOI 10.1021/ja00017a056; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1991, EUR J BIOCHEM, V198, P437, DOI 10.1111/j.1432-1033.1991.tb16033.x; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KATAYANAGI K, 1993, IN PRESS PROTEINS ST; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MORIKAWA K, 1992, B I PASTEUR, V90, P71; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; ODA Y, 1991, Journal of Biomolecular NMR, V1, P247, DOI 10.1007/BF01875518; ODA Y, 1993, J BIOL CHEM, V268, P88; STEIGEMANN W, 1974, THESIS TU MUNICH; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; YANG W, 1990, J BIOL CHEM, V265, P13553; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	40	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22092	22099						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408067				2022-12-25	WOS:A1993MC80900097
J	KONDO, T; YOSHIDA, T; MIURA, N; NAKANISHI, M				KONDO, T; YOSHIDA, T; MIURA, N; NAKANISHI, M			TEMPERATURE-SENSITIVE PHENOTYPE OF A MUTANT SENDAI VIRUS-STRAIN IS CAUSED BY ITS INSUFFICIENT ACCUMULATION OF THE M-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-GENE-THERAPY; GEL-ELECTROPHORESIS; VACCINIA VIRUS; RNA-POLYMERASE; MESSENGER-RNA; CDNA CLONING; EXPRESSION; DNA; SEQUENCES; HEPATITIS	We investigated the process interrupting the production of a temperature-sensitive mutant strain of Sendai virus, Cl.151, at the nonpermissive temperature (38-degrees-C). The amount of virus M protein increased up to 6-fold when the cells persistently infected with Cl.151 strain at 38-degrees-C are transferred to 32-degrees-C, while the amount of nucleocapsid proteins did not alter. Cl.151 strain could restore virus production at 38-degrees-C not only by the supplementation of M protein of wild type (Z) strain but also by the supplementation of M protein of Cl.151 strain. Neither the amount of M mRNA nor the rate of synthesis of M protein was altered by temperature in cells infected with the Cl.151 strain. However, we found that M protein of Cl.151 virus, which has 3-amino acid alterations from the wild type, was highly unstable at 38-degrees-C when expressed under the control of an actin promoter. These results clearly show that Sendai virus M protein has a critical role in the production of virus particles without affecting virus gene expression.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT BACTERIOL,HIROSHIMA 734,JAPAN	Osaka University; Hiroshima University			Kondo, Toru/F-9420-2012					BILLETER MA, 1991, PARAMYXOVIRUSES, P323; BLONDEL D, 1990, J VIROL, V64, P1716, DOI 10.1128/JVI.64.4.1716-1725.1990; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COCHRAN MA, 1985, P NATL ACAD SCI USA, V82, P19, DOI 10.1073/pnas.82.1.19; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; ISHIHARA H, 1990, ANAL BIOCHEM, V184, P207, DOI 10.1016/0003-2697(90)90670-5; KAN T, 1970, BIKEN J, V13, P183; KATO K, 1991, J BIOL CHEM, V266, P22071; KATO K, 1991, J BIOL CHEM, V266, P3361; KINGSBURY DW, 1970, VIROLOGY, V42, P857, DOI 10.1016/0042-6822(70)90335-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCSHARRY JJ, 1975, VIROLOGY, V67, P365, DOI 10.1016/0042-6822(75)90438-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NAKANISHI M, 1985, EXP CELL RES, V195, P399; NGO TT, 1990, J CHROMATOGR, V510, P281, DOI 10.1016/S0021-9673(01)93762-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKADA Y, 1961, BIKEN J, V4, P209; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PORTNER A, 1974, J VIROL, V13, P298, DOI 10.1128/JVI.13.2.298-304.1974; PRINGLE CR, 1991, PARAMYXOVIRUSES, P1; RANDALL RE, 1991, PARAMYXOVIRUSES, P299; RE GG, 1986, J VIROL, V58, P578, DOI 10.1128/JVI.58.2.578-582.1986; RE GG, 1991, PARAMYXOVIRUSES, P275; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUX L, 1982, CELL, V28, P293, DOI 10.1016/0092-8674(82)90347-6; SALK JE, 1944, J IMMUNOL, V69, P87; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU K, 1975, VIROLOGY, V67, P427, DOI 10.1016/0042-6822(75)90444-4; SHIODA T, 1986, NUCLEIC ACIDS RES, V14, P1545, DOI 10.1093/nar/14.4.1545; SOKOL F, 1964, ACTA VIROL, V8, P59; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TADOKORO J, 1985, BIKEN J, V1, P118; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUFFEREAU C, 1988, VIROLOGY, V162, P417, DOI 10.1016/0042-6822(88)90482-5; YOSHIDA T, 1979, VIROLOGY, V92, P139, DOI 10.1016/0042-6822(79)90220-4; YOSHIDA T, 1976, VIROLOGY, V71, P143, DOI 10.1016/0042-6822(76)90101-X; YOSHIDA T, 1982, VIROLOGY, V120, P329, DOI 10.1016/0042-6822(82)90034-4	46	27	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21924	21930						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408048				2022-12-25	WOS:A1993MC80900074
J	THORNELL, A; HOLM, M; GRUNDSTROM, T				THORNELL, A; HOLM, M; GRUNDSTROM, T			PURIFICATION OF SEF1 PROTEINS BINDING TO TRANSCRIPTIONAL ENHANCER ELEMENTS ACTIVE IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE RETROVIRUS SL3-3; MURINE LEUKEMIA-VIRUS; SEQUENCE; IDENTIFICATION; SPECIFICITY; EXPRESSION; ACTIVATORS; DOMAIN; TUMOR; CORE	Binding sites for SL3-3 enhancer factor 1 (SEF1) are important for the transcriptional activity in T lymphocytes and the tumorigenicity of SL3-3 murine leukemia virus. SEF1 is also implicated in the activity of many other leukemia, lymphoma, and sarcoma virus enhancers, and enhancers of genes for T cell receptor-CD3 subunits. We have purified several proteins binding to SEF1 sites from bovine thymus using a five-step purification procedure. The proteins migrated as 19 distinct bands representing molecular masses from 23 kDa to about 200 kDa in SDS-polyacrylamide gel electrophoresis. Ten DNA binding proteins, with molecular masses between 23 and 67 kDa, could be isolated after separation by SDS-polyacrylamide gel electrophoresis. The DNA binding specificities of these proteins were similar and corresponded to that of the SEF1 binding activity in nuclear extracts. Each of these isolated SEF1 proteins also bound to the essential delta-E3 element of the human T cell receptor delta enhancer. Antibodies against one SEF1 protein only reacted with the protein used for immunization, which indicates a limited homology between at least some SEF1 proteins. We also present data suggesting that SEF1 proteins exist in multiple forms with differences in their DNA binding specificity, and that high affinity DNA binding of the SEF1 proteins requires protein phosphorylation.	UMEA UNIV, DEPT APPL CELL & MOLEC BIOL, S-90187 UMEA, SWEDEN	Umea University			Holm, Magnus/B-8932-2008					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BERK AJ, 1989, BIOCHIM BIOPHYS ACTA, V1009, P103, DOI 10.1016/0167-4781(89)90087-0; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GARGIABLANCO MA, 1989, GENE DEV, V3, P739, DOI 10.1101/gad.3.6.739; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRANELLIPIPERNO A, 1991, P NATL ACAD SCI USA, V88, P11431, DOI 10.1073/pnas.88.24.11431; HALLBERG B, 1988, NUCLEIC ACIDS RES, V16, P5927, DOI 10.1093/nar/16.13.5927; HALLBERG B, 1991, J VIROL, V65, P4177, DOI 10.1128/JVI.65.8.4177-4181.1991; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; JAKCOSN WP, 1992, TRENDS CELL BIOL, V2, P104; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; PEDERSEN FS, 1981, NATURE, V292, P167, DOI 10.1038/292167a0; REDONDO JM, 1991, MOL CELL BIOL, V11, P5671, DOI 10.1128/MCB.11.11.5671; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952	26	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21946	21954						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408051				2022-12-25	WOS:A1993MC80900077
J	ALLGOOD, VE; OAKLEY, RH; CIDLOWSKI, JA				ALLGOOD, VE; OAKLEY, RH; CIDLOWSKI, JA			MODULATION BY VITAMIN-B6 OF GLUCOCORTICOID RECEPTOR-MEDIATED GENE-EXPRESSION REQUIRES TRANSCRIPTION FACTORS IN ADDITION TO THE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; ESTROGEN-RECEPTOR; RESPONSE ELEMENTS; PYRIDOXAL-PHOSPHATE; NUCLEAR RECEPTORS; DNA-SEQUENCES; MMTV PROMOTER; FAR UPSTREAM; C-JUN; HORMONE	We have investigated the mechanism by which vitamin B-6 acts to modulate steroid hormone-mediated gene expression. We show that the level of glucocorticoid-induced gene expression from simple promoters, containing only hormone response elements and a TATA sequence, was not affected by alterations in intracellular vitamin B-6 concentration. However, modulation of hormone-induced gene expression was restored with the inclusion of a binding site for the transcription factor nuclear factor 1 (NF1) within the hormone-responsive promoter; glucocorticoid-induced gene expression was reduced by 44% under conditions of elevated intracellular vitamin B-6 concentration and enhanced by 98% in mild vitamin deficiency. Under these conditions, neither glucocorticoid receptor sedimentation characteristics, receptor activation, nor DNA binding capacity was affected. Quantitatively analogous effects were detected with estrogen-induced gene expression when an NF1 binding site was removed from or introduced into an estrogen-responsive promoter. NF1-mediated constitutive transcription was not affected by alterations in vitamin concentration. The modulatory effect of vitamin did not require strict positioning of or spacing between the glucocorticoid response element and NF1 binding site. Moreover, a heterologous transcriptional activator, composed of the viral E1a transactivation domain and the GAL4 DNA binding domain, does not substitute for NF1 in restoring vitamin B-6 modulation of hormone-induced gene expression. These results suggest that vitamin B-6 modulates steroid hormone-mediated gene expression through its influence on a functional or cooperative interaction between steroid hormone receptors and the transcription factor NF1.	UNIV N CAROLINA,DEPT PHYSIOL,460 MED SCI RES BLDG,CB 7545,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NIDDK NIH HHS [DK 32459] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032459] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1992, J BIOL CHEM, V267, P3819; ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424; BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BRADSHAW MS, 1988, J BIOL CHEM, V263, P8485; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CIDLOWSKI JA, 1980, BIOCHEMISTRY-US, V19, P6162, DOI 10.1021/bi00567a033; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DEFRANCO D, 1985, UCLA S MOL CELL BIOL, V20, P305; EBADI M, 1978, INT J BIOCHEM, V9, P607, DOI 10.1016/0020-711X(78)90122-2; EBADI MS, 1970, J NEUROCHEM, V17, P941, DOI 10.1111/j.1471-4159.1970.tb02247.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LEKLEM JE, 1988, CLIN PHYSL APPL VITA, P3; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MEISLER NT, 1988, CANCER RES, V48, P1080; MERRILL AH, 1984, J NUTR, V114, P1664, DOI 10.1093/jn/114.9.1664; PFAHL M, 1983, SCIENCE, V222, P1341, DOI 10.1126/science.6318311; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1988, SCIENCE, V242, P1418; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TULLY DB, 1989, BIOCHEMISTRY-US, V28, P1968, DOI 10.1021/bi00431a003; TULLY DB, 1990, BIOCHEMISTRY-US, V29, P6662, DOI 10.1021/bi00480a016; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WANG LH, 1987, NATURE, V262, P16080; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; ZHANG YL, 1990, MOL ENDOCRINOL, V4, P1219, DOI 10.1210/mend-4-8-1219; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	53	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20870	20876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407919				2022-12-25	WOS:A1993MA28800039
J	ANDERSSON, H; VONHEIJNE, G				ANDERSSON, H; VONHEIJNE, G			POSITION-SPECIFIC ASP-LYS PAIRING CAN AFFECT SIGNAL SEQUENCE FUNCTION AND MEMBRANE-PROTEIN TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; CHARGED AMINO-ACIDS; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; HYDROPHOBIC DOMAIN; SECRETORY PROTEINS; INNER MEMBRANE; EXPORT; TRANSLOCATION; RESIDUES	Positively charged amino acids are major determinants of the topology of bacterial inner membrane proteins, whereas negatively charged residues by themselves have little or no influence on the transmembrane orientation. Further, positively charged amino acids can very efficiently block the function of signal sequences when placed immediately downstream, while negatively charged residues are much less potent also in this regard. Here, we show that a negatively charged aspartic acid situated close to a positively charged lysine can attenuate both of these effects in a position-specific manner, suggesting that intra- or intermolecular charge pairing can modulate the interactions between positively charged residues in the nascent chain and parts of the secretory machinery or membrane phospholipids. These observations further underscore the importance of charged amino acids during protein translocation and membrane protein assembly.	NOVUM,KAROLINSKA INST CTR STRUCT BIOCHEM,DEPT MOLEC BIOL,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet			von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DALBEY RE, 1987, J BIOL CHEM, V262, P13241; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DALBEY RE, 1991, MOL MICROBIOL, V5, P2855, DOI 10.1111/j.1365-2958.1991.tb01844.x; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; LEE JI, 1992, J BIOL CHEM, V267, P938; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LISS LR, 1985, J BACTERIOL, V164, P925, DOI 10.1128/JB.164.2.925-928.1985; MACINTYRE S, 1990, MOL GEN GENET, V221, P466; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; SASAKI S, 1990, J BIOL CHEM, V265, P4358; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; YAMANE K, 1988, J BIOL CHEM, V263, P19690; ZHU HY, 1989, J BIOL CHEM, V264, P11833	40	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21389	21393						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407979				2022-12-25	WOS:A1993MA28800107
J	ELIEZER, D; FRANK, P; GILLIS, N; NEWTON, WE; DONIACH, S; HODGSON, KO				ELIEZER, D; FRANK, P; GILLIS, N; NEWTON, WE; DONIACH, S; HODGSON, KO			SMALL-ANGLE X-RAY-SCATTERING STUDIES OF THE IRON-MOLYBDENUM COFACTOR FROM AZOTOBACTER-VINELANDII NITROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUBANE CLUSTER COMPLEXES; PROTEIN-ALPHA-SUBUNIT; KLEBSIELLA-PNEUMONIAE; FEMO-COFACTOR; MOFE PROTEIN; STRUCTURAL INSIGHTS; ABSORPTION; EDGE; SPECTROSCOPY; COORDINATION	The nitrogenase enzyme complex, consisting of the molybdenum-iron protein and the iron protein, plays a critical role in the biological reduction of dinitrogen to ammonia (nitrogen fixation). The nitrogen-fixing site within the molybdenum-iron protein is an iron-molybdenum-sulfur cofactor (FeMoco) of roughly 1000-2000 Dalton mass. Structural aspects of FeMoco have been determined by spectroscopic and more recently by crystallographic studies. In order to determine the radius of gyration (R(g)) of isolated FeMoco, we have performed small-angle x-ray scattering studies of FeMoco in N-methylformamide solution, in the absence of the molybdenum-iron protein. Model compounds of known structure have also been examined in similar solvents, N,N-dimethylformamide and acetonitrile, as controls and for calibration purposes. The R(g) values obtained for the models are in good agreement with calculations based upon their respective crystal structures. However, the R(g) obtained for FeMoco clearly indicates that the cofactor is not monomeric in solution, but rather aggregated and possibly polydisperse. Further, R(g) values were also measured after addition of thiol, dithionite, and thiol and dithionite, to the FeMoco samples. The results indicate, surprisingly, that oxidation state and putative thiol coordination have no detectable effect on the aggregation behavior of FeMoco in solution, as determined by these measurements.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305; STANFORD UNIV,STANFORD SYNCHROTRON RADIAT LAB,STANFORD,CA 94305; VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & NUTR,BLACKSBURG,VA 24061	Stanford University; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Virginia Polytechnic Institute & State University					NCRR NIH HHS [RR01209] Funding Source: Medline; NIDDK NIH HHS [DK37255] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBER JM, 1988, BIOCHEM J, V252, P421, DOI 10.1042/bj2520421; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; BURGESS BK, 1980, J BIOL CHEM, V255, P353; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; CONRADSON SD, 1985, J AM CHEM SOC, V107, P7935, DOI 10.1021/ja00312a022; CRAVEN BM, 1976, J CHEM SOC P2, V7, P814; Feigin L.A., 1987, STRUCTURE ANAL SMALL; FRANK P, 1989, BIOCHEM BIOPH RES CO, V163, P746, DOI 10.1016/0006-291X(89)92286-9; GABRIEL A, 1977, REV SCI INSTRUM, V48, P1303, DOI 10.1063/1.1134870; Guinier A., 1955, SMALL ANGLE SCATTERI; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; NEWTON WE, 1989, J BIOL CHEM, V264, P1924; NEWTON WE, 1991, BIOL NITROGEN FIXATI, P877; RAYLEIGH L, 1911, P ROY SOC LOND A MAT, V84, P25; SCHULTZ FA, 1985, J AM CHEM SOC, V107, P5364, DOI 10.1021/ja00305a007; SCHULTZ FA, 1990, INORG CHIM ACTA, V170, P115, DOI 10.1016/S0020-1693(00)80417-X; SCHULTZ FA, 1988, BIOCHEM BIOPH RES CO, V152, P629, DOI 10.1016/S0006-291X(88)80085-8; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; THOMANN H, 1987, J AM CHEM SOC, V109, P7913, DOI 10.1021/ja00259a067; THOMANN H, 1991, P NATL ACAD SCI USA, V88, P6620, DOI 10.1073/pnas.88.15.6620; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; TRUE AE, 1990, J AM CHEM SOC, V112, P651, DOI 10.1021/ja00158a024; WAKATSUKI S, 1992, REV SCI INSTRUM, V63, P1736, DOI 10.1063/1.1143332; WOLFF TE, 1980, J AM CHEM SOC, V102, P4694, DOI 10.1021/ja00534a023; WOLFF TE, 1979, J AM CHEM SOC, V101, P4140, DOI 10.1021/ja00509a021; YOU JF, 1988, J AM CHEM SOC, V110, P6589, DOI 10.1021/ja00227a064	32	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20953	20957						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407930				2022-12-25	WOS:A1993MA28800050
J	SAITO, Y; PETERSON, PA; MATSUMURA, M				SAITO, Y; PETERSON, PA; MATSUMURA, M			QUANTITATION OF PEPTIDE ANCHOR RESIDUE CONTRIBUTIONS TO CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; INFLUENZA NUCLEOPROTEIN; VIRAL PEPTIDES; INTACT-CELLS; AMINO-ACIDS; MHC-BINDING; ANTIGENS; ANTIBODIES; HLA-B27; H-2K(B)	Class I major histocompatibility complex molecules play an important role in cellular immunity by presenting antigenic peptides to cytotoxic T cells. Deep polymorphic pockets in the peptide-binding groove of class I major histocompatibility complex molecules provide structural complementarity for peptide ''anchor'' side chains. However, the minimum requirements of a peptide for high-affinity binding and the contribution of anchor side chains to binding have not been determined yet. To address these issues, we have compared the affinities of various octapeptides for purified, soluble H-2K(b) molecules. The results revealed that at least 2 anchor residues are necessary for high-affinity binding, and that high-affinity binding occurs only when anchor side chains are optimally packed within the groove. The estimated free energy contribution of two anchor side chains to binding is unexpectedly large and comparable with that of peptide backbone, suggesting a crucial role of anchor residues in high-affinity, and hence specific, binding to class I molecules.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCI NIH HHS [CA-97489] Funding Source: Medline; NIAID NIH HHS [AI-31965] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031965] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARINAGA M, 1990, SCIENCE, V250, P1657, DOI 10.1126/science.2270477; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MULLER R, 1983, METHOD ENZYMOL, V92, P589; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PARTHAM P, 1992, NATURE, V360, P300; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; VANBLEEK GM, 1990, NATURE, V348, P213; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	39	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21309	21317						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407969				2022-12-25	WOS:A1993MA28800097
J	MILLIGAN, DL; KOSHLAND, DE				MILLIGAN, DL; KOSHLAND, DE			PURIFICATION AND CHARACTERIZATION OF THE PERIPLASMIC DOMAIN OF THE ASPARTATE CHEMORECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; LIGAND-BINDING DOMAIN; HUMAN GROWTH-HORMONE; ESCHERICHIA-COLI; EXTRACELLULAR DOMAIN; BACTERIAL CHEMOTAXIS; PROTEIN CHROMATOGRAPHY; HYDROXYAPATITE COLUMNS; TAR CHEMORECEPTOR; INSULIN-RECEPTOR	In order to facilitate biochemical studies of cell-surface receptors, a plasmid allowing the expression of the periplasmic domain of the aspartate receptor from Salmonella typhimurium as a soluble periplasmic protein has been constructed. This 18-kDa protein is exported to the periplasm, where it may be extracted by mild osmotic lysis. This isolated domain behaves as a normal, soluble protein and has been purified to homogeneity by standard techniques. The purified periplasmic domain binds aspartate with a k(D) similar to that of the full-length receptor, and the binding occurs with negative cooperativity, i.e. the binding of one molecule of aspartate induces a conformational change that interferes with the binding of the second aspartate. Unlike the full-length receptor, the periplasmic domain undergoes a protein concentration- and aspartate-dependent monomer-dimer equilibrium. At low protein concentrations and in the absence of aspartate, the protein is monomeric. At higher protein concentrations or in the presence of saturating aspartate, the protein is dimeric. Two charge variants of the protein have been identified on native polyacrylamide gels. The more acidic form is blocked to Edman degradation, indicating that modification of the amino terminus of this protein can occur after cleavage of the signal peptide in the periplasm.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley								BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; Cantor C.R., 1980, TECHNIQUES STUDY BIO; CHANG CN, 1986, GENE, V44, P121; CLARKE S, 1979, J BIOL CHEM, V254, P9695; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOWER SK, 1989, J IMMUNOL, V142, P4314; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; FUH G, 1990, J BIOL CHEM, V265, P3111; GORBUNOFF MJ, 1985, METHOD ENZYMOL, V117, P370; GORBUNOFF MJ, 1990, METHOD ENZYMOL, V182, P329; HAZELBAUER GL, 1975, J BACTERIOL, V122, P206, DOI 10.1128/JB.122.1.206-214.1975; HEPPEL LA, 1971, STRUCTURE FUNCTION B; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; JANCARIK J, 1991, J MOL BIOL, V221, P31, DOI 10.1016/0022-2836(91)80198-4; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEVITZKI A, 1984, RECEPTORS QUANTITATI; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCMEEKIN TL, 1952, SCIENCE, V116, P142, DOI 10.1126/science.116.3006.142; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Scopes RK., 1987, PROTEIN PURIFICATION, V2nd ed; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; XIE YB, 1990, J BIOL CHEM, V265, P21411	34	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19991	19997						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397194				2022-12-25	WOS:A1993LY01900014
J	STOCKERT, RJ				STOCKERT, RJ			REGULATION OF THE HUMAN ASIALOGLYCOPROTEIN RECEPTOR BY CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC BINDING-PROTEIN; DEPENDENT EXPRESSION; LIVER-REGENERATION; MESSENGER-RNA; RAT-LIVER; INTERLEUKIN-6; DEGRADATION; MODULATION; SUBUNITS; PHOSPHORYLATION	The mechanism of regulated expression of the asialoglycoprotein receptor (ASGR) by cAMP was investigated in the human hepatoblastoma cell line, HepG2. Incubation of HepG2 cells with the cell-permeant 8-bromo-cAMP or induction of intracellular cAMP with forskolin reduced receptor expression in confluent HepG2 cultures. Immunoblot analysis established that this reduction of receptor activity was due to a reduction of expression of both ASGR subunit polypeptides H1 and H2. Estimates of the steady-state levels of H1- and H2-related mRNA by Northern blot analysis indicated that reduced ASGR expression was a result of a decrease in gene transcript number. By a combination of run-on and mRNA turnover studies, it was suggested that this reduction of ASGR-related mRNA resulted from its destabilization induced by 8-bromo-cAMP. The effect of 8-bromo-cAMP appears not to be limited to ASGR expression as a rapid reduction in the albumin mRNA was also observed. In contrast, both the beta-actin and glyceraldehyde-3-phosphate dehydrogenase mRNA levels were elevated by exposure to 8-bromo-cAMP.			STOCKERT, RJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,DEPT MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P50DK017702] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK-32972, DK-17702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM LJ, 1990, MOL BIOL MED, V7, P261; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CERBONAMBRIZ J, 1987, LAB INVEST, V57, P392; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND D W, 1989, New Biologist, V1, P121; COLLINS JC, 1988, HEPATOLOGY, V8, P108, DOI 10.1002/hep.1840080122; COLLINS JC, 1984, HEPATOLOGY, V4, P80, DOI 10.1002/hep.1840040114; COLLINS JC, 1988, J BIOL CHEM, V263, P11280; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; ENRICH C, 1992, J CELL PHYSIOL, V150, P344, DOI 10.1002/jcp.1041500218; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; GARTNER U, 1981, HEPATOLOGY, V1, P99, DOI 10.1002/hep.1840010203; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOD Y, 1988, J BIOL CHEM, V263, P7747; HOWARD DJ, 1982, J BIOL CHEM, V257, P2856; HUBER BE, 1986, J BIOL CHEM, V261, P2400; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LOTZ M, 1989, ANN NY ACAD SCI, V557, P509; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSHAGE HJ, 1987, J CLIN INVEST, V79, P1634; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; PETELL JK, 1985, ARCH BIOCHEM BIOPHYS, V241, P550, DOI 10.1016/0003-9861(85)90580-6; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; STOCKERT RJ, 1983, HEPATOLOGY, V3, P750; STOCKERT RJ, 1992, J BIOL CHEM, V267, P56; STOCKERT RJ, 1980, CANCER RES, V40, P3632; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; THEILMANN L, 1983, BIOCHIM BIOPHYS ACTA, V762, P475, DOI 10.1016/0167-4889(83)90015-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WILMAN T, 1985, BIOCHEM J, V232, P1; WOLKOFF AW, 1986, P SOC EXP BIOL MED, V181, P270; WONG MWC, 1979, LIFE SCI, V25, P827, DOI 10.1016/0024-3205(79)90540-X	44	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19540	19544						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396140				2022-12-25	WOS:A1993LW81900061
J	BERLINGIERI, MT; SANTORO, M; BATTAGLIA, C; GRIECO, M; FUSCO, A				BERLINGIERI, MT; SANTORO, M; BATTAGLIA, C; GRIECO, M; FUSCO, A			THE ADENOVIRUS E1A GENE BLOCKS THE DIFFERENTIATION OF A THYROID EPITHELIAL-CELL LINE, HOWEVER THE NEOPLASTIC PHENOTYPE IS ACHIEVED ONLY AFTER COOPERATION WITH OTHER ONCOGENES	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; TRANSFORMATION; TRANSCRIPTION; RETROVIRUS; SEQUENCES; DNA; THYROGLOBULIN; INFECTIVITY; ACTIVATION; EXPRESSION	The PC Cl 3 cell line is a well characterized epithelial thyroid cell fine of Fischer rat origin. This cell line has the peculiarity of retaining in vitro the typical markers of thyroid differentiation (i.e. thyroglobulin synthesis and secretion, iodide uptake and dependence on TSH for growth). The PC Cl 3 cells have been transfected with the E1A gene of Adenovirus 5. The E1A transfected cells, PC E1A, partially lost the dependency on TSH for growth and completely lost the ability to trap iodide and synthesize thyroglobulin; however they did not acquire the typical markers of the neoplastic phenotype. A highly malignant phenotype was achieved after infection of the PC E1A cells with retroviruses carrying the v-raf, v-abl and polyoma virus middle T oncogenes. In contrast, the PC E1A cells transfected with the E1B gene of Adenovirus were not tumorigenic at all, and those infected with retroviruses carrying oncogenes of the ras family displayed a very weak tumorigenic phenotype.	UNIV NAPOLI,FAC MED & CHIRURG 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria				Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197				AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P226; BRAITHWAITE AW, 1981, NEW BIOL, V3, P18; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IKEKUBO K, 1980, METABOLISM, V29, P673, DOI 10.1016/0026-0495(80)90113-4; ITO T, 1992, CANCER RES, V52, P1369; JACKSON P, 1985, J VIROL, V55, P644, DOI 10.1128/JVI.55.3.644-650.1985; KELAKAR A, 1986, MOL CELL BIOL, V6, P7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LYNCH MJ, 1989, CANCER RES, V49, P5429; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T., 1982, MOL CLONING; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PARASKEVA C, 1980, INT J CANCER, V25, P631, DOI 10.1002/ijc.2910250513; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHITE P, 1988, NATURE, V334, P124; YAN DH, 1991, ONCOGENE, V6, P343; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	34	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					249	255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426735				2022-12-25	WOS:A1993KN00600003
J	BLEE, E; WILCOX, AL; MARNETT, LJ; SCHUBER, F				BLEE, E; WILCOX, AL; MARNETT, LJ; SCHUBER, F			MECHANISM OF REACTION OF FATTY-ACID HYDROPEROXIDES WITH SOYBEAN PEROXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN BOND-CLEAVAGE; IRON(III) PORPHYRINS; LINOLEIC-ACID; SUBSTRATE HYDROXYLATION; DEPENDENT EPOXIDATION; LIPOXYGENASE PATHWAY; CYTOCHROME-P-450; STEREOCHEMISTRY; IDENTIFICATION; MONOOXYGENASES	13(S)-Hydroperoxyoctadeca-9(Z),11(E),15(Z)-trienoic acid (13-HPOT) was used to probe the mechanism of the hydroperoxide O-O bond cleavage catalyzed by solubilized and partially purified soybean peroxygenase. When reacted with this ferrihemoprotein, it was converted to 13(S)-hydroxyoctadeca-9(Z),11(E), 15(Z)-trienoic acid (13-HOT) and a single epoxide regioisomer, i.e. 15,16-cis-epoxy-13(S)-hydroxyoctadeca-9(Z),11(E)-dienoic acid (15,16-EHOD). In the absence of co-oxidizable substrates, such as oleic acid or thiobenzamide, this latter compound accounted for about two-thirds of the reaction products. 13-HOT and 15,16-EHOD are products of heterolytic scission of the O-O bond of 13-HPOT; no products arising by homolytic scission could be detected. Therefore, soybean peroxygenase catalyzes hydroperoxide reduction exclusively by a heterolytic mechanism leading to a ferryl-oxo complex analogous to peroxidase compound I. In similar experiments, 13(S)-hydroperoxyoctadeca-9(Z),11(E)-dienoic acid gave 13(S)-hydroxyoctadeca-9(Z),11(E)-dienoic acid and 9,10 epoxy-13(S)-hydroxyoctadec-11(E)-enoic acid. Experiments with O-18-labeled 13-HPOT indicated that about 83% of the oxygen atom incorporated into the epoxide group of 15,16-EHOD, originated from the hydroperoxide group. Moreover, using mixtures of unlabeled and O-18-labeled 13-HPOT, it was established that this transfer takes place predominantly (about 3:1) by an intramolecular process. In the intermolecular reaction 13-HOT, formed after reduction of the hydroperoxide, diffuses from the active site and, after reassociation, is epoxidized at the 15,16-double bond. A unifying mechanistic scheme, which takes into account all of the reactions catalyzed by the peroxygenase, is proposed.	INST BOT,DEPT ENZYMOL CELLULAIRE & MOLEC,INST BIOL MOLEC PLANTES,CNRS,UPR 406,F-67083 STRASBOURG,FRANCE; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT BIOCHEM,AB HANCOCK JR MEM LAB,NASHVILLE,TN 37232; FAC PHARM ILLKIRCH,CHIM BIOORGAN LAB,CNRS,URA 1386,F-67400 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vanderbilt University; Centre National de la Recherche Scientifique (CNRS)					NCI NIH HHS [CA 47479] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAKE RC, 1981, J BIOL CHEM, V256, P2127; BLEE E, 1990, J BIOL CHEM, V265, P12887; BLEE E, 1987, ARCH BIOCHEM BIOPHYS, V254, P43, DOI 10.1016/0003-9861(87)90079-8; BLEE E, 1989, BIOCHEMISTRY-US, V28, P4962, DOI 10.1021/bi00438a009; BLEE E, 1990, BIOCHEM BIOPH RES CO, V173, P1354, DOI 10.1016/S0006-291X(05)80937-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUICE TC, 1988, J AM CHEM SOC, V110, P7890, DOI 10.1021/ja00231a057; CASHMAN JR, 1981, BIOCHEM BIOPH RES CO, V98, P147, DOI 10.1016/0006-291X(81)91881-7; CLAEYS M, 1985, BIOCHIM BIOPHYS ACTA, V837, P35, DOI 10.1016/0005-2760(85)90083-9; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DIX TA, 1985, J BIOL CHEM, V260, P5351; GARDNER HW, 1991, PLANT PHYSIOL, V97, P1059, DOI 10.1104/pp.97.3.1059; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GARDNER HW, 1984, CHEM PHYS LIPIDS, V35, P87, DOI 10.1016/0009-3084(84)90015-X; GARSSEN GJ, 1976, EUR J BIOCHEM, V62, P33, DOI 10.1111/j.1432-1033.1976.tb10094.x; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P434; GRAVELAND A, 1970, J AM OIL CHEM SOC, V47, P352, DOI 10.1007/BF02639001; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMBERG M, 1975, LIPIDS, V10, P87, DOI 10.1007/BF02532161; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V877, P447, DOI 10.1016/0005-2760(86)90211-0; LABEQUE R, 1988, BIOCHEMISTRY-US, V27, P7060, DOI 10.1021/bi00418a059; LABEQUE R, 1987, J AM CHEM SOC, V109, P2828, DOI 10.1021/ja00243a048; LEE WA, 1985, J AM CHEM SOC, V107, P513, DOI 10.1021/ja00288a046; MANSUY D, 1989, EUR J BIOCHEM, V184, P267, DOI 10.1111/j.1432-1033.1989.tb15017.x; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; POULOS TL, 1980, J BIOL CHEM, V255, P8199; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; THOMPSON JA, 1989, DRUG METAB REV, V20, P365, DOI 10.3109/03602538909103548; THOMPSON JA, 1985, J BIOL CHEM, V260, P637; TRAYLOR TG, 1989, J AM CHEM SOC, V111, P8009, DOI 10.1021/ja00202a049; WHITE RE, 1980, J BIOL CHEM, V255, P1108; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M; WILCOX AL, 1991, 201ST AM CHEM SOC NA	34	53	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1708	1715						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420948				2022-12-25	WOS:A1993KH62000033
J	STEGMANN, T				STEGMANN, T			INFLUENZA HEMAGGLUTININ-MEDIATED MEMBRANE-FUSION DOES NOT INVOLVE INVERTED PHASE LIPID INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE-CONTAINING LIPOSOMES; VESICULAR STOMATITIS-VIRUS; HEXAGONAL HII PHASE; DIPALMITOYLPHOSPHATIDYLCHOLINE VESICLES; BILAYER-MEMBRANES; L-ALPHA; LOW PH; TRANSITIONS; LAMELLAR; FLUORESCENCE	Intermediate lipid structures such as inverted micelles and interlamellar attachments, which can form near liquid crystalline lamellar (L(alpha)) to inverted hexagonal (H(II)) phase boundaries, are thought to play a role in membrane fusion. To investigate whether these structures are also involved in influenza hemagglutinin-mediated membrane fusion, measurement of fusion under conditions where such structures could not form was attempted. It was found that the fusion of influenza virus with liposomal membranes containing phosphatidylcholine and gangliosides, which cannot form H(II) phases, was only slightly slower than fusion with liposomes that also contained the H(II) competent phosphatidylethanolamine. Furthermore, the virus fused efficiently with liposomes consisting either of pure saturated phosphatidylcholines or phosphatidylcholine/ganglioside mixtures, even when the liposomal membranes were in the gel (L(beta')) phase and thus far from L(alpha)/H(II) transitions. Isolated hemagglutinin, reconstituted into dimyristoylphosphatidylcholine membranes, induced fusion with liposomes composed of dimyristoylphosphatidylcholine and gangliosides at temperatures below the L(beta') to L(alpha) phase transition temperature of dimyristoylphosphatidylcholine. This latter finding excluded the possibility that the viral lipids alone could have formed inverted phase intermediates, thus enabling them to fuse with liposomes that do not contain lipids capable of forming inverted phases. Therefore, it is concluded that structures resembling intermediates in L(alpha)/H(II) transitions are most likely not involved in influenza hemagglutinin-mediated fusion.			STEGMANN, T (corresponding author), UNIV BASEL,BIOZENTRUM,BIOPHYS CHEM ABT,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BENTZ J, 1987, BIOCHEMISTRY-US, V26, P2105, DOI 10.1021/bi00382a008; BENTZ J, 1991, ADV MEMBRANE FLUIDIT, V5, P259; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; BURGER KNJ, 1990, NATO ADV SCI I H-CEL, V40, P185; BURGER KNJ, 1988, BIOCHIM BIOPHYS ACTA, V939, P89, DOI 10.1016/0005-2736(88)90050-8; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; CHERNOMORDIK LV, 1985, BIOCHIM BIOPHYS ACTA, V812, P643, DOI 10.1016/0005-2736(85)90257-3; DOMS RW, 1986, J VIROL, V57, P603, DOI 10.1128/JVI.57.2.603-613.1986; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GAGNE J, 1985, BIOCHEMISTRY-US, V24, P4400, DOI 10.1021/bi00337a022; HARDMAN PD, 1982, EUR J BIOCHEM, V124, P95, DOI 10.1111/j.1432-1033.1982.tb05910.x; HARTER C, 1989, J BIOL CHEM, V264, P6459; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HUI SW, 1981, NATURE, V290, P427, DOI 10.1038/290427a0; KOZLOV MM, 1989, EUR BIOPHYS J BIOPHY, V17, P121; MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133; Markin V, 1984, GEN PHYSL BIOPHYS, V5, P361; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; MEERS P, 1992, BIOCHEMISTRY-US, V31, P6372, DOI 10.1021/bi00143a003; PETRI WA, 1980, BIOCHEMISTRY-US, V19, P3088, DOI 10.1021/bi00554a039; PETRI WA, 1981, BIOCHEMISTRY-US, V20, P2796, DOI 10.1021/bi00513a014; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SIEGEL DP, 1986, CHEM PHYS LIPIDS, V42, P279, DOI 10.1016/0009-3084(86)90087-3; SIEGEL DP, 1986, BIOPHYS J, V49, P1171, DOI 10.1016/S0006-3495(86)83745-6; SIEGEL DP, 1989, BIOPHYS J, V56, P161, DOI 10.1016/S0006-3495(89)82661-X; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; SIEGEL DP, 1984, BIOPHYS J, V45, P399, DOI 10.1016/S0006-3495(84)84164-8; SIEGEL DP, 1992, VIRAL FUSION MECHANI; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1992, IN PRESS VIRAL FUSIO; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VERKLEIJ AJ, 1984, BIOCHIM BIOPHYS ACTA, V779, P43, DOI 10.1016/0304-4157(84)90003-0; VERKLEIJ AJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P620, DOI 10.1016/0005-2736(80)90465-4; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WONG M, 1982, BIOCHEMISTRY-US, V21, P4126, DOI 10.1021/bi00260a032	58	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1716	1722						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420949				2022-12-25	WOS:A1993KH62000034
J	SZCZESNASKORUPA, E; KEMPER, B				SZCZESNASKORUPA, E; KEMPER, B			AN N-TERMINAL GLYCOSYLATION SIGNAL ON CYTOCHROME-P450 IS RESTRICTED TO THE ENDOPLASMIC-RETICULUM IN A LUMINAL ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROME-P-450; TRANSMEMBRANE PROTEINS; MICROSOMAL MEMBRANE; RECYCLING PATHWAY; GOLGI-APPARATUS; ER PROTEINS; RETENTION; IDENTIFICATION; SEQUENCE; COMPARTMENT	The mechanism of retention of cytochrome P450 in the endoplasmic reticulum is unknown, and the membrane topology of the N-terminal region remains controversial. To address these problems, a sequence of 29 amino acids encoding an internal N-glycosylation site of rabbit cytochrome P450 2C2 was attached to the N terminus of cytochrome P450 2C1. This protein is glycosylated at a single site in a cell-free translation system containing microsomal membranes, as indicated by gel mobility and sensitivity to endoglycosidase H. When expressed in COS1 cells, an immunoreactive species with the same gel mobility as the in vitro synthesized glycosylated product was detected. Treatment with endoglycosidase H changed its mobility to that of unglycosylated hybrid cytochrome P450 2C1. These results indicate that in intact cells, as in the cell-free system, the N terminus of cytochrome P450 is luminally oriented which is not consistent with a hairpin loop conformation. Sensitivity of the glycosylated protein to endoglycosidase H suggests that the protein does not reach the Golgi compartments. When transfected cells were incubated at low temperatures to inhibit retrograde transport from the intermediate pre-Golgi compartment into the endoplasmic reticulum, localization of cytochrome P450 was not changed, as assayed by subcellular fractionation and immunofluorescent staining. These observations suggest that cytochrome P450 is restricted to the endoplasmic reticulum membrane by a mechanism different from recycling through the intermediate compartment, which is a pathway utilized by soluble endoplasmic reticulum proteins.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, URBANA, IL 61801 USA; UNIV ILLINOIS, COLL MED, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM 35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNUN S, 1980, P NATL ACAD SCI USA, V84, P5783; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; BROWN CA, 1989, J BIOL CHEM, V264, P4442; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Ingelman-Sundberg M, 1986, CYTOCHROME P450 STRU, P119; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KABCENELL AK, 1985, J CELL BIOL, V101, P1270, DOI 10.1083/jcb.101.4.1270; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MASAKI R, 1987, J CELL BIOL, V104, P1207, DOI 10.1083/jcb.104.5.1207; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SETHUMADHAVAN K, 1991, MOL CELL ENDOCRINOL, V78, P25, DOI 10.1016/0303-7207(91)90182-R; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SZCZESNASKORUPA E, 1991, METHOD ENZYMOL, V206, P64; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VERGERES G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P235, DOI 10.1016/0005-2736(91)90376-J; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; YAMAMOTO A, 1985, J CELL BIOL, V101, P1733, DOI 10.1083/jcb.101.5.1733; ZHAO J, 1990, DNA CELL BIOL, V9, P37, DOI 10.1089/dna.1990.9.37	42	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1757	1762						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420952				2022-12-25	WOS:A1993KH62000040
J	JONSSON, CB; DONZELLA, GA; ROTH, MJ				JONSSON, CB; DONZELLA, GA; ROTH, MJ			CHARACTERIZATION OF THE FORWARD AND REVERSE INTEGRATION REACTIONS OF THE MOLONEY MURINE LEUKEMIA-VIRUS INTEGRASE PROTEIN PURIFIED FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV DNA INTEGRATION; RETROVIRAL DNA; VIRAL-DNA; INVITRO; POL; SEQUENCE; BINDING; PURIFICATION; CLEAVAGE; GENES	The forward and reverse reactions for integration were characterized for the Moloney murine leukemia virus integrase (M-MuLV IN) protein. The M-MuLV IN was recombinantly produced in Escherichia coli, and was purified to greater than 90% homogeneity by a one-step affinity purification scheme. M-MuLV IN was highly active for integration as measured by in vitro cleavage and strand transfer assays. Furthermore, the integration of a model viral substrate into lambda concatamers by IN correctly produced the flanking 4-base pair duplications characteristic of M-MuLV IN. The reverse reaction of integration, disintegration, was also catalyzed by the recombinant M-MuLV IN. Two products were generated, a 3'-recessed long terminal repeat and a ligated target DNA, from a model integration-intermediate substrate in the presence of M-MuLV IN. The requirements and optimal conditions for maximal integration and disintegration activity for M-MuLV IN were determined. The forward and reverse reactions required different concentrations of manganese ion and reductant. Salt was also titrated for the forward and reverse reactions. Sodium chloride inhibited integration, but had little affect on disintegration. Low concentrations of potassium chloride enhanced integration, but had no affect on disintegration. The dinucleotide cleavage, strand transfer, and the disintegration reactions each had a unique pH profile of activity.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center			Jonsson, Colleen/GPC-4424-2022; Roth, Monica/AAN-8742-2020	Jonsson, Colleen/0000-0002-2640-7672; 				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; DONEHOWER LA, 1988, J VIROL, V62, P3958, DOI 10.1128/JVI.62.11.3958-3964.1988; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; GOFF SP, 1987, BIOCHIM BIOPHYS ACTA, V907, P93, DOI 10.1016/0304-419X(87)90001-1; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P839; LIN TH, 1989, PROTEINS, V5, P156, DOI 10.1002/prot.340050210; ROTH MJ, 1991, J VIROL, V65, P2141, DOI 10.1128/JVI.65.4.2141-2145.1991; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROTH MJ, 1988, J MOL BIOL, V203, P131, DOI 10.1016/0022-2836(88)90097-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1986, J VIROL, V59, P328, DOI 10.1128/JVI.59.2.328-340.1986; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615	33	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1462	1469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419346				2022-12-25	WOS:A1993KG07700104
J	BELINSKY, MG; BRITTON, E; DINTERGOTTLIEB, G				BELINSKY, MG; BRITTON, E; DINTERGOTTLIEB, G			MODIFICATION INTERFERENCE ANALYSIS OF A SELF-CLEAVING RNA FROM HEPATITIS-DELTA VIRUS	FASEB JOURNAL			English	Article						HEPATITIS-DELTA VIRUS; RIBOZYME; RNA STRUCTURE	ANTIGENOMIC RNA; CLEAVAGE; RIBOZYMES; SEQUENCES; GENOME	A chemical modification-interference as say was used to evaluate the sequence requirements for self-cleavage of a 73-nucleotide self-cleaving RNA from the genomic hepatitis delta virus (HDV). Twenty-two nucleotides were categorized as individually essential for self-cleavage, shown by loss of activity when modified. All of these required nucleotides fell within 38 nucleotides downstream of the cleavage site, suggesting an essential structural or functional role for this region. Lesser effects were seen for nucleotides further 3' of the cleavage site. and a small number of nucleotides had a negligible effect on the extent of self-cleavage when modified. Several modifications increased the extent of self-cleavage, suggesting these nucleotides may act to inhibit the reaction when unmodified. The functional requirements for certain nucleotides are discussed in the light of structural probing data and conventional mutational analysis available for other HDV RNAs.	DREXEL UNIV, DEPT BIOSCI & BIOTECHNOL, 32ND & CHESTNUT ST, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT BIOCHEM, PHILADELPHIA, PA 19104 USA	Drexel University; University of Pennsylvania					NIAID NIH HHS [AI 31821] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031821] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELINSKY MG, 1991, NUCLEIC ACIDS RES, V19, P559, DOI 10.1093/nar/19.3.559; BELINSKY MG, 1992, HEPATITIS DELTA VIRU; BRANCH AD, 1991, P NATL ACAD SCI USA, V88, P10163, DOI 10.1073/pnas.88.22.10163; BROWN DM, 1967, METHODS ENZYMOL    A, V12, P31; CASHMORE AR, 1978, NUCLEIC ACIDS RES, V5, P2485, DOI 10.1093/nar/5.7.2485; CHEN PJ, 1986, P NATL ACAD SCI USA, V83, P8774, DOI 10.1073/pnas.83.22.8774; CONWAY L, 1989, METHOD ENZYMOL, V180, P369; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; PRASAD Y, 1992, ANTISENSE STRATEGIES, V660, P277; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; SMITH JB, 1991, NUCLEIC ACIDS RES, V19, P1285, DOI 10.1093/nar/19.6.1285; SUH YA, 1992, NUCLEIC ACIDS RES, V20, P747, DOI 10.1093/nar/20.4.747; THILL G, 1991, NUCLEIC ACIDS RES, V19, P6519, DOI 10.1093/nar/19.23.6519; VINCZE A, 1973, J AM CHEM SOC, V95, P2677, DOI 10.1021/ja00789a045; WU HN, 1992, J MOL BIOL, V223, P233, DOI 10.1016/0022-2836(92)90728-3; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	26	24	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					130	136		10.1096/fasebj.7.1.8422959	http://dx.doi.org/10.1096/fasebj.7.1.8422959			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422959				2022-12-25	WOS:A1993KH88000019
J	JAKUBOWSKI, H				JAKUBOWSKI, H			ENERGY-COST OF PROOFREADING INVIVO - THE CHARGING OF METHIONINE TRANSFER-RNAS IN ESCHERICHIA-COLI	FASEB JOURNAL			English	Article						TRANSLATIONAL ACCURACY; DEACYLATION OF AMINOACYL-TRANSFER RNA; S-METHYL-HOMOCYSTEINE THIOLACTONE; METHIONYL-TRANSFER RNA SYNTHETASE	AMINO-ACIDS; SYNTHETASE; HOMOCYSTEINE; MECHANISM; BINDING; MET	Previous in vitro work has shown that Escherichia coli methionyl-tRNA synthetase has a limited ability to discriminate against cognate methionine in the editing site designed for noncognate homocysteine. As a result, a small fraction of the correct product Met-tRNA is deacylated with the formation of a cyclic sulfonium compound, S-methyl-homocysteine thiolactone. This is exploited here to estimate energy costs associated with the destruction of a correct product by methionyl-tRNA synthetase in bacterial cells. In vivo measurements of S-methyl-homocysteine thiolactone indicate that in Escherichia coli 3.3 molecules of Met-tRNA are destroyed by deacylation per 10,000 molecules of Met-tRNA successfully transferring methionine to protein. This number of destroyed molecules of a correct product. Met-tRNA, is 30 times lower than the number of destroyed molecules of an incorrect product, homocysteinyl adenylate. Thus, most of the energy cost of proofreading in vivo is due to editing of the noncognate amino acid.			JAKUBOWSKI, H (corresponding author), UMDNJ, NEW JERSEY MED SCH, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; BLANQUET S, 1973, EUR J BIOCHEM, V36, P213, DOI 10.1111/j.1432-1033.1973.tb02903.x; BLANQUET S, 1976, J MOL BIOL, V103, P765, DOI 10.1016/0022-2836(76)90208-4; DEV IK, 1984, J BIOL CHEM, V259, P8402; ERIANI G, 1989, NUCLEIC ACIDS RES, V17, P5725, DOI 10.1093/nar/17.14.5725; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P9569, DOI 10.1021/bi00104a002; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1988, J THEOR BIOL, V133, P363, DOI 10.1016/S0022-5193(88)80327-8; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JAKUBOWSKI H, 1992, IN PRESS J BIOL CHEM; JAKUBOWSKI HZ, 1977, ANAL BIOCHEM, V82, P29, DOI 10.1016/0003-2697(77)90130-0; SAVAGEAU MA, 1979, P NATL ACAD SCI USA, V76, P4507, DOI 10.1073/pnas.76.9.4507; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23	17	11	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					168	172		10.1096/fasebj.7.1.8422964	http://dx.doi.org/10.1096/fasebj.7.1.8422964			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422964				2022-12-25	WOS:A1993KH88000025
J	SHAUGHNESSY, JD; OWENS, JD; WIENER, F; HILBERT, DM; HUPPI, K; POTTER, M; MUSHINSKI, JF				SHAUGHNESSY, JD; OWENS, JD; WIENER, F; HILBERT, DM; HUPPI, K; POTTER, M; MUSHINSKI, JF			RETROVIRAL ENHANCER INSERTION 5' OF C-MYC IN 2 TRANSLOCATION-NEGATIVE MOUSE PLASMACYTOMAS UP-REGULATES C-MYC EXPRESSION TO DIFFERENT EXTENTS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; MESSENGER-RNA; DNA FRAGMENTS; TRANSCRIPTIONAL ACTIVATION; CHROMOSOME TRANSLOCATIONS; NUCLEOTIDE-SEQUENCE; AGAROSE GELS; T-LYMPHOMAS; ONC GENE; V-ABL	Essentially all murine plasmacytomas have deregulated c-myc expression that is typically brought about by chromosomal translocations between the c-myc/Pvt-1 locus and one of the immunoglobulin loci. ABPC 22 and RFPC 2782 are BALB/c plasmacytomas that lack chromosomal translocations yet have Southern blot evidence of c-myc gene rearrangements. In this report we show that proviral integrations 5' of the c-myc gene can deregulate c-myc expression in mouse plasmacytomas. Analysis of DNA sequences 5' of the c-myc genes from both tumors demonstrated that rearrangements were caused by retroviral integrations 5' of c-myc exon 1. The proviral insertion in RFPC 2782 was associated with a high steady-state c-myc mRNA level comparable to that seen in plasmacytomas with typical translocations. An analogous proviral insertion in ABPC 22 was associated with a c-myc RNA level that was only 38% of that of RFPC 2782. Nuclear run-on studies of c-myc transcription showed that ABPC 22 has both a lower rate of transcription and a greater degree of transcriptional attenuation than RFPC 2782. DNA sequencing of the long terminal repeat of each tumor provirus showed that the ABPC 22 provirus harbors a deletion of one of the two direct repeats in the viral enhancer, whereas both repeats are present in the RFPC 2782 provirus. These data indicate that maximum LTR enhancer effectiveness in plasmacytomas in vivo requires the presence of both LTR direct repeats. The documentation of the low level of steady-state c-myc mRNA in ABPC 22 supports the notion that deregulated c-myc expression, even at low steady state levels, is effective in supporting the development of plasmacytomas.	NCI,GENET LAB,BETHESDA,MD 20892; UNIV MARYLAND,DEPT ZOOL,COLL PK,MD 20742; KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park; Karolinska Institutet								AXELSON H, 1991, ONCOGENE, V6, P2263; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAUER SR, 1989, ONCOGENE, V4, P615; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CLURMAN BE, 1988, CELLULAR ONCOGENE AC, P55; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; CUYPERS HT, 1984, CELL, V37, P141; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KRAFT R, 1988, BIOTECHNIQUES, V6, P554; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA AM, 1988, GENETIC RECOMBINATIO, P701; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SRINIVASAN A, 1984, SCIENCE, V233, P286; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WIENER F, 1984, P NATL ACAD SCI-BIOL, V81, P1159, DOI 10.1073/pnas.81.4.1159; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1972, J HERED, V63, P69	53	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3111	3121						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414513				2022-12-25	WOS:A1993MC09300028
J	BARBOUR, SE; DENNIS, EA				BARBOUR, SE; DENNIS, EA			ANTISENSE INHIBITION OF GROUP-II PHOSPHOLIPASE-A(2) EXPRESSION BLOCKS THE PRODUCTION OF PROSTAGLANDIN-E(2) BY P388D(1) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MEMBRANE-ASSOCIATED PHOSPHOLIPASE-A2; RAT PLATELET PHOSPHOLIPASE-A2; MESSENGER-RNA SYNTHESIS; 2 DISTINCT MECHANISMS; SMOOTH-MUSCLE CELLS; EXTRACELLULAR PHOSPHOLIPASE-A2; ALVEOLAR MACROPHAGES	Macrophage-like P388D1 cells release [H-3]arachidonic acid and produce prostaglandin E2 (PGE2) upon stimulation with bacterial lipopolysaccharide (LPS) and platelet-activating factor (PAF). To determine whether group II phospholipase A2 (PLA2) is involved in this release, we treated P388D, cells with antisense inhibitors specific for group II PLA2 RNA. Treatment with oligonucleotide ASGII decreased PLA2 activity in P388D1 cell homogenates by approximately 60% and reduced the release of [H-3]arachidonic acid and PGE2 from activated cells to nearly resting cell levels. The inhibition by antisense oligonucleotide ASGII was blocked when its sense complement, SGII, was included in the incubation mixture. Stably transfected P388D1 cells expressing an antisense construct for group II PLA2 also produced reduced quantities of PGE2 in response to LPS and PAF. These data suggest that prostaglandin production by activated P388D1 cells involves phospholipid hydrolysis by group II PLA2. Oligonucleotide ASGII also blocked the appearance of a heparin-releasable group II PLA2 in the culture supernatants of P388D, cells. The disappearance of this protein correlated with reduced PGE2 production by activated cells, indicating that an extracellular heparin-associated pool of groUP II PLA2 is involved in prostaglandin production by P388D1 cells.	UNIV CALIF SAN DIEGO, DEPT CHEM, 0601, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015279] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 15279] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; DICCIANNI MB, 1991, BIOCHEMISTRY-US, V30, P9090, DOI 10.1021/bi00101a026; FU JY, 1990, J BIOL CHEM, V265, P16737; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HOFFMAN T, 1992, BIOCHEM PHARMACOL, V44, P955, DOI 10.1016/0006-2952(92)90128-6; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; INADA M, 1991, BIOCHEM BIOPH RES CO, V174, P1077, DOI 10.1016/0006-291X(91)91530-P; Innis MA, 1990, PCR PROTOCOLS GUIDE; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUDO I, 1989, DERMATOLOGICA, V179, P72, DOI 10.1159/000248454; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; McLean L R, 1986, Methods Enzymol, V129, P738; MOHRI M, 1990, J IMMUNOL, V144, P2678; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1005, P270; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OKA S, 1991, J BIOL CHEM, V266, P9956; ONO T, 1988, J BIOL CHEM, V263, P5732; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; REYNOLDS LJ, 1991, METHOD ENZYMOL, V197, P3; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; Sambrook J, 1989, MOL CLONING LABORATO; SAUTES C, 1992, IMMUNOL RES, V11, P181, DOI 10.1007/BF02919125; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V174, P268, DOI 10.1016/0006-291X(91)90515-9; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; Stout J T, 1987, Methods Enzymol, V151, P519; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; WASHBURN WN, 1991, J BIOL CHEM, V266, P5042; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; YU L, 1990, J BIOL CHEM, V265, P2657	63	170	170	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21875	21882						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408042				2022-12-25	WOS:A1993MC80900067
J	STRAUB, P; LLOYD, M; JOHNSON, EF; KEMPER, B				STRAUB, P; LLOYD, M; JOHNSON, EF; KEMPER, B			CASSETTE MUTAGENESIS OF A POTENTIAL SUBSTRATE RECOGNITION REGION OF CYTOCHROME-P450-2C2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE DEFICIENCY; SITE-DIRECTED MUTAGENESIS; AMINO-ACID; CATALYTIC ACTIVITY; ELECTRON-TRANSFER; EXPRESSION; DEBRISOQUINE; MUTATIONS; PROTEINS; MEMBRANE	Cassette mutagenesis was used to analyze the effects of mutations at amino acid positions 107-120 in cytochrome P450 2C2 which are part of a predicted substrate recognition site, SRS-1 (Gotoh, O. (1992) J. BioL Chem. 267, 83-90), and terminate with a highly conserved tryptophan. All the mutant enzymes were expressed in COS1 cells at approximately the same level as wild type as determined by immunoprecipitation of radiolabeled products. Substitutions of amino acids from 107 to 110 and from 116 to 119 resulted in mutant enzymes that retained substantial lauric acid hydroxylase activity suggesting that these residues are not critical determinants of substrate specificity. In contrast, amino acids 112-115 were characterized by strong decreases in activity in at least one mutation tested. A substitution of phenylalanine for valine 112 reduced activity about 3-fold. At position 113, substitution of leucine for isoleucine had little effect, but activity was reduced 15-fold by substitution with cysteine. A conservative mutation at position 114 reduced activity 5-fold, a nonconservative mutation at position 115 resulted in a 30-fold reduction of lauric acid hydroxylation. Substitution of glutamic acid for glycine at position 109 had little effect on activity, while more conservative substitutions of valine for glycines at positions 111 and 117 resulted in about 50- and 7-fold reductions of activity, respectively. Substitution of leucine for tryptophan 120 resulted in a 7-fold reduction of activity indicating that tryptophan at this position contributes to, but is not essential for, enzymatic activity in spite of its presence in nearly all eukaryotic cytochromes P450. The results are consistent with a model in which amino acids 112-114, and possibly 115, align with a loop of bacterial P450cam sequence containing substrate contacting amino acids, tyrosine 96 and phenylalanine 98. Glycines at either end of the loop in cytochrome P450 2C2 appear to be critical for activity.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, 524 BURRILL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM NX4, LA JOLLA, CA 92037 USA	University of Illinois System; University of Illinois Urbana-Champaign; Scripps Research Institute					NIGMS NIH HHS [GM31001, GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001, R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALDWIN JE, 1991, P ROY SOC B-BIOL SCI, V245, P43, DOI 10.1098/rspb.1991.0086; BROLY F, 1991, DNA CELL BIOL, V10, P545, DOI 10.1089/dna.1991.10.545; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; CHRISTOU M, 1992, BIOCHEMISTRY-US, V31, P2835, DOI 10.1021/bi00125a027; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; JOHNSON EF, 1990, BIOCHEMISTRY-US, V29, P873, DOI 10.1021/bi00456a004; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LEWIS DFV, 1992, J COMPUT AID MOL DES, V6, P235, DOI 10.1007/BF00123379; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OLIPHANT AR, 1987, METHOD ENZYMOL, V155, P568; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; TUSIELUNA MT, 1990, J BIOL CHEM, V265, P20916; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074; ZVELEBIL MJJ, 1991, PROTEIN ENG, V4, P172	36	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21997	22003						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408056				2022-12-25	WOS:A1993MC80900084
J	LEE, SF; COTE, GP				LEE, SF; COTE, GP			ISOLATION AND CHARACTERIZATION OF 3 DICTYOSTELIUM MYOSIN-I ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACTIVATED ATPASE ACTIVITY; ACTIN-BINDING-SITES; ACANTHAMOEBA MYOSIN; UNCONVENTIONAL MYOSIN; PROTEIN PHOSPHATASES; LIMITED PROTEOLYSIS; CASTELLANII; LOCALIZATION; DISCOIDEUM	Using ion exchange chromatography and an ATP-dependent actin precipitation step, we have isolated three myosin-I isozymes that, together, account for most of the K+EDTA-ATPase activity recovered from extracts of Dictyostelium. The two major myosin-I isozymes, present in approximately equal amounts, had apparent molecular masses of 125 kDa on SDS gels and have been identified by amino acid sequence analysis as the products of the Dictyostelium myosin-IB (DMIB) and myosin-ID (DMID) genes. DMIB, with a specific K+EDTA-ATPase activity 10-fold higher than DMID, was responsible for most of the activity in cell extracts. The third isozyme, present in low amounts, had an apparent molecular mass of 137 kDa on SDS gels and is too large to be the product of any of the known myosin-I genes. DMIB eluted from DE53 cellulose columns as two distinct peaks (II and III). Addition of the phosphatase inhibitor okadaic acid to the extraction buffer increased the fraction of DMIB recovered from growth phase cells in peak III from 35 to 70%. DMIB isolated from peak III, but not from peak II, displayed a significant level of actin-activated MgATPase activity. These results indicate that peak III represents a phosphorylated, actin-activatable form of DMIB.			LEE, SF (corresponding author), QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ONTARIO, CANADA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; ALBANESI JP, 1986, J BIOL CHEM, V261, P445; ALBANESI JP, 1983, J BIOL CHEM, V258, P176; ALBANESI JP, 1985, J BIOL CHEM, V260, P3276; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; BRZESKA H, 1988, J BIOL CHEM, V263, P427; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN P, 1989, J BIOL CHEM, V264, P21435; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COTE GP, 1985, J BIOL CHEM, V260, P4543; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1983, J BIOL CHEM, V258, P168; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1993, J BIOL CHEM, V268, P14981; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KORN ED, 1988, J CELL BIOCHEM, V36, P37, DOI 10.1002/jcb.240360105; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KORN ED, 1991, CURR TOP MEMBR, V38, P13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH TJ, 1987, J BIOL CHEM, V262, P13842; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; SIMON MN, 1992, BIOCHEM BIOPH RES CO, V184, P1142, DOI 10.1016/S0006-291X(05)80002-6; SPUDICH JA, 1989, CELL REGUL, V1, P1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; VARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1990, J CELL BIOL, V111, P1137, DOI 10.1083/jcb.111.3.1137; WESSELS M, 1991, CELL MOTIL CYTOSKEL, V20, P301; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	54	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20923	20929						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407927				2022-12-25	WOS:A1993MA28800047
J	LIM, MY; DAILEY, D; MARTIN, GS; THORNER, J				LIM, MY; DAILEY, D; MARTIN, GS; THORNER, J			YEAST MCK1 PROTEIN-KINASE AUTOPHOSPHORYLATES AT TYROSINE AND SERINE BUT PHOSPHORYLATES EXOGENOUS SUBSTRATES AT SERINE AND THREONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERK-1 GENE-PRODUCT; MAP KINASE; SACCHAROMYCES-CEREVISIAE; CONSERVED FEATURES; IDENTIFICATION; PURIFICATION; ACTIVATION; RECEPTOR; ENCODES; DOMAIN	The product of the Saccharomyces cerevisiae MCK1 gene is a protein kinase that phosphorylates poly (Glu,Tyr) in vitro and is itself phosphorylated at both tyrosine and serine in vivo. To characterize the substrate specificity of Mck1, the enzyme was purified to apparent homogeneity from the soluble fraction of yeast cell extracts by ammonium sulfate precipitation, followed by ion exchange chromatography (Q- and S-Sepharose), dye-ligand affinity chromatography (Orange A-agarose), adsorption chromatography (hydroxylapatite), and ion exchange fast protein liquid chromatography (Mono-S). In the absence of an exogenous substrate, purified Mck1 was able to autophosphorylate on tyrosine and serine. A catalytically inactive mutant (K68R in conserved kinase domain II) expressed in an mck1DELTA strain did not contain detectable phosphotyrosine, confirming that the tyrosine phosphorylation observed in vivo is due to autophosphorylation, but did contain phosphoserine, suggesting that Mck1 is a target for other cellular protein kinases. Purified Mck1 phosphorylated a variety of proteins in heat-inactivated yeast extracts, primarily on serine (and threonine). The purified enzyme also used a number of mammalian proteins as phosphoacceptors, including myelin basic protein (MBP), microtubule-associated protein 2 (MAP-2), and tau protein. All of these substrates were phosphorylated on either serine or threonine (or both). Mck1 isolated from yeast extracts by immunoprecipitation with an anti-Mck1 antibody directed against its C terminus also phosphorylated MBP at serine. In the same immune complex kinase assay, the K68R mutant did not detectably phosphorylate MBP, indicating that the serine-specific phosphotransferase activity of Mck1 is intrinsic and not due to contamination by an associated kinase. These findings demonstrate that Mck1 is a member of a novel class of protein kinases that displays the ability to phosphorylate all three hydroxyamino acids in proteins.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL, RM 401,BARKER HALL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044173, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM44173, GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN S, 1984, J BIOL CHEM, V259, P2051; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DAILEY D, 1991, MOL CELL BIOL, V11, P2333; DAILEY D, 1992, THESIS U CALIFORNIA; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; SCHIEVEN G, 1986, SCIENCE, V231, P390, DOI 10.1126/science.2417318; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHERMAN F, 1986, LABORATORY COURSE MA; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987	47	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21155	21164						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407952				2022-12-25	WOS:A1993MA28800077
J	LINDQVIST, Y; SCHNEIDER, G; VIHKO, P				LINDQVIST, Y; SCHNEIDER, G; VIHKO, P			3-DIMENSIONAL STRUCTURE OF RAT ACID-PHOSPHATASE IN COMPLEX WITH L(+)-TARTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TARTRATE-RESISTANT; MOLECULAR-CLONING; SEQUENCE; TYPE-5	The crystal structure of recombinant rat prostatic acid phosphatase in complex with the inhibitor L(+)-tartrate was determined to 3-angstrom resolution with protein crystallographic methods. The inhibitor binds at the carboxyl end of the parallel strands of the alpha/beta domain. One of the carboxyl groups of the tartrate molecule interacts with the conserved residues Arg-11, His-12, and Arg-15, which form part of the phosphate binding site. Furthermore, the C2 and C3 hydroxyl groups interact with His-257 and Arg-79. The second carboxyl group is close to Arg-79 but makes no direct hydrogen bonds to the protein. A sequence comparison between tartrate-sensitive and -resistant acid phosphatases suggests that these enzymes have different three-dimensional structures.	UNIV OULU,BIOCTR,SF-90220 OULU,FINLAND; UNIV OULU,DEPT CLIN CHEM,SF-90220 OULU,FINLAND	University of Oulu; University of Oulu	LINDQVIST, Y (corresponding author), SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT MOLEC BIOL,BOX 590,S-75124 UPPSALA,SWEDEN.		Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Schneider, Gunter/0000-0003-0622-5713				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; Bodansky O, 1972, Adv Clin Chem, V15, P43, DOI 10.1016/S0065-2423(08)60159-6; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; EKRYLANDER B, 1991, J BIOL CHEM, V266, P24684; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KETCHAM CM, 1989, J BIOL CHEM, V264, P557; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; ROIKO K, 1990, GENE, V89, P223, DOI 10.1016/0378-1119(90)90009-G; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VIHKO P, 1988, FEBS LETT, V236, P275, DOI 10.1016/0014-5793(88)80037-1; VIHKO P, 1981, CANCER RES, V41, P1180; VIHKO P, 1993, P NATL ACAD SCI USA, V90, P799, DOI 10.1073/pnas.90.3.799; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6	15	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20744	20746						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407898				2022-12-25	WOS:A1993MA28800017
J	PAN, ZQ; HURWITZ, J				PAN, ZQ; HURWITZ, J			RECONSTITUTION OF CYCLIN-DEPENDENT CDC2 AND CDK2 KINASE-ACTIVITIES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; PROTEIN-KINASE; DNA-REPLICATION; ACTIVATION; GENE; PHOSPHORYLATION; P34CDC2; COMPLEX; SUBUNIT; MITOSIS	The genes that encode human cdc2 and cdk2 proteins are essential for cell cycle progression. In this report, we describe the purification of cyclin-associated cdc2 and cdk2 kinases as well as cyclin-free cdc2 and cdk2 protein preparations from HeLa cells. The cdc2-cyclin B kinase complex that we have isolated, consisting of two polypeptides of p60 (cyclin B) and p34 (cdc2), phosphorylated both the p34 and p70 subunits of the three-subunit human single-stranded DNA-binding protein (also called RP-A), a DNA replication and repair factor. We also partially purified a histone H1 kinase activity that is associated with the cdk2 and cyclin A proteins. Purified human cyclins A and B1, overproduced in bacteria, complemented a cellular fraction enriched in cdc2 and cdk2 proteins to reconstitute histone H1 kinase activity. Using this complementation system, human cdc2 and cdk2 proteins were purified and separated from one another. Glycerol gradient analyses demonstrated that the purified cdk2 (p33) protein co-sedimented with a cyclin A-dependent H1 kinase activity. Thus, cdk2 and cyclin A proteins are components that assemble to yield a kinase complex that catalyzes the phosphorylation of histone H1.			PAN, ZQ (corresponding author), MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.				NIGMS NIH HHS [5RO GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELIEAGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KENNY MK, 1990, J BIOL CHEM, V265, P769; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1991, J BIOL CHEM, V266, P594; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	43	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20433	20442						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397206				2022-12-25	WOS:A1993LY01900076
J	KAIN, SR; JEN, TI; FIRESTONE, GL				KAIN, SR; JEN, TI; FIRESTONE, GL			GLUCOCORTICOID-REGULATED TRAFFICKING OF MOUSE MAMMARY-TUMOR VIRUS PROTEINS IN PERMEABILIZED HEPATOMA-CELLS - REQUIREMENTS OF INTRACELLULAR MEMBRANE-TRANSPORT FOR MATURATION OF THE CYTOPLASMIC PHOSPHORYLATED POLYPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; SURFACE-ASSOCIATED GLYCOPROTEINS; PFIZER MONKEY VIRUS; SEMI-INTACT CELLS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; STREPTOLYSIN-O; GAG PROTEINS; BREFELDIN-A; STRUCTURAL PROTEINS	Glucocorticoids coincidentally regulate the localization of mouse mammary tumor virus (MMTV) glycoproteins and maturation of viral phosphoproteins in viral infected rat hepatoma cells. To test for a functional interaction between MMTV transmembrane glycoproteins and cytoplasmic phosphoproteins, the bacterial cytolysin streptolysin-O was utilized to selectively permeabilize the plasma membrane and reconstitute exocytic trafficking. Streptolysin-O-permeabilized M1.54 cells pretreated with glucocorticoids retained the capability for proteolytic processing, cell surface delivery, and externalization of MMTV glycoproteins as determined by immunoprecipitation and immunofluorescence microscopy. The efficient maturation of MMTV phosphoproteins indicated that these viral proteins are properly transported near or to the plasma membrane in permeabilized cells. These maturation events in semi-intact cells were dependent on the addition of cell cytosol and were specifically inhibited by the membrane impermeant GTP analog guanosine 5'3-O-(thio)triphosphate, an agent known to impede vesicular transport of membrane proteins, but which has not previously been shown to alter cytoplasmic protein maturation or transport. The addition of anti-MMTV antibodies directed against the cytoplasmic domain of the glycoprotein precursor to transport competent semi-intact Ml.54 cells resulted in the dramatic inhibition of both MMTV glycoprotein and phosphoprotein maturation. These results were not obtained using either preimmune sera or antiserum specific for the luminal portion of the glycoprotein precursor. Our findings suggest that the functional interaction of cytosolic MMTV phosphoproteins with the cytoplasmic domain of the viral membrane glycoprotein is required for the efficient transport and processing of each class of proteins in glucocorticoid-treated cells and provides the first evidence for the involvement of vesicular transport in the delivery and maturation of cytoplasmic viral proteins at the plasma membrane or the pericellular region.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BOX 591 LSA, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [F32CA009053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA09053] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; AMACHER SL, 1989, MOL ENDOCRINOL, V3, P1634, DOI 10.1210/mend-3-10-1634; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO DA, 1991, MOL ENDOCRINOL, V5, P336, DOI 10.1210/mend-5-3-336; BRODY BA, 1992, J VIROL, V66, P3466, DOI 10.1128/JVI.66.6.3466-3475.1992; BRODY BA, 1992, P NATL ACAD SCI USA, V89, P3443, DOI 10.1073/pnas.89.8.3443; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; CARDIFF RD, 1978, VIROLOGY, V85, P157, DOI 10.1016/0042-6822(78)90420-8; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EINFELD D, 1988, P NATL ACAD SCI USA, V85, P8688, DOI 10.1073/pnas.85.22.8688; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FIRESTONE GL, 1988, ENDOCRINE GENES ANAL, P95; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GOODMAN LJ, 1993, MOL ENDOCRINOL, V7, P94, DOI 10.1210/me.7.1.94; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HAFFAR OK, 1987, MOL CELL BIOL, V7, P1508, DOI 10.1128/MCB.7.4.1508; HAFFAR OK, 1990, J VIROL, V64, P3100, DOI 10.1128/JVI.64.6.3100-3103.1990; HAFFAR OK, 1988, J CELL BIOL, V106, P1463, DOI 10.1083/jcb.106.5.1463; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANSEN M, 1990, J VIROL, V64, P5306, DOI 10.1128/JVI.64.11.5306-5316.1990; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAIN SK, 1991, J BIOL CHEM, V266, P5756; JOHN NJ, 1988, P NATL ACAD SCI USA, V85, P797, DOI 10.1073/pnas.85.3.797; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KARLSEN K, 1986, MOL CELL BIOL, V6, P574, DOI 10.1128/MCB.6.2.574; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KURZCHALIA TV, 1992, J BIOL CHEM, V267, P18419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARCUS SL, 1978, VIROLOGY, V86, P398, DOI 10.1016/0042-6822(78)90080-6; MASSEY RJ, 1979, VIROLOGY, V99, P358, DOI 10.1016/0042-6822(79)90015-1; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PFEFFERSR, 1992, TRENDS CELL BIOL, V2, P41; PLATT EJ, 1986, ANAL BIOCHEM, V156, P126, DOI 10.1016/0003-2697(86)90163-6; PLATT EJ, 1991, J BIOL CHEM, V266, P19384; PLATT EJ, 1991, MOL ENDOCRINOL, V5, P1696, DOI 10.1210/mend-5-11-1696; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RACEVSKIS J, 1978, J VIROL, V25, P374, DOI 10.1128/JVI.25.1.374-383.1978; RACEVSKIS J, 1980, J VIROL, V35, P937, DOI 10.1128/JVI.35.3.937-948.1980; RHEE SS, 1990, J VIROL, V64, P3844, DOI 10.1128/JVI.64.8.3844-3852.1990; RINGOLD GM, 1979, P NATL ACAD SCI USA, V76, P665, DOI 10.1073/pnas.76.2.665; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEAVER TA, 1990, J VIROL, V64, P3995, DOI 10.1128/JVI.64.8.3995-4001.1990; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WINGUTH SD, 1987, MOL ENDOCRINOL, V1, P823, DOI 10.1210/mend-1-11-823	76	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19640	19649						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8396142				2022-12-25	WOS:A1993LW81900076
J	LEE, Y; MAHDAVI, V				LEE, Y; MAHDAVI, V			THE D-DOMAIN OF THE THYROID-HORMONE RECEPTOR-ALPHA-1 SPECIFIES POSITIVE AND NEGATIVE TRANSCRIPTIONAL REGULATION FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; C-ERB-A; CHICKEN PROGESTERONE-RECEPTOR; RETINOIC ACID RECEPTORS; HUMAN ESTROGEN-RECEPTOR; NUCLEAR-LOCALIZATION; V-ERBA; DNA-BINDING; SIGNAL TRANSDUCTION; GENE-TRANSCRIPTION	Four structural domains are characteristic of the members of the thyroid/steroid receptor superfamily. Of these, the A/B and D domains are the least conserved. We have investigated the role of two clusters of positively charged amino acids within the D domain of the thyroid hormone receptor alpha1 (TRalpha1). The sequences Lys134-Arg-Lys and Arg188-Arg-Lys, individually or together, were substituted to the neutral residues TIT in three mutants named alpha1-1, alpha1-2, and alpha1-3, respectively. Subcellular localization of transiently transfected wild-type and mutated TRs was monitored by immunostaining, using a TRalpha1-specific antibody. The wild-type and the alpha1-2 TRs were detected exclusively in the nucleus, in the presence or absence of thyroid hormone. In contrast, the alpha1-1 and alpha1-3 mutants accumulated in both cytoplasm and nucleus, underscoring the importance of the Lys134-Arg-Lys residues for correct nuclear targeting. More importantly, although the mutants had unimpaired DNA- and hormone-binding activities, all three had lost positive and negative transcriptional regulatory functions. Thus, transactivation and repression functions can be entirely dissociated from the other properties of the receptor. In addition, substitution of either one of the positively charged amino acid clusters was sufficient to convert the native TRalpha1 into a dominant, thyroid hormone-dependent receptor antagonist. These observations, which underline the functional relevance of the D domain for TRalpha1 function, may also have implications for the autosomal dominant syndrome of generalized resistance to thyroid hormone.	HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	LEE, Y (corresponding author), CHILDRENS HOSP MED CTR, DEPT CARDIOL, MOLEC & CELLULAR CARDIOL LAB, BOSTON, MA 02115 USA.							BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANG CV, 1989, J BIOL CHEM, V264, P18019; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1987, NATURE, V329, P739; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; ICHIKAWA K, 1987, METABOLISM, V36, P392, DOI 10.1016/0026-0495(87)90214-9; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEE YS, 1989, J BIOL CHEM, V264, P13701; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAHDAVI V, 1989, UCLA S MOL CELL BIOL, V93, P369; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SILVER P, 1989, CRIT REV BIOCHEM MOL, V24, P419, DOI 10.3109/10409238909082557; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; Utiger R.D, 1989, ENDOCRINOLOGY, V1, P702; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	69	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2021	2028						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420976				2022-12-25	WOS:A1993KH62000080
J	ITOH, K; TAKIYAMA, N; KASE, R; KONDOH, K; SANO, A; OSHIMA, A; SAKURABA, H; SUZUKI, Y				ITOH, K; TAKIYAMA, N; KASE, R; KONDOH, K; SANO, A; OSHIMA, A; SAKURABA, H; SUZUKI, Y			PURIFICATION AND CHARACTERIZATION OF HUMAN LYSOSOMAL PROTECTIVE PROTEIN EXPRESSED IN STABLY TRANSFORMED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPODOPTERA-FRUGIPERDA CELLS; HUMAN BETA-GALACTOSIDASE; ACTIVATOR PROTEIN; NEURAMINIDASE DEFICIENCY; GALACTOSIALIDOSIS; CDNA; GLOBOTRIAOSYLCERAMIDE; FIBROBLASTS; DEGRADATION; GLUCOSIDASE	Chinese hamster ovary cells were transfected with a recombinant DNA containing the entire coding sequence of human lysosomal protective protein cDNA under the control of mouse metallothionein I promoter. Neomycin and methotrexate-resistant stably transformed cell lines expressing this protein were isolated. Immunoprecipitation of the product with antiserum against human placental protective protein-beta-galactosidase complex revealed a 52-kDa protective protein precursor, which was then processed to mature form, a heterodimer of 32- and 20-kDa polypeptides. The precursor secreted in the culture medium was taken up by the mannose 6-phosphate receptor system and restored acid carboxypeptidase, beta-galactosidase, and neuraminidase activities in galactosialidosis fibroblasts. The expressed protein showed a granular pattern in intracellular distribution, was fractionated at the density of lysosomes, and had serine esterase activities; acid carboxypeptidase at pH 5.6, esterase at pH 7.0, and carboxyl-terminal deamidase at pH 7.0. They were inhibited simultaneously by phenylmethyl-sulfonyl fluoride, N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone, or iodoacetamide. The acid carboxypeptidase activity of the purified monomeric mature protective protein was labile in vitro under the acidic condition. Saposins (sphingolipid activator proteins) stabilized the activity at micromolar level concentrations.	EHIME UNIV, SCH MED, DEPT NEUROPSYCHIAT, SHIGENOBU, EHIME 79102, JAPAN	Ehime University	ITOH, K (corresponding author), TOKYO METROPOLITAN INST MED SCI, DEPT CLIN GENET, 3-18-22 HONKOMAGOME, BUNKYO KU, TOKYO 113, JAPAN.			Sano, Akira/0000-0001-5843-9786				BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GARTNER S, 1983, J BIOL CHEM, V258, P2378; HOGEVEEN AT, 1983, J BIOL CHEM, V258, P12143; INUI K, 1983, P NATL ACAD SCI-BIOL, V80, P3074, DOI 10.1073/pnas.80.10.3074; ITOH K, 1990, BIOCHEM BIOPH RES CO, V167, P746, DOI 10.1016/0006-291X(90)92088-H; ITOH K, 1991, J INHERIT METAB DIS, V14, P813, DOI 10.1007/BF01799955; ITOH K, 1991, JPN J HUM GENET, V36, P169; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; KASE R, 1990, BIOCHEM BIOPH RES CO, V172, P1175, DOI 10.1016/0006-291X(90)91572-A; KLEINSCHMIDT T, 1988, BIOL CHEM HOPPESEYLE, V369, P1351; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1985, J BIOL CHEM, V260, P1867; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; NANBA E, 1987, BIOCHEM BIOPH RES CO, V144, P138, DOI 10.1016/S0006-291X(87)80486-2; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; SAKURABA H, 1982, CLIN CHIM ACTA, V125, P275; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; SHIMMOTO M, 1990, P JPN ACAD B-PHYS, V66, P217, DOI 10.2183/pjab.66.217; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SORENSEN SB, 1988, CARLSBERG RES COMMUN, V54, P193; Suzuki Y, 1988, BRAIN DYSFUNCT, V1, P285; Suzuki Y., 1985, DEV BRAIN ITS DISORD, P161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; Umezawa H, 1976, Methods Enzymol, V45, P678; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDIGGELEN OP, 1981, BIOCHEM J, V200, P143, DOI 10.1042/bj2000143; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	43	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1180	1186						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419322				2022-12-25	WOS:A1993KG07700063
J	RONG, L; KLEIN, HL				RONG, L; KLEIN, HL			PURIFICATION AND CHARACTERIZATION OF THE SRS2 DNA HELICASE OF THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; RAD3 PROTEIN; RECOMBINATION; MUTANTS; REPAIR; SEQUENCE; MUTATION; LOCALIZATION; REPLICATION	The SRS2 gene of Saccharomyces cerevisiae was identified through mutational analysis as a suppressor of radiation-sensitive mutations in the error-prone repair pathway and by a hyper-recombination phenotype. Comparison of the derived amino acid sequence revealed the gene to have high homology to the bacterial DNA helicases UvrD and Rep (Aboussekhra, A., Chanet, R., Zgaga, Z., Cassier-Chauvat, C., Heude, M., and Fabre, F. (1989) Nucleic Acids Res. 17, 7211-7219). We have purified the SRS2 protein from Escherichia coli extracts by tagging the SRS2 gene with 6 carboxyl-terminal histidine residues and overexpressing the tagged protein in a pET-3c vector. Extracts were passed over a metal-chelating affinity chromatography column followed by gel filtration to obtain an enriched protein fraction. Sephacryl gel filtration of pooled fractions containing the SRS2 protein yielded purified SRS2 protein by Coomassie Blue stain of SDS-polyacrylamide gel electrophoresis gels. The purified SRS2 protein was found to have in vitro DNA-dependent ATPase and DNA helicase activities. The polarity of the helicase activity was determined to be 3' to 5', the same polarity as that found for the UvrD and Rep proteins. The carboxyl-terminal region of the protein is shown to contain a sequence for nuclear localization. Expression of the SRS2 in yeast was examined and found to be extremely low.	NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University	RONG, L (corresponding author), NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA.			Klein, Hannah/0000-0003-4228-8535				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; AGUILERA A, 1988, GENETICS, V119, P779; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; DUGUET M, 1979, COLD SPRING HARB SYM, V43, P335, DOI 10.1101/SQB.1979.043.01.040; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; FOURY F, 1985, EMBO J, V4, P3525, DOI 10.1002/j.1460-2075.1985.tb04112.x; Friedberg E., 1991, MOL CELLULAR BIOL YE; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HAROSH I, 1986, BIOL CHEM, V264, P20532; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Johnson SL, 1991, THESIS U WASHINGTON; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAWRENCE CW, 1979, J BACTERIOL, V139, P866, DOI 10.1128/JB.139.3.866-876.1979; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1986, J BIOL CHEM, V261, P169; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYLIN LM, 1990, METHOD ENZYMOL, V185, P308; NAEGELI H, 1992, J BIOL CHEM, V267, P392; PALLADINO F, 1992, GENETICS, V132, P23; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; RONG L, 1991, GENETICS, V127, P75; Rose M. D., 1991, METHODS YEAST GENETI; SAMBROOK J, 1989, MOL CLONNG LABORATOR; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TJIAN R, 1975, J BIOL CHEM, V250, P8824; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	49	131	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1252	1259						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419328				2022-12-25	WOS:A1993KG07700073
J	MELLGREN, RL; SONG, K; MERICLE, MT				MELLGREN, RL; SONG, K; MERICLE, MT			M-CALPAIN REQUIRES DNA FOR ACTIVITY ON NUCLEAR PROTEINS AT LOW CALCIUM CONCENTRATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE; PURIFICATION; PROTEOLYSIS; SUBUNIT; CA-2+	m-Calpain (calpain II, m-CANP), which normally requires millimolar Ca2+ for activity in vitro, was capable of proteolyzing a number of matrix proteins in isolated rat liver nuclei at Ca2+ concentrations as low as 3 muM (Mellgren, R. L. (1991) J. Biol. Chem. 266, 13920-13924). Treatment of nuclei with deoxyribonuclease I eliminated the activity of m-calpain at low Ca2+ concentrations, while ribonuclease A and phospholipase C had no effect. Addition of DNA to DNase-treated nuclei restored m-calpain activity at low Ca2+. RNA had little if any effect. Eukaryotic and prokaryotic DNA were equally effective, and synthetic poly-deoxyribonucleotides were also activators. m-Calpain did not bind to a DNA-cellulose column in the presence of 200 muM Ca2+, and m-calpain preincubated in the presence of DNA and 200 muM Ca2+ was not activated at low Ca2+ concentrations following removal of the DNA. DNA did not alter the Ca2+ requirement for m-calpain-catalyzed cleavage of casein. These results demonstrate that the Ca2+ requirement for proteolysis of nuclear matrix proteins by m-calpain can be dramatically decreased in the presence of DNA. Activation did not seem to be a result of DNA binding directly to calpain but appeared to require interaction of DNA, calpain, and calpain substrates in the nuclear matrix.	MED COLL OHIO, DEPT PHARMACOL & THERAPEUT, TOLEDO, OH 43699 USA						NHLBI NIH HHS [HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; DAYTON WR, 1976, BIOCHEMISTRY-US, V15, P2159, DOI 10.1021/bi00655a020; EARNSHAW WC, 1991, EUKARYOTIC NUCLEUS, P639; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCH K, 1991, Journal of the American College of Cardiology, V17, p24A; MELLGREN RL, 1988, BIOCHIM BIOPHYS ACTA, V954, P154, DOI 10.1016/0167-4838(88)90066-0; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLGREN RL, 1988, PREP BIOCHEM, V18, P183, DOI 10.1080/00327488808062520; Murachi T, 1980, Adv Enzyme Regul, V19, P407; MURRAY AW, 1989, J CELL SCI, P65; PICARD A, 1985, DEV BIOL, V109, P311, DOI 10.1016/0012-1606(85)90458-0; PONTREMOLI S, 1984, BIOCHEM BIOPH RES CO, V123, P331, DOI 10.1016/0006-291X(84)90417-0; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SORIMACHI H, 1990, BIOL CHEM H-S, V371, P171; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; Suzuki K S, 1987, PROG CLIN BIOCH MED, V5, P44; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	28	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					653	657						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416968				2022-12-25	WOS:A1993KE60300098
J	YAO, KQ; FALICK, AM; PATEL, N; CORREIA, MA				YAO, KQ; FALICK, AM; PATEL, N; CORREIA, MA			CUMENE HYDROPEROXIDE-MEDIATED INACTIVATION OF CYTOCHROME-P450 2B1 - IDENTIFICATION OF AN ACTIVE-SITE HEME-MODIFIED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATIC CYTOCHROME-P-450; LIVER CYTOCHROME-P-450; SUICIDE INACTIVATION; PROTEIN ADDUCTS; PROSTHETIC HEME; HEMOPROTEINS; DEGRADATION; METABOLISM; MYOGLOBIN; 3,5-DICARBETHOXY-2,6-DIMETHYL-4-ETHYL-1,4-DIHYDROPYRIDINE	Cumene hydroperoxide (CuOOH)-mediated inactivation of cytochromes P450 (P450) results in the degradation of their prosthetic heme to products that alkylate the apoprotein. Indirect approaches suggest that this alkylation occurs at the active site. in order to identify the specific apoprotein site(s) alkylated, purified H-3- or C-14-heme-labeled P450 2B1 was incubated with CuOOH and subjected to lysyl endopeptidase-C digestion. Two major peaks (L1 and L2) containing H-3- or C-14-labeled peptides were detected by reverse-phase high pressure liquid chromatography of the digest. L1 contained the highest specific radioactivity and after Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis yielded 3 peptide bands (M(r) almost-equal-to 3,500 (P1), 5,000 (P2), and 7,000 (P3)). Although all 3 bands were found radiolabeled, the yield of P1 was higher than that of P2 or P3. Amino acid sequence analysis of the first 13 N-terminal residues of P1 revealed the sequence RICLGEGIARNEL, corresponding to residues 434-446 of the reported 2B1 sequence. A species with the molecular mass of 3771 +/- 1 Da was detected in preliminary electrospray mass spectrometric analysis of L1. Since the theoretical average mass of the predicted peptide (residues 434-466) is 3721.99 Da, the additional 49 +/- 1 Da are considered to be contributed by the alkylating heme fragment. This alkylated 2B1 sequence contains not only Cys436, the conserved residue that provides the SH ligand for heme, but also other highly conserved residues, and therefore corresponds to the heme-sandwiching helix L of P450cam. To our knowledge, this is the first report to localize CuOOH-induced heme alkylation of 2B1 to its active site.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,BOX 0450,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK 26743] Funding Source: Medline; NIGMS NIH HHS [GM 44037] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORNHEIM LM, 1987, MOL PHARMACOL, V32, P299; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CANTONI L, 1981, INT J BIOCHEM, V13, P823, DOI 10.1016/0020-711X(81)90102-6; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; CORREIA MA, 1989, DRUG METAB REV, V20, P615, DOI 10.3109/03602538909103565; DAVIES HW, 1986, ARCH BIOCHEM BIOPHYS, V244, P387, DOI 10.1016/0003-9861(86)90128-1; DECKER C, 1986, BIOCHEM BIOPH RES CO, V136, P1162, DOI 10.1016/0006-291X(86)90456-0; DECKER CJ, 1989, BIOCHEMISTRY-US, V28, P5128, DOI 10.1021/bi00438a033; DEMONTELANO PRO, 1986, CYTOCHROME, V450, P217; DEMONTELLANO PRO, 1989, CYTOCHROME P, V450, P273; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; GUENGERICH FP, 1986, BIOCHEM BIOPH RES CO, V138, P193, DOI 10.1016/0006-291X(86)90265-2; GUENGERICH FP, 1987, MAMMALIAN CYTOCHRO P, V2; GUENGERICH FP, 1987, MAMMALIAN CYTOCHRO P, V1; HALPERT J, 1983, MOL PHARMACOL, V23, P445; HALPERT J, 1981, BIOCHEM PHARMACOL, V30, P875, DOI 10.1016/S0006-2952(81)80010-X; LUNETTA JM, 1989, MOL PHARMACOL, V35, P10; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, CYTOCHROME P, V450, P505; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SUGIYAMA K, 1989, CHEM RES TOXICOL, V2, P400, DOI 10.1021/tx00012a008; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446	31	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					59	65						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416964				2022-12-25	WOS:A1993KE60300011
J	TULCHINSKY, E; KRAMEROV, D; FORD, HL; RESHETNYAK, E; LUKANIDIN, E; ZAIN, S				TULCHINSKY, E; KRAMEROV, D; FORD, HL; RESHETNYAK, E; LUKANIDIN, E; ZAIN, S			CHARACTERIZATION OF A POSITIVE REGULATORY ELEMENT IN THE MTS1 GENE	ONCOGENE			English	Article							CALCIUM-BINDING PROTEIN; LIGATION-MEDIATED PCR; CULTURED MOUSE CELLS; 1ST INTRON; DNA METHYLATION; MESSENGER-RNAS; CD3-DELTA GENE; COLLAGEN GENE; PROMOTER; TRANSCRIPTION	The first intron of the mts1 gene, a gene that is selectively expressed in metastatic cells and in normal cells that are motile, was found to be highly homologous to the CD3delta enhancer element. Because of the homology between the CD3delta enhancer and the first intron of mts1, we analysed the first intron of the mts1 gene to determine whether it functions as a transcriptional regulatory element. Highly metastatic CSML-100 cells transfected with chloramphenicol acetyl transferase-containing plasmids demonstrated the ability of the mts1 first intron to function as a positive regulatory element. In vitro foot-printing analysis using extracts from CSML-0 cells (which express mts1 at low levels) or CSML-100 cells (which express mts1 at high levels) identified a protected 16-nucleotide element in the first intron of mts1, regardless of the extract used. However, in vivo footprinting analysis of the same region identified the protected 16-nucleotide fragment only in the mts1 intron from CSML-100 cells, not from CSML-0 cells. Differences in the methylation pattern of the mts1 gene in CSML-100 cells and CSML-0 cells are known to exist, and may in part be responsible for the mts1 footprinting differences observed in vivo from the different cell tines.	UNIV ROCHESTER,601 ELMWOOD AVE,ROCHESTER,NY 14642; MOSCOW GENE BIOL INST,MOSCOW,RUSSIA	University of Rochester; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Tulchinsky, Eugene/ABD-7070-2021		NCI NIH HHS [R01 CA46635, R01-CA36432, 2-P30-CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R01CA036432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1984, DNA METHYLATION BIOC, P147; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; DELEON M, 1991, J NEUROSCI RES, V29, P155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; Maniatis T, 1989, DECONTAMINATION DILU; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RASSART E, 1986, J VIROL, V58, P96, DOI 10.1128/JVI.58.1.96-106.1986; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	46	34	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					79	86						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423998				2022-12-25	WOS:A1993KN00500009
J	BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C				BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C			RB MAY ACT AS A TRANSCRIPTIONAL COACTIVATOR IN UNDIFFERENTIATED F9 CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; EIIA EARLY PROMOTER; HUMAN MYC PROMOTER; SV40 LARGE-T; SUSCEPTIBILITY GENE; FACTOR E2F; DNA-BINDING; TRANS-ACTIVATION; ADENOVIRUS-E1A PREVENTS; MOLECULAR-CLONING	The reversible interaction of the retinoblastoma susceptibility gene product (Rb) with the cellular transcription factor E2F has recently been demonstrated. Activation of the adenovirus E2a promoter by the products of the viral E1a gene correlates with the ability of both early E1a proteins to sequester Rb, thereby releasing E2F from inactive complexes with this protein. The E2a promoter is also efficiently stimulated by a product (17.5 kDa) of the viral E4 gene. The specific interaction of this E4 protein with E2F results in the formation of complexes that bind cooperatively to the two neighboring E2F binding sites in the E2a promoter. We have previously shown that in undifferentiated F9 cells (F9EC) the E2a promoter is refractory to E2F-mediated activation by E1a, but not by E4. Using both band-shift and transfection experiments, we now demonstrate (i) that in F9EC cells the E4 product, in combination with E2F, recruits Rb into a stable multiprotein complex and (ii) that in these undifferentiated cells, as opposed to their differentiated counterpart, Rb is actively involved in the transcriptional stimulation of the E2a promoter by E4. Our results suggest that, depending on the cell state, Rb may behave either as a transcriptional activator (F9EC cells) or as a transcriptional inhibitor (differentiated F9 cells).	INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			CHATTON, Bruno/R-3813-2019	Bocco, Jose Luis/0000-0002-9682-1270; CHATTON, Bruno/0000-0003-4515-7119				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, ONCOGENE, V5, P691; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GODING C, 1985, EMBO J, V4, P1523, DOI 10.1002/j.1460-2075.1985.tb03812.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P875, DOI 10.1128/MCB.4.5.875; JACKS T, 1992, NATURE, V359, P395; JALINOT P, 1987, MOL CELL BIOL, V7, P3806, DOI 10.1128/MCB.7.10.3806; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1991, Current Biology, V1, P281, DOI 10.1016/0960-9822(91)90084-A; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAJCHOWSKI DA, 1987, GENE, V58, P243, DOI 10.1016/0378-1119(87)90379-9; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	83	15	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2977	2986						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414500				2022-12-25	WOS:A1993MC09300011
J	CARNAC, G; ALBAGLICURIEL, O; DESCLOZEAUX, M; VANDROMME, M; GLINEUR, C; BEGUE, A; LAUDET, V; BONNIEU, A				CARNAC, G; ALBAGLICURIEL, O; DESCLOZEAUX, M; VANDROMME, M; GLINEUR, C; BEGUE, A; LAUDET, V; BONNIEU, A			OVEREXPRESSION OF C-ERBA PROTOONCOGENE ENHANCES MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE RECEPTORS; MUSCLE-SPECIFIC GENES; V-ERBA; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; MESSENGER-RNA; SKI ONCOGENE; MYOD1 GENE; EXPRESSION	Triiodothyronine (T3) positively regulates both the expression of the MyoD gene, a key myogenic regulator, and C2 muscle cell differentiation. To directly examine the role of its nuclear receptors in the control of myogenesis, we introduced a c-erbA expression vector into C2 muscle cells by transient or stable transfection. Our results show that c-erbA can play a potent role in the triggering of muscle terminal differentiation since its overexpression leads to: (1) a complete abrogation of the activity of the myogenesis inhibitor Ap-1 (fos/jun) transcription factor; (2) an enhanced induction of MyoD expression upon T3 treatment; (3) the acquisition by T3 of the ability to trigger both growth arrest and terminal differentiation in the presence of large amounts of serum mitogens, a property that is otherwise specific to retinoic acid (RA). Thus, c-erbA is one of the two proto-oncogenes (with c-ski) that acts as positive regulator of muscle differentiation. Furthermore, the fact that c-erbA overexpression allows T3 to largely mimic the RA effects indicates that their biological differences in the modulation of myogenic program primarily rely on the differential expression of their receptors in C2 muscle cells rather than on an intrinsic specificity of their target genes.	INRA,DIFFERENCIAT CELLULAIRE & CROISSANCE LAB,F-34060 MONTPELLIER,FRANCE; CTR RECH BIOCHIM MACROMOLEC,DEPT CELL BIOL,CNRS,INSERM,F-34033 MONTPELLIER,FRANCE; INST PASTEUR,CNRS,URA 1160,ONCOL MOLEC U186,F-59019 LILLE,FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Vandromme, Marie M/N-6615-2018; Bonnieu, Anne/ABA-7182-2020; Vandromme, Marie/ABC-3003-2021; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774; vandromme, Marie/0000-0002-5675-7999				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUWANO Y, 1985, J BIOCHEM-TOKYO, V97, P983, DOI 10.1093/oxfordjournals.jbchem.a135175; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOORE D D, 1990, New Biologist, V2, P100; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAIN B, 1990, New Biologist, V2, P284; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	56	19	19	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3103	3110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414512				2022-12-25	WOS:A1993MC09300027
J	HWANG, LY; SIEGELMAN, M; DAVIS, L; OPPENHEIMERMARKS, N; BAER, R				HWANG, LY; SIEGELMAN, M; DAVIS, L; OPPENHEIMERMARKS, N; BAER, R			EXPRESSION OF THE TAL1 PROTOONCOGENE IN CULTURED ENDOTHELIAL-CELLS AND BLOOD-VESSELS OF THE SPLEEN	ONCOGENE			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING MOTIF; T-CELL; CHROMOSOME-TRANSLOCATION; ENHANCER-BINDING; GENE-EXPRESSION; LEUKEMIA; SCL; ACTIVATION; MYOD	The TALI proto-oncogene encodes a basic helix-loop-helix (bHLH) protein that has been implicated in the pathogenesis of T-cell acute lymphoblastic leukemia. Normal expression of TALI is observed in erythrocytic, megakaryocytic and mastocytic cells of the hematopoietic lineage. We now report that both RNA transcripts and polypeptide products of TALI are present in human umbilical vein endothelial cells cultured in vitro. Moreover, in situ hybridization revealed a restricted pattern of TALI expression in endothelial cells in vivo, including vessels within the white pulp and follicles of the spleen. In view of its presumptive role as a transcriptional factor, the TAL1 gene product may serve during normal development as a regulator of endothelial cell growth or differentiation.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS ARTHRIT RES CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA046593] Funding Source: NIH RePORTER; NCI NIH HHS [CA46593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1993, IN PRESS BLOOD; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FUJITA T, 1983, SURV IMMUNOL RES, V2, P375; FUNK WD, 1991, MOL BIOL MED, V8, P185; GOLDFARB AN, 1992, BLOOD, V80, P2858; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; LEE ME, 1991, J BIOL CHEM, V266, P16188; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MUELLER C, 1988, IMMUNOL REV, V103, P73, DOI 10.1111/j.1600-065X.1988.tb00750.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; VISVADER J, 1991, ONCOGENE, V6, P187; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	32	68	68	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3043	3046						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414504				2022-12-25	WOS:A1993MC09300019
J	MALLAMACI, MA; CHIZZONITE, R; GRIFFIN, M; NETTLETON, M; HAKIMI, J; TSIEN, WH; KOCHAN, JP				MALLAMACI, MA; CHIZZONITE, R; GRIFFIN, M; NETTLETON, M; HAKIMI, J; TSIEN, WH; KOCHAN, JP			IDENTIFICATION OF SITES ON THE HUMAN FC-EPSILON-RI-ALPHA SUBUNIT WHICH ARE INVOLVED IN BINDING HUMAN AND RAT IGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; GAMMA SUBUNIT; GENE; CHAIN; CELLS; EXPRESSION; PRODUCTS	The high affinity IgE Fe receptor (FcepsilonRI), found on mast cells and basophils, is a tetrameric receptor complex. The extracellular portion of the FcepsilonRIalpha subunit consists of two immunoglobulin-like domains and binds IgE in the absence of the other subunits. To localize the high affinity IgE binding site within the FcepsilonRIalpha subunit, we generated a series of chimeric receptor constructs where one of the two immunoglobulin-like domains was either deleted or substituted with those from the human FcgammaRIIIAalpha or the rat FcepsilonRIalpha subunit. The chimeric receptors were monitored for their capacity to bind human and rat IgE, and their reactivity with different antireceptor antibodies. Domain I substitutions maintained high affinity human IgE binding. Domain II substitutions resulted in a total loss of both human and rat IgE binding. Single-domain alpha subunits could not bind IgE, suggesting that both extracellular domains are required for proper protein folding or IgE binding. To further localize the IgE binding sites, homolog-scanning mutagenesis was performed. At least three independent regions of domain II encompassing residues 118-129, 136-150, and 148-162 were required for IgE binding. Our results suggest that domain II of the human FcepsilonRIalpha confers most of the important contributions to the binding of the human IgE Fc molecule, whereas domain I of the rat FcepsilonRIalpha makes important contributions to the binding of rat IgE.	HOFFMANN LA ROCHE INC,DEPT BRONCHOPULM RES,340 KINGSLAND ST,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110	Roche Holding; Roche Holding								BANIYASH M, 1987, J IMMUNOL, V138, P2999; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; CONRAD DH, 1983, J IMMUNOL, V130, P327; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4606; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; KUSTER H, 1990, J BIOL CHEM, V265, P6448; KUSTER H, 1992, J BIOL CHEM, V267, P12782; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RISKE F, 1991, J BIOL CHEM, V266, P11245; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907	24	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22076	22083						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408065				2022-12-25	WOS:A1993MC80900095
J	SRIRAMARAO, P; STEFFNER, P; GEHLSEN, KR				SRIRAMARAO, P; STEFFNER, P; GEHLSEN, KR			BIOCHEMICAL-EVIDENCE FOR A HOMOPHILIC INTERACTION OF THE ALPHA-3-BETA-1 INTEGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; LAMININ RECEPTOR; FIBRONECTIN RECEPTOR; BINDING-SITE; GPIIB-IIIA; ADHESION; ALPHA-2-BETA-1; FAMILY; LOCALIZATION; VITRONECTIN	The purpose of this study was to determine if the alpha3beta1 integrin could interact in a homophilic manner. Several earlier reports have shown that certain integrin adhesion receptors, namely alpha2beta1, alpha3beta1, and alpha6beta4 localize to intercellular adhesion structures and, therefore, may participate in cell-cell interactions (Carter, W. G., Wayner, E. A., Bouchard, T. S., and Kaur, P. (1990) J. Cell Biol. 110, 1387-1404; Kaufmann, R., Frosch, D., Westphal, C., Weber, L., and Klein, C. E. (1989) J. Cell Biol. 109, 1807-1815; Hynes, R. O. (1987) Cell 48, 549-554; Symington, B. E., Takada, Y., and Carter, W. G. (1993) J. Cell Biol. 120, 523-535). We present data herein suggesting that the integrin alpha3beta1 may interact homophilically in such cell-cell adhesion structures which contain this specific receptor or, alternatively, in receptor aggregates found in focal adhesions. The alpha3beta1 receptor was purified by affinity chromatography on either human laminin or peptide GD-6-Sepharose and subsequently used as a substrate in cell adhesion assays. The immobilized alpha3beta1 supported the adhesion of cells containing alpha3beta1, and this attachment was specifically inhibited by monoclonal antibodies to both beta1 and alpha3 subunits. In addition, an affinity matrix containing purified alpha3beta1 showed specific binding of only alpha3beta1 from detergent extracts of cell surface proteins and such binding was cation-dependent. Finally, using biosensor technology involving the principle of surface plasmon resonance (BIAcore(TM), Pharmacia Biosensor), alpha3beta1, when bound to a carboxymethyl dextran-modified gold surface, was found to bind only other soluble alpha3beta1 receptors and did not bind other purified integrins, including alpha5beta1 and alphavbeta3. These data strongly suggest that alpha3beta1 likely interacts in a homophilic manner under our experimental conditions.	CALIF INST BIOL RES, LA JOLLA, CA 92037 USA; PHARMACIA BIOSENSOR, PISCATAWAY, NJ 08855 USA					Rao, Srirama/0000-0001-9082-1029	NATIONAL CANCER INSTITUTE [R01CA057202] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BREGMAN MD, 1983, PROSTAGLANDINS, V27, P17; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CULLEN DC, 1987, BIOSENSORS, V3, P211; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SRIRAMARAO P, 1993, IN PRESS J CELL SCI; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211	35	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22036	22041						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408061				2022-12-25	WOS:A1993MC80900089
J	UTAISINCHAROEN, P; MACKESSY, SP; MILLER, RA; TU, AT				UTAISINCHAROEN, P; MACKESSY, SP; MILLER, RA; TU, AT			COMPLETE PRIMARY STRUCTURE AND BIOCHEMICAL-PROPERTIES OF GILATOXIN, A SERINE-PROTEASE WITH KALLIKREIN-LIKE AND ANGIOTENSIN-DEGRADING ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; MEXICAN BEADED LIZARD; AMINO-ACID-SEQUENCE; GILA MONSTER VENOM; HELODERMA-HORRIDUM; ACETYLCHOLINE-RECEPTORS; ENZYME; PURIFICATION; TOXIN; PHOSPHOLIPASE-A2	The activity and the complete primary structure of gilatoxin, a glycoprotein component from the venom of the Mexican beaded lizard (Heloderma horridum horridum) has been elucidated. Gilatoxin, a serine protease, showed kallikrein-like activity, releasing bradykinin from kininogen; toxin-treated kininogen also produced lowered blood pressure in rats and contraction of isolated rat uterus smooth muscle. Gilatoxin catalyzed the hydrolysis of various arginine ester substrates for trypsin and thrombin and degraded both angiotensin I and II by cleavage of the dipeptide Asp-Arg from the NH2-terminal end. Fibrinogen was degraded but a fibrin clot was not produced, indicating that gilatoxin has specificities different from thrombin and snake venom thrombin-like proteases. The complete amino acid sequence of gilatoxin (245 residues) was deduced from NH2-terminal sequencing of overlapping peptide fragments cleaved from the reduced and alkylated toxin by enzymatic and chemical methods. The toxin is extensively glycosylated, containing approximately 8 mol of monosaccharide/mol of toxin, but appears to lack O-glycosylation sites. Amino acid sequence alignment of gilatoxin with batroxobin, crotalase, kallikrein, thrombin, trypsin, and several partial sequences of other Heloderma toxins reveals that there is considerable homology between these enzymes, particularly in the regions of the presumed catalytic site. Gilatoxin contains an additional 7 residues in the highly conserved catalytic region of serine proteases (including Asp-96, in the basic specificity pocket of thrombin) which may contribute to the unusual substrate specificity of the toxin.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523; UNIV NO COLORADO,DEPT BIOL SCI,GREELEY,CO 80639	Colorado State University; University of Northern Colorado			Mackessy, Stephen/GPT-0793-2022	Mackessy, Stephen/0000-0003-4515-2545	NIGMS NIH HHS [5R37 GM15591] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015591] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ALAGON A, 1986, J EXP MED, V164, P1835, DOI 10.1084/jem.164.6.1835; ALEXANDER G, 1988, TOXICON, V26, P953, DOI 10.1016/0041-0101(88)90260-7; BJARNASON JB, 1978, BIOCHEMISTRY-US, V17, P3395, DOI 10.1021/bi00609a033; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2092, DOI 10.1021/bi00681a008; CHEN YH, 1982, BIOCHEMISTRY-US, V21, P2592, DOI 10.1021/bi00540a003; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELION J, 1977, CHEM BIOL THROMBIN, P97; Fontana A, 1972, Methods Enzymol, V25, P419, DOI 10.1016/S0076-6879(72)25037-6; GOMEZ F, 1989, EUR J BIOCHEM, V186, P23, DOI 10.1111/j.1432-1033.1989.tb15172.x; HENDON RA, 1981, BIOCHEMISTRY-US, V20, P3517, DOI 10.1021/bi00515a033; ITOH N, 1987, J BIOL CHEM, V262, P3132; Khosla M.C., 1974, HDB EXPT PHARMACOLOG, P126; KOMORI Y, 1988, BIOCHEM BIOPH RES CO, V154, P613, DOI 10.1016/0006-291X(88)90183-0; KOMORIY, 1988, BIOCHIM BIOPHYS ACTA, V967, P92; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSTROM J, 1980, J BIOL CHEM, V255, P8340; MACKESSY S P, 1989, Toxicon, V27, P61; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MARKLAND FS, 1982, P NATL ACAD SCI-BIOL, V79, P1688, DOI 10.1073/pnas.79.6.1688; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; MURPHY SA, 1976, ARK ACAD SCI P, V30, P60; NIKAI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P270, DOI 10.1016/0003-9861(88)90594-2; PARKER DS, 1984, J BIOL CHEM, V259, P1751; PIRKLE H, 1981, BIOCHEM BIOPH RES CO, V99, P715, DOI 10.1016/0006-291X(81)91802-7; PIRKLE H, 1991, HDB NATURAL TOXINS, V5, P225; Pirkle H., 1988, HEMOSTASIS ANIMAL VE; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; RAUFMAN JP, 1982, AM J PHYSIOL, V242, pG471; ROBERTS PS, 1958, J BIOL CHEM, V232, P285; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SHIEH JC, 1988, J BIOCHEM-TOKYO, V103, P596; SOSA BP, 1986, BIOCHEMISTRY-US, V25, P2927, DOI 10.1021/bi00358a029; SWIFT GH, 1982, P NATL ACAD SCI-BIOL, V79, P7263, DOI 10.1073/pnas.79.23.7263; TITANI K, 1975, BIOCHEMISTRY-US, V14, P1358, DOI 10.1021/bi00678a003; TRAUTSCHOLD I, 1970, HDB EXP PHARM, V5, P53; TU AT, 1967, COMP BIOCHEM PHYSIOL, V22, P389, DOI 10.1016/0010-406X(67)90602-0; TU AT, 1983, COMP BIOCHEM PHYS B, V76, P377, DOI 10.1016/0305-0491(83)90086-X; TU AT, 1991, HDB NATURAL TOXINS, V5, P755; VANDERMEEERS A, 1987, EUR J BIOCHEM, V164, P321, DOI 10.1111/j.1432-1033.1987.tb11061.x; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; WILLIS TW, 1988, BIOCHEMISTRY-US, V53, P19; YABUKI Y, 1991, TOXICON, V29, P73, DOI 10.1016/0041-0101(91)90040-X	44	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21975	21983						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408054				2022-12-25	WOS:A1993MC80900081
J	ZDANOVSKY, AG; CHIRON, M; PASTAN, I; FITZGERALD, DJ				ZDANOVSKY, AG; CHIRON, M; PASTAN, I; FITZGERALD, DJ			MECHANISM OF ACTION OF PSEUDOMONAS EXOTOXIN - IDENTIFICATION OF A RATE-LIMITING STEP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; LIPOPROTEIN RECEPTOR; CELLULAR PROTEASE; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; AERUGINOSA; SITE; GLYCOPROTEIN; CYTOTOXICITY; MUTAGENESIS	Pseudomonas exotoxin (PE) enters cells by receptor-mediated endocytosis and is cleaved by a cellular protease between Arg279 and Gly280 to produce an NH2-terminal fragment of 28 kDa which contains the toxin's binding domain and a COOH-terminal fragment of 37 kDa which has translocating and ADP-ribosylating activity. After proteolysis, the COOH-terminal fragment reaches the endoplasmic reticulum by retrograde transport where it translocates to the cytosol and inhibits protein synthesis by ADP-ribosylating elongation factor 2. To understand how the 37-kDa fragment functions, we focused on the role of specific amino acids located near its NH2 terminus. We found that there was a 4-250-fold loss in toxic activity when tryptophan 281, leucine 284, or tyrosine 289 were changed to other residues. Mutations at these three positions did not interfere with the receptor binding, cell-mediated proteolytic cleavage, or ADP-ribosylating activity. To determine the role of these amino acids, a competition assay was devised in which the addition of excess PEDELTA553, a mutant form of PE that lacks ADP-ribosylation activity, competed efficiently for the toxicity of PE. Excess PE with mutations near the NH2 terminus of the 37-kDa fragment competed poorly. This competition occurred after proteolysis since PEGly276, a mutant form of PE that is not cleaved, did not compete. We conclude that specific amino acids at the NH2 terminus of the 37-kDa fragment interact in a saturable manner with an unknown intracellular component.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDRY GJ, 1989, J BIOL CHEM, V264, P15151; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DOUGLAS CM, 1987, J BACTERIOL, V169, P4962, DOI 10.1128/jb.169.11.4962-4966.1987; FRYLING C, 1992, INFECT IMMUN, V60, P497, DOI 10.1128/IAI.60.2.497-502.1992; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; JIINO Y, 1988, J BIOL CHEM, V263, P13203; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUKAC M, 1988, INFECT IMMUN, V56, P3095, DOI 10.1128/IAI.56.12.3095-3098.1988; MANHART MD, 1984, INFECT IMMUN, V45, P596, DOI 10.1128/IAI.45.3.596-603.1984; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUER CP, 1992, J BIOL CHEM, V267, P16872; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390	22	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21791	21799						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8408034				2022-12-25	WOS:A1993MC80900057
J	SORCITHOMAS, M; KEARNS, MW; LEE, JP				SORCITHOMAS, M; KEARNS, MW; LEE, JP			APOLIPOPROTEIN-A-I DOMAINS INVOLVED IN LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVATION - STRUCTURE-FUNCTION-RELATIONSHIPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; SITE-DIRECTED MUTAGENESIS; PEPTIDES; SEGMENT; MODEL; SERUM; ACID; GENE	A series of mutant apolipoprotein (apoA-I) constructs were designed and then expressed in cell culture to identify structural domains within the mature native apoA-I protein that participate in the activation of the plasma enzyme, lecithin-cholesterol acyltransferase (LCAT). Evolutionary conservation analysis has shown previously that apoA-I contains eight repeats containing 22 amino acids and two repeats containing 11 amino acids that are highly conserved among species as well as within the apolipoprotein supergene family. These tandem repeats begin at residue 44 and are usually marked by a proline residue, with six of the 22-mer repeats showing high amphipathic alpha-helical character. To determine if specific 11- or 22-amino acid domains are essential for maximal LCAT activation within the entire native protein, each of the 10 repeats was sequentially deleted using a polymerase chain reaction based method of mutagenesis. The wild-type and mutant apoA-I gene constructs were expressed in Chinese hamster ovary (CHO) cells and stable lines established. Wild-type and mutant apoA-I protein were purified from 48-96-h conditioned serum-free medium and characterized by SDS-polyacrylamide gel electrophoresis and Western blot analysis. Wild-type apoA-I showed a single migrating band of 28,000 daltons that corresponded to the mobility of human plasma apoA-I, whereas apoA-I deletion mutants (lacking 22- or 11-mer repeats) showed the corresponding shift to lower molecular size. To measure the relative LCAT activation of all deletion mutant apoA-I proteins relative to wild-type apoA-I, an assay system utilizing small unilamellar vesicles as the lipid substrate was used. The results of these studies suggest that several central amphipathic alpha-helical regions within the mature protein are critical in LCAT activation.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center	SORCITHOMAS, M (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.			Sorci-Thomas, Mary/0000-0002-6464-5006	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041916, P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49373, HL-41916] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albers J J, 1986, Methods Enzymol, V129, P763; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRUHN H, 1991, BIOL CHEM H-S, V372, P225, DOI 10.1515/bchm3.1991.372.1.225; DEEB SS, 1991, J BIOL CHEM, V266, P13654; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FITCH WM, 1977, GENETICS, V86, P623; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KORITNIK DL, 1983, J LIPID RES, V24, P1639; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MALLORY JB, 1987, J BIOL CHEM, V262, P4241; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MINNICH A, 1992, J BIOL CHEM, V267, P16553; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; RALL SC, 1984, J BIOL CHEM, V259, P63; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SORCITHOMAS M, 1992, J LIPID RES, V33, P1147; SORCITHOMAS M, 1991, J BIOL CHEM, V266, P18045; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; SORCITHOMAS M, 1990, J BIOL CHEM, V265, P2665; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; UTERMANN G, 1984, EUR J BIOCHEM, V144, P326; WALD JH, 1990, J BIOL CHEM, V265, P20044	35	119	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21403	21409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407982				2022-12-25	WOS:A1993MA28800110
J	SUSIN, S; ABIAN, J; SANCHEZBAEZA, F; PELEATO, ML; ABADIA, A; GELPI, E; ABADIA, J				SUSIN, S; ABIAN, J; SANCHEZBAEZA, F; PELEATO, ML; ABADIA, A; GELPI, E; ABADIA, J			RIBOFLAVIN 3'-SULFATE AND 5'-SULFATE, 2 NOVEL FLAVINS ACCUMULATING IN THE ROOTS OF IRON-DEFICIENT SUGAR-BEET (BETA-VULGARIS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC LEGHEMOGLOBIN; HIGHER-PLANTS; REDUCTION; MECHANISMS; NODULES; ANALOGS	Roots from iron-deficient sugar beet grown in the presence of calcium carbonate exhibit a yellow color and autofluorescence typical of flavin-like compounds, whereas roots of control, iron-sufficient plants exhibited no yellow color and extremely low autofluorescence. The two major flavins whose accumulation is induced by iron deficiency have been shown to be different from riboflavin, FMN, and FAD by reversed-phase high performance liquid chromatography. These flavins, accounting for 82 and 15% of the total flavin concentration in deficient roots, have been shown unequivocally to be riboflavin 3'-sulfate and riboflavin 5'-sulfate, respectively, by electrospray-mass spectrometry, inductively coupled plasma emission spectroscopy, infrared spectrometry, and H-1 nuclear magnetic resonance. These flavin sulfates have not been found previously in biological systems. The localization of riboflavin sulfates in deficient roots is similar, but not identical, to that of high iron reductase activity. The concentration of riboflavin sulfates has been estimated from root extracts to be at least 1 mM. We hypothesize, based on the similar localization of flavin and that of iron reduction, that the accumulation of riboflavin sulfates induced by iron deficiency may be an integral part of the turbo iron-reducing system in sugar beet roots.	CSIC, ESTAC EXPTL AULA DEI, DEPT PLANT NUTR, APDO 202, E-50080 ZARAGOZA, SPAIN; CSIC, CTR INVEST DESARROLLO, DEPT NEUROCHEM, E-08034 BARCELONA, SPAIN; CSIC, CTR INVEST DESARROLLO, DEPT BIOL CHEM, E-08034 BARCELONA, SPAIN; UNIV ZARAGOZA, FAC CIENCIAS, DEPT BIOCHEM & MOLEC & CELLULAR BIOL, E-50009 ZARAGOZA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Aula Dei (EEAD); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); University of Zaragoza			Abian, Joaquin/M-1965-2014; Abadia, Javier/H-3123-2019; Susin, Santos A/Q-6754-2017; Abadía, Anunciación/A-7474-2010	Abian, Joaquin/0000-0003-2823-5429; Abadia, Javier/0000-0001-5470-5901; Susin, Santos A/0000-0002-3366-1628; Abadía, Anunciación/0000-0003-3609-7070; /0000-0002-2742-3711				BARNESS E, 1992, PLANT PHYSIOL, V99, P1329, DOI 10.1104/pp.99.4.1329; BARRON D, 1988, PHYTOCHEMISTRY, V27, P2375, DOI 10.1016/0031-9422(88)87003-1; BECANA M, 1990, P NATL ACAD SCI USA, V87, P7295, DOI 10.1073/pnas.87.18.7295; BECANA M, 1991, PLANTA, V183, P575, DOI 10.1007/BF00194279; BIENFAIT HF, 1988, J PLANT NUTR, V11, P605, DOI 10.1080/01904168809363828; BIENFAIT HF, 1983, PHYSIOL PLANTARUM, V59, P196, DOI 10.1111/j.1399-3054.1983.tb00757.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JC, 1973, AGRON J, V65, P311, DOI 10.2134/agronj1973.00021962006500020037x; CAKMAK I, 1987, PLANT PHYSIOL, V85, P310, DOI 10.1104/pp.85.1.310; CERLETTI P., 1971, Methods in Enzymology, V18B, P285, DOI 10.1016/S0076-6879(71)18090-1; FRIEDRICH W, 1988, VITAMINS, P403; GRANDE HJ, 1977, HELV CHIM ACTA, V60, P348, DOI 10.1002/hlca.19770600207; HARBORNE JB, 1975, PHYTOCHEMISTRY, V14, P1147, DOI 10.1016/S0031-9422(00)98585-6; JOHNSON GV, 1982, J PLANT NUTR, V5, P499, DOI 10.1080/01904168209362977; KAINOSHO M, 1972, BIOCHEMISTRY-US, V11, P741, DOI 10.1021/bi00755a011; KANNAN S, 1988, J PLANT NUTR, V11, P1185, DOI 10.1080/01904168809363877; LANDSBERG EC, 1986, PLANT PHYSIOL, V82, P511, DOI 10.1104/pp.82.2.511; NAGARAJAH S, 1966, SOIL SCI, V102, P399, DOI 10.1097/00010694-196612000-00008; Raju K. V., 1972, Zeitschrift fur Pflanzenernahrung und Bodenkunde, V132, P177, DOI 10.1002/jpln.19721320302; Romheld V., 1986, Advances in Plant Nutrition, V2, P155; ROMHELD V, 1983, PLANT PHYSIOL, V71, P949, DOI 10.1104/pp.71.4.949; Romheld V., 1979, The soil-root interface [Harley, J.L.; Scott Russell, R. (Editors)]., P405; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; VARIN L, 1991, PLANT PHYSIOL, V95, P1254, DOI 10.1104/pp.95.4.1254; WALSH C, 1978, BIOCHEMISTRY-US, V17, P1942, DOI 10.1021/bi00603a022; WEINSTEIN LH, 1954, J AGR FOOD CHEM, V2, P421, DOI 10.1021/jf60028a006; WELKIE G, 1906, PLANT PHYSIOL, V35, P516; Welkie George W., 1993, P345; WELKIE GW, 1988, J PLANT NUTR, V11, P691, DOI 10.1080/01904168809363834; WELKIE GW, 1990, DEV PLANT SOIL SCI, V41, P207; WILLIAMSON G, 1986, METHOD ENZYMOL, V122, P240; YAGI K, 1971, METHOD ENZYMOL, V18, P465	32	83	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20958	20965						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8407931				2022-12-25	WOS:A1993MA28800051
J	GHOSH, PK; ANDERSON, J; COHEN, N; TAKESHITA, K; ATWEH, GF; LEBOWITZ, P				GHOSH, PK; ANDERSON, J; COHEN, N; TAKESHITA, K; ATWEH, GF; LEBOWITZ, P			EXPRESSION OF THE LEUKEMIA-ASSOCIATED GENE, P18, IN NORMAL AND MALIGNANT-TISSUES - INACTIVATION OF EXPRESSION IN A PATIENT WITH CLEAVED B-CELL LYMPHOMA LEUKEMIA	ONCOGENE			English	Note							GROWTH ARREST; PHORBOL ESTER; PHOSPHOPROTEIN; DIFFERENTIATION; PHOSPHORYLATION; IDENTIFICATION; CHROMOSOME-1; CONSERVATION; STATHMIN; LIGHT	p18 is a well conserved gene coding for an 18 kDa cytosolic phosphoprotein. Although the function of p18 is unknown, it is suspected of playing a role in regulation of cell proliferation or the proliferation-differentiation switch. Here we have found p18 mRNA expression highest in testis, brain, thymus and a multipotent hematopoietic stem cell line and lowest in liver. p18 was also expressed vigorously in all but one of 85 diverse tumor cell lines and primary human malignant specimens examined. In five primary tumors, expression was substantially elevated with respect to expression in contiguous normal tissue. Expression in chronic phase chronic myelogenous leukemia cells was far greater than in normal blood cells and increased with progression of disease. In liver material, the highest level of p18 was found in a primary hepatoblastoma, a stem cell tumor, whereas a benign adenoma demonstrated very low level expression. Cells from a cleaved B cell lymphoma/leukemia failed to express p18 whereas 18 specimens from other B lymphoid malignancies, including a second cleaved cell malignancy, expressed p18 at substantial levels. These data are consistent with p18 playing a role in control of cell proliferation in at least certain tissues. The questions arise if high level p18 expression in certain malignancies may play a primary role in driving cell proliferation or, based on chromosomal localization and inactivation of p18 expression in one lymphoma, if p18 may act as a tumor suppressor.	YALE UNIV,SCH MED,HEMATOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,GASTROENTEROL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510; CUNY MT SINAI SCH MED,DEPT MED,HEMATOL SECT,NEW YORK,NY 10029	Yale University; Yale University; Yale University; Yale University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER HL, 1989, J IMMUNOL, V143, P956; DOYE V, 1989, J BIOL CHEM, V264, P12134; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FERRUCCI JT, 1990, BILIARY LITHOTRIPSY, V2, P1; FEUERSTEIN N, 1984, J BIOL CHEM, V259, P2782; FONG C, 1989, P NATL ACAD SCI USA, V86, P3756; HANASH S, 1989, BLOOD S1, V74, pA347; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; ZHU XX, 1989, J BIOL CHEM, V264, P14556	19	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2869	2872						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397372				2022-12-25	WOS:A1993LX34300032
J	ROE, JA; GOODIN, DB				ROE, JA; GOODIN, DB			ENHANCED OXIDATION OF ANILINE DERIVATIVES BY 2 MUTANTS OF CYTOCHROME-C PEROXIDASE AT TRYPTOPHAN-51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; AROMATIC DONOR MOLECULES; FREE-RADICAL SITE; HORSERADISH-PEROXIDASE; ELECTRON-TRANSFER; COMPOUND-II; PHANEROCHAETE-CHRYSOSPORIUM; FERROCYTOCHROME-C; CRYSTAL-STRUCTURE	Two hyperactive mutants of cytochrome c peroxidase (CCP), W51F and W51A, catalyze the enhanced oxidation of a number of substituted anilines. The reaction of CCP compound ES with mesidine is biphasic, while similar reactions using compound II give monophasic kinetics. These data, in addition to the ratio of the Fe4+=O and free-radical species observed during steady-state turnover, indicate that reduction of the Trp=191 free radical of compound ES is more rapid than the reduction of the Fe4+=O species. Transient kinetics were examined for the oxidation of eight mono-substituted anilines by CCP, W51F, and W51A. Each of the aniline derivatives were oxidized by the mutants at rates that exceeded that of the wild-type enzyme, and the rate constant for m-chloroaniline was 400-fold faster for W51F than for wild-type CCP. Variations in the rate constants for the different substrates follow a linear free-energy relationship using the Hammet substituent effect parameter sigma+, implicating electron transfer from the aniline ring in the transition state. For aniline oxidation, the free energy of activation is 3 kcal/mol lower for the mutants than for wild-type CCP, and this is due primarily to an increase in the activation entropy. These results indicate that the enhanced kinetics of W51F and W51A result from a generalized increase in enzyme reactivity characterized by an exo-entropic transition state such as dissociation of bound H2O from the Fe4+=O center.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041049, R01GM041049, R37GM041049] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041049, GM41049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALNY C, 1987, FEBS LETT, V221, P349, DOI 10.1016/0014-5793(87)80954-7; CHEN GX, 1990, J BIOL CHEM, V265, P2775; COULSON AFW, 1971, J BIOL CHEM, V246, P917; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEPILLIS GD, 1991, J BIOL CHEM, V266, P19334; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1975, BIOCHIM BIOPHYS ACTA, V397, P36, DOI 10.1016/0005-2744(75)90176-X; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; GEORGE P, 1952, NATURE, V169, P612, DOI 10.1038/169612a0; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GOODIN DB, 1987, J BIOL CHEM, V262, P7719; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HAHM S, 1993, J AM CHEM SOC, V115, P3372, DOI 10.1021/ja00061a063; HAZZARD JT, 1987, BIOCHEMISTRY-US, V26, P2836, DOI 10.1021/bi00384a027; HO PS, 1983, J BIOL CHEM, V258, P4356; HO PS, 1984, BIOCHEMISTRY-US, V23, P4122, DOI 10.1021/bi00313a017; HUANG J, 1990, CAN J CHEM, V68, P2159, DOI 10.1139/v90-331; HUANG J, 1991, ARCH BIOCHEM BIOPHYS, V287, P257, DOI 10.1016/0003-9861(91)90476-Y; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; JORDI HC, 1974, BIOCHEMISTRY-US, V13, P3734, DOI 10.1021/bi00715a018; Kolthoff I., 1957, VOLUMETRIC ANAL, V3, DOI 10.1002/jps.3030470330; MARCH J, 1985, ADV ORGANIC CHEM; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MILLER MA, 1990, BIOCHEMISTRY-US, V29, P1777, DOI 10.1021/bi00459a017; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MORISHIMA I, 1979, J BIOL CHEM, V254, P2814; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PEREZ U, 1990, BIOCHEMISTRY-US, V29, P2757, DOI 10.1021/bi00463a019; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; PURCELL WL, 1976, J AM CHEM SOC, V98, P7033, DOI 10.1021/ja00438a049; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAKURADA J, 1990, BIOCHEMISTRY-US, V29, P4093, DOI 10.1021/bi00469a011; Saunders BC, 1973, INORGANIC BIOCH, V2, P988; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SMULEVICH G, 1990, BIOCHEMISTRY-US, V29, P7174, DOI 10.1021/bi00483a004; SUMMERS FE, 1988, J BIOL CHEM, V263, P14267; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; VEITCH NC, 1990, EUR J BIOCHEM, V189, P351, DOI 10.1111/j.1432-1033.1990.tb15496.x; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; YONETANI T, 1966, J BIOL CHEM, V241, P3240; YONETANI T, 1965, J BIOL CHEM, V240, P4503; Yonetani T., 1976, ENZYMES, P345	49	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20037	20045						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8397197				2022-12-25	WOS:A1993LY01900021
J	KALTHOFF, H; SCHMIEGEL, W; ROEDER, C; KASCHE, D; SCHMIDT, A; LAUER, G; THIELE, HG; HONOLD, G; PANTEL, K; RIETHMULLER, G; SCHERER, E; MAURER, J; MAACKE, H; DEPPERT, W				KALTHOFF, H; SCHMIEGEL, W; ROEDER, C; KASCHE, D; SCHMIDT, A; LAUER, G; THIELE, HG; HONOLD, G; PANTEL, K; RIETHMULLER, G; SCHERER, E; MAURER, J; MAACKE, H; DEPPERT, W			P53 AND K-RAS ALTERATIONS IN PANCREATIC EPITHELIAL-CELL LESIONS	ONCOGENE			English	Article							GROWTH FACTOR-ALPHA; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; COLORECTAL TUMORIGENESIS; ADENOCARCINOMA CELLS; EXOCRINE PANCREAS; SIMIAN VIRUS-40; TUMOR-ANTIGEN; GENE; MUTATIONS	We have analysed the expression of p53 at the mRNA level, and extensively at the protein level by immunostaining, Western blotting, and ELISA measurements revealing a p53 increase in 8 out of 14 cell lines established from human pancreatic carcinomas. The mRNA levels closely paralleled the protein levels in most of the cell lines. Overexpression of p53 in tumor cells correlated with mutations in the p53 gene. Immunocytochemistry was also performed with tissue cryosections showing a nuclear p53 staining in 8 out of 12 exocrine, and 2 out of 2 endocrine tumors. In addition, nonmalignant peri-tumoral tissue specimens and cells derived from pancreatic juice of acute pancreatic patients were also positively stained. These findings may suggest functions of p53 in stress situations induced by acute inflammation or tissue regeneration. Genomic mutations in the tumor suppressor gene were associated with point mutations in either codon 12, 13 or 61 in the c-K-RAS oncogene in about two-thirds of cell lines. The frequent activations of a RAS oncogene in combination with mutations of a tumor suppressor gene are likely to contribute to the malignant phenotype of pancreatic adenocarcinomas.	UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH 2,GERMANY; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; FU BERLIN,KLINIKUM STEGLITZ,INNERE MED ABT,W-1000 BERLIN 45,GERMANY; HEINRICH PETTE INST,TUMORVIROL ABT,HAMBURG,GERMANY	University of Munich; Netherlands Cancer Institute; Free University of Berlin; Heinrich Pette Institute	KALTHOFF, H (corresponding author), UNIV HAMBURG,MED KLIN,IMMUNOL ABT,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Kalthoff, Holger/B-1618-2010; Lauer, Georg/J-1467-2018	Lauer, Georg/0000-0002-9792-4271				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1992, IN PRESS J CELL SCI; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, NATO ASI SERIES H, V34, P399; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERNANDEZPOL JA, 1989, J CELL BIOCHEM, V41, P159, DOI 10.1002/jcb.240410306; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KAKU M, 1980, GANN, V71, P596; KALTHOFF H, 1991, ONCOGENE, V6, P1015; KALTHOFF H, 1992, IN PRESS INT S CLIN; KLOPPEL G, 1988, PANCREAS CONNECTION, P122; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; LEMOINE NR, 1991, J PATHOL, V165, P7; LEMOINE NR, 1991, GASTROENTEROLOGY, V101, P1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; METZGAR RS, 1982, CANCER RES, V42, P601; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1987, ONCOGENE, V1, P453; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHMURA E, 1990, CANCER RES, V50, P103; OKABE T, 1983, CANCER, V51, P662, DOI 10.1002/1097-0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SHIBATA D, 1990, BAILLIERE CLIN GASTR, V4, P151, DOI 10.1016/0950-3528(90)90044-H; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; VANKRANEN HJ, 1991, CARCINOGENESIS, V12, P1477, DOI 10.1093/carcin/12.8.1477; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERRAHN J, 1992, ONCOGENE, V7, P1371	54	211	213	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					289	298						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426738				2022-12-25	WOS:A1993KN00600007
J	SIPPEL, CJ; SUCHY, FJ; ANANTHANARAYANAN, M; PERLMUTTER, DH				SIPPEL, CJ; SUCHY, FJ; ANANTHANARAYANAN, M; PERLMUTTER, DH			THE RAT-LIVER ECTO-ATPASE IS ALSO A CANALICULAR BILE-ACID TRANSPORT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANE; CELL-ADHESION MOLECULE; COMPLEMENTARY-DNA; EXPRESSION; SYSTEM; RECEPTOR; SEQUENCE; SALT; TAUROCHOLATE; RETICULUM	A approximately 110-kDa glycoprotein purified from canalicular vesicles by bile acid affinity chromatography has been identified as the canalicular bile acid transport protein. Internal amino acid sequence and chemical and immunochemical characteristics of this protein were found to be identical to a rat liver canalicular ecto-ATPase. In order to definitively determine whether these were two activities of a single polypeptide, we examined the possibility that transfection of cDNA for the ecto-ATPase would confer bile acid transport characteristics, as well as ecto-ATPase activity, on heterologous cells. The results show that transfection of the ecto-ATPase cDNA conferred on COS cells de novo synthesis of a approximately 110-kDa polypeptide, as immunoprecipitated by antibody to the purified canalicular bile acid transport protein and conferred on COS cells the capacity to pump out [H-3]taurocholate with efflux characteristics comparable with those previously determined in canalicular membrane vesicles (K(m) = 100 muM; V(max) = 200 pmol/mg of protein/20 s). A truncated ecto-ATPase cDNA, missing the cytoplasmic tail, was targeted correctly to the cell surface but did not confer bile acid transport activity on COS cells. The results of this study also show that the canalicular ecto- ATPase/bile acid transport protein is phosphorylated on its cytoplasmic tail and that its phosphorylation is stimulated by activation of protein kinase C and inhibited by inhibitors of protein kinase C activation. Moreover, inhibition of protein kinase C activation by staurosporine completely abrogates bile acid transport but does not affect ATPase activity. This study, therefore, demonstrates that the rat liver canalicular ecto-ATPase is also a bile acid transport protein, that the capacitiy to pump out bile acid can be conferred on a heterologous cell by DNA-mediated gene transfer, and that phosphorylation within the cytoplasmic tail of the transporter is essential for bile acid efflux activity but not for ATPase activity.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06510	Washington University (WUSTL); Washington University (WUSTL); Yale University	SIPPEL, CJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [KO8 HD00954-01, T32 HD07409, HD20632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000954, T32HD007409, R01HD020632, R37HD020632] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANA.M, 1991, AM J PHYSIOL, V261, pG2810; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HARRISON BC, 1991, J NEUROCHEM, V56, P1723, DOI 10.1111/j.1471-4159.1991.tb02073.x; HINDO Y, 1988, P NATL ACAD SCI USA, V85, P6959; HIXSON DC, 1985, CANCER RES, V45, P3742; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1989, J BIOL CHEM, V264, P14403; LIN SH, 1985, J BIOL CHEM, V260, P976; LIN SH, 1992, FASEB J, V6, P353; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NOVAK DA, 1991, AM J PHYSIOL, V260, pG743, DOI 10.1152/ajpgi.1991.260.5.G743; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SKEHEL JJ, 1992, NATURE, V358, P110, DOI 10.1038/358110b0; SKORSGAARD T, 1978, CANCER RES, V38, P1785; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; THOMAS P, 1990, BIOCHIM BIOPHYS ACTA, V1032, P177, DOI 10.1016/0304-419X(90)90003-J	38	120	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2083	2091						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	8420979				2022-12-25	WOS:A1993KH62000088
J	BARLOWE, C; DENFERT, C; SCHEKMAN, R				BARLOWE, C; DENFERT, C; SCHEKMAN, R			PURIFICATION AND CHARACTERIZATION OF SAR1P, A SMALL GTP-BINDING PROTEIN REQUIRED FOR TRANSPORT VESICLE FORMATION FROM THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; YEAST SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; MEMBRANE GLYCOPROTEIN; GUANINE-NUCLEOTIDES; POLYACRYLAMIDE GELS; ADENYLATE-CYCLASE; GOLGI TRANSPORT; BOVINE BRAIN; RAS	SEC12 encodes an integral membrane glycoprotein essential for vesicle formation from the endoplasmic reticulum (ER) in yeast. The SAR1 gene was discovered as a multicopy suppressor of a sec12t8 strain and encodes a 21-kDa GTP-binding protein also required for protein transport from the ER to the Golgi apparatus (Nakano, A., and Muramatsu, M. (1989) J. Cell Biol. 109, 2677-2691). We have purified Sar1p to apparent homogeneity from cells harboring a galactose-regulated recombinant SAR1. Purified Sar1p binds guanine nucleotides specifically and exhibits GTPase activity (0.001 min-1). Nucleotide exchange and hydrolysis rates are greatly increased in the presence of Mg2+ and nonionic detergents or phospholipids. An assay that measures the formation of a vesicle intermediate in ER to Golgi transport was devised that is dependent on the addition of purified Sar1p. This assay employs membranes prepared from wild-type cells and cytosol fractions depleted of Sar1p due to overproduction of Sec12p or by gel filtration chromatography. The gel-filtered cytosol requires the addition of Sar1p and GTP to support vesicle budding. Sar1p prebound with GTPgammaS inhibits Sar1p function in the vesicle formation assay. The results indicate a role for Sar1p in vesicle budding from the ER and suggest that GTP hydrolysis by Sar1p is required for this event.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720; INST PASTEUR,UNITE MYCOL,F-75824 PARIS 15,FRANCE	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				d'Enfert, Christophe/0000-0002-6235-3886				BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HARLOW E, 1988, ANTIBODIES LABORATOR; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; UEDA T, 1990, J BIOL CHEM, V265, P9373; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; WUESTEHUBE LJ, 1992, IN PRESS METHODS ENZ	38	142	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					873	879						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419365				2022-12-25	WOS:A1993KG07700021
J	HIRATA, R; UMEMOTO, N; HO, MN; OHYA, Y; STEVENS, TH; ANRAKU, Y				HIRATA, R; UMEMOTO, N; HO, MN; OHYA, Y; STEVENS, TH; ANRAKU, Y			VMA12 IS ESSENTIAL FOR ASSEMBLY OF THE VACUOLAR H+-ATPASE SUBUNITS ONTO THE VACUOLAR MEMBRANE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; PROTON MOTIVE FORCE; NUCLEAR GENE; CATALYTIC SUBUNIT; ACTIVE-TRANSPORT; PET PHENOTYPE; YEAST VACUOLE; AMINO-ACIDS; CELL-CYCLE; PROTEIN	vma12 mutants of the yeast Saccharomyces cerevisiae, which were originally identified as calcium-sensitive (cls) mutants that were also respiratory deficient (Pet-), have a defect in vacuolar membrane H+-ATPase activity (Ohya, Y., Umemoto, N., Tanida, I., Ohta, A., Iida, H., and Anraku, Y. (1991) J. Biol. Chem. 266, 13971-13977). The VMA12 gene was cloned by complementation of the growth defects of vma12 mutants. The nucleotide sequence of the gene predicts a polypeptide of 215 amino acids (25.2 kDa) with two putative membrane-spanning domains. A null vma12 mutant, constructed by chromosomal deletion of the gene, is viable but has completely lost the vacuolar membrane H+-ATPase activity and exhibits the same growth defects as observed for the original vma12 mutants. Synthesis and targeting of the subunits of the H+-ATPase in the DELTAvma12 mutant cells were examined by Western blotting analyses of whole cell and vacuolar membrane protein extracts. None of the peripheral membrane subunits that we analyzed (the 69-, 60-, 42-, and 27-kDa subunits) was detected in the vacuolar membrane fractions, although the cellular levels of these polypeptides appeared to be normal. The 100- and 17-kDa integral membrane subunits of the enzyme were absent or present at a substantially reduced level in mutant vacuolar membrane fractions. Anti-Vma12p antibodies recognized a vacuolar protein with the expected molecular mass of 25 kDa. However, the Vma12 protein was not detected in the vacuolar membrane ATPase complex that had been solubilized with a zwitterionic detergent, ZW3-14, and purified by glycerol gradient centrifugation (Kane, P. M., Yamashiro, C. T., and Stevens, T. H. (1989) J. Biol. Chem. 264, 19236-19244). These results indicate that the VMA12 gene product is not a component of the active vacuolar ATPase complex and instead suggest that this protein is required during the process of assembly and/or targeting of the enzyme complex to the vacuolar membrane.	UNIV TOKYO, FAC SCI, DEPT BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Tokyo; University of Oregon			Umemoto, Naoyuki/C-9712-2017; Hirata, Ryogo/C-7424-2017	Umemoto, Naoyuki/0000-0001-5507-0848; Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1991, FEBS LETT, V278, P234, DOI 10.1016/0014-5793(91)80124-L; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Anraku Y, 1987, PLANT VACUOLES, P255; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; GALONS JP, 1990, EUR J BIOCHEM, V193, P111, DOI 10.1111/j.1432-1033.1990.tb19311.x; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRATA R, 1989, FEBS LETT, V244, P397, DOI 10.1016/0014-5793(89)80571-X; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PRESTON RA, 1992, GENETICS, V131, P551; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1984, J BIOL CHEM, V259, P1505; SAUREZRENDUELS MP, 1981, FEBS LETT, V131, P296; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	62	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					961	967						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419376				2022-12-25	WOS:A1993KG07700033
J	PASCO, DS; BOYUM, KW; ELBI, C; SIU, CS; FAGAN, JB				PASCO, DS; BOYUM, KW; ELBI, C; SIU, CS; FAGAN, JB			INDUCER-DEPENDENT TRANSCRIPTIONAL ACTIVATION OF THE P4501A2 GENE INVIVO AND IN ISOLATED HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS; MESSENGER-RNAS; AH LOCUS; DNA; RAT; CDNA; 3-METHYLCHOLANTHRENE; CYTOCHROME-P1-450; EXPRESSION	In vitro nuclear run-on transcription analysis using probes directed against different regions of CYP1A2 revealed that the 70-100-fold induction of CYP1A2 mRNA by polycyclic aromatic compounds is associated with a corresponding increase in the transcriptional activation of this gene in rat liver. Probes from regions of the 1st, 2nd, and 4th introns detected approximately 50-100-fold higher CYP1A2 run-on transcription in liver nuclei from inducer-treated animals than in nuclei from untreated animals. The run-on signals from untreated rats were 3-5-fold above background signals. Additional experiments using single-stranded DNA probes and a probe from a region 5' to the CYP1A2 transcription start site revealed that the inducer-dependent transcripts were colinear with the CYP1A2 mRNA and that they did not result from read through of an inititation event 5' to CYP1A2. Run-on transcription analyses were also carried out with nuclei from isolated hepatocytes using the same series of probes spanning CYP1A2. These analyses indicated that the inducer-dependent accumulation of CYP1A2 mRNA in hepatocytes is associated with at least a 20-fold increase in CYP1A2 transcription. In contrast to liver and hepatocytes, these probes failed to detect run-on transcripts from kidney nuclei, indicating that the lack of CYP1A2 mRNA in this tissue is due to the lack of transcriptional activation of this gene by polycyclic aromatic compounds.			PASCO, DS (corresponding author), MAHARISHI INT UNIV,MOLEC BIOL LAB,1000 N 4TH ST,FAIRFIELD,IA 52557, USA.				NCI NIH HHS [R01-CA38655] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038655] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; FAGAN JB, 1986, ARCH BIOCHEM BIOPHYS, V244, P261, DOI 10.1016/0003-9861(86)90116-5; FALETTO MB, 1988, J BIOL CHEM, V263, P12187; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; KADLUBAR FF, 1987, MAMMALIAN CYTOCHROME, V2, P81; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KIMURA S, 1984, J BIOL CHEM, V259, P705; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LU AYH, 1980, PHARMACOL REV, V31, P277; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEWHOLD LA, 1989, MOL CELL BIOL, V9, P2378; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PELKONEN O, 1982, PHARMACOL REV, V34, P190; SILVER G, 1990, J BIOL CHEM, V265, P3134; SILVER G, 1988, J BIOL CHEM, V263, P11802; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	30	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1053	1057						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419313				2022-12-25	WOS:A1993KG07700046
J	SCHRODER, I; DARIE, S; GUNSALUS, RP				SCHRODER, I; DARIE, S; GUNSALUS, RP			ACTIVATION OF THE ESCHERICHIA-COLI NITRATE REDUCTASE (NARGHJI) OPERON BY NARL AND FNR REQUIRES INTEGRATION HOST FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-PRODUCT; FUMARATE REDUCTASE; ANAEROBIC RESPIRATION; HIMA GENE; DNA; EXPRESSION; PROTEIN; BINDING; OXYGEN; SITE	Integration host factor protein (IHF) was shown to be required for Fnr- and NarL-dependent activation of the nitrate reductase (narGHJI) operon of Escherichia coli in response to nitrate availability and anaerobiosis. Using a narG-lacZ reporter fusion to evaluate narGHJI expression in vivo both the nitrate and anaerobic dependent controls were severely impaired in a himA mutant compared with the wild type strain. IHF was also required for Fnr-independent anaerobic control of narGHJI expression. In vitro, purified IHF protein was shown to bind to a narG promoter fragment with an apparent dissociation value of 5 nM by use of a gel shift assay. DNase I footprinting studies revealed that IHF protects a 37-base pair region centered 125 base pairs 5' of the narG transcription site. These studies suggest that the IHF protein performs a DNA bending function at the narG promoter to allow nitrate-dependent activation by the NarL regulatory protein, and second, it enhances the Fnr-dependent expression from the narG promoter under anaerobic cell growth conditions. A model whereby three transcriptional activators, NarL, IHF, and Fnr, induce expression of a sigma70-dependent promoter for the narGHJI operon is discussed.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021678] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21678] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHIANG RC, 1992, MOL MICROBIOL, V6, P1913, DOI 10.1111/j.1365-2958.1992.tb01364.x; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COTTER PA, 1990, J BACTERIOL, V172, P6333, DOI 10.1128/jb.172.11.6333-6338.1990; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DONG XR, 1992, J BIOL CHEM, V267, P14122; FILUTOWICZ M, 1991, J BIOL CHEM, V266, P24077; FRIEDMAN DI, 1984, J BACTERIOL, V157, P484, DOI 10.1128/JB.157.2.484-489.1984; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUANG L, 1990, J BACTERIOL, V172, P5293, DOI 10.1128/jb.172.9.5293-5298.1990; IUCHI S, 1987, P NATL ACAD SCI USA, V84, P3901, DOI 10.1073/pnas.84.11.3901; JONES HM, 1987, J BACTERIOL, V169, P3340, DOI 10.1128/jb.169.7.3340-3349.1987; KALMAN LV, 1988, J BACTERIOL, V170, P623, DOI 10.1128/jb.170.2.623-629.1988; KALMAN LV, 1990, J BACTERIOL, V172, P7049, DOI 10.1128/jb.172.12.7049-7056.1990; KALMAN LV, 1989, J BACTERIOL, V171, P3810, DOI 10.1128/jb.171.7.3810-3816.1989; KOLESNIKOW T, 1992, J BACTERIOL, V174, P7104, DOI 10.1128/jb.174.22.7104-7111.1992; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; MILLER HI, 1984, COLD SPRING HARB SYM, V49, P691, DOI 10.1101/SQB.1984.049.01.078; MILLER HI, 1981, NATURE, V290, P523, DOI 10.1038/290523a0; MILLER HI, 1979, COLD SPRING HARB SYM, V43, P1121, DOI 10.1101/SQB.1979.043.01.125; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; PERBAL B, 1988, PRACTICAL GUIDE MOL, P550; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; STEWART V, 1982, J BACTERIOL, V151, P1320, DOI 10.1128/JB.151.3.1320-1325.1982; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WALKER MS, 1991, MOL MICROBIOL, V5, P353, DOI 10.1111/j.1365-2958.1991.tb02116.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; WU YF, 1992, J BACTERIOL, V174, P233, DOI 10.1128/jb.174.1.233-240.1992	40	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					771	774						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	8419352				2022-12-25	WOS:A1993KG07700005
J	TAYLOR, ME; DRICKAMER, K				TAYLOR, ME; DRICKAMER, K			STRUCTURAL REQUIREMENTS FOR HIGH-AFFINITY BINDING OF COMPLEX LIGANDS BY THE MACROPHAGE MANNOSE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ASIALOGLYCOPROTEIN RECEPTOR; RAT; PROTEINS; GLYCOPROTEINS; CONTAINS	The mannose receptor of macrophage and hepatic endothelial cells discriminates between endogenous and exogenous sugar-bearing structures. Previous competition studies have indicated that the receptor binds the monosaccharides mannose, fucose, and N-acetylglucosamine but displays much higher affinity for multivalent oligosaccharides, such as those found on the surface of potentially pathogenic microorganisms. The hydrodynamic properties of the receptor have been examined, revealing that the receptor is a monomer. This result suggests that multiple carbohydrate recognition domains (CRDs) in the extracellular domain of a single receptor polypeptide cooperate to achieve high affinity binding of complex ligands. In order to determine the importance of individual CRDs, properties of receptor segments containing groups of CRDs expressed in insect cells have been examined. The results indicate that two of the CRDs (4 and 5) form a protease-resistant, ligand-binding core but that five CRDs in tandem (4-8) are required to match the affinity of the intact receptor for yeast mannan. A consequence of the organization of the receptor is that both valency and geometry of glycoconjugates are important determinants of binding affinity.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University				Taylor, Maureen/0000-0001-8300-4987	NIGMS NIH HHS [GM 42628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHIACCHIA KB, 1984, J BIOL CHEM, V259, P5440; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COHN EJ, 1943, PROTEINS AMINO ACIDS, P372; DRICKAMER K, 1989, CIBA F SYMP, V145, P45; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1992, IN PRESS NATURE; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GIBBONS RA, 1972, GLYCOPROTEINS A, V5, P29; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; KIM SJ, 1992, IN PRESS GENOMICS; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LOEB JA, 1987, J BIOL CHEM, V262, P3022; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OTTER M, 1991, J BIOL CHEM, V266, P13931; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; RICE KG, 1990, J BIOL CHEM, V265, P18429; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; Summers MD, 1987, MANUAL METHODS BACUL; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; WARR GA, 1980, BIOCHEM BIOPH RES CO, V93, P737, DOI 10.1016/0006-291X(80)91139-0; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, IN PRESS NATURE; WILSON ME, 1986, J IMMUNOL, V136, P4681	34	199	207	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					399	404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	8416946				2022-12-25	WOS:A1993KE60300061
